<SEC-DOCUMENT>0001104506-22-000019.txt : 20220804
<SEC-HEADER>0001104506-22-000019.hdr.sgml : 20220804
<ACCEPTANCE-DATETIME>20220804073056
ACCESSION NUMBER:		0001104506-22-000019
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220804
DATE AS OF CHANGE:		20220804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INSMED Inc
		CENTRAL INDEX KEY:			0001104506
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				541972729
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30739
		FILM NUMBER:		221134704

	BUSINESS ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		908-977-9900

	MAIL ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INSMED INC
		DATE OF NAME CHANGE:	20000128
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>insm-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:f29bbe7c-3fe7-4edc-bd43-5e98e923844d,g:47f91642-8422-4809-9855-6a3312b42bf8,d:252108b308054887a46901fe227627f1--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:insm="http://www.insmed.com/20220630" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>insm-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80L2ZyYWc6OTMyZDk4NTgxNGI3NGM0NzkwMjhiOGIyYmJkZGVkYjEvdGFibGU6Yjg4NjFmYjlhYThkNDkwZGIwYzdjMGYxMDVlZTU1MmMvdGFibGVyYW5nZTpiODg2MWZiOWFhOGQ0OTBkYjBjN2MwZjEwNWVlNTUyY18zLTEtMS0xLTI4OTQ3_624a896e-7c5e-44a3-93ef-83200b643dcb">0001104506</ix:nonNumeric><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80L2ZyYWc6OTMyZDk4NTgxNGI3NGM0NzkwMjhiOGIyYmJkZGVkYjEvdGFibGU6Yjg4NjFmYjlhYThkNDkwZGIwYzdjMGYxMDVlZTU1MmMvdGFibGVyYW5nZTpiODg2MWZiOWFhOGQ0OTBkYjBjN2MwZjEwNWVlNTUyY180LTEtMS0xLTI4OTQ3_02dd1398-e7ec-4ea6-bd6c-434064aba73e">false</ix:nonNumeric><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80L2ZyYWc6OTMyZDk4NTgxNGI3NGM0NzkwMjhiOGIyYmJkZGVkYjEvdGFibGU6Yjg4NjFmYjlhYThkNDkwZGIwYzdjMGYxMDVlZTU1MmMvdGFibGVyYW5nZTpiODg2MWZiOWFhOGQ0OTBkYjBjN2MwZjEwNWVlNTUyY181LTEtMS0xLTI4OTQ3_ad2898e8-ab48-45ff-ba57-dd0de2a8fdf6">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80L2ZyYWc6OTMyZDk4NTgxNGI3NGM0NzkwMjhiOGIyYmJkZGVkYjEvdGFibGU6Yjg4NjFmYjlhYThkNDkwZGIwYzdjMGYxMDVlZTU1MmMvdGFibGVyYW5nZTpiODg2MWZiOWFhOGQ0OTBkYjBjN2MwZjEwNWVlNTUyY182LTEtMS0xLTI4OTQ3_2a7b9371-2b25-4913-87ef-6cc868298064">2022</ix:nonNumeric><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80L2ZyYWc6OTMyZDk4NTgxNGI3NGM0NzkwMjhiOGIyYmJkZGVkYjEvdGFibGU6Yjg4NjFmYjlhYThkNDkwZGIwYzdjMGYxMDVlZTU1MmMvdGFibGVyYW5nZTpiODg2MWZiOWFhOGQ0OTBkYjBjN2MwZjEwNWVlNTUyY183LTEtMS0xLTI4OTQ3_40478f43-2c76-4b64-be7a-d6dadae3a9bb">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy0wLTEtMS0yODk0Nw_5170a57a-1eda-4542-9bcc-d9f790c05e2e">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy0wLTEtMS0yODk0Nw_5fbc7803-cbbe-4bcb-b5af-540dd0804389">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy0wLTEtMS0yODk0Nw_62156160-2395-4d30-a04e-38d15c472e4f">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy0wLTEtMS0yODk0Nw_71b55fa8-736f-46bf-86da-41456bd986cc">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi0wLTEtMS0yODk0Nw_2e37e237-166c-4368-81f8-ac870cd6c5b4">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi0wLTEtMS0yODk0Nw_4aef5557-06f5-48ae-8810-c00dfa86ec5a">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi0wLTEtMS0yODk0Nw_e533229d-73dc-4061-a116-6e06fda709bc">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi0wLTEtMS0yODk0Nw_ff82a8a8-fd7a-4c2e-a1b3-ebc868884937">http://fasb.org/us-gaap/2022#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="ib522b19ddff7498ba35a485c8ecf846e_D20210101-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTUtMC0xLTEtMzAzOTY_6eb28c14-79b4-4b78-b3a4-04fcfc83126c">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNTQ_a1983cb3-6ebb-4561-babb-c381ced619fe">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="iccd7845446c64a369164bb9ead8f5b59_D20180101-20180131" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81NS9mcmFnOjcxZWQ5MTg4MTEzYzQzMjg4OGYwNDUzNWM2OWJhZTA4L3RhYmxlOjc0M2ZjY2ZkOTRjMTQwY2JiMjgxNmM4NmU0MGZmN2NlL3RhYmxlcmFuZ2U6NzQzZmNjZmQ5NGMxNDBjYmIyODE2Yzg2ZTQwZmY3Y2VfMi0xLTEtMS0yODk0Nw_5437fee6-3734-4401-a19d-a50bdd31c946">25.5384</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ibb904a2de5514e68a11f4cbaec8fa4d2_D20210501-20210531" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81NS9mcmFnOjcxZWQ5MTg4MTEzYzQzMjg4OGYwNDUzNWM2OWJhZTA4L3RhYmxlOjc0M2ZjY2ZkOTRjMTQwY2JiMjgxNmM4NmU0MGZmN2NlL3RhYmxlcmFuZ2U6NzQzZmNjZmQ5NGMxNDBjYmIyODE2Yzg2ZTQwZmY3Y2VfNC0xLTEtMS0yODk0Nw_0e3aec01-05d3-463e-b0ba-a0b6d0b1c2d8">0.0255384</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i0f13738b91a24ea68cfbd83444c1fda2_D20180101-20180131" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81NS9mcmFnOjcxZWQ5MTg4MTEzYzQzMjg4OGYwNDUzNWM2OWJhZTA4L3RhYmxlOjc0M2ZjY2ZkOTRjMTQwY2JiMjgxNmM4NmU0MGZmN2NlL3RhYmxlcmFuZ2U6NzQzZmNjZmQ5NGMxNDBjYmIyODE2Yzg2ZTQwZmY3Y2VfNi0xLTEtMS0yODk0Nw_4e06a061-5c92-4463-9503-c2cb40c28297">30.7692</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i3e690606ed2949018b852163daddc302_D20210501-20210531" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81NS9mcmFnOjcxZWQ5MTg4MTEzYzQzMjg4OGYwNDUzNWM2OWJhZTA4L3RhYmxlOjc0M2ZjY2ZkOTRjMTQwY2JiMjgxNmM4NmU0MGZmN2NlL3RhYmxlcmFuZ2U6NzQzZmNjZmQ5NGMxNDBjYmIyODE2Yzg2ZTQwZmY3Y2VfOC0xLTEtMS0yODk0Nw_563db70a-b4a0-4433-959c-1ed29e259257">0.0307692</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="insm-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4a1faee4d59482ea066bbdc84f02467_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i92ecd30d90114111bd1344c30c28673d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i164351f40c6a48a5bce7be7cbbb95393_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefa9467fe6ae4ae7be463ef02bd03331_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35baa1a10636413abb12d0a528eb7da0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74180eb633f24734a1c4c9c66a934ef6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14d1bd5fb1694a178730b0cd705a3cd4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2de1a6fdaa74c7cade5245529b85f53_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i828764c93d1d45929aa04ca248ea4fad_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if48dc576429648f1a4016567fa86b396_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ac8060b82014b21b0613cda3d7a60c6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55f0b2b681c841419600222a85ea3546_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3276d1a28daa4225b9fcdb3cc08af201_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd691c6a90574493ba24a86f882bb91a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24591cad2f4544ef997c8b46679d9352_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34b29fd1e2a04660a3bb612c3f24dde5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06b533b795524ae29ed13dc8973a1aba_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia867ec38918e444f8e2d1d14ce332ec5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f812dff96b74536ae44f954590aa428_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie86bfdf9f6d24ddfa8e132dc25af8978_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c0613ed6dde4e01bc2b4e47830856f9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d40fdfd16fc451fb491730b4a9173d4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9db84f87eeb341579e4fe91899a2f3f5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c724ef416fd4b8d83a5292521f39be3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ccd6a0b87204d16adb14a3d22bcda4e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0182cad036cc492c902e8768cc1bdc6a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f7e3e3f5c7949eb926f4685e8a1dd75_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0b176cdccb74943960953e16068e6a8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadd45892aa3342cbbeff3a291a11105b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ea404b9803f4458944b7dbf3eefe5d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3f49f20915e465aa2c3491edb04f079_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b6083ac1b4641ee80d7fbb9322f6ff4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3240a301c3b4a8092fcd0ff21adb6f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic11e1e3142e048009002fc987716b4e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6afe0edb9cc44adca52bd18a9cba27db_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d76fce0871a49f997118895b8cc5d9e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i048e3b2eae994f98967e9743c0322e99_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0471829afd7d49ec8d77526fcd9e579e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b3892dcb478479cbc9399beec69b27e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4522e02284f8410db6010810d897bb79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5eb0968295fa457c8b850a6bb24fd24e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if525baf875694aeebfb3e8f1ee7895c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib522b19ddff7498ba35a485c8ecf846e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf38b8e15b4544b69ae00a7699d5915d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86ea5250e3bb45aa81e5c43a0000647d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide697d4ed12846f7b2b2e749378e6fb5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05cbb40265d44701a893071c4123f466_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d0519eefc5a4372aa09bac3494eed11_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94bf3b66b78947dcb8fe7cb4478bc7f1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e5d191ee0284b228ad30f1ed1e95735_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2feebc246964bc390c0f21deae432ad_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i7a28ddcd6f5348cc9084640011f760dd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec080385c64348cb8d266b6830480fb9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d7e6f6374b34f27b308f84f2889e800_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic90ba27634af46b9a9e3cde8cc10fe96_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47041a589d9840429204e4bf3b7e196d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93327d100c39469e95dec29690f01bda_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ee4597ee72a49a1b044f1c8dbb4f863_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71d3efb8da424928ad39dfb3ae7f93e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie148fe14821246d98cdbbf096f0dc154_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>insm:security</xbrli:measure></xbrli:unit><xbrli:context id="ib690063402dd47c4ae80bed8cc5946a2_D20210804-20210804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-04</xbrli:startDate><xbrli:endDate>2021-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbf98dd2c06941fba02468ff74fe15f4_D20210804-20210804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-04</xbrli:startDate><xbrli:endDate>2021-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63cf6ce83c0a452894be75c49ed8e241_D20210804-20210804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-04</xbrli:startDate><xbrli:endDate>2021-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie99f3a85a4be4eee9b9643513ffb1f49_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">insm:AccruedLiabilitiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0173aaf93ae46c0804c04edc71dcf3d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if515e39443fc4bab983e5485d58c4067_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i060750a8e6764e58986207b6fa039245_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fc0d05a849b4f9f8363d09eb7a2297f_D20210804-20210804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-04</xbrli:startDate><xbrli:endDate>2021-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d34c58061f249e18f61f07687b0331b_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:AlgaeneXIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a656fb7732145c9a71bf1d21a49bd5d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4df89726368c42908ecdb1dc00da2381_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:PriorityReviewVoucherMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i281fbad9a3524e6396eb4972fe1bde0a_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:PriorityReviewVoucherMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sale"><xbrli:measure>insm:sale</xbrli:measure></xbrli:unit><xbrli:context id="ia8937d9bce474ef99c2f8fd821f06dfd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26bcf703891e40a19cb16e952a3c238c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">insm:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7956fe4d32d6415888053fe7ac3dece8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">insm:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfb81df3017f4c52b5f695219f80bcb0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:PriorityReviewVoucherMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01b8767d1be2471ea778276a43af86f0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:PriorityReviewVoucherMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">insm:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i694933442abe4684b8238d717a4bc7b2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:PriorityReviewVoucherMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9029a1175b8d4c0bb7ad648dd57b8b45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DeferredConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id65b00fb345d4a73968a60a9f00ec86b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DeferredConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cfafbc2904c4fd78825be70c0ebb580_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DeferredConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32f0450653644e2c821879326a4be32c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e6f98ddcb9a41259b5ad644d8e7762b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf3af52789dd4962b7190f4bb7f153e7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i008ce45b9b5447059371d7e92096d9ff_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a35e946668040f5b6acb3c5b856b0e7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7436f64e366c4208874055741be8f683_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3ba44aaad2b44359ffdef500ffbb2d8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb495f010db54c2ebbb407f2ea54e2ba_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idae99b8ad22540cba6959e639a4bc3d9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18c239d8a4b84368b0ec193e679d9382_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45292554e7184f898ba749676eba1941_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd20c886bcbb4ec881a57bf89c5feefa_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75d345a205d14a869a001fc3d932ca19_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32487a941bfc4076b54815cf8c60211b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5de10744d8f445ae87da00f994d29fcd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i826dc379d52b4e8d8be78b58060e1979_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11458fa48bb841a7b70bf22cafac3a40_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04f0a1a4c2144c658e9faeab5bacbf34_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0771a886122a4116af16d7e597aac7e8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f46d4b8f14b4f9a9806c15e65465675_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib57ecc23938042cfa725b197115046c8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88a276ac0d54475b9c03c7440a1608fe_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cfd6327542a4ec28651deb81d520e2c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62c8f1c4a72145a8a38686730f07d96d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaa2f8ddc972496d9af74169e0443d41_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d56f2cd3eaf416e8ea5e63692228a23_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ae9ec03bdda4b058bca71221c9a7996_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8297b16fe1be40cb95165a0bea1fa1fe_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34fcb92cc2b441f1a0c7f4c6e848c031_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f40504b772844eb858783a727551877_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i661418bb0674414b9010ff5b70067d3d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30c3f2d8839a4faa9a1c05047301e4f7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5334091cc884a859ad2228b90a2795f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b44c6e566f24a9882c1b3f8f3b4c0ee_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea9322ea7e7a46f9bb59dc10b38f0897_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1448668a7228445d80ba936243ca7fe7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5726053c5da4536a1e11ec19e99b532_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bed069934724804b94a28374dea16e9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6931c30dc02f44cf8d0a90632e1f5ce4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80224a3dd22c4d58966aae71eacb8cc4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cd49603d9354e39a28f04178c247b10_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e5abaf4f46249c2b605b4b4d53db50a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:EuropeAndTheRestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad77b69398bc4c9dbef47393b9c7c0e7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:EuropeAndTheRestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1df549ad601429bbc4b64c37aee2eb3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:EuropeAndTheRestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77947eb926944d7f9ef2b3f148ffcb51_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:EuropeAndTheRestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefdd31e6154343f0a080337167a74a77_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaf84c60d3d749089c4d2329ec941ffe_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1380329539b4132829f56ecd925fdf8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cd9cfdd737546e99d0b622013e7ca48_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc4ec61359d24f0caa4c62d971da1288_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i278371e151d544e6a212c9d2aa2a655b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dd5b90d56364a53a5da8bdf154bec64_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife46a9fb88034d28981626beb4a29946_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5640268efe1f4be6b786aed558989d41_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b3c794885af4e1f921fd241ba143529_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f13532abba943b0b557fd68637dbf22_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i413f715068c444d2a9f6c5865f2e54fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58319fe25f124f3b8246c1b27bb7cb08_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefdd99d19aab444dbfcd286f3daa9339_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1686617c86b644caae372fe8d75fcec3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if38a8d02ea544cb4b9317034c9910cb3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id72977157672403489742e38fb8ca59b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i344bca01b9d34f3aa441d482b0f2f475_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c4bd98ffad14ac78e43425f54977d3d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedecef4e6b1d4166a9b79f3e0c853064_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51ea7721be4640ed9298ced46bffdeae_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb7b544503ac43e48d6444664e6c74da_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i805564f130794c159907d4cd7218c011_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaef54a8191e044bf93f11f4bc2a4e911_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic131085d4cfa45ffaa948fcbbe39e100_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74052c73b62e4b3ca8e440d6a7b6b48a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia326b8c20ab24d99baac8636d47b1d21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1378d80bd52a41168942eacca8002c0e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34f0289767e04e32a7cfdbeba5d34a52_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eae84db78bc47d8b25e7ed4a65b6f34_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4791157952514b1fb66954d88f405f1a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i483f5f82cf52494c8e648b074f86b53e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7daf1615bf64212badeff54cd466033_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ce4bf905b02467b8dfd8172fa04331a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfd0d2a201514ed9a710f3e15a4be0ec_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf90ef381262457fb02ac15abe61db23_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ff8e585d8da4a4eadbb4f76e2229297_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bcb57d4e9ec41c3913ce6375172ce80_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1e1185e028b41649a95d8db0860d1ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab7551ae213f49089690e61c379022e7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i345e38b73d984ac7acfa140fc7af5a1a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3905fa6bad2f4f878b2411f148bf023a_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b10eb0c1f2944019b12df6a3c668f5b_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78d8e00c8ae5498c94772ed4b961f0bb_I20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc290352fb8049bea385a8284c77e6de_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b3c8791efbd4b76898c1f2be69fa04b_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aafae0ef97940e9afdb689e748f167a_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccd7845446c64a369164bb9ead8f5b59_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f13738b91a24ea68cfbd83444c1fda2_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i360c8f6cf0d349aa971816bd2ab768a8_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>insm:day</xbrli:measure></xbrli:unit><xbrli:context id="i677c8198ab1b4318bd9f81ef52a60fbd_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d34cc38f62945cc8de38c2b34b77333_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i120ab819124c4ec7955b853c7979a0e0_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie08ca784c1914a3d9e58680c070a1adb_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief82ea409318476187e7caeb47194f48_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbcdfbf9e8254e929522a467310b9522_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0d8b12165884f4ab863204524ec1168_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82d7c106dda746228e53977a22a4368f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94cb8d7603c84b26a3152ca2f217dbcf_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb904a2de5514e68a11f4cbaec8fa4d2_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e690606ed2949018b852163daddc302_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63fc774e8854431ba4eafe553558adf0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4043f106b7ff4d2aa5e7c93a3a3ae9cd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1861d72030824ced8ef920fa4c278220_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e74b1e1d79d4206a35bd3d6cae5a699_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5cf4cca2bb1485f813f9ef62c61797a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b9b0a45175146259bc231dc8f5ee5c6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i171123b4124b445eba208fcf196842fc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f2cf2d9e0294d689a5e13786a2e00a2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a78bc5894c84095aa559149f1fe6c13_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7b0a51fe15b40af849fca272f472e3a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i317c38eb43ca4b2da0d5950221ff472a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2c3209fc64e4317a4091a1502a77db1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91561c5c770b4119b0528f79d05ba9b9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47631aa0607443aa837dd0c862dfd781_I20190516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanThirdAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4fa2223aeb44fe2b0cdb87788b4adaf_D20200512-20200512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanThirdAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-12</xbrli:startDate><xbrli:endDate>2020-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5861a2f40e5462983cc26a47179e376_D20210512-20210512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanSecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-12</xbrli:startDate><xbrli:endDate>2021-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0288ec411bda42658bcabbda47913862_D20210512-20210512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanThirdAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-12</xbrli:startDate><xbrli:endDate>2021-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89ae304eebb24882b6d4e002897820e6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanThirdAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62d1dc130d494fe6805b85220bf3941a_I20180515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic196e790147b4d15a6d6b4c68f8a6472_D20180515-20180515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-15</xbrli:startDate><xbrli:endDate>2018-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib97d0fd95e2844cd80ddb0c2a4049481_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22331278b70c4d298ba0751f16fcf4b1_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab99f87cba69456faa7114cb972e768f_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ceb0c5b59ec456684a1a621d375db23_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i117be86acfcb4eebbf356e9bca57ec66_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3990da618f7430d9bbd1e66442f7851_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4386f9644da41bea1baa490a37085c2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a8cd663f8b34900a9dc46cfc889dbb2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d1f7158600c4c6fb173fb60e3b43c76_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dcac17f493744c29df2003d99cf399b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4249e6eea7944feab2165125682bd3e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id29b955148664a0eb00d37f9dc631961_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic006f1ab997e4bf98ba5840a6a977cfb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i700526f8aa8c42d3b0a44747d7347c9a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad0d6bd3de9743b49ef5056bd1b0629d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2574040e81cf45fdb63c1f0620c5cc9a_I20210804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfe80c21994c4bb9b647c882148aa2b8_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ff8bc31f64b484687adf08bd1e1364c_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:AlgaeneXIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07acd876919448939ae3e9671ddb5ce7_D20210524-20210524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-24</xbrli:startDate><xbrli:endDate>2021-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="days"><xbrli:measure>insm:days</xbrli:measure></xbrli:unit><xbrli:context id="ieb37f5b95f6243009bf267154d33f563_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncAndAlgaeneXIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i252108b308054887a46901fe227627f1_1"></div><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTky_32c12730-3d5b-46bc-ae1d-d78e7b184e23">10-Q</ix:nonNumeric> </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTg2_0bc43272-d0fd-462c-b99f-c9230f88b74a">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMjQ_2b21062c-d825-4a2e-ab5a-91cbd88b479d">June&#160;30, 2022</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTg3_77747433-7264-46c3-8d01-ff847232387a">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTg4_b718c4bf-045c-44b0-b34c-07273a5f4df3">000-30739</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTkz_18e16006-9641-496d-9271-d2bd24f2d366">INSMED INC</ix:nonNumeric>ORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.306%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YzBjMDhmZjllNDE4NGM3N2IzYjRlNzFhMDYwMDJjNzMvdGFibGVyYW5nZTpjMGMwOGZmOWU0MTg0Yzc3YjNiNGU3MWEwNjAwMmM3M18wLTAtMS0xLTI4OTQ3_835a6bb6-519c-45b8-9af5-4642329ee754">Virginia</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YzBjMDhmZjllNDE4NGM3N2IzYjRlNzFhMDYwMDJjNzMvdGFibGVyYW5nZTpjMGMwOGZmOWU0MTg0Yzc3YjNiNGU3MWEwNjAwMmM3M18wLTItMS0xLTI4OTQ3_b1ea255e-4ec2-47d5-91e8-fc38a091806c">54-1972729</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. employer identification no.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YzBjMDhmZjllNDE4NGM3N2IzYjRlNzFhMDYwMDJjNzMvdGFibGVyYW5nZTpjMGMwOGZmOWU0MTg0Yzc3YjNiNGU3MWEwNjAwMmM3M18zLTAtMS0xLTI4OTQ3L3RleHRyZWdpb246MGI3YWI4ODdlMDJlNDlmOTgwN2E5Zjg4MTNkYjg3OGFfNA_e48d7fae-5603-4002-bd50-a30e9a52e275">700 US Highway 202/206</ix:nonNumeric>,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YzBjMDhmZjllNDE4NGM3N2IzYjRlNzFhMDYwMDJjNzMvdGFibGVyYW5nZTpjMGMwOGZmOWU0MTg0Yzc3YjNiNGU3MWEwNjAwMmM3M180LTAtMS0xLTI4OTQ3L3RleHRyZWdpb246ZTkwZGMwNmUxYmI4NDI1ODk1NDk1MGMxN2Q0ZmYzMjRfNA_6524f075-9753-4669-9e02-de30a127bbfc">Bridgewater</ix:nonNumeric>, <ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YzBjMDhmZjllNDE4NGM3N2IzYjRlNzFhMDYwMDJjNzMvdGFibGVyYW5nZTpjMGMwOGZmOWU0MTg0Yzc3YjNiNGU3MWEwNjAwMmM3M180LTAtMS0xLTI4OTQ3L3RleHRyZWdpb246ZTkwZGMwNmUxYmI4NDI1ODk1NDk1MGMxN2Q0ZmYzMjRfOA_0a5d4cb4-2fd1-4b6f-be0c-d00ed5e52d43">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YzBjMDhmZjllNDE4NGM3N2IzYjRlNzFhMDYwMDJjNzMvdGFibGVyYW5nZTpjMGMwOGZmOWU0MTg0Yzc3YjNiNGU3MWEwNjAwMmM3M180LTItMS0xLTI4OTQ3_784514e2-666f-4c6b-9dff-6ea8e4d91a25">08807</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTk0_38788310-2aeb-4e48-ba37-c9959f32da38">908</ix:nonNumeric>) <ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTk1_27ff7f41-3811-4ae1-bc32-c9d037c7f8a9">977-9900</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number including area code)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section12(b) of the Act:</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.196%"><tr><td style="width:1.0%"></td><td style="width:36.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Trading symbols</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6NWQ0ZjAwNjc4ZGQzNDQ3YWFhODc4MGEwMjA3ZDdkNTMvdGFibGVyYW5nZTo1ZDRmMDA2NzhkZDM0NDdhYWE4NzgwYTAyMDdkN2Q1M18xLTAtMS0xLTI4OTQ3_a52c4db2-5f28-46b7-8ed5-981c55b9c850">Common stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6NWQ0ZjAwNjc4ZGQzNDQ3YWFhODc4MGEwMjA3ZDdkNTMvdGFibGVyYW5nZTo1ZDRmMDA2NzhkZDM0NDdhYWE4NzgwYTAyMDdkN2Q1M18xLTEtMS0xLTI4OTQ3_2e94bc3b-7127-486b-8e2f-7d7d4afe04d3">INSM</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6NWQ0ZjAwNjc4ZGQzNDQ3YWFhODc4MGEwMjA3ZDdkNTMvdGFibGVyYW5nZTo1ZDRmMDA2NzhkZDM0NDdhYWE4NzgwYTAyMDdkN2Q1M18xLTItMS0xLTI4OTQ3_2e17aae3-68d6-4a85-bfb1-f09762a11367">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;<ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTkw_5ebe2f1d-1138-4374-90e2-a167b3593773">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTg5_8453d5c2-5602-4657-bfbf-3990a4c9edef">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.306%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YmYwMjUxMDYyNTM2NGJmYjhhMTM2NWEzMmI1YjY2ZDgvdGFibGVyYW5nZTpiZjAyNTEwNjI1MzY0YmZiOGExMzY1YTMyYjViNjZkOF8wLTAtMS0xLTI4OTQ3L3RleHRyZWdpb246M2EyZjFhYjAwOTc0NDZlOGEzN2E1Zjc0Y2RlMmU2YzBfNQ_c65d3dc0-839c-48e2-9505-239bb58482a0">Large accelerated filer</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">o</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller reporting company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YmYwMjUxMDYyNTM2NGJmYjhhMTM2NWEzMmI1YjY2ZDgvdGFibGVyYW5nZTpiZjAyNTEwNjI1MzY0YmZiOGExMzY1YTMyYjViNjZkOF8yLTItMS0xLTI4OTQ3L3RleHRyZWdpb246YzE0NGM3MjhkNzE4NDEzZWI5NGM2NmJkZDBiNzhmYzBfMzE_7ed4af81-67ef-480d-84bc-3780a23034fb">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YmYwMjUxMDYyNTM2NGJmYjhhMTM2NWEzMmI1YjY2ZDgvdGFibGVyYW5nZTpiZjAyNTEwNjI1MzY0YmZiOGExMzY1YTMyYjViNjZkOF8zLTAtMS0xLTI4OTQ3L3RleHRyZWdpb246ZWIwMjhhNjFhOTQyNDIzOTkwNTAyNThjOTM1ZmI0MmVfMjk_49c50227-76e1-4af5-a53c-ca41a30c2be9">&#9744;</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTkx_fb037ed5-fa85-4925-9b22-c3bc8d58f19a">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of August&#160;1, 2022, there were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie4a1faee4d59482ea066bbdc84f02467_I20220801" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTMw_17709b47-5be5-41d2-ae04-69ec3a236d03">119,975,265</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">hares of the registrant&#8217;s common stock outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i252108b308054887a46901fe227627f1_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTER ENDED JUNE&#160;30, 2022 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_10">PART&#160;I.&#160;&#160;FINANCIAL&#160;INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_13">ITEM 1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_16">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_16">Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_16">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_16"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_16">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_16">, 2022 (unaudited) and December&#160;31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_16">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_19">Consolidated Statements of Comprehensive Loss (unaudited) for the three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_19"> and six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_19"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_19">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_19"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_19">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_19">, 2022 and&#160;2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_19">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_22">Consolidated Statements of Shareholders' Equity (unaudited) for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_22">and six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_22">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_22">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_22"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_22">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_22">, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_22">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_25">Consolidated Statements of Cash Flows (unaudited) for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_25">six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_25">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_25">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_25">, 2022 and&#160;2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_25">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_28">Notes to Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_28">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_73">ITEM 2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_73">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_91">ITEM 3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_91">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_91">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_94">ITEM 4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_94">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_94">39</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_97">PART&#160;II.&#160;&#160;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_100">ITEM 1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_100">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_100">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_103">ITEM 1A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_103">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_103">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_106">ITEM 2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_106">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_106">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_109">ITEM 5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_109">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_109">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_112">ITEM 6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_112">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_112">40</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_115">SIGNATURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_115">41</a></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise indicates, references in this Form&#160;10-Q to &#8220;Insmed Incorporated&#8221; refers to Insmed Incorporated, a Virginia corporation, and &#8220;Company,&#8221; &#8220;Insmed,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Insmed Incorporated together with its consolidated subsidiaries. INSMED, PULMOVANCE, ARIKARES and ARIKAYCE are trademarks of Insmed Incorporated. This Form&#160;10-Q also contains trademarks of third parties. Each trademark of another company appearing in this Form&#160;10-Q is the property of its owner.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i252108b308054887a46901fe227627f1_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I.&#160; FINANCIAL INFORMATION</span></div><div id="i252108b308054887a46901fe227627f1_13"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i252108b308054887a46901fe227627f1_16"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except par value and share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNS0xLTEtMS0yODk0Nw_2607d978-9e38-4605-8b3f-9b1b677d7da5">416,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNS0zLTEtMS0yODk0Nw_6d4391c8-125a-4190-b427-286a841c2c2d">716,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNi0xLTEtMS0yODk0Nw_74e8d0ec-f015-4645-bdf3-78823ca1cdbe">138,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNi0zLTEtMS0yODk0Nw_997c90ed-099c-417f-90fe-814d168c53c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNy0xLTEtMS0yODk0Nw_86fdc309-78e7-40a7-b69a-4527bf627ea2">29,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNy0zLTEtMS0yODk0Nw_b3277476-eb3c-42ee-8985-c9498e582fff">24,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfOC0xLTEtMS0yODk0Nw_dce60381-2d1b-4bdd-956a-99ffa89fd6de">67,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfOC0zLTEtMS0yODk0Nw_f37d7ad6-e1d4-4b90-bcb4-ce73a68c42c5">67,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfOS0xLTEtMS0yODk0Nw_ef777c84-0abf-4fce-8829-d8a4f0aa4c37">23,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfOS0zLTEtMS0yODk0Nw_be4e34be-591b-4c22-830e-782701264264">28,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTAtMS0xLTEtMjg5NDc_519448f9-2a4c-475a-ad36-87aaf766bd93">674,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTAtMy0xLTEtMjg5NDc_1b35fe0c-7bb8-452d-91b3-4e8967d9e933">837,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTEtMS0xLTEtMjg5NDc_02a9d2c7-3c6b-4df1-bf4c-0230bc4990f7">9,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTEtMy0xLTEtMjg5NDc_d1d6b7ff-435e-4762-a6ac-028765ecc39a">50,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTItMS0xLTEtMjg5NDc_729a892b-1bd2-42f8-9797-176737015252">53,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTItMy0xLTEtMjg5NDc_67a64dc6-e86d-4a1a-a03b-d0ad4d3e8158">52,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTMtMS0xLTEtMjg5NDc_f6f20b56-e94d-41cb-b858-a9db92945a18">17,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTMtMy0xLTEtMjg5NDc_a683d5bb-8134-49d2-bc84-29779affaf1a">9,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTQtMS0xLTEtMjg5NDc_283dab01-082e-49b4-8d4c-d372b72c2372">24,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTQtMy0xLTEtMjg5NDc_d9e368e9-fe22-4365-8618-f8c225232dca">33,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTUtMS0xLTEtMjg5NDc_3b4641ac-3c2e-4204-98ae-259d1d659136">71,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTUtMy0xLTEtMjg5NDc_8a4215f1-9116-404b-956a-2a1768c15a28">73,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTYtMS0xLTEtMjg5NDc_1c42c9e6-a7b3-4c77-a2f6-c4cd0d99298d">136,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTYtMy0xLTEtMjg5NDc_b04c629f-9acc-4e2c-9b0d-c653fe1fae7c">136,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTctMS0xLTEtMjg5NDc_ecef1028-d787-4e71-a12f-c5134e93a934">66,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTctMy0xLTEtMjg5NDc_7de19b3a-7058-45f4-8bed-375ea45ae437">50,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTgtMS0xLTEtMjg5NDc_f341414f-1931-494f-a5c4-cf7afc7f5e84">1,053,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTgtMy0xLTEtMjg5NDc_493ab6c4-3069-478a-9e6b-c3377b580cd6">1,243,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjItMS0xLTEtMjg5NDc_001c8b3f-dcbb-4074-8e31-4beceecc0739">31,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjItMy0xLTEtMjg5NDc_11f64916-af7d-40d2-a7a5-8d1364bf0d06">35,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjMtMS0xLTEtMjg5NDc_7898c60b-cad2-4df7-9432-e297db5f6c41">58,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjMtMy0xLTEtMjg5NDc_fe15fd8b-f900-44ab-b8e6-dde47423404f">60,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjQtMS0xLTEtMjg5NDc_186e1a1e-f429-4086-b488-4f724e8fb2bb">18,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjQtMy0xLTEtMjg5NDc_a59fd840-150a-4e8f-979c-71114a10d6bc">28,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjUtMS0xLTEtMjg5NDc_a5359e0b-cd5a-499d-97cd-1edf7183d52a">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjUtMy0xLTEtMjg5NDc_72c3f204-ee05-43c6-888e-040b0c0a4c24">609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjYtMS0xLTEtMjg5NDc_cf8dcc88-6fdd-428d-93db-082c50eedd6a">5,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjYtMy0xLTEtMjg5NDc_22f644ea-c089-41c4-b6c3-1ed253b7c099">9,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjgtMS0xLTEtMjg5NDc_283ae226-a5f8-45c4-b77a-6fc89483381f">113,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjgtMy0xLTEtMjg5NDc_8b818aed-4d7e-4441-9a1c-996f734105ad">135,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzAtMS0xLTEtMjg5NDc_d5c4856f-7d1b-40df-a8d7-2957e6fd9ff2">783,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzAtMy0xLTEtMjg5NDc_fd34ccff-85c1-41d7-a716-dc8eb5e59aba">566,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzEtMS0xLTEtMjg5NDc_782248ed-910c-4440-a091-3a910a59f282">55,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzEtMy0xLTEtMjg5NDc_b5526629-6953-460a-aa56-3d538770f963">75,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, long-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzItMS0xLTEtMjg5NDc_12bfb070-e241-490a-a609-c398db53b8c2">23,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzItMy0xLTEtMjg5NDc_1f8edf7e-372d-40b1-a53d-c9c907d95b52">14,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzMtMS0xLTEtMjg5NDc_89f9f658-ae64-4a0b-b3d6-dc6135deaf99">18,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzMtMy0xLTEtMjg5NDc_423342fd-cd66-48a5-ba6a-42c3cc588145">21,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzQtMS0xLTEtMjg5NDc_a4fd8955-589d-450b-9cd3-cb7fdc0a91fd">14,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzQtMy0xLTEtMjg5NDc_e4016cb8-2fae-4207-9cb6-c4bcc8d6b28f">20,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzUtMS0xLTEtMjg5NDc_92a49199-4681-4591-a533-e3d9b68f2eaf">1,009,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzUtMy0xLTEtMjg5NDc_1887eda9-dace-4035-a5af-27eb3135dd7c">833,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjozNjJkNGRiMmYxNzI0YTUzODNmODkyZDdkNzkwNzFkZl8xOQ_02a54711-a8d6-4461-bdb5-ac1cb6140bfc"><ix:nonFraction unitRef="usdPerShare" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjozNjJkNGRiMmYxNzI0YTUzODNmODkyZDdkNzkwNzFkZl8xOQ_09943df4-af85-4a52-966c-c0153d483c7f">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjozNjJkNGRiMmYxNzI0YTUzODNmODkyZDdkNzkwNzFkZl8zMw_5e0eb7d8-b73f-4435-8353-8f607af64de7"><ix:nonFraction unitRef="shares" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjozNjJkNGRiMmYxNzI0YTUzODNmODkyZDdkNzkwNzFkZl8zMw_bfc7e49e-881b-47a6-89ca-ef9745c871c5">500,000,000</ix:nonFraction></ix:nonFraction> authorized shares, <ix:nonFraction unitRef="shares" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjozNjJkNGRiMmYxNzI0YTUzODNmODkyZDdkNzkwNzFkZl81NQ_c7a5ba9f-5658-4a68-ac35-45d33f60cd72"><ix:nonFraction unitRef="shares" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjozNjJkNGRiMmYxNzI0YTUzODNmODkyZDdkNzkwNzFkZl81NQ_f38db630-3ce8-4e52-a794-163cdf534116">119,865,023</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjozNjJkNGRiMmYxNzI0YTUzODNmODkyZDdkNzkwNzFkZl82Mg_531c17c8-e51a-46e6-804f-1ee4be74ac96"><ix:nonFraction unitRef="shares" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjozNjJkNGRiMmYxNzI0YTUzODNmODkyZDdkNzkwNzFkZl82Mg_8b4165be-5b62-4ccd-ad2f-53f5aa6246c3">118,738,266</ix:nonFraction></ix:nonFraction> issued and outstanding shares at June&#160;30, 2022 and December&#160;31, 2021,&#160;respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMS0xLTEtMjg5NDc_e6f89a71-beab-4b05-ab18-4acf14d1ef25">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMy0xLTEtMjg5NDc_8edf0abc-564f-44d6-92b1-692d3b2ebc23">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzktMS0xLTEtMjg5NDc_4bdd8660-b253-4e0f-8df7-49303c9cb445">2,449,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzktMy0xLTEtMjg5NDc_9d9d0de2-e432-4a6f-bb3b-656c82df8cf7">2,673,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNDAtMS0xLTEtMjg5NDc_5086bc59-4daa-4c85-b505-5a6906728963">2,405,310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNDAtMy0xLTEtMjg5NDc_7ec45b1b-68e8-47c1-9397-cf1ea0b237bd">2,265,243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNDEtMS0xLTEtMjg5NDc_5c7b1e5c-65be-418a-a309-d9df1b4e3773">929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNDEtMy0xLTEtMjg5NDc_5b620085-b866-4aad-98ac-f4b380f2e13a">968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNDItMS0xLTEtMjg5NDc_784d9799-107b-4937-96b0-e1ad00741142">44,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNDItMy0xLTEtMjg5NDc_99adaaca-667d-4d5d-a939-9947d0c627a3">410,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNDMtMS0xLTEtMjg5NDc_c81aa444-817b-40f2-9dbe-5390b16fe86c">1,053,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNDMtMy0xLTEtMjg5NDc_09af7ee3-443b-44b8-8685-494e5f7dbd61">1,243,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i252108b308054887a46901fe227627f1_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> INSMED INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy0wLTEtMS0yODk0Nw_5170a57a-1eda-4542-9bcc-d9f790c05e2e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy0wLTEtMS0yODk0Nw_5fbc7803-cbbe-4bcb-b5af-540dd0804389"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy0wLTEtMS0yODk0Nw_62156160-2395-4d30-a04e-38d15c472e4f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy0wLTEtMS0yODk0Nw_71b55fa8-736f-46bf-86da-41456bd986cc">Product revenues, net</span></span></span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy0xLTEtMS0yODk0Nw_5eb8c872-b53d-405a-b1b0-46167ccad53a">65,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy0zLTEtMS0yODk0Nw_828985a2-6d8f-45e4-901d-6adc80edd6bc">45,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy01LTEtMS0yODk0Nw_8784e0c1-acf3-4219-b31b-272ac357a091">118,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy03LTEtMS0yODk0Nw_10615e32-b248-4bb4-91a9-fc775e1f69e8">85,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi0wLTEtMS0yODk0Nw_2e37e237-166c-4368-81f8-ac870cd6c5b4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi0wLTEtMS0yODk0Nw_4aef5557-06f5-48ae-8810-c00dfa86ec5a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi0wLTEtMS0yODk0Nw_e533229d-73dc-4061-a116-6e06fda709bc"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi0wLTEtMS0yODk0Nw_ff82a8a8-fd7a-4c2e-a1b3-ebc868884937">Cost of product revenues (excluding amortization of intangible assets)</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi0xLTEtMS0yODk0Nw_1e4f82f8-f3ea-4d1b-886d-58e23448088c">16,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi0zLTEtMS0yODk0Nw_610fbdb7-b7df-48f0-a8f1-76a00ccf2ed9">10,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi01LTEtMS0yODk0Nw_47aa1eb1-99f4-4c3a-a434-806aea5bab4f">28,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi03LTEtMS0yODk0Nw_1f5dcd2e-0f4c-4c67-8935-9f9168bc1d66">20,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNy0xLTEtMS0yODk0Nw_9e1837e3-139e-483a-bd0f-d9d9ba66662d">88,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNy0zLTEtMS0yODk0Nw_4fa44974-2e4a-4728-a970-2768aa7e12af">64,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNy01LTEtMS0yODk0Nw_59ecc59a-be4b-49b7-a8da-c80aaa74dff8">172,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNy03LTEtMS0yODk0Nw_6d5a6623-d72e-4889-a34d-3692c157e54a">126,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfOC0xLTEtMS0yODk0Nw_63512397-313e-4844-8b98-0785848429c0">59,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfOC0zLTEtMS0yODk0Nw_98566766-0aa5-4d3a-9ed0-a1e8c2b6f430">57,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfOC01LTEtMS0yODk0Nw_f3260863-2e28-466a-867f-b5f46944da93">116,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfOC03LTEtMS0yODk0Nw_e2d5da28-7ccd-447d-86fb-dc31bdbc7548">108,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfOS0xLTEtMS0yODk0Nw_9f018b8c-940a-4584-85b8-8c820d6ba38c">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfOS0zLTEtMS0yODk0Nw_83b671d5-2f73-4f3b-8fbb-3541fea1cc44">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfOS01LTEtMS0yODk0Nw_8cb76d76-4401-48ef-8bc4-f9405a05dd49">2,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfOS03LTEtMS0yODk0Nw_311b0432-3fe8-409c-b41b-2638174983c9">2,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of deferred and contingent consideration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTAtMS0xLTEtMjg5NDc_42bf965d-c924-4470-91f7-cf5bd0afd563">12,622</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTAtMy0xLTEtMjg5NDc_1e2d7435-8981-4f14-a3fb-53204a3838be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTAtNS0xLTEtMjg5NDc_6a45110a-cc7f-4b55-b27a-7a43adc11a3d">24,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTAtNy0xLTEtMjg5NDc_a2eeb2d3-583c-4001-b143-7eefd487b4cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTEtMS0xLTEtMjg5NDc_d4f9a2cc-9cf8-4626-ab6c-65d7b1dea1b0">153,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTEtMy0xLTEtMjg5NDc_1675706f-4e9f-4c54-97da-f66252a86d08">133,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTEtNS0xLTEtMjg5NDc_1b57b459-6258-4ebc-9b16-41ec7f7047c5">296,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTEtNy0xLTEtMjg5NDc_17361646-39dc-4f39-82dc-6732056042c0">257,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTMtMS0xLTEtMjg5NDc_1c42ff09-c43a-4154-9f7d-d80914921d50">88,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTMtMy0xLTEtMjg5NDc_0a9aed5f-bcd5-4a05-9003-47c00b1cbcf4">88,566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTMtNS0xLTEtMjg5NDc_690bdf7f-e7ce-4a58-b1b6-5cbccfeed57a">178,149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTMtNy0xLTEtMjg5NDc_eb66289d-19df-4973-918e-630b76b63ca6">172,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTUtMS0xLTEtMjg5NDc_67917a64-5344-4172-9733-9810da2f6149">835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTUtMy0xLTEtMjg5NDc_0cf1a375-7834-456d-b0f7-22611cbc9542">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTUtNS0xLTEtMjg5NDc_65094417-6831-4848-a10d-106ca581b331">972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTUtNy0xLTEtMjg5NDc_1152de5d-2203-457c-bbf7-bf7b303608ab">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTYtMS0xLTEtMjg5NDc_ce858a20-8454-4b90-9b80-019057f3f7ab">3,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTYtMy0xLTEtMjg5NDc_1cfb2d66-430f-41cd-81a9-bfaa5c5f1697">10,319</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTYtNS0xLTEtMjg5NDc_3f69f05d-bd17-4136-b718-26e578d94011">6,648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTYtNy0xLTEtMjg5NDc_8975a307-450d-4db9-8b12-57a3c83abdb0">17,878</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTctMS0xLTEtMjg5NDc_4bd26852-4abc-41b4-b4f3-ebd4126e4d2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTctMy0xLTEtMjg5NDc_14bcc9cf-79f8-42fa-9211-702670445c90">17,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTctNS0xLTEtMjg5NDc_14d1cbd1-7796-4b27-9d5e-9111b803c196">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTctNy0xLTEtMjg5NDc_f17b4f7e-2f5b-4599-9865-55ddd6eddc4c">17,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTgtMS0xLTEtMjg5NDc_3486a701-a5a0-4745-a1d3-64666639b880">4,306</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTgtMy0xLTEtMjg5NDc_294c42b7-35b7-45fc-8940-583ef3ae227a">159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTgtNS0xLTEtMjg5NDc_e8b2d1ec-c80c-411a-b957-11895273a09a">5,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTgtNy0xLTEtMjg5NDc_8e0a65ed-08cc-4730-af07-6818697ce23e">202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTktMS0xLTEtMjg5NDc_dac6ff35-aceb-4c7d-83ab-9e1851fe6ec2">95,144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTktMy0xLTEtMjg5NDc_761ec55c-d30d-4d1b-b02d-4c3227114ce3">116,699</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTktNS0xLTEtMjg5NDc_c1e16dd0-9496-46df-a2c7-26f83fe4466b">189,380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTktNy0xLTEtMjg5NDc_bfbdc243-9593-47b9-a89d-12ea610047ef">208,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjEtMS0xLTEtMjg5NDc_bf882885-3aa7-4b6a-b64d-a8f500dff3ff">501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjEtMy0xLTEtMjg5NDc_cb7b2320-4f1b-455a-b584-f7a69855a51a">622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjEtNS0xLTEtMjg5NDc_722171e4-9e17-4774-8744-dff8b0f6715d">886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjEtNy0xLTEtMjg5NDc_6ec08203-889c-462c-9d6c-f9e06cbf51cd">861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjMtMS0xLTEtMjg5NDc_e4f1733a-ea25-4ba5-a990-9614741ba606">95,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjMtMy0xLTEtMjg5NDc_9d0c7e03-3f33-4e32-8ca6-d82a22f2cd38">117,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjMtNS0xLTEtMjg5NDc_0fa2d9c5-6144-4afa-ad85-7d421ed131e7">190,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjMtNy0xLTEtMjg5NDc_0eec960d-5b3f-42a1-876e-ede6f0e000b5">208,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjUtMS0xLTEtMjg5NDc_158cf2be-137e-443c-9177-c66c4b20a62c"><ix:nonFraction unitRef="usdPerShare" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjUtMS0xLTEtMjg5NDc_d9d6b2cd-ece6-4507-b60d-602d23b2bd36">0.80</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjUtMy0xLTEtMjg5NDc_eb23f72c-ed77-429c-86b3-f4d621d3c29c"><ix:nonFraction unitRef="usdPerShare" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjUtMy0xLTEtMjg5NDc_fce503b7-520d-41ce-8082-568827a7d801">1.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjUtNS0xLTEtMjg5NDc_ae60624a-6caf-45a8-ab2f-271392cb2a1d"><ix:nonFraction unitRef="usdPerShare" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjUtNS0xLTEtMjg5NDc_dcfe8ea5-6517-46de-bb88-6c78ffd31d7c">1.60</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjUtNy0xLTEtMjg5NDc_0b72783b-0c9f-48e0-8519-71114bd82987"><ix:nonFraction unitRef="usdPerShare" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjUtNy0xLTEtMjg5NDc_cd37c5b0-2b10-49bf-b88a-d3322a2bb84d">1.97</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average basic and diluted common shares&#160;outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjctMS0xLTEtMjg5NDc_30e62dbe-a9b8-4112-af03-fff7f7109a9e"><ix:nonFraction unitRef="shares" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjctMS0xLTEtMjg5NDc_4ce10b2f-b028-41b6-bfb0-ea319a2db242">119,602</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjctMy0xLTEtMjg5NDc_36612006-4d48-47eb-9074-e011af665b78"><ix:nonFraction unitRef="shares" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjctMy0xLTEtMjg5NDc_6a11d76b-a1dc-452e-9300-423620700251">109,580</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjctNS0xLTEtMjg5NDc_c515cb85-9b6a-4f13-b33c-aa17bfe62b1b"><ix:nonFraction unitRef="shares" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjctNS0xLTEtMjg5NDc_e267c423-ce4c-4049-8afa-566243b08276">119,267</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjctNy0xLTEtMjg5NDc_0f7c6f19-55d2-4394-9823-8cc932be5782"><ix:nonFraction unitRef="shares" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjctNy0xLTEtMjg5NDc_a131d3fe-d527-4cae-90be-dec09f4ce3a5">106,328</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjktMS0xLTEtMjg5NDc_98b05ce8-0065-492a-b35b-113be52524e1">95,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjktMy0xLTEtMjg5NDc_710b699f-0c80-4bf4-8fe9-2912e01ac502">117,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjktNS0xLTEtMjg5NDc_4a6756cf-3b00-4bed-a248-3201583f3b55">190,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjktNy0xLTEtMjg5NDc_c2eef02d-3948-4a92-91c3-48a73854b96a">208,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzEtMS0xLTEtMjg5NDc_9003deb3-88b9-4b89-8c2f-076d536c9f8d">208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzEtMy0xLTEtMjg5NDc_495488c1-96dc-46a7-b9d4-14ba9bfd6ac6">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzEtNS0xLTEtMjg5NDc_53fbcb38-9bbc-4f73-b935-28e5bdabab0f">702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzEtNy0xLTEtMjg5NDc_affc55ca-c084-497d-9fab-57b3faefc3e4">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzItMS0xLTEtMjk1ODM_607fa55e-564e-4b63-ac08-9cc22a0c97d8">491</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzItMy0xLTEtMjk1ODM_dac74579-6c82-4431-bf0c-f02a509f33d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzItNS0xLTEtMjg5NDc_824388b6-0f37-4db9-8ed5-b61246d18caa">1,195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzItNy0xLTEtMjg5NDc_965a4071-7e38-4846-b77c-d020c0a00201">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzMtMS0xLTEtMjg5NDc_6b43c904-33d0-4718-9944-68abe064de65">96,344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzMtMy0xLTEtMjg5NDc_d9e42c9f-98c2-4800-ae09-1fdbeb3c2892">116,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzMtNS0xLTEtMjg5NDc_a1849e6e-b288-4870-9b98-7251d840a22d">192,163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzMtNy0xLTEtMjg5NDc_7c75ae95-7896-41e6-956d-b8741a35c6a2">208,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i252108b308054887a46901fe227627f1_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Shareholders' Equity (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated <br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i164351f40c6a48a5bce7be7cbbb95393_I20210331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMi0xLTEtMS0yODk0Nw_9a912101-e02f-46fe-b02c-99df63c65c54">103,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164351f40c6a48a5bce7be7cbbb95393_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMi0zLTEtMS0yODk0Nw_65891b08-c7ad-4ac8-ab39-6a6d780bd558">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefa9467fe6ae4ae7be463ef02bd03331_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMi01LTEtMS0yODk0Nw_6c0de8ba-3dcb-4d3a-9294-fd840c86a6cf">2,122,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35baa1a10636413abb12d0a528eb7da0_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMi03LTEtMS0yODk0Nw_eb8ab600-a6dc-45b2-af18-f2e80536731f">1,922,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74180eb633f24734a1c4c9c66a934ef6_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMi05LTEtMS0yODk0Nw_cdf14b1a-0aa0-4c24-970b-b3149c5ba02d">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d1bd5fb1694a178730b0cd705a3cd4_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMi0xMS0xLTEtMjg5NDc_cf5c8757-ca55-4ed4-a600-5781f2311f0b">201,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2de1a6fdaa74c7cade5245529b85f53_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNC03LTEtMS0yODk0Nw_4858d488-3cff-4ac2-907f-cbbd529ade10">117,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNC0xMS0xLTEtMjg5NDc_befa90b5-74a7-4533-a90f-3eaf6c389e28">117,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828764c93d1d45929aa04ca248ea4fad_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNS05LTEtMS0yODk0Nw_18843314-8ed3-4534-9fbd-96bcf562cadc">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNS0xMS0xLTEtMjg5NDc_da8e5bf2-8b8c-4304-93c4-12bface5df34">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options and ESPP shares issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if48dc576429648f1a4016567fa86b396_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNi0xLTEtMS0yODk0Nw_0a332534-ef31-4a92-b1af-6e57aef8a79e">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if48dc576429648f1a4016567fa86b396_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNi0zLTEtMS0yODk0Nw_25606f8e-fcb5-4aa9-918b-f523cd70ffd3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac8060b82014b21b0613cda3d7a60c6_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNi01LTEtMS0yODk0Nw_54c3a0aa-96b7-4e38-b064-80f6e1485bda">6,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNi0xMS0xLTEtMjg5NDc_7d75de0d-10f9-494c-8c46-ba228df11f86">6,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if48dc576429648f1a4016567fa86b396_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNy0xLTEtMS0yOTUyNw_d187f8c0-b27f-475a-a439-7458760474f4">11,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if48dc576429648f1a4016567fa86b396_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNy0zLTEtMS0yOTUyNw_186bd324-78a4-4abb-93fa-2f4df6ee8591">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac8060b82014b21b0613cda3d7a60c6_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNy01LTEtMS0yOTUyNw_252ec528-4991-486c-bde5-c13c12faafed">269,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNy0xMS0xLTEtMjk1Mjc_5c619c67-a9b9-456f-9fbd-8fc91631b063">269,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity component of convertible debt issuance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac8060b82014b21b0613cda3d7a60c6_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOC01LTEtMS0yOTUyNw_87514ee6-ed12-4f31-bb51-f016ba2c432b">196,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOC0xMS0xLTEtMjk1Mjc_4891c124-e0e7-4fcb-8d81-4e8f42412097">196,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity component of convertible debt redemption</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ac8060b82014b21b0613cda3d7a60c6_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOS01LTEtMS0yOTUyNw_8eef3d72-67c6-4405-820a-0c83b92dfe91">37,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOS0xMS0xLTEtMjk1Mjc_53277b78-bd8f-453e-a376-b3914a203929">37,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for vesting of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if48dc576429648f1a4016567fa86b396_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOC0xLTEtMS0yODk0Nw_0e4352cd-c6cf-41d2-a1be-99c2cded6806">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if48dc576429648f1a4016567fa86b396_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOC0zLTEtMS0yODk0Nw_5ec82b09-10da-4598-8fae-70dee788f98a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOC0xMS0xLTEtMjg5NDc_1a5196a1-6ae8-44a4-bcc3-17967cfbd471">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac8060b82014b21b0613cda3d7a60c6_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOS01LTEtMS0yODk0Nw_dca457c3-885e-4ee5-8e41-fd836d094a5b">11,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOS0xMS0xLTEtMjg5NDc_93f6465f-2f41-48f8-ab68-c71c634bf398">11,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55f0b2b681c841419600222a85ea3546_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTAtMS0xLTEtMjg5NDc_a1fb58aa-4061-4a41-a2f2-76e4a5289439">115,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f0b2b681c841419600222a85ea3546_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTAtMy0xLTEtMjg5NDc_eb4273a2-aff4-4424-88fe-05f884a589a4">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3276d1a28daa4225b9fcdb3cc08af201_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTAtNS0xLTEtMjg5NDc_58c227e4-65e4-45fc-ae6e-6cdf74c86fdc">2,569,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd691c6a90574493ba24a86f882bb91a_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTAtNy0xLTEtMjg5NDc_3fabade6-ac22-4673-8c27-caa986f211e9">2,039,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24591cad2f4544ef997c8b46679d9352_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTAtOS0xLTEtMjg5NDc_1629403e-ae65-4bca-b325-37d792795828">424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34b29fd1e2a04660a3bb612c3f24dde5_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTAtMTEtMS0xLTI4OTQ3_70d599e6-f25d-4c59-8a7b-0d102acd3fe8">531,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06b533b795524ae29ed13dc8973a1aba_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTItMS0xLTEtMjg5NDc_dee403fc-bd49-4f9b-881d-9d5053e22b5b">119,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b533b795524ae29ed13dc8973a1aba_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTItMy0xLTEtMjg5NDc_35d9db2f-052d-4323-b200-7ea485e1a77e">1,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia867ec38918e444f8e2d1d14ce332ec5_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTItNS0xLTEtMjg5NDc_3acdcece-2ebe-409a-97ca-0b99482679ba">2,428,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f812dff96b74536ae44f954590aa428_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTItNy0xLTEtMjg5NDc_5fe0ebb8-09ec-477a-b870-65fe3b56783d">2,309,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie86bfdf9f6d24ddfa8e132dc25af8978_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTItOS0xLTEtMjg5NDc_4ce34e48-965b-474a-a63f-8b13e19eef9f">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c0613ed6dde4e01bc2b4e47830856f9_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTItMTEtMS0xLTI4OTQ3_36ee53b3-a7c5-47dd-bf75-6dd9d8c25e9f">119,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d40fdfd16fc451fb491730b4a9173d4_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTUtNy0xLTEtMjg5NDc_7d68817a-9da4-4858-a1bf-2210565777bb">95,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTUtMTEtMS0xLTI4OTQ3_954ce802-ef2f-4776-bb0a-e0cb915f7d0c">95,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9db84f87eeb341579e4fe91899a2f3f5_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTYtOS0xLTEtMjg5NDc_73e81f4e-662c-4195-8e84-6c7f0cd67231">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTYtMTEtMS0xLTI4OTQ3_e0631ee6-e1a0-414f-bba0-a2ca0177c82e">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options and ESPP shares issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c724ef416fd4b8d83a5292521f39be3_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTctMS0xLTEtMjg5NDc_2f18c458-5f89-44bd-a76a-297cd6104d98">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c724ef416fd4b8d83a5292521f39be3_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTctMy0xLTEtMjg5NDc_bab606f0-6853-45be-9e9a-0f0ca829e654">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ccd6a0b87204d16adb14a3d22bcda4e_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTctNS0xLTEtMjg5NDc_83df2f15-58be-429d-89e9-f58618151c4a">6,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTctMTEtMS0xLTI4OTQ3_10dd6cb3-2d59-41d6-ab69-4fa979d3cfc1">6,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for vesting of RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c724ef416fd4b8d83a5292521f39be3_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjAtMS0xLTEtMjg5NDc_8b9198b2-926c-498f-add0-50aa7db7bbc4">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c724ef416fd4b8d83a5292521f39be3_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjAtMy0xLTEtMjg5NDc_4fd6cc88-fd74-45fd-b562-35d070a4777c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjAtMTEtMS0xLTI4OTQ3_2bbd6a35-d37f-40a9-b7f5-707206c5f264">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ccd6a0b87204d16adb14a3d22bcda4e_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjItNS0xLTEtMjg5NDc_4952457c-2984-49dd-a4c1-d3f5f8785c12">14,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjItMTEtMS0xLTI4OTQ3_e8dc9a8e-d35d-40ae-8a68-f3d5f7f97a0d">14,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0182cad036cc492c902e8768cc1bdc6a_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjMtMS0xLTEtMjg5NDc_83789d39-1b78-4a9c-98e7-a5491e984986">119,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0182cad036cc492c902e8768cc1bdc6a_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjMtMy0xLTEtMjg5NDc_13503e48-bb45-4d40-bf27-d75ad3cf2b45">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f7e3e3f5c7949eb926f4685e8a1dd75_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjMtNS0xLTEtMjg5NDc_2a684dbb-1f3c-4e1a-9329-3f68227ddb28">2,449,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b176cdccb74943960953e16068e6a8_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjMtNy0xLTEtMjg5NDc_35b68540-f65c-40d9-ade8-dcb615d27ffb">2,405,310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadd45892aa3342cbbeff3a291a11105b_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjMtOS0xLTEtMjg5NDc_65f1587e-531d-4fd2-a224-04faba197761">929</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjMtMTEtMS0xLTI4OTQ3_a0ab27f0-9a44-48f1-81ee-808ceefc77d6">44,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Shareholders' Equity (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated <br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ea404b9803f4458944b7dbf3eefe5d8_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMi0xLTEtMS0yOTM0Ng_864de8f7-ec30-4277-ac3c-760dac715873">102,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ea404b9803f4458944b7dbf3eefe5d8_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMi0zLTEtMS0yOTM0Ng_80545474-fde5-4e55-af0d-b2e89a212bff">1,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f49f20915e465aa2c3491edb04f079_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMi01LTEtMS0yOTM0Ng_bbdaf47f-1997-4bcd-911f-d470c865b0a4">2,105,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b6083ac1b4641ee80d7fbb9322f6ff4_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMi03LTEtMS0yOTM0Ng_ec421382-5f6e-41d1-8793-f4bd94e83fcb">1,830,589</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3240a301c3b4a8092fcd0ff21adb6f8_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMi05LTEtMS0yOTM0Ng_8daa9875-f4dc-4eec-91c9-a174bcd99e82">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic11e1e3142e048009002fc987716b4e8_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMi0xMS0xLTEtMjkzNDY_2e5738c5-ff15-44b5-a87d-777514183978">275,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6afe0edb9cc44adca52bd18a9cba27db_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNC03LTEtMS0yOTM0Ng_af6ad58c-c957-4451-97c2-7497affe8e91">208,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNC0xMS0xLTEtMjkzNDY_52b9600b-d3c9-43fe-9bc8-aa83307ffff5">208,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d76fce0871a49f997118895b8cc5d9e_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNS05LTEtMS0yOTM0Ng_749af3a2-9929-4f60-a04e-981d4d87b2e8">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNS0xMS0xLTEtMjkzNDY_eccde558-eb00-4d6a-96ca-8d8d5285bf91">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options and ESPP shares issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i048e3b2eae994f98967e9743c0322e99_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNi0xLTEtMS0yOTM0Ng_5b901eb8-33c2-4cb1-876b-909e59e49dc3">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048e3b2eae994f98967e9743c0322e99_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNi0zLTEtMS0yOTM0Ng_dbc46183-dc27-463d-82d6-8a40580026ba">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0471829afd7d49ec8d77526fcd9e579e_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNi01LTEtMS0yOTM0Ng_d78ca729-f808-4c20-b0a2-f4fa8801840d">13,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNi0xMS0xLTEtMjkzNDY_11c66d28-51e7-4267-8d0b-03b4a48f2aa2">13,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i048e3b2eae994f98967e9743c0322e99_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNy0xLTEtMS0yOTM0Ng_6bd9f5e8-4394-46ef-bd44-fbbc2e38ca8f">11,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048e3b2eae994f98967e9743c0322e99_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNy0zLTEtMS0yOTM0Ng_fb30a6e8-4f4a-4821-aad7-72371d77414d">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0471829afd7d49ec8d77526fcd9e579e_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNy01LTEtMS0yOTM0Ng_f09439c5-b8d4-4b16-85f3-e7141112438e">269,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNy0xMS0xLTEtMjkzNDY_92af8646-ae82-42c4-a0e3-c0ba3b0af837">269,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity component of convertible debt issuance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0471829afd7d49ec8d77526fcd9e579e_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfOC01LTEtMS0yOTM0Ng_383950cd-fac5-4ab3-b7b7-716781793944">196,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfOC0xMS0xLTEtMjkzNTk_31737e44-9471-42aa-a19f-71f7bf3f509b">196,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity component of convertible debt redemption</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0471829afd7d49ec8d77526fcd9e579e_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfOS01LTEtMS0yOTM0Ng_df26ec66-8c3d-4584-879a-c942bed09c77">37,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfOS0xMS0xLTEtMjkzNTk_f95350a8-f7cd-4e3e-8d38-a91d7e9bbeda">37,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for vesting of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i048e3b2eae994f98967e9743c0322e99_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTAtMS0xLTEtMjkzNDY_77a3765d-639e-4c4b-b2a5-9c4a3734039d">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048e3b2eae994f98967e9743c0322e99_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTAtMy0xLTEtMjkzNDY_e9693845-92ba-4d65-9ea1-d025327790d1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTAtMTEtMS0xLTI5MzQ2_4daa6491-7c59-42d4-94f5-186ebe87682d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0471829afd7d49ec8d77526fcd9e579e_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTEtNS0xLTEtMjkzNDY_ebe18872-c8ae-4a93-973e-0c6321ab92cc">22,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTEtMTEtMS0xLTI5MzQ2_bb61144c-6bae-4240-8899-589a979f19d9">22,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55f0b2b681c841419600222a85ea3546_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItMS0xLTEtMjkzNDY_a18c0af1-82bb-4b6f-98c9-ba933d03b3af">115,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f0b2b681c841419600222a85ea3546_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItMy0xLTEtMjkzNDY_f2f5da05-9b81-4c4a-96dc-6632e967b038">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3276d1a28daa4225b9fcdb3cc08af201_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItNS0xLTEtMjkzNDY_7d0d86d0-cde0-4614-8304-df43181694bf">2,569,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd691c6a90574493ba24a86f882bb91a_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItNy0xLTEtMjkzNDY_bed5f2ea-27e3-4759-a25f-d9f1252c869c">2,039,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24591cad2f4544ef997c8b46679d9352_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItOS0xLTEtMjkzNDY_5a31d85e-9d64-4a67-9988-e11460313265">424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34b29fd1e2a04660a3bb612c3f24dde5_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItMTEtMS0xLTI5MzQ2_a69f3e6f-b028-4d73-a48b-8fbf87662ce5">531,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b3892dcb478479cbc9399beec69b27e_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItMS0xLTEtMjkzMjY_178d468e-0158-4887-9058-e03a572f4bed">118,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b3892dcb478479cbc9399beec69b27e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItMy0xLTEtMjkzMjY_fe4a3d6d-3ce0-4a83-b91d-c9c023b9993f">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4522e02284f8410db6010810d897bb79_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItNS0xLTEtMjkzMjY_46568dbd-590d-4be2-a99d-6272dfcf07bf">2,673,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5eb0968295fa457c8b850a6bb24fd24e_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItNy0xLTEtMjkzMjY_8589bee0-a977-4d02-af03-2efa1b313605">2,265,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if525baf875694aeebfb3e8f1ee7895c3_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItOS0xLTEtMjkzMjY_ff15d462-2736-45be-9232-7c99e3690806">968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItMTEtMS0xLTI5MzI2_d17d53a0-ce26-45e2-b2f3-229dcc79e999">410,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTUtMC0xLTEtMzAzOTY_6eb28c14-79b4-4b78-b3a4-04fcfc83126c">Cumulative impact of ASU 2020-06 adoption</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf38b8e15b4544b69ae00a7699d5915d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTUtNS0xLTEtMjkzNzM_e952f6a0-5051-4909-9453-7be7eb3ddf75">264,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ea5250e3bb45aa81e5c43a0000647d_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTUtNy0xLTEtMjkzNzM_271665c4-2633-4660-9d11-0ecff2c956be">50,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide697d4ed12846f7b2b2e749378e6fb5_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTUtMTEtMS0xLTI5Mzcz_e3afd109-1b91-4105-aad5-687e3548a160">214,410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05cbb40265d44701a893071c4123f466_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTQtNy0xLTEtMjkzMjY_b047fb14-7edd-438e-9321-32a45cf7698f">190,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTQtMTEtMS0xLTI5MzI2_557a1755-2b5a-4787-93e3-5b2409bec84b">190,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d0519eefc5a4372aa09bac3494eed11_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTUtOS0xLTEtMjkzMjY_cf2b596d-04b5-4ca4-9277-19050f779d7f">1,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTUtMTEtMS0xLTI5MzI2_f16a1691-b51c-49e7-a723-9db586142de1">1,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options and ESPP shares issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94bf3b66b78947dcb8fe7cb4478bc7f1_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTYtMS0xLTEtMjkzMjY_9b5a2ce5-a9f2-4b25-9cca-ff2f9bbaa58a">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94bf3b66b78947dcb8fe7cb4478bc7f1_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTYtMy0xLTEtMjkzMjY_c62656d2-cc7b-4a0f-96c6-989258511bab">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e5d191ee0284b228ad30f1ed1e95735_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTYtNS0xLTEtMjkzMjY_17c548a4-f84e-49b6-8256-cca002a3d9eb">13,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTYtMTEtMS0xLTI5MzI2_2ce005a3-36eb-44d1-91e9-fcda1afb99a4">13,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for vesting of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94bf3b66b78947dcb8fe7cb4478bc7f1_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItMS0xLTEtMjkzNzM_539bd9da-77a1-4af8-a55e-993284524c02">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94bf3b66b78947dcb8fe7cb4478bc7f1_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItMy0xLTEtMjkzNzM_160752a8-6bda-49ce-9adc-c2f257612ae3">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItMTEtMS0xLTI5Mzcz_7f14f1ef-78fd-4a99-8647-c4cc52712d44">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e5d191ee0284b228ad30f1ed1e95735_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjEtNS0xLTEtMjkzMjY_c98b270f-9908-4fcf-a966-e397b50f8bb1">27,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjEtMTEtMS0xLTI5MzI2_6c02d157-98d7-4a4c-87d6-5ad68f5d1d5b">27,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0182cad036cc492c902e8768cc1bdc6a_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItMS0xLTEtMjkzMjY_76c6a0ed-f4ac-451f-816f-8b65828b6bd7">119,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0182cad036cc492c902e8768cc1bdc6a_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItMy0xLTEtMjkzMjY_27cdef87-a736-4a20-959b-face3a25c284">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f7e3e3f5c7949eb926f4685e8a1dd75_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItNS0xLTEtMjkzMjY_cabfe89e-b29f-4c21-8b00-5e657a016c58">2,449,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b176cdccb74943960953e16068e6a8_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItNy0xLTEtMjkzMjY_1f8aaf8b-1ea3-4b48-b3e0-eace53bbcde6">2,405,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadd45892aa3342cbbeff3a291a11105b_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItOS0xLTEtMjkzMjY_fec3d436-3ceb-49b8-861c-2a5ecceeb1d2">929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItMTEtMS0xLTI5MzI2_33f52dc6-a692-46e3-ba12-5214257153db">44,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i252108b308054887a46901fe227627f1_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:70.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.975%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMy0xLTEtMS0yODk0Nw_5f8c1a91-4c9e-47f8-a6ad-11762bfb5742">190,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMy0zLTEtMS0yODk0Nw_f55ede71-e9fc-42a2-a867-9ea330acfec8">208,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNS0xLTEtMS0yODk0Nw_e5bacac5-7b73-4792-8fe8-48a924229f16">2,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNS0zLTEtMS0yODk0Nw_dd3f2112-9c63-4a04-9b93-651d06090ed0">4,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNi0xLTEtMS0yODk0Nw_518f196b-0b16-4c3f-8467-51dd3c4b4a42">2,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNi0zLTEtMS0yODk0Nw_6660a68c-54f6-42f0-bdc5-c5aed510c90e">2,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNy0xLTEtMS0yODk0Nw_290de874-9c44-4c6e-8bff-842eb6a2ac5e">27,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNy0zLTEtMS0yODk0Nw_558bc39f-baed-4abd-8903-6b85568d5cd3">22,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfOC0xLTEtMS0yODk0Nw_372ddcdc-48fe-4d9d-bacc-061600cce048">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfOC0zLTEtMS0yODk0Nw_7d273011-691e-4865-9176-dbf964795ed1">17,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs and accretion of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfOS0xLTEtMS0yODk0Nw_837ad996-7ca0-44c6-8014-c3450ed246f5">1,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfOS0zLTEtMS0yODk0Nw_32f7f1a2-4ead-4919-8704-0842f4de2a6a">13,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTEtMS0xLTEtMjg5NDc_e9e5a70a-3eb4-42a6-8ac9-0f94d10709f6">1,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTEtMy0xLTEtMjg5NDc_b832828c-efc7-4968-ab3c-01228a360375">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="insm:NoncashOperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTItMS0xLTEtMjg5NDc_62d096fc-a07a-4b07-824e-44f28a90103c">9,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="insm:NoncashOperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTItMy0xLTEtMjg5NDc_269da958-dd27-4852-bc7b-e6951f106a3d">9,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of deferred and contingent consideration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTMtMS0xLTEtMjg5NDc_f58876e1-f34e-4a43-8ca1-db2a9dcce0c0">24,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTMtMy0xLTEtMjg5NDc_03f886d3-59a4-4791-894d-f82ead7685aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTUtMS0xLTEtMjg5NDc_cc0ba23f-eca5-4e5c-a931-533458a97eb4">6,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTUtMy0xLTEtMjg5NDc_c4e83e27-9473-43b5-a8e8-ef17971545d4">1,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTYtMS0xLTEtMjg5NDc_cba4701f-39a8-40e5-a80f-86d11bd3cf6b">724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTYtMy0xLTEtMjg5NDc_f6a8d0b9-5121-45d8-adbe-61e985340dba">11,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTctMS0xLTEtMjg5NDc_737b4f4a-0989-4eef-a69b-7de057a1f66e">4,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTctMy0xLTEtMjg5NDc_621eaff3-1711-41d7-90fe-8385b051cd3c">7,484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTgtMS0xLTEtMjg5NDc_63e7dabf-71aa-44d2-8205-0208c0ed4b58">15,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTgtMy0xLTEtMjg5NDc_684b0da4-72cd-48fd-825b-871f4911647d">22,623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTktMS0xLTEtMjg5NDc_72fbdadd-559a-47dd-9480-b9ea80638b6b">3,558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTktMy0xLTEtMjg5NDc_224f3232-7070-4043-be94-b440145a04f2">11,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities, accrued compensation and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjAtMS0xLTEtMjg5NDc_23794767-cf66-4030-a692-1faf15d910ac">16,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" sign="-" name="insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjAtMy0xLTEtMjg5NDc_fc7bcb37-bb77-457c-a7b9-6ae11196d42d">10,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjItMS0xLTEtMjg5NDc_b97c5dc5-4d49-4178-97e5-1c979c568dc7">207,462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjItMy0xLTEtMjg5NDc_a5e67332-0ad9-419d-8327-f81bfe231966">203,725</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjQtMS0xLTEtMjg5NDc_b81b0149-2b67-4f82-b141-d5c2d55a5da6">4,605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjQtMy0xLTEtMjg5NDc_68f672ee-44ec-474c-9623-c1041ec0d4ab">4,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjUtMS0xLTEtMjg5NDc_889b6eaa-a7e4-4f78-bdc7-1d742edb020e">99,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjUtMy0xLTEtMjg5NDc_5442fc8a-a712-4a8c-815a-6d9299f2b56b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjgtMS0xLTEtMjg5NDc_417cab3d-933a-47fa-8c64-1d57d2b9a945">104,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjgtMy0xLTEtMjg5NDc_c0c047af-60ea-4c3f-ac60-5372bcf28518">4,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options, ESPP, and RSU vestings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzAtMS0xLTEtMjg5NDc_dae1c190-7dee-465e-8cfb-a2f034ae07e8">13,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzAtMy0xLTEtMjg5NDc_ee6709e5-63ad-4e68-a324-0f90670930db">13,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzEtMS0xLTEtMjg5NDc_b1c0e174-a6ad-4911-9e0e-d701b3ed9151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzEtMy0xLTEtMjg5NDc_109f8dd8-b8f4-40fc-8190-23e1af40b2c0">269,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment on extinguishment of <ix:nonFraction unitRef="number" contextRef="if2feebc246964bc390c0f21deae432ad_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzItMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjo0Yzk2YmYxODU5Mzk0YTUzYTk5NWEyYWYwNTFmOGMyZl8zMw_cbc3592e-f818-4689-b259-d304c1c13ab7">1.75</ix:nonFraction>% convertible senior notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzItMS0xLTEtMjg5NDc_0f6adf04-fd26-4adf-aac9-e4282679d35b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzItMy0xLTEtMjg5NDc_377f4bc3-7d09-4014-86a2-2f13648bb35c">12,578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of principal on <ix:nonFraction unitRef="number" contextRef="if2feebc246964bc390c0f21deae432ad_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzMtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjplZWI3MGFkNzNiMjc0NjdjYjJhNzcwODJlZGI4Y2E0Nl8yOA_cbc3592e-f818-4689-b259-d304c1c13ab7">1.75</ix:nonFraction>% convertible senior notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzMtMS0xLTEtMjg5NDc_7826b71c-ba38-45ed-8101-e47561ee951c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzMtMy0xLTEtMjg5NDc_e4195cc6-2868-4b98-a08c-3a37cfb47101">225,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of <ix:nonFraction unitRef="number" contextRef="i7a28ddcd6f5348cc9084640011f760dd_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzQtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjo5MjYwYmQ5ZjY4NTM0Zjc2OWY1OTBiYjMwODNiNTU1M18zMA_88f1aeb4-37f3-482e-9737-51136e21db02">0.75</ix:nonFraction>% convertible senior notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzQtMS0xLTEtMjg5NDc_91bda5e7-a41f-41a0-b6a9-a2ea68c045e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzQtMy0xLTEtMjg5NDc_7d0f1f14-1c23-4ce8-9741-3d5682e5a473">575,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzUtMS0xLTEtMjg5NDc_13008aa5-c721-4f5e-92b9-c844147e5823">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzUtMy0xLTEtMjg5NDc_8e6cd781-1802-4e5a-b98a-c4a511ef3d7a">16,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of finance lease principal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzYtMS0xLTEtMjg5NDc_6681db9d-c65e-4c2e-8d2a-78e9c2091cfb">494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzYtMy0xLTEtMjg5NDc_c0860905-dda2-4168-a53e-f2e997541858">522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzgtMS0xLTEtMjg5NDc_afca1201-3a7b-4deb-953c-c848cc2e5b45">12,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzgtMy0xLTEtMjg5NDc_86e13db8-0c3c-49ec-9136-c4e76d1df876">604,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzktMS0xLTEtMjg5NDc_3b2605dc-2e01-4bd6-ab60-0e18a482bba4">1,701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzktMy0xLTEtMjg5NDc_cfe89de9-6dc9-46f1-809e-5dbec30eb068">338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDAtMS0xLTEtMjg5NDc_eb07ff4c-c5a5-427b-9677-2ad002de1da5">300,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDAtMy0xLTEtMjg5NDc_7d23cf5f-22dc-4b84-b4f9-e3939827edc8">395,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDEtMS0xLTEtMjg5NDc_cfec8400-fb71-48bd-90d6-272349146b8b">716,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic11e1e3142e048009002fc987716b4e8_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDEtMy0xLTEtMjg5NDc_fef69cf3-18fd-46ab-94ab-de1309937990">532,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDItMS0xLTEtMjg5NDc_ac23a72b-6c32-4cd2-8056-fa2a3b61fa17">416,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34b29fd1e2a04660a3bb612c3f24dde5_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDItMy0xLTEtMjg5NDc_7866b43f-25f7-4f2c-bc1d-9c31ebcbf834">928,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDQtMS0xLTEtMjg5NDc_057bac2e-54ac-41d5-b7a5-90791b53fb3e">5,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDQtMy0xLTEtMjg5NDc_fb69e983-2e6d-44c7-9c8d-f35d1ed522ae">5,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDUtMS0xLTEtMjg5NDc_aaa21f03-168a-4a14-9b12-d9ecc896e703">1,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDUtMy0xLTEtMjg5NDc_5f8aad99-1c70-4a1b-b246-41135c775d43">997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i252108b308054887a46901fe227627f1_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i252108b308054887a46901fe227627f1_31"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zMS9mcmFnOmNmMDA2YTA2ZTFlMTQ4Zjk5NmM5OWE0MmEyNGMzNTliL3RleHRyZWdpb246Y2YwMDZhMDZlMWUxNDhmOTk2Yzk5YTQyYTI0YzM1OWJfNjEyNg_ae9bf907-6d20-4bcd-81d8-6c344a0c3aa3" continuedAt="ic783bc270ea7462fb522ddefe4626a70" escape="true">The Company and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="ic783bc270ea7462fb522ddefe4626a70" continuedAt="idcd45e09d5f249b484634473a3f13e47"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States (US) as ARIKAYCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mycobacterium avium</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nontuberculous mycobacterial (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NTM) lung infections caused by MAC in adults with limited treatment options who do not have </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cystic fibrosis (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F). In March 2021, Japan's Ministry of Health, Labour and Welfare (MHLW) approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis, CF and other neutrophil-mediated diseases</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the Commonwealth of Virginia on November&#160;29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules&#160;and regulations for reporting on Form&#160;10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the US for complete consolidated financial statements are not included herein. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000110450622000008/insm-20211231.htm">Annual Report on Form&#160;10-K for the year ended December&#160;31, 20</a>21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;The Company had $<ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zMS9mcmFnOmNmMDA2YTA2ZTFlMTQ4Zjk5NmM5OWE0MmEyNGMzNTliL3RleHRyZWdpb246Y2YwMDZhMDZlMWUxNDhmOTk2Yzk5YTQyYTI0YzM1OWJfMzQ3MA_6a65c2c4-1362-4475-bbfd-8238c495ad2d">416.1</ix:nonFraction> million in cash and cash equivalents and marketable securities totaling $<ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zMS9mcmFnOmNmMDA2YTA2ZTFlMTQ4Zjk5NmM5OWE0MmEyNGMzNTliL3RleHRyZWdpb246Y2YwMDZhMDZlMWUxNDhmOTk2Yzk5YTQyYTI0YzM1OWJfMTY0OTI2NzQ0Nzk1Nw_2758945b-3f35-46a3-8506-7299d7af9b36">148.6</ix:nonFraction> million as of June&#160;30, 2022 and reported a net loss of $<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zMS9mcmFnOmNmMDA2YTA2ZTFlMTQ4Zjk5NmM5OWE0MmEyNGMzNTliL3RleHRyZWdpb246Y2YwMDZhMDZlMWUxNDhmOTk2Yzk5YTQyYTI0YzM1OWJfMzU3Ng_cec23ba5-bb9f-456e-83dc-e873560c4cd2">190.3</ix:nonFraction> million for the six months ended June&#160;30, 2022. Historically, the Company has funded its operations through public offerings of equity securities and debt financings. The Company expects to continue to incur consolidated operating losses, including losses in its US and certain international entities, while funding research and development (R&amp;D) activities for ARIKAYCE, brensocatib, TPIP and its other pipeline programs, and continuing and commencing pre-commercial, commercialization and regulatory activities for ARIKAYCE, and funding other general and administrative activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects its future cash requirements to be substantial, and the Company may need to raise additional capital to fund operations, including the Phase 3 ASPEN study, the continued commercialization of ARIKAYCE, the ARISE and ENCORE clinical trials related to ARIKAYCE, launch readiness activities for the potential launch of brensocatib, if approved, other clinical trials for brensocatib, TPIP, and its future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company&#8217;s commercial, regulatory and development activities. Any equity or debt financing will also be contingent upon equity and debt market conditions and interest rates at the time. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts. The Company believes it currently has sufficient funds to meet its financial needs for at least the next 12 months.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many uncertainties regarding the novel coronavirus (COVID-19) pandemic, and the Company is closely monitoring the impact of the pandemic on all aspects of its business, including how the pandemic will impact its patients, employees, suppliers, vendors, business partners and distribution channels. While the pandemic did not materially affect the Company's financial results and business operations for the six months ended June 30, 2022, the Company is unable to predict the impact that COVID-19 will have on its financial position and operating results in future periods due to </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idcd45e09d5f249b484634473a3f13e47">numerous uncertainties. The Company will continue to assess the evolving impact of the COVID-19 pandemic and will make adjustments to its operations as necessary.</ix:continuation></span></div><div id="i252108b308054887a46901fe227627f1_34"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNDI_ab0a91d3-6594-420b-984a-04fca2015d8e" continuedAt="i25fb3d5531c44b158cec1ac62d1f072c" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i25fb3d5531c44b158cec1ac62d1f072c" continuedAt="i74befe3cfb75493690b4c206c7032c0f"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The following are the required interim disclosure updates to the Company's significant accounting policies described in Note 2 of the notes to the consolidated financial statements in the Company's </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000110450622000008/insm-20211231.htm">Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNzA_0a2d5689-4b97-4a3d-b0e2-3282c1b1c90f" continuedAt="ib581871546c84d759edcdfe4a5682cda" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span></ix:nonNumeric></div><ix:continuation id="ib581871546c84d759edcdfe4a5682cda" continuedAt="id30b2d59ce2d4192afac918b94c41e67"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.</span></div><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNzE_78fcb8d3-0449-4160-942d-ed8cbbc3b77e" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:36.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June&#160;30, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec080385c64348cb8d266b6830480fb9_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfMy0xLTEtMS0yODk0Nw_63fa237f-9d50-4ff8-b38f-a9d90a3daf02">416.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d7e6f6374b34f27b308f84f2889e800_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfMy0zLTEtMS0yODk0Nw_d97f6510-ae21-4482-a925-37fd4491d3fc">416.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic90ba27634af46b9a9e3cde8cc10fe96_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfMy01LTEtMS0yODk0Nw_fef88d88-9082-40d4-9d26-e4091b48e40a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47041a589d9840429204e4bf3b7e196d_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfMy03LTEtMS0yODk0Nw_bd530e80-c0c3-4762-8980-762ea01805bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec080385c64348cb8d266b6830480fb9_I20220630" decimals="-5" name="us-gaap:MarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNC0xLTEtMS0yODk0Nw_a47e131a-3018-4fb3-98e4-bf5256c9cf83">148.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d7e6f6374b34f27b308f84f2889e800_I20220630" decimals="-5" name="us-gaap:MarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNC0zLTEtMS0yODk0Nw_28213017-b701-411c-ab6c-14dd7d33ab7a">148.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic90ba27634af46b9a9e3cde8cc10fe96_I20220630" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNC01LTEtMS0yODk0Nw_e68a3002-75d7-4c43-8dca-aa8b2cd5283e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47041a589d9840429204e4bf3b7e196d_I20220630" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNC03LTEtMS0yODk0Nw_d21c7acc-9227-4b24-903f-24ff39aeb07b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec080385c64348cb8d266b6830480fb9_I20220630" decimals="-5" name="insm:BusinessCombinationDeferredLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNS0xLTEtMS0yODk0Nw_d36c61b2-bf1a-4f49-a44b-ab71690e7d67">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d7e6f6374b34f27b308f84f2889e800_I20220630" decimals="-5" name="insm:BusinessCombinationDeferredLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNS0zLTEtMS0yODk0Nw_2fab413c-163f-4417-a887-57a3dfbb1a68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic90ba27634af46b9a9e3cde8cc10fe96_I20220630" decimals="-5" name="insm:BusinessCombinationDeferredLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNS01LTEtMS0yODk0Nw_f4086e6a-38bd-4eab-bd2a-2b049e7006d9">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47041a589d9840429204e4bf3b7e196d_I20220630" decimals="-5" name="insm:BusinessCombinationDeferredLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNS03LTEtMS0yODk0Nw_762fee13-1da0-43c0-b4ca-2939dbf75dde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec080385c64348cb8d266b6830480fb9_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNi0xLTEtMS0yODk0Nw_208f54b1-5291-491a-83a2-211b856ca227">55.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d7e6f6374b34f27b308f84f2889e800_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNi0zLTEtMS0yODk0Nw_48dff41d-9521-4e9f-93bc-c7ff76258baa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic90ba27634af46b9a9e3cde8cc10fe96_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNi01LTEtMS0yODk0Nw_b55ebd9e-b6d1-4312-90cc-71cfd165d439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47041a589d9840429204e4bf3b7e196d_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNi03LTEtMS0yODk0Nw_750d68de-aa03-44b2-b99b-afe27851f983">55.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:36.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93327d100c39469e95dec29690f01bda_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfMy0xLTEtMS0yODk0Nw_790ea9bd-4c62-4c56-81c1-fc2767a1b303">716.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ee4597ee72a49a1b044f1c8dbb4f863_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfMy0zLTEtMS0yODk0Nw_1241be3d-18b1-4166-9ce5-aa620273338e">716.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d3efb8da424928ad39dfb3ae7f93e8_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfMy01LTEtMS0yODk0Nw_465a3222-7165-46c1-a14a-88778f1701cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie148fe14821246d98cdbbf096f0dc154_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfMy03LTEtMS0yODk0Nw_7f71b398-4af7-445d-98df-02fa32f0b358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93327d100c39469e95dec29690f01bda_I20211231" decimals="-5" name="us-gaap:MarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNC0xLTEtMS0yODk0Nw_555f3aa1-3e6a-42a7-b8e3-975d6fc9b3cc">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ee4597ee72a49a1b044f1c8dbb4f863_I20211231" decimals="-5" name="us-gaap:MarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNC0zLTEtMS0yODk0Nw_bf333812-e381-4134-b893-34d76958230d">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d3efb8da424928ad39dfb3ae7f93e8_I20211231" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNC01LTEtMS0yODk0Nw_7a0d8e28-c7af-4fed-9837-83880802e055">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie148fe14821246d98cdbbf096f0dc154_I20211231" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNC03LTEtMS0yODk0Nw_20ad9d4c-d8ba-4c94-8c90-b4c8237fbbfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93327d100c39469e95dec29690f01bda_I20211231" decimals="-5" name="insm:BusinessCombinationDeferredLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNS0xLTEtMS0yODk0Nw_d63f798f-ffde-4aca-a317-1d6239ff273f">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ee4597ee72a49a1b044f1c8dbb4f863_I20211231" decimals="-5" name="insm:BusinessCombinationDeferredLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNS0zLTEtMS0yODk0Nw_7d230bf7-2c9d-4991-bd56-cb09d619c4e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d3efb8da424928ad39dfb3ae7f93e8_I20211231" decimals="-5" name="insm:BusinessCombinationDeferredLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNS01LTEtMS0yODk0Nw_8c3a24a7-8946-4343-9128-4caef8f69233">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie148fe14821246d98cdbbf096f0dc154_I20211231" decimals="-5" name="insm:BusinessCombinationDeferredLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNS03LTEtMS0yODk0Nw_ad331a7b-4994-4152-875d-7d94567c5f7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93327d100c39469e95dec29690f01bda_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNi0xLTEtMS0yODk0Nw_59e19f02-482d-4ee4-a516-35da9dae302e">75.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ee4597ee72a49a1b044f1c8dbb4f863_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNi0zLTEtMS0yODk0Nw_f6059230-efc3-4aa8-827d-bcf986ddd8ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d3efb8da424928ad39dfb3ae7f93e8_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNi01LTEtMS0yODk0Nw_1d315fba-b83c-4eaa-998b-d68e42779fb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie148fe14821246d98cdbbf096f0dc154_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNi03LTEtMS0yODk0Nw_5a8c917c-a289-48c1-ac2a-eed0b5267a70">75.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> six months ended June&#160;30, 2022, the Company purchased $<ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-5" name="insm:MarketableSecuritiesAdditional" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMjQ0MQ_05e626db-bbea-425e-9004-85d5db8835ca">99.7</ix:nonFraction>&#160;million of additional m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arketable securities consisting of US Treasury Notes. There were <ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="INF" name="insm:FairValueLevel1Level2Level3TransfersAmount" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNzI_15b251da-2199-4777-b98f-773bb41f0229"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="INF" name="insm:FairValueLevel1Level2Level3TransfersAmount" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNzI_819765af-b8d3-4bdc-ad1e-1f7a652a5a2b">no</ix:nonFraction></ix:nonFraction> other transfers in or out of Level 1, Level 2 or Level 3 during the six months ended June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company held $<ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMjY2Mw_2af81f3b-aecb-4f27-9bcd-f072238c2c07">138.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMjY3MA_ec3ec963-2ab6-4f24-a767-e1b11ca2cec8">9.8</ix:nonFraction> million of current and non-current available-for-sale securities, respectively, net of an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMjc3NA_3810478c-88c1-45e2-bfe5-f30450ac03bd">1.3</ix:nonFraction>&#160;million recorded in accumulated other comprehensive income. Marketable securities maturing in one year or less are classified as current assets and marketable securities maturing in more </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><ix:continuation id="i74befe3cfb75493690b4c206c7032c0f" continuedAt="ia12fd584d52b4f71b2a86635e9ce63c7"><ix:continuation id="id30b2d59ce2d4192afac918b94c41e67" continuedAt="ib45c7404ad7e4e7da2e4db2701b69a9f"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">than one year are classified as non-current assets. As of December&#160;31, 2021, the Company held <ix:nonFraction unitRef="security" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="INF" name="insm:AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMjg1Ng_ac1e8a0e-57be-4281-a1c9-ad082ab53ce1">no</ix:nonFraction> securities that were in an unrealized gain or loss position.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2) whether the security was rated below investment grade; (3) how long the security has been in an unrealized loss position; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover. The Company has determined that there were no other-than-temporary impairments during the quarter ended June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred consideration arose from the acquisitions of Motus Biosciences, Inc. (Motus) and AlgaeneX, Inc. (AlgaeneX) (the Business Acquisition) in August 2021 (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_70">Note 13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Company is obligated to issue to Motus equityholders an aggregate of <ix:nonFraction unitRef="shares" contextRef="ib690063402dd47c4ae80bed8cc5946a2_D20210804-20210804" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzc5Mw_10df3dcf-c035-4ae8-84b3-227068a45494"><ix:nonFraction unitRef="shares" contextRef="ibbf98dd2c06941fba02468ff74fe15f4_D20210804-20210804" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzc5Mw_b56647dd-78a2-4b73-9a8b-ed734d3ebc6f"><ix:nonFraction unitRef="shares" contextRef="i63cf6ce83c0a452894be75c49ed8e241_D20210804-20210804" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzc5Mw_e86db486-0dca-40c3-b55c-d1df63ba9786">184,433</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s common stock on each of the first, second and third anniversaries of the closing date, subject to certain reductions. A valuation of the deferred consideration is performed quarterly with gains and losses included within change in fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss. As the deferred consideration is settled in shares, there is no discount rate applied in the fair value calculation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred consideration has been classified as a Level 2 recurring liability as its valuation utilizes an input, the Insmed share price on the valuation date, which is a directly observable input at the measurement date and for the duration of the liabilities' anticipated lives. Deferred consideration expected to be settled within twelve months or less is classified as a current liability and are included in accrued liabilities. As of June&#160;30, 2022, the fair value of deferred consideration included in accrued liabilities was $<ix:nonFraction unitRef="usd" contextRef="ie99f3a85a4be4eee9b9643513ffb1f49_I20220630" decimals="-5" name="insm:BusinessCombinationDeferredLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfNDgwOQ_7268a789-ae70-41d1-a829-0a46ac7e5609">3.5</ix:nonFraction> million. Deferred consideration expected to be settled in more than twelve months is classified as a non-current liability and is included in other long-term liabilities. As of June&#160;30, 2022, the fair value of deferred consideration included in other long-term liabilities was $<ix:nonFraction unitRef="usd" contextRef="ic0173aaf93ae46c0804c04edc71dcf3d_I20220630" decimals="-5" name="insm:BusinessCombinationDeferredLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfNTA3MA_09f9a086-9b76-4ed0-b115-6a56eebfa8a5">7.3</ix:nonFraction> million.</span></div><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNTU_93837828-4d58-444d-b94c-628be2bf7b4c" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following observable input was used in the valuation of the deferred consideration as of June&#160;30, 2022:</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"></td><td style="width:21.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.531%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June&#160;30, 2022 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Input</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="if515e39443fc4bab983e5485d58c4067_I20220630" decimals="-5" name="insm:BusinessCombinationDeferredLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjQwOWFjOTlhMmY0MzQ2YzU4NWQ0NjQyYTA2MGZmNGU0L3RhYmxlcmFuZ2U6NDA5YWM5OWEyZjQzNDZjNTg1ZDQ2NDJhMDYwZmY0ZTRfMS0xLTEtMS0yODk0Nw_d966bb40-5fdb-4f7e-8093-2a7c2b597ae9">10.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed share price as of June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i060750a8e6764e58986207b6fa039245_I20220630" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjQwOWFjOTlhMmY0MzQ2YzU4NWQ0NjQyYTA2MGZmNGU0L3RhYmxlcmFuZ2U6NDA5YWM5OWEyZjQzNDZjNTg1ZDQ2NDJhMDYwZmY0ZTRfMS0zLTEtMS0yODk0Nw_4cba88f6-e6dc-49a6-97c5-7407a0770661">19.72</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities arose from the Business Acquisition in August 2021 (Note 13). The contingent consideration liabilities consist of developmental and regulatory milestones, a priority review voucher milestone and net sales milestones. Upon the achievement of certain development and regulatory milestone events, the Company is obligated to issue to Motus equityholders up to <ix:nonFraction unitRef="shares" contextRef="i4fc0d05a849b4f9f8363d09eb7a2297f_D20210804-20210804" decimals="INF" name="insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfNTYwMA_8a7cf677-5d05-45d7-9feb-d2e953685384">5,348,572</ix:nonFraction> shares in the aggregate and AlgaeneX equityholders up to <ix:nonFraction unitRef="shares" contextRef="i7d34c58061f249e18f61f07687b0331b_D20210801-20210831" decimals="INF" name="insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfNTY2MA_df84c9d3-ef12-41e0-bba6-949165c43452">368,867</ix:nonFraction> shares in the aggregate. The fair value of the development and regulatory milestones are estimated utilizing a probability-adjusted approach. At June&#160;30, 2022, the weighted average probability of success was <ix:nonFraction unitRef="number" contextRef="i8a656fb7732145c9a71bf1d21a49bd5d_I20220630" decimals="2" name="insm:WeightedAverageProbabilityOfReachingMilestone" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfNTg2MA_103174e8-1924-4df4-b956-0dc6cc722b9e">42</ix:nonFraction>%. The development and regulatory milestones will be settled in shares of the Company's common stock. As such, there is no discount rate applied in the fair value calculation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company were to receive a priority review voucher, the Company is obligated to pay to the Motus equityholders a portion of the value of the priority review voucher, subject to certain reductions. The potential payout will be either <ix:nonFraction unitRef="number" contextRef="i4df89726368c42908ecdb1dc00da2381_I20210831" decimals="2" name="insm:ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfNjI3Ng_50618d2c-4b54-4890-a7b5-88660fc5863b">50</ix:nonFraction>% of the after tax net proceeds received by the Company from a sale of the priority review voucher or <ix:nonFraction unitRef="number" contextRef="i4df89726368c42908ecdb1dc00da2381_I20210831" decimals="2" name="insm:AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfNjM3OQ_87e5d242-abb1-44a8-8605-4acde37dad2e">50</ix:nonFraction>% of the average of the sales prices for the last <ix:nonFraction unitRef="sale" contextRef="i281fbad9a3524e6396eb4972fe1bde0a_D20210801-20210831" decimals="INF" name="insm:NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfNjQzMA_1fb46f28-c532-44ab-bcd2-efac9688f967">three</ix:nonFraction> publicly disclosed priority review voucher sales, less certain adjustments. The fair value of the priority review voucher milestone is estimated utilizing a probability-adjusted discounted cash flow approach. This obligation will be settled in cash. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities for net sales milestones were valued using an option pricing model with Monte Carlo simulation. As of June&#160;30, 2022, the fair value of these net sales milestones were deemed immaterial to the overall fair value of the contingent consideration. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities have been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the inputs to the valuation approach, the estimated fair value could be significantly different than the fair value the Company determined. Contingent consideration liabilities expected to be settled in more than twelve months are classified as a non-current liability. A valuation of the contingent consideration liabilities is performed quarterly with gains and losses included within change in fair value of contingent consideration liabilities in the consolidated statements of comprehensive loss.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><ix:continuation id="ia12fd584d52b4f71b2a86635e9ce63c7" continuedAt="ia2c5e196b2414d0198e64c11640cf3d6"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNjY_d3251ba4-6d48-446a-b415-4acc11ec1a5c" escape="true"><ix:continuation id="ib45c7404ad7e4e7da2e4db2701b69a9f"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the contingent consideration liabilities as of June&#160;30, 2022 (in millions):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June&#160;30, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ia8937d9bce474ef99c2f8fd821f06dfd_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjg4ZGI1NzRlMjQyMjQwZWY5ODE5MzM5ZjNiY2Y0N2Q2L3RhYmxlcmFuZ2U6ODhkYjU3NGUyNDIyNDBlZjk4MTkzMzlmM2JjZjQ3ZDZfMS0xLTEtMS0yODk0Nw_7bfde89b-4279-4429-96a0-bd1f80ce51c5">50.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probabilities of success</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26bcf703891e40a19cb16e952a3c238c_I20220630" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjg4ZGI1NzRlMjQyMjQwZWY5ODE5MzM5ZjNiY2Y0N2Q2L3RhYmxlcmFuZ2U6ODhkYjU3NGUyNDIyNDBlZjk4MTkzMzlmM2JjZjQ3ZDZfMS00LTEtMS0yODk0Ny90ZXh0cmVnaW9uOjVkYjFlODQ5ZTZjODQzNWE4NjM3ZmQwNWZmYzIxYjQ2XzQ_1b71e4e5-af08-46b6-b4b9-284c296add0b">14</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i7956fe4d32d6415888053fe7ac3dece8_I20220630" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjg4ZGI1NzRlMjQyMjQwZWY5ODE5MzM5ZjNiY2Y0N2Q2L3RhYmxlcmFuZ2U6ODhkYjU3NGUyNDIyNDBlZjk4MTkzMzlmM2JjZjQ3ZDZfMS00LTEtMS0yODk0Ny90ZXh0cmVnaW9uOjVkYjFlODQ5ZTZjODQzNWE4NjM3ZmQwNWZmYzIxYjQ2Xzk_99cd3802-67bf-4db4-af91-80c3d61c8ec2">95</ix:nonFraction>%</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority review voucher milestone</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ibfb81df3017f4c52b5f695219f80bcb0_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjg4ZGI1NzRlMjQyMjQwZWY5ODE5MzM5ZjNiY2Y0N2Q2L3RhYmxlcmFuZ2U6ODhkYjU3NGUyNDIyNDBlZjk4MTkzMzlmM2JjZjQ3ZDZfMi0xLTEtMS0yODk0Nw_6a0a5858-6331-49a4-bb17-03d41958ea44">5.0</ix:nonFraction></span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i01b8767d1be2471ea778276a43af86f0_I20220630" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjg4ZGI1NzRlMjQyMjQwZWY5ODE5MzM5ZjNiY2Y0N2Q2L3RhYmxlcmFuZ2U6ODhkYjU3NGUyNDIyNDBlZjk4MTkzMzlmM2JjZjQ3ZDZfMi00LTEtMS0yODk0Nw_de7de334-aa5d-47a5-857e-6cd6a60b3075">13.5</ix:nonFraction>%</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i694933442abe4684b8238d717a4bc7b2_I20220630" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjg4ZGI1NzRlMjQyMjQwZWY5ODE5MzM5ZjNiY2Y0N2Q2L3RhYmxlcmFuZ2U6ODhkYjU3NGUyNDIyNDBlZjk4MTkzMzlmM2JjZjQ3ZDZfMy00LTEtMS0yODk0Nw_d3862473-5366-4c3e-9ac3-e6824e397923">10.7</ix:nonFraction>%</span></div></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the six months ended June 30, 2022 (in thousands):</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:22.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.568%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.568%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.568%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.568%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9029a1175b8d4c0bb7ad648dd57b8b45_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMi0yLTEtMS0yODk0Nw_6197816b-ed64-47c9-8370-7fa2c4812f8e">14,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id65b00fb345d4a73968a60a9f00ec86b_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMi00LTEtMS0yODk0Nw_0db3dfba-0ca3-40c5-9bcf-bcecd28f3f01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id65b00fb345d4a73968a60a9f00ec86b_D20220101-20220630" decimals="-3" sign="-" name="insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMi02LTEtMS0yODk0Nw_d15b8497-8e7d-49f8-a310-cca639aabc4d">4,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id65b00fb345d4a73968a60a9f00ec86b_D20220101-20220630" decimals="-3" name="insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMi04LTEtMS0yODk0Nw_1a2e3e71-6470-4d1b-9c51-b14fb6408b9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cfafbc2904c4fd78825be70c0ebb580_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMi0xMC0xLTEtMjg5NDc_ce43192e-fc37-4267-8bd5-8f0b79d08759">10,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32f0450653644e2c821879326a4be32c_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMy0yLTEtMS0yODk0Nw_e0677547-1bc2-4c89-844e-49224296dc07">75,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6f98ddcb9a41259b5ad644d8e7762b_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMy00LTEtMS0yODk0Nw_0eab99a5-7773-45c7-9ee1-ef3b0cef99bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e6f98ddcb9a41259b5ad644d8e7762b_D20220101-20220630" decimals="-3" sign="-" name="insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMy02LTEtMS0yODk0Nw_f98a954e-b406-4ed6-8b24-12d900bbe8ac">20,068</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6f98ddcb9a41259b5ad644d8e7762b_D20220101-20220630" decimals="-3" name="insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMy04LTEtMS0yODk0Nw_e73a4faa-ab67-464d-a7f3-38a5f95302c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf3af52789dd4962b7190f4bb7f153e7_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMy0xMC0xLTEtMjg5NDc_458d19ea-0a87-43e2-bba0-09a40ede81b0">55,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the liability component of the Company's <ix:nonFraction unitRef="number" contextRef="i7a28ddcd6f5348cc9084640011f760dd_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfODE0Mg_48875725-1e99-4b14-b61a-f0ea0cfee3d5">0.75</ix:nonFraction>% convertible senior notes due 2028 (the 2028 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of June&#160;30, 2022 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i008ce45b9b5447059371d7e92096d9ff_I20220630" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfODI5NA_17fd57b1-dece-4624-a0db-94805916315f">496.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the 2028 Convertible Notes. The $<ix:nonFraction unitRef="usd" contextRef="i8a35e946668040f5b6acb3c5b856b0e7_I20220630" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfODQzOQ_65068504-2858-4803-8a58-6f52338a4ed3">561.6</ix:nonFraction> million carrying value of the 2028 Convertible Notes as of June&#160;30, 2022 excludes the $<ix:nonFraction unitRef="usd" contextRef="i7a28ddcd6f5348cc9084640011f760dd_I20220630" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfODUwOQ_adb7c62f-8264-4a74-aeac-4f0c0e303304">13.4</ix:nonFraction> million of the unamortized portion of the debt issuance costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the liability component of the Company's <ix:nonFraction unitRef="number" contextRef="if2feebc246964bc390c0f21deae432ad_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfODYzNg_26be90e9-0cc0-4187-8198-426bf80da17c">1.75</ix:nonFraction>% convertible senior notes due 2025 (the 2025 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of June&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i7436f64e366c4208874055741be8f683_I20220630" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfODc4OA_366664b9-59f2-4f96-8ec4-4ff56fda275e">208.3</ix:nonFraction> million, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the 2025 Convertible Notes. The $<ix:nonFraction unitRef="usd" contextRef="id3ba44aaad2b44359ffdef500ffbb2d8_I20220630" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfODkzMw_b50e46ec-d9a7-4f14-8dee-7ceddc9053ce">222.4</ix:nonFraction> million carrying value of the 2025 Convertible Notes as of June&#160;30, 2022 excludes the $<ix:nonFraction unitRef="usd" contextRef="if2feebc246964bc390c0f21deae432ad_I20220630" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfOTAwMw_d81dbf33-b137-4f52-977a-a3bec817619f">2.6</ix:nonFraction> million of the unamortized portion of the debt issuance costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNTY_66631dfe-88ed-4efd-9cd0-13fd535652a7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock, restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.</span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><ix:continuation id="ia2c5e196b2414d0198e64c11640cf3d6" continuedAt="i91a3af7ad98f45b89b3c5fb14c32fb6f"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNjc_c43785b5-1694-47e8-ab5e-cc28a5b15b41" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three and six months ended June&#160;30, 2022 and 2021: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfNC0xLTEtMS0yODk0Nw_0fa841cb-4408-49b8-b26f-c56b016befc9">95,645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfNC0zLTEtMS0yODk0Nw_a9c9bb01-ad9f-44e3-afac-4810e4b9af4b">117,321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfNC01LTEtMS0yODk0Nw_7a9f7763-516e-444f-9d03-4ed1720f4327">190,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfNC03LTEtMS0yODk0Nw_d86864ca-22f1-4b39-9c12-88250a12b4b5">208,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of basic net loss per share:</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfNi0xLTEtMS0yODk0Nw_aa00f784-a20f-4901-af67-a06b38d76ef4">119,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfNi0zLTEtMS0yODk0Nw_8d68d3da-adc5-4cc6-90cf-7a0f36ada5d0">109,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfNi01LTEtMS0yODk0Nw_bea6d411-3b04-40c2-928e-f32f4019dd5a">119,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfNi03LTEtMS0yODk0Nw_bcd5d814-2da4-4e5a-b9fd-08c2c7215fe0">106,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb495f010db54c2ebbb407f2ea54e2ba_D20220401-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfOC0xLTEtMS0yODk0Nw_ebc91f2b-9267-48cc-bc49-8b8be4445ef5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idae99b8ad22540cba6959e639a4bc3d9_D20210401-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfOC0zLTEtMS0yODk0Nw_ff00a43a-5b51-4dfb-a1e5-4af26479f6f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18c239d8a4b84368b0ec193e679d9382_D20220101-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfOC01LTEtMS0yODk0Nw_be981fb4-2e06-4c9a-8596-fff1a041857f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45292554e7184f898ba749676eba1941_D20210101-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfOC03LTEtMS0yODk0Nw_3632d162-55c6-4db7-ba3a-8a1111283a0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd20c886bcbb4ec881a57bf89c5feefa_D20220401-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfOS0xLTEtMS0yODk0Nw_b2fa229a-fed5-4b06-aefb-146186116f9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75d345a205d14a869a001fc3d932ca19_D20210401-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfOS0zLTEtMS0yODk0Nw_89d81f0d-63da-4e6d-8880-2908a6c9c879">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32487a941bfc4076b54815cf8c60211b_D20220101-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfOS01LTEtMS0yODk0Nw_2ecb3795-5acd-445f-8a61-a7e9931d6a09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5de10744d8f445ae87da00f994d29fcd_D20210101-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfOS03LTEtMS0yODk0Nw_3ed74e1d-947d-46e4-9de2-93ceb074d0b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i826dc379d52b4e8d8be78b58060e1979_D20220401-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTAtMS0xLTEtMzA5OTg_5a0f11e7-ee5e-423e-ba4b-06d50b5dbcd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11458fa48bb841a7b70bf22cafac3a40_D20210401-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTAtMy0xLTEtMzA5OTg_7dabdf2c-9e87-4685-bc8b-f3be05c0ef8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04f0a1a4c2144c658e9faeab5bacbf34_D20220101-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTAtNS0xLTEtMjg5NDc_8b1a178e-db44-45ec-85a0-c34cda468d6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0771a886122a4116af16d7e597aac7e8_D20210101-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTAtNy0xLTEtMjg5NDc_952e90a2-9df7-41bb-a5a3-94ae09586a6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTEtMS0xLTEtMjg5NDc_bb906f52-85d0-4dc0-bc1c-5f510aee6922">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTEtMy0xLTEtMjg5NDc_9df15973-f5dd-4de3-93f6-8710bf4327c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTEtNS0xLTEtMjg5NDc_a6027673-2804-4457-981a-3e2ffa4cbd31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTEtNy0xLTEtMjg5NDc_0d7c31db-5600-415f-807c-98b8cdeceb94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTItMS0xLTEtMjg5NDc_d679a62b-f751-4b35-b564-7bb2c96484f0">119,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTItMy0xLTEtMjg5NDc_d3bdd63c-99df-41f0-9eb4-73c939730def">109,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTItNS0xLTEtMjg5NDc_fb03a1ab-3ccd-42a6-9229-dc5fb9548511">119,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTItNy0xLTEtMjg5NDc_33d36e96-f763-4dcf-bf36-ba0231697873">106,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTQtMS0xLTEtMjg5NDc_79fdc737-dc90-450b-b615-6e2f199fac6d"><ix:nonFraction unitRef="usdPerShare" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTQtMS0xLTEtMjg5NDc_dc9a6b0f-614f-47cd-bcbd-cb8751789c88">0.80</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTQtMy0xLTEtMjg5NDc_60865546-5bcd-4ef1-96b0-88752e49c756"><ix:nonFraction unitRef="usdPerShare" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTQtMy0xLTEtMjg5NDc_9ebb67cd-2d2d-4fa8-bf84-2d04cec0b8ae">1.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTQtNS0xLTEtMjg5NDc_ad58294b-38af-435f-8d19-121f9a8d00b8"><ix:nonFraction unitRef="usdPerShare" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTQtNS0xLTEtMjg5NDc_f88b12c6-0400-4fac-b559-d4c7cc142d17">1.60</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTQtNy0xLTEtMjg5NDc_d2e5ebd2-0577-47f5-87e7-4d42c07114b3"><ix:nonFraction unitRef="usdPerShare" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTQtNy0xLTEtMjg5NDc_e3f99b0e-9b87-4e22-b3d5-c5b842b3074a">1.97</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNzg_3e105956-5f00-41c8-b854-a54476ea5912" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of June&#160;30, 2022 and 2021, respectively, as their effect would have been anti-dilutive (in thousands):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:66.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.553%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.555%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f46d4b8f14b4f9a9806c15e65465675_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmRjMzBkNzZkYWMxMjQzNmE5NjBhYzE0NzRhZjVhYzk3L3RhYmxlcmFuZ2U6ZGMzMGQ3NmRhYzEyNDM2YTk2MGFjMTQ3NGFmNWFjOTdfMi0xLTEtMS0yODk0Nw_b96cf7b3-8de1-4c80-a48b-b79f14e51597">17,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib57ecc23938042cfa725b197115046c8_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmRjMzBkNzZkYWMxMjQzNmE5NjBhYzE0NzRhZjVhYzk3L3RhYmxlcmFuZ2U6ZGMzMGQ3NmRhYzEyNDM2YTk2MGFjMTQ3NGFmNWFjOTdfMi0zLTEtMS0yODk0Nw_066c3997-44b4-4790-80bd-e97ebeab9b6f">14,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock and RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88a276ac0d54475b9c03c7440a1608fe_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmRjMzBkNzZkYWMxMjQzNmE5NjBhYzE0NzRhZjVhYzk3L3RhYmxlcmFuZ2U6ZGMzMGQ3NmRhYzEyNDM2YTk2MGFjMTQ3NGFmNWFjOTdfMy0xLTEtMS0yODk0Nw_ca8ccb39-2870-4c1e-91ba-9eaf83dd3a3d">1,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1cfd6327542a4ec28651deb81d520e2c_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmRjMzBkNzZkYWMxMjQzNmE5NjBhYzE0NzRhZjVhYzk3L3RhYmxlcmFuZ2U6ZGMzMGQ3NmRhYzEyNDM2YTk2MGFjMTQ3NGFmNWFjOTdfMy0zLTEtMS0yODk0Nw_69063923-da28-4695-8f31-c310b3213a7b">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62c8f1c4a72145a8a38686730f07d96d_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmRjMzBkNzZkYWMxMjQzNmE5NjBhYzE0NzRhZjVhYzk3L3RhYmxlcmFuZ2U6ZGMzMGQ3NmRhYzEyNDM2YTk2MGFjMTQ3NGFmNWFjOTdfNC0xLTEtMS0yODk0Nw_1b3463d4-d9ef-4e5f-bff7-456f9b5b752d">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibaa2f8ddc972496d9af74169e0443d41_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmRjMzBkNzZkYWMxMjQzNmE5NjBhYzE0NzRhZjVhYzk3L3RhYmxlcmFuZ2U6ZGMzMGQ3NmRhYzEyNDM2YTk2MGFjMTQ3NGFmNWFjOTdfNC0zLTEtMS0yODk0Nw_ebc6bf4c-8865-43ea-a8c0-1c896f77976e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d56f2cd3eaf416e8ea5e63692228a23_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmRjMzBkNzZkYWMxMjQzNmE5NjBhYzE0NzRhZjVhYzk3L3RhYmxlcmFuZ2U6ZGMzMGQ3NmRhYzEyNDM2YTk2MGFjMTQ3NGFmNWFjOTdfNS0xLTEtMS0yODk0Nw_172e2764-bc44-4f03-9100-54909dcee879">23,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ae9ec03bdda4b058bca71221c9a7996_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmRjMzBkNzZkYWMxMjQzNmE5NjBhYzE0NzRhZjVhYzk3L3RhYmxlcmFuZ2U6ZGMzMGQ3NmRhYzEyNDM2YTk2MGFjMTQ3NGFmNWFjOTdfNS0zLTEtMS0yODk0Nw_2d794adf-c920-49c4-adbd-576f13223dcf">23,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNDY_0e049d87-25ad-4697-84a7-82a029949f27" continuedAt="ibb18facabe4b495aa4d28ca3d0b2fd5a" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for collectible trade receivables. <ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNzk_60270b67-9aac-447f-9625-24876b4c0864" continuedAt="i3f2d197a050444c3b953cfdf47ee0610" escape="true">The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the six months ended June&#160;30, 2022 and 2021.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><ix:continuation id="i3f2d197a050444c3b953cfdf47ee0610"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"><tr><td style="width:1.0%"></td><td style="width:33.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.934%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.936%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8297b16fe1be40cb95165a0bea1fa1fe_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzZDA5NjBiMGI1NjRiM2Q4M2M2NTAzNmNiMjcwNjQ0L3RhYmxlcmFuZ2U6NTNkMDk2MGIwYjU2NGIzZDgzYzY1MDM2Y2IyNzA2NDRfMi0xLTEtMS0yODk0Nw_dda8ae57-e37f-4b2e-b87e-70d9908c1c6e">36</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34fcb92cc2b441f1a0c7f4c6e848c031_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzZDA5NjBiMGI1NjRiM2Q4M2M2NTAzNmNiMjcwNjQ0L3RhYmxlcmFuZ2U6NTNkMDk2MGIwYjU2NGIzZDgzYzY1MDM2Y2IyNzA2NDRfMi0zLTEtMS0yODk0Nw_43b6c1cb-d060-4156-b39d-22c4a4f02c3b">25</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f40504b772844eb858783a727551877_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzZDA5NjBiMGI1NjRiM2Q4M2M2NTAzNmNiMjcwNjQ0L3RhYmxlcmFuZ2U6NTNkMDk2MGIwYjU2NGIzZDgzYzY1MDM2Y2IyNzA2NDRfMy0xLTEtMS0yODk0Nw_f927fb54-4d2c-4d21-a011-9ff65f0b55b7">32</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i661418bb0674414b9010ff5b70067d3d_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzZDA5NjBiMGI1NjRiM2Q4M2M2NTAzNmNiMjcwNjQ0L3RhYmxlcmFuZ2U6NTNkMDk2MGIwYjU2NGIzZDgzYzY1MDM2Y2IyNzA2NDRfMy0zLTEtMS0yODk0Nw_785826e4-5c4f-48ac-966f-532950769d7f">23</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i30c3f2d8839a4faa9a1c05047301e4f7_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzZDA5NjBiMGI1NjRiM2Q4M2M2NTAzNmNiMjcwNjQ0L3RhYmxlcmFuZ2U6NTNkMDk2MGIwYjU2NGIzZDgzYzY1MDM2Y2IyNzA2NDRfNC0xLTEtMS0yODk0Nw_b61c82b8-2b62-4810-88c9-d00afa3e8efc">19</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5334091cc884a859ad2228b90a2795f_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzZDA5NjBiMGI1NjRiM2Q4M2M2NTAzNmNiMjcwNjQ0L3RhYmxlcmFuZ2U6NTNkMDk2MGIwYjU2NGIzZDgzYzY1MDM2Y2IyNzA2NDRfNC0zLTEtMS0yODk0Nw_98987177-fc88-4038-9006-39c023d7e58e">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><ix:continuation id="i91a3af7ad98f45b89b3c5fb14c32fb6f" continuedAt="i535f08dbd8b94861b53e3ae4e413328e"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibb18facabe4b495aa4d28ca3d0b2fd5a">operating results. A change in the relationship with the suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.</ix:continuation></span></div><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNzY_25811d64-bd55-4c56-8fb6-2aaf9835b330" continuedAt="i16e69f38c1a643588961a311d20b1f62" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract to determine which are performance obligations and to assess whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consist of net sales of ARIKAYCE. The Company's customers in the US include specialty pharmacies and specialty distributors. In December 2020, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Europe. In July 2021, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Japan. Globally, product revenues are recognized once the Company performs and satisfies all five steps of the revenue recognition criteria mentioned above.</span></div><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNjI_1272141b-c7a5-4f4e-9df2-680a842db996" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the Company's product revenues, net, by geographic location for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:33.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b44c6e566f24a9882c1b3f8f3b4c0ee_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfMi0xLTEtMS0yODk0Nw_484212d3-e35e-4d23-9f8f-a043fc090050">47,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea9322ea7e7a46f9bb59dc10b38f0897_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfMi0zLTEtMS0yODk0Nw_7db51831-ed5c-47bf-a77e-a9df69df4b91">41,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1448668a7228445d80ba936243ca7fe7_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfMi01LTEtMS0yODk0Nw_e5d1f8cb-cf64-4979-9fc0-935a64cd4c37">87,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5726053c5da4536a1e11ec19e99b532_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfMi03LTEtMS0yODk0Nw_974547ce-f18d-4008-aba8-f98834dd4e35">79,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bed069934724804b94a28374dea16e9_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfMy0xLTEtMS0yODk0Nw_a081daa3-8c92-440e-b1e5-44a210edd2b7">15,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6931c30dc02f44cf8d0a90632e1f5ce4_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfMy0zLTEtMS0yODk0Nw_bdd6195c-9acb-4b9e-be17-ad18ba6f7104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80224a3dd22c4d58966aae71eacb8cc4_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfMy01LTEtMS0yODk0Nw_78f25cac-5833-40bb-ad9c-4c309b74c765">26,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cd49603d9354e39a28f04178c247b10_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfMy03LTEtMS0yOTczNg_f91b10eb-baa5-430c-810d-7d9854fc6548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5abaf4f46249c2b605b4b4d53db50a_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfNC0xLTEtMS0yODk0Nw_b8de8a18-c191-40ce-ad1a-fdc0452ff468">2,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad77b69398bc4c9dbef47393b9c7c0e7_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfNC0zLTEtMS0yODk0Nw_b487aa16-9086-41bb-9b2e-435018f3d2ba">3,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1df549ad601429bbc4b64c37aee2eb3_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfNC01LTEtMS0yODk0Nw_41433c15-b66c-4377-93e3-f295d95ec2d7">3,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77947eb926944d7f9ef2b3f148ffcb51_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfNC03LTEtMS0yODk0Nw_ca506835-b4af-49c4-8d03-f20065c38522">6,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total product revenues, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfNS0xLTEtMS0yODk0Nw_2b164e93-715e-4027-b4f0-e338704cf100">65,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfNS0zLTEtMS0yODk0Nw_f6e56e75-3252-4692-880a-06ae7e5cdf71">45,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfNS01LTEtMS0yODk0Nw_530c3a39-4972-4b26-bbed-143ebe990715">118,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfNS03LTEtMS0yODk0Nw_d8f2ed00-1782-4c86-b74a-95dcc6fa44b8">85,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer credits: The Company's customers are offered various forms of consideration, including prompt payment discounts. The payment terms for sales to specialty pharmacies for prompt payment discounts are based on contractual rates agreed with the respective specialty pharmacies. The Company anticipates that its customers will earn these discounts and, therefore, deducts the full amount of these discounts from total gross product revenues at the time such revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates: The Company contracts with government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accrued liabilities on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><ix:continuation id="i535f08dbd8b94861b53e3ae4e413328e" continuedAt="i3291c9cfdccd41e8a2efc0de82dc98fc"><ix:continuation id="i16e69f38c1a643588961a311d20b1f62"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recognizes revenue related to various early access programs (EAPs) in Europe, predominantly in France. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.</span></div></ix:continuation><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="insm:InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNTg_41b22ea3-77e4-4819-affb-3b54e4b34874" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Cost of Product Revenues (excluding amortization of intangible assets) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Inventory is stated at the lower of cost and net realizable value. The Company began capitalizing inventory costs following US Food and Drug Administration (FDA) approval of ARIKAYCE in September 2018. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestone payments. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to FDA approval of ARIKAYCE, the Company expensed all inventory-related costs in the period incurred. Inventory used for clinical development purposes is expensed to R&amp;D expense when consumed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyODE_73d6c496-6f56-4e0b-bf8a-50756c7d72ab" continuedAt="idbf44125f07c4816a36a4c8f39e66057" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business combinations and asset acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for the Company&#8217;s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><ix:continuation id="i3291c9cfdccd41e8a2efc0de82dc98fc" continuedAt="ib84cc9cb12e84b76be13b6f9fee4e578"><ix:continuation id="idbf44125f07c4816a36a4c8f39e66057"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets&#8217; carrying amounts on the acquiring entity&#8217;s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.</span></div></ix:continuation><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNjM_567f0cef-a4ac-4796-8970-f086a2256162" continuedAt="ie1350d6f37f94ca4b7a0a68f8f734093" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Indefinite-lived intangible assets consist of In Process Research &amp; Development (IPR&amp;D). IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&amp;D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#8217;s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company&#8217;s outlook and market performance of the Company&#8217;s industry and recent and forecasted financial performance. The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finite-lived Intangible Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Finite-lived intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the acquired ARIKAYCE R&amp;D intangible asset, at the date of subsequent adjustments of fair value. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Assessment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing to the carrying value of the assets to the fair value of the assets. The Company determined that no indicators of impairment of finite-lived intangible assets or long-lived assets existed at June&#160;30, 2022.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="ie1350d6f37f94ca4b7a0a68f8f734093" continuedAt="i5310a890fdac4d11bd09e255db111503">Goodwill</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5310a890fdac4d11bd09e255db111503"> - Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#8217;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassesses its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company will perform its next annual impairment testing for goodwill on October 1, 2022.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNjE_0a3db3d9-835a-4c7c-83ca-3e12a808ff65" continuedAt="i7824dd78bced4ba5939fae6b8ef5a0fa" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in </span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><ix:continuation id="ib84cc9cb12e84b76be13b6f9fee4e578" continuedAt="iafced6af91274722b536f3491dcd59c3"><ix:continuation id="i7824dd78bced4ba5939fae6b8ef5a0fa"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7 - Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for details about the Company's lease portfolio, including required disclosures.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNjk_c546d673-657e-487b-bbc1-9baddc67b3ca" continuedAt="ica94b64a51744cc9a37ba3a45630d9aa" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also promote consistent application of and simplify US generally accepted accounting principles (GAAP) for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance was effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. The Company adopted this guidance January 1, 2021. The adoption of the guidance did not have a material impact on the Company's consolidated financial statements and accompanying notes.</span></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iafced6af91274722b536f3491dcd59c3" continuedAt="id9dd2117205541c086bcbfe9e39841e1"><ix:continuation id="ica94b64a51744cc9a37ba3a45630d9aa" continuedAt="i6b9988cbfa9a4ee69abc10fba685e445">In August 2020, the FASB issued <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNTQ_a1983cb3-6ebb-4561-babb-c381ced619fe">ASU 2020-06</span>, Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, to reduce the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. For convertible instruments, the number of accounting models for convertible debt instruments is reduced, which results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Only convertible instruments that meet the definition of a derivative or are issued with substantial premiums will continue to be subject to the separation models. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and a share of convertible preferred stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation and recognition as derivatives. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021. </ix:continuation></ix:continuation></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id9dd2117205541c086bcbfe9e39841e1"><ix:continuation id="i6b9988cbfa9a4ee69abc10fba685e445">The Company transitioned using the modified retrospective method. The impact of adopting ASU 2020-06 on January 1, 2022 resulted in an opening balance sheet adjustment increasing debt by $<ix:nonFraction unitRef="usd" contextRef="iefdd31e6154343f0a080337167a74a77_I20220101" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMwMTI_b234aa0e-136c-414f-9ac8-8cf000c3013a">221.9</ix:nonFraction>&#160;million, increasing issuance costs classified to debt by $<ix:nonFraction unitRef="usd" contextRef="iefdd31e6154343f0a080337167a74a77_I20220101" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMwNjQ_777c12ac-3c62-4dbe-8b5a-9aa9170df321">6.1</ix:nonFraction>&#160;million, decreasing the deferred tax liability by $<ix:nonFraction unitRef="usd" contextRef="iefdd31e6154343f0a080337167a74a77_I20220101" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMxMDk_0b8ad9eb-77d2-472f-bb9d-159771786fe1">1.4</ix:nonFraction>&#160;million, and causing an increase to retained earnings of $<ix:nonFraction unitRef="usd" contextRef="ieaf84c60d3d749089c4d2329ec941ffe_I20220101" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMxNjE_05e1c47a-c014-4259-86b0-abb8137bbe5d">50.2</ix:nonFraction> million, with an offsetting reduction to additional paid-in-capital of $<ix:nonFraction unitRef="usd" contextRef="iefdd31e6154343f0a080337167a74a77_I20220101" decimals="-5" sign="-" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyMjc_12737303-729e-4521-9773-a3883821989b">264.6</ix:nonFraction> million, net of tax.</ix:continuation></ix:continuation> </span></div><div id="i252108b308054887a46901fe227627f1_37"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RleHRyZWdpb246YzA3NmQyZjlhY2VhNGIwMTlkM2YyMjFjZGM1NGUwNjBfNTY1_ffce17e9-a112-4587-8052-54351fa7b2ab" continuedAt="i81c02f5a471a4aadbd261f0e720b0d3c" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="i81c02f5a471a4aadbd261f0e720b0d3c"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RleHRyZWdpb246YzA3NmQyZjlhY2VhNGIwMTlkM2YyMjFjZGM1NGUwNjBfNTY2_9d9707a5-6bd6-41f4-96da-0b833edd4741" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, the Company's inventory balance consists of the following (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:49.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.261%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RhYmxlOjFlYzU5YTFmNzQ5ZjQ5ZGVhNDZkYzM0ZjcxZjJmYmY0L3RhYmxlcmFuZ2U6MWVjNTlhMWY3NDlmNDlkZWE0NmRjMzRmNzFmMmZiZjRfMi0xLTEtMS0yODk0Nw_f72f27d2-36d1-42d7-9573-2d055ca2c77e">29,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RhYmxlOjFlYzU5YTFmNzQ5ZjQ5ZGVhNDZkYzM0ZjcxZjJmYmY0L3RhYmxlcmFuZ2U6MWVjNTlhMWY3NDlmNDlkZWE0NmRjMzRmNzFmMmZiZjRfMi0zLTEtMS0yODk0Nw_9824613b-cc78-4e0a-8226-92c30f5585c5">29,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RhYmxlOjFlYzU5YTFmNzQ5ZjQ5ZGVhNDZkYzM0ZjcxZjJmYmY0L3RhYmxlcmFuZ2U6MWVjNTlhMWY3NDlmNDlkZWE0NmRjMzRmNzFmMmZiZjRfMy0xLTEtMS0yODk0Nw_b8d4c80e-c714-4a73-9b44-37ffab41dc8c">15,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RhYmxlOjFlYzU5YTFmNzQ5ZjQ5ZGVhNDZkYzM0ZjcxZjJmYmY0L3RhYmxlcmFuZ2U6MWVjNTlhMWY3NDlmNDlkZWE0NmRjMzRmNzFmMmZiZjRfMy0zLTEtMS0yODk0Nw_fce72d94-e60d-42a3-98d6-c456034b540d">18,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RhYmxlOjFlYzU5YTFmNzQ5ZjQ5ZGVhNDZkYzM0ZjcxZjJmYmY0L3RhYmxlcmFuZ2U6MWVjNTlhMWY3NDlmNDlkZWE0NmRjMzRmNzFmMmZiZjRfNC0xLTEtMS0yODk0Nw_0cd5d02e-572b-481e-ad1d-4b8dc1025aff">21,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RhYmxlOjFlYzU5YTFmNzQ5ZjQ5ZGVhNDZkYzM0ZjcxZjJmYmY0L3RhYmxlcmFuZ2U6MWVjNTlhMWY3NDlmNDlkZWE0NmRjMzRmNzFmMmZiZjRfNC0zLTEtMS0yODk0Nw_8beb5633-27da-4245-917d-dd3651abac81">18,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RhYmxlOjFlYzU5YTFmNzQ5ZjQ5ZGVhNDZkYzM0ZjcxZjJmYmY0L3RhYmxlcmFuZ2U6MWVjNTlhMWY3NDlmNDlkZWE0NmRjMzRmNzFmMmZiZjRfNS0xLTEtMS0yODk0Nw_2edf4095-e82f-448d-845e-2424fa85d88e">67,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RhYmxlOjFlYzU5YTFmNzQ5ZjQ5ZGVhNDZkYzM0ZjcxZjJmYmY0L3RhYmxlcmFuZ2U6MWVjNTlhMWY3NDlmNDlkZWE0NmRjMzRmNzFmMmZiZjRfNS0zLTEtMS0yODk0Nw_afa6c68b-3f1c-41a0-9ed2-febb63e0eed2">67,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company began capitalizing inventory costs following FDA approval of ARIKAYCE in September 2018. The Company has not recorded any significant inventory write-downs since that time. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.</span></div></ix:continuation><div id="i252108b308054887a46901fe227627f1_40"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfMTIyMw_88912313-1ef1-46a7-9ce3-b3252396d178" continuedAt="ibf891c59394f4b37a1ea190b09c9b3f1" escape="true">Intangibles, Net and Goodwill</ix:nonNumeric></span></div><ix:continuation id="ibf891c59394f4b37a1ea190b09c9b3f1" continuedAt="i1d39b901a17e4d08b63080e435411ed0"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangibles, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finite-lived Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&amp;D and the milestones paid to PARI Pharma GmbH (PARI) for the license to use PARI's Lamira&#174; Nebulizer System (Lamira) for the delivery of ARIKAYCE to patients as a result of the FDA and EC approvals of ARIKAYCE in September 2018 and October 2020, respectively. The Company began amortizing its acquired ARIKAYCE R&amp;D and PARI milestones intangible assets in </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><ix:continuation id="i1d39b901a17e4d08b63080e435411ed0" continuedAt="i95d75b32abad4138b5fa5b64e3e0b427"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 2018, over ARIKAYCE's initial regulatory exclusivity period of <ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfNjM5_7e25c660-2a4f-4035-ae33-80c809dd753f">12</ix:nonNumeric> years. Amortization of these assets during each of the next five years is estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfNzQw_21027bfe-ecf2-433a-969e-5f8d5ce676ef"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfNzQw_2521f9ad-60b9-463a-af9d-5ed56270386d"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfNzQw_26f07fe2-18b9-4885-9619-16979d7bf41e"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfNzQw_4d9e95f2-45ab-484f-a9e1-2af45fdc734f"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfNzQw_c64930ac-1273-4e3e-a375-7bdc90a59de6">5.1</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million per year.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-lived Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company's indefinite-lived intangible assets consisted of acquired in process research and development (IPR&amp;D) from the Business Acquisition (Note 13). Indefinite-lived intangible assets are not amortized.</span></div><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfMTIyMA_a5072df4-aec4-4c2a-a189-c2ec8a57afa4" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the Company's intangible assets for the six months ended June 30, 2022 and June&#160;30, 2021 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"></td><td style="width:36.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.303%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Intangible Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1380329539b4132829f56ecd925fdf8_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMi0xLTEtMS0yODk0Nw_90f802ce-90cf-4740-a5fe-55009a297218">42,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cd9cfdd737546e99d0b622013e7ca48_D20220101-20220630" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMi0zLTEtMS0yODk0Nw_7884990d-44e5-4548-97d2-a8ce66d58355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cd9cfdd737546e99d0b622013e7ca48_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMi01LTEtMS0yODk0Nw_c66ba15a-03c6-4266-91cd-e7c304c8cc12">2,425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc4ec61359d24f0caa4c62d971da1288_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMi03LTEtMS0yODk0Nw_a8607716-00fa-46d1-9074-bfe03ab6c533">40,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i278371e151d544e6a212c9d2aa2a655b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMy0xLTEtMS0yODk0Nw_de415bdd-5694-4e44-8ca7-931c65ff9408">29,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd5b90d56364a53a5da8bdf154bec64_D20220101-20220630" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMy0zLTEtMS0yODk0Nw_71c6d90f-30b7-4609-a086-eb1d1c7387a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd5b90d56364a53a5da8bdf154bec64_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMy01LTEtMS0yODk0Nw_7cf78a5a-70cd-47a8-9720-50260bfe5281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife46a9fb88034d28981626beb4a29946_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMy03LTEtMS0yODk0Nw_6add4a08-fe38-4f31-9f65-47b23982e1bf">29,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5640268efe1f4be6b786aed558989d41_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfNC0xLTEtMS0yODk0Nw_6c18e19d-fa9a-4b92-bb77-66937a0ac8c2">1,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b3c794885af4e1f921fd241ba143529_D20220101-20220630" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfNC0zLTEtMS0yODk0Nw_fd1a4691-6647-47b4-ac01-8051d626a0e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b3c794885af4e1f921fd241ba143529_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfNC01LTEtMS0yODk0Nw_2dfba3d7-622b-494d-b42f-2a9b87210abe">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f13532abba943b0b557fd68637dbf22_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfNC03LTEtMS0yODk0Nw_7fc677ea-78da-4f90-b0ce-2697f10845e7">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfNS0xLTEtMS0yODk0Nw_4df069e6-5f34-475b-bfb0-fe51dee5121f">73,809</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfNS0zLTEtMS0yODk0Nw_f6e3d262-1f5d-46b0-878d-37088401e1ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfNS01LTEtMS0yODk0Nw_63a0c0be-3372-4112-b3e3-e7909db4b630">2,526</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfNS03LTEtMS0yODk0Nw_1421e04d-25f1-4cb8-b595-ca1760c4bbff">71,283</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Intangible Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i413f715068c444d2a9f6c5865f2e54fa_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfOC0xLTEtMS0yODk0Nw_601608ec-c6a7-4d1e-958a-c1e46e87d491">47,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58319fe25f124f3b8246c1b27bb7cb08_D20210101-20210630" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfOC0zLTEtMS0yODk0Nw_31efb23d-aa94-4680-a4e6-b5e84d5cc756">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58319fe25f124f3b8246c1b27bb7cb08_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfOC01LTEtMS0yODk0Nw_ff0254d0-112b-4e77-9485-498a8ab086e7">2,425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefdd99d19aab444dbfcd286f3daa9339_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfOC03LTEtMS0yODk0Nw_687ffae4-48e1-4393-ab62-83b8890d162d">44,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1686617c86b644caae372fe8d75fcec3_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMTAtMS0xLTEtMjg5NDc_4e32330e-3031-4118-8651-a7be5ce80acb">1,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38a8d02ea544cb4b9317034c9910cb3_D20210101-20210630" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMTAtMy0xLTEtMjg5NDc_1500e983-9fdd-49f4-ba2f-5f67ef0266cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if38a8d02ea544cb4b9317034c9910cb3_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMTAtNS0xLTEtMjg5NDc_354081a1-0265-497a-8913-51aea1c79f3a">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id72977157672403489742e38fb8ca59b_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMTAtNy0xLTEtMjg5NDc_b0792863-1619-4f93-8d4f-90fdd7a5a755">1,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic11e1e3142e048009002fc987716b4e8_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMTEtMS0xLTEtMjg5NDc_f09e0353-ac18-4688-a4de-77f76524d4d3">49,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMTEtMy0xLTEtMjg5NDc_d9640a95-3b9a-4265-8e29-2b7f22a35f65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMTEtNS0xLTEtMjg5NDc_872e0358-789c-4927-9a6c-9b8b8b3297c0">2,526</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34b29fd1e2a04660a3bb612c3f24dde5_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMTEtNy0xLTEtMjg5NDc_ce0b197e-1e67-4497-9c9b-532547696b51">46,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i95d75b32abad4138b5fa5b64e3e0b427">The Company's goodwill balance of $<ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfMTE1NA_51e87c31-8405-4a0f-85be-c322f2eed211">136.1</ix:nonFraction> million as of June&#160;30, 2022, resulted from the Business Acquisition (Note 13).</ix:continuation>&#160;</span></div><div id="i252108b308054887a46901fe227627f1_43"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RleHRyZWdpb246MDIyZDViNzAxOWJlNDQxOTk2ZmZjOWUxYjU4ZjA4Y2ZfMTU3_097f0cf7-5e61-4a94-8c10-8ebd2d48108e" continuedAt="i581237f015214c77829460b24f5c7db6" escape="true">Fixed Assets, Net</ix:nonNumeric></span></div><ix:continuation id="i581237f015214c77829460b24f5c7db6"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RleHRyZWdpb246MDIyZDViNzAxOWJlNDQxOTk2ZmZjOWUxYjU4ZjA4Y2ZfMTU4_5c57161c-5a14-4468-b74d-5c8b9288f7ce" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:31.926%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.635%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i344bca01b9d34f3aa441d482b0f2f475_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMy0yLTEtMS0yODk0Nw_458ec0a6-e180-4ff3-bced-dee9f61867c0">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c4bd98ffad14ac78e43425f54977d3d_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMy00LTEtMS0yODk0Nw_58522dc5-cb5b-463d-976c-e9d2b33c7005">14,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedecef4e6b1d4166a9b79f3e0c853064_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMy02LTEtMS0yODk0Nw_69d8eed7-2513-429b-97aa-f05ee8a1a599">11,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51ea7721be4640ed9298ced46bffdeae_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNC0yLTEtMS0yODk0Nw_0d71d33d-1790-479c-aee8-8ff0b5d04658">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb7b544503ac43e48d6444664e6c74da_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNC00LTEtMS0yODk0Nw_7c82ce01-d3e6-4e5a-9d11-d16698b5e909">6,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805564f130794c159907d4cd7218c011_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNC02LTEtMS0yODk0Nw_19626c8f-5bc0-4ca2-86a7-cd08bc744e53">5,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaef54a8191e044bf93f11f4bc2a4e911_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNS0yLTEtMS0yODk0Ny90ZXh0cmVnaW9uOmZlYjA2NzUyNmE1NzQ5MmNiNDM4MGRhNDdiODMwYTk2XzQ_784cb2c3-d4c3-4349-af96-5d157ded768a">3</ix:nonNumeric>-<ix:nonNumeric contextRef="ic131085d4cfa45ffaa948fcbbe39e100_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNS0yLTEtMS0yODk0Ny90ZXh0cmVnaW9uOmZlYjA2NzUyNmE1NzQ5MmNiNDM4MGRhNDdiODMwYTk2Xzc_371f242a-ea87-484c-b932-f10f8d2730c4">5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74052c73b62e4b3ca8e440d6a7b6b48a_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNS00LTEtMS0yODk0Nw_eba44f83-3974-490a-946c-65e19e62482d">7,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia326b8c20ab24d99baac8636d47b1d21_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNS02LTEtMS0yODk0Nw_363a7618-21c6-43c4-9e54-46fec06c6c9d">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1378d80bd52a41168942eacca8002c0e_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNi0yLTEtMS0yODk0Nw_b60bd648-ba84-4324-90d4-5be5ec378be9">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34f0289767e04e32a7cfdbeba5d34a52_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNi00LTEtMS0yODk0Nw_c91cd72f-3cfd-4b35-8c04-7a087c8457ff">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eae84db78bc47d8b25e7ed4a65b6f34_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNi02LTEtMS0yODk0Nw_2679e3dc-4e4e-480f-83d3-b4db35f802bf">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4791157952514b1fb66954d88f405f1a_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNy0yLTEtMS0yODk0Nw_5d7ac262-b075-4a33-b14a-f6d68d5cc224">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i483f5f82cf52494c8e648b074f86b53e_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNy00LTEtMS0yODk0Nw_8ef81da7-a780-4da3-8108-3fc11563c8a5">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7daf1615bf64212badeff54cd466033_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNy02LTEtMS0yODk0Nw_e2106dfd-6ecb-486b-91f3-4499aa7a0b8a">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0ce4bf905b02467b8dfd8172fa04331a_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfOC0yLTEtMS0yODk0Ny90ZXh0cmVnaW9uOmQ0ODRkYmI3YTNiYzQwYTZiNThlMTMwZTNmZTNjNTQ4XzE2NDkyNjc0NDE2NzI_df41f858-cf72-4cd7-9511-35a65b9d2ca1">2</ix:nonNumeric>-<ix:nonNumeric contextRef="icfd0d2a201514ed9a710f3e15a4be0ec_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfOC0yLTEtMS0yODk0Ny90ZXh0cmVnaW9uOmQ0ODRkYmI3YTNiYzQwYTZiNThlMTMwZTNmZTNjNTQ4XzE2NDkyNjc0NDE2NzY_393027cc-ccc6-49f9-9c6e-1cb60ee29506">10</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf90ef381262457fb02ac15abe61db23_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfOC00LTEtMS0yODk0Nw_230f3303-5bfe-47d0-950a-46ad3f256daf">37,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff8e585d8da4a4eadbb4f76e2229297_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfOC02LTEtMS0yODk0Nw_450e3efd-5881-4ad1-bb6a-5833ad0cbfc0">36,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress (CIP)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bcb57d4e9ec41c3913ce6375172ce80_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfOS00LTEtMS0yODk0Nw_6767c663-b0ed-4402-a659-04bd16c61997">27,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e1185e028b41649a95d8db0860d1ed_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfOS02LTEtMS0yODk0Nw_81a45d3e-6fa2-41f6-9126-c31df74dd490">27,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMTAtNC0xLTEtMjg5NDc_3e32329c-695d-4a13-9e56-b45e8eec2ba3">93,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMTAtNi0xLTEtMjg5NDc_aecf528a-3f1d-42e4-a10d-023d5e39cba3">90,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMTEtNC0xLTEtMjg5NDc_1249cd34-7e50-4e66-af5e-3f7bca02e5f4">39,305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMTEtNi0xLTEtMjg5NDc_5985298a-1c1e-4cc2-9c56-6bda7f5b035e">37,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMTItNC0xLTEtMjg5NDc_cd67cc9a-e896-42cc-b01e-57108ac45f9b">53,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMTItNi0xLTEtMjg5NDc_b2e92b16-fc50-4d17-ba70-c94040fc2c78">52,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i252108b308054887a46901fe227627f1_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RleHRyZWdpb246MzEzMzE4MTQ5NTE4NDNlNjgxNGYyODNiMDYyODU4MmZfMTcw_ee7ea84a-e066-4547-bd81-cd1097a03354" continuedAt="i5660acd2266e4e17a0859eb45ea0764a" escape="true">Accrued Liabilities</ix:nonNumeric></span></div><ix:continuation id="i5660acd2266e4e17a0859eb45ea0764a"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RleHRyZWdpb246MzEzMzE4MTQ5NTE4NDNlNjgxNGYyODNiMDYyODU4MmZfMTcy_218c405c-e15c-4a6d-ade4-b14c92365a79" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, the Company's accrued liabilities balance consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:57.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="insm:AccruedClinicalTrialExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfMS0xLTEtMS0yODk0Nw_cea52145-c282-4963-bc3d-d0bf4c35425a">17,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="insm:AccruedClinicalTrialExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfMS0zLTEtMS0yODk0Nw_0df72799-a996-42b2-befe-150ca800d2e6">19,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfMi0xLTEtMS0yODk0Nw_76cba81f-f178-449f-91ba-f834b47b73b3">11,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfMi0zLTEtMS0yODk0Nw_4cab2f77-51c0-482b-97be-026638649a56">10,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued technical operation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="insm:AccruedTechnicalOperationExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfMy0xLTEtMS0yODk0Nw_1925ea72-bb80-4b67-be7f-680167087792">4,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="insm:AccruedTechnicalOperationExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfMy0zLTEtMS0yODk0Nw_938a893c-88c9-4438-9770-5a04ef648447">6,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="insm:AccruedRoyaltiesAndMilestonePaymentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfNC0xLTEtMS0yODk0Nw_4ec06238-bcf4-4de8-bf35-b92161951d58">7,182</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="insm:AccruedRoyaltiesAndMilestonePaymentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfNC0zLTEtMS0yODk0Nw_4fa62d47-6f9f-4904-b250-7562bfaaa3bb">6,655</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfNS0xLTEtMS0yODk0Nw_436fac95-3c41-4302-b591-c915cf60902f">2,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfNS0zLTEtMS0yODk0Nw_f92a929f-71a3-4e7f-8b52-059e82e09ecd">2,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales allowances and related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="insm:AccruedSalesAllowancesAndRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfNi0xLTEtMS0yODk0Nw_bf95da8b-c03a-4a39-bb2f-54988665b4eb">11,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="insm:AccruedSalesAllowancesAndRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfNi0zLTEtMS0yODk0Nw_71501136-e310-449d-a05e-7730555acbf0">8,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="insm:BusinessCombinationDeferredPaymentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfNy0xLTEtMS0yODk0Nw_a7205b21-ae47-4b7e-bd84-3701530b1f0d">3,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="insm:BusinessCombinationDeferredPaymentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfNy0zLTEtMS0yODk0Nw_dd39e2ff-e5d3-4ca3-929b-10321215c70b">4,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="insm:AccruedConstructionLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfOC0xLTEtMS0yODk0Nw_855dcbbe-5242-4d9b-8eb8-22beac9a690b">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="insm:AccruedConstructionLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfOC0zLTEtMS0yODk0Nw_d87d8dbf-bc08-40a5-90c4-365c2916eedc">551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfOS0xLTEtMS0yODk0Nw_48d13737-5642-4362-bf1a-60a8d75eed67">1,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfOS0zLTEtMS0yODk0Nw_460f9346-e21b-45fb-a6e8-1cb3c8821b6e">1,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfMTAtMS0xLTEtMjg5NDc_57b7e41f-7630-42c5-97c9-84463f940f90">58,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfMTAtMy0xLTEtMjg5NDc_d3888018-aa3c-4cc9-9144-fcb1d7018479">60,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i252108b308054887a46901fe227627f1_49"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfMzUxOQ_284f597f-bc62-47ad-a955-6db0b16b352a" continuedAt="i7e7e2684e6564c59adab863e96714f32" escape="true"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfMzUxOQ_b8e74e8d-bb58-4e82-a355-33328a11e8c9" continuedAt="i821f7b47330646dfafa542ad58816473" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i7e7e2684e6564c59adab863e96714f32" continuedAt="i7b67283e662e48c59cd5ea0baaa9df77"><ix:continuation id="i821f7b47330646dfafa542ad58816473" continuedAt="i778a25e8220648a5bec6f0a62eda6894"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than <ix:nonNumeric contextRef="iab7551ae213f49089690e61c379022e7_D20220101-20220630" name="insm:LeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfNDg1_7a49d804-e392-496b-bafe-57e68b63930f">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="i345e38b73d984ac7acfa140fc7af5a1a_D20220101-20220630" name="insm:LeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfNDkx_cf17fd5f-18d1-46d5-bdc8-0272bde2e54b">ten years, ten months</ix:nonNumeric>. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $<ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfMTk4Ng_531dcf37-c775-487d-99f0-dbfa44ef9ecb">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfMTk5Mw_49511a40-3d16-4c33-a97d-12490614a5ac">0.2</ix:nonFraction> million for the three months ended June&#160;30, 2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfMjc0ODc3OTA3MzAyMA_04eaf325-e29f-4f9c-815f-8468521c9777">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfMjc0ODc3OTA3MzAyNw_638e51c2-dd74-47a9-b7db-50b28137007b">0.3</ix:nonFraction> million for the six months ended June 30, 2022 and 2021, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.</span></div><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfMzUxOA_609ae0f3-3220-4ed5-b81d-5ce7b8ec448e" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the supplemental noncash disclosures of the Company's leases included in its consolidated financial statements (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.256%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RhYmxlOjUzMjE1ZTEzNzU2YTRkYTdiYzg3ZjZmZmE3YTUzYjkyL3RhYmxlcmFuZ2U6NTMyMTVlMTM3NTZhNGRhN2JjODdmNmZmYTdhNTNiOTJfMi0xLTEtMS0yODk0Nw_a86f5e56-f55d-4406-a8e9-6daac88ff3a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RhYmxlOjUzMjE1ZTEzNzU2YTRkYTdiYzg3ZjZmZmE3YTUzYjkyL3RhYmxlcmFuZ2U6NTMyMTVlMTM3NTZhNGRhN2JjODdmNmZmYTdhNTNiOTJfMi0zLTEtMS0yODk0Nw_aa0a40c3-44cf-4c7d-b22c-a8b2f7d699c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RhYmxlOjUzMjE1ZTEzNzU2YTRkYTdiYzg3ZjZmZmE3YTUzYjkyL3RhYmxlcmFuZ2U6NTMyMTVlMTM3NTZhNGRhN2JjODdmNmZmYTdhNTNiOTJfMi01LTEtMS0yODk0Nw_daca5dc4-6730-4dd4-b713-705e1038e0ab">9,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RhYmxlOjUzMjE1ZTEzNzU2YTRkYTdiYzg3ZjZmZmE3YTUzYjkyL3RhYmxlcmFuZ2U6NTMyMTVlMTM3NTZhNGRhN2JjODdmNmZmYTdhNTNiOTJfMi03LTEtMS0yODk0Nw_6afd11c7-2583-40fb-86e0-cee9823862c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RhYmxlOjUzMjE1ZTEzNzU2YTRkYTdiYzg3ZjZmZmE3YTUzYjkyL3RhYmxlcmFuZ2U6NTMyMTVlMTM3NTZhNGRhN2JjODdmNmZmYTdhNTNiOTJfMy0xLTEtMS0yODk0Nw_fda9daaf-81c5-4541-a9e1-a05e56f5afb4">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RhYmxlOjUzMjE1ZTEzNzU2YTRkYTdiYzg3ZjZmZmE3YTUzYjkyL3RhYmxlcmFuZ2U6NTMyMTVlMTM3NTZhNGRhN2JjODdmNmZmYTdhNTNiOTJfMy0zLTEtMS0yODk0Nw_7145a166-f459-4fbc-8760-1a24a90e2d53">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RhYmxlOjUzMjE1ZTEzNzU2YTRkYTdiYzg3ZjZmZmE3YTUzYjkyL3RhYmxlcmFuZ2U6NTMyMTVlMTM3NTZhNGRhN2JjODdmNmZmYTdhNTNiOTJfMy01LTEtMS0yODk0Nw_9b876b0c-291d-4970-85c8-4f5c87be3b59">507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RhYmxlOjUzMjE1ZTEzNzU2YTRkYTdiYzg3ZjZmZmE3YTUzYjkyL3RhYmxlcmFuZ2U6NTMyMTVlMTM3NTZhNGRhN2JjODdmNmZmYTdhNTNiOTJfMy03LTEtMS0yODk0Nw_d2dbd245-a2e9-4916-aa2e-3ae88e5d10e9">8,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-5" name="insm:LesseeOperatingLeaseLeaseNotYetCommencedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfMzE4OQ_328b9bd9-30a6-44d2-a718-2257ea088d16">36.3</ix:nonFraction> million incurred by the </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i7b67283e662e48c59cd5ea0baaa9df77" continuedAt="icbc1a79ee7444316a84636a5d2112d13"><ix:continuation id="i778a25e8220648a5bec6f0a62eda6894" continuedAt="i1eedc4beb55b49f4b23cc614c81b4679"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company under these additional agreements have been classified within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icbc1a79ee7444316a84636a5d2112d13"><ix:continuation id="i1eedc4beb55b49f4b23cc614c81b4679">other assets in the Company's consolidated balance sheet. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.</ix:continuation></ix:continuation> </span></div><div id="i252108b308054887a46901fe227627f1_52"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNzg0OA_62f02a4e-a978-4a17-8978-af56d449c909" continuedAt="i54d0d56f1c584d4cabb3bc264c690af5" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i54d0d56f1c584d4cabb3bc264c690af5" continuedAt="ibe62e677a3cf4363a5e95e92418bfccb"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company completed an underwritten public offering of the 2028 Convertible Notes, in which the Company sold $<ix:nonFraction unitRef="usd" contextRef="i3905fa6bad2f4f878b2411f148bf023a_I20210531" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMTcy_1cefba15-63ff-4fe4-804b-4b9ffeb39903">575.0</ix:nonFraction> million aggregate principal amount of the 2028 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $<ix:nonFraction unitRef="usd" contextRef="i3905fa6bad2f4f878b2411f148bf023a_I20210531" decimals="-5" name="insm:DebtInstrumentOptionToPurchaseAdditionalDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMzE4_b15933bd-24d3-4c96-a3e1-8abf6e9a1f80">75.0</ix:nonFraction> million in aggregate principal amount of 2028 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i3905fa6bad2f4f878b2411f148bf023a_I20210531" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNTEw_bc44149d-ff86-4e84-9536-d7f0d63e7c21">15.7</ix:nonFraction>&#160;million, were approximately $<ix:nonFraction unitRef="usd" contextRef="i3b10eb0c1f2944019b12df6a3c668f5b_D20210501-20210531" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNTMz_ff75ef31-e9c0-4a36-afeb-c574be03effc">559.3</ix:nonFraction> million. The 2028 Convertible Notes bear interest payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2021. The 2028 Convertible Notes mature on June 1, 2028, unless earlier converted, redeemed, or repurchased. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company completed an underwritten public offering of the 2025 Convertible Notes, in which the Company sold $<ix:nonFraction unitRef="usd" contextRef="i78d8e00c8ae5498c94772ed4b961f0bb_I20180131" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfOTEy_920d5d10-fa24-4797-ab12-1535e63cbcbc">450.0</ix:nonFraction> million aggregate principal amount of the 2025 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $<ix:nonFraction unitRef="usd" contextRef="i78d8e00c8ae5498c94772ed4b961f0bb_I20180131" decimals="-5" name="insm:DebtInstrumentOptionToPurchaseAdditionalDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMTA1OA_c0a748d4-d3f9-4427-9914-f7fa94300350">50.0</ix:nonFraction> million in aggregate principal amount of 2025 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i78d8e00c8ae5498c94772ed4b961f0bb_I20180131" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMTI1MA_d071af20-4ea1-4f04-92db-2b430b8948a8">14.2</ix:nonFraction> million, were approximately $<ix:nonFraction unitRef="usd" contextRef="ibc290352fb8049bea385a8284c77e6de_D20180101-20180131" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMTI3Mw_90844759-2c3c-4b7f-8192-680d6454e267">435.8</ix:nonFraction> million. The 2025 Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The 2025 Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the net proceeds from the 2028 Convertible Notes was used to repurchase $<ix:nonFraction unitRef="usd" contextRef="i3b3c8791efbd4b76898c1f2be69fa04b_I20210531" decimals="-5" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMTYxMQ_45dd9dc5-00b8-4183-bf10-26222f1cc44e">225.0</ix:nonFraction> million of the Company's outstanding 2025 Convertible Notes. The Company recorded a loss on early extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i2aafae0ef97940e9afdb689e748f167a_D20210501-20210531" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMTczMA_0bc44c9e-58b4-48ef-b31e-86809dfaf15e">17.7</ix:nonFraction> million, primarily related to the premium paid on extinguishment of a portion the 2025 Convertible Notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after October&#160;15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their 2025 Convertible Notes at any time. The initial conversion rate for the 2025 Convertible Notes is <ix:nonFraction unitRef="number" contextRef="iccd7845446c64a369164bb9ead8f5b59_D20180101-20180131" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMjA4OQ_5437fee6-3734-4401-a19d-a50bdd31c946">25.5384</ix:nonFraction> shares of common stock per $1,000 principal amount of 2025 Convertible Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i78d8e00c8ae5498c94772ed4b961f0bb_I20180131" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMjIyOQ_e0de3a19-7ee1-4137-8e2c-c3004aa47212">39.16</ix:nonFraction> per share of common stock). On or after March 1, 2028, until the close of business on the second scheduled trading day immediately preceding June 1, 2028, holders may convert their 2028 Convertible Notes at any time. The initial conversion rate for the 2028 Convertible Notes is <ix:nonFraction unitRef="number" contextRef="i0f13738b91a24ea68cfbd83444c1fda2_D20180101-20180131" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMjUxMQ_4e06a061-5c92-4463-9503-c2cb40c28297">30.7692</ix:nonFraction> shares of common stock per $1,000 principal amount of 2028 Convertible Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i3905fa6bad2f4f878b2411f148bf023a_I20210531" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMjY1MQ_a005b621-15d9-409c-b893-c9bc9e9ef81d">32.50</ix:nonFraction> per share of common stock). Upon conversion of either the 2025 Convertible Notes or the 2028 Convertible Notes, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The conversion rates will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2025 Convertible Notes prior to October 15, 2024 or their 2028 Convertible Notes prior to March 1, 2028, only under the following circumstances, subject to the conditions set forth in the applicable indenture: (i) during the <ix:nonFraction unitRef="day" contextRef="i360c8f6cf0d349aa971816bd2ab768a8_D20210501-20210531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMzMwMA_0b2165cb-623d-427b-af50-8a5abe8a41d6"><ix:nonFraction unitRef="day" contextRef="i677c8198ab1b4318bd9f81ef52a60fbd_D20180101-20180131" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMzMwMA_30de4bb1-bb15-41dd-b858-00c97c1099d3">five</ix:nonFraction></ix:nonFraction> business day period immediately after any <ix:nonFraction unitRef="day" contextRef="i677c8198ab1b4318bd9f81ef52a60fbd_D20180101-20180131" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMzM0NQ_1a041a52-5bfb-4d0a-a0cf-97307dcf640e"><ix:nonFraction unitRef="day" contextRef="i360c8f6cf0d349aa971816bd2ab768a8_D20210501-20210531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMzM0NQ_ed2146b8-390d-48d2-bf3e-2b2e94c5177a">five</ix:nonFraction></ix:nonFraction> consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of the applicable series of convertible notes, as determined following a request by a holder of such convertible notes, for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="i677c8198ab1b4318bd9f81ef52a60fbd_D20180101-20180131" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMzY0MA_09fa8de6-1982-4e99-aec5-fed6e06f3b3a"><ix:nonFraction unitRef="number" contextRef="i360c8f6cf0d349aa971816bd2ab768a8_D20210501-20210531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMzY0MA_88b61ef3-a480-48dd-a187-793df27253ce">98</ix:nonFraction></ix:nonFraction>% of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than <ix:nonFraction unitRef="day" contextRef="i0d34cc38f62945cc8de38c2b34b77333_D20180101-20180131" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNDA5OQ_4eb4c166-734a-4eab-bb95-4910b944c621"><ix:nonFraction unitRef="day" contextRef="i120ab819124c4ec7955b853c7979a0e0_D20210501-20210531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNDA5OQ_764c19e2-8f96-4956-aad6-b7f2a02c4846">45</ix:nonFraction></ix:nonFraction> days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the <ix:nonFraction unitRef="day" contextRef="i120ab819124c4ec7955b853c7979a0e0_D20210501-20210531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNDMyMA_737c6d6f-53d3-44da-94c5-6f9b9a68c41c"><ix:nonFraction unitRef="day" contextRef="i0d34cc38f62945cc8de38c2b34b77333_D20180101-20180131" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNDMyMA_8fa3305a-fb34-454a-bb89-89ced26d27cf">10</ix:nonFraction></ix:nonFraction> consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company's assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding <ix:nonFraction unitRef="number" contextRef="i120ab819124c4ec7955b853c7979a0e0_D20210501-20210531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNDY2MA_5762dbd9-e16b-4883-884f-a825f6cba314"><ix:nonFraction unitRef="number" contextRef="i0d34cc38f62945cc8de38c2b34b77333_D20180101-20180131" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNDY2MA_91eaf0d6-f62a-47d3-bbf1-8ea4079a0dab">10</ix:nonFraction></ix:nonFraction>% of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the applicable series of convertible notes may be surrendered by a holder for conversion at any time from or after the date that is <ix:nonFraction unitRef="day" contextRef="ie08ca784c1914a3d9e58680c070a1adb_D20210501-20210531" decimals="INF" name="insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNTU1OA_2c716545-402f-428c-8f02-4bedb94386f8"><ix:nonFraction unitRef="day" contextRef="ief82ea409318476187e7caeb47194f48_D20180101-20180131" decimals="INF" name="insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNTU1OA_30c32a69-853d-433f-8f7e-793901920ef3">30</ix:nonFraction></ix:nonFraction> scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2018 or June 30, 2021 for the 2025 Convertible Notes and the 2028 Convertible Notes, respectively (and only during such calendar quarter), the last reported sale price of the common stock for at least <ix:nonFraction unitRef="day" contextRef="ibbcdfbf9e8254e929522a467310b9522_D20180101-20180131" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNTkzNg_0a74d119-0020-4699-8cd5-33818e3ac440"><ix:nonFraction unitRef="day" contextRef="ie0d8b12165884f4ab863204524ec1168_D20210501-20210531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNTkzNg_4eedb926-02e1-4bed-8809-f56a2b42d6da">20</ix:nonFraction></ix:nonFraction> trading days (whether or not consecutive) during the period of <ix:nonFraction unitRef="day" contextRef="ibbcdfbf9e8254e929522a467310b9522_D20180101-20180131" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNjAwMg_98b56e3d-23cb-4303-997d-a50a1ea8b8f1"><ix:nonFraction unitRef="day" contextRef="ie0d8b12165884f4ab863204524ec1168_D20210501-20210531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNjAwMg_a2185195-79c1-43d2-a7ff-cf0bdfb7b042">30</ix:nonFraction></ix:nonFraction> consecutive trading days ending on the last trading day of the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><ix:continuation id="ibe62e677a3cf4363a5e95e92418bfccb"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immediately preceding calendar quarter is greater than or equal to <ix:nonFraction unitRef="number" contextRef="ibbcdfbf9e8254e929522a467310b9522_D20180101-20180131" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNjEzNQ_1fc410d3-865b-4bdb-84b9-1d540f9d6cd5"><ix:nonFraction unitRef="number" contextRef="ie0d8b12165884f4ab863204524ec1168_D20210501-20210531" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNjEzNQ_f2b24bf6-45c0-4f1a-b756-23d0184c023d">130</ix:nonFraction></ix:nonFraction>% of the conversion price on each applicable trading day, or (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its convertible notes to which the notice of redemption relates for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a)&#160;the second business day immediately preceding the related redemption date or (b)&#160;if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid. To date, there have not been any holder-initiated redemption requests of either series of convertible notes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each series of convertible notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in both series of convertible notes are not required to be separately accounted for as a derivative. The 2025 Convertible Notes and 2028 Convertible Notes have remaining terms of approximately <ix:nonNumeric contextRef="i82d7c106dda746228e53977a22a4368f_D20220101-20220630" name="insm:ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNzI0Mw_12c5a51b-9280-4fb2-898e-dfc56fd12ab4">2.54</ix:nonNumeric> years and <ix:nonNumeric contextRef="i94cb8d7603c84b26a3152ca2f217dbcf_D20220101-20220630" name="insm:ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNzI1MA_5fa48c08-9c7b-44cc-9e74-c28a845c6714">5.92</ix:nonNumeric> years, respectively. <ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNzg1MQ_68e140e9-3e3c-45f3-bfb9-3426bb1d84fe" continuedAt="i24870bf5d7bf45d988ebca3933d4ab49" escape="true">The following table presents the carrying value of the Company's debt balance (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><ix:continuation id="i24870bf5d7bf45d988ebca3933d4ab49"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:58.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.230%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of outstanding convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjEyY2VhMzFhMWMxMTQ3MGJhN2FmNWJiYjE4YzFmNWRjL3RhYmxlcmFuZ2U6MTJjZWEzMWExYzExNDcwYmE3YWY1YmJiMThjMWY1ZGNfMS0xLTEtMS0yODk0Nw_6178aac6-2eb5-436f-97f1-1f008eb1dbe2">800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjEyY2VhMzFhMWMxMTQ3MGJhN2FmNWJiYjE4YzFmNWRjL3RhYmxlcmFuZ2U6MTJjZWEzMWExYzExNDcwYmE3YWY1YmJiMThjMWY1ZGNfMS0zLTEtMS0yODk0Nw_3499e579-b47f-4a30-9f3a-b66932fb8444">800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs, unamortized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjEyY2VhMzFhMWMxMTQ3MGJhN2FmNWJiYjE4YzFmNWRjL3RhYmxlcmFuZ2U6MTJjZWEzMWExYzExNDcwYmE3YWY1YmJiMThjMWY1ZGNfMi0xLTEtMS0yODk0Nw_9b750a8e-0201-4b7b-92e3-b4aeae65cec1">16,023</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjEyY2VhMzFhMWMxMTQ3MGJhN2FmNWJiYjE4YzFmNWRjL3RhYmxlcmFuZ2U6MTJjZWEzMWExYzExNDcwYmE3YWY1YmJiMThjMWY1ZGNfMi0zLTEtMS0yODk0Nw_50b5bfd3-1b1e-459f-9a9e-dacf0759bd7a">11,539</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjEyY2VhMzFhMWMxMTQ3MGJhN2FmNWJiYjE4YzFmNWRjL3RhYmxlcmFuZ2U6MTJjZWEzMWExYzExNDcwYmE3YWY1YmJiMThjMWY1ZGNfMy0xLTEtMS0yODk0Nw_9bcaf11f-6b9a-422d-8474-4db0a158bf0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjEyY2VhMzFhMWMxMTQ3MGJhN2FmNWJiYjE4YzFmNWRjL3RhYmxlcmFuZ2U6MTJjZWEzMWExYzExNDcwYmE3YWY1YmJiMThjMWY1ZGNfMy0zLTEtMS0yODk0Nw_e3d4e8b6-739f-4af0-9560-e1f1e30493ab">221,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjEyY2VhMzFhMWMxMTQ3MGJhN2FmNWJiYjE4YzFmNWRjL3RhYmxlcmFuZ2U6MTJjZWEzMWExYzExNDcwYmE3YWY1YmJiMThjMWY1ZGNfNC0xLTEtMS0yODk0Nw_76640a30-ad3f-4fb5-a5fe-ecc21333ce56">783,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjEyY2VhMzFhMWMxMTQ3MGJhN2FmNWJiYjE4YzFmNWRjL3RhYmxlcmFuZ2U6MTJjZWEzMWExYzExNDcwYmE3YWY1YmJiMThjMWY1ZGNfNC0zLTEtMS0yODk0Nw_b2e0eedc-cecf-4bd8-bb6f-7e2ec3327afe">566,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNzg0NQ_7e9556a8-7510-4403-aa32-ed8fa559e758" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, future principal repayments of the notes for each of the years through maturity were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.543%"><tr><td style="width:1.0%"></td><td style="width:64.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOmFkZWU2N2QxNDAwMTQ2YmY4NTVmZGQ1ZjI3ZTEzNzIyL3RhYmxlcmFuZ2U6YWRlZTY3ZDE0MDAxNDZiZjg1NWZkZDVmMjdlMTM3MjJfMS0xLTEtMS0yODk0Nw_46171134-26c4-4fb9-be71-62372253a80b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOmFkZWU2N2QxNDAwMTQ2YmY4NTVmZGQ1ZjI3ZTEzNzIyL3RhYmxlcmFuZ2U6YWRlZTY3ZDE0MDAxNDZiZjg1NWZkZDVmMjdlMTM3MjJfMi0xLTEtMS0yODk0Nw_30872827-b1ff-435e-8dca-42e5cb2823f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOmFkZWU2N2QxNDAwMTQ2YmY4NTVmZGQ1ZjI3ZTEzNzIyL3RhYmxlcmFuZ2U6YWRlZTY3ZDE0MDAxNDZiZjg1NWZkZDVmMjdlMTM3MjJfMy0xLTEtMS0yODk0Nw_3978a6ac-fb8b-44f4-a150-739bf058f53f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOmFkZWU2N2QxNDAwMTQ2YmY4NTVmZGQ1ZjI3ZTEzNzIyL3RhYmxlcmFuZ2U6YWRlZTY3ZDE0MDAxNDZiZjg1NWZkZDVmMjdlMTM3MjJfNC0xLTEtMS0yODk0Nw_e71ed570-8084-4381-a126-608ea6ecd783">225,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOmFkZWU2N2QxNDAwMTQ2YmY4NTVmZGQ1ZjI3ZTEzNzIyL3RhYmxlcmFuZ2U6YWRlZTY3ZDE0MDAxNDZiZjg1NWZkZDVmMjdlMTM3MjJfNS0xLTEtMS0yODk0Nw_0c2e34df-634d-4317-aac3-4d09fa0abfb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="insm:LongTermDebtMaturityAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOmFkZWU2N2QxNDAwMTQ2YmY4NTVmZGQ1ZjI3ZTEzNzIyL3RhYmxlcmFuZ2U6YWRlZTY3ZDE0MDAxNDZiZjg1NWZkZDVmMjdlMTM3MjJfNi0xLTEtMS0yODk0Nw_e6916dc7-701f-4beb-bdc5-714bb7f0c8b6">575,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOmFkZWU2N2QxNDAwMTQ2YmY4NTVmZGQ1ZjI3ZTEzNzIyL3RhYmxlcmFuZ2U6YWRlZTY3ZDE0MDAxNDZiZjg1NWZkZDVmMjdlMTM3MjJfNy0xLTEtMS0yODk0Nw_e4ba93d5-ccb6-4ade-bdf5-d32cfa305d01">800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNzg1NQ_d7af5d90-ebe7-452c-9ff4-2f2c2081f300" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to debt and finance leases for the three and six months ended June&#160;30, 2022 and 2021 is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:34.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfMi0xLTEtMS0yODk0Nw_6b02a679-e14a-4b93-97a8-58e8d2e48a43">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfMi0zLTEtMS0yODk0Nw_98f79f6a-8f11-4bb4-89b9-683bb0788174">2,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfMi01LTEtMS0yODk0Nw_6ef752f8-8929-4d71-a972-726e9ce2031c">4,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfMi03LTEtMS0yODk0Nw_b3a6993f-4104-4f8d-976c-a2411075ce82">4,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfMy0xLTEtMS0yODk0Nw_e15af06a-fb4a-42c5-8e0a-5d2cfeff4dff">821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfMy0zLTEtMS0yODk0Nw_09f99ae1-39fb-41db-8901-3c724293073b">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfMy01LTEtMS0yODk0Nw_209dc564-8ff7-40c5-ad97-e0de0d8d6755">1,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfMy03LTEtMS0yODk0Nw_ebb56437-f05c-4c76-9eef-19b5a328f6ff">807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNS0xLTEtMS0yODk0Nw_3285c2b7-5fbd-43bc-91f6-983d136c0647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNS0zLTEtMS0yODk0Nw_4170eb2c-abbf-47c1-991e-85000cded2bf">7,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNS01LTEtMS0yODk0Nw_f34928bb-ba5c-4b6b-8403-ab1968987c76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNS03LTEtMS0yODk0Nw_98de35f2-7719-445e-a178-e275e62409e6">12,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible debt interest expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="insm:ConvertibleDebtInterestExpenseTotal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNi0xLTEtMS0yODk0Nw_fe45ee21-054c-4d39-be86-34cb23f9c9c7">2,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="insm:ConvertibleDebtInterestExpenseTotal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNi0zLTEtMS0yODk0Nw_9db9e5c7-c8b1-4676-b5b1-f7e4ad24ffe6">9,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="insm:ConvertibleDebtInterestExpenseTotal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNi01LTEtMS0yODk0Nw_d49e9752-0768-4ae9-842c-9cd1e09c9dc7">5,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="insm:ConvertibleDebtInterestExpenseTotal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNi03LTEtMS0yODk0Nw_7d2973e5-7751-4dc9-89a3-a5b4b0e86206">17,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNy0xLTEtMS0yODk0Nw_8375b0cd-e5ca-4cde-ad52-a72b32824aa1">474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNy0zLTEtMS0yODk0Nw_e521dd40-c8fb-4706-aee9-8b0a511cc347">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNy01LTEtMS0yODk0Nw_06944604-cfde-4f15-94e2-7df97d4b86b6">880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNy03LTEtMS0yODk0Nw_4da6c5fa-740e-478d-96de-6d325455a510">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfOC0xLTEtMS0yODk0Nw_243fc86d-2979-4214-b0d5-927dcab1ee34">3,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfOC0zLTEtMS0yODk0Nw_38b3f48e-a82a-435a-9781-efae54f553bc">10,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfOC01LTEtMS0yODk0Nw_3838b551-35f6-4541-a6a7-9ed522c26066">6,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfOC03LTEtMS0yODk0Nw_4bf59a08-b314-4b32-889f-90369e858c55">17,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Company's transition using the modified retrospective method upon adopting ASU 2020-06, Debt &#8212; Accounting for Convertible Instruments, on January 1, 2022, the Company ceased accreting debt discount.</span></div></ix:continuation><div id="i252108b308054887a46901fe227627f1_58"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMzI4Mw_d1741e3f-3148-4dd9-a910-15d8f1a81bd3" continuedAt="ie6ca227795d34f569e00384203386875" escape="true">Shareholders&#8217; Equity</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><ix:continuation id="ie6ca227795d34f569e00384203386875" continuedAt="i954458adbd0c495eba1f27eb21c13342"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; As of June&#160;30, 2022, the Company had <ix:nonFraction unitRef="shares" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMTA3_84f2e7e7-aa6b-46ae-a196-ea7c1e85032d">500,000,000</ix:nonFraction> shares of common stock authorized with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMTY0_7ccf62f0-d5cc-4662-aae7-d955ba3bd105">0.01</ix:nonFraction> per share and <ix:nonFraction unitRef="shares" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMTgx_43714ff7-a5ad-4bb3-925b-54a7942e5146"><ix:nonFraction unitRef="shares" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMTgx_e462868d-96ba-4b4a-b5dc-672dcc606de4">119,865,023</ix:nonFraction></ix:nonFraction> shares of common stock issued and outstanding. In addition, as of June&#160;30, 2022, the Company had reserved <ix:nonFraction unitRef="shares" contextRef="i63fc774e8854431ba4eafe553558adf0_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMjc5_ab8262b5-3e71-44c8-b3a8-6539cbc86f07">17,805,766</ix:nonFraction> shares of common stock for issuance upon the exercise of outstanding stock options, <ix:nonFraction unitRef="shares" contextRef="i4043f106b7ff4d2aa5e7c93a3a3ae9cd_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMzY2_0b9c3d1a-4441-49be-a135-2744a2d6ec6d">1,619,225</ix:nonFraction> shares of common stock for issuance upon the vesting of RSUs and <ix:nonFraction unitRef="shares" contextRef="i1861d72030824ced8ef920fa4c278220_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfNDM0_0738cd0e-9265-406b-a31e-4d3a517aba65">670,168</ix:nonFraction> shares for issuance upon the vesting of PSUs. The Company has also reserved <ix:nonFraction unitRef="shares" contextRef="i2e74b1e1d79d4206a35bd3d6cae5a699_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfNTEz_5d827237-37bc-4322-81ed-8d0005604bb6">23,438,430</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock in the aggregate for issuance upon conversion of the 2025 Convertible Notes and 2028 Convertible Notes, subject to adjustment in accordance with the applicable indentures. In </span></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><ix:continuation id="i954458adbd0c495eba1f27eb21c13342"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">connection with the Business Acquisition, the Company reser</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ved <ix:nonFraction unitRef="shares" contextRef="ie5cf4cca2bb1485f813f9ef62c61797a_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfNzc4_147758ee-4efc-497e-9814-d0f70ba78941">9,406,112</ix:nonFraction> s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hares of the Company&#8217;s common stock, subject to certain closing-related reductions. The shares of the Company&#8217;s common stock reserved in connection with the Motus acquisition were partly issued as acquisition consideration at closing, and will also be issued upon the first, second and third anniversaries of the closing date of the acquisition and upon the achievement of certain development and regulatory milestone events, subject to certain reductions. The shares of the Company&#8217;s common stock reserved in connection with the AlgaeneX acquisition will be issued upon the achievement of a development milestone event, subject to certain reductions. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Of the <ix:nonFraction unitRef="shares" contextRef="ie5cf4cca2bb1485f813f9ef62c61797a_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMTQzOA_75e2cb0e-869b-4515-8666-ffdcd4aab3d6">9,406,112</ix:nonFraction> shares reserved, subject to certain closing-related reductions, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company issued <ix:nonFraction unitRef="shares" contextRef="i0b9b0a45175146259bc231dc8f5ee5c6_D20210701-20210930" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMTUyNA_f4862f4b-0f40-4def-9ce5-af9f426bdd36">2,889,367</ix:nonFraction> shares of the Company's common stock in connection with the Business Acquisition (Note 13) i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n the third quarter</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of 2021, after certain closing-related deductions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of 2021, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i171123b4124b445eba208fcf196842fc_D20210401-20210630" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMTg0OQ_6d44f35e-5764-41e4-825e-8464fb1f5338">11,500,000</ix:nonFraction> shares of the Company's common stock, including <ix:nonFraction unitRef="shares" contextRef="i7f2cf2d9e0294d689a5e13786a2e00a2_D20210401-20210630" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMTkwMA_8325ef04-a12e-40ae-ac88-1e6e5d8daf3d">1,500,000</ix:nonFraction> shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares from the Company, a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i34b29fd1e2a04660a3bb612c3f24dde5_I20210630" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMjA1Ng_ac999290-06cb-4e17-ac5a-370c1a747e58">25.00</ix:nonFraction> per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMjE5NA_b4d90a47-30a2-4312-b363-8c7c22e9b8cd">17.5</ix:nonFraction> million, were $<ix:nonFraction unitRef="usd" contextRef="i171123b4124b445eba208fcf196842fc_D20210401-20210630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMjIwMw_277d3418-3e0c-48ae-9997-5ba20975e499">270.1</ix:nonFraction> million. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, the Company entered into a sales agreement with SVB Leerink LLC (now known as SVB Securities LLC) (SVB Securities), to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="i7a78bc5894c84095aa559149f1fe6c13_D20210101-20210331" decimals="-5" name="insm:CommonStockAuthorizedAggregateGrossSalesProceeds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMjQ0Mg_2c9ed86c-fd2e-4f54-a2a7-f7a8537467ee">250.0</ix:nonFraction>&#160;million, from time to time, through an &#8220;at the market&#8221; equity offering program (the ATM program), under which SVB Securities acts as sales agent. As of June&#160;30, 2022, the Company had not sold or issued any shares under the ATM program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of 2020, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="ib7b0a51fe15b40af849fca272f472e3a_D20200401-20200630" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMjc0Nw_c963567d-96db-46e8-bcc8-0745566fa3cc">11,155,000</ix:nonFraction> shares of the Company's common stock, including <ix:nonFraction unitRef="shares" contextRef="i317c38eb43ca4b2da0d5950221ff472a_D20200401-20200630" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMjc5OA_f4490102-4bee-41eb-929d-a79d90fb9953">1,455,000</ix:nonFraction> shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares from the Company, a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id2c3209fc64e4317a4091a1502a77db1_I20200630" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMjk1NA_1cac932f-576e-464a-aac7-1b1140c5e57d">23.25</ix:nonFraction> per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i91561c5c770b4119b0528f79d05ba9b9_D20200401-20200630" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMzA5Mg_a4522973-becd-4779-acab-8042e9a89140">13.5</ix:nonFraction> million, were $<ix:nonFraction unitRef="usd" contextRef="ib7b0a51fe15b40af849fca272f472e3a_D20200401-20200630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMzEwMQ_d3e75353-c396-4fe2-bd76-6538092b9161">245.9</ix:nonFraction> million. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; As of June&#160;30, 2022, the Company had <ix:nonFraction unitRef="shares" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMzE1MA_5b7c0c30-7f07-4928-a6c5-218d9a0930a7">200,000,000</ix:nonFraction> shares of preferred stock authorized with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMzIxMA_4bae7a23-1ff5-4f7a-9c8d-fc15fbcb1500">0.01</ix:nonFraction> per share and <ix:nonFraction unitRef="shares" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMzIyNw_83578d7d-2894-4706-a281-b9b3a396246c"><ix:nonFraction unitRef="shares" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMzIyNw_e175c1b6-21f6-49ed-bcc4-8ed63699d55a">no</ix:nonFraction></ix:nonFraction> shares of preferred stock were issued and outstanding.</span></div></ix:continuation><div id="i252108b308054887a46901fe227627f1_61"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNjE1Mw_41d0e573-aede-4848-9085-e08de98cc2ba" continuedAt="id06645da1cc649eaae7fac9fb8df7d49" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="id06645da1cc649eaae7fac9fb8df7d49" continuedAt="i4ce0148ebc70434d9e12263cf01df9ca"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's current equity compensation plan, the Insmed Incorporated 2019 Incentive Plan (as amended, the 2019 Incentive Plan), was approved by shareholders at the Company's Annual Meeting of Shareholders in May&#160;2019.&#160;The 2019 Incentive Plan is administered by the Compensation Committee of the Board of Directors of the Company.&#160;Under the terms of the 2019 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards to eligible employees and non-employee directors.&#160;On May&#160;16, 2019, upon the approval of the 2019 Incentive Plan by shareholders, <ix:nonFraction unitRef="shares" contextRef="i47631aa0607443aa837dd0c862dfd781_I20190516" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfODA3_7cc609ea-b22b-4196-a182-1b136d64db9e">3,500,000</ix:nonFraction> shares were authorized for issuance thereunder, plus any shares subject to then-outstanding awards under the Company's 2017 Incentive Plan, the 2015 Incentive Plan and the 2013 Incentive Plan that subsequently were canceled, terminated unearned, expired, were forfeited, lapsed for any reason or were settled in cash without the delivery of shares. On May 12, 2020, at the Company's 2020 Annual Meeting of Shareholders, the Company's shareholders approved an amendment of the 2019 Incentive Plan providing for the issuance of an additional <ix:nonFraction unitRef="shares" contextRef="ib4fa2223aeb44fe2b0cdb87788b4adaf_D20200512-20200512" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMTM0MA_ae7017bd-aee7-417f-b1ed-d2b52355f973">4,500,000</ix:nonFraction> shares under the plan. On May 12, 2021, at the Company's 2021 Annual Meeting of Shareholders, the Company's shareholders approved the second amendment to the 2019 Incentive Plan providing for the issuance of an additional <ix:nonFraction unitRef="shares" contextRef="ie5861a2f40e5462983cc26a47179e376_D20210512-20210512" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMTU2NQ_a943ddb8-40e3-415c-9b3f-8dfd314c9959">2,750,000</ix:nonFraction> shares under the plan. On May 11, 2022, at the Company's 2022 Annual Meeting of Shareholders, the Company's shareholders approved the third amendment to the 2019 Incentive Plan, providing for the issuance of an additional <ix:nonFraction unitRef="shares" contextRef="i0288ec411bda42658bcabbda47913862_D20210512-20210512" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMTg1Ng_52a5ab27-dfbf-4e7c-a74d-5f2a6708746d">3,000,000</ix:nonFraction> shares under the plan. As of June&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="i89ae304eebb24882b6d4e002897820e6_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMTg3Nw_0976bec7-6b79-400b-bbb3-6ecaa362e908">2,145,104</ix:nonFraction> shares remain available for future issuance under the 2019 Incentive Plan. The 2019 Incentive Plan will terminate on May&#160;16, 2029 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options to new hires, which awards are made pursuant to the Nasdaq's inducement grant exception to the shareholder approval requirement for grants of equity compensation. During the six months ended June&#160;30, 2022, the Company granted inducement stock options covering <ix:nonFraction unitRef="shares" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="INF" name="insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMjQwMg_4283c9a8-115a-4531-9082-a86e037cf9bd">471,790</ix:nonFraction> shares of the Company's common stock to new employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2018, the 2018 Employee Stock Purchase Plan (2018 ESPP) was approved by shareholders at the Company's 2018 Annual Meeting of Shareholders. The Company has reserved the following for issuance under the 2018 ESPP: (i) <ix:nonFraction unitRef="shares" contextRef="i62d1dc130d494fe6805b85220bf3941a_I20180515" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMjY4Nw_cc2d5e0f-b6e9-4bee-899b-8654dc472d51">1,000,000</ix:nonFraction> shares of common stock,&#160;plus&#160;(ii)&#160;commencing on January&#160;1, 2019 and ending on December&#160;31, 2023, an additional number of shares to be added on the first day of each calendar year equal to the lesser of (A) <ix:nonFraction unitRef="shares" contextRef="ic196e790147b4d15a6d6b4c68f8a6472_D20180515-20180515" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMjg5Ng_e92ef0d7-bbdd-4233-b507-b2689828b2d8">1,200,000</ix:nonFraction> shares of common stock, (B) <ix:nonFraction unitRef="number" contextRef="ic196e790147b4d15a6d6b4c68f8a6472_D20180515-20180515" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMjkyNw_bb9b5ba1-ce44-41f5-affc-f5aff7b52045">2</ix:nonFraction>% of the number of outstanding shares of common stock on such date and (C)&#160;an amount determined by the administrator.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; As of June&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i63fc774e8854431ba4eafe553558adf0_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMzA4Mg_c05419f1-80c3-45f7-bd3e-c7bec600704c">122.5</ix:nonFraction>&#160;million of unrecognized compensation expense related to unvested stock options.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted performance-conditioned options to certain of its employees. Vesting of these options is subject to the Company achieving certain performance criteria established at the date of grant and the grantees </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><ix:continuation id="i4ce0148ebc70434d9e12263cf01df9ca"><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fulfilling a service condition (continued employment). As of June&#160;30, 2022, the Company had performance-conditioned options totaling <ix:nonFraction unitRef="shares" contextRef="i1861d72030824ced8ef920fa4c278220_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMzUyMw_13a10f62-caac-42c0-bf09-8e85a8512b5d">114,780</ix:nonFraction> shares outstanding which had not yet met the recognition criteria. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; As of June&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i4043f106b7ff4d2aa5e7c93a3a3ae9cd_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMzYzOQ_f3f86cb1-7742-4777-bd57-65bb5613c3b8">32.5</ix:nonFraction>&#160;million of unrecognized compensation expense related to unvested RSU awards.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Stock Units</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#8212; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="ib97d0fd95e2844cd80ddb0c2a4049481_D20220101-20220131" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMzc3Mw_5a163704-581b-41a0-ab5b-748ba68d9f90">271,612</ix:nonFraction> PSUs. For these PSUs, there are two performance conditions, a service condition, and a market condition. The performance conditions are the issuance of a press release announcing certain top-line results from a clinical trial and the acceptance of a new drug application (NDA) by the FDA for brensocatib. The service condition is continuous employment with the Company through the later of the third anniversary of the grant date of the PSU award and the date an NDA for brensocatib is accepted by the FDA. The potential payout of the awards ranges from <ix:nonFraction unitRef="number" contextRef="i22331278b70c4d298ba0751f16fcf4b1_D20220101-20220131" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNDMzMA_e8292a8f-c787-4597-82d5-84e04ec1028c">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="iab99f87cba69456faa7114cb972e768f_D20220101-20220131" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNDMzNg_5346fb42-fd13-4377-9a70-255d36af6e23">250</ix:nonFraction>% of the target, dependent on a market condition that is based on the Company's total shareholder return compared to a defined peer group. Due to the multiple vesting conditions, uncertain timing and variable payout of these PSUs, a Monte Carlo simulation was performed to determine the fair value of the awards. Compensation cost will be recognized on the date the performance conditions become probable, with an initial recording of the cumulative expense that would have been recognized if the PSU expense had been recognized on a straight-line basis since the date of grant. The remaining unamortized fair value of the awards will then be expensed prospectively on a straight-line basis over the remaining service period. Since the market condition is reflected in the grant-date fair value and is not a condition for the award to vest, it does not impact the requisite service period. The volatility, risk-free interest rate and weighted-average grant date fair value of the PSUs granted are <ix:nonFraction unitRef="number" contextRef="ib97d0fd95e2844cd80ddb0c2a4049481_D20220101-20220131" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNTMyOQ_b57f7e72-0d23-4b19-9f43-5c100c342460">65.4</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ib97d0fd95e2844cd80ddb0c2a4049481_D20220101-20220131" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNTMzMw_c5807554-f6fc-4353-bcd4-204922e03bd4">1.03</ix:nonFraction>% and $<ix:nonFraction unitRef="usdPerShare" contextRef="ib97d0fd95e2844cd80ddb0c2a4049481_D20220101-20220131" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNTM0MA_b8e578d4-2c96-41f7-9c5d-f28efe61a96f">39.12</ix:nonFraction>, respectively. Any forfeitures that occur after compensation cost recognition commences will result in the cumulative reversal of expense in the period in which the forfeiture occurs. As of June&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i1861d72030824ced8ef920fa4c278220_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNTU0Nw_1bce32c1-2727-4078-9a06-1cbfe118cdc4">10.5</ix:nonFraction> million of unrecognized compensation expense related to unvested PSU awards, which assumes a payout of <ix:nonFraction unitRef="number" contextRef="ib97d0fd95e2844cd80ddb0c2a4049481_D20220101-20220131" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNTY0NQ_965372a8-6dc3-4803-9794-88374fd83029">100</ix:nonFraction>% of the target.</span></div><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNjE1MA_42d701f5-2702-40b2-9216-229449b51fc1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the three and six months ended June&#160;30, 2022 and 2021, respectively (in millions):&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"><tr><td style="width:1.0%"></td><td style="width:34.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ceb0c5b59ec456684a1a621d375db23_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfMi0xLTEtMS0yODk0Nw_18a5209c-8301-46d0-84d5-a3a4ba7ec91c">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i117be86acfcb4eebbf356e9bca57ec66_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfMi0zLTEtMS0yODk0Nw_d6397dfd-e0f4-40cc-a409-7a32d1f86ddc">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3990da618f7430d9bbd1e66442f7851_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfMi01LTEtMS0yODk0Nw_5c652690-268b-4866-b1b9-17b70e6fd09c">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4386f9644da41bea1baa490a37085c2_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfMi03LTEtMS0yODk0Nw_659b5110-b77d-49eb-838b-d01a16d9d1ab">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a8cd663f8b34900a9dc46cfc889dbb2_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfMy0xLTEtMS0yODk0Nw_e1c1dea8-373a-4f06-b249-47aaa0ddb106">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d1f7158600c4c6fb173fb60e3b43c76_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfMy0zLTEtMS0yODk0Nw_1f2f43bd-bd46-43d4-918b-067984e0cd37">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcac17f493744c29df2003d99cf399b_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfMy01LTEtMS0yODk0Nw_bcbf70ac-834e-4270-9634-b86658454223">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4249e6eea7944feab2165125682bd3e_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfMy03LTEtMS0yODk0Nw_3b915996-bc73-46b6-b25e-2cf370905e16">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id29b955148664a0eb00d37f9dc631961_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfNC0xLTEtMS0yODk0Nw_f9a6ad09-135e-4381-abb8-6a66703fc9c7">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic006f1ab997e4bf98ba5840a6a977cfb_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfNC0zLTEtMS0yODk0Nw_f662731b-eabd-4ec5-ac20-6e0730ce98c6">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i700526f8aa8c42d3b0a44747d7347c9a_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfNC01LTEtMS0yODk0Nw_0dbf98a6-d4d5-4341-8111-ab88c8108c09">27.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad0d6bd3de9743b49ef5056bd1b0629d_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfNC03LTEtMS0yODk0Nw_083eff16-b0cd-4769-8164-6cf5c39f4495">22.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="i04f0a1a4c2144c658e9faeab5bacbf34_D20220101-20220630" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNjE0OQ_7810a8e2-d978-45ec-a67c-f2bb97b8ad01"><ix:nonFraction unitRef="usd" contextRef="i826dc379d52b4e8d8be78b58060e1979_D20220401-20220630" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNjE0OQ_f6bcca76-2d08-4d83-8e13-52458e6d4968">no</ix:nonFraction></ix:nonFraction> stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to PSUs during the three and six months ended June&#160;30, 2022, as the performance conditions associated with the PSU awards were not probable as of June&#160;30, 2022.</span></div></ix:continuation><div id="i252108b308054887a46901fe227627f1_64"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82NC9mcmFnOjZiZmUxNWNiNzc3YTQ3OGI5YTgxZWRhZWY1ZWQ1ZjQ3L3RleHRyZWdpb246NmJmZTE1Y2I3NzdhNDc4YjlhODFlZGFlZjVlZDVmNDdfMTY3Ng_4453dca1-bfe9-4803-9659-2e9a687beb1f" continuedAt="ib8e060fe4654461eb7bcf8c9464d4866" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="ib8e060fe4654461eb7bcf8c9464d4866"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a provision for income taxes of $<ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82NC9mcmFnOjZiZmUxNWNiNzc3YTQ3OGI5YTgxZWRhZWY1ZWQ1ZjQ3L3RleHRyZWdpb246NmJmZTE1Y2I3NzdhNDc4YjlhODFlZGFlZjVlZDVmNDdfMTA3_fcf722b9-6e8a-4742-9c3c-2cee617ef3a3">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82NC9mcmFnOjZiZmUxNWNiNzc3YTQ3OGI5YTgxZWRhZWY1ZWQ1ZjQ3L3RleHRyZWdpb246NmJmZTE1Y2I3NzdhNDc4YjlhODFlZGFlZjVlZDVmNDdfMTE0_46998994-91ed-4a8e-b669-d3963b6cd2cd">0.6</ix:nonFraction> million for the three months ended June 30, 2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82NC9mcmFnOjZiZmUxNWNiNzc3YTQ3OGI5YTgxZWRhZWY1ZWQ1ZjQ3L3RleHRyZWdpb246NmJmZTE1Y2I3NzdhNDc4YjlhODFlZGFlZjVlZDVmNDdfMjc0ODc3OTA3MTE2OQ_fb040c4f-f8a1-407d-bf12-395aa48bda8a">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82NC9mcmFnOjZiZmUxNWNiNzc3YTQ3OGI5YTgxZWRhZWY1ZWQ1ZjQ3L3RleHRyZWdpb246NmJmZTE1Y2I3NzdhNDc4YjlhODFlZGFlZjVlZDVmNDdfMjc0ODc3OTA3MTE3Mg_9e665722-ead9-432e-904f-5f779aa6cde9">0.9</ix:nonFraction> million for the six months ended June 30, 2022 and 2021, respectively. The provisions are primarily a result of certain of the Company's international subsidiaries, which had taxable income during the periods. Additionally, the Company is impacted by certain state taxes which effectively impose income tax on modified gross revenues. In jurisdictions where the Company has net losses, there was a full valuation allowance recorded against the Company's deferred tax assets and therefore <ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="INF" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82NC9mcmFnOjZiZmUxNWNiNzc3YTQ3OGI5YTgxZWRhZWY1ZWQ1ZjQ3L3RleHRyZWdpb246NmJmZTE1Y2I3NzdhNDc4YjlhODFlZGFlZjVlZDVmNDdfNTY3_51b47281-663e-4ae8-abf2-600d98b852d8">no</ix:nonFraction> tax benefit was recorded. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to US federal and state income taxes and the statute of limitations for tax audit is open for the Company's federal tax returns for the years ended 2018 and later, and is generally open for certain states for the years 2017 and later. The Company has incurred net operating losses since inception, except for the year ended December&#160;31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin. As of June&#160;30, 2022 and December&#160;31, 2021, the Company had recorded reserves for unrecognized income tax benefits against certain deferred tax assets in the US.&#160;However, given the Company&#8217;s valuation allowance position, these reserves do not have an impact on the balance sheet as of June&#160;30, 2022 and December&#160;31, 2021 or the consolidated statements of comprehensive loss for the three and six months ended June&#160;30, 2022 and 2021.&#160;The Company has <ix:nonFraction unitRef="usd" contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82NC9mcmFnOjZiZmUxNWNiNzc3YTQ3OGI5YTgxZWRhZWY1ZWQ1ZjQ3L3RleHRyZWdpb246NmJmZTE1Y2I3NzdhNDc4YjlhODFlZGFlZjVlZDVmNDdfMTQ3Mw_abe8a078-9fe9-4784-8821-5bf77cc781a3"><ix:nonFraction unitRef="usd" contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82NC9mcmFnOjZiZmUxNWNiNzc3YTQ3OGI5YTgxZWRhZWY1ZWQ1ZjQ3L3RleHRyZWdpb246NmJmZTE1Y2I3NzdhNDc4YjlhODFlZGFlZjVlZDVmNDdfMTQ3Mw_c474ee7a-da82-46a9-88be-e6198ddc0b8a">no</ix:nonFraction></ix:nonFraction>t recorded any accrued interest or penalties related to uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next 12 months.</span></div></ix:continuation><div id="i252108b308054887a46901fe227627f1_67"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82Ny9mcmFnOjgyZGFjNTA3MGUwYzQ1NmE4MjIzM2RhZTk1ZjNjOTRmL3RleHRyZWdpb246ODJkYWM1MDcwZTBjNDU2YTgyMjMzZGFlOTVmM2M5NGZfNTY0_e477aadb-be00-4424-91f0-d0b22a7dca6d" continuedAt="i829770d60a4e4c8981a581cd976c9b9d" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i829770d60a4e4c8981a581cd976c9b9d" continuedAt="i12a54ee762fe4b699290024d965278db">Rent expense charged to operations was $<ix:nonFraction unitRef="usd" contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82Ny9mcmFnOjgyZGFjNTA3MGUwYzQ1NmE4MjIzM2RhZTk1ZjNjOTRmL3RleHRyZWdpb246ODJkYWM1MDcwZTBjNDU2YTgyMjMzZGFlOTVmM2M5NGZfMTA4_f8ef1c55-bcfc-4df7-8233-a402d8c91627">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82Ny9mcmFnOjgyZGFjNTA3MGUwYzQ1NmE4MjIzM2RhZTk1ZjNjOTRmL3RleHRyZWdpb246ODJkYWM1MDcwZTBjNDU2YTgyMjMzZGFlOTVmM2M5NGZfMTE1_6a3a3730-7bed-4251-8eb2-b9e225c3fdeb">1.1</ix:nonFraction> million for the three months ended June 30, 2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82Ny9mcmFnOjgyZGFjNTA3MGUwYzQ1NmE4MjIzM2RhZTk1ZjNjOTRmL3RleHRyZWdpb246ODJkYWM1MDcwZTBjNDU2YTgyMjMzZGFlOTVmM2M5NGZfMjc0ODc3OTA3MDA1NQ_e985e45c-3585-4836-ba1e-e6b761b3be01">3.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82Ny9mcmFnOjgyZGFjNTA3MGUwYzQ1NmE4MjIzM2RhZTk1ZjNjOTRmL3RleHRyZWdpb246ODJkYWM1MDcwZTBjNDU2YTgyMjMzZGFlOTVmM2M5NGZfMjc0ODc3OTA3MDA1OA_dbe271e8-72e9-4ce4-8cf1-2fc29051069c">2.3</ix:nonFraction> million for the six months ended June 30, 2022 and 2021, respectively.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><ix:continuation id="i12a54ee762fe4b699290024d965278db"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.</span></div></ix:continuation><div id="i252108b308054887a46901fe227627f1_70"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfNDg3NQ_fdf98686-dc8f-4c45-a91d-67ec9c3b7bc4" continuedAt="i85f2b26963ec4094b534123e0ae3e96f" escape="true">Business Acquisition</ix:nonNumeric></span></div><ix:continuation id="i85f2b26963ec4094b534123e0ae3e96f"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2021, the Company acquired all of the equity interests of Motus and AlgaeneX, each a privately held, preclinical stage company. In connection with the closing of the Company&#8217;s acquisition of Motus, the Company issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="i4fc0d05a849b4f9f8363d09eb7a2297f_D20210804-20210804" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfMjc3_4d1da8b6-d7ed-460b-acca-b79ba674986f">2,889,367</ix:nonFraction> shares of the Company&#8217;s common stock, following certain closing-related reductions, to Motus&#8217;s former stockholders and option holders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, Motus equityholders), subject to certain adjustments. The Company is obligated to issue to Motus equityholders an aggregate of <ix:nonFraction unitRef="shares" contextRef="ib690063402dd47c4ae80bed8cc5946a2_D20210804-20210804" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfNjUx_10df3dcf-c035-4ae8-84b3-227068a45494"><ix:nonFraction unitRef="shares" contextRef="ibbf98dd2c06941fba02468ff74fe15f4_D20210804-20210804" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfNjUx_b56647dd-78a2-4b73-9a8b-ed734d3ebc6f"><ix:nonFraction unitRef="shares" contextRef="i63cf6ce83c0a452894be75c49ed8e241_D20210804-20210804" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfNjUx_e86db486-0dca-40c3-b55c-d1df63ba9786">184,433</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s common stock on each of the first, second and third anniversaries of the closing date and up to <ix:nonFraction unitRef="shares" contextRef="i4fc0d05a849b4f9f8363d09eb7a2297f_D20210804-20210804" decimals="INF" name="insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfNzc0_8a7cf677-5d05-45d7-9feb-d2e953685384">5,348,572</ix:nonFraction> shares in the aggregate upon the achievement of certain development and regulatory milestone events, and to pay to the Motus equityholders an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i2574040e81cf45fdb63c1f0620c5cc9a_I20210804" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfOTMy_3d10960b-d139-43e9-b0e1-91dce0e9501d">35</ix:nonFraction>&#160;million upon the achievement of certain net sales-based milestones and a portion of the value of a priority review voucher (to the extent issued to the Company), in each case, subject to certain reductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing of the Company&#8217;s acquisition of AlgaeneX, the Company paid $<ix:nonFraction unitRef="usd" contextRef="i7d34c58061f249e18f61f07687b0331b_D20210801-20210831" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfMTIwOA_8d227353-3e32-41cf-bbb6-280c97f980b6">1.5</ix:nonFraction>&#160;million in cash to AlgaeneX&#8217;s former stockholders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, the AlgaeneX equityholders). The Company is obligated to issue to AlgaeneX&#8217;s equityholders an aggregate of <ix:nonFraction unitRef="shares" contextRef="i7d34c58061f249e18f61f07687b0331b_D20210801-20210831" decimals="INF" name="insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfMTQ3MA_df84c9d3-ef12-41e0-bba6-949165c43452">368,867</ix:nonFraction> shares of the Company&#8217;s common stock upon the achievement of a development milestone event and pay to AlgaeneX equityholders a mid-single digits licensing fee on certain future payments received by the Company in licensing transactions for AlgaeneX&#8217;s manufacturing technology, in each case, subject to certain reductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the Company&#8217;s common stock issued to the Motus equityholders and the AlgaeneX equityholders were issued, and the shares issuable in the future will be issued, pursuant to Section 4(a)(2) of the Securities Act of 1933, and the numbers of such issued and issuable shares was calculated based on a per share value of $<ix:nonFraction unitRef="usdPerShare" contextRef="icfe80c21994c4bb9b647c882148aa2b8_I20210831" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfMjEyMw_19f2c816-0c42-47c3-95d9-3b7265eeead8"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ff8bc31f64b484687adf08bd1e1364c_I20210831" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfMjEyMw_a4618e7c-3c63-41fd-ab0d-6f1f1dcd86a6">27.11</ix:nonFraction></ix:nonFraction>, which is the weighted average price per share of the Company's common stock preceding the closing of the Business Acquisition for the <ix:nonFraction unitRef="days" contextRef="i07acd876919448939ae3e9671ddb5ce7_D20210524-20210524" decimals="INF" name="insm:BusinessAcquisitionConsecutiveTradingDayPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfMjI2MQ_018223ef-7ce0-4301-935b-cd619729aa93">45</ix:nonFraction> consecutive trading day period beginning on May 24, 2021. The Company will not receive any proceeds from the issuance of common stock to the Motus equityholders or the AlgaeneX equityholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Business Acquisition under ASC 805 and ASU 2017-01. The Company concluded that substantially all of the fair value of the gross assets acquired is not concentrated in a single identifiable asset or a group of similar identifiable assets. The transaction does not pass the screen test and thus management performed a full assessment to determine if the acquired entities met the definition of a business. For the full assessment, management considered whether it has acquired (a) inputs, (b) substantive processes, and (c) outputs. Under ASC 805, to be considered a business, a set of activities and assets is required to have only the first two of the three elements, which together are or will be used in the future to create outputs. Management determined that the acquired entities met the definition of a business since the Company acquired inputs and substantive processes capable of producing outputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, the transaction has been accounted for under the acquisition method of accounting. Under the acquisition method, the total purchase price of the acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on the fair values as of the date of the acquisition. The fair value of the consideration totaled approximately $<ix:nonFraction unitRef="usd" contextRef="ieb37f5b95f6243009bf267154d33f563_D20210801-20210831" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfMzg2NA_1511c777-d1ed-40c4-958c-aaf6374f17af">165.5</ix:nonFraction>&#160;million. The results of Motus's and AlgaeneX's operations have been included in the Company's consolidated statements of comprehensive loss beginning on the acquisition date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D was capitalized as of the acquisition date and accounted for as indefinite-lived intangible assets until completion or disposition of the assets or abandonment of the associated research and development efforts. Upon successful completion of the development efforts, the useful lives of the IPR&amp;D assets will be determined based on the anticipated period of regulatory exclusivity and will be amortized within operating expenses. Until that time, the IPR&amp;D assets will be subject to impairment testing and will not be amortized. The goodwill recorded related to the acquisition is the excess of the fair value of the consideration transferred by the acquirer over the fair value of the net identifiable assets acquired and liabilities assumed at the date of acquisition. The goodwill recorded is not deductible for tax purposes.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i252108b308054887a46901fe227627f1_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form&#160;10-Q contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) identify forward-looking statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements are based on our current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">failure to successfully commercialize ARIKAYCE, our only approved product, in the US, Europe or Japan (amikacin liposome inhalation suspension, Liposomal 590 mg Nebuliser Dispersion, and amikacin sulfate inhalation drug product, respectively), or to maintain US, European or Japanese approval for ARIKAYCE;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties in the degree of market acceptance of ARIKAYCE by physicians, patients, third-party payors and others in the healthcare community;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to obtain full approval of ARIKAYCE from the FDA, including the risk that we will not successfully or in a timely manner complete the study to validate a patient reported outcome (PRO) tool and the confirmatory post-marketing clinical trial required for full approval of ARIKAYCE;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">inability of us, PARI or our other third-party manufacturers to comply with regulatory requirements related to ARIKAYCE or the Lamira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Nebulizer System;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to obtain adequate reimbursement from government or third-party payors for ARIKAYCE or acceptable prices for ARIKAYCE;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">development of unexpected safety or efficacy concerns related to ARIKAYCE or our product candidates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">inaccuracies in our estimates of the size of the potential markets for ARIKAYCE, brensocatib, TPIP or our other product candidates or in data we have used to identify physicians, expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE or any of our product candidates that are approved in the future;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">failure to obtain regulatory approval to expand ARIKAYCE&#8217;s indication to a broader patient population;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risk that brensocatib does not prove to be effective or safe for patients in ongoing and future clinical studies, including the ASPEN study;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risk that TPIP does not prove to be effective or safe for patients in ongoing and future clinical studies;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risk that our competitors may obtain orphan drug exclusivity for a product that is essentially the same as a product we are developing for a particular indication;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully predict the time and cost of development, regulatory approval and commercialization for novel gene therapy products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully conduct future clinical trials for ARIKAYCE, brensocatib, TPIP and our other product candidates due to our limited experience in conducting preclinical development activities and clinical trials necessary for regulatory approval and our potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other things;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks that our clinical studies will be delayed or that serious side effects will be identified during drug development;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">failure to obtain, or delays in obtaining, regulatory approvals for ARIKAYCE outside the US, Europe or Japan, or for our product candidates in the US, Europe, Japan or other markets, including separate regulatory approval for Lamira and other product candidate devices in each market and for each usage;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">failure of third parties on which we are dependent to manufacture sufficient quantities of ARIKAYCE or our product candidates for commercial or clinical needs, to conduct our clinical trials, or to comply with our agreements or laws and regulations that impact our business or agreements with us;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to attract and retain key personnel or to effectively manage our growth;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to successfully integrate our recent acquisitions and appropriately manage the amount of management&#8217;s time and attention devoted to integration activities;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks that our acquired technologies, products and product candidates are not commercially successful;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to adapt to our highly competitive and changing environment;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risk that we are unable to maintain our significant customers;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risk that government healthcare reform materially increases our costs and damages our financial condition;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">impact of the COVID-19 pandemic and efforts to reduce its spread on our business, employees, including key personnel, patients, partners and suppliers;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to adequately protect our intellectual property rights or prevent disclosure of our trade secrets and other proprietary information and costs associated with litigation or other proceedings related to such matters;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions or other obligations imposed on us by agreements related to ARIKAYCE or our product candidates, including our license agreements with PARI and AstraZeneca AB (AstraZeneca), and failure to comply with our obligations under such agreements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and potential reputational damage resulting from litigation to which we are or may become a party, including product liability claims;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risk that our operations are subject to a material disruption in the event of a cybersecurity attack or issue;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">business disruptions or expenses related to the upgrade to our enterprise resource planning system;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our limited experience operating internationally;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws and regulations applicable to our business, including any pricing reform, and failure to comply with such laws and regulations;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our history of operating losses, and the possibility that we never achieve or maintain profitability;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">goodwill impairment charges affecting our results of operations and financial condition;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">inability to repay our existing indebtedness and uncertainties with respect to our ability to access future capital; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">delays in the execution of plans to build out an additional third-party manufacturing facility approved by the appropriate regulatory authorities and unexpected expenses associated with those plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Any forward-looking statement is based on information current as of the date of this Quarterly Report on Form 10-Q and speaks only as of the date on which such statement is made. Actual events or results may differ materially from the results, plans, intentions or expectations anticipated in these forward-looking statements as a result of a variety of factors, many of which are beyond our control. More information on factors that could cause actual results to differ materially from those anticipated is included from time to time in our reports filed with the Securities and Exchange Commission (SEC), including, but not limited to, those described in the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this Quarterly Report on Form 10-Q and included in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000110450622000008/insm-20211231.htm">Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We disclaim any obligation, except as specifically required by law and the rules&#160;of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on&#160;Form&#160;10-Q and the consolidated financial statements and related notes thereto in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000110450622000008/insm-20211231.htm">Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i252108b308054887a46901fe227627f1_76"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;We are a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our first commercial product, ARIKAYCE, is approved in the US as ARIKAYCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the EC approved ARIKAYCE for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have CF. In March 2021, Japan's MHLW approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prior treatment with a multidrug regimen. NTM lung disease caused by MAC (which we refer to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical-stage pipeline includes brensocat</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ib and TPIP. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brensocatib is a small molecule, oral, reversible inhibitor of DPP1, which we are developing for the treatment of patients with bronchiectasis, CF and other neutrophil-mediated diseases, including </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRSsNP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and HS. TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for PH-ILD and PAH. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the current status and anticipated milestones for ARIKAYCE and our product candidates brensocatib and TPIP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:18.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.196%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Product/Product&#160;Candidate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Next&#160;Expected&#160;Milestones</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARIKAYCE for&#160;MAC lung&#160;disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; We continue to focus on the commercialization of ARIKAYCE. We commenced commercial shipments of ARIKAYCE in the US in October 2018, in Europe in November 2020, and in Japan in July 2021.</span></div><div style="padding-left:13.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; In December 2020, we commenced the post-marketing confirmatory frontline clinical trial program for ARIKAYCE in patients with MAC lung disease, consisting of the ARISE trial and the ENCORE trial. We are currently enrolling patients for these trials and are running these global studies in parallel.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; We will continue to advance the post-marketing confirmatory, frontline clinical trial program for ARIKAYCE. In ARISE, we anticipate completing enrollment by the end of 2022 and sharing data during 2023. In ENCORE, we anticipate completing enrollment by the end of 2023.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Brensocatib (oral reversible&#160;inhibitor of&#160;DPP1)&#160;for bronchiectasis and other neutrophil-mediated diseases</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; In June 2020, we announced full results from our global, randomized, double-blind placebo-controlled Phase 2 WILLOW study, which were published online in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">September 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; In December 2020, we commenced a Phase 3 trial (the ASPEN trial) through which we will seek to confirm the positive results seen in the WILLOW study. We are currently enrolling patients globally for this trial.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; We will continue to advance the ASPEN trial and anticipate completing enrollment in the first quarter of 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; We are advancing a clinical development program for brensocatib in CF. The Phase 2 pharmacokinetics/pharmacodynamics multiple-dose study is underway, and we anticipate having results from the CF transmembrane conductance regulator (CFTR) arm of the study by the end of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; We plan to explore the potential of brensocatib in additional neutrophil-mediated diseases, including </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CRSsNP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and HS.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">TPIP (dry-powder inhalation formulation of a treprostinil prodrug) for PH-ILD and PAH</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; In February 2021, we announced topline results from the Phase 1 study of TPIP in healthy volunteers. Data from the study supports continued development into Phase 2 with once-daily dosing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; We are advancing the development of TPIP in both PH-ILD and PAH.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; We currently have two parallel Phase 2 studies ongoing, both with a 16-week treatment period: a study in patients with PH-ILD to assess safety and tolerability; and a study in PAH patients to evaluate the effect of TPIP on pulmonary vascular resistance (PVR) and six-minute walk distance. </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; We will continue to advance our Phase 2 development work in both PH-ILD and PAH.</span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our earlier-stage pipeline includes preclinical compounds that we are evaluating in multiple rare diseases with unmet medical nee</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To complement our internal research and development, we actively evaluate in-licensing and acquisition opportunities for a broad range of rare diseases.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy focuses on the needs of patients with rare diseases. We secured approval for ARIKAYCE in the US as ARIKAYCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590mg (amikacin sulfate inhalation drug product). We are not aware of any other approved inhaled therapies specifically indicated to treat MAC lung disease in North America, Europe or Japan. We believe that ARIKAYCE has the potential to prove beneficial in other patients with MAC. Our product candidates are brensocatib, our Phase 3 product candidate which we are developing for patients with bronchiectasis, CF and other neutrophil-mediated diseases, and TPIP, our product candidate that may offer a differentiated product profile for patients with PH-ILD and PAH. We are also advancing earlier-stage programs in other rare disorders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current priorities are as follows:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continue our efforts to ensure the successful commercialization and expansion of ARIKAYCE globally;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advance our Phase 3 ASPEN trial for brensocatib in patients with bronchiectasis;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop and validate a PRO tool for NTM lung disease to be used in, among other trials, the ENCORE trial required for the full US approval of ARIKAYCE by the FDA in patients with MAC lung disease;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ensure our product supply chain will support the global commercialization and potential future lifecycle management programs of ARIKAYCE;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Maintain or obtain determinations of coverage and reimbursement in the US, Europe and Japan for ARIKAYCE from governmental and other third-party payors;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Support further research and lifecycle management strategies for ARIKAYCE, including the potential use of ARIKAYCE as part of a frontline, multi-drug regimen;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Advance the brensocatib program in CF and other neutrophil mediated diseases, such as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRSsNP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and HS;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advance the Phase 2 TPIP development programs;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Generate preclinical findings from our earlier-stage programs and advance translational medicine; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expand our pipeline through corporate development.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARIKAYCE for Patients with MAC Lung Disease</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARIKAYCE is our first approved product. ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of refractory MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. In October 2020, ARIKAYCE received approval in Europe for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have CF. In March 2021, ARIKAYCE received approval in Japan for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Amikacin solution for parenteral administration is an established drug that has activity against a variety of NTM; however, its use is limited by the need to administer it intravenously and by toxicity to hearing, balance, and kidney function. Unlike amikacin solution for intravenous administration, our proprietary Pulmovance&#8482; technology uses charge-neutral liposomes to deliver amikacin directly to the lungs where liposomal amikacin is taken up by the lung macrophages where the MAC infection resides. This technology also prolongs the release of amikacin in the lungs, while minimizing systemic exposure, thereby offering the potential for decreased systemic toxicities. ARIKAYCE's ability to deliver high levels of amikacin directly to the lung and sites of MAC infection via the use of our Pulmovance technology distinguishes it from intravenous amikacin. ARIKAYCE is administered once-daily using Lamira, an inhalation device developed and manufactured by PARI. Lamira is a portable nebulizer that enables aerosolization of liquid medications via a vibrating, perforated membrane, and was designed specifically for ARIKAYCE delivery.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has designated ARIKAYCE as an orphan drug and a Qualified Infectious Disease Product (QIDP) for NTM lung disease. Orphan designated drugs are eligible for seven years of exclusivity for the orphan indication. QIDP designation provides an additional five years of exclusivity for the designated indication. The FDA granted a total of 12 years of exclusivity in the indication for which ARIKAYCE was approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARIKAYCE also has been included in the international treatment guidelines for NTM lung disease. The evidence-based guidelines, issued by the American Thoracic Society (ATS), European Respiratory Society (ERS), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and Infectious Diseases Society of America (IDSA), now strongly recommend the use of ARIKAYCE for MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options who have failed to convert to a negative sputum culture after at least six months of treatment.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FDA approved an sNDA for ARIKAYCE, adding important efficacy data regarding the durability and sustainability of culture conversion to the ARIKAYCE label. The data, which are from the Phase 3 CONVERT study of ARIKAYCE, demonstrate that the addition of ARIKAYCE to guideline-based therapy (GBT) was associated with sustained culture conversion through the end of treatment as well as durable culture conversion three months post-treatment compared with GBT alone.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accelerated Approval</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we submitted an NDA for ARIKAYCE to the FDA to request accelerated approval. Accelerated approval allows drugs that (i) are being developed to treat a serious or life-threatening disease or condition and (ii) provide a meaningful therapeutic benefit over existing treatments to be approved substantially based on an intermediate endpoint or a surrogate endpoint that is reasonably likely to predict clinical benefit, rather than a clinical endpoint such as survival or irreversible morbidity. In September 2018, the FDA granted accelerated approval for ARIKAYCE under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) for the treatment of refractory MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options via the accelerated approval pathway. LPAD, which was enacted as part of the 21st Century Cures Act, serves to advance the development of new antibacterial drugs to treat serious or life-threatening infections in limited populations of patients with unmet needs. As required for drugs approved under the LPAD pathway, labeling for ARIKAYCE includes certain statements to convey that the drug has been shown to be safe and effective only for use in a limited population.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of accelerated approval, we must conduct a post-marketing confirmatory clinical trial. In December 2020, we commenced the post-marketing confirmatory frontline clinical trial program for ARIKAYCE in patients with MAC lung disease. The frontline clinical trial program consists of the ARISE trial, an interventional study designed to validate cross-sectional and longitudinal characteristics of a PRO tool in MAC lung disease, and the ENCORE trial, designed to establish the clinical benefits and evaluate the safety of ARIKAYCE in patients with newly diagnosed MAC lung disease using the PRO tool validated in the ARISE trial. We are running these global studies in parallel and approximately 200 sites are expected to be initiated for these clinical trials. The frontline clinical program is intended to fulfill the FDA&#8217;s post-marketing requirement to allow for full approval of ARIKAYCE by the FDA, and verification and description of clinical benefit in the ENCORE trial will be necessary for full approval of ARIKAYCE.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Pathway Outside of the US</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, the EC granted marketing authorization for ARIKAYCE for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have CF. We have launched ARIKAYCE in Germany, the Netherlands, Wales,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and Scotland, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and plan to launch in other European Union (EU) countries and the UK, subject to local reimbursement processes. Effective September 1, 2022, patient supply of ARIKAYCE in Germany will be enabled by import from other EU countries. We have worked with the German National Association of Statutory Health Insurance Funds (GKV-SV) towards an agreement on the price of ARIKAYCE that would allow us effectively to serve the needs of patients in Germany; however, to date, we have been unable to reach an agreement. Ensuring an uninterrupted supply of medicine for patients in Germany is our top priority, and we are working to ensure that physicians and pharmacists have the information they need to obtain ARIKAYCE for their patients through the importation pathway. Discussions remain ongoing with the GKV-SV with the goal of reaching an agreement and re-initiating direct access to ARIKAYCE.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021, Japan's MHLW approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. In July 2021, we launched ARIKAYCE in Japan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Further Research and Lifecycle Management</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently exploring and supporting research and lifecycle management programs for ARIKAYCE beyond treatment of refractory MAC lung disease as part of a combination antibacterial regimen for adult patients who have limited or no treatment options. As noted above, we will continue to advance the post-marketing confirmatory, frontline clinical trial program for ARIKAYCE, through the ARISE and ENCORE trials, which are intended to fulfill the FDA's post-marketing requirement to allow for the full approval of ARIKAYCE in the US. We believe these studies will support the use of ARIKAYCE as a frontline treatment for patients with MAC lung disease.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ARISE trial is a randomized, double-blind, placebo-controlled Phase 3b study in adult patients with newly diagnosed MAC lung disease that aims to generate evidence demonstrating the domain specification, reliability, validity, and responsiveness of PRO-based scores, including a respiratory symptom score. Patients will be randomized 1:1 to receive ARIKAYCE plus background regimen or placebo plus background regimen once daily for six months. Patients will then discontinue all study treatments and remain in the trial for one month for the continued assessment of PRO endpoints. The study is currently enrolling patients and is expected to enroll approximately 100 patients. We anticipate completing enrollment by the end of 2022. We anticipate sharing data on the reliability and reproducibility of the respiratory score used in the PRO in the first half of 2023 and we anticipate sharing responsivity, culture conversion, and safety and tolerability data in the second half of 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ENCORE trial is a randomized, double-blind, placebo-controlled Phase 3b study to evaluate the efficacy and safety of an ARIKAYCE-based regimen in patients with newly diagnosed MAC lung disease. Patients will be randomized 1:1 to receive ARIKAYCE plus background regimen or placebo plus background regimen once daily for 12 months. Patients will then discontinue all study treatments and remain in the trial for three months for the assessment of durability of culture conversion. The primary endpoint is change from baseline to Month 13 in respiratory symptom score. The key secondary endpoint is the proportion of subjects achieving durable culture conversion at Month 15. The study is currently enrolling patients and is expected to enroll approximately 250 patients. We anticipate completing enrollment by the end of 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated the frontline clinical trial program of ARIKAYCE in December 2020 and are running the ARISE and ENCORE trials in parallel in approximately 200 sites.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent lifecycle management studies could also potentially enable us to reach more patients. These initiatives include investigator-initiated studies, which are clinical studies initiated and sponsored by physicians or research institutions with funding from us and may also include new clinical studies sponsored by us.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Pipeline</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Brensocatib</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brensocatib is a small molecule, oral, reversible inhibitor of DPP1, which we licensed from AstraZeneca in October 2016. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs) in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. Neutrophils contain the NSPs (including neutrophil elastase, proteinase 3, and cathepsin G) that have been implicated in a variety of inflammatory diseases. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the positive results of the WILLOW study discussed below, in December 2020 we commenced our Phase 3 trial, ASPEN, which will investigate brensocatib in bronchiectasis. ASPEN is a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with bronchiectasis. Patients with bronchiectasis due to CF may not be enrolled in the study. Patients will be randomized to receive brensocatib 10 mg, brensocatib 25 mg, or placebo once daily for 52 weeks. The primary endpoint is the rate of pulmonary exacerbations over the 52-week treatment period. Secondary endpoints include time to first pulmonary exacerbation, percentage of subjects who remain pulmonary exacerbation-free, change from baseline in post-bronchodilator FEV1, rate of severe pulmonary exacerbations, change from baseline in the Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score, and incidence and severity of treatment-emergent adverse events (AEs). This study is currently enrolling patients and is expected to enroll approximately 1,620 patients (540 in each arm) at approximately 460 sites in 40 countries. We anticipate completing enrollment in the first quarter of 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, AstraZeneca exercised its first option pursuant to our October 2016 license agreement under which AstraZeneca can advance clinical development of brensocatib in the indications of chronic obstructive pulmonary disease (COPD) or asthma. Under the terms of the agreement, upon exercise of this option, AstraZeneca is solely responsible for all aspects of the development of brensocatib up to and including Phase 2b clinical trials in COPD or asthma. The agreement also includes a second and final option which, if exercised, would permit AstraZeneca to further develop brensocatib beyond Phase 2b clinical trials upon reaching agreement on commercial terms satisfactory to each party for the further development and commercialization of brensocatib in COPD or asthma. We retain full development and commercialization rights for brensocatib in all other indications and geographies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the FDA granted breakthrough therapy designation for brensocatib for the treatment of adult patients with non-cystic fibrosis bronchiectasis (NCFBE) for reducing exacerbations. The FDA's breakthrough therapy designation is designed to expedite the development and review of therapies that are intended to treat serious or life-threatening diseases and for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy. The benefits of breakthrough therapy designation include more frequent communication and meetings with FDA, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eligibility for rolling and priority review, intensive guidance on an efficient drug development program, and organizational commitment from the FDA involving senior managers. In November 2020, brensocatib was granted access to the PRIME scheme from the European Medicines Agency (EMA) for patients with NCFBE.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the EMA&#8217;s Paediatric Committee approved the brensocatib Pediatric Investigational Plan for the treatment of patients with NCFBE. Subsequently, the ASPEN trial will now include 40 adolescent patients between ages 12 to 17, which will fulfill the pediatric study requirements to support marketing applications in this patient population in the US, Europe and Japan. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The WILLOW Study</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The WILLOW study was a randomized, double-blind, placebo-controlled, parallel-group, multi-center, multi-national, Phase 2 study to assess the efficacy, safety and tolerability, and pharmacokinetics of brensocatib administered once daily for 24 weeks in patients with NCFBE. The WILLOW study was conducted at 116 sites and enrolled 256 adult patients diagnosed with NCFBE who had at least two documented pulmonary exacerbations in the 12 months prior to screening. Patients were randomized 1:1:1 to receive either 10 mg or 25 mg of brensocatib or matching placebo. The primary efficacy endpoint was the time to first pulmonary exacerbation over the 24-week treatment period in the brensocatib arms compared to the placebo arm. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WILLOW Efficacy Data</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We announced topline data for the WILLOW study in February 2020 and full data for the WILLOW study in June 2020. In September 2020, final results from the WILLOW study were published online in the New England Journal of Medicine. The data demonstrate that the WILLOW study met its primary endpoint of time to first pulmonary exacerbation over the 24-week treatment period for both the 10 mg and 25 mg dosage groups of brensocatib compared to placebo (p=0.027, p=0.044, respectively). The risk of exacerbation at any time during the trial was reduced by 42% for the 10 mg group versus placebo (HR 0.58, p=0.029) and by 38% for the 25 mg group versus placebo (HR 0.62, p=0.046). In addition, treatment with brensocatib 10 mg resulted in a significant reduction in the rate of pulmonary exacerbations, a key secondary endpoint, versus placebo. Specifically, patients treated with brensocatib experienced a 36% reduction in the 10 mg arm (p=0.041) and a 25% reduction in the 25 mg arm (p=0.167) versus placebo. Change in concentration of active NE in sputum versus placebo from baseline to the end of the treatment period was also statistically significant (p=0.034 for 10 mg, p=0.021 for 25 mg).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WILLOW Safety and Tolerability Data</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brensocatib was generally well-tolerated in the study. Rates of AEs leading to discontinuation in patients treated with placebo, brensocatib 10 mg, and brensocatib 25 mg were 10.6%, 7.4%, and 6.7%, respectively. The most common AEs in patients treated with brensocatib were cough, headache, sputum increase, dyspnea, fatigue, and upper respiratory tract infection. Rates of adverse events of special interest (AESIs) in patients treated with placebo, brensocatib 10 mg, and brensocatib 25 mg, respectively, were as follows: rates of skin events (including hyperkeratosis) were 11.8%, 14.8%, and 23.6%; rates of dental events were 3.5%, 16.0%, and 10.1%; and rates of infections that were considered AESIs were 17.6%, 13.6%, and 16.9%.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Further Research and Development</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we received notice from the FDA that we were awarded a development grant of $1.8 million for specific work to be performed on a PRO tool. The grant funding is for the development of a novel PRO tool for use in clinical trials to measure symptoms in patients with NCFBE with and without NTM lung infection.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently advancing a clinical development program for brensocatib in CF. The CF Therapeutics Development Network (CFTDN) has sanctioned our study protocol for brensocatib in CF. The CFTDN is an organization composed of specialists in CF clinical research and is the largest CF clinical trials network globally. Feedback from the CFTDN does not have any bearing on FDA regulatory approval. The Phase 2, multiple-dose, pharmacokinetics/pharmacodynamics study, which includes both patients who are on background CFTR modulator drugs and patients who are not on CFTR modulator drugs, is underway. We have completed enrollment in the CFTR modulator group and are on track to have results from this arm of the study by the end of 2022. We also plan to explore the potential of brensocatib in additional neutrophil-mediated diseases, including </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRSsNP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and HS.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Opportunity for brensocatib in bronchiectasis</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bronchiectasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a severe, chronic pulmonary disorder in which the bronchi become permanently dilated due to a cycle of infection, inflammation, and lung tissue damage. The condition is marked by f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requent pulmonary exacerbations requiring antibiotic therapy and/or hospitalizations. Symptoms include chronic cough, excessive sputum production, shortness of breath, and repeated respiratory infections, which can worsen the underlying condition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on information from external sources, including market research funded by us and third parties, and internal analyses and calculations, we estimate the potential addressable market at launch</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n the US, the European 5 (comprised of France, Germany, Italy, Spain and the UK) and Japan will be as follows (approximately):</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.807%"><tr><td style="width:1.0%"></td><td style="width:40.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Potential Market</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Number of Patients Diagnosed with Bronchiectasis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European 5</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, there are no approved therapies in the US, Europe, or Japan for the treatment of patients with br</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">onchiectasis. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treprostinil Palmitil Inhalation Powder</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TPIP is an investigational inhaled formulation of a treprostinil prodrug that has the potential to address certain of the current limitations of existing prostanoid therapies. We believe that TPIP prolongs duration of effect and may provide patients with greater consistency in pulmonary arterial pressure reduction over time. Current inhaled prostanoid therapies must be dosed four to nine times per day. Reducing dose frequency has the potential to ease patient burden and improve compliance. Additionally, we believe that TPIP may be associated with fewer side effects, including severity and/or frequency of cough, headache, throat irritation, nausea, flushing and dizziness that are associated with high initial drug levels and local upper airway exposure when using current inhaled prostanoid therapies. We believe TPIP may offer a differentiated product profile for PH-ILD and PAH.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we announced topline results from the Phase 1 study of TPIP in healthy volunteers. The objective of this first-in-human single ascending dose and multiple ascending dose study was to assess the pharmacokinetics and tolerability profile of TPIP. Data from the study demonstrated that TPIP was generally well tolerated, with a pharmacokinetic profile that supports continued development with once-daily dosing. The most common AEs across all cohorts in the study were cough, dizziness, headache, and nausea. Most AEs were mild in severity and consistent in nature with those typically seen with other inhaled prostanoid therapies. There were few moderate AEs and no severe or serious AEs. Subjects in the multiple dose panel that incorporated an up-titration approach beginning at 112.5 &#181;g once-daily and progressing to 225 &#181;g once-daily reported fewer AEs compared to the panel dosed with 225 &#181;g once-daily from the first dose.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall pharmacokinetic results demonstrated that treprostinil exposure (AUC and C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) was dose-proportional, with low to moderate inter-subject variability. Treprostinil was detected in the plasma at 24 hours at all doses and throughout the 48-hour sampling period for the two highest doses. Compared with currently available inhaled treprostinil therapy, TPIP showed substantially lower C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and longer half-life. Data from this study were presented in an oral session at the European Society of Cardiology Congress in August 2021.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing the development of TPIP with two studies in patients with PAH. The first is an open-label, proof-of-mechanism study to understand the impact of a single dose of TPIP on PVR over a 24-hour period. The second will aim to investigate the effect of TPIP on PVR and six-minute walk distance over a 16-week treatment period using an up-titration, once-daily dosing schedule. One patient has completed the 24-hour period study at a dose of 112.5 micrograms. This patient also went on to complete the 16-week extension period study and was titrated to a dose of 320 micrograms once daily, which was found to be safe and tolerable. We did not observe any safety concerns with TPIP, and the data suggested a trend towards improvement in various cardiac measures during the study period. Beyond PAH, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we continue to explore potential development pathways for TPIP in patients with other rare pulmonary disorders, including PH-ILD. We initiated a Phase 2 study in patients with PH-ILD using an up-titration, once-daily dosing schedule in early 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Translational Medicine</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our translational medicine efforts are comprised of the Company&#8217;s preclinical programs, advanced through our internal research and development and augmented through business development activities. In March 2021, we acquired a proprietary protein deimmunization platform, called Deimmunized by Design, focused on the reengineering of therapeutic proteins to evade immune recognition and reaction. In August 2021, we acquired Motus and AlgaeneX, preclinical stage companies engaged in the research, development and manufacturing of gene therapies for rare genetic disorders. We believe that animal studies may demonstrate the viability of these potential medicines to address serious unmet medical needs in various therapeutic areas.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Development</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to develop, acquire, in-license or co-promote other products, product candidates and technologies, including those that address serious and rare diseases that currently have significant unmet needs. We are focused broadly on serious and rare disease therapeutics and prioritizing those areas that best align with our core competencies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i252108b308054887a46901fe227627f1_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KEY COMPONENTS OF OUR RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Revenues, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net, consist of net sales of ARIKAYCE. In October 2018, we began shipping ARIKAYCE to our customers in the US, which include specialty pharmacies and specialty distributors. In December 2020 and February 2021, we began commercial sales of ARIKAYCE in Germany and the Netherlands, respectively. In July 2021, we began recognizing product revenue from commercial sales of ARIKAYCE in Japan. We recognize revenue for product received by our customers net of allowances for customer credits, including prompt pay discounts, service fees, estimated rebates, including government rebates, such as Medicaid rebates and Medicare Part D coverage gap reimbursements in the US, and chargebacks.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Product Revenues (Excluding Amortization of Intangible Assets)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestones. We began capitalizing inventory upon FDA approval of ARIKAYCE. All costs related to inventory for ARIKAYCE prior to FDA approval were expensed as incurred and therefore not included in cost of product revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development (R&amp;D) Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in our research and development functions, including medical affairs and program management. R&amp;D expenses also includes other internal operating expenses, the cost of manufacturing product candidates, including the medical devices for drug delivery, for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, R&amp;D expenses include payments to third parties for the license rights to products in development (prior to marketing approval), such as brensocatib. Our R&amp;D expenses related to manufacturing our product candidates and medical devices for clinical study are primarily related to activities at CMOs that manufacture brensocatib and TPIP. Our R&amp;D expenses related to clinical trials are primarily related to activities at contract research organizations (CROs) that conduct and manage clinical trials on our behalf. These contracts with CROs set forth the scope of work to be completed at a fixed fee or amount per patient enrolled. Payments under these contracts with CROs primarily depend on performance criteria such as the successful enrollment of patients or the completion of clinical trial milestones as well as time-based fees. Expenses are accrued based on contracted amounts applied to the level of patient enrollment and to activity according to the clinical trial protocol. Deposits for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative (SG&amp;A) Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for our non-employee directors and personnel serving in our executive, finance and accounting, legal and compliance, commercial and pre-commercial, corporate development, field sales, information technology and human resource functions. SG&amp;A expenses also include professional fees for legal services, consulting services, including commercial activities, insurance, board of director fees, tax and accounting services and certain milestones related to ARIKAYCE.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of ARIKAYCE, our intangible assets began to be amortized over their estimated useful lives. The fair values assigned to our intangible assets are based on estimates and assumptions we believe are reasonable based on available facts and circumstances. Unanticipated events or circumstances may occur that require us to review the assets for impairment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Fair Value of Deferred and Contingent Consideration Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Business Acquisition in August 2021, we recorded deferred and contingent consideration liabilities related to potential future milestone payments. Adjustments to the fair value are due to changes in: the probability of achieving milestones; our stock price; or certain other estimated assumptions. The change in fair value of deferred and contingent consideration liabilities is calculated quarterly with gains and losses recorded in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Income and Interest Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income consists of interest and dividend income earned on our cash and cash equivalents and marketable securities. Interest expense consists primarily of the accretion of debt discount, contractual interest costs and the amortization of debt issuance costs related to our debt. Debt discount was accreted prior to the adoption of ASU 2020-06, and debt issuance costs are amortized, to interest expense using the effective interest rate method over the term of the debt. Our balance sheet </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reflects debt, net of the debt discount, debt issuance costs paid to the lender, and other third-party costs. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</span></div><div id="i252108b308054887a46901fe227627f1_82"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees (other than our laboratory personnel) have been provided a flexible approach to where and how they work in order to more easily manage business and personal responsibilities. We have enhanced our internal communications and touch points to ensure connectivity to our workforce. For when employees do work from the office, all of our facilities have been appropriately evaluated and sanitized on a daily basis in line with state and CDC guidelines. We will continue to manage this situation with a focus on the safety of our employees, ARIKAYCE physicians, caregivers and patients.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Though we continue to see use of ARIKAYCE, including new patient adds and continued prescription renewals, there remains a general uncertainty regarding the impact of COVID-19 on all aspects of our business, including how it will impact our patients, physicians, employees, suppliers, vendors, business partners and distribution channels. While the pandemic did not materially affect our financial results and business operations through the six months ended June 30, 2022, we are unable to predict the impact that COVID-19 will have on our financial position and operating results in future periods due to these and other numerous uncertainties. We will continue to assess the evolving impact of the COVID-19 pandemic and will make adjustments to our operations as necessary.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Three Months Ended June 30, 2022 and 2021 </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview - Operating Results</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results for the three months ended June 30, 2022, included the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product revenues, net, increased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$19.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to the same period in the prior year as a result of the growth in ARIKAYCE sales;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost of product revenues (excluding amortization of intangible assets) increased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.6 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to the same period in the prior year as a result of the increase in sales volumes of ARIKAYCE;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">R&amp;D expenses increased $23.9 million as compared to the same period in the prior year primarily resulting from increases in clinical development and research costs for our ongoing clinical trials;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SG&amp;A expenses increased $2.8 million as compared to the same period in the prior year resulting primarily from increases in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other internal expenses due to resuming certain internal commercial activities and increased travel expenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Amortization of intangible assets of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was consistent with the same period in the prior year; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Change in fair value of contingent consideration liabilities was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$(12.6) million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, primarily as a result of the change in our share price; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interest expense decreased $7.0 million as compared to the same period in the prior year due to the cessation of accreting debt discount in accordance with the adoption of ASU 2020-06.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Revenues, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net, consists of net sales of ARIKAYCE. The following table summarizes revenue by geography for the three months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.350%"><tr><td style="width:1.0%"></td><td style="width:33.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.084%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.6)%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total product revenues, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.8%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net, for the three months ended June 30, 2022 increased to $65.2 million as compared to $45.4 million in the same period in 2021, an increase of 43.8% as a result of the launch of ARIKAYCE in Japan and growth in ARIKAYCE sales in the US. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Product Revenues (excluding amortization of intangible assets)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) for the three months ended June 30, 2022 and 2021 were comprised of the following (in thousands):</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"></td><td style="width:37.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenues (excluding amortization of intangible assets)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cost of product revenues, as % of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) increased by $5.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or 51.3%,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to $16.4 million for the three months ended June 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the same period in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in cost of product revenues (excluding amortization of intangibles) in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended June 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was primarily attributable to the increase in product revenues discussed above.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R&amp;D Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses for the three months ended June 30, 2022 and 2021 were comprised of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:41.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.863%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.863%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase&#160;(decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">External Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical development&#160;and research</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,333&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory, quality assurance, and medical affairs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,993&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal&#8212;external expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Internal Expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefit related expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,647&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other internal operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal&#8212;internal expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,251&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,028&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total R&amp;D expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,527&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses increased to $88.5 million during the three months ended June 30, 2022 from $64.7 million in the same period in 2021. The $23.9 million increase was primarily due to a $7.8 million increase in clinical development and research costs related to the ongoing Phase 3 ASPEN trial of brensocatib and the ARIKAYCE frontline clinical trial program. The increase was also due to a $7.8 million increase in compensation and benefit related expenses and stock-based compensation due to an increase in headcount, as well as a $4.3 million increase in manufacturing expenses to support ongoing clinical trials. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">External R&amp;D expenses by product for the three months ended June&#160;30, 2022 and 2021 were comprised of the following (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:36.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARIKAYCE external R&amp;D expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brensocatib external R&amp;D expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external R&amp;D expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total external R&amp;D expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,248&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,404&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,844&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect R&amp;D expenses to continue to increase in 2022 relative to 2021 primarily due to our clinical trial activities and related spend, including our Phase 3 ASPEN trial of brensocatib, our confirmatory clinical trial of ARIKAYCE in a frontline treatment setting for patients with MAC lung disease, our TPIP clinical trials and our research efforts in translational medicine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SG&amp;A Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses for the three months ended June 30, 2022 and 2021 were comprised of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.753%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefit related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and other external expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(801)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility related and other internal expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total SG&amp;A expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,974&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,797&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses increased to $60.0 million during the three months ended June 30, 2022 from $57.2 million in the same period in 2021. The $2.8 million increase resulted primarily from a $2.6 million increase in other internal expenses due to resuming certain internal commercial meetings and increased travel expenses. We expect SG&amp;A expenses to continue to increase due, in part, to commercial readiness activities for brensocatib.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets for both the three months ended June&#160;30, 2022 and 2021 was $1.3 million. Amortization of intangible assets is comprised of amortization of acquired ARIKAYCE R&amp;D and amortization of the milestones paid to PARI for the FDA and EC approvals of ARIKAYCE.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Fair Value of Deferred and Contingent Consideration Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of deferred and contingent consideration liabilities for the three months ended June&#160;30, 2022 was $(12.6)&#160;million. The change is related to the fair value of the potential future consideration to be paid to former equityholders of the acquired businesses. Adjustments to the fair value are due to changes in: the probability of achieving milestones; our stock price; or certain other estimated assumptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased to $3.4 million for the three months ended June&#160;30, 2022 as compared to $10.3 million in the same period in 2021 due to the cessation of accreting debt discount in accordance with the adoption of ASU 2020-06.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Six Months Ended June 30, 2022 and 2021 </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview - Operating Results</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results for the six months ended June 30, 2022, included the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product revenues, net, increased $32.7 million as compared to the same period in the prior year as a result of the growth in ARIKAYCE sales;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost of product revenues (excluding amortization of intangible assets) increased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to the same period in the prior year as a result of the increase in sales volumes of ARIKAYCE;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">R&amp;D expenses increased $46.8 million as compared to the same period in the prior year primarily resulting from increases in clinical development and research costs for our ongoing clinical trials;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SG&amp;A expenses increased $8.0 million as compared to the same period in the prior year resulting primarily from increases in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other internal expenses and compensation and benefit related costs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Amortization of intangible assets of $2.5 million was consistent with the same period in the prior year; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Change in fair value of contingent consideration liabilities was $(24.2) million, primarily as a result of the change in our share price; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interest expense decreased $11.2 million as compared to the same period in the prior year due to the cessation of accreting debt discount in accordance with the adoption of ASU 2020-06.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Revenues, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net, consists of net sales of ARIKAYCE. The following table summarizes revenue by geography for the six months ended June 30, 2022 and 2021 (in thousands):</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.350%"><tr><td style="width:1.0%"></td><td style="width:33.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.084%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.7)%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total product revenues, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,328&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,580&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,748&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net, for the six months ended June 30, 2022 increased to $118.3 million as compared to $85.6 million in the same period in 2021, an increase of 38.3% as a result of the launch of ARIKAYCE in Japan and growth in ARIKAYCE sales in the US. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Product Revenues (excluding amortization of intangible assets)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) for the six months ended June 30, 2022 and 2021 were comprised of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"></td><td style="width:37.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenues (excluding amortization of intangible assets)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cost of product revenues, as % of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) increased by $7.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or 38.2%,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to $28.6 million for the six months ended June 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to $20.7 million in the same period in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in cost of product revenues (excluding amortization of intangibles) in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was attributable to the increase in product revenues discussed above.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R&amp;D Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses for the six months ended June 30, 2022 and 2021 were comprised of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:41.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.863%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.863%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase&#160;(decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">External Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical development&#160;and research</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory, quality assurance, and medical affairs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,989&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal&#8212;external expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Internal Expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefit related expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,262&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other internal operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal&#8212;internal expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,065&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total R&amp;D expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,838&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses increased to $172.9 million during the six months ended June 30, 2022 from $126.0 million in the same period in 2021. The $46.8 million increase was primarily due to a $17.5 million increase in clinical development and research costs related to the ongoing Phase 3 ASPEN trial of brensocatib and the ARIKAYCE frontline clinical trial program. The increase was also due to a $14.7 million increase in compensation and benefit related expenses and stock-based compensation due to an increase in headcount, as well as a $7.5 million increase in manufacturing expenses to support ongoing clinical trials. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">External R&amp;D expenses by product for the six months ended June 30, 2022 and 2021 were comprised of the following (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:36.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARIKAYCE external R&amp;D expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brensocatib external R&amp;D expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external R&amp;D expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total external R&amp;D expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,718&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,945&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,773&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect R&amp;D expenses to continue to increase in 2022 relative to 2021 primarily due to our clinical trial activities and related spend, including our Phase 3 ASPEN trial of brensocatib, our confirmatory clinical trial of ARIKAYCE in a frontline treatment setting for patients with MAC lung disease, our TPIP clinical trials and our research efforts in translational medicine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SG&amp;A Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses for the six months ended June 30, 2022 and 2021 were comprised of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.753%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefit related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and other external expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility related and other internal expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total SG&amp;A expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,722&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,727&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,995&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SG&amp;A expenses increased to $116.7 million during the six months ended June 30, 2022 from $108.7 million in the same period in 2021. The $8.0 million increase resulted primarily from a $3.4 million increase in other internal expenses resulting from increased travel expenses, increased licenses and software fees and resuming certain internal commercial meetings, as well as a $2.6 million increase in compensation and benefit related expenses and stock-based compensation due to an increase in global headcount. We expect SG&amp;A expenses to continue to increase due, in part, to commercial readiness activities for brensocatib.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets for both the six months ended June 30, 2022 and 2021 was $2.5 million. Amortization of intangible assets is comprised of amortization of acquired ARIKAYCE R&amp;D and amortization of the milestones paid to PARI for the FDA and EC approvals of ARIKAYCE.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Fair Value of Deferred and Contingent Consideration Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of deferred and contingent consideration liabilities for the six months ended June 30, 2022 was $(24.2) million. The change is related to the fair value of the potential future consideration to be paid to former equityholders of the acquired businesses. Adjustments to the fair value are due to changes in: the probability of achieving milestones; our stock price; or certain other estimated assumptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased to $6.6 million for the six months ended June 30, 2022 as compared to $17.9 million in the same period in 2021 due to the cessation of accreting debt discount in accordance with the adoption of ASU 2020-06.</span></div><div id="i252108b308054887a46901fe227627f1_85"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;There is considerable time and cost associated with developing potential pharmaceutical products to the point of regulatory approval and commercialization. We commenced commercial shipments of ARIKAYCE in October 2018. We expect to continue to incur consolidated operating losses, including losses at our US and certain international entities, as we plan to fund R&amp;D for ARIKAYCE, brensocatib, TPIP and our other pipeline programs, continue pre-commercial, commercialization and regulatory activities for ARIKAYCE, and other general and administrative activities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we completed an underwritten public offering of $575.0 million aggregate principal amount of the 2028 Convertible Notes, including the exercise in full of the underwriters' option to purchase additional 2028 Convertible Notes. Our net proceeds from the offering, after deducting underwriting discounts and offering expenses of $15.7 million, were $559.3 million. A portion of the net proceeds from the 2028 Convertible Notes was used to repurchase $225.0 million of our outstanding 2025 Convertible Notes. We recorded a loss on early extinguishment of debt of $17.7 million, primarily related to the premium paid on extinguishment of a portion of the 2025 Convertible Notes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2021, we also completed an underwritten public offering of 11,500,000 shares of our common stock, including 1,500,000 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares from us, a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t a public offering price of $25.00 per share. Our net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expenses of $17.5 million, were $270.1 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we entered into a sales agreement with SVB Securities to sell shares of our common stock, with aggregate gross sales proceeds of up to $250.0 million, from time to time, through an ATM program, under which SVB Securities acts as sales agent. As of June&#160;30, 2022, we had not sold or issued any shares under the ATM program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to raise additional capital to fund our operations, including the Phase 3 ASPEN study, the continued commercialization of ARIKAYCE, the ARISE and ENCORE clinical trials related to ARIKAYCE, launch readiness activities for the potential launch of brensocatib, if approved, other clinical trials for brensocatib, TPIP, and our future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. While we believe we currently have sufficient funds to meet our financial needs for at least the next 12 months, we expect to opportunistically raise additional capital and may do so through equity or debt financing(s), strategic transactions or otherwise. Our cash requirements for the next 12 months will be impacted by a number of factors, the most significant of which we expect to be the ASPEN trial, expenses related to our commercialization efforts and our ARISE and ENCORE clinical trials for ARIKAYCE, and other development activities for brensocatib, and to a lesser extent, expenditures related to the clinical development of TPIP and other product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had cash and cash equivalents of $416.1 million, as compared with $716.8 million as of December&#160;31, 2021. In addition, as of June&#160;30, 2022, we had marketable securities of $148.6 million. The $300.7 million decrease in cash and cash equivalents was primarily due to the purchase of marketable securities and cash used in operating activities. Our working capital was $560.9 million as of June&#160;30, 2022, as compared with $701.9 million as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $207.5 million and $203.7 million for the six months ended June&#160;30, 2022 and 2021, respectively. The net cash used in operating activities during the six months ended June&#160;30, 2022 and 2021 was primarily for the commercial, clinical and manufacturing activities related to ARIKAYCE, as well as other SG&amp;A expenses and clinical trial expenses related to brensocatib and TPIP. The increase in cash used in operating activities for the six months ended June 30, 2022 compared to the corresponding period in 2021 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily due to the increase in net loss, excluding the adjustments to reconcile net loss to net cash used in operating activities, partially offset by the decrease in working capital, driven primarily by deposits paid in 2021 to our CROs for our initiated clinical trials and the $12.5 million milestone payment to AstraZeneca in 2021 related to the first dosing in our Phase 3 ASPEN trial.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $104.3 million and $4.7 million for the six months ended June&#160;30, 2022 and 2021, respectively. The increase in 2022 is due to purchases of marketable securities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $12.8 million and $604.3 million for the six months ended June&#160;30, 2022 and 2021, respectively. The decrease in 2022 is due to net cash proceeds from the issuance and extinguishment of debt during the six months ended June 30, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes outside of the ordinary course of business in our contractual obligations during the six months ended June 30, 2022 from those disclosed in Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources&#8212;Contractual Obligations&#8221; in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000110450622000008/insm-20211231.htm">Annual Report on Form&#160;10-K for the year ended December&#160;31, 20</a>21.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. We do not have any interest in special purpose entities, structured finance entities or other variable interest entities.</span></div><div id="i252108b308054887a46901fe227627f1_88"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting policies and estimates as disclosed in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000110450622000008/insm-20211231.htm">Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the required interim disclosure updates related to our accounting policies and estimates, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in this Quarterly Report on Form&#160;10-Q.</span></div><div id="i252108b308054887a46901fe227627f1_91"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our cash and cash equivalents were in cash accounts and money market funds. Our investments in money market funds are not insured by the federal government. As of June&#160;30, 2022, our marketable securities were invested in US treasury notes with an original maturity of greater than 90 days.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had $800.0 million of convertible notes outstanding. Our 2025 Convertible Notes and our 2028 Convertible Notes bear interest at a coupon rate of 1.75% and 0.75%, respectively. If a 10% change in interest rates had occurred on June&#160;30, 2022, it would not have had a material effect on the fair value of our debt as of that date, nor would it have had a material effect on our future earnings or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our business is conducted in US dollars. However, we do conduct certain transactions in other currencies, including Euros, British Pounds, and Japanese Yen. Historically, fluctuations in foreign currency exchange rates have not materially affected our results of operations and during the six months ended June&#160;30, 2022 and 2021, our results of operations were not materially affected by fluctuations in foreign currency exchange rates.</span></div><div id="i252108b308054887a46901fe227627f1_94"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June&#160;30, 2022.&#160;The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities and Exchange Act of 1934, as amended (the Exchange Act), means controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit with the SEC is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules&#160;and forms, and to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.&#160;Based on that evaluation as of June&#160;30, 2022, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the six months ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i252108b308054887a46901fe227627f1_97"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II. OTHER INFORMATION</span></div><div id="i252108b308054887a46901fe227627f1_100"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of our business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on our consolidated financial position, results of operations or cash flows.</span></div><div id="i252108b308054887a46901fe227627f1_103"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to substantial risks and uncertainties. You should carefully consider the risk factors set forth below as well as the other information contained in this Quarterly Report on Form 10-Q and in our other public filings in evaluating our business, including our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000110450622000008/insm-20211231.htm">Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed with the SEC on February 17, 2022. Any of the risks and uncertainties described below and in our other filings with the SEC, either alone or taken together, could materially and adversely affect our business, financial condition, results of operations, prospects for growth, and the value of an investment in our common stock. In addition, these risks and uncertainties could cause actual results to differ materially from those expressed or implied by forward-looking statements contained in this Form 10-Q (please read the Cautionary Note Regarding Forward-Looking Statements in this Form 10-Q).</span></div><div id="i252108b308054887a46901fe227627f1_106"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i252108b308054887a46901fe227627f1_109"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div id="i252108b308054887a46901fe227627f1_112"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBITS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit Index</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000114036113012797/ex3_1.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Articles of Incorporation of Insmed Incorporated, as amended through June&#160;14, 2012 (incorporated by reference from Exhibit&#160;3.1 to Insmed Incorporated&#8217;s Annual Report on Form&#160;10-K filed on March&#160;18, 2013).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465920040374/tm2014206d1_ex3-1.htm">3.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Bylaws of Insmed Incorporated (incorporated by reference from Exhibit&#160;3.1 to Insmed Incorporated&#8217;s Current Report on Form&#160;8-K filed on March&#160;30, 2020).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20220630ex101.htm">10.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, effective as of May 23, 2022, between Insmed Incorporated and J. Drayton Wise.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20220630ex311.htm">31.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of William H. Lewis, Chair and Chief Executive Officer (Principal Executive Officer) of Insmed Incorporated, pursuant to Rules&#160;13a-14(a)&#160;and 15d-14(a)&#160;promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes Oxley Act of 2002.</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20220630ex312.htm">31.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Sara Bonstein, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) of Insmed Incorporated, pursuant to Rules&#160;13a-14(a)&#160;and 15d-14(a)&#160;promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes Oxley Act of 2002.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20220630ex321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of William H. Lewis, Chair and Chief Executive Officer (Principal Executive Officer) of Insmed Incorporated, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes Oxley Act of 2002.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20220630ex322.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Sara Bonstein, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) of Insmed Incorporated, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes Oxley Act of 2002.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Insmed Incorporated&#8217;s quarterly report on Form&#160;10-Q for the quarter ended June 30, 2022 formatted in iXBRL (Inline eXtensible Business Reporting Language): (i)&#160;Consolidated Balance Sheets as of June 30, 2022 and December&#160;31, 2021, (ii)&#160;Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2022 and 2021, (iii)&#160;Consolidated Statements of Shareholders' Equity for the three and six months ended June 30, 2022 and 2021, (iv) Consolidated Statements of Cash Flows for the six months ended June 30, 2022 and 2021, (v)&#160;Notes to the Unaudited Consolidated Financial Statements, and (vi) Cover Page.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cover page from the Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, formatted in iXBRL and contained in Exhibit 101.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*      Certain portions of this exhibit have been redacted.</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**     Management contract or compensatory plan or arrangement.</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i252108b308054887a46901fe227627f1_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i252108b308054887a46901fe227627f1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INSMED INCORPORATED</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 4, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sara Bonstein</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sara Bonstein</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>insm-20220630ex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iaf21c45876594cbd926fe5fcf65cfe0a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Employment Agreement (&#8220;Agreement&#8221;) is effective on May 23, 2022 (the &#8220;Effective Date&#8221;), by and between Insmed Incorporated, a Virginia corporation (&#8220;Insmed&#8221;), and J. Drayton Wise (hereinafter, the &#8220;Executive&#8221; and collectively with Insmed, the &#8220;Parties&#8221;).  When referring to the Executive, the term &#8220;he&#8221; or &#8220;she&#8221; throughout this Agreement is intended to be gender neutral.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WITNESSETH&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Insmed desires to continue to employ the Executive and the Executive desires to continue to be employed by Insmed on the terms herein described.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the promises and mutual covenants set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are mutually acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. When used in this Agreement, the following terms shall have the following meanings&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-24.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">all accrued but unpaid Base Salary through the end of the Term of Employment&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27.66pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">any unpaid or unreimbursed expenses incurred in accordance with Insmed policy, including amounts due under Section 5(a) hereof, to the extent incurred during the Term of Employment&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-30.99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">any accrued but unpaid benefits provided under Insmed&#8217;s employee benefit plans, subject to and in accordance with the terms of those plans&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-30.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt"> rights to indemnification by virtue of the Executive&#8217;s position as an officer or director of Insmed or its subsidiaries and the benefits under any directors&#8217; and officers&#8217; liability insurance policy maintained by Insmed, in accordance with its terms thereof.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">&#8220;Affiliate&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means any entity in which Insmed has a substantial direct or indirect equity interest. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Base Salary&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the salary provided for in Section 4(a) hereof or any increased salary granted to Executive pursuant to Section 4(a) hereof.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Beneficial Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term in Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Board of Directors of Insmed. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.01pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any bonus payable to the Executive pursuant to Section 4(b) hereof.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-24.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">a conviction of the Executive, or a plea of nolo contendere, to a felony involving moral turpitude&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27.66pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">willful misconduct or gross negligence by the Executive resulting, in either case, in material economic harm to Insmed or any Affiliate&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-30.99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">a willful failure by the Executive to carry out the reasonable and lawful directions of the Board and failure by the Executive to remedy the failure within thirty (30) days after receipt of written notice of same from the Board&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-30.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">fraud, embezzlement, theft or dishonesty of a material nature by the Executive against Insmed or any Affiliate, or a willful material violation by the Executive of a policy or procedure of Insmed or any Affiliate, resulting, in any case, in material economic harm to Insmed or any Affiliate&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">a willful material breach by the Executive of this Agreement and failure by the Executive to remedy the material breach within 30 days after receipt of written notice of same from the Board.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-24.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">The acquisition by any Person of Beneficial Ownership of at least 40% of either (A) the value of the then outstanding shares of common stock of Insmed (the &#8220;Outstanding Company Common Stock&#8221;) or (B) the combined voting power of the then outstanding voting securities of Insmed entitled to vote generally in the election of directors (the &#8220;Outstanding Company Voting Securities&#8221;) (the foregoing Beneficial Ownership hereinafter being referred to as a &#8220;Controlling Interest&#8221;)&#59; provided, however, that for purposes of this definition, the following acquisitions shall not constitute or result in a Change of Control&#58; (v) any acquisition directly from Insmed&#59; (w) any acquisition by Insmed&#59; (x) any acquisition by any Person that as of the Effective Date owns Beneficial Ownership of a Controlling Interest&#59; (y) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by Insmed or any subsidiary of Insmed&#59; or (z) any acquisition by any corporation pursuant to a transaction which complies with clauses (A), (B) and (C) of subsection (iii) below&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27.66pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">During any period of two consecutive years (not including any period prior to the Effective Date) individuals who constitute the Board on the Effective Date (the &#8220;Incumbent Board&#8221;) cease for any reason to constitute at least a majority of the Board&#59; provided, however, that any individual becoming a director subsequent to the Effective Date whose election, or nomination for election by Insmed&#8217;s shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-30.99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">Consummation of a reorganization, merger, statutory share exchange or consolidation or similar corporate transaction involving Insmed or any of its subsidiaries, a sale or other disposition of all or substantially all of the assets of Insmed, or the acquisition of assets or stock of another entity by Insmed or any of its subsidiaries (each a &#8220;Business Combination&#8221;), in each case, unless, following such Business Combination, (A) all or substantially all of the Persons who were the Beneficial Owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 60% of the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns Insmed or all or substantially all of Insmed&#8217;s assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the &#8220;Acquiring Corporation&#8221;) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) of Insmed or such Acquiring Corporation) beneficially owns, directly or indirectly, more than 40% of the then outstanding shares of common stock of the corporation resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior to the Business Combination, and (C) at least a majority of the members of the Board of Directors of the corporation resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-30.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">approval by the shareholders of Insmed of a complete liquidation or dissolution of Insmed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, no event or transaction will constitute a Change in Control hereunder unless it also constitutes a &#8220;change in control event&#8221; under Section 409A of the Code.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended from time to time.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Internal Revenue Code of 1986, as amended.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Competitive Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i) the discovery, design, development, distribution, marketing or sale of therapies for rare lung diseases and&#47;or disorders, or (ii) any other activity in competition with the material activities of Insmed or any of its Affiliates, in either case in any of the States within the United States, or countries within the world, in which Insmed or any of its Affiliates conducts business.  For this purpose, the activities of Insmed and its Affiliates, and where Insmed and its Affiliates do business, will be determined as of the earlier of the date of the application of this definition or the Termination Date.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all trade secrets and information disclosed to the Executive or known by the Executive as a consequence of or through the unique position of his employment with Insmed or any Affiliate (including information conceived, originated, discovered or developed by the Executive and information acquired by Insmed or any Affiliate from others) prior to, on or after the date hereof, and not generally or publicly known (other than as a result of unauthorized disclosure by the Executive), about Insmed or any Affiliate or its business. Confidential Information includes, but is not limited to, inventions, ideas, designs, computer programs, circuits, schematics, formulas, algorithms, trade secrets, works of authorship, mask works, developmental or experimental work, processes, techniques, improvements, methods of manufacturing, know-how, data, financial information and forecasts, product plans, marketing plans and strategies, price lists, customer lists and contractual obligations and terms thereof, data, documentation and other information, in whatever form disclosed, relating to Insmed or any Affiliate, including, but not limited to, financial statements, financial projections, business plans, listings and contractual obligations and terms thereof, components of intellectual property, unique designs, methods of manufacturing or other technology of Insmed or any Affiliate.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Executive&#8217;s inability, or failure, to perform the essential functions of his position, with or without reasonable accommodation, for any period of six months or more in any 12-month period, by reason of any medically determinable physical or mental impairment.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:11.01pt">&#8220;Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any stock options, restricted stock, restricted stock units, stock appreciation rights, phantom stock or other equity-based awards granted by Insmed to the Executive.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any excise tax imposed by Section 4999 of the Code, together with any interest and penalties imposed with respect thereto, or any interest or penalties that are incurred by the Executive with respect to any such excise tax.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the occurrence of any of the following&#58; (i) a material diminution in the Executive&#8217;s base compensation&#59; (ii) a material diminution in the Executive&#8217;s authority, duties, or responsibilities&#59; (iii) a material diminution in the authority, duties, or responsibilities of the supervisor to whom the Executive is required to report&#59; (iv) Insmed&#8217;s or any Affiliate&#8217;s requiring the Executive to be based at any office or location outside of 50 miles from the location of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">employment or service as of the Effective Date, except for travel reasonably required in the performance of the Executive&#8217;s responsibilities&#59; or (v) any other action or inaction that constitutes a material breach by Insmed of this Agreement.  For purposes of this Agreement, Good Reason shall not be deemed to exist unless the Executive&#8217;s termination of employment for Good Reason occurs within six months following the initial existence of one of the conditions specified in clauses (i) through (v) above, the Executive provides Insmed with written notice of the existence of such condition within 90 days after the initial existence of the condition, and Insmed fails to remedy the condition within 30 days after its receipt of such notice.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.67pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term in Section 13(d) of the Securities Exchange Act of 1934.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.67pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term in Section 3(a)(9) of the Securities Exchange Act of 1934 and used in Sections 13(d) and 14(d) thereof. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">&#8220;Pro-Rata Bonus&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Bonus based on actual corporate performance outcomes (75% of overall bonus) and 100% of personal performance at target (25% of overall bonus) for that year that, but for the cessation of the Executive&#8217;s employment, would otherwise have been payable to the Executive for the fiscal year in which the Termination Date occurs, multiplied by the following fraction&#58; (i) the number of days that the Executive was employed by Insmed during that fiscal year, divided by (ii) 365.  For this purpose, the Bonus that would otherwise have been payable to the Executive shall be determined in good faith and in the same manner applicable to active named executive officers of Insmed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.67pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be the Executive&#8217;s period of employment with Insmed and the one year period immediately following the termination thereof.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:5.67pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Severance Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean an amount equal to the Executive&#8217;s annual Base Salary, as in effect immediately prior to the Termination Date.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">n.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning described in Section 4(b).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">o.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the period during which the Executive shall be employed by Insmed pursuant to the terms of this Agreement, which period shall begin on the Effective Date and continue until terminated in accordance with Section 6 hereof.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">p.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the date on which the Term of Employment ends.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Insmed hereby agrees to continue to employ the Executive and the Executive hereby agrees to continue to serve Insmed during the Term of Employment on the terms and conditions set forth herein.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Duties of Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the Term of Employment, the Executive shall be employed and serve as the Chief Commercial Officer and shall have such duties typically associated with such title, including, without limitation, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">leading global commercial operations and playing a key management and leadership role for Insmed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Executive shall faithfully and diligently perform all services consistent with his position as may be assigned to him </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">by executive management or the Board in their discretion.  The Executive shall devote his full business time, attention and efforts to the performance of his duties under this Agreement, render such services to the best of his ability, and use his reasonable best efforts to promote the interests of Insmed.  The Executive shall not engage in any other business or occupation during the Term of Employment, including, without limitation, any activity that (i) conflicts with the interests of Insmed or its subsidiaries, (ii) interferes with the proper and efficient performance of his duties for Insmed, (iii) constitutes a Competitive Activity, or (iv) interferes with the exercise of his judgment in Insmed&#8217;s best interests.  Notwithstanding the foregoing or any other provision of this Agreement, it shall not be a breach or violation of this Agreement for the Executive to (w) serve on up to two outside corporate or scientific advisory boards with prior notice to, and approval by, the Board, (x) serve on civic or charitable boards or committees, (y) deliver lectures, fulfill speaking engagements or teach at educational institutions, or (z) manage personal investments, so long as such activities do not constitute a Competitive Activity or significantly interfere with or significantly detract from the performance of the Executive&#8217;s responsibilities to Insmed in accordance with this Agreement. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9.68pt">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Executive shall receive a Base Salary at the annual rate of $500,000.00 during the Term of Employment, with such Base Salary payable in installments consistent with Insmed&#8217;s normal payroll schedule, subject to applicable withholding and other taxes.  The Base Salary shall be reviewed, at least annually, for merit increases and may, by action and in the discretion of the Board, be increased at any time or from time to time, but may not be decreased from the then current Base Salary.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Bonuses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term of Employment, the Executive shall participate in Insmed&#8217;s annual incentive compensation plan, program and&#47;or arrangements applicable to senior-level executives, as established and modified from time to time by the Compensation Committee of the Board in its sole discretion.  The Executive shall have a target bonus opportunity under such plan or program equal to 40% of his current Base Salary (the &#8220;Target Bonus&#8221;). The actual bonus payout, if any, shall be based on the satisfaction of performance criteria to be established by the Compensation Committee of the Board within the first three months of each fiscal year that begins during the Term of Employment. Payment of annual incentive compensation awards shall be made in the same manner and at the same time that other senior-level executives receive their annual incentive compensation awards and, except as otherwise provided herein, will be subject to the Executive&#8217;s continued employment through the applicable payment date.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Expense Reimbursement and Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9.68pt">Reimbursement of Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon the submission of proper substantiation by the Executive, and subject to such rules and guidelines as Insmed may from time to time adopt with respect to the reimbursement of expenses of executive personnel, Insmed shall reimburse the Executive for all reasonable expenses actually paid or incurred by the Executive during the Term of Employment in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">course of and pursuant to the business of Insmed.  The Executive shall account to Insmed in writing for all expenses for which reimbursement is sought and shall supply to Insmed copies of all relevant invoices, receipts or other evidence reasonably requested by Insmed. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Compensation&#47;Benefit Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the Term of Employment, the Executive shall be entitled to participate in all medical, dental, hospitalization, accidental death and dismemberment, disability, travel and life insurance plans, and any and all other plans as are from time to time offered by Insmed to its executive personnel, including savings, pension, profit-sharing and deferred compensation plans, subject to the general eligibility and participation provisions set forth in such plans&#59; provided, however, that (i) the Executive&#8217;s right to participate in such plans will not affect Insmed&#8217;s right to amend or terminate any such plan in accordance with the terms of such plan, and (ii) the Executive acknowledges that the Executive will have no vested rights under any such plan except as expressly provided under the terms thereof.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9.68pt">Working Facilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the Term of Employment, Insmed shall furnish the Executive with an office, administrative help and such other facilities similar to those provided to similarly situated executives of Insmed.  The Executive&#8217;s principal location of employment or service (subject to reasonable travel) shall be Bridgewater, NJ.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Stock Options.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> As a material inducement to entering into this Agreement, the Executive has received an award of restricted stock units (&#8220;RSU&#8221;) and an option to purchase a number of common shares of Insmed having an aggregate value of $2,100,000. The value of the RSUs is $525,000. The RSUs will vest on a four-year vesting schedule, with twenty-five percent (25%) vesting on each of the first, second, third, and fourth anniversaries of the grant date, so that the entire grant will be fully vested on the fourth anniversary of the grant date, subject to Executive&#8217;s continued employment with Insmed on each vesting date. The value of the options is $1,575,000. The number of shares underlying the options will be determined using a Black-Scholes calculation based upon the closing price on the grant date.  The exercise price per share will be equal to the fair market value per share determined based upon the closing price of an Insmed common share on the grant date. The options will vest on a four-year vesting schedule, with twenty-five percent (25%)  of the shares subject to the option vesting on the first anniversary of the grant date and twelve and one-half percent (12.5%) of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the grant date, so that the entire grant will be fully vested on the fourth anniversary of the grant date, subject to Executive&#8217;s continued employment with Insmed on each vesting date. The terms and conditions of the restricted stock unit award and options will be consistent with Insmed&#8217;s standard RSU award agreement and stock option award agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9.68pt">Vacation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Executive shall be entitled to take vacation time as per Insmed&#8217;s Professional Judgment Vacation Policy.  This policy provides the Executive the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ability, with advanced approval from his manager, to take vacation days as and when appropriate throughout the calendar year. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9.68pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Term of Employment shall terminate upon the earliest to occur of (i) the Executive&#8217;s death, (ii) a termination by Insmed by reason of the Executive&#8217;s Disability, (iii) a termination by Insmed with or without Cause, or (iv) a termination by Executive with or without Good Reason.  Upon any termination of Executive&#8217;s employment for any reason, except as may otherwise be requested by Insmed in writing and agreed upon in writing by Executive, the Executive shall resign from any and all directorships, committee memberships or any other positions Executive holds with Insmed or any of its Affiliates.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Termination by Company for Cause.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Insmed shall at all times have the right, upon written notice to the Executive, to terminate the Term of Employment for Cause.  In no event shall a termination of the Executive&#8217;s employment for Cause occur unless Insmed gives written notice to the Executive in accordance with this Agreement stating with reasonable specificity the events or actions that constitute Cause and providing the Executive with an opportunity to cure (if curable) within a reasonable period of time.  Cause shall in no event be deemed to exist except upon a decision made by the Board, at a meeting, duly called and noticed, to which the Executive (and the Executive&#8217;s counsel) shall be invited upon proper notice and shall be permitted to present evidence.  For purposes of this Section 6(b), any good faith determination by the Board of Cause shall be binding and conclusive on all interested parties.  In the event that the Term of Employment is terminated by Insmed for Cause, Executive shall be entitled only to the Accrued Obligations, payable as and when those amounts would have been payable had the Term of Employment not ended. Nothing in this paragraph shall be construed as a release of any claims against Insmed and the Board&#8217;s determination of Cause shall not be considered a waiver of any claims the Executive may have.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9.68pt">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Insmed shall have the option, in accordance with applicable law, to terminate the Term of Employment upon written notice to the Executive, at any time during which the Executive is suffering from a Disability.  In the event that the Term of Employment is terminated due to the Executive&#8217;s Disability, the Executive shall be entitled to (i) the Accrued Obligations, payable as and when those amounts would have been paid had the Term of Employment not ended, (ii) any earned but unpaid Bonus in respect to any completed fiscal year that has ended on or prior to the Termination Date, payable within 2 &#189; months following the last day of the month in which the Termination Date occurs, (iii) the Pro-Rata Bonus, payable within 2 &#189; months following the end of the fiscal year in which the Termination Date occurs, and (iv) any insurance benefits to which he and his beneficiaries are entitled as a result of his Disability.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event that the Term of Employment is terminated due to the Executive&#8217;s death, the Executive&#8217;s estate shall be entitled to (i) the Accrued Obligations, payable as and when those amounts would have been paid had the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Term of Employment not ended, (ii) any earned but unpaid Bonus in respect to any completed fiscal year that has ended on or prior to the Termination Date, payable within 2 &#189; months following the last day of the month in which the Termination Date occurs, (iii) the Pro-Rata Bonus, payable within 2 &#189; months following the end of the fiscal year in which the Termination Date occurs, and (iv) any insurance benefits to which he and his beneficiaries are entitled as a result of his death.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9.68pt">Termination Without Cause or Resignation with Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Insmed may terminate the Term of Employment without Cause, and the Executive may terminate the Term of Employment for Good Reason, at any time upon written notice.  If the Term of Employment is terminated by Insmed without Cause (other than due to the Executive&#8217;s death or Disability) or by the Executive for Good Reason, in either case prior to the date of a Change in Control or more than two years after a Change in Control, the Executive shall be entitled to the following&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-24.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">The Accrued Obligations, payable as and when those amounts would have been paid had the Term of Employment not ended&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27.66pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">Any earned but unpaid Bonus in respect to any completed fiscal year that has ended on or prior to the Termination Date, payable within 2 &#189; months following the last day of the month in which the Termination Date occurs&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-30.99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">The Pro-Rata Bonus, payable within 2 &#189; months following the end of the fiscal year in which the Termination Date occurs&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-30.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">The Severance Amount, payable in equal installments consistent with Insmed&#8217;s normal payroll schedule over the 12 month period beginning with the first regularly scheduled payroll date that occurs after the later of (a) 30 days following the Termination Date or (b) the effective date of the Release&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">Provided that the Executive timely elects continued coverage under COBRA, Insmed will reimburse the Executive for the monthly COBRA cost of continued health and dental coverage of the Executive and his qualified beneficiaries paid by the Executive under the health and dental plans of Insmed, less the amount that the Executive would be required to contribute for health and dental coverage if the Executive were an active employee of Insmed, for 12 months (or, if less, for the duration that such COBRA coverage is available to Executive)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-30.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">vi.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">Accelerated vesting of any time-based Equity Awards that would have otherwise vested within 12 months following the Termination Date. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:11.01pt">Termination by Executive Without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Executive may terminate his employment without Good Reason by providing Insmed 30 days&#8217; written notice of such termination.  In the event of a termination of employment by the Executive under this Section 6(f), the Executive shall be entitled only to the Accrued Obligations payable as and when those amounts would have been </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">payable had the Term of Employment not ended.  In the event of termination of the Executive&#8217;s employment under this Section 6(f), Insmed may, in its sole and absolute discretion, by written notice, accelerate such date of termination and still have it treated as a termination without Good Reason.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Change in Control of Insmed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If the Executive&#8217;s employment is terminated by Insmed (or any entity to which the obligations and benefits under this Agreement have been assigned, pursuant to Section 11) without Cause or by the Executive for Good Reason during the 24 month period immediately following a Change in Control, then the Executive shall be entitled to the same payments, rights and benefits described in Section 6(e), subject to the following enhancements&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-24.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">One and a half times the Target Bonus paid in a lump-sum on the first regularly scheduled payroll date that occurs after the later of (a) 30 days following the Termination Date or (b) the effective date of the Release&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27.66pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">the Pro-Rata Bonus, as defined in this Section 6(g), paid in a lump-sum on the first regularly scheduled payroll date that occurs after the later of (a) 30 days following the Termination Date or (b) the effective date of the Release. For the purposes of this Section 6(g), and only this Section 6(g), &#8220;Pro-Rata Bonus&#8221; means the Target Bonus, as defined in Section 4(b), for the fiscal year in which the Termination Date occurs, multiplied by the following fraction&#58; (x) the number of days that the Executive was employed by Insmed during the fiscal year, divided by (y) 365</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-30.99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">One and a half times the Severance Amount paid in a lump-sum on the first regularly scheduled payroll date that occurs after the later of (a) 30 days following the Termination Date or (b) the effective date of the Release</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-30.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">Provided that the Executive timely elects continued coverage under COBRA, Insmed will reimburse the Executive for the monthly COBRA cost of continued health and dental coverage of the Executive and his qualified beneficiaries paid by the Executive under the health and dental plans of Insmed, less the amount that the Executive would be required to contribute for health and dental coverage if the Executive were an active employee of Insmed, for 18 months, rather than 12 months (or, if less, for the duration that such COBRA coverage is available to Executive)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">All Equity Awards will vest in full (other than any performance-vesting restricted stock units, which shall vest in accordance with the applicable award agreement).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All rights, payments and benefits due to the Executive under this Article 6 (other than the Accrued Obligations or any insurance benefits to which the Executive or his beneficiaries are entitled as a result of the Executive&#8217;s death or Disability) shall be conditioned on the Executive&#8217;s execution of a separate separation agreement to be provided by Insmed at that time that includes a general release of claims against Insmed and its Affiliates substantially in the form </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">attached hereto as Exhibit A (the &#8220;Release&#8221;) and on that Release becoming effective and irrevocable within 30 days following the Termination Date, or within 45 days if required by law.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:11.67pt">Section 280G Certain Reductions of Payments by Insmed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-24.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">Anything in this Agreement to the contrary notwithstanding, in the event it shall be determined that any payment or distribution by Insmed to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (a &#8220;Payment&#8221;), would be nondeductible by Insmed for Federal income tax purposes because of Section 280G of the Code, then the aggregate present value of amounts payable or distributable to or for the benefit of the Executive pursuant to this Agreement (such payments or distributions pursuant to this Agreement are hereinafter referred to as &#8220;Agreement Payments&#8221;) shall be reduced to the Reduced Amount.  The &#8220;Reduced Amount&#8221; shall be an amount expressed in present value that avoids any Payment being nondeductible by Insmed because of Section 280G of the Code.  To the extent necessary to avoid imposition of the Excise Tax, the amounts payable or benefits to be provided to the Executive shall be reduced such that the reduction of compensation to be provided to the Executive is minimized.  In applying this principle, the reduction shall be made in a manner consistent with the requirements of Section 409A of the Code, and where two economically equivalent amounts are subject to reduction but payable at different times, such amounts shall be reduced on a pro rata basis (but not below zero).  Anything to the contrary notwithstanding, if the Reduced Amount is zero and it is determined further that any Payment which is not an Agreement Payment would nevertheless be nondeductible by Insmed for Federal income tax purposes because of Section 280G of the Code, then the aggregate present value of Payments which are not Agreement Payments shall also be reduced (but not below zero) to an amount expressed in present value which maximizes the aggregate present value of Payments without causing any Payment to be nondeductible by Insmed because of Section 280G of the Code.  If a reduction of any Payment is required pursuant to this Section 6(i), such reduction shall occur to the amounts in the order that results in the greatest economic present value of all payments and benefits actually made or provided to the Executive.  For purposes of this Section 6(i), present value shall be determined in accordance with Section 280G(d)(4) of the Code.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27.66pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">All determinations required to be made under this Section 6(i) shall be made by a tax or compensation consulting firm of national reputation selected by Insmed (the &#8220;Consulting Firm&#8221;), which shall provide detailed supporting calculations both to Insmed and the Executive within 20 business days of the date of termination or such earlier time as is requested by Insmed and an opinion to the Executive that he has substantial </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">authority not to report any excise tax on his Federal income tax return with respect to any Payments.  Any such determination by the Consulting Firm shall be binding upon Insmed and the Executive.  Within five business days thereafter, Insmed shall pay to or distribute to or for the benefit of the Executive such amounts as are then due to the Executive under this Agreement.  All fees and expenses of the Consulting Firm incurred in connection with the determinations contemplated by this Section 6(i) shall be borne by Insmed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-30.99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">As a result of the uncertainty in the application of Section 280G of the Code at the time of the initial determination by the Consulting Firm hereunder, it is possible that Payments will have been made by Insmed which should not have been made (&#8220;Overpayment&#8221;) or that additional Payments which will not have been made by Insmed could have been made (&#8220;Underpayment&#8221;), in each case, consistent with the calculations required to be made hereunder. In the event that the Consulting Firm, based upon the assertion of a deficiency by the Internal Revenue Service against the Executive which the Consulting Firm believes has a high probability of success, determines that an Overpayment has been made, any such Overpayment paid or distributed by Insmed to or for the benefit of the Executive shall be promptly repaid to Insmed by the Executive.  In the event that the Consulting Firm, based upon controlling precedent or other substantial authority, determines that an Underpayment has occurred, any such Underpayment shall be promptly paid by Insmed to or for the benefit of the Executive together with interest at the applicable federal rate provided for in Section 7872(f)(2) of the Code.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:11.67pt">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Following the Term of Employment, the Executive shall give his assistance and cooperation willingly, upon reasonable advance notice with due consideration for his other business or personal commitments, in any matter relating to his position with Insmed, or his expertise or experience as Insmed may reasonably request, including his attendance and truthful testimony where deemed appropriate by Insmed, with respect to any investigation or Insmed&#8217;s defense or prosecution of any existing or future claims or litigations or other proceedings relating to matters in which he was involved or potentially had knowledge by virtue of his employment with Insmed. In no event shall his cooperation materially interfere with his services for a subsequent employer or other similar service recipient. To the extent permitted by law, Insmed agrees that (i) it shall promptly reimburse the Executive for his reasonable and documented expenses in connection with his rendering assistance and&#47;or cooperation under this Section 6(j) upon his presentation of documentation for such expenses and (ii) the Executive shall be reasonably compensated for any continued material services as required under this Section 6(j).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Return of Insmed Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Following the Termination Date, the Executive or his personal representative shall return all Insmed property in his possession, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">including but not limited to all computer equipment (hardware and software), telephones, facsimile machines, and other communication devices, credit cards, office keys, security access cards, badges, identification cards and all copies (including drafts) of any documentation or information (however stored) relating to the business of Insmed, its customers and clients or its prospective customers and clients (provided that the Executive may retain a copy of the addresses contained in his rolodex, smart phone or similar device).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:11.67pt">Compliance with Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-24.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:18pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  It is the intention of both Insmed and the Executive that the benefits and rights to which the Executive could be entitled pursuant to this Agreement comply with Section 409A of the Code and the Treasury Regulations and other guidance promulgated or issued thereunder (&#8220;Section 409A&#8221;), to the extent that the requirements of Section 409A are applicable thereto, and the provisions of this Agreement shall be construed in a manner consistent with that intention. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27.66pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:18pt">Distributions on Account of Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If and to the extent required to comply with Section 409A, no payment or benefit required to be paid under this Agreement on account of termination of the Executive&#8217;s employment shall be made unless and until the Executive incurs a &#8220;separation from service&#8221; within the meaning of Section 409A. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-30.99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:18pt">Six Month Delay for Specified Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If the Executive is a &#8220;specified employee&#8221; (within the meaning of Section 409A(a)(2)(B)(i) of the Code), then no payment or benefit that is considered deferred compensation subject to Section 409A of the Code (and not exempt from Section 409A of the Code as a short term deferral or otherwise) that is payable on account of the Executive&#8217;s &#8220;separation from service&#8221;, as that term is defined for purposes of Section 409A, shall be made before the date that is six months after the Executive&#8217;s &#8220;separation from service&#8221; (or, if earlier, the date of the Executive&#8217;s death) if and to the extent that such payment or benefit constitutes deferred compensation (or may be nonqualified deferred compensation) under Section 409A and such deferral is required to comply with the requirements of Section 409A.  Any payment or benefit delayed by reason of the prior sentence shall be paid out or provided in a single lump sum at the end of such required delay period in order to catch up to the original payment schedule.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-30.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:18pt">Treatment of Each Installment as a Separate Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of applying the provisions of Section 409A to this Agreement, each separately identified amount to which the Executive is entitled under this Agreement shall be treated as a separate payment.  In addition, any series of installment payments under this Agreement shall be treated as a right to a series of separate payments.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:18pt">Taxable Reimbursements and In-Kind Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:180pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Any reimbursements by Insmed to the Executive of any eligible expenses under this Agreement that are not excludable from the Executive&#8217;s income for Federal income tax purposes (the &#8220;Taxable Reimbursements&#8221;) shall be made by no later than the last day of the taxable year of the Executive following the year in which the expense was incurred.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:180pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The amount of any Taxable Reimbursements, and the value of any in-kind benefits to be provided to the Executive, during any taxable year of the Executive shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year of the Executive.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:180pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">The right to Taxable Reimbursement, or in-kind benefits, shall not be subject to liquidation or exchange for another benefit.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-30.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">vi.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:18pt">No Guaranty of 409A Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding the foregoing, Insmed does not make any representation to the Executive that the payments or benefits provided under this Agreement are exempt from, or satisfy, the requirements of Section 409A, and Insmed shall have no liability or other obligation to indemnify or hold harmless the Executive or any beneficiary of the Executive for any tax, additional tax, interest or penalties that the Executive or any beneficiary of the Executive may incur in the event that any provision of this Agreement, or any amendment or modification thereof, or any other action taken with respect thereto, is deemed to violate any of the requirements of Section 409A.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9.68pt">Non-competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. At all times during the Restricted Period, the Executive shall not, directly or indirectly (whether as a principal, agent, partner, employee, officer, investor, owner, consultant, board member, security holder, creditor or otherwise), engage in any Competitive Activity, or have any direct or indirect interest in any sole proprietorship, corporation, company, partnership, association, venture or business or any other person or entity that directly or indirectly (whether as a principal, agent, partner, employee, officer, investor, owner, consultant, board member, security holder, creditor, or otherwise) engages in a Competitive Activity&#59; provided that the foregoing shall not apply to the Executive&#8217;s ownership of securities of Insmed or the acquisition by the Executive, solely as an investment, of securities of any issuer that is registered under Section 12(b) or 12(g) of the Securities Exchange Act of 1934, and that are listed or admitted for trading on any United States national securities exchange or that are quoted on the Nasdaq Stock Market, or any similar system or automated dissemination of quotations of securities prices in common use, so long as the Executive does not control, acquire a controlling interest in, or become a member </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of a group which exercises direct or indirect control of, more than five percent of any class of capital stock of such corporation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Non-solicitation of Employees and Certain Other Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. At all times during the Restricted Period, the Executive shall not, directly or indirectly, for himself or for any other person, firm, corporation, partnership, association or other entity (i) employ or attempt to employ or enter into any contractual arrangement with any employee, consultant or individual contractor performing services for Insmed, or any Affiliate, unless such employee, consultant or independent contractor has not been employed or engaged by Insmed for a period in excess of six months, and&#47;or (ii) call on, solicit, or engage in business with, any of the actual or targeted prospective customers or clients of Insmed or any Affiliate on behalf of any person or entity in connection with any Competitive Activity, nor shall the Executive make known the names and addresses of such actual or targeted prospective customers or clients, or any information relating in any manner to the trade or business relationships of Insmed or any Affiliates with such customers or clients, other than in connection with the performance of the Executive&#8217;s duties under this Agreement, and&#47;or (iii) persuade or encourage or attempt to persuade or encourage any persons or entities with whom Insmed or any Affiliate does business or has some business relationship to cease doing business or to terminate its business relationship with Insmed or any Affiliate or to engage in any Competitive Activity on its own or with any competitor of Insmed or any Affiliate.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9.68pt">Confidential Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The Executive shall not at any time divulge, communicate, use to the detriment of Insmed or any Affiliate or for the benefit of any other person or persons, or misuse in any way, any Confidential Information pertaining to the business of Insmed. Any Confidential Information or data now or hereafter acquired by the Executive with respect to the business of Insmed or any Affiliate (which shall include, but not be limited to, information concerning Insmed&#8217;s or any Affiliate&#8217;s financial condition, prospects, technology, customers, suppliers, sources of leads and methods of doing business) shall be deemed a valuable, special and unique asset of Insmed and its Affiliates that is received by the Executive in confidence and as a fiduciary, and the Executive shall remain a fiduciary to Insmed and its Affiliates with respect to all of such information. Upon request by Insmed, the Executive shall deliver promptly to Insmed upon termination of his services for Insmed, or at any time thereafter as Insmed may request, all memoranda, notes, records, reports, manuals, drawings, designs, computer files in any media and other documents (and all copies thereof) containing such Confidential Information. Notwithstanding the foregoing, nothing in this Agreement shall be deemed to restrict or prohibit Executive from initiating communications directly with, responding to any inquiries from, providing testimony before, providing confidential information to, reporting possible violations of law or regulation to, or from filing a claim or assisting with an investigation directly with a self-regulatory authority or a government agency or entity, including the U.S. Equal Employment Opportunity Commission </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;EEOC&#8221;), the Department of Labor (&#8220;DOL&#8221;), the National Labor Relations Board (&#8220;NLRB&#8221;), the Department of Justice (&#8220;DOJ&#8221;), the Securities and Exchange Commission (&#8220;SEC&#8221;), the Congress, and any agency Inspector General (collectively, the &#8220;Regulators&#8221;), or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation. Federal law provides criminal and civil immunity to federal and state claims for trade secret misappropriation to individuals who disclose a trade secret to their attorney, a court, or a government official in certain, confidential circumstances that are set forth at 18 U.S.C. &#167;&#167; 1833(b)(1) and 1833(b)(2), related to the reporting or investigation of a suspected violation of the law, or in connection with a lawsuit for retaliation for reporting a suspected violation of the law.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Ownership of Developments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All processes, concepts, techniques, inventions and works of authorship, including new contributions, improvements, formats, packages, programs, systems, machines, compositions of matter manufactured, developments, applications and discoveries, and all copyrights, patents, trade secrets, or other intellectual property rights associated therewith conceived, invented, made, developed or created by the Executive during the Executive&#8217;s period of employment with Insmed either during the course of performing work for Insmed or its Affiliates, or their clients, or which are related in any manner to the business (commercial or experimental) of Insmed or its Affiliates or their clients (collectively, the &#8220;Work Product&#8221;) shall belong exclusively to Insmed and its Affiliates and shall, to the extent possible, be considered a work made by the Executive for hire for Insmed and its Affiliates within the meaning of Title 17 of the United States Code. To the extent the Work Product may not be considered work made by the Executive for hire for Insmed and its Affiliates, the Executive agrees to assign, and automatically assign at the time of creation of the Work Product, without any requirement of further consideration, any right, title, or interest the Executive may have in such Work Product. Upon the request of Insmed, the Executive shall take such further actions, including execution and delivery of instruments of conveyance, as may be appropriate to give full and proper effect to such assignment. The Executive shall further&#58; (i) promptly disclose the Work Product to Insmed&#59; (ii) assign to Insmed or its assignee, without additional compensation, all patent or other rights to such Work Product for the United States and foreign countries&#59; (iii) sign all papers necessary to carry out the foregoing&#59; and (iv) give testimony in support of his inventions, all at the sole cost and expense of Insmed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9.68pt">Books and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All books, records, and accounts relating in any manner to the customers or clients of Insmed or its Affiliates, whether prepared by the Executive or otherwise coming into the Executive&#8217;s possession, shall be the exclusive property of Insmed and its Affiliates and shall be returned immediately to Insmed on termination of the Executive&#8217;s employment hereunder or on Insmed&#8217;s request at any time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:11.01pt">Acknowledgment by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Executive acknowledges and confirms that the restrictive covenants contained in this Section 7 (including without limitation the length of the term of the provisions of this Section 7) are reasonably necessary to protect the legitimate business interests of Insmed and its Affiliates, and are not overbroad, overlong, or unfair and are not the result of overreaching, duress or coercion of any kind. The Executive further acknowledges and confirms that the compensation payable to the Executive under this Agreement is in consideration for the duties and obligations of the Executive hereunder, including the restrictive covenants contained in this Section 7, and that such compensation is sufficient, fair and reasonable. The Executive further acknowledges and confirms that his full, uninhibited and faithful observance of each of the covenants contained in this Section 7 will not cause him any undue hardship, financial or otherwise, and that enforcement of each of the covenants contained herein will not impair his ability to obtain employment commensurate with his abilities and on terms fully acceptable to him or otherwise to obtain income required for the comfortable support of him and his family and the satisfaction of the needs of his creditors. The Executive acknowledges and confirms that his special knowledge of the business of Insmed and its Affiliates is such as would cause Insmed and its Affiliates serious injury or loss if he were to use such ability and knowledge to the benefit of a competitor or were to compete with Insmed or its Affiliates in violation of the terms of this Section 7. The Executive further acknowledges that the restrictions contained in this Section 7 are intended to be, and shall be, for the benefit of and shall be enforceable by, Insmed&#8217;s successors and assigns. The Executive expressly agrees that upon any breach or violation of the provisions of this Section 7, Insmed shall be entitled to seek in addition to any other rights or remedies it may have, to (i) temporary and&#47;or permanent injunctive relief in any court of competent jurisdiction as described in Section 7(i) hereof, and (ii) such damages as are provided at law or in equity. The existence of any claim or cause of action against Insmed or its Affiliates, whether predicated upon this Agreement or otherwise, shall not constitute a defense to the enforcement of the restrictions contained in this Section 7.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Reformation by Court</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event that a court of competent jurisdiction shall determine that any provision of this Section 7 is invalid or more restrictive than permitted under the governing law of such jurisdiction, then only as to enforcement of this Section 7 within the jurisdiction of such court, such provision shall be interpreted or reformed and enforced as if it provided for the maximum restriction permitted under such governing law.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Extension of Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If the Executive shall be in violation of any provision of this Section 7, then each time limitation set forth in this Section 7 shall be extended for a period of time equal to the period of time during which such violation or violations occur.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:11.67pt">Injunction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. It is recognized and hereby acknowledged by the parties hereto that a breach by the Executive of any of the covenants contained in Section 7 of this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agreement may cause irreparable harm and damage to Insmed, and its Affiliates, the monetary amount of which may be virtually impossible to ascertain.  As a result, the Executive recognizes and hereby acknowledges that Insmed and its Affiliates shall be entitled to seek an injunction from any court of competent jurisdiction enjoining and restraining any violation of any or all of the covenants contained in Section 7 of this Agreement by the Executive or any of his affiliates, associates, partners or agents, either directly or indirectly, and that such right to injunction shall be cumulative and in addition to whatever other remedies Insmed may possess.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Representations and Warranties of Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Executive represents and warrants to Insmed that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">The Executive&#8217;s employment will not conflict with or result in his breach of any agreement to which he is a party or otherwise may be bound&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The Executive has not violated, and in connection with his employment with Insmed will not violate, any non-solicitation, non-competition or other similar covenant or agreement of a prior employer or service recipient by which he is or may be bound&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">In connection with Executive&#8217;s employment with Insmed, he will not use any confidential or proprietary information that he may have obtained in connection with employment with any prior employer or service provided to any prior service recipient&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The Executive has not (i) been convicted of any felony&#59; or (ii) committed any criminal act with respect to Executive&#8217;s current or any prior employment or services&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">The Executive is not debarred under the provisions of the U.S. Generic Drug Enforcement Act of 1992, including without limitation, 21 U.S.C. 335a or under the provisions of any equivalent legislation or regulation, and to the Executive&#8217;s knowledge he is not under investigation or otherwise aware of any circumstances which may result in being debarred or excluded from participation in any federal or state healthcare program&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.01pt">The Executive is not dependent on alcohol or the illegal use of drugs. The Executive recognizes that Insmed shall have the right to conduct random drug testing of its employees and that Executive may be called upon in such a manner.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:9pt">Agreement to Abide by Insmed Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; By executing this Agreement, the Executive acknowledges and agrees to comply with any Insmed policies, standard operating procedures (&#8220;SOPs&#8221;), and additional agreements between the Executive and Insmed which may be in effect from time to time, including, but not limited to (i) Insmed&#8217;s Code of Conduct&#59; (ii) Insmed policies against harassment and discrimination&#59; and (iii) Insmed&#8217;s Code of Ethics.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All payments or transfers of property made by Insmed to the Executive or his estate or beneficiaries shall be subject to the withholding of such amounts relating to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">taxes as Insmed may reasonably determine it should withhold pursuant to any applicable law or regulation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Insmed shall have the right to assign this Agreement and its rights and obligations hereunder in whole, but not in part, to any corporation or other entity with or into which Insmed may hereafter merge or consolidate or to which Insmed may transfer all or substantially all of its assets, if in any such case said corporation or other entity shall by operation of law or expressly in writing assume all obligations of Insmed hereunder as fully as if it had been originally made a party hereto, but may not otherwise assign this Agreement or its rights and obligations hereunder.  The Executive may not assign or transfer this Agreement or any rights or obligations hereunder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New Jersey, without regard to principles of conflict of laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">Jurisdiction and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The parties acknowledge that a substantial portion of the negotiations, anticipated performance and execution of this Agreement occurred or shall occur in Somerset, New Jersey, and that, therefore, without limiting the jurisdiction or venue of any other federal or state courts, each of the parties irrevocably and unconditionally (i) agrees that any suit, action or legal proceeding arising out of or relating to this Agreement which is expressly permitted by the terms of this Agreement to be brought in a court of law, may be brought in the courts of record of the Superior Court of the State of New Jersey, Somerset County, or the court of the United States, District of New Jersey&#59; (ii) consents to the jurisdiction of each such court in any such suit, action or proceeding&#59; (iii) waives any objection which it or he may have to the laying of venue of any such suit, action or proceeding in any of such courts&#59; and (iv) agrees that service of any court papers may be effected on such party by mail, as provided in this Agreement and as permitted by New Jersey or Federal law, or in such other manner as may be provided under applicable laws or court rules in such courts.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement, together with the exhibit attached hereto, constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and, upon its effectiveness, shall supersede all prior agreements, understandings and arrangements, both oral and written, between the Executive and Insmed (or any of its Affiliates) with respect to such subject matter including any prior employment agreements or amendments thereto entered into between the Parties.  This Agreement may not be modified in any way unless by a written instrument signed by both Insmed and the Executive.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All notices required or permitted to be given hereunder shall be in writing and shall be personally delivered by courier, sent by registered or certified mail, return receipt requested or sent by confirmed facsimile transmission addressed as set forth herein. Notices personally delivered, sent by facsimile or sent by overnight courier shall be deemed given on the date of delivery and notices mailed in accordance with the foregoing shall be deemed given upon receipt by the addressee, as evidenced by the return receipt thereof.  Notice shall be sent (i) if to Insmed, addressed to, 700 US Highway 202&#47;206, Bridgewater, NJ 08807-1704, Attention&#58; General Counsel, and (ii) if to the Executive, to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">his address as reflected on the payroll records of Insmed, or to such other address as either party shall request by notice to the other in accordance with this provision.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">Benefits&#59; Binding Effect.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> This Agreement shall be for the benefit of and binding upon the parties hereto and their respective heirs, personal representatives, legal representatives, successors and, where permitted and applicable, assigns, including, without limitation, any successor to Insmed, whether by merger, consolidation, sale of stock, sale of assets or otherwise.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">Right to Consult with Counsel&#59; No Drafting Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Executive acknowledges having read and considered all of the provisions of this Agreement carefully, and having had the opportunity to consult with counsel of his own choosing, and, given this, the Executive agrees that the obligations created hereby are not unreasonable.  The Executive acknowledges that he has had an opportunity to negotiate any and all of these provisions and no rule of construction shall be used that would interpret any provision in favor of or against a party on the basis of who drafted the Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The invalidity of any one or more of the words, phrases, sentences, clauses, provisions, sections or articles contained in this Agreement shall not affect the enforceability of the remaining portions of this Agreement or any part thereof, all of which are inserted conditionally on their being valid in law, and, in the event that any one or more of the words, phrases, sentences, clauses, provisions, sections or articles contained in this Agreement shall be declared invalid, this Agreement shall be construed as if such invalid word or words, phrase or phrases, sentence or sentences, clause or clauses, provisions or provisions, section or sections or article or articles had not been inserted.  If such invalidity is caused by length of time or size of area, or both, the otherwise invalid provision will be considered to be reduced to a period or area which would cure such invalidity.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">Waivers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The waiver by either party hereto of a breach or violation of any term or provision of this Agreement shall not operate nor be construed as a waiver of any subsequent breach or violation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">Damages&#59; Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing contained herein shall be construed to prevent Insmed or the Executive from seeking and recovering from the other damages sustained by either or both of them as a result of its or his breach of any term or provision of this Agreement.  Each party shall bear its own costs and attorneys&#8217; fees.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Executive hereby knowingly, voluntarily and intentionally waives any right that the Executive may have to a trial by jury in respect of any litigation arising out of, under or in connection with the express terms of this Agreement and any agreement, document or instrument contemplated to be executed in connection herewith. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">No Set-off or Mitigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Insmed&#8217;s obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any setoff, counterclaim, recoupment, defense or other claim, right or action which Insmed may have against the Executive or others.  In the event of any termination of the Executive&#8217;s employment under this Agreement, he shall be under no obligation to seek </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">other employment or otherwise in any way to mitigate the amount of any payment provided for hereunder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">Section Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The article, section and paragraph headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">No Third Party Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Affiliates are intended third party beneficiaries of this Agreement.  Otherwise, nothing expressed or implied in this Agreement is intended, or shall be construed, to confer upon or give any person other than Insmed, the Executive and their respective heirs, personal representatives, legal representatives, successors and permitted assigns, any rights or remedies under or by reason of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument and agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:3pt">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Subject to limitations imposed by law, Insmed shall indemnify and hold harmless the Executive to the fullest extent permitted by law from and against any and all claims, damages, expenses (including attorneys&#8217; fees), judgments, penalties, fines, settlements, and all other liabilities incurred or paid by him in connection with the investigation, defense, prosecution, settlement or appeal of any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative and to which the Executive was or is a party or is threatened to be made a party by reason of the fact that the Executive is or was an officer, employee or agent of Insmed, or by reason of anything done or not done by the Executive in any such capacity or capacities, provided that the Executive acted in good faith, in a manner that was not grossly negligent or constituted willful misconduct and in a manner he reasonably believed to be in or not opposed to the best interests of Insmed, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. Insmed also shall pay any and all expenses (including attorney&#8217;s fees) incurred by the Executive as a result of the Executive being called as a witness in his capacity as a current or former officer or director of Insmed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Insmed shall pay any expenses (including attorneys&#8217; fees, judgments, penalties, fines, settlements, and other liabilities) incurred by the Executive in investigating, defending, settling or appealing any action, suit or proceeding described in this Section 26 in advance of the final disposition of such action, suit or proceeding.  Insmed shall promptly pay the amount of such expenses to the Executive, but in no event later than ten days following the Executive&#8217;s delivery to Insmed of a written request for an advance pursuant to this Section 26, together with a reasonable accounting of such expenses.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">The Executive hereby undertakes and agrees to repay to Insmed any advances made pursuant to this Section 26 if and to the extent that it shall ultimately be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">found that the Executive is not entitled to be indemnified by Insmed for such amounts.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Insmed shall make the advances contemplated by this Section 26 regardless of the Executive&#8217;s financial ability to make repayment, and regardless whether indemnification of the Executive by Insmed will ultimately be required.  Any advances and undertakings to repay pursuant to this Section 26 shall be unsecured and interest-free.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">The provisions of this Section 26 shall survive the Term of Employment.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#91;Signatures on Following Page&#93;</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the Effective Date.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INSMED&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insmed Incorporated, a Virginia corporation</font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; William H. Lewis                     </font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;  William H. Lewis </font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;    Chair and CEO</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXECUTIVE&#58; </font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:216pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; J. Drayton Wise       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">______________</font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58; J. Drayton Wise</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">23</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                           Exhibit A</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">General Release of Claims</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">J. Drayton Wise (&#34;Executive&#34;), for himself and his family, heirs, executors, administrators, legal representatives and their respective successors and assigns (collectively, the &#8220;Releasors&#8221;), in exchange for the consideration received pursuant to Sections &#91;6(c)&#93;&#91;6(d)&#93;&#91;6(e) &#91;and 6(g)&#93;&#93; of the Employment Agreement (the &#8220;Severance Benefits&#8221;) to which this release is attached as Exhibit A (the &#34;Employment Agreement&#34;), does hereby release and forever discharge Insmed Incorporated (&#8220;Insmed&#34;), its subsidiaries, and affiliated companies, and each of their respective predecessors, successors and assigns, and each of their respective current or former directors, officers, employees, shareholders or agents, both individually and in such official capacities (collectively with Insmed, the &#34;Released Parties&#34;) from any and all actions, causes of action, suits, controversies, claims and demands whatsoever, for or by reason of any matter, cause or thing whatsoever, whether known or unknown including, but not limited to, all claims under any applicable laws arising under or in connection with Executive's employment or termination thereof, whether for tort, breach of express or implied employment contract, wrongful discharge, intentional infliction of emotional distress, or defamation or injuries incurred on the job or incurred as a result of loss of employment.  Without limiting the generality of the release provided above, Executive and the Releasors expressly waive any and all claims under the Age Discrimination in Employment Act (as amended, &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ADEA'</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">'), that he may have as of the date hereof.  Executive further understands that, by signing this General Release of Claims, he is in fact waiving, releasing and forever giving up any claim under the ADEA, as well as all other laws within the scope of this paragraph 1 that may have existed on or prior to the date hereof.  Notwithstanding anything in this paragraph 1 to the contrary, this General Release of Claims shall not apply to (i) any rights to receive any payments or benefits to which the Executive is entitled under COBRA, (ii) any rights or claims that may arise as a result of events occurring after the date this General Release of Claims is executed, (iii) any indemnification and advancement rights Executive may have as a former employee, officer or director of Insmed or its subsidiaries or affiliated companies (including any rights under Section 26 of the Employment Agreement or under Insmed&#8217;s charter or bylaws), (iv) any claims for benefits under any directors' and officers' liability policy maintained by Insmed or its subsidiaries or affiliated companies in accordance with the terms of such policy, (v) rights to vested benefits under Insmed&#8217;s 401(k) plan, (vii) any rights as a holder of equity securities or debt securities&#47;notes of Insmed, and (viii) any rights that cannot be waived as a matter of law.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Nothing in this General Release of Claims restricts or prohibits Executive from initiating communications directly with, responding to any inquiries from, providing testimony before, providing confidential information to, reporting possible violations of law or regulation to, or from filing a claim or assisting with an investigation directly with a self-regulatory authority or a government agency or entity, including the U.S. Equal Employment Opportunity Commission (&#8220;EEOC&#8221;), the Department of Labor (&#8220;DOL&#8221;), the National Labor Relations Board (&#8220;NLRB&#8221;&#8220;), the Department of Justice (&#8220;DOJ&#8221;), the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">24</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Securities and Exchange Commission (&#8220;SEC&#8221;), the Congress, and any agency Inspector General (collectively, the &#8220;Regulators&#8221;), or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation.  However, to the maximum extent permitted by law, Executive is waiving his right to receive any individual monetary relief from Insmed or any others covered by this General Release of Claims resulting from such claims or conduct, regardless of whether Executive or another party has filed them, and in the event Executive obtains such monetary relief Insmed will be entitled to an offset for the payments made pursuant to the Employment Agreement.  This General Release of Claims does not limit Executive&#8217;s right to receive an award from any Regulator that provides awards for information relating to a potential violation of law.  Executive does not need the prior authorization of Insmed to engage in conduct protected by this paragraph, nor is Executive required to notify Insmed that he or she has engaged in such conduct.  Federal law provides criminal and civil immunity to federal and state claims for trade secret misappropriation to individuals who disclose a trade secret to their attorney, a court, or a government official in certain, confidential circumstances that are set forth at 18 U.S.C. &#167;&#167; 1833(b)(1) and 1833(b)(2), related to the reporting or investigation of a suspected violation of the law, or in connection with a lawsuit for retaliation for reporting a suspected violation of the law. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Executive acknowledges that, in the absence of his execution of this General Release of Claims, the Severance Benefits would not otherwise be due to him.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Executive acknowledges and agrees that he received adequate consideration in exchange for agreeing to the covenants contained in Section 7 of the Employment Agreement, that such covenants remain reasonable and necessary to protect the legitimate business interests of Insmed and its affiliates and that he will continue to comply with those covenants.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Executive hereby acknowledges that Insmed has informed him that he has up to 21 days to sign this General Release of Claims and he may knowingly and voluntarily waive that 21 day period by signing this General Release of Claims earlier.  Executive also understands that he shall have seven days following the date on which he signs this General Release of Claims within which to revoke it by providing a written notice of his revocation to Insmed in the manner described in Section 15 of the Employment Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Executive acknowledges and agrees that this General Release of Claims will be governed by and construed and enforced in accordance with the internal laws of the State of New Jersey applicable to contracts made and to be performed entirely within such State.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Executive acknowledges that he has read this General Release of Claims, that he has been advised that he should consult with an attorney before he executes this General Release of Claims, and that he understands all of its terms and executes it voluntarily and with full knowledge of its significance and the consequences thereof.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">This General Release of Claims shall become irrevocable on the eighth day following Executive's execution of this General Release of Claims, unless previously revoked in accordance with paragraph 5, above.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">25</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Intending to be legally bound hereby, Executive has executed this General Release of Claims on ___________, 20__.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">26</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>insm-20220630ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8a40844f3a034e2a8b1372c74e945fdb_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 Certification</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, William H. Lewis, Chief Executive Officer of Insmed Incorporated, certify that&#58;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) I have reviewed this quarterly report on Form 10-Q of Insmed Incorporated&#59;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Date&#58;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">August&#160;4, 2022</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                                                                                                            &#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; William H. Lewis</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William H. Lewis</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>insm-20220630ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i42fdd7b7b8634ca280ce3690e9c7321e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 Certification</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sara Bonstein, Chief Financial Officer of Insmed Incorporated, certify that&#58;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) I have reviewed this quarterly report on Form 10-Q of Insmed Incorporated&#59;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;August&#160;4, 2022</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                  </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sara Bonstein</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sara Bonstein</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>insm-20220630ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if8bb61ddde60495eb1b0c69fc84be564_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2003</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this Quarterly Report on Form 10-Q of Insmed Incorporated (the &#34;Company&#34;) for the period ended June&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), I, William H. Lewis, Chief Executive Officer of the Company, certify, pursuant to 18 USC. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2003, that&#58;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                                                                                                    </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                                                                                                      &#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; William H. Lewis</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William H. Lewis</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August&#160;4, 2022</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Insmed Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>insm-20220630ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5ad46543e84647898e953a7b1c9f5cc2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;32.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2003</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this Quarterly Report on Form 10-Q of Insmed Incorporated (the &#34;Company&#34;) for the period ended June&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), I, Sara Bonstein, Chief Financial Officer of the Company, certify, pursuant to 18 USC. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2003, that&#58;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)  the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)  the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                                                                                                      &#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sara Bonstein</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sara Bonstein</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August&#160;4, 2022</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Insmed Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>insm-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f29bbe7c-3fe7-4edc-bd43-5e98e923844d,g:47f91642-8422-4809-9855-6a3312b42bf8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:insm="http://www.insmed.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.insmed.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.insmed.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossunaudited" roleURI="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited">
        <link:definition>1003004 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquityunaudited" roleURI="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited">
        <link:definition>1004005 - Statement - Consolidated Statements of Shareholders' Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsunaudited" roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited">
        <link:definition>1005006 - Statement - Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsunauditedParenthetical" roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyandBasisofPresentation" roleURI="http://www.insmed.com/role/TheCompanyandBasisofPresentation">
        <link:definition>2101101 - Disclosure - The Company and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyandBasisofPresentationDetails" roleURI="http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - The Company and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Significant Observable Inputs of Deferred Business Acquisition Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Significant Unobservable Inputs Of Contingent Consideration Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Changes in the Fair Value of Deferred and Contingent Consideration Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails">
        <link:definition>2411407 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails">
        <link:definition>2412408 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails">
        <link:definition>2413409 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails">
        <link:definition>2414410 - Disclosure - Summary of Significant Accounting Policies - Summary of Revenues by Geographic Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.insmed.com/role/Inventory">
        <link:definition>2115103 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.insmed.com/role/InventoryTables">
        <link:definition>2316302 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleofInventoryCurrentDetails" roleURI="http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails">
        <link:definition>2417411 - Disclosure - Inventory - Schedule of Inventory, Current (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesNetandGoodwill" roleURI="http://www.insmed.com/role/IntangiblesNetandGoodwill">
        <link:definition>2118104 - Disclosure - Intangibles, Net and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesNetandGoodwillTables" roleURI="http://www.insmed.com/role/IntangiblesNetandGoodwillTables">
        <link:definition>2319303 - Disclosure - Intangibles, Net and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesNetandGoodwillDetails" roleURI="http://www.insmed.com/role/IntangiblesNetandGoodwillDetails">
        <link:definition>2420412 - Disclosure - Intangibles, Net and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsNet" roleURI="http://www.insmed.com/role/FixedAssetsNet">
        <link:definition>2121105 - Disclosure - Fixed Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsNetTables" roleURI="http://www.insmed.com/role/FixedAssetsNetTables">
        <link:definition>2322304 - Disclosure - Fixed Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsNetDetails" roleURI="http://www.insmed.com/role/FixedAssetsNetDetails">
        <link:definition>2423413 - Disclosure - Fixed Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.insmed.com/role/AccruedLiabilities">
        <link:definition>2124106 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.insmed.com/role/AccruedLiabilitiesTables">
        <link:definition>2325305 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.insmed.com/role/AccruedLiabilitiesDetails">
        <link:definition>2426414 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.insmed.com/role/Leases">
        <link:definition>2127107 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.insmed.com/role/LeasesTables">
        <link:definition>2328306 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.insmed.com/role/LeasesNarrativeDetails">
        <link:definition>2429415 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasecostsDetailsDetails" roleURI="http://www.insmed.com/role/LeasesLeasecostsDetailsDetails">
        <link:definition>2430416 - Disclosure - Leases - Lease, costs (Details) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.insmed.com/role/Debt">
        <link:definition>2131108 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.insmed.com/role/DebtTables">
        <link:definition>2332307 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.insmed.com/role/DebtNarrativeDetails">
        <link:definition>2433417 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtComponentsofDebtDetails" roleURI="http://www.insmed.com/role/DebtComponentsofDebtDetails">
        <link:definition>2434418 - Disclosure - Debt - Components of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtFuturePrincipalRepaymentsofDebtDetails" roleURI="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails">
        <link:definition>2435419 - Disclosure - Debt - Future Principal Repayments of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseDetails" roleURI="http://www.insmed.com/role/DebtInterestExpenseDetails">
        <link:definition>2436420 - Disclosure - Debt - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.insmed.com/role/ShareholdersEquity">
        <link:definition>2137109 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNarrativeDetails" roleURI="http://www.insmed.com/role/ShareholdersEquityNarrativeDetails">
        <link:definition>2438421 - Disclosure - Shareholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.insmed.com/role/StockBasedCompensation">
        <link:definition>2139110 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.insmed.com/role/StockBasedCompensationTables">
        <link:definition>2340308 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2441422 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" roleURI="http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails">
        <link:definition>2442423 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.insmed.com/role/IncomeTaxes">
        <link:definition>2143111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.insmed.com/role/IncomeTaxesDetails">
        <link:definition>2444424 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.insmed.com/role/CommitmentsandContingencies">
        <link:definition>2145112 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2446425 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisition" roleURI="http://www.insmed.com/role/BusinessAcquisition">
        <link:definition>2147113 - Disclosure - Business Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionNarrativeDetails" roleURI="http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails">
        <link:definition>2448426 - Disclosure - Business Acquisition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="insm_AlgaeneXIncMember" abstract="true" name="AlgaeneXIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" abstract="false" name="NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="insm_EuropeAndTheRestOfTheWorldMember" abstract="true" name="EuropeAndTheRestOfTheWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_A2019IncentivePlanSecondAmendmentMember" abstract="true" name="A2019IncentivePlanSecondAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" abstract="false" name="IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_DebtInstrumentConversionTermFourMember" abstract="true" name="DebtInstrumentConversionTermFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_ComputerHardwareAndSoftwareMember" abstract="true" name="ComputerHardwareAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_EmployeeStockPurchasePlan2018Member" abstract="true" name="EmployeeStockPurchasePlan2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_ConvertibleDebtInterestExpenseTotal" abstract="false" name="ConvertibleDebtInterestExpenseTotal" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_MeasurementInputProbabilityOfSuccessMember" abstract="true" name="MeasurementInputProbabilityOfSuccessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_LeaseRemainingLeaseTerm" abstract="false" name="LeaseRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="insm_AccruedLiabilitiesCurrentMember" abstract="true" name="AccruedLiabilitiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" abstract="true" name="ScheduleofEarningsPerShareBasicandDilutedLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="insm_FairValueLevel1Level2Level3TransfersAmount" abstract="false" name="FairValueLevel1Level2Level3TransfersAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_MotusBiosciencesIncAndAlgaeneXIncMember" abstract="true" name="MotusBiosciencesIncAndAlgaeneXIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_DebtInstrumentConversionTermOneMember" abstract="true" name="DebtInstrumentConversionTermOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" abstract="false" name="AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="insm_BusinessAcquisitionConsecutiveTradingDayPeriod" abstract="false" name="BusinessAcquisitionConsecutiveTradingDayPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" abstract="false" name="DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="insm_DebtInstrumentConversionTermAxis" abstract="true" name="DebtInstrumentConversionTermAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="insm_BusinessCombinationDeferredLiability" abstract="false" name="BusinessCombinationDeferredLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_WeightedAverageProbabilityOfReachingMilestone" abstract="false" name="WeightedAverageProbabilityOfReachingMilestone" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="insm_AccruedTechnicalOperationExpenses" abstract="false" name="AccruedTechnicalOperationExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" abstract="false" name="BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_AccruedRoyaltiesAndMilestonePaymentsCurrent" abstract="false" name="AccruedRoyaltiesAndMilestonePaymentsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_DeferredConsiderationMember" abstract="true" name="DeferredConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_ManufacturingEquipmentMember" abstract="true" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_DebtInstrumentConversionTermThreeMember" abstract="true" name="DebtInstrumentConversionTermThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" abstract="false" name="InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="insm_LongTermDebtMaturityAfterYearFour" abstract="false" name="LongTermDebtMaturityAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_MarketableSecuritiesAdditional" abstract="false" name="MarketableSecuritiesAdditional" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_CustomerAMember" abstract="true" name="CustomerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_NoncashOperatingLeaseExpense" abstract="false" name="NoncashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" abstract="false" name="ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" abstract="false" name="ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="insm_AccruedClinicalTrialExpenses" abstract="false" name="AccruedClinicalTrialExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_AtTheMarketAgreementMember" abstract="true" name="AtTheMarketAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_DevelopmentAndRegulatoryMilestonesMember" abstract="true" name="DevelopmentAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities" abstract="false" name="AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_MotusBiosciencesIncMember" abstract="true" name="MotusBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_AccruedConstructionLiabilitiesCurrent" abstract="false" name="AccruedConstructionLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_PriorityReviewVoucherMilestoneMember" abstract="true" name="PriorityReviewVoucherMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_A2019IncentivePlanThirdAmendmentMember" abstract="true" name="A2019IncentivePlanThirdAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_DebtInstrumentOptionToPurchaseAdditionalDebt" abstract="false" name="DebtInstrumentOptionToPurchaseAdditionalDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_AcquiredResearchAndDevelopmentMember" abstract="true" name="AcquiredResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_DebtInstrumentConversionTermDomain" abstract="true" name="DebtInstrumentConversionTermDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" abstract="true" name="OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member" abstract="true" name="ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_DebtInstrumentConversionTermTwoMember" abstract="true" name="DebtInstrumentConversionTermTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_ScheduleofEarningsPerShareBasicandDilutedTable" abstract="true" name="ScheduleofEarningsPerShareBasicandDilutedTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="insm_CommonStockAuthorizedAggregateGrossSalesProceeds" abstract="false" name="CommonStockAuthorizedAggregateGrossSalesProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_BusinessCombinationDeferredPaymentsCurrent" abstract="false" name="BusinessCombinationDeferredPaymentsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_CustomerCMember" abstract="true" name="CustomerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_AccruedSalesAllowancesAndRelatedCosts" abstract="false" name="AccruedSalesAllowancesAndRelatedCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_CustomerBMember" abstract="true" name="CustomerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>insm-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f29bbe7c-3fe7-4edc-bd43-5e98e923844d,g:47f91642-8422-4809-9855-6a3312b42bf8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="insm-20220630.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_513c72ae-acc7-4dcd-b675-b1f9411cc7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_10c3ee81-007b-435d-8f0a-3fedc9643759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_513c72ae-acc7-4dcd-b675-b1f9411cc7fc" xlink:to="loc_us-gaap_Liabilities_10c3ee81-007b-435d-8f0a-3fedc9643759" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6bfd973d-d4f0-44e9-8839-624fba605394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_513c72ae-acc7-4dcd-b675-b1f9411cc7fc" xlink:to="loc_us-gaap_StockholdersEquity_6bfd973d-d4f0-44e9-8839-624fba605394" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cac1b749-8f4b-458e-a41f-806893a2c413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4fdac02d-f43b-4a1d-a9f7-5e23587dd346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cac1b749-8f4b-458e-a41f-806893a2c413" xlink:to="loc_us-gaap_CommonStockValue_4fdac02d-f43b-4a1d-a9f7-5e23587dd346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4cf31b01-dcba-4bf8-b0d3-cff1a45fcfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cac1b749-8f4b-458e-a41f-806893a2c413" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4cf31b01-dcba-4bf8-b0d3-cff1a45fcfa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a1e9861d-046f-45b8-9d85-7ba32c1310c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cac1b749-8f4b-458e-a41f-806893a2c413" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a1e9861d-046f-45b8-9d85-7ba32c1310c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_40961e13-dc3a-4ee3-a358-5ff5e3767b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cac1b749-8f4b-458e-a41f-806893a2c413" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_40961e13-dc3a-4ee3-a358-5ff5e3767b24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cc54ae1a-ef93-4539-bc63-2038ba2a012f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b507caf-e5a1-4cf0-b3b6-7a8cd195af98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cc54ae1a-ef93-4539-bc63-2038ba2a012f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b507caf-e5a1-4cf0-b3b6-7a8cd195af98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_b4323ba5-18cc-4a34-bc6d-2def2580adb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cc54ae1a-ef93-4539-bc63-2038ba2a012f" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_b4323ba5-18cc-4a34-bc6d-2def2580adb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3e0b0d39-a3ac-4c16-9465-d96c7d48da13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cc54ae1a-ef93-4539-bc63-2038ba2a012f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3e0b0d39-a3ac-4c16-9465-d96c7d48da13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0e27ef7b-721d-414e-886f-486bc9167962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cc54ae1a-ef93-4539-bc63-2038ba2a012f" xlink:to="loc_us-gaap_InventoryNet_0e27ef7b-721d-414e-886f-486bc9167962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b51e1161-d019-4f8d-885a-c964a0cd0081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cc54ae1a-ef93-4539-bc63-2038ba2a012f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b51e1161-d019-4f8d-885a-c964a0cd0081" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7b079b3e-7019-4138-bfde-1e83c3256bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0ea2f1fa-3e66-4f55-9f58-00ec1b723bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b079b3e-7019-4138-bfde-1e83c3256bdd" xlink:to="loc_us-gaap_AssetsCurrent_0ea2f1fa-3e66-4f55-9f58-00ec1b723bbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_93a6a135-3dd7-4d17-93c6-d8e318a16604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b079b3e-7019-4138-bfde-1e83c3256bdd" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_93a6a135-3dd7-4d17-93c6-d8e318a16604" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_afbd9b61-81bf-4f5b-934c-dda885a83227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b079b3e-7019-4138-bfde-1e83c3256bdd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_afbd9b61-81bf-4f5b-934c-dda885a83227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_e867ada3-9e6b-436f-8244-3cd5a98ed7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b079b3e-7019-4138-bfde-1e83c3256bdd" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_e867ada3-9e6b-436f-8244-3cd5a98ed7ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_129aa660-3902-4492-b21a-cc1a9eee7e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b079b3e-7019-4138-bfde-1e83c3256bdd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_129aa660-3902-4492-b21a-cc1a9eee7e0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4b731cdf-6e34-43fa-bdcf-c8d475ffd6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b079b3e-7019-4138-bfde-1e83c3256bdd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4b731cdf-6e34-43fa-bdcf-c8d475ffd6ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6e4df3cd-fe37-40a0-b602-999ee2e8d677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b079b3e-7019-4138-bfde-1e83c3256bdd" xlink:to="loc_us-gaap_Goodwill_6e4df3cd-fe37-40a0-b602-999ee2e8d677" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_af8dc577-3e86-4e10-8543-73abb41a67ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b079b3e-7019-4138-bfde-1e83c3256bdd" xlink:to="loc_us-gaap_OtherAssets_af8dc577-3e86-4e10-8543-73abb41a67ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f7473a7a-d1b8-4fca-a284-1c675b159b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_85c8ad71-8161-4267-93fa-81bb1ae65162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f7473a7a-d1b8-4fca-a284-1c675b159b71" xlink:to="loc_us-gaap_LiabilitiesCurrent_85c8ad71-8161-4267-93fa-81bb1ae65162" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3d05bca2-a314-4ad1-ad58-c7b208034fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f7473a7a-d1b8-4fca-a284-1c675b159b71" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3d05bca2-a314-4ad1-ad58-c7b208034fc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2e3642ac-dbed-43c0-8dc9-730fa7ffba76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f7473a7a-d1b8-4fca-a284-1c675b159b71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2e3642ac-dbed-43c0-8dc9-730fa7ffba76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1c9959aa-1dbc-4f36-9a54-6705ff736e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f7473a7a-d1b8-4fca-a284-1c675b159b71" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1c9959aa-1dbc-4f36-9a54-6705ff736e1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ea5d3100-7575-439b-9042-a335792cb217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f7473a7a-d1b8-4fca-a284-1c675b159b71" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ea5d3100-7575-439b-9042-a335792cb217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c3e4a5bf-a6f2-45a1-a8f9-09257fe9bcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f7473a7a-d1b8-4fca-a284-1c675b159b71" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c3e4a5bf-a6f2-45a1-a8f9-09257fe9bcf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_36f7db48-fd3b-412d-97db-c6e9add46f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e6226b57-bc95-4a34-ac13-d74eb4167cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_36f7db48-fd3b-412d-97db-c6e9add46f91" xlink:to="loc_us-gaap_AccountsPayableCurrent_e6226b57-bc95-4a34-ac13-d74eb4167cca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9a4ef7a3-b3ab-4c75-8a20-3a711a245e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_36f7db48-fd3b-412d-97db-c6e9add46f91" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9a4ef7a3-b3ab-4c75-8a20-3a711a245e23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b1317752-fe6f-41bb-b914-5b7eef2ac947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_36f7db48-fd3b-412d-97db-c6e9add46f91" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b1317752-fe6f-41bb-b914-5b7eef2ac947" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_7f44670d-dfad-4bc3-a94a-2f46cc3be6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_36f7db48-fd3b-412d-97db-c6e9add46f91" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_7f44670d-dfad-4bc3-a94a-2f46cc3be6eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cf90c23a-bd1f-4ce6-ab5a-155883a123fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_36f7db48-fd3b-412d-97db-c6e9add46f91" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cf90c23a-bd1f-4ce6-ab5a-155883a123fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="simple" xlink:href="insm-20220630.xsd#ConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4b84299a-759d-4e33-8888-f9ab4639b191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_934dd4ff-3eec-4ec7-a029-84cce2e8bdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4b84299a-759d-4e33-8888-f9ab4639b191" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_934dd4ff-3eec-4ec7-a029-84cce2e8bdfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ee169d10-0406-40a8-b24f-c2a84d256d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4b84299a-759d-4e33-8888-f9ab4639b191" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ee169d10-0406-40a8-b24f-c2a84d256d45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e67f781e-bb40-4b3e-9a1d-e72566f6e37f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2d01225d-9845-4f2e-afab-ddcd2821088a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e67f781e-bb40-4b3e-9a1d-e72566f6e37f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2d01225d-9845-4f2e-afab-ddcd2821088a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2eefdd6d-347e-4e18-86e8-698eb189aa2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e67f781e-bb40-4b3e-9a1d-e72566f6e37f" xlink:to="loc_us-gaap_CostsAndExpenses_2eefdd6d-347e-4e18-86e8-698eb189aa2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f56cf81a-0c56-4647-9f64-80feb3942779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f9ca4501-3faa-4ae6-8cf6-7f6a2d2f6d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f56cf81a-0c56-4647-9f64-80feb3942779" xlink:to="loc_us-gaap_OperatingIncomeLoss_f9ca4501-3faa-4ae6-8cf6-7f6a2d2f6d05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_352d8085-e80d-4555-a460-6558fc1ab7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f56cf81a-0c56-4647-9f64-80feb3942779" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_352d8085-e80d-4555-a460-6558fc1ab7fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5c2b46c9-8c0a-448c-9e08-5fc6c05befd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f56cf81a-0c56-4647-9f64-80feb3942779" xlink:to="loc_us-gaap_InterestExpense_5c2b46c9-8c0a-448c-9e08-5fc6c05befd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7ecd8b88-82ab-4a9d-8ea7-93019aa888ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f56cf81a-0c56-4647-9f64-80feb3942779" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7ecd8b88-82ab-4a9d-8ea7-93019aa888ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bd85e243-ddd4-405a-a739-dae5c818d4da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f56cf81a-0c56-4647-9f64-80feb3942779" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bd85e243-ddd4-405a-a739-dae5c818d4da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c7115f5a-da60-4fc8-9cee-0ce1af458ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3b073d1a-c091-427d-bfe5-aa9bac31c7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c7115f5a-da60-4fc8-9cee-0ce1af458ae6" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3b073d1a-c091-427d-bfe5-aa9bac31c7c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_b8b21de1-2b22-4986-a95e-15479c9d9f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c7115f5a-da60-4fc8-9cee-0ce1af458ae6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_b8b21de1-2b22-4986-a95e-15479c9d9f35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_136e6085-4851-42b5-bbc8-d701da89bc07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c7115f5a-da60-4fc8-9cee-0ce1af458ae6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_136e6085-4851-42b5-bbc8-d701da89bc07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_15c9cf96-b348-4bf8-8611-47ce8bfe777b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_87dd1c35-9d22-4687-a683-734278004f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_15c9cf96-b348-4bf8-8611-47ce8bfe777b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_87dd1c35-9d22-4687-a683-734278004f68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_14a390e9-910e-444b-a240-320b85072ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_15c9cf96-b348-4bf8-8611-47ce8bfe777b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_14a390e9-910e-444b-a240-320b85072ebe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_386b12b6-3d72-4850-a8d8-edb42749e778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_15c9cf96-b348-4bf8-8611-47ce8bfe777b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_386b12b6-3d72-4850-a8d8-edb42749e778" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7a3afca2-20ae-4a9c-a233-09e78f8dd0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_15c9cf96-b348-4bf8-8611-47ce8bfe777b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7a3afca2-20ae-4a9c-a233-09e78f8dd0bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9cc5a9fb-9513-4dfd-ba62-953495089339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_15c9cf96-b348-4bf8-8611-47ce8bfe777b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9cc5a9fb-9513-4dfd-ba62-953495089339" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="insm-20220630.xsd#ConsolidatedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57f1c8f-7a96-4707-87b5-b929fef5ecc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87265dc2-158e-4026-bc1b-b0f284ee93db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57f1c8f-7a96-4707-87b5-b929fef5ecc8" xlink:to="loc_us-gaap_NetIncomeLoss_87265dc2-158e-4026-bc1b-b0f284ee93db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_23c032dd-c148-4274-8dac-727d701c407b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57f1c8f-7a96-4707-87b5-b929fef5ecc8" xlink:to="loc_us-gaap_Depreciation_23c032dd-c148-4274-8dac-727d701c407b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3bcfb220-55ba-4474-a613-55dd1bb24e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57f1c8f-7a96-4707-87b5-b929fef5ecc8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3bcfb220-55ba-4474-a613-55dd1bb24e53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_029f1bf5-fd82-4c80-a40b-e5a1b996c875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57f1c8f-7a96-4707-87b5-b929fef5ecc8" xlink:to="loc_us-gaap_ShareBasedCompensation_029f1bf5-fd82-4c80-a40b-e5a1b996c875" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a2de3df6-ea3d-4ae5-9f8e-32d3991cb50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57f1c8f-7a96-4707-87b5-b929fef5ecc8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a2de3df6-ea3d-4ae5-9f8e-32d3991cb50a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_24486996-8080-4906-9a46-1a1e7b69088e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57f1c8f-7a96-4707-87b5-b929fef5ecc8" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_24486996-8080-4906-9a46-1a1e7b69088e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2b7027fe-4ff7-4eb8-a72c-48c21f8eb5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57f1c8f-7a96-4707-87b5-b929fef5ecc8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2b7027fe-4ff7-4eb8-a72c-48c21f8eb5d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e31441bc-8786-4e80-a8a6-c1106ea99cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57f1c8f-7a96-4707-87b5-b929fef5ecc8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e31441bc-8786-4e80-a8a6-c1106ea99cf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NoncashOperatingLeaseExpense_c65d9a39-c140-4a89-ae5b-e8d2619164e0" xlink:href="insm-20220630.xsd#insm_NoncashOperatingLeaseExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57f1c8f-7a96-4707-87b5-b929fef5ecc8" xlink:to="loc_insm_NoncashOperatingLeaseExpense_c65d9a39-c140-4a89-ae5b-e8d2619164e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1fa5cdbf-6763-4b08-8f76-01f74b39818d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57f1c8f-7a96-4707-87b5-b929fef5ecc8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1fa5cdbf-6763-4b08-8f76-01f74b39818d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5142ff3e-96ce-48ff-8594-1eb1f699644a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57f1c8f-7a96-4707-87b5-b929fef5ecc8" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_5142ff3e-96ce-48ff-8594-1eb1f699644a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b5fcf6aa-a04b-4681-9ecd-b6bdecbd729a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57f1c8f-7a96-4707-87b5-b929fef5ecc8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b5fcf6aa-a04b-4681-9ecd-b6bdecbd729a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ffe63000-2e54-4453-9bab-4f195d487732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57f1c8f-7a96-4707-87b5-b929fef5ecc8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ffe63000-2e54-4453-9bab-4f195d487732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5a9e9ecb-def3-451b-bbeb-a8a74c5e1ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57f1c8f-7a96-4707-87b5-b929fef5ecc8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5a9e9ecb-def3-451b-bbeb-a8a74c5e1ab7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_e7d9c691-c9de-4f92-9543-2d757e8a7f52" xlink:href="insm-20220630.xsd#insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c57f1c8f-7a96-4707-87b5-b929fef5ecc8" xlink:to="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_e7d9c691-c9de-4f92-9543-2d757e8a7f52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_819d38c0-2f62-4724-9743-ced5c7364280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bac96cf-1820-43ee-8b53-857efc7f0a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_819d38c0-2f62-4724-9743-ced5c7364280" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bac96cf-1820-43ee-8b53-857efc7f0a46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7b04ca89-f393-4ea8-8fe2-4c8e974b6c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_819d38c0-2f62-4724-9743-ced5c7364280" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7b04ca89-f393-4ea8-8fe2-4c8e974b6c4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4129389-9384-4817-b27a-9cd54d7f040e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_819d38c0-2f62-4724-9743-ced5c7364280" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4129389-9384-4817-b27a-9cd54d7f040e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e7cb6fcb-4a38-4a3e-8d02-c50dabba1f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_819d38c0-2f62-4724-9743-ced5c7364280" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e7cb6fcb-4a38-4a3e-8d02-c50dabba1f88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3dec2bae-bf0a-4b2c-b7ac-3557c292a895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c6612fc2-9361-48a3-87c0-eba9e1e78d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3dec2bae-bf0a-4b2c-b7ac-3557c292a895" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c6612fc2-9361-48a3-87c0-eba9e1e78d12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6cfa4859-3982-4ad3-b4f4-a45a6b72d8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3dec2bae-bf0a-4b2c-b7ac-3557c292a895" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6cfa4859-3982-4ad3-b4f4-a45a6b72d8a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c1d056e1-479d-447e-9ded-bdf29c83c074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_bdb4040e-c38c-426c-aaac-fd13501fb6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c1d056e1-479d-447e-9ded-bdf29c83c074" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_bdb4040e-c38c-426c-aaac-fd13501fb6a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5c27b0b8-8068-4bef-9016-ef86284d1aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c1d056e1-479d-447e-9ded-bdf29c83c074" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5c27b0b8-8068-4bef-9016-ef86284d1aad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e6e32408-15b3-4b33-9a47-52fa04edd502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c1d056e1-479d-447e-9ded-bdf29c83c074" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e6e32408-15b3-4b33-9a47-52fa04edd502" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_62e52a7f-3d44-426b-9e4b-6279a71637de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c1d056e1-479d-447e-9ded-bdf29c83c074" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_62e52a7f-3d44-426b-9e4b-6279a71637de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_4c9aaa73-bf87-4e25-ac21-efa4caa67cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c1d056e1-479d-447e-9ded-bdf29c83c074" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_4c9aaa73-bf87-4e25-ac21-efa4caa67cc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_6a697dd7-f662-4470-adad-567e92fd8de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c1d056e1-479d-447e-9ded-bdf29c83c074" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_6a697dd7-f662-4470-adad-567e92fd8de8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_47815602-5422-4d55-a49b-72b848f6c276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c1d056e1-479d-447e-9ded-bdf29c83c074" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_47815602-5422-4d55-a49b-72b848f6c276" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_39bfdaa7-ae36-44f5-a23f-e47ffc6c5a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_819dfd00-59ae-4d68-9a7a-035c948374da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_39bfdaa7-ae36-44f5-a23f-e47ffc6c5a5b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_819dfd00-59ae-4d68-9a7a-035c948374da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_bdda3bc1-0257-4c34-9b0f-0b98b891328f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_39bfdaa7-ae36-44f5-a23f-e47ffc6c5a5b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_bdda3bc1-0257-4c34-9b0f-0b98b891328f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_400e3514-4e65-4e55-9da5-b657964e433a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_39bfdaa7-ae36-44f5-a23f-e47ffc6c5a5b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_400e3514-4e65-4e55-9da5-b657964e433a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#InventoryScheduleofInventoryCurrentDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_78e9ce82-b5be-4062-9f0e-2c88d19e2219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_7a5d1065-7265-4b8e-a6be-96186ac0d0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_78e9ce82-b5be-4062-9f0e-2c88d19e2219" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_7a5d1065-7265-4b8e-a6be-96186ac0d0f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_e6a54d85-281f-457a-9d34-7dce63d197b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_78e9ce82-b5be-4062-9f0e-2c88d19e2219" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_e6a54d85-281f-457a-9d34-7dce63d197b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_37f15050-f4db-4b07-9f13-4ef29bf0f980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_78e9ce82-b5be-4062-9f0e-2c88d19e2219" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_37f15050-f4db-4b07-9f13-4ef29bf0f980" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#FixedAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b207baee-ce98-48d4-8c19-941a80fe24ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_441ce694-5967-48ff-841c-f6bf837c8187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_b207baee-ce98-48d4-8c19-941a80fe24ed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_441ce694-5967-48ff-841c-f6bf837c8187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_07fe6669-ca32-4df0-b7b6-31b5daa64b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_b207baee-ce98-48d4-8c19-941a80fe24ed" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_07fe6669-ca32-4df0-b7b6-31b5daa64b59" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0ad9122d-d3c2-4df0-a484-46b2a0d40fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedClinicalTrialExpenses_6790d98c-6e61-4426-bdc0-41beaa08e510" xlink:href="insm-20220630.xsd#insm_AccruedClinicalTrialExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0ad9122d-d3c2-4df0-a484-46b2a0d40fba" xlink:to="loc_insm_AccruedClinicalTrialExpenses_6790d98c-6e61-4426-bdc0-41beaa08e510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_f1d46019-2427-40bc-a4d9-3cd8461b633f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0ad9122d-d3c2-4df0-a484-46b2a0d40fba" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_f1d46019-2427-40bc-a4d9-3cd8461b633f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedTechnicalOperationExpenses_2e21a83d-5f92-4be5-a4bd-eb7598cdc2dc" xlink:href="insm-20220630.xsd#insm_AccruedTechnicalOperationExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0ad9122d-d3c2-4df0-a484-46b2a0d40fba" xlink:to="loc_insm_AccruedTechnicalOperationExpenses_2e21a83d-5f92-4be5-a4bd-eb7598cdc2dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedRoyaltiesAndMilestonePaymentsCurrent_73d326a2-6e1f-43e2-a1ec-55806c3817d5" xlink:href="insm-20220630.xsd#insm_AccruedRoyaltiesAndMilestonePaymentsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0ad9122d-d3c2-4df0-a484-46b2a0d40fba" xlink:to="loc_insm_AccruedRoyaltiesAndMilestonePaymentsCurrent_73d326a2-6e1f-43e2-a1ec-55806c3817d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_e01360e3-74b7-4d9f-8f7b-d05d78f0aff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0ad9122d-d3c2-4df0-a484-46b2a0d40fba" xlink:to="loc_us-gaap_InterestPayableCurrent_e01360e3-74b7-4d9f-8f7b-d05d78f0aff0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedSalesAllowancesAndRelatedCosts_0d4333e6-ac63-48dd-b288-b7fc347aaff9" xlink:href="insm-20220630.xsd#insm_AccruedSalesAllowancesAndRelatedCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0ad9122d-d3c2-4df0-a484-46b2a0d40fba" xlink:to="loc_insm_AccruedSalesAllowancesAndRelatedCosts_0d4333e6-ac63-48dd-b288-b7fc347aaff9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredPaymentsCurrent_9c96437b-16e8-426d-ad2e-37be34fd9d26" xlink:href="insm-20220630.xsd#insm_BusinessCombinationDeferredPaymentsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0ad9122d-d3c2-4df0-a484-46b2a0d40fba" xlink:to="loc_insm_BusinessCombinationDeferredPaymentsCurrent_9c96437b-16e8-426d-ad2e-37be34fd9d26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedConstructionLiabilitiesCurrent_0801e649-c85b-433a-ba85-4f45aeacc3cc" xlink:href="insm-20220630.xsd#insm_AccruedConstructionLiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0ad9122d-d3c2-4df0-a484-46b2a0d40fba" xlink:to="loc_insm_AccruedConstructionLiabilitiesCurrent_0801e649-c85b-433a-ba85-4f45aeacc3cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e3d1bf9c-4fe7-4c74-abd4-7d4e695566d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0ad9122d-d3c2-4df0-a484-46b2a0d40fba" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e3d1bf9c-4fe7-4c74-abd4-7d4e695566d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtComponentsofDebtDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#DebtComponentsofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtComponentsofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f9581ec6-7bd4-4eb5-8621-2a81ca02370a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_43570f46-3cf9-41f8-a1b7-4ed35aa1628a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_f9581ec6-7bd4-4eb5-8621-2a81ca02370a" xlink:to="loc_us-gaap_SecuredDebt_43570f46-3cf9-41f8-a1b7-4ed35aa1628a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_ebc8de3c-4a2e-4e04-9f58-4f269efe579e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_f9581ec6-7bd4-4eb5-8621-2a81ca02370a" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_ebc8de3c-4a2e-4e04-9f58-4f269efe579e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2be00da7-2842-4931-b961-b94a357a90a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_f9581ec6-7bd4-4eb5-8621-2a81ca02370a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2be00da7-2842-4931-b961-b94a357a90a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#DebtFuturePrincipalRepaymentsofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4c44ab71-0155-4d3f-b7ba-13b2864157fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_4a4b91f2-a795-4c09-9e5c-2eed0429c505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4c44ab71-0155-4d3f-b7ba-13b2864157fb" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_4a4b91f2-a795-4c09-9e5c-2eed0429c505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6217fbb8-d794-4bcb-a8fe-632b673c4892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4c44ab71-0155-4d3f-b7ba-13b2864157fb" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6217fbb8-d794-4bcb-a8fe-632b673c4892" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_225e6c51-bd2e-47f4-afda-ef5bb3cb165c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4c44ab71-0155-4d3f-b7ba-13b2864157fb" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_225e6c51-bd2e-47f4-afda-ef5bb3cb165c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3b4b6270-af1e-4f65-a1c5-764b2676eba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4c44ab71-0155-4d3f-b7ba-13b2864157fb" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3b4b6270-af1e-4f65-a1c5-764b2676eba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_924a5ade-2f95-4897-8804-99dc7fa1beb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4c44ab71-0155-4d3f-b7ba-13b2864157fb" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_924a5ade-2f95-4897-8804-99dc7fa1beb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LongTermDebtMaturityAfterYearFour_2f77c140-b269-4a9f-87d5-0067aa16a8e3" xlink:href="insm-20220630.xsd#insm_LongTermDebtMaturityAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4c44ab71-0155-4d3f-b7ba-13b2864157fb" xlink:to="loc_insm_LongTermDebtMaturityAfterYearFour_2f77c140-b269-4a9f-87d5-0067aa16a8e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#DebtInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConvertibleDebtInterestExpenseTotal_3a139b3f-211d-4170-8530-5ab90b38449b" xlink:href="insm-20220630.xsd#insm_ConvertibleDebtInterestExpenseTotal"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_bde9cc42-ba14-4606-90f1-3481cb7f259f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_insm_ConvertibleDebtInterestExpenseTotal_3a139b3f-211d-4170-8530-5ab90b38449b" xlink:to="loc_us-gaap_InterestExpenseDebt_bde9cc42-ba14-4606-90f1-3481cb7f259f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_4d5e007d-89d4-42f7-98cc-cbaf6b2f1a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_insm_ConvertibleDebtInterestExpenseTotal_3a139b3f-211d-4170-8530-5ab90b38449b" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_4d5e007d-89d4-42f7-98cc-cbaf6b2f1a41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_ea0e2f53-c26c-4218-b47d-cbf02d68ca05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_insm_ConvertibleDebtInterestExpenseTotal_3a139b3f-211d-4170-8530-5ab90b38449b" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_ea0e2f53-c26c-4218-b47d-cbf02d68ca05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e8b089f6-6c98-43c2-8d95-22a800469e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConvertibleDebtInterestExpenseTotal_4f12dfbb-71f4-4f51-8ad4-ca128d63c745" xlink:href="insm-20220630.xsd#insm_ConvertibleDebtInterestExpenseTotal"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_e8b089f6-6c98-43c2-8d95-22a800469e32" xlink:to="loc_insm_ConvertibleDebtInterestExpenseTotal_4f12dfbb-71f4-4f51-8ad4-ca128d63c745" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_9165a365-c0cb-455b-a298-a31e11edad0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_e8b089f6-6c98-43c2-8d95-22a800469e32" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_9165a365-c0cb-455b-a298-a31e11edad0e" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>insm-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f29bbe7c-3fe7-4edc-bd43-5e98e923844d,g:47f91642-8422-4809-9855-6a3312b42bf8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" xlink:type="simple" xlink:href="insm-20220630.xsd#ConsolidatedStatementsofShareholdersEquityunaudited"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" xlink:type="extended" id="i2865ce969f9e4a829d091a86bc586789_ConsolidatedStatementsofShareholdersEquityunaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_48b85f8d-324c-49bf-9cca-1b7b354084bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48b85f8d-324c-49bf-9cca-1b7b354084bd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_5917f4a9-c5c6-4748-9f2a-cde7fc2c33d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_SharesOutstanding_5917f4a9-c5c6-4748-9f2a-cde7fc2c33d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_375445df-6d2c-4a04-86e0-04f23ec8f34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_StockholdersEquity_375445df-6d2c-4a04-86e0-04f23ec8f34f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_71b61463-8abf-49c5-998a-e589bdd526be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_71b61463-8abf-49c5-998a-e589bdd526be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ef34baa5-b0cc-4812-9732-7ba719ba3b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_71b61463-8abf-49c5-998a-e589bdd526be" xlink:to="loc_us-gaap_NetIncomeLoss_ef34baa5-b0cc-4812-9732-7ba719ba3b1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3ab2bcbb-0b85-42ba-95a0-005e42c77530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_71b61463-8abf-49c5-998a-e589bdd526be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3ab2bcbb-0b85-42ba-95a0-005e42c77530" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_489d2f61-52c2-430c-a60a-434d9b8fb02a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_489d2f61-52c2-430c-a60a-434d9b8fb02a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_acd71cb9-c62a-44f1-971a-018429b666e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_acd71cb9-c62a-44f1-971a-018429b666e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_694e80a1-41c7-48ba-b017-07edfa4e76a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_694e80a1-41c7-48ba-b017-07edfa4e76a6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_777f2701-dbe2-4682-b121-a15777e48be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_777f2701-dbe2-4682-b121-a15777e48be4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_1951255b-4635-4ffa-8d9d-6cf9ab74f4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_1951255b-4635-4ffa-8d9d-6cf9ab74f4ea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_611630a1-1d37-4679-b09d-4af40756cb88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_611630a1-1d37-4679-b09d-4af40756cb88" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_36b3fcff-6e45-4041-b6e6-b8f5d9aae127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_36b3fcff-6e45-4041-b6e6-b8f5d9aae127" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_49fd1952-d5cd-4ddd-b871-64e6d43a5ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_49fd1952-d5cd-4ddd-b871-64e6d43a5ec6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6a9cbf1b-eea8-42e9-81cb-02f6041e6ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6a9cbf1b-eea8-42e9-81cb-02f6041e6ac7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b04d873c-8761-41bc-befc-d5d5cc1cd1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6ccc054c-2f1d-4648-89d1-e0de8fa17973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_1a233c94-307d-4123-970d-73a73eac7cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_1a233c94-307d-4123-970d-73a73eac7cd0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3108012b-99bf-46f2-81fd-43e5a40f21c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_48b85f8d-324c-49bf-9cca-1b7b354084bd" xlink:to="loc_us-gaap_StatementTable_3108012b-99bf-46f2-81fd-43e5a40f21c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b88fc45c-cce2-4c0a-85d1-d9851191da48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3108012b-99bf-46f2-81fd-43e5a40f21c8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b88fc45c-cce2-4c0a-85d1-d9851191da48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b88fc45c-cce2-4c0a-85d1-d9851191da48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b88fc45c-cce2-4c0a-85d1-d9851191da48" xlink:to="loc_us-gaap_EquityComponentDomain_b88fc45c-cce2-4c0a-85d1-d9851191da48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8ff0d021-bbdc-4e85-9eca-c799ef6a3f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b88fc45c-cce2-4c0a-85d1-d9851191da48" xlink:to="loc_us-gaap_EquityComponentDomain_8ff0d021-bbdc-4e85-9eca-c799ef6a3f75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e647ff0d-edcd-40fe-b432-f3f8ba55b996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8ff0d021-bbdc-4e85-9eca-c799ef6a3f75" xlink:to="loc_us-gaap_CommonStockMember_e647ff0d-edcd-40fe-b432-f3f8ba55b996" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8a15c39d-e1d1-4c11-9487-01d4774729fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8ff0d021-bbdc-4e85-9eca-c799ef6a3f75" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8a15c39d-e1d1-4c11-9487-01d4774729fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_91e89434-5468-42f5-a93f-9f27d95bb8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8ff0d021-bbdc-4e85-9eca-c799ef6a3f75" xlink:to="loc_us-gaap_RetainedEarningsMember_91e89434-5468-42f5-a93f-9f27d95bb8f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_611feb83-d9d6-490e-a051-2aaeb225614d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8ff0d021-bbdc-4e85-9eca-c799ef6a3f75" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_611feb83-d9d6-490e-a051-2aaeb225614d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_35e429b4-5200-4892-afe5-8e3a18547aed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3108012b-99bf-46f2-81fd-43e5a40f21c8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_35e429b4-5200-4892-afe5-8e3a18547aed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_35e429b4-5200-4892-afe5-8e3a18547aed_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_35e429b4-5200-4892-afe5-8e3a18547aed" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_35e429b4-5200-4892-afe5-8e3a18547aed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_00b96945-d864-4858-ab6c-4660540e7815" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_35e429b4-5200-4892-afe5-8e3a18547aed" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_00b96945-d864-4858-ab6c-4660540e7815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_943431a1-71fe-449c-b9d1-ea42449196a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_00b96945-d864-4858-ab6c-4660540e7815" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_943431a1-71fe-449c-b9d1-ea42449196a3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical" xlink:type="simple" xlink:href="insm-20220630.xsd#ConsolidatedStatementsofCashFlowsunauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical" xlink:type="extended" id="i4f8ec449130342cf84dcbd99a4e3390c_ConsolidatedStatementsofCashFlowsunauditedParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3ffff402-ea47-4678-8502-1d4eec0b8f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ed294423-2539-4f16-bc9a-82f5af55ff50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ffff402-ea47-4678-8502-1d4eec0b8f1d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ed294423-2539-4f16-bc9a-82f5af55ff50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_375ccbda-0b13-4894-a576-c3fa11b5ae86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3ffff402-ea47-4678-8502-1d4eec0b8f1d" xlink:to="loc_us-gaap_StatementTable_375ccbda-0b13-4894-a576-c3fa11b5ae86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_21340fb2-9191-4c8c-bae0-846950c2df2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_375ccbda-0b13-4894-a576-c3fa11b5ae86" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_21340fb2-9191-4c8c-bae0-846950c2df2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_21340fb2-9191-4c8c-bae0-846950c2df2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_21340fb2-9191-4c8c-bae0-846950c2df2c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_21340fb2-9191-4c8c-bae0-846950c2df2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019ba5dc-7f80-46bc-9e55-ed66394917db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_21340fb2-9191-4c8c-bae0-846950c2df2c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019ba5dc-7f80-46bc-9e55-ed66394917db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_7f5e32fe-d3e5-4c05-a6fc-b0413bd07776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019ba5dc-7f80-46bc-9e55-ed66394917db" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_7f5e32fe-d3e5-4c05-a6fc-b0413bd07776" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c1fc40af-18d1-4da6-b410-416e6c3faf62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_375ccbda-0b13-4894-a576-c3fa11b5ae86" xlink:to="loc_us-gaap_DebtInstrumentAxis_c1fc40af-18d1-4da6-b410-416e6c3faf62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c1fc40af-18d1-4da6-b410-416e6c3faf62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c1fc40af-18d1-4da6-b410-416e6c3faf62" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c1fc40af-18d1-4da6-b410-416e6c3faf62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9df16bb7-e7dd-4e4b-9c4c-c19b45196f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c1fc40af-18d1-4da6-b410-416e6c3faf62" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9df16bb7-e7dd-4e4b-9c4c-c19b45196f10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_abdb4b37-64a4-47d5-aec7-07bf8f37f0bf" xlink:href="insm-20220630.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9df16bb7-e7dd-4e4b-9c4c-c19b45196f10" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_abdb4b37-64a4-47d5-aec7-07bf8f37f0bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_8e0fd072-7e91-4686-93cd-b0e81214e28d" xlink:href="insm-20220630.xsd#insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9df16bb7-e7dd-4e4b-9c4c-c19b45196f10" xlink:to="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_8e0fd072-7e91-4686-93cd-b0e81214e28d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended" id="i9f733abcca964071b52af9d624a1dcbd_SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_407952f6-718d-43a6-85f7-024dd1a294ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_59030c96-c4f4-4cd2-8c83-ad2d63dae0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_407952f6-718d-43a6-85f7-024dd1a294ae" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_59030c96-c4f4-4cd2-8c83-ad2d63dae0cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_bf420569-b6b4-4d35-a3df-29b0c214745d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_407952f6-718d-43a6-85f7-024dd1a294ae" xlink:to="loc_us-gaap_MarketableSecurities_bf420569-b6b4-4d35-a3df-29b0c214745d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredLiability_a5ba53b6-802d-4fb6-95fc-041bedc5e4b1" xlink:href="insm-20220630.xsd#insm_BusinessCombinationDeferredLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_407952f6-718d-43a6-85f7-024dd1a294ae" xlink:to="loc_insm_BusinessCombinationDeferredLiability_a5ba53b6-802d-4fb6-95fc-041bedc5e4b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1a3c48c3-b3b3-4cd9-9478-8927739c5825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_407952f6-718d-43a6-85f7-024dd1a294ae" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1a3c48c3-b3b3-4cd9-9478-8927739c5825" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_54afbac9-d725-40e3-b71c-14231eed7673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_407952f6-718d-43a6-85f7-024dd1a294ae" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_54afbac9-d725-40e3-b71c-14231eed7673" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1ecc8c3-a86a-4ece-90fa-ce7179774365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_54afbac9-d725-40e3-b71c-14231eed7673" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1ecc8c3-a86a-4ece-90fa-ce7179774365" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1ecc8c3-a86a-4ece-90fa-ce7179774365_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1ecc8c3-a86a-4ece-90fa-ce7179774365" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1ecc8c3-a86a-4ece-90fa-ce7179774365_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e098a362-f57b-4a55-b569-2adecf7fa780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1ecc8c3-a86a-4ece-90fa-ce7179774365" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e098a362-f57b-4a55-b569-2adecf7fa780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f9b8ef96-8f43-4de0-96cf-5b2908d85cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e098a362-f57b-4a55-b569-2adecf7fa780" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f9b8ef96-8f43-4de0-96cf-5b2908d85cf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_147c01c5-66af-4ab6-b22c-0d4c5accb6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_54afbac9-d725-40e3-b71c-14231eed7673" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_147c01c5-66af-4ab6-b22c-0d4c5accb6e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_147c01c5-66af-4ab6-b22c-0d4c5accb6e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_147c01c5-66af-4ab6-b22c-0d4c5accb6e5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_147c01c5-66af-4ab6-b22c-0d4c5accb6e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7d6600fa-fb49-4ccc-ae28-2c151065d0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_147c01c5-66af-4ab6-b22c-0d4c5accb6e5" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7d6600fa-fb49-4ccc-ae28-2c151065d0cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6d0aabfb-d463-452b-a9a6-cda6c445faf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7d6600fa-fb49-4ccc-ae28-2c151065d0cd" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6d0aabfb-d463-452b-a9a6-cda6c445faf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_2ff87ed2-e074-4dcc-beaf-f24d24ecceb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6d0aabfb-d463-452b-a9a6-cda6c445faf2" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_2ff87ed2-e074-4dcc-beaf-f24d24ecceb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0098c304-bfb6-4065-94a6-73f5c6d38a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6d0aabfb-d463-452b-a9a6-cda6c445faf2" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0098c304-bfb6-4065-94a6-73f5c6d38a0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_48fcab87-42de-4570-9866-72ded91fa3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_54afbac9-d725-40e3-b71c-14231eed7673" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_48fcab87-42de-4570-9866-72ded91fa3dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_48fcab87-42de-4570-9866-72ded91fa3dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_48fcab87-42de-4570-9866-72ded91fa3dc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_48fcab87-42de-4570-9866-72ded91fa3dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8926cd7-a259-4c45-bceb-df3b8b7889e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_48fcab87-42de-4570-9866-72ded91fa3dc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8926cd7-a259-4c45-bceb-df3b8b7889e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6c4fab64-c3af-46f6-827d-a5dee8a167a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8926cd7-a259-4c45-bceb-df3b8b7889e3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6c4fab64-c3af-46f6-827d-a5dee8a167a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8feef5c6-418b-4c76-87af-0f98403eacb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8926cd7-a259-4c45-bceb-df3b8b7889e3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8feef5c6-418b-4c76-87af-0f98403eacb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_67ab4287-0ec7-481b-8411-c322e3debbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8926cd7-a259-4c45-bceb-df3b8b7889e3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_67ab4287-0ec7-481b-8411-c322e3debbe6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i990cf3f707a44e2e960761309f32b594_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MarketableSecuritiesAdditional_b8063e4c-ce06-41e0-b5e1-77894dcaf512" xlink:href="insm-20220630.xsd#insm_MarketableSecuritiesAdditional"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_MarketableSecuritiesAdditional_b8063e4c-ce06-41e0-b5e1-77894dcaf512" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FairValueLevel1Level2Level3TransfersAmount_d8213c8c-ab08-45dd-a02a-d7f26dde8ee6" xlink:href="insm-20220630.xsd#insm_FairValueLevel1Level2Level3TransfersAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_FairValueLevel1Level2Level3TransfersAmount_d8213c8c-ab08-45dd-a02a-d7f26dde8ee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1357330f-b5a4-43f4-ba61-f4e1a97e0918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1357330f-b5a4-43f4-ba61-f4e1a97e0918" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9d9642a5-0816-48bb-acea-c5387b15c38d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9d9642a5-0816-48bb-acea-c5387b15c38d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_58d1facc-516e-41ea-8a07-e0c5694e9087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_58d1facc-516e-41ea-8a07-e0c5694e9087" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities_9fba1665-15f5-4df9-b3da-f2d4558f1e79" xlink:href="insm-20220630.xsd#insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities_9fba1665-15f5-4df9-b3da-f2d4558f1e79" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_f834f911-2eb5-4fc0-834c-3c9e698774bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_f834f911-2eb5-4fc0-834c-3c9e698774bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredLiability_e80a2cec-3fb6-47e2-aee3-7fe205f1e5a8" xlink:href="insm-20220630.xsd#insm_BusinessCombinationDeferredLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_BusinessCombinationDeferredLiability_e80a2cec-3fb6-47e2-aee3-7fe205f1e5a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_25dd0569-5b2d-4189-a643-fea076895f93" xlink:href="insm-20220630.xsd#insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_25dd0569-5b2d-4189-a643-fea076895f93" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_WeightedAverageProbabilityOfReachingMilestone_5e65dba1-41f8-4eed-b56f-9abe8e1a98be" xlink:href="insm-20220630.xsd#insm_WeightedAverageProbabilityOfReachingMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_WeightedAverageProbabilityOfReachingMilestone_5e65dba1-41f8-4eed-b56f-9abe8e1a98be" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage_fa1bc19f-d707-498b-b7fd-ebc3934923f0" xlink:href="insm-20220630.xsd#insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage_fa1bc19f-d707-498b-b7fd-ebc3934923f0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage_0239cb58-8474-45b8-9742-3f9d581c54d7" xlink:href="insm-20220630.xsd#insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage_0239cb58-8474-45b8-9742-3f9d581c54d7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders_ca83e98c-e633-4f0b-a599-e314d0b8cc0e" xlink:href="insm-20220630.xsd#insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders_ca83e98c-e633-4f0b-a599-e314d0b8cc0e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_75f171dc-6e4c-446e-8726-c2a18750af68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_75f171dc-6e4c-446e-8726-c2a18750af68" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_d217942d-d65f-4faf-b946-e61e5c2351e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_d217942d-d65f-4faf-b946-e61e5c2351e7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_de2e625c-4b38-4280-984c-d2c8b94e8b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_de2e625c-4b38-4280-984c-d2c8b94e8b37" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5682b4e2-c367-4c7a-b885-1c1715fedffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5682b4e2-c367-4c7a-b885-1c1715fedffa" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_b711e9c5-faf2-4557-869a-8680ca9be8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_b711e9c5-faf2-4557-869a-8680ca9be8ed" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_afaa9d90-ee26-4f8e-9282-bad778d26285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_afaa9d90-ee26-4f8e-9282-bad778d26285" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0d8b734-69a5-457e-b1bc-716430173676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0d8b734-69a5-457e-b1bc-716430173676" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2dc507a3-182d-49f7-9629-7da3a48de28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2dc507a3-182d-49f7-9629-7da3a48de28d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4efa8485-a843-491b-bea0-706ba85f41bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4efa8485-a843-491b-bea0-706ba85f41bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4efa8485-a843-491b-bea0-706ba85f41bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4efa8485-a843-491b-bea0-706ba85f41bc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4efa8485-a843-491b-bea0-706ba85f41bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd887f85-0194-457b-8fa1-2895eada11c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4efa8485-a843-491b-bea0-706ba85f41bc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd887f85-0194-457b-8fa1-2895eada11c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncMember_2eddfe01-b42e-4977-88f9-d91ec2f019a8" xlink:href="insm-20220630.xsd#insm_MotusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd887f85-0194-457b-8fa1-2895eada11c8" xlink:to="loc_insm_MotusBiosciencesIncMember_2eddfe01-b42e-4977-88f9-d91ec2f019a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AlgaeneXIncMember_fb5492a7-982b-4f17-8dcd-ddefde5dee64" xlink:href="insm-20220630.xsd#insm_AlgaeneXIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd887f85-0194-457b-8fa1-2895eada11c8" xlink:to="loc_insm_AlgaeneXIncMember_fb5492a7-982b-4f17-8dcd-ddefde5dee64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_23f3a4fd-e75d-414d-bb31-f41461383c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_VestingAxis_23f3a4fd-e75d-414d-bb31-f41461383c02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_23f3a4fd-e75d-414d-bb31-f41461383c02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_23f3a4fd-e75d-414d-bb31-f41461383c02" xlink:to="loc_us-gaap_VestingDomain_23f3a4fd-e75d-414d-bb31-f41461383c02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_9594e9a5-8971-4cc6-9811-8dd29639ad74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_23f3a4fd-e75d-414d-bb31-f41461383c02" xlink:to="loc_us-gaap_VestingDomain_9594e9a5-8971-4cc6-9811-8dd29639ad74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e855ca2d-eba0-4c9a-8207-fb294f082f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_9594e9a5-8971-4cc6-9811-8dd29639ad74" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e855ca2d-eba0-4c9a-8207-fb294f082f88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_41a05cb4-8ac7-4b76-9698-469eee6edba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_9594e9a5-8971-4cc6-9811-8dd29639ad74" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_41a05cb4-8ac7-4b76-9698-469eee6edba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_bb1a2bad-c2c3-428d-a574-be0ad38faece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_9594e9a5-8971-4cc6-9811-8dd29639ad74" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_bb1a2bad-c2c3-428d-a574-be0ad38faece" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_73d3e4ed-868a-4497-9b43-9ef09f341d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_73d3e4ed-868a-4497-9b43-9ef09f341d5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_73d3e4ed-868a-4497-9b43-9ef09f341d5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_73d3e4ed-868a-4497-9b43-9ef09f341d5f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_73d3e4ed-868a-4497-9b43-9ef09f341d5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ab023e6a-1374-479f-9da6-1ed377b3685b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_73d3e4ed-868a-4497-9b43-9ef09f341d5f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ab023e6a-1374-479f-9da6-1ed377b3685b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedLiabilitiesCurrentMember_67fbd991-cf58-4cae-848c-e046e2164832" xlink:href="insm-20220630.xsd#insm_AccruedLiabilitiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ab023e6a-1374-479f-9da6-1ed377b3685b" xlink:to="loc_insm_AccruedLiabilitiesCurrentMember_67fbd991-cf58-4cae-848c-e046e2164832" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_424c85d7-439f-4c82-bd15-ae064e54edfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ab023e6a-1374-479f-9da6-1ed377b3685b" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_424c85d7-439f-4c82-bd15-ae064e54edfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_25110d12-5fd6-47d5-b4e7-2e01c78782ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_25110d12-5fd6-47d5-b4e7-2e01c78782ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_25110d12-5fd6-47d5-b4e7-2e01c78782ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_25110d12-5fd6-47d5-b4e7-2e01c78782ec" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_25110d12-5fd6-47d5-b4e7-2e01c78782ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_46fb770d-6c62-4f65-8aa6-0a720a824acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_25110d12-5fd6-47d5-b4e7-2e01c78782ec" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_46fb770d-6c62-4f65-8aa6-0a720a824acd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DevelopmentAndRegulatoryMilestonesMember_e2c51f1d-ddd7-4f45-bf84-12a1dc6994f3" xlink:href="insm-20220630.xsd#insm_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_46fb770d-6c62-4f65-8aa6-0a720a824acd" xlink:to="loc_insm_DevelopmentAndRegulatoryMilestonesMember_e2c51f1d-ddd7-4f45-bf84-12a1dc6994f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PriorityReviewVoucherMilestoneMember_506f8563-d785-4441-8d6e-b20ab75245f7" xlink:href="insm-20220630.xsd#insm_PriorityReviewVoucherMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_46fb770d-6c62-4f65-8aa6-0a720a824acd" xlink:to="loc_insm_PriorityReviewVoucherMilestoneMember_506f8563-d785-4441-8d6e-b20ab75245f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_760df49a-9aaa-4526-90ef-b7b164863959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_DebtInstrumentAxis_760df49a-9aaa-4526-90ef-b7b164863959" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_760df49a-9aaa-4526-90ef-b7b164863959_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_760df49a-9aaa-4526-90ef-b7b164863959" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_760df49a-9aaa-4526-90ef-b7b164863959_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fc8e3870-d4bb-4120-b2c9-fd3005ccd546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_760df49a-9aaa-4526-90ef-b7b164863959" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fc8e3870-d4bb-4120-b2c9-fd3005ccd546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_560e3563-ccbc-4f6a-9514-7071338a8db0" xlink:href="insm-20220630.xsd#insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fc8e3870-d4bb-4120-b2c9-fd3005ccd546" xlink:to="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_560e3563-ccbc-4f6a-9514-7071338a8db0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_e13d7583-ad37-44b8-bb09-d3d1a02d843c" xlink:href="insm-20220630.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fc8e3870-d4bb-4120-b2c9-fd3005ccd546" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_e13d7583-ad37-44b8-bb09-d3d1a02d843c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d3410619-25b3-4632-8824-b16c0d7749ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d3410619-25b3-4632-8824-b16c0d7749ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d3410619-25b3-4632-8824-b16c0d7749ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d3410619-25b3-4632-8824-b16c0d7749ab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d3410619-25b3-4632-8824-b16c0d7749ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a9bfbb24-0236-4fa8-ae1d-f71351399204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d3410619-25b3-4632-8824-b16c0d7749ab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a9bfbb24-0236-4fa8-ae1d-f71351399204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_56299dad-86fa-42dc-9cd3-98b5b79a689a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a9bfbb24-0236-4fa8-ae1d-f71351399204" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_56299dad-86fa-42dc-9cd3-98b5b79a689a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41715d26-a5e3-40c4-9da6-9d75417190f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41715d26-a5e3-40c4-9da6-9d75417190f3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41715d26-a5e3-40c4-9da6-9d75417190f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41715d26-a5e3-40c4-9da6-9d75417190f3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41715d26-a5e3-40c4-9da6-9d75417190f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78f45302-3999-4219-a313-58c347a881aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41715d26-a5e3-40c4-9da6-9d75417190f3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78f45302-3999-4219-a313-58c347a881aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_373a3507-cbce-4194-a787-8fd652545c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78f45302-3999-4219-a313-58c347a881aa" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_373a3507-cbce-4194-a787-8fd652545c7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_2abdbaf5-6e53-42e5-9996-8e2fb27f31a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_2abdbaf5-6e53-42e5-9996-8e2fb27f31a4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2abdbaf5-6e53-42e5-9996-8e2fb27f31a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_2abdbaf5-6e53-42e5-9996-8e2fb27f31a4" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2abdbaf5-6e53-42e5-9996-8e2fb27f31a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fe56a888-25eb-44ac-9517-1d6be2fde746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_2abdbaf5-6e53-42e5-9996-8e2fb27f31a4" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fe56a888-25eb-44ac-9517-1d6be2fde746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1112d92d-71f4-4fcf-95d8-f8edb6fe63ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fe56a888-25eb-44ac-9517-1d6be2fde746" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1112d92d-71f4-4fcf-95d8-f8edb6fe63ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_f1ee02b7-4520-4029-9a38-565401548114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fe56a888-25eb-44ac-9517-1d6be2fde746" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_f1ee02b7-4520-4029-9a38-565401548114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_1ce4ab2f-ba56-44c8-b04b-a2110fddc165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fe56a888-25eb-44ac-9517-1d6be2fde746" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_1ce4ab2f-ba56-44c8-b04b-a2110fddc165" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0ace23c-8d5c-498c-ade7-a4dba6e37339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0ace23c-8d5c-498c-ade7-a4dba6e37339" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a0ace23c-8d5c-498c-ade7-a4dba6e37339_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0ace23c-8d5c-498c-ade7-a4dba6e37339" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a0ace23c-8d5c-498c-ade7-a4dba6e37339_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_12c79312-9159-4175-a144-b236348094f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0ace23c-8d5c-498c-ade7-a4dba6e37339" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_12c79312-9159-4175-a144-b236348094f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d7de3caa-327d-470e-a0fa-e7a20d76c107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_12c79312-9159-4175-a144-b236348094f4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d7de3caa-327d-470e-a0fa-e7a20d76c107" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f9cec09f-2928-4784-adb2-2726a4a7c922" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f9cec09f-2928-4784-adb2-2726a4a7c922" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f9cec09f-2928-4784-adb2-2726a4a7c922_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f9cec09f-2928-4784-adb2-2726a4a7c922" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f9cec09f-2928-4784-adb2-2726a4a7c922_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_143665a2-4548-46ed-8678-f5a57d6724c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f9cec09f-2928-4784-adb2-2726a4a7c922" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_143665a2-4548-46ed-8678-f5a57d6724c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f6d141d4-2081-40c8-bd1d-46ba93b9f1d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_143665a2-4548-46ed-8678-f5a57d6724c9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f6d141d4-2081-40c8-bd1d-46ba93b9f1d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3505fd8a-54bb-4ea9-8f36-5179c70e6773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3505fd8a-54bb-4ea9-8f36-5179c70e6773" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3505fd8a-54bb-4ea9-8f36-5179c70e6773_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3505fd8a-54bb-4ea9-8f36-5179c70e6773" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3505fd8a-54bb-4ea9-8f36-5179c70e6773_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1676bd9c-e710-4a30-af06-11f370a2b5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3505fd8a-54bb-4ea9-8f36-5179c70e6773" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1676bd9c-e710-4a30-af06-11f370a2b5a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_1e6d0cb7-f661-43fd-b754-eee1092ffdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1676bd9c-e710-4a30-af06-11f370a2b5a8" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_1e6d0cb7-f661-43fd-b754-eee1092ffdfa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails" xlink:type="extended" id="i86639b79d1114c7982f7f31b7c01368a_SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2b2a7e82-11ff-4e0f-a4aa-b0152f880946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredLiability_610b5833-4f89-433d-b23c-0bf618016a1e" xlink:href="insm-20220630.xsd#insm_BusinessCombinationDeferredLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2b2a7e82-11ff-4e0f-a4aa-b0152f880946" xlink:to="loc_insm_BusinessCombinationDeferredLiability_610b5833-4f89-433d-b23c-0bf618016a1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_46f4f9ff-e82e-4b59-a972-a911572c25d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2b2a7e82-11ff-4e0f-a4aa-b0152f880946" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_46f4f9ff-e82e-4b59-a972-a911572c25d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ab8d3c-72bb-47f9-8624-5c4695428749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2b2a7e82-11ff-4e0f-a4aa-b0152f880946" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ab8d3c-72bb-47f9-8624-5c4695428749" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17aa76a9-5259-4ac8-9d11-12a8f7f74505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ab8d3c-72bb-47f9-8624-5c4695428749" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17aa76a9-5259-4ac8-9d11-12a8f7f74505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17aa76a9-5259-4ac8-9d11-12a8f7f74505_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17aa76a9-5259-4ac8-9d11-12a8f7f74505" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_17aa76a9-5259-4ac8-9d11-12a8f7f74505_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e898ecc3-b3d4-40fa-995c-d4f0a1c8d051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17aa76a9-5259-4ac8-9d11-12a8f7f74505" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e898ecc3-b3d4-40fa-995c-d4f0a1c8d051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_402ab36a-f27f-4297-bdbb-79e4bfbd41ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e898ecc3-b3d4-40fa-995c-d4f0a1c8d051" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_402ab36a-f27f-4297-bdbb-79e4bfbd41ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_41ad6bf9-cf15-4a18-b758-bfc136b3941e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ab8d3c-72bb-47f9-8624-5c4695428749" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_41ad6bf9-cf15-4a18-b758-bfc136b3941e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_41ad6bf9-cf15-4a18-b758-bfc136b3941e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_41ad6bf9-cf15-4a18-b758-bfc136b3941e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_41ad6bf9-cf15-4a18-b758-bfc136b3941e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a42bff0d-7215-4d8d-b606-4e33a32726b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_41ad6bf9-cf15-4a18-b758-bfc136b3941e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a42bff0d-7215-4d8d-b606-4e33a32726b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_92cb49f5-eb8e-49b7-ae6a-e809ff6bbd82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a42bff0d-7215-4d8d-b606-4e33a32726b0" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_92cb49f5-eb8e-49b7-ae6a-e809ff6bbd82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d8a5de8b-ff48-4e47-a7a3-d3a6bc051a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ab8d3c-72bb-47f9-8624-5c4695428749" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d8a5de8b-ff48-4e47-a7a3-d3a6bc051a46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d8a5de8b-ff48-4e47-a7a3-d3a6bc051a46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d8a5de8b-ff48-4e47-a7a3-d3a6bc051a46" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d8a5de8b-ff48-4e47-a7a3-d3a6bc051a46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46d29fe8-dbf0-45f8-8e2a-43bddf00b455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d8a5de8b-ff48-4e47-a7a3-d3a6bc051a46" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46d29fe8-dbf0-45f8-8e2a-43bddf00b455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncMember_567c6120-2dda-4f99-bcb2-1bbbe8dfd159" xlink:href="insm-20220630.xsd#insm_MotusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46d29fe8-dbf0-45f8-8e2a-43bddf00b455" xlink:to="loc_insm_MotusBiosciencesIncMember_567c6120-2dda-4f99-bcb2-1bbbe8dfd159" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails" xlink:type="extended" id="iaa9448c7a8144fb3994c8765741adb0a_SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6a82c037-9b0e-4b39-9bb5-944dd0bb1c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_16b854c6-d081-48d3-8615-d34da4f907fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6a82c037-9b0e-4b39-9bb5-944dd0bb1c8c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_16b854c6-d081-48d3-8615-d34da4f907fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_00196675-d7d1-45d3-bfcd-32a8811b507b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6a82c037-9b0e-4b39-9bb5-944dd0bb1c8c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_00196675-d7d1-45d3-bfcd-32a8811b507b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0584592f-f031-427a-9a94-cd3ff1ee9666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6a82c037-9b0e-4b39-9bb5-944dd0bb1c8c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0584592f-f031-427a-9a94-cd3ff1ee9666" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d4914ac-7167-42da-8964-612b9e81fe0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0584592f-f031-427a-9a94-cd3ff1ee9666" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d4914ac-7167-42da-8964-612b9e81fe0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d4914ac-7167-42da-8964-612b9e81fe0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d4914ac-7167-42da-8964-612b9e81fe0f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d4914ac-7167-42da-8964-612b9e81fe0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ccff161c-2f9b-4bcd-8527-8ae8938e0d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d4914ac-7167-42da-8964-612b9e81fe0f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ccff161c-2f9b-4bcd-8527-8ae8938e0d58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_06d02494-6da0-4339-bc9a-9a9277d110de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ccff161c-2f9b-4bcd-8527-8ae8938e0d58" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_06d02494-6da0-4339-bc9a-9a9277d110de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_abd3813d-d741-491f-9b77-b9f374f0536b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0584592f-f031-427a-9a94-cd3ff1ee9666" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_abd3813d-d741-491f-9b77-b9f374f0536b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_abd3813d-d741-491f-9b77-b9f374f0536b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_abd3813d-d741-491f-9b77-b9f374f0536b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_abd3813d-d741-491f-9b77-b9f374f0536b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_895f1778-d11c-4c78-b988-e48e9a1b590d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_abd3813d-d741-491f-9b77-b9f374f0536b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_895f1778-d11c-4c78-b988-e48e9a1b590d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DevelopmentAndRegulatoryMilestonesMember_21dfa22e-77ae-4bcb-ab17-7a44f104d1b8" xlink:href="insm-20220630.xsd#insm_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_895f1778-d11c-4c78-b988-e48e9a1b590d" xlink:to="loc_insm_DevelopmentAndRegulatoryMilestonesMember_21dfa22e-77ae-4bcb-ab17-7a44f104d1b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PriorityReviewVoucherMilestoneMember_5352d2d5-9970-4b84-8ca5-445e95e6aab3" xlink:href="insm-20220630.xsd#insm_PriorityReviewVoucherMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_895f1778-d11c-4c78-b988-e48e9a1b590d" xlink:to="loc_insm_PriorityReviewVoucherMilestoneMember_5352d2d5-9970-4b84-8ca5-445e95e6aab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_d0fa5fa4-3721-4e63-8d47-1f711480562f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0584592f-f031-427a-9a94-cd3ff1ee9666" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_d0fa5fa4-3721-4e63-8d47-1f711480562f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d0fa5fa4-3721-4e63-8d47-1f711480562f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d0fa5fa4-3721-4e63-8d47-1f711480562f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d0fa5fa4-3721-4e63-8d47-1f711480562f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cc06ad9a-4f9f-43fc-9eaa-e1ff70ae17cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d0fa5fa4-3721-4e63-8d47-1f711480562f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cc06ad9a-4f9f-43fc-9eaa-e1ff70ae17cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MeasurementInputProbabilityOfSuccessMember_bd2e9a3d-9f0a-4be1-af4a-9744e8c5bec1" xlink:href="insm-20220630.xsd#insm_MeasurementInputProbabilityOfSuccessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cc06ad9a-4f9f-43fc-9eaa-e1ff70ae17cf" xlink:to="loc_insm_MeasurementInputProbabilityOfSuccessMember_bd2e9a3d-9f0a-4be1-af4a-9744e8c5bec1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_46ca1e10-4bf2-4c73-bc7c-ca4e43812458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cc06ad9a-4f9f-43fc-9eaa-e1ff70ae17cf" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_46ca1e10-4bf2-4c73-bc7c-ca4e43812458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_78e270a8-3e74-4506-bb3e-12b8bfbc3e09" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0584592f-f031-427a-9a94-cd3ff1ee9666" xlink:to="loc_srt_RangeAxis_78e270a8-3e74-4506-bb3e-12b8bfbc3e09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_78e270a8-3e74-4506-bb3e-12b8bfbc3e09_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_78e270a8-3e74-4506-bb3e-12b8bfbc3e09" xlink:to="loc_srt_RangeMember_78e270a8-3e74-4506-bb3e-12b8bfbc3e09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3bdfeed0-cce6-443a-b1d8-4d61ec958ce6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_78e270a8-3e74-4506-bb3e-12b8bfbc3e09" xlink:to="loc_srt_RangeMember_3bdfeed0-cce6-443a-b1d8-4d61ec958ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3c91db05-0500-4b8f-8ab7-84e6c76b21da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3bdfeed0-cce6-443a-b1d8-4d61ec958ce6" xlink:to="loc_srt_MinimumMember_3c91db05-0500-4b8f-8ab7-84e6c76b21da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_769a6d28-26a5-4ee2-b4df-e1c289db97af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3bdfeed0-cce6-443a-b1d8-4d61ec958ce6" xlink:to="loc_srt_MaximumMember_769a6d28-26a5-4ee2-b4df-e1c289db97af" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails" xlink:type="extended" id="i56e106aefbbd4e91aa8629b903831234_SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ae6adb85-d600-4ad4-9144-bbaa699a4afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8d01d81-b548-4ff6-b2a5-40a4aefa1241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ae6adb85-d600-4ad4-9144-bbaa699a4afe" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8d01d81-b548-4ff6-b2a5-40a4aefa1241" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_aed2cc4a-4101-425f-abc4-53ac5e7db963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8d01d81-b548-4ff6-b2a5-40a4aefa1241" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_aed2cc4a-4101-425f-abc4-53ac5e7db963" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_e72912fe-5e20-4633-a139-7bd52fd8c678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8d01d81-b548-4ff6-b2a5-40a4aefa1241" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_e72912fe-5e20-4633-a139-7bd52fd8c678" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue_f0a8ec13-73ac-48c0-a474-648eee8795a6" xlink:href="insm-20220630.xsd#insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8d01d81-b548-4ff6-b2a5-40a4aefa1241" xlink:to="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue_f0a8ec13-73ac-48c0-a474-648eee8795a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments_ceaa7921-566f-49dd-ba62-3212b7b5d796" xlink:href="insm-20220630.xsd#insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8d01d81-b548-4ff6-b2a5-40a4aefa1241" xlink:to="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments_ceaa7921-566f-49dd-ba62-3212b7b5d796" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7b2bc694-7742-42b3-81ba-f613f542503f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ffeb77bd-06d3-435e-b730-f5da8a286b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ae6adb85-d600-4ad4-9144-bbaa699a4afe" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ffeb77bd-06d3-435e-b730-f5da8a286b4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_46e1e967-9df2-40a5-9ae9-83ddb66fc378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ffeb77bd-06d3-435e-b730-f5da8a286b4a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_46e1e967-9df2-40a5-9ae9-83ddb66fc378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46e1e967-9df2-40a5-9ae9-83ddb66fc378_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_46e1e967-9df2-40a5-9ae9-83ddb66fc378" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46e1e967-9df2-40a5-9ae9-83ddb66fc378_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e932e60-c791-4bad-86f2-5dcab7ab98ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_46e1e967-9df2-40a5-9ae9-83ddb66fc378" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e932e60-c791-4bad-86f2-5dcab7ab98ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_41cd2016-984e-4712-8ad2-77c7a8438b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e932e60-c791-4bad-86f2-5dcab7ab98ae" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_41cd2016-984e-4712-8ad2-77c7a8438b24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_a825ce36-5956-48d9-8e5d-ad1c88a3d053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ffeb77bd-06d3-435e-b730-f5da8a286b4a" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_a825ce36-5956-48d9-8e5d-ad1c88a3d053" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a825ce36-5956-48d9-8e5d-ad1c88a3d053_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_a825ce36-5956-48d9-8e5d-ad1c88a3d053" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a825ce36-5956-48d9-8e5d-ad1c88a3d053_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35c494ec-7ddb-444f-b5d6-2b2c92444a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_a825ce36-5956-48d9-8e5d-ad1c88a3d053" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35c494ec-7ddb-444f-b5d6-2b2c92444a01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredConsiderationMember_19ea09d5-6a32-4fa9-8811-b4770e4dd404" xlink:href="insm-20220630.xsd#insm_DeferredConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35c494ec-7ddb-444f-b5d6-2b2c92444a01" xlink:to="loc_insm_DeferredConsiderationMember_19ea09d5-6a32-4fa9-8811-b4770e4dd404" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContingentConsiderationMember_51d79ab3-f927-4e34-a5d7-30c03a77c9cd" xlink:href="insm-20220630.xsd#insm_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35c494ec-7ddb-444f-b5d6-2b2c92444a01" xlink:to="loc_insm_ContingentConsiderationMember_51d79ab3-f927-4e34-a5d7-30c03a77c9cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6f090bca-c809-4b28-a112-794147c40368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ffeb77bd-06d3-435e-b730-f5da8a286b4a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6f090bca-c809-4b28-a112-794147c40368" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6f090bca-c809-4b28-a112-794147c40368_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6f090bca-c809-4b28-a112-794147c40368" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6f090bca-c809-4b28-a112-794147c40368_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9d0a3a27-d747-4546-a95c-2e83dd620e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6f090bca-c809-4b28-a112-794147c40368" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9d0a3a27-d747-4546-a95c-2e83dd620e71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e14ed3b0-14d9-43af-a799-ad50d6b08586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9d0a3a27-d747-4546-a95c-2e83dd620e71" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e14ed3b0-14d9-43af-a799-ad50d6b08586" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="extended" id="i290ad4d23fb74e95afdfb7b6a7e0f0b5_SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_ddced350-fb94-4f0e-99e9-ffb79ae44b06" xlink:href="insm-20220630.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8bfe9e49-82b3-4980-89e8-1c7cac0412af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_ddced350-fb94-4f0e-99e9-ffb79ae44b06" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8bfe9e49-82b3-4980-89e8-1c7cac0412af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9a4215f5-bf76-4eab-90fa-d272e6bcd494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8bfe9e49-82b3-4980-89e8-1c7cac0412af" xlink:to="loc_us-gaap_NetIncomeLoss_9a4215f5-bf76-4eab-90fa-d272e6bcd494" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d16da805-7a94-46d6-9e13-1dba9522a32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_ddced350-fb94-4f0e-99e9-ffb79ae44b06" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d16da805-7a94-46d6-9e13-1dba9522a32d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3dbbc66d-feb7-413f-8a83-212942ad27fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d16da805-7a94-46d6-9e13-1dba9522a32d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3dbbc66d-feb7-413f-8a83-212942ad27fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_7a6ea3db-3e77-4ee7-a17a-0408b196a04a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d16da805-7a94-46d6-9e13-1dba9522a32d" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_7a6ea3db-3e77-4ee7-a17a-0408b196a04a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_50c39c91-02c1-476f-b9d3-962136127996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_7a6ea3db-3e77-4ee7-a17a-0408b196a04a" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_50c39c91-02c1-476f-b9d3-962136127996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_390b5a76-66d5-4dbf-b1f3-9d5951b1be8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_7a6ea3db-3e77-4ee7-a17a-0408b196a04a" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_390b5a76-66d5-4dbf-b1f3-9d5951b1be8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1981cddf-602b-4f5d-b92e-ab19dceebf35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d16da805-7a94-46d6-9e13-1dba9522a32d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1981cddf-602b-4f5d-b92e-ab19dceebf35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_56adaed7-f2be-446c-8b1c-5eb7bd9a9a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_ddced350-fb94-4f0e-99e9-ffb79ae44b06" xlink:to="loc_us-gaap_EarningsPerShareAbstract_56adaed7-f2be-446c-8b1c-5eb7bd9a9a0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d7232be7-1de3-4c4f-98bc-de2f0e849f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_56adaed7-f2be-446c-8b1c-5eb7bd9a9a0e" xlink:to="loc_us-gaap_EarningsPerShareBasic_d7232be7-1de3-4c4f-98bc-de2f0e849f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3f0f0ec7-f1e3-484b-9e32-5f40ec1a5dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_56adaed7-f2be-446c-8b1c-5eb7bd9a9a0e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3f0f0ec7-f1e3-484b-9e32-5f40ec1a5dcf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_15565ad9-4726-413c-8cf5-d882ea90241a" xlink:href="insm-20220630.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_ddced350-fb94-4f0e-99e9-ffb79ae44b06" xlink:to="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_15565ad9-4726-413c-8cf5-d882ea90241a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac4779c3-78bd-4eb0-bb9f-17fe330b1799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_15565ad9-4726-413c-8cf5-d882ea90241a" xlink:to="loc_us-gaap_AwardTypeAxis_ac4779c3-78bd-4eb0-bb9f-17fe330b1799" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac4779c3-78bd-4eb0-bb9f-17fe330b1799_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ac4779c3-78bd-4eb0-bb9f-17fe330b1799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac4779c3-78bd-4eb0-bb9f-17fe330b1799_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385ce82b-28c5-4b4b-9665-414acb0ade2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ac4779c3-78bd-4eb0-bb9f-17fe330b1799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385ce82b-28c5-4b4b-9665-414acb0ade2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_22ce432e-7eaf-4e62-8c29-c84ed149d685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385ce82b-28c5-4b4b-9665-414acb0ade2c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_22ce432e-7eaf-4e62-8c29-c84ed149d685" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_15e62e2f-24bf-4903-9ffa-80c290aec860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385ce82b-28c5-4b4b-9665-414acb0ade2c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_15e62e2f-24bf-4903-9ffa-80c290aec860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_24ac305d-9b3a-4636-9e55-f1c70b9fb6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385ce82b-28c5-4b4b-9665-414acb0ade2c" xlink:to="loc_us-gaap_PerformanceSharesMember_24ac305d-9b3a-4636-9e55-f1c70b9fb6a4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended" id="if64e00df63394dcba9268ec6a08a1b4c_SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c106b9e-e612-41aa-8624-b0d9a446d598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2c70df20-6aa7-4efc-9a18-96a63a54687a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c106b9e-e612-41aa-8624-b0d9a446d598" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2c70df20-6aa7-4efc-9a18-96a63a54687a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_17bf130b-bd58-4194-84f9-0e9e90227c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c106b9e-e612-41aa-8624-b0d9a446d598" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_17bf130b-bd58-4194-84f9-0e9e90227c1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e97d7897-86b6-40b8-8858-22955591a189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_17bf130b-bd58-4194-84f9-0e9e90227c1d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e97d7897-86b6-40b8-8858-22955591a189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e97d7897-86b6-40b8-8858-22955591a189_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e97d7897-86b6-40b8-8858-22955591a189" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e97d7897-86b6-40b8-8858-22955591a189_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f025f473-6140-4470-80c3-907a704a1144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e97d7897-86b6-40b8-8858-22955591a189" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f025f473-6140-4470-80c3-907a704a1144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_85eba2b5-65e0-414f-a0b2-41f4023f34e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f025f473-6140-4470-80c3-907a704a1144" xlink:to="loc_us-gaap_EmployeeStockOptionMember_85eba2b5-65e0-414f-a0b2-41f4023f34e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_69b12a03-bf47-4153-81f7-95f943a4deb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f025f473-6140-4470-80c3-907a704a1144" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_69b12a03-bf47-4153-81f7-95f943a4deb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ba92badc-6421-4169-ab33-69d445e59b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f025f473-6140-4470-80c3-907a704a1144" xlink:to="loc_us-gaap_PerformanceSharesMember_ba92badc-6421-4169-ab33-69d445e59b43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_bdde15d9-372c-47a1-80ec-37a98de59e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f025f473-6140-4470-80c3-907a704a1144" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_bdde15d9-372c-47a1-80ec-37a98de59e80" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="extended" id="ie2b326ac70414840ba9fe915dfa36643_SummaryofSignificantAccountingPoliciesConcentrationRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_594c53ba-5aa1-4b05-90f2-0efca8ac1958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fc6af9ab-21ce-49f0-ac2d-764d6c1f9000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_594c53ba-5aa1-4b05-90f2-0efca8ac1958" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fc6af9ab-21ce-49f0-ac2d-764d6c1f9000" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_10eb8301-6e0d-4a14-8963-45cc394922bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_594c53ba-5aa1-4b05-90f2-0efca8ac1958" xlink:to="loc_us-gaap_ConcentrationRiskTable_10eb8301-6e0d-4a14-8963-45cc394922bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_942aedaa-211f-4613-b55b-2b82b30f0722" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_10eb8301-6e0d-4a14-8963-45cc394922bf" xlink:to="loc_srt_MajorCustomersAxis_942aedaa-211f-4613-b55b-2b82b30f0722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_942aedaa-211f-4613-b55b-2b82b30f0722_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_942aedaa-211f-4613-b55b-2b82b30f0722" xlink:to="loc_srt_NameOfMajorCustomerDomain_942aedaa-211f-4613-b55b-2b82b30f0722_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5d110c00-4b6f-428a-992e-54dfdcad444a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_942aedaa-211f-4613-b55b-2b82b30f0722" xlink:to="loc_srt_NameOfMajorCustomerDomain_5d110c00-4b6f-428a-992e-54dfdcad444a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerAMember_295ed0ea-f9b2-49d7-a9c8-b512e4ac9d27" xlink:href="insm-20220630.xsd#insm_CustomerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5d110c00-4b6f-428a-992e-54dfdcad444a" xlink:to="loc_insm_CustomerAMember_295ed0ea-f9b2-49d7-a9c8-b512e4ac9d27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerBMember_46271127-d55b-4219-9299-1ddf77b2e2ff" xlink:href="insm-20220630.xsd#insm_CustomerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5d110c00-4b6f-428a-992e-54dfdcad444a" xlink:to="loc_insm_CustomerBMember_46271127-d55b-4219-9299-1ddf77b2e2ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerCMember_bbc5a29c-e1e2-41d9-ad69-0f32a33af357" xlink:href="insm-20220630.xsd#insm_CustomerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5d110c00-4b6f-428a-992e-54dfdcad444a" xlink:to="loc_insm_CustomerCMember_bbc5a29c-e1e2-41d9-ad69-0f32a33af357" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_49241b2d-e7a0-4711-bc97-107b84625bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_10eb8301-6e0d-4a14-8963-45cc394922bf" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_49241b2d-e7a0-4711-bc97-107b84625bf3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_49241b2d-e7a0-4711-bc97-107b84625bf3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_49241b2d-e7a0-4711-bc97-107b84625bf3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_49241b2d-e7a0-4711-bc97-107b84625bf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a09cd1a3-2850-4f6c-b444-c28e7389c37d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_49241b2d-e7a0-4711-bc97-107b84625bf3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a09cd1a3-2850-4f6c-b444-c28e7389c37d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_5e75701c-dae1-46ff-b870-d53cbb8f0208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a09cd1a3-2850-4f6c-b444-c28e7389c37d" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_5e75701c-dae1-46ff-b870-d53cbb8f0208" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d6da03a2-f028-4cd5-a7aa-6eb3d5b9906d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_10eb8301-6e0d-4a14-8963-45cc394922bf" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d6da03a2-f028-4cd5-a7aa-6eb3d5b9906d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d6da03a2-f028-4cd5-a7aa-6eb3d5b9906d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d6da03a2-f028-4cd5-a7aa-6eb3d5b9906d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d6da03a2-f028-4cd5-a7aa-6eb3d5b9906d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cb0d1c19-5593-4d64-bed9-88d08a244280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d6da03a2-f028-4cd5-a7aa-6eb3d5b9906d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cb0d1c19-5593-4d64-bed9-88d08a244280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e403796d-fff7-4ef3-ac34-ac008916189f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_cb0d1c19-5593-4d64-bed9-88d08a244280" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e403796d-fff7-4ef3-ac34-ac008916189f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails" xlink:type="extended" id="i75faf528b30f4326940a5483c8ceba9b_SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5a71ec6c-d888-4328-a888-dbcc299608cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_027e2205-ca94-4b61-9701-abcb2a8b280a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5a71ec6c-d888-4328-a888-dbcc299608cd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_027e2205-ca94-4b61-9701-abcb2a8b280a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_75ecc766-85c6-4610-a7a1-959c164f1a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5a71ec6c-d888-4328-a888-dbcc299608cd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_75ecc766-85c6-4610-a7a1-959c164f1a44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bb3015c4-d21c-4239-9d0f-52c7123cbd89" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75ecc766-85c6-4610-a7a1-959c164f1a44" xlink:to="loc_srt_StatementGeographicalAxis_bb3015c4-d21c-4239-9d0f-52c7123cbd89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bb3015c4-d21c-4239-9d0f-52c7123cbd89_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_bb3015c4-d21c-4239-9d0f-52c7123cbd89" xlink:to="loc_srt_SegmentGeographicalDomain_bb3015c4-d21c-4239-9d0f-52c7123cbd89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_737b87d4-060e-4a4f-96e2-ef77bfb57dbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_bb3015c4-d21c-4239-9d0f-52c7123cbd89" xlink:to="loc_srt_SegmentGeographicalDomain_737b87d4-060e-4a4f-96e2-ef77bfb57dbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_535093d9-5951-4ce3-8be1-e89dfc1be325" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_737b87d4-060e-4a4f-96e2-ef77bfb57dbb" xlink:to="loc_country_US_535093d9-5951-4ce3-8be1-e89dfc1be325" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_729caf62-d96d-4b6c-876f-b9a43be311e5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_737b87d4-060e-4a4f-96e2-ef77bfb57dbb" xlink:to="loc_country_JP_729caf62-d96d-4b6c-876f-b9a43be311e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EuropeAndTheRestOfTheWorldMember_4c7f03ff-29e8-43ab-a411-10ded586b901" xlink:href="insm-20220630.xsd#insm_EuropeAndTheRestOfTheWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_737b87d4-060e-4a4f-96e2-ef77bfb57dbb" xlink:to="loc_insm_EuropeAndTheRestOfTheWorldMember_4c7f03ff-29e8-43ab-a411-10ded586b901" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#IntangiblesNetandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" xlink:type="extended" id="i5254ca429ffb4efda54433dae39d1cdc_IntangiblesNetandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9d806a8d-71c0-4275-986c-e9c6085f5bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6a855817-5ba0-42d7-a28b-7dc4ca7346e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9d806a8d-71c0-4275-986c-e9c6085f5bc5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6a855817-5ba0-42d7-a28b-7dc4ca7346e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3409103d-69bb-4345-b995-62c63685997c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6a855817-5ba0-42d7-a28b-7dc4ca7346e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3409103d-69bb-4345-b995-62c63685997c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_eca530e9-f752-446d-b41a-f355e8d4f698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6a855817-5ba0-42d7-a28b-7dc4ca7346e0" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_eca530e9-f752-446d-b41a-f355e8d4f698" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c6b810ae-955b-4065-9b6b-9bcefc69b0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6a855817-5ba0-42d7-a28b-7dc4ca7346e0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c6b810ae-955b-4065-9b6b-9bcefc69b0dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b133af81-5289-48a1-a978-d4c02f81c0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6a855817-5ba0-42d7-a28b-7dc4ca7346e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b133af81-5289-48a1-a978-d4c02f81c0e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0db2ac59-70d3-4102-8321-244e5e300204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9d806a8d-71c0-4275-986c-e9c6085f5bc5" xlink:to="loc_us-gaap_Goodwill_0db2ac59-70d3-4102-8321-244e5e300204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d4b1329a-6e27-4e08-8ef8-f17f28c0fe35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9d806a8d-71c0-4275-986c-e9c6085f5bc5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d4b1329a-6e27-4e08-8ef8-f17f28c0fe35" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3d7e2db-40ed-4200-9348-f20b4b832b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d4b1329a-6e27-4e08-8ef8-f17f28c0fe35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3d7e2db-40ed-4200-9348-f20b4b832b3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3d7e2db-40ed-4200-9348-f20b4b832b3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3d7e2db-40ed-4200-9348-f20b4b832b3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3d7e2db-40ed-4200-9348-f20b4b832b3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fd3d7b1-1653-436a-90b6-5f63762eb401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3d7e2db-40ed-4200-9348-f20b4b832b3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fd3d7b1-1653-436a-90b6-5f63762eb401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AcquiredResearchAndDevelopmentMember_69ebf176-99f9-4b40-9f2e-9e0d77e7d505" xlink:href="insm-20220630.xsd#insm_AcquiredResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fd3d7b1-1653-436a-90b6-5f63762eb401" xlink:to="loc_insm_AcquiredResearchAndDevelopmentMember_69ebf176-99f9-4b40-9f2e-9e0d77e7d505" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8089bf5b-1908-4ff5-9847-f82eafaaeb08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fd3d7b1-1653-436a-90b6-5f63762eb401" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8089bf5b-1908-4ff5-9847-f82eafaaeb08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_3625347f-cc8f-4cc3-b6f2-f8b376b314a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fd3d7b1-1653-436a-90b6-5f63762eb401" xlink:to="loc_us-gaap_LicensingAgreementsMember_3625347f-cc8f-4cc3-b6f2-f8b376b314a5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#FixedAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:type="extended" id="i02e86a4e9201484396455b4bb303c053_FixedAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243b3064-d34a-402d-add7-217ee8d3380d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_94dd6f85-ef6e-4f4b-84aa-abb1d96c3806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243b3064-d34a-402d-add7-217ee8d3380d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_94dd6f85-ef6e-4f4b-84aa-abb1d96c3806" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7e597766-d05c-4a3c-a4a3-e0978a9ec172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243b3064-d34a-402d-add7-217ee8d3380d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7e597766-d05c-4a3c-a4a3-e0978a9ec172" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f5b43579-7350-487f-9355-4d88cd95e6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243b3064-d34a-402d-add7-217ee8d3380d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f5b43579-7350-487f-9355-4d88cd95e6bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8111203b-2457-4162-aed1-66b293c2d188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243b3064-d34a-402d-add7-217ee8d3380d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8111203b-2457-4162-aed1-66b293c2d188" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34cef78f-0f45-470d-8677-11c97fd1ace4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243b3064-d34a-402d-add7-217ee8d3380d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34cef78f-0f45-470d-8677-11c97fd1ace4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_beb64343-a6d6-4c60-a96d-1da7fb173a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34cef78f-0f45-470d-8677-11c97fd1ace4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_beb64343-a6d6-4c60-a96d-1da7fb173a81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_beb64343-a6d6-4c60-a96d-1da7fb173a81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_beb64343-a6d6-4c60-a96d-1da7fb173a81" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_beb64343-a6d6-4c60-a96d-1da7fb173a81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_beb64343-a6d6-4c60-a96d-1da7fb173a81" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_b746b407-8ca0-4dce-9266-f19c59ce3b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:to="loc_us-gaap_EquipmentMember_b746b407-8ca0-4dce-9266-f19c59ce3b42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_bc02a35a-6186-4b3b-9a42-256104052c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_bc02a35a-6186-4b3b-9a42-256104052c8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember_d30ecbfa-d183-4426-9b22-c5390eb5f97e" xlink:href="insm-20220630.xsd#insm_ComputerHardwareAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:to="loc_insm_ComputerHardwareAndSoftwareMember_d30ecbfa-d183-4426-9b22-c5390eb5f97e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_cc411871-3245-4156-be1c-917020623aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:to="loc_us-gaap_OfficeEquipmentMember_cc411871-3245-4156-be1c-917020623aed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ManufacturingEquipmentMember_ab889d68-510c-4cc3-b11c-79297be371c0" xlink:href="insm-20220630.xsd#insm_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:to="loc_insm_ManufacturingEquipmentMember_ab889d68-510c-4cc3-b11c-79297be371c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1d2dd8bc-a426-457e-a8e5-6faad48ebca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1d2dd8bc-a426-457e-a8e5-6faad48ebca6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_4f657990-f40d-4579-a5ce-7f663341bd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:to="loc_us-gaap_ConstructionInProgressMember_4f657990-f40d-4579-a5ce-7f663341bd0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_16a88eb1-aa12-41b1-ab71-469af39a28a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34cef78f-0f45-470d-8677-11c97fd1ace4" xlink:to="loc_srt_RangeAxis_16a88eb1-aa12-41b1-ab71-469af39a28a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_16a88eb1-aa12-41b1-ab71-469af39a28a3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_16a88eb1-aa12-41b1-ab71-469af39a28a3" xlink:to="loc_srt_RangeMember_16a88eb1-aa12-41b1-ab71-469af39a28a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8007cfb4-4f54-40b7-b7e4-86d0c8c3af6a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_16a88eb1-aa12-41b1-ab71-469af39a28a3" xlink:to="loc_srt_RangeMember_8007cfb4-4f54-40b7-b7e4-86d0c8c3af6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_617994f4-2afa-4743-b985-0b5486e8521e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8007cfb4-4f54-40b7-b7e4-86d0c8c3af6a" xlink:to="loc_srt_MinimumMember_617994f4-2afa-4743-b985-0b5486e8521e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5d9a1be3-56fb-4d0e-94d7-052880af8130" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8007cfb4-4f54-40b7-b7e4-86d0c8c3af6a" xlink:to="loc_srt_MaximumMember_5d9a1be3-56fb-4d0e-94d7-052880af8130" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i3b9cb310b3ea4ba282ecd30937b17dd4_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1ece60d-1a19-4d2c-90c8-1d0eb18b4a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LeaseRemainingLeaseTerm_a1935f61-15ed-4e31-a291-e79cacd4521c" xlink:href="insm-20220630.xsd#insm_LeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1ece60d-1a19-4d2c-90c8-1d0eb18b4a8b" xlink:to="loc_insm_LeaseRemainingLeaseTerm_a1935f61-15ed-4e31-a291-e79cacd4521c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_cf118c0b-be9d-4f33-84ef-18ba02c13011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1ece60d-1a19-4d2c-90c8-1d0eb18b4a8b" xlink:to="loc_us-gaap_VariableLeaseCost_cf118c0b-be9d-4f33-84ef-18ba02c13011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount_cdc28448-ec6d-4a4b-83e7-0b924a0e5925" xlink:href="insm-20220630.xsd#insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1ece60d-1a19-4d2c-90c8-1d0eb18b4a8b" xlink:to="loc_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount_cdc28448-ec6d-4a4b-83e7-0b924a0e5925" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_508a38d1-da47-4033-ac13-3876f4083645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1ece60d-1a19-4d2c-90c8-1d0eb18b4a8b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_508a38d1-da47-4033-ac13-3876f4083645" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f353e1fb-ab87-4c5f-8b00-20e5e240414d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_508a38d1-da47-4033-ac13-3876f4083645" xlink:to="loc_srt_RangeAxis_f353e1fb-ab87-4c5f-8b00-20e5e240414d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f353e1fb-ab87-4c5f-8b00-20e5e240414d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f353e1fb-ab87-4c5f-8b00-20e5e240414d" xlink:to="loc_srt_RangeMember_f353e1fb-ab87-4c5f-8b00-20e5e240414d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a38211cb-0f28-4db8-b8f1-95432fde9ab1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f353e1fb-ab87-4c5f-8b00-20e5e240414d" xlink:to="loc_srt_RangeMember_a38211cb-0f28-4db8-b8f1-95432fde9ab1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_febb1ef5-bebb-423a-88bf-3f11d1efebe5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a38211cb-0f28-4db8-b8f1-95432fde9ab1" xlink:to="loc_srt_MinimumMember_febb1ef5-bebb-423a-88bf-3f11d1efebe5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8b00c53c-bf3b-4bc7-997f-4f18679a6602" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a38211cb-0f28-4db8-b8f1-95432fde9ab1" xlink:to="loc_srt_MaximumMember_8b00c53c-bf3b-4bc7-997f-4f18679a6602" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtNarrativeDetails" xlink:type="extended" id="if719b1ac2ccc45fb9ec4f5f3ae3d3dea_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ae626a75-71d8-4e32-8737-6eec44b4b9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ae626a75-71d8-4e32-8737-6eec44b4b9b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_4200d377-0fcc-4129-b884-c5ab45b0dd1d" xlink:href="insm-20220630.xsd#insm_DebtInstrumentOptionToPurchaseAdditionalDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_4200d377-0fcc-4129-b884-c5ab45b0dd1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_0c9c262e-b66a-41d4-b401-7de4a9125cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_0c9c262e-b66a-41d4-b401-7de4a9125cf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_ebdfd548-0d45-4349-bc0f-696da2be2a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_ebdfd548-0d45-4349-bc0f-696da2be2a6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_26284758-c21f-4077-b145-58e0a8cda842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_26284758-c21f-4077-b145-58e0a8cda842" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d2da896d-6249-4076-93af-1d4b3599bf25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d2da896d-6249-4076-93af-1d4b3599bf25" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_300304bb-5a64-49a1-b3c0-a9aec8e25bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_300304bb-5a64-49a1-b3c0-a9aec8e25bf3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7fa708d4-0155-44e0-830b-1d82061f6eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7fa708d4-0155-44e0-830b-1d82061f6eb9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5815ebb4-1c0b-44fd-9ddc-29f792af8c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5815ebb4-1c0b-44fd-9ddc-29f792af8c52" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_574f74cb-14d3-413e-bb9c-e0eabb5707f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_574f74cb-14d3-413e-bb9c-e0eabb5707f3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_1b3362e3-28ae-4eac-81bb-50bbaa2dec0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_1b3362e3-28ae-4eac-81bb-50bbaa2dec0e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_9b2a5c58-9c39-441b-b8a7-ffbd0473c06e" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_9b2a5c58-9c39-441b-b8a7-ffbd0473c06e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining_fbd764c6-79fd-4b1b-aff6-f4bb67b4b199" xlink:href="insm-20220630.xsd#insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining_fbd764c6-79fd-4b1b-aff6-f4bb67b4b199" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_07accd24-e37b-4f63-a83e-3d3f14f597cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DebtInstrumentTable_07accd24-e37b-4f63-a83e-3d3f14f597cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bfc6a203-ac89-43d1-88cd-cbdb4a931ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_07accd24-e37b-4f63-a83e-3d3f14f597cd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bfc6a203-ac89-43d1-88cd-cbdb4a931ec5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bfc6a203-ac89-43d1-88cd-cbdb4a931ec5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfc6a203-ac89-43d1-88cd-cbdb4a931ec5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bfc6a203-ac89-43d1-88cd-cbdb4a931ec5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c230224f-d008-4bcf-ac73-941c31f635d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfc6a203-ac89-43d1-88cd-cbdb4a931ec5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c230224f-d008-4bcf-ac73-941c31f635d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_dfb8ae97-ad53-454c-bfea-3c7984879769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c230224f-d008-4bcf-ac73-941c31f635d4" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_dfb8ae97-ad53-454c-bfea-3c7984879769" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0452000e-eaad-4c96-b829-a0b79d37dae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_07accd24-e37b-4f63-a83e-3d3f14f597cd" xlink:to="loc_us-gaap_DebtInstrumentAxis_0452000e-eaad-4c96-b829-a0b79d37dae0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0452000e-eaad-4c96-b829-a0b79d37dae0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0452000e-eaad-4c96-b829-a0b79d37dae0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0452000e-eaad-4c96-b829-a0b79d37dae0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2b5fc68f-06fb-425c-8abf-e613502fdae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0452000e-eaad-4c96-b829-a0b79d37dae0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2b5fc68f-06fb-425c-8abf-e613502fdae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_ccf72e0a-c41c-4c10-b87b-66e4b7eaf6c6" xlink:href="insm-20220630.xsd#insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2b5fc68f-06fb-425c-8abf-e613502fdae2" xlink:to="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_ccf72e0a-c41c-4c10-b87b-66e4b7eaf6c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_0ac2a693-4bec-4861-8300-13f1d65d6174" xlink:href="insm-20220630.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2b5fc68f-06fb-425c-8abf-e613502fdae2" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_0ac2a693-4bec-4861-8300-13f1d65d6174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermAxis_622c5801-7732-4b3e-a134-74f3c10b0b94" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_07accd24-e37b-4f63-a83e-3d3f14f597cd" xlink:to="loc_insm_DebtInstrumentConversionTermAxis_622c5801-7732-4b3e-a134-74f3c10b0b94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_622c5801-7732-4b3e-a134-74f3c10b0b94_default" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_622c5801-7732-4b3e-a134-74f3c10b0b94" xlink:to="loc_insm_DebtInstrumentConversionTermDomain_622c5801-7732-4b3e-a134-74f3c10b0b94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_2a283175-9a9f-483e-9af4-a1d3e8ba1c0a" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_622c5801-7732-4b3e-a134-74f3c10b0b94" xlink:to="loc_insm_DebtInstrumentConversionTermDomain_2a283175-9a9f-483e-9af4-a1d3e8ba1c0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermOneMember_f7cbd67d-5995-47e8-8d15-d6668d42ce8a" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_2a283175-9a9f-483e-9af4-a1d3e8ba1c0a" xlink:to="loc_insm_DebtInstrumentConversionTermOneMember_f7cbd67d-5995-47e8-8d15-d6668d42ce8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermTwoMember_6792b35e-7647-4295-83c0-a8f67792543a" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_2a283175-9a9f-483e-9af4-a1d3e8ba1c0a" xlink:to="loc_insm_DebtInstrumentConversionTermTwoMember_6792b35e-7647-4295-83c0-a8f67792543a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermThreeMember_db9e7b73-5c33-40bd-b747-74721ac250f6" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_2a283175-9a9f-483e-9af4-a1d3e8ba1c0a" xlink:to="loc_insm_DebtInstrumentConversionTermThreeMember_db9e7b73-5c33-40bd-b747-74721ac250f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermFourMember_3de3d1de-b8e4-4daa-afc9-604cb96ab9d2" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_2a283175-9a9f-483e-9af4-a1d3e8ba1c0a" xlink:to="loc_insm_DebtInstrumentConversionTermFourMember_3de3d1de-b8e4-4daa-afc9-604cb96ab9d2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended" id="i891bb8c9186947eab00af275fbc86e60_ShareholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4a540f1d-9425-4a4a-8865-fffbbcb864ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4a540f1d-9425-4a4a-8865-fffbbcb864ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_13b3953c-0486-4a89-b376-2941c39696e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_13b3953c-0486-4a89-b376-2941c39696e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_788814c8-a9c3-47c6-a64e-3598f4f261be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_CommonStockSharesIssued_788814c8-a9c3-47c6-a64e-3598f4f261be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e52fb68e-aeee-4a1e-936d-170274080665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e52fb68e-aeee-4a1e-936d-170274080665" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dd411ad0-45df-4b04-b25a-d34d2cdb6e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dd411ad0-45df-4b04-b25a-d34d2cdb6e16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0d8deae2-b5a5-4e75-8c81-052c4a4c29ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0d8deae2-b5a5-4e75-8c81-052c4a4c29ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_30330c4f-554e-46eb-9525-f3f84880740d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_30330c4f-554e-46eb-9525-f3f84880740d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0d55bc1b-25d3-47b5-99bb-80aaaa2a2407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0d55bc1b-25d3-47b5-99bb-80aaaa2a2407" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e57b62d0-17fc-4317-b491-cc565f98a176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e57b62d0-17fc-4317-b491-cc565f98a176" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_09ec1f04-7447-402d-8d26-109c271fb3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_09ec1f04-7447-402d-8d26-109c271fb3e4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommonStockAuthorizedAggregateGrossSalesProceeds_5248742f-55b3-4c7c-8039-ba33b2fe67be" xlink:href="insm-20220630.xsd#insm_CommonStockAuthorizedAggregateGrossSalesProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_insm_CommonStockAuthorizedAggregateGrossSalesProceeds_5248742f-55b3-4c7c-8039-ba33b2fe67be" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f519f2a1-6b53-4329-b129-1cc3a3b320aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f519f2a1-6b53-4329-b129-1cc3a3b320aa" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_492e0d76-3478-4a08-8f76-6952e7c076ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_492e0d76-3478-4a08-8f76-6952e7c076ae" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7b1db8f6-9eca-46b3-949d-e523b0e620ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7b1db8f6-9eca-46b3-949d-e523b0e620ed" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f8cd3216-5531-44f4-bda2-3dd5adcec146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f8cd3216-5531-44f4-bda2-3dd5adcec146" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_798d49b7-00f2-41be-bc89-94ec482d6957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_798d49b7-00f2-41be-bc89-94ec482d6957" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3ac1a4ee-a908-4e89-83f7-ba2d26ed7ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_798d49b7-00f2-41be-bc89-94ec482d6957" xlink:to="loc_us-gaap_AwardTypeAxis_3ac1a4ee-a908-4e89-83f7-ba2d26ed7ed0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ac1a4ee-a908-4e89-83f7-ba2d26ed7ed0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3ac1a4ee-a908-4e89-83f7-ba2d26ed7ed0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ac1a4ee-a908-4e89-83f7-ba2d26ed7ed0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_afa9071a-6f49-498e-96f5-12bc6604d20a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3ac1a4ee-a908-4e89-83f7-ba2d26ed7ed0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_afa9071a-6f49-498e-96f5-12bc6604d20a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_24247904-6e71-49e1-8464-16237ab0ac29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_afa9071a-6f49-498e-96f5-12bc6604d20a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_24247904-6e71-49e1-8464-16237ab0ac29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_aa13a182-d397-4d37-b650-a2aebdb5c72a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_afa9071a-6f49-498e-96f5-12bc6604d20a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_aa13a182-d397-4d37-b650-a2aebdb5c72a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_8111e6c7-871d-47ff-9758-045d2060ccde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_afa9071a-6f49-498e-96f5-12bc6604d20a" xlink:to="loc_us-gaap_PerformanceSharesMember_8111e6c7-871d-47ff-9758-045d2060ccde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_532f2e14-7299-4bbe-bc23-abba08d7cd18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_798d49b7-00f2-41be-bc89-94ec482d6957" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_532f2e14-7299-4bbe-bc23-abba08d7cd18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_532f2e14-7299-4bbe-bc23-abba08d7cd18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_532f2e14-7299-4bbe-bc23-abba08d7cd18" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_532f2e14-7299-4bbe-bc23-abba08d7cd18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_41e3d6e5-86d5-42b0-b8c5-3bf7fd19b57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_532f2e14-7299-4bbe-bc23-abba08d7cd18" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_41e3d6e5-86d5-42b0-b8c5-3bf7fd19b57f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_03ceec7a-98a7-4c8c-b602-3bd7d035bb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_41e3d6e5-86d5-42b0-b8c5-3bf7fd19b57f" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_03ceec7a-98a7-4c8c-b602-3bd7d035bb5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ddbe99fc-02ba-4cb2-ba1d-9f6d8a2b06ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_798d49b7-00f2-41be-bc89-94ec482d6957" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ddbe99fc-02ba-4cb2-ba1d-9f6d8a2b06ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ddbe99fc-02ba-4cb2-ba1d-9f6d8a2b06ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ddbe99fc-02ba-4cb2-ba1d-9f6d8a2b06ab" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ddbe99fc-02ba-4cb2-ba1d-9f6d8a2b06ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_21536ad2-e43d-4fd8-bf3a-40c035f5022b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ddbe99fc-02ba-4cb2-ba1d-9f6d8a2b06ab" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_21536ad2-e43d-4fd8-bf3a-40c035f5022b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PublicStockOfferingMember_f669421d-2f59-4d90-a04c-f77357505aa8" xlink:href="insm-20220630.xsd#insm_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_21536ad2-e43d-4fd8-bf3a-40c035f5022b" xlink:to="loc_insm_PublicStockOfferingMember_f669421d-2f59-4d90-a04c-f77357505aa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_ecd3e61f-e4c8-4cfa-a824-2899f41c9884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_21536ad2-e43d-4fd8-bf3a-40c035f5022b" xlink:to="loc_us-gaap_OverAllotmentOptionMember_ecd3e61f-e4c8-4cfa-a824-2899f41c9884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AtTheMarketAgreementMember_236fabba-6054-439e-bf38-f755b1acc3f2" xlink:href="insm-20220630.xsd#insm_AtTheMarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_21536ad2-e43d-4fd8-bf3a-40c035f5022b" xlink:to="loc_insm_AtTheMarketAgreementMember_236fabba-6054-439e-bf38-f755b1acc3f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c7f15337-b67c-44ab-9727-3113bc8e9629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_798d49b7-00f2-41be-bc89-94ec482d6957" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c7f15337-b67c-44ab-9727-3113bc8e9629" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c7f15337-b67c-44ab-9727-3113bc8e9629_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c7f15337-b67c-44ab-9727-3113bc8e9629" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c7f15337-b67c-44ab-9727-3113bc8e9629_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0d03e04f-fde7-4b01-8318-cc144e9b94f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c7f15337-b67c-44ab-9727-3113bc8e9629" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0d03e04f-fde7-4b01-8318-cc144e9b94f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncMember_b377dc7b-f3d5-402c-90fb-ed77fc54213e" xlink:href="insm-20220630.xsd#insm_MotusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0d03e04f-fde7-4b01-8318-cc144e9b94f5" xlink:to="loc_insm_MotusBiosciencesIncMember_b377dc7b-f3d5-402c-90fb-ed77fc54213e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="ic05c753b310f440691bb1a06fa9c39f9_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ad32ff4e-67fe-453a-b34a-a34b0860e272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ad32ff4e-67fe-453a-b34a-a34b0860e272" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b1efbbba-9624-4109-91df-c0eb0b51ba27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b1efbbba-9624-4109-91df-c0eb0b51ba27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22d5f517-0b93-4151-8cd9-7a784ec3f362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22d5f517-0b93-4151-8cd9-7a784ec3f362" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_3ed09ccf-8b08-4a6f-a7fe-7dafb33a291a" xlink:href="insm-20220630.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_3ed09ccf-8b08-4a6f-a7fe-7dafb33a291a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_df7be340-1124-4aff-8f09-a5ab621bca4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_df7be340-1124-4aff-8f09-a5ab621bca4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4d4aa120-9efa-42bd-9bf8-a5947e736dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4d4aa120-9efa-42bd-9bf8-a5947e736dfd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9964ad1a-dadd-4fdc-ac09-b6220aa53c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9964ad1a-dadd-4fdc-ac09-b6220aa53c66" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_319a6c93-71bc-40ea-80fd-6c32b523bec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_319a6c93-71bc-40ea-80fd-6c32b523bec5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d7e16f52-defc-4c46-8856-1d12da726b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d7e16f52-defc-4c46-8856-1d12da726b82" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_871384a3-ba0b-4c3d-967b-d2caa3b97d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_871384a3-ba0b-4c3d-967b-d2caa3b97d38" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a4d79250-fc83-4b48-9bf1-34a5cdd97a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a4d79250-fc83-4b48-9bf1-34a5cdd97a81" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e0b751c2-2472-4993-a788-bb4dd37514f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e0b751c2-2472-4993-a788-bb4dd37514f1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1377e57f-8c78-4b6c-ad45-9ca12ec46184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1377e57f-8c78-4b6c-ad45-9ca12ec46184" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ea94d067-18e1-47ab-bdcf-ff87a02a831e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ea94d067-18e1-47ab-bdcf-ff87a02a831e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2d256575-d5b8-4f68-b6d9-1f1daf34ba8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2d256575-d5b8-4f68-b6d9-1f1daf34ba8e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72daae71-e379-4945-a919-48d9f8bb6b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72daae71-e379-4945-a919-48d9f8bb6b9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9d3aed09-0fcd-4d84-bc65-d792d5e6de1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72daae71-e379-4945-a919-48d9f8bb6b9c" xlink:to="loc_us-gaap_PlanNameAxis_9d3aed09-0fcd-4d84-bc65-d792d5e6de1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9d3aed09-0fcd-4d84-bc65-d792d5e6de1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9d3aed09-0fcd-4d84-bc65-d792d5e6de1b" xlink:to="loc_us-gaap_PlanNameDomain_9d3aed09-0fcd-4d84-bc65-d792d5e6de1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c2ab39f3-eaad-40cb-8e26-a287e5b19e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9d3aed09-0fcd-4d84-bc65-d792d5e6de1b" xlink:to="loc_us-gaap_PlanNameDomain_c2ab39f3-eaad-40cb-8e26-a287e5b19e3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2019IncentivePlanThirdAmendmentMember_29d03182-1bb5-4890-a5b1-44dc034163f9" xlink:href="insm-20220630.xsd#insm_A2019IncentivePlanThirdAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c2ab39f3-eaad-40cb-8e26-a287e5b19e3b" xlink:to="loc_insm_A2019IncentivePlanThirdAmendmentMember_29d03182-1bb5-4890-a5b1-44dc034163f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2019IncentivePlanSecondAmendmentMember_f32af6b1-516d-4b25-95c1-dc15c532b15e" xlink:href="insm-20220630.xsd#insm_A2019IncentivePlanSecondAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c2ab39f3-eaad-40cb-8e26-a287e5b19e3b" xlink:to="loc_insm_A2019IncentivePlanSecondAmendmentMember_f32af6b1-516d-4b25-95c1-dc15c532b15e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EmployeeStockPurchasePlan2018Member_a47f323d-b872-4dca-8ed7-2deca6b1b3fe" xlink:href="insm-20220630.xsd#insm_EmployeeStockPurchasePlan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c2ab39f3-eaad-40cb-8e26-a287e5b19e3b" xlink:to="loc_insm_EmployeeStockPurchasePlan2018Member_a47f323d-b872-4dca-8ed7-2deca6b1b3fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b6d532ef-0ea5-4635-a2f9-c028c0a2fcab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72daae71-e379-4945-a919-48d9f8bb6b9c" xlink:to="loc_us-gaap_AwardTypeAxis_b6d532ef-0ea5-4635-a2f9-c028c0a2fcab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6d532ef-0ea5-4635-a2f9-c028c0a2fcab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b6d532ef-0ea5-4635-a2f9-c028c0a2fcab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6d532ef-0ea5-4635-a2f9-c028c0a2fcab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f7804bd-4237-4a42-a4b8-150f85c12223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b6d532ef-0ea5-4635-a2f9-c028c0a2fcab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f7804bd-4237-4a42-a4b8-150f85c12223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3678f620-9d40-41e3-907e-897aca46f421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f7804bd-4237-4a42-a4b8-150f85c12223" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3678f620-9d40-41e3-907e-897aca46f421" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_43d8902d-9608-4e36-86a1-17de914e18ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f7804bd-4237-4a42-a4b8-150f85c12223" xlink:to="loc_us-gaap_PerformanceSharesMember_43d8902d-9608-4e36-86a1-17de914e18ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8be88ace-d6c1-4121-9cef-bc4c5f6b9b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f7804bd-4237-4a42-a4b8-150f85c12223" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8be88ace-d6c1-4121-9cef-bc4c5f6b9b60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_082f9287-761c-4f7b-895f-3f6bdd377edf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72daae71-e379-4945-a919-48d9f8bb6b9c" xlink:to="loc_srt_RangeAxis_082f9287-761c-4f7b-895f-3f6bdd377edf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_082f9287-761c-4f7b-895f-3f6bdd377edf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_082f9287-761c-4f7b-895f-3f6bdd377edf" xlink:to="loc_srt_RangeMember_082f9287-761c-4f7b-895f-3f6bdd377edf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f3354906-81ba-461f-b242-4085967a4a74" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_082f9287-761c-4f7b-895f-3f6bdd377edf" xlink:to="loc_srt_RangeMember_f3354906-81ba-461f-b242-4085967a4a74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e59c0c69-86ba-4f02-b348-73c5b3f298da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f3354906-81ba-461f-b242-4085967a4a74" xlink:to="loc_srt_MinimumMember_e59c0c69-86ba-4f02-b348-73c5b3f298da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_137206dc-0acb-4ff1-b394-b8da47044a4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f3354906-81ba-461f-b242-4085967a4a74" xlink:to="loc_srt_MaximumMember_137206dc-0acb-4ff1-b394-b8da47044a4b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended" id="i54957ca2032d4ea5842c18e926b71ea1_StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_974aed95-2d21-404c-b4fa-3b28da38048e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3bf72b8d-eba4-49ab-8547-46ce3960d726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_974aed95-2d21-404c-b4fa-3b28da38048e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3bf72b8d-eba4-49ab-8547-46ce3960d726" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8319b83e-601e-4da9-a088-928f15366316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_974aed95-2d21-404c-b4fa-3b28da38048e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8319b83e-601e-4da9-a088-928f15366316" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c06efc81-fe13-44d7-9b2f-0bd08a1d1810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8319b83e-601e-4da9-a088-928f15366316" xlink:to="loc_us-gaap_AwardTypeAxis_c06efc81-fe13-44d7-9b2f-0bd08a1d1810" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c06efc81-fe13-44d7-9b2f-0bd08a1d1810_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c06efc81-fe13-44d7-9b2f-0bd08a1d1810" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c06efc81-fe13-44d7-9b2f-0bd08a1d1810_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e8d5e60-49cd-44a9-a942-134ffa92b271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c06efc81-fe13-44d7-9b2f-0bd08a1d1810" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e8d5e60-49cd-44a9-a942-134ffa92b271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember_99ef1cee-991c-473f-b61f-6f93786850c6" xlink:href="insm-20220630.xsd#insm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e8d5e60-49cd-44a9-a942-134ffa92b271" xlink:to="loc_insm_StockOptionsAndRestrictedStockUnitsMember_99ef1cee-991c-473f-b61f-6f93786850c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_24ba6b64-08b8-4948-a43f-c3e5b752bd41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8319b83e-601e-4da9-a088-928f15366316" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_24ba6b64-08b8-4948-a43f-c3e5b752bd41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_24ba6b64-08b8-4948-a43f-c3e5b752bd41_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24ba6b64-08b8-4948-a43f-c3e5b752bd41" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_24ba6b64-08b8-4948-a43f-c3e5b752bd41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_db0ff62a-dc6c-4f8e-8137-00b3bfa649ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24ba6b64-08b8-4948-a43f-c3e5b752bd41" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_db0ff62a-dc6c-4f8e-8137-00b3bfa649ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_61b8b72d-87cc-4136-8041-98b412dae4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db0ff62a-dc6c-4f8e-8137-00b3bfa649ad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_61b8b72d-87cc-4136-8041-98b412dae4ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1e08546e-99ce-4681-8f58-da937362a2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db0ff62a-dc6c-4f8e-8137-00b3bfa649ad" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1e08546e-99ce-4681-8f58-da937362a2f4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#BusinessAcquisitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails" xlink:type="extended" id="i3b06ef4b5c914479a58501a5606fe198_BusinessAcquisitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_b8b2436f-c015-4afd-a051-de279879051b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_b8b2436f-c015-4afd-a051-de279879051b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_67ac0578-32b9-41d7-b2de-7f703411ad0e" xlink:href="insm-20220630.xsd#insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:to="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_67ac0578-32b9-41d7-b2de-7f703411ad0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a268d7b1-b6bf-404d-a575-ff0f13a1b78e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a268d7b1-b6bf-404d-a575-ff0f13a1b78e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f06ad81a-8b18-41d2-85c7-5532a12b3ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f06ad81a-8b18-41d2-85c7-5532a12b3ebf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_a0d7ee05-7aaf-4667-8f85-c512f5677d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_a0d7ee05-7aaf-4667-8f85-c512f5677d8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessAcquisitionConsecutiveTradingDayPeriod_497b18d3-a961-43ed-9d6c-156d0e873574" xlink:href="insm-20220630.xsd#insm_BusinessAcquisitionConsecutiveTradingDayPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:to="loc_insm_BusinessAcquisitionConsecutiveTradingDayPeriod_497b18d3-a961-43ed-9d6c-156d0e873574" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2389e514-aa56-4438-a4bf-18df92b6be3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2389e514-aa56-4438-a4bf-18df92b6be3c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4135a7f6-fc82-4b06-a90b-358efd4b6065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4135a7f6-fc82-4b06-a90b-358efd4b6065" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ff3c8b4c-9be1-427d-92a9-655afc958081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4135a7f6-fc82-4b06-a90b-358efd4b6065" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ff3c8b4c-9be1-427d-92a9-655afc958081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ff3c8b4c-9be1-427d-92a9-655afc958081_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ff3c8b4c-9be1-427d-92a9-655afc958081" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ff3c8b4c-9be1-427d-92a9-655afc958081_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f3e537b-a0f1-49cf-8617-ecb0613279a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ff3c8b4c-9be1-427d-92a9-655afc958081" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f3e537b-a0f1-49cf-8617-ecb0613279a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember_4a3e7c97-21ad-4d2e-99b4-de7b13100cd3" xlink:href="insm-20220630.xsd#insm_MotusBiosciencesIncAndAlgaeneXIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f3e537b-a0f1-49cf-8617-ecb0613279a6" xlink:to="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember_4a3e7c97-21ad-4d2e-99b4-de7b13100cd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncMember_c38ab139-3364-4ca2-a029-b2f474be3ff0" xlink:href="insm-20220630.xsd#insm_MotusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember_4a3e7c97-21ad-4d2e-99b4-de7b13100cd3" xlink:to="loc_insm_MotusBiosciencesIncMember_c38ab139-3364-4ca2-a029-b2f474be3ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AlgaeneXIncMember_62f4c204-3ad4-4d8b-aa0e-0e7d132cd2d2" xlink:href="insm-20220630.xsd#insm_AlgaeneXIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember_4a3e7c97-21ad-4d2e-99b4-de7b13100cd3" xlink:to="loc_insm_AlgaeneXIncMember_62f4c204-3ad4-4d8b-aa0e-0e7d132cd2d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_43067f28-b127-4616-85d6-0ce759f58415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4135a7f6-fc82-4b06-a90b-358efd4b6065" xlink:to="loc_us-gaap_VestingAxis_43067f28-b127-4616-85d6-0ce759f58415" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_43067f28-b127-4616-85d6-0ce759f58415_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_43067f28-b127-4616-85d6-0ce759f58415" xlink:to="loc_us-gaap_VestingDomain_43067f28-b127-4616-85d6-0ce759f58415_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_0c23a903-a8bb-4fdc-b4af-e4aa97db978f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_43067f28-b127-4616-85d6-0ce759f58415" xlink:to="loc_us-gaap_VestingDomain_0c23a903-a8bb-4fdc-b4af-e4aa97db978f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f4f66f8a-bbd9-4feb-8cd4-e532a02cfe84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_0c23a903-a8bb-4fdc-b4af-e4aa97db978f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f4f66f8a-bbd9-4feb-8cd4-e532a02cfe84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c6c911cc-061d-4563-8906-d47daef47df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_0c23a903-a8bb-4fdc-b4af-e4aa97db978f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c6c911cc-061d-4563-8906-d47daef47df2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_db6897e8-7d6e-4aee-af6b-082b38eef599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_0c23a903-a8bb-4fdc-b4af-e4aa97db978f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_db6897e8-7d6e-4aee-af6b-082b38eef599" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>insm-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f29bbe7c-3fe7-4edc-bd43-5e98e923844d,g:47f91642-8422-4809-9855-6a3312b42bf8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_insm_NoncashOperatingLeaseExpense_550f4fe8-ea62-4141-b9df-e27c68e1af7e_terseLabel_en-US" xlink:label="lab_insm_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash operating lease expense</link:label>
    <link:label id="lab_insm_NoncashOperatingLeaseExpense_label_en-US" xlink:label="lab_insm_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Operating Lease Expense</link:label>
    <link:label id="lab_insm_NoncashOperatingLeaseExpense_documentation_en-US" xlink:label="lab_insm_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Operating Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NoncashOperatingLeaseExpense" xlink:href="insm-20220630.xsd#insm_NoncashOperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_NoncashOperatingLeaseExpense" xlink:to="lab_insm_NoncashOperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_648a6c45-42db-4227-83e4-cd58c920cdad_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_052b3da9-d0dc-478f-ad04-b08128cceea4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CustomerAMember_1d3fa50d-770d-4e09-825e-1d4ab2860208_terseLabel_en-US" xlink:label="lab_insm_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_insm_CustomerAMember_label_en-US" xlink:label="lab_insm_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_insm_CustomerAMember_documentation_en-US" xlink:label="lab_insm_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerAMember" xlink:href="insm-20220630.xsd#insm_CustomerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CustomerAMember" xlink:to="lab_insm_CustomerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_281eee89-dbd6-482f-83d4-764039de646b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_83b35193-8bd9-478a-8cfb-dd1c397a89be_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConversionTermAxis_7f91d4c3-36ed-49d6-827b-ca5767b8103a_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermAxis_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermAxis_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermAxis" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermAxis" xlink:to="lab_insm_DebtInstrumentConversionTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_EuropeAndTheRestOfTheWorldMember_938b4679-db70-4fa2-a490-7a18e3f18fa7_terseLabel_en-US" xlink:label="lab_insm_EuropeAndTheRestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe And The Rest Of The World</link:label>
    <link:label id="lab_insm_EuropeAndTheRestOfTheWorldMember_label_en-US" xlink:label="lab_insm_EuropeAndTheRestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe And The Rest Of The World [Member]</link:label>
    <link:label id="lab_insm_EuropeAndTheRestOfTheWorldMember_documentation_en-US" xlink:label="lab_insm_EuropeAndTheRestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe And The Rest Of The World</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EuropeAndTheRestOfTheWorldMember" xlink:href="insm-20220630.xsd#insm_EuropeAndTheRestOfTheWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_EuropeAndTheRestOfTheWorldMember" xlink:to="lab_insm_EuropeAndTheRestOfTheWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DeferredConsiderationMember_dd75da5a-7507-4d32-8e9f-1d4925b55133_terseLabel_en-US" xlink:label="lab_insm_DeferredConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Consideration</link:label>
    <link:label id="lab_insm_DeferredConsiderationMember_label_en-US" xlink:label="lab_insm_DeferredConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Consideration [Member]</link:label>
    <link:label id="lab_insm_DeferredConsiderationMember_documentation_en-US" xlink:label="lab_insm_DeferredConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredConsiderationMember" xlink:href="insm-20220630.xsd#insm_DeferredConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DeferredConsiderationMember" xlink:to="lab_insm_DeferredConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_0a402969-93e7-4a40-b316-201f2bf7eeb1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_60f6a2b9-615e-4376-ad97-f39e3b050896_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d63c56ec-b990-4a70-8efe-957122d6ea69_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_30a3c506-5c1b-4ea8-b022-3c5b44656765_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations and Asset Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_6e70c8ea-3861-4fb0-bbf7-fc37c3ce67eb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_d734292a-bd12-42d4-af03-582c0f7efad3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_0c76bee1-ffa5-4566-81db-a44f0dcdaf93_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_781c73ef-b3bd-4b1e-81cd-2fc4947539bb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible List]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_a2781ec0-2177-4796-9bae-c20ce997d3e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d7ae8cfe-2e72-4773-8120-e4589c6caddb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConversionTermDomain_a7341f77-430a-4b7b-9428-1a5b6e7568cd_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term [Domain]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermDomain_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term [Domain]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermDomain_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Debt Instrument Conversion Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermDomain" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermDomain" xlink:to="lab_insm_DebtInstrumentConversionTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1fa6aa9b-0c8f-4c63-8191-eddc77144a00_terseLabel_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_label_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_documentation_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:href="insm-20220630.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:to="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_1c909d95-25dc-407a-84eb-0eec005985b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_aed7129b-8a76-4ae9-a748-e44996242f52_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_d0b4e7e1-f986-4cbf-86bc-1d76451cbd3a_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_b9274fb9-f80a-49fe-8c4a-763e568468ad_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for vesting of RSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_05c00383-13b5-4ee7-b405-af5625ff1e6f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7da942e0-945a-4e96-aee1-c9a124c32b4d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of 0.75% convertible senior notes due 2028</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_MeasurementInputProbabilityOfSuccessMember_8b95afe1-e80f-402c-aac1-22e442d8dbaa_terseLabel_en-US" xlink:label="lab_insm_MeasurementInputProbabilityOfSuccessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probabilities of success</link:label>
    <link:label id="lab_insm_MeasurementInputProbabilityOfSuccessMember_label_en-US" xlink:label="lab_insm_MeasurementInputProbabilityOfSuccessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Success [Member]</link:label>
    <link:label id="lab_insm_MeasurementInputProbabilityOfSuccessMember_documentation_en-US" xlink:label="lab_insm_MeasurementInputProbabilityOfSuccessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Success</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MeasurementInputProbabilityOfSuccessMember" xlink:href="insm-20220630.xsd#insm_MeasurementInputProbabilityOfSuccessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MeasurementInputProbabilityOfSuccessMember" xlink:to="lab_insm_MeasurementInputProbabilityOfSuccessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a7563cf1-adb2-450c-baff-b54d220f3ef2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d0786a56-c202-4440-bc79-8cd3fa665276_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_27a99716-cd9b-4464-b818-a69d68782554_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_0481765c-0051-4fb7-8f78-c1da2c8617a3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4206b4f2-5042-4073-ac04-5d14309dca02_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_c3648a94-8686-460e-9d63-e92c26fde6bc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b0885cab-2f73-4c83-9388-b9a6d6dba6b8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_3ebdbc7f-940a-4a34-aee6-fbfc92e3e2cd_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebt_699df36c-ff91-47c8-81a2-712d3a1df1a2_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face value of outstanding convertible notes</link:label>
    <link:label id="lab_us-gaap_SecuredDebt_label_en-US" xlink:label="lab_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebt" xlink:to="lab_us-gaap_SecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_8e38014a-8b48-4ca1-948d-8f3666fa653b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Principal Repayments of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0238d575-e199-4d1e-a43f-528f38dab86f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_a0de9c53-cf60-4839-813e-7ee15a9361af_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_BusinessCombinationDeferredPaymentsCurrent_d136cd11-967a-4697-a9e9-c398c78e3211_terseLabel_en-US" xlink:label="lab_insm_BusinessCombinationDeferredPaymentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred consideration</link:label>
    <link:label id="lab_insm_BusinessCombinationDeferredPaymentsCurrent_label_en-US" xlink:label="lab_insm_BusinessCombinationDeferredPaymentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Deferred Payments, Current</link:label>
    <link:label id="lab_insm_BusinessCombinationDeferredPaymentsCurrent_documentation_en-US" xlink:label="lab_insm_BusinessCombinationDeferredPaymentsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Deferred Payments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredPaymentsCurrent" xlink:href="insm-20220630.xsd#insm_BusinessCombinationDeferredPaymentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_BusinessCombinationDeferredPaymentsCurrent" xlink:to="lab_insm_BusinessCombinationDeferredPaymentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_f4c5aa68-a9e4-4f72-aa37-ae9b670edacc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_264c8838-7f04-472c-98e6-c474f1b67551_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease amortization expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_4402bc2a-4ea2-470b-9515-8c7e199d8078_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_1fbf222a-5eb1-46eb-8e5b-ba4495b3faf7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_84ca4218-ec82-4da9-9247-0eb6aae51089_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_81af29a8-9513-4cc2-9f32-873ebb05ea5e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price used to calculate issuable shares (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_048698a7-d55b-49dc-a143-48f51bef2b16_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4eea3504-b6e8-4f39-b821-bda05b7f10ae_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to unvested RSU awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_e09aba33-4642-4385-98a2-3f9436ff51bf_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AccruedRoyaltiesAndMilestonePaymentsCurrent_4061a5d7-8add-4f45-aa82-2b5ad80ed5cc_terseLabel_en-US" xlink:label="lab_insm_AccruedRoyaltiesAndMilestonePaymentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalty payable</link:label>
    <link:label id="lab_insm_AccruedRoyaltiesAndMilestonePaymentsCurrent_label_en-US" xlink:label="lab_insm_AccruedRoyaltiesAndMilestonePaymentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties and Milestone Payments, Current</link:label>
    <link:label id="lab_insm_AccruedRoyaltiesAndMilestonePaymentsCurrent_documentation_en-US" xlink:label="lab_insm_AccruedRoyaltiesAndMilestonePaymentsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties and Milestone Payments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedRoyaltiesAndMilestonePaymentsCurrent" xlink:href="insm-20220630.xsd#insm_AccruedRoyaltiesAndMilestonePaymentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedRoyaltiesAndMilestonePaymentsCurrent" xlink:to="lab_insm_AccruedRoyaltiesAndMilestonePaymentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_efa9664c-da9a-4e6e-afca-d18f42501331_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of convertible debt issuance</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_8999a0b2-6583-430e-a666-1a38e40c9f7e_terseLabel_en-US" xlink:label="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement stock options granted to new employees (in shares)</link:label>
    <link:label id="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Inducement Options Grants In Period Gross</link:label>
    <link:label id="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_documentation_en-US" xlink:label="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross number of inducement share options (or share units) granted during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:href="insm-20220630.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:to="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e537a75d-217a-4d39-a631-91b1c87170ba_verboseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_BusinessAcquisitionConsecutiveTradingDayPeriod_d33ac430-e26d-4a0b-9b4f-cee117c7551e_terseLabel_en-US" xlink:label="lab_insm_BusinessAcquisitionConsecutiveTradingDayPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive trading day period</link:label>
    <link:label id="lab_insm_BusinessAcquisitionConsecutiveTradingDayPeriod_label_en-US" xlink:label="lab_insm_BusinessAcquisitionConsecutiveTradingDayPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Consecutive Trading Day Period</link:label>
    <link:label id="lab_insm_BusinessAcquisitionConsecutiveTradingDayPeriod_documentation_en-US" xlink:label="lab_insm_BusinessAcquisitionConsecutiveTradingDayPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Consecutive Trading Day Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessAcquisitionConsecutiveTradingDayPeriod" xlink:href="insm-20220630.xsd#insm_BusinessAcquisitionConsecutiveTradingDayPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_BusinessAcquisitionConsecutiveTradingDayPeriod" xlink:to="lab_insm_BusinessAcquisitionConsecutiveTradingDayPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_8c578a68-2545-4ea6-8a7e-72994c973feb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_d554a9bd-2654-4ff3-9291-b00ff3e7d98e_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities, convertible debt (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_668fc81f-ac46-445e-a84a-1549e53050c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_68897593-41c2-41a3-9283-2bbdddb39324_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_03ffe72e-dc01-459d-89ed-83818425d3f0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a22073e6-f95b-4230-91dd-1b623bb94281_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_MarketableSecuritiesAdditional_8411816e-a971-46cb-86cf-a9e871a31499_negatedTerseLabel_en-US" xlink:label="lab_insm_MarketableSecuritiesAdditional" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, additional</link:label>
    <link:label id="lab_insm_MarketableSecuritiesAdditional_label_en-US" xlink:label="lab_insm_MarketableSecuritiesAdditional" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Additional</link:label>
    <link:label id="lab_insm_MarketableSecuritiesAdditional_documentation_en-US" xlink:label="lab_insm_MarketableSecuritiesAdditional" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Additional</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MarketableSecuritiesAdditional" xlink:href="insm-20220630.xsd#insm_MarketableSecuritiesAdditional"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MarketableSecuritiesAdditional" xlink:to="lab_insm_MarketableSecuritiesAdditional" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_05322f11-deee-45aa-8b23-1b2cd6876f5d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_9a03aa9b-e4b0-4e96-99c1-779987a2dcf5_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75c4586f-a011-4614-8bc5-94ac0f1b070e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_bf563096-f4cb-4372-b598-d520248cfe59_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_ac6e0da2-8f5b-432c-9829-45f5a75964d0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, long-term</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_362ca6e9-6844-40ef-87d8-27ac56c36565_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, long-term</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_503cd56f-034b-43ce-b606-215db0a99d61_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cd56ab3e-613b-4145-8f7a-b05df57deb1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_3190ca62-add9-4e53-a9bf-9f900e8a066a_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ba1326ed-c7df-4d4c-b59a-fa69c09b97f7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_99ea9dd3-25e5-4c89-a0b0-7d8e03818c63_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of convertible debt redemption</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3388702c-8eda-44ec-9a6f-01c6a34cac3f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_517cd53f-50a7-4f6e-9d7c-5542757fd13d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_26b2b99a-1d29-46c5-b241-e22aef80abb1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_82834eb2-93a9-40a9-96d1-62e7b9166ed6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4b2dfdcb-355c-4cae-bdff-bfd31cacfc76_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_fa189594-e37b-4c75-b3ca-47c18c280851_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_fcf4f411-84df-4e28-9632-cfe13051cc44_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_90f2a8b2-40ad-4717-a244-ef21c1b6a7e6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Life (years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_2f0c3223-35ea-4e87-b62c-4487b791e150_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc004606-3f2c-4d61-9ebf-f852629cae5f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConversionTermFourMember_58f365e8-6128-45f1-a4f2-c356ecdb0fbf_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Term (iv)</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermFourMember_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion Term Four [Member]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermFourMember_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion Term Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermFourMember" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermFourMember" xlink:to="lab_insm_DebtInstrumentConversionTermFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_e4b5a978-b380-4145-acac-23fb47554aaa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a52488ff-5d6b-434f-a99f-618199b34591_verboseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_db4b7c40-d7a9-4783-9852-de4d4cf17055_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_3b762b0b-361d-4f05-bd03-b2b7b51f2f15_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_EmployeeStockPurchasePlan2018Member_89f2be2e-d832-4674-a1f6-2499d04572c2_terseLabel_en-US" xlink:label="lab_insm_EmployeeStockPurchasePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 ESPP</link:label>
    <link:label id="lab_insm_EmployeeStockPurchasePlan2018Member_label_en-US" xlink:label="lab_insm_EmployeeStockPurchasePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan 2018 [Member]</link:label>
    <link:label id="lab_insm_EmployeeStockPurchasePlan2018Member_documentation_en-US" xlink:label="lab_insm_EmployeeStockPurchasePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EmployeeStockPurchasePlan2018Member" xlink:href="insm-20220630.xsd#insm_EmployeeStockPurchasePlan2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_EmployeeStockPurchasePlan2018Member" xlink:to="lab_insm_EmployeeStockPurchasePlan2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1844db5c-a176-419d-8d2d-a7c4a9f5b19d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_StockOptionsAndRestrictedStockUnitsMember_02fef6e7-fe6b-4465-a71d-ce15f7182a79_terseLabel_en-US" xlink:label="lab_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and RSUs</link:label>
    <link:label id="lab_insm_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_insm_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. It also includes stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:href="insm-20220630.xsd#insm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2accd78c-32a9-4d5b-90fa-41c8fb7cfc4c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_24ce4d2b-c8d4-4839-8ff8-7b474662c380_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e4fccde9-f03a-4818-bc8a-cf88d68f248b_verboseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e4317b54-6efe-450e-866f-73d6cfc29b7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First anniversary of closing date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_9bc61025-1fe9-4cee-8051-30faaf5b2cb1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_de6ea196-9f5c-451b-8ce0-b6d522609e71_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_bc17a8f2-e387-4934-938c-18c1dfe9f6e3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_cd3bbd70-6a77-4e57-97d4-35df8b70e197_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_2c93cb93-fe19-42ef-be0e-7ae8cfba773b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third anniversary of closing date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0a7a54b4-d54e-4a35-986f-faa8e649a681_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_17fb5091-da38-43e8-804a-8bd8d247bf9f_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_f59215b4-e9b4-4eaf-a582-b5f86889037e_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance options</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ce2d6ce2-56fb-426c-8980-5dc3ba034640_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_560101ae-159f-4d79-9a6b-9552bfba0e7c_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_0fe2155c-a8ab-4d96-a432-34626a88b865_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AccruedLiabilitiesCurrentMember_5e9172d6-3f1f-4269-bd70-267472e998fc_terseLabel_en-US" xlink:label="lab_insm_AccruedLiabilitiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:label id="lab_insm_AccruedLiabilitiesCurrentMember_label_en-US" xlink:label="lab_insm_AccruedLiabilitiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Member]</link:label>
    <link:label id="lab_insm_AccruedLiabilitiesCurrentMember_documentation_en-US" xlink:label="lab_insm_AccruedLiabilitiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedLiabilitiesCurrentMember" xlink:href="insm-20220630.xsd#insm_AccruedLiabilitiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedLiabilitiesCurrentMember" xlink:to="lab_insm_AccruedLiabilitiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_594afe75-3916-435b-84ec-9e50f255e507_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_87b3d199-6f05-483f-b90a-15e2682d2a50_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_1b44b325-e157-4d0d-a5c2-ed9cb55cba03_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_b05db4b8-b934-4035-ba4f-2ebbef644432_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease, cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_54f60778-7800-42f2-872a-fffeeeb77fa6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_33c4e2e5-beba-4cb7-96e4-59dfb6906e85_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1ff1c761-3dc3-4684-a896-d9474dfd227e_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_7ebcb082-3f7e-4bf8-a0de-bfeb413e1800_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_601ba8c1-b746-4533-b605-2e799440a71e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs and accretion of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_13c334eb-3d8c-46c6-8cf8-616de3fdaab1_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_dbff141e-c6a3-43ef-824a-89634203f4f7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_4633202d-6add-499b-a551-2aaa928f0932_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities, long-term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount_2d80f4c3-9656-44e7-b527-591dd42f97e1_terseLabel_en-US" xlink:label="lab_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost, future right-of-use asset</link:label>
    <link:label id="lab_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount_label_en-US" xlink:label="lab_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Amount</link:label>
    <link:label id="lab_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount_documentation_en-US" xlink:label="lab_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:href="insm-20220630.xsd#insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:to="lab_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc72a04b-cd75-45ae-9e20-7717d5ba265b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4240c80c-59be-42fb-b67e-0c137de98be5_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_ef8874d3-2c1f-4dc7-b715-0563b22df4d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining_2516423a-a30c-4cff-b11f-3670e317ab0b_terseLabel_en-US" xlink:label="lab_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining discount amortization period</link:label>
    <link:label id="lab_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining_label_en-US" xlink:label="lab_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Instrument, Discount Amortization Period, Remaining</link:label>
    <link:label id="lab_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining_documentation_en-US" xlink:label="lab_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Instrument, Discount Amortization Period, Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" xlink:href="insm-20220630.xsd#insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" xlink:to="lab_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ManufacturingEquipmentMember_b9638fce-9781-4585-86d3-e00e1119580b_terseLabel_en-US" xlink:label="lab_insm_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_insm_ManufacturingEquipmentMember_label_en-US" xlink:label="lab_insm_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_insm_ManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_insm_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ManufacturingEquipmentMember" xlink:href="insm-20220630.xsd#insm_ManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ManufacturingEquipmentMember" xlink:to="lab_insm_ManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_73460f37-c76c-4dae-84a8-12f6755a9246_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rollforward of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_eb9b3ae2-282f-47ac-a0d5-775f030da18d_terseLabel_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Line Items]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_label_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Line Items]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_documentation_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:href="insm-20220630.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:to="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_6e30df4b-a9c6-47b4-9fa8-472ce4788184_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid in acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_ecf5e424-aff6-4cf7-ac9d-0fbf77b59007_terseLabel_en-US" xlink:label="lab_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% convertible senior notes due 2028</link:label>
    <link:label id="lab_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_label_en-US" xlink:label="lab_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Seven Five Percent Convertible Senior Note Due 2028 [Member]</link:label>
    <link:label id="lab_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_documentation_en-US" xlink:label="lab_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Seven Five Percent Convertible Senior Note Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member" xlink:href="insm-20220630.xsd#insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member" xlink:to="lab_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1ef47524-f1e8-46b5-80d8-ca84bbeed92e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3014f9b3-0f4c-448e-bd3b-6d7af5d3db2c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_43231255-fdfb-41bb-8a3f-67bdd9e8383e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0022588c-d935-47a7-a41e-3bd81ff83f60_verboseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a6c1c513-d452-4da0-b888-4407e777ed9b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_d0c0dd4b-1381-4770-8879-3c873aa6b646_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for vesting of RSUs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_b95b94b6-17cb-464a-8765-0b324e77196d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_dd59fee4-d9a8-40b2-91b3-2f3da6331e08_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CustomerCMember_1f45f5a0-496c-466f-85eb-fa2f85efdd06_terseLabel_en-US" xlink:label="lab_insm_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C</link:label>
    <link:label id="lab_insm_CustomerCMember_label_en-US" xlink:label="lab_insm_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_insm_CustomerCMember_documentation_en-US" xlink:label="lab_insm_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerCMember" xlink:href="insm-20220630.xsd#insm_CustomerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CustomerCMember" xlink:to="lab_insm_CustomerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_71bc19e2-6ea7-4adf-87c2-37d9209c154a_verboseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5450dd61-94ed-45f1-a58e-2176e37ba111_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_a3fb961d-b0f7-4163-bbc2-efd1fef798e3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_a522b8b7-411c-4284-8435-6ba747a8f5c3_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_af50bd0c-505d-4e7a-bbae-17b645ba00cc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting discounts and commissions and other offering expenses</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_a7bbbdce-3eed-4406-a14d-36d6e862ce80_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, unamortized</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AccruedTechnicalOperationExpenses_40633986-237a-4d9a-97fd-9cabc3925f2d_terseLabel_en-US" xlink:label="lab_insm_AccruedTechnicalOperationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued technical operation expenses</link:label>
    <link:label id="lab_insm_AccruedTechnicalOperationExpenses_label_en-US" xlink:label="lab_insm_AccruedTechnicalOperationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Technical Operation Expenses</link:label>
    <link:label id="lab_insm_AccruedTechnicalOperationExpenses_documentation_en-US" xlink:label="lab_insm_AccruedTechnicalOperationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedTechnicalOperationExpenses" xlink:href="insm-20220630.xsd#insm_AccruedTechnicalOperationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedTechnicalOperationExpenses" xlink:to="lab_insm_AccruedTechnicalOperationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4816a73f-c1de-4cc2-a9fb-f7001f76011f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_058c1fd5-bc78-478d-b358-71a6878ce91b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d0ed6dc3-7d55-4dd8-ac71-fe351c4bfa6f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_4562c947-2854-4a8f-93eb-065720fd49be_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_360777c9-19ae-4c30-a38d-497920ed42ec_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, Net and Goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage_4acbac51-66a9-414e-b940-e93f2d39c041_terseLabel_en-US" xlink:label="lab_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential payout percentage</link:label>
    <link:label id="lab_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage_label_en-US" xlink:label="lab_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Of Sale of Priority Review Voucher Obligated to Pay to Equity Holders, Percentage</link:label>
    <link:label id="lab_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage_documentation_en-US" xlink:label="lab_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Of Sale of Priority Review Voucher Obligated to Pay to Equity Holders, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" xlink:href="insm-20220630.xsd#insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" xlink:to="lab_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bc65559c-ea43-429e-a7ef-4e982fe3c8ac_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets, 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_451d68db-5f52-4db6-a54f-2db2f021ee9f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ad8e8861-33e1-46e4-ae14-53b6885e3558_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_0fbd7049-2f95-40e4-961c-cb37f3122fce_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b54f5023-96a8-4bb4-b59b-35db1d8c0fa8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6eecabf8-a250-492d-96f3-7effcd4e56fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs issued</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_77b20508-9d1a-4475-b7f5-948ab4ee72b8_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock and RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_bf9d7263-dc4f-4e00-ab38-b95cc42194c8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock and RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_16fe3e18-3da2-4c2a-bf8b-d9718d1da08c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_2d2f68ea-bb41-4a6c-8dca-4975a0fd19a6_terseLabel_en-US" xlink:label="lab_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon milestone achievements (in shares)</link:label>
    <link:label id="lab_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_label_en-US" xlink:label="lab_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares</link:label>
    <link:label id="lab_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_documentation_en-US" xlink:label="lab_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" xlink:href="insm-20220630.xsd#insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" xlink:to="lab_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_51b4f976-da27-48fb-b74c-24045b7d5ec6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c45e4734-d66b-4865-800c-4484ff731d8d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_352c3f4a-41e5-4684-a126-d2df359367a5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_bde45080-dee3-4105-a00a-bb8a95ebce4f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_42343a0f-f3af-4d58-94f4-4e11b9195ba9_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_169a9388-8f6b-4af5-88a6-b19c12ffa953_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_212a875f-f196-45e3-a784-d1d0fb61ddf5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_74255c2e-6328-4e75-b18b-74b030205fbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_66a4b306-c4aa-45a9-a26e-0daa89361831_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_9d0bbe30-bf00-4353-a8b4-4274b9089f88_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment on extinguishment of 1.75% convertible senior notes due 2025</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_5a3b2057-f73f-4b24-9506-255327c71949_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AlgaeneXIncMember_b5ff434d-f6c7-4313-b261-239a88365840_terseLabel_en-US" xlink:label="lab_insm_AlgaeneXIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AlgaeneX</link:label>
    <link:label id="lab_insm_AlgaeneXIncMember_label_en-US" xlink:label="lab_insm_AlgaeneXIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AlgaeneX, Inc. [Member]</link:label>
    <link:label id="lab_insm_AlgaeneXIncMember_documentation_en-US" xlink:label="lab_insm_AlgaeneXIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AlgaeneX, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AlgaeneXIncMember" xlink:href="insm-20220630.xsd#insm_AlgaeneXIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AlgaeneXIncMember" xlink:to="lab_insm_AlgaeneXIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_01fedb59-60e8-4f27-8647-b85d7a0b4512_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_05327a7b-9fcf-4a95-ade6-8286f9a41ac6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_6931e4f4-871b-4aae-9197-7264d60e49a3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2e4c81f0-f600-433d-b609-f5dc2e3608df_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_cbac8fa0-8b55-4e09-8cf5-27f3950fee4f_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_bb3b51ac-4913-4c4e-b5c4-df0e5524758c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_ec7908a2-2002-444a-8ab9-31b86a4bfac7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of principal on 1.75% convertible senior notes due 2025</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c30c7e09-2943-4cb2-986b-f8905b2dd8ab_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c3bf90a9-366a-4fc3-8483-0a954a5ee0ed_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f12b0aa8-51e5-4430-8eca-62773a9ab5e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_e0a1b54e-d7a1-42f6-90b3-14a428557943_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_0dae43a6-3edb-4aa0-927e-1b45cb926c34_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c5793ad8-2814-45e6-bcdf-c3107e745c14_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_425c8498-d847-48d3-b528-52e05806db63_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CustomerBMember_520b2880-c335-4f5a-b8e4-bea33657c494_terseLabel_en-US" xlink:label="lab_insm_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_insm_CustomerBMember_label_en-US" xlink:label="lab_insm_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_insm_CustomerBMember_documentation_en-US" xlink:label="lab_insm_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerBMember" xlink:href="insm-20220630.xsd#insm_CustomerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CustomerBMember" xlink:to="lab_insm_CustomerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2548d1e6-6b1b-4ad9-b11a-bfc9ea6908ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d85a87c-46c7-4daf-8377-52fdc0b3b670_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_da9b465f-173c-4f07-8c6f-fcd490d470f2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets, 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_004c4495-0f24-4d4e-99c7-fff275ab139a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payables</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_aff0383e-74dd-4cb7-93dc-1916a1f67f6c_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9ce06027-c712-43ab-8093-899c854dbdc8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_07c2888f-314d-48c3-9cba-c8ad824fe175_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CommonStockAuthorizedAggregateGrossSalesProceeds_850f1306-4051-498a-84b2-bfad19bcf72f_terseLabel_en-US" xlink:label="lab_insm_CommonStockAuthorizedAggregateGrossSalesProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized, aggregate gross sales proceeds (up to)</link:label>
    <link:label id="lab_insm_CommonStockAuthorizedAggregateGrossSalesProceeds_label_en-US" xlink:label="lab_insm_CommonStockAuthorizedAggregateGrossSalesProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Authorized, Aggregate Gross Sales Proceeds</link:label>
    <link:label id="lab_insm_CommonStockAuthorizedAggregateGrossSalesProceeds_documentation_en-US" xlink:label="lab_insm_CommonStockAuthorizedAggregateGrossSalesProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Authorized, Aggregate Gross Sales Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommonStockAuthorizedAggregateGrossSalesProceeds" xlink:href="insm-20220630.xsd#insm_CommonStockAuthorizedAggregateGrossSalesProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CommonStockAuthorizedAggregateGrossSalesProceeds" xlink:to="lab_insm_CommonStockAuthorizedAggregateGrossSalesProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c4a116da-3a2a-488e-bfeb-0d735acc050e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_37b012e6-a4f1-4ddb-ba81-850434d5ea53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Allocation of Employee Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b302cdbc-bb9a-4169-91a3-458af9cc2297_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a6cbb9ce-d0bb-4a3c-852d-bf9757aec6e8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and ESPP shares issuance</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_ee3417cc-aafd-4a34-9fbb-5f9f881d7d70_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Supplemental Noncash Disclosures included in Consolidated Financial Statements</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6e7dd71d-3198-4d87-bb91-25ab85e71074_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_b59140ce-8aba-4625-8599-721dc6d4d1f6_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9fbf35e5-d3e6-49a7-9a06-13a062ff962d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash to be paid upon achievement of milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_0c6dfd1e-38b5-4e1e-8252-952195d12f5f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_156f7d27-4fc8-4de0-b9a1-66429231dc00_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, non-current</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b2ac8666-4584-4930-a6d1-f39f95b75b63_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_c73ea1c5-765c-46ad-aab0-8cd921549b89_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_db65328c-d653-46d6-9a93-c7a47992f593_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_3a555f22-f3e4-4991-8931-db27416e69d2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_A2019IncentivePlanSecondAmendmentMember_be89002c-513d-4cff-8f5d-8f871c36d690_terseLabel_en-US" xlink:label="lab_insm_A2019IncentivePlanSecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Plan, Second Amendment</link:label>
    <link:label id="lab_insm_A2019IncentivePlanSecondAmendmentMember_label_en-US" xlink:label="lab_insm_A2019IncentivePlanSecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Plan, Second Amendment [Member]</link:label>
    <link:label id="lab_insm_A2019IncentivePlanSecondAmendmentMember_documentation_en-US" xlink:label="lab_insm_A2019IncentivePlanSecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Plan, Second Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2019IncentivePlanSecondAmendmentMember" xlink:href="insm-20220630.xsd#insm_A2019IncentivePlanSecondAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_A2019IncentivePlanSecondAmendmentMember" xlink:to="lab_insm_A2019IncentivePlanSecondAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ddca5a3c-c61b-47e9-803c-875f8ff54fde_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Observable Inputs in Valuation of Deferred Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_50165e7d-b53a-40a3-bb8c-8b17ff8bb606_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_b0f7f6c9-181a-4583-84d9-5c956007a06f_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to purchase additional debt</link:label>
    <link:label id="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_label_en-US" xlink:label="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Option To Purchase Additional Debt</link:label>
    <link:label id="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_documentation_en-US" xlink:label="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Option To Purchase Additional Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:href="insm-20220630.xsd#insm_DebtInstrumentOptionToPurchaseAdditionalDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:to="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_cbb366a3-93ba-4028-9916-46b92ed30fb4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_c78dd8f9-f822-446f-acd2-6668ec609319_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0f2787fc-aa71-4a9d-b296-673c70b62533_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_9f802516-8fdd-4cb3-b284-b4b3fd6594cf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of 0.75% convertible senior notes due 2028</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_f002d521-928e-4fc9-9555-587415a2446c_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c244d22e-3073-4c7c-8575-67bba4dcbac4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_33a531ef-3109-4afa-a9d4-d74a5cd4a953_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_3f64a036-a42c-4a8e-89d2-5cf2fcf63d15_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_b729d470-9a50-4069-bc08-838037b1ae9a_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_401d0504-4fc9-40d9-99e3-d814abdcc47b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_1b34b864-8276-46e6-b6df-59c31902c284_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConversionTermThreeMember_344a49b5-98d4-4a8c-bdec-aa9c1f208079_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Term (iii)</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermThreeMember_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion Term Three [Member]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermThreeMember_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion Term Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermThreeMember" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermThreeMember" xlink:to="lab_insm_DebtInstrumentConversionTermThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_fff53557-6fa2-4f1e-9fb0-b66a4b343988_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b3974dff-4eea-4a80-8c6a-7e5d36820c23_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6297ccec-4df2-4c7a-9365-8f96e3adee58_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_406da015-5736-463e-9d45-cdc4eb0c274c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of finance lease principal</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_2a471b41-e10e-48f6-9148-3d99f41fb3b9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4e2d11cd-7925-48dc-820b-3d41bc8d3c22_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_c614f7c3-9a2c-4c4a-9633-d5b9ab78fcbd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_MotusBiosciencesIncAndAlgaeneXIncMember_d46513bc-14fc-41e6-adeb-e00f201f29f2_terseLabel_en-US" xlink:label="lab_insm_MotusBiosciencesIncAndAlgaeneXIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Motus and AlgaeneX</link:label>
    <link:label id="lab_insm_MotusBiosciencesIncAndAlgaeneXIncMember_label_en-US" xlink:label="lab_insm_MotusBiosciencesIncAndAlgaeneXIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Motus Biosciences, Inc. And AlgaeneX, Inc. [Member]</link:label>
    <link:label id="lab_insm_MotusBiosciencesIncAndAlgaeneXIncMember_documentation_en-US" xlink:label="lab_insm_MotusBiosciencesIncAndAlgaeneXIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Motus Biosciences, Inc. And AlgaeneX, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember" xlink:href="insm-20220630.xsd#insm_MotusBiosciencesIncAndAlgaeneXIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember" xlink:to="lab_insm_MotusBiosciencesIncAndAlgaeneXIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8411d769-7be4-486e-aa00-7676bb13c213_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of deferred and contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6157b39c-369e-41dd-93ba-25cf46de3894_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_42b7b8aa-b7dc-4f58-a99e-cc50ec4f37b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_8758c3c0-6b04-4cb1-9af6-21eaf96a81fb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense charged to operations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8e9f58de-994d-4f60-9c01-34c98c150ce4_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ConvertibleDebtInterestExpenseTotal_ed20f8e6-0320-4601-9d25-c5e0f9cb70cd_totalLabel_en-US" xlink:label="lab_insm_ConvertibleDebtInterestExpenseTotal" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total convertible debt interest expense</link:label>
    <link:label id="lab_insm_ConvertibleDebtInterestExpenseTotal_label_en-US" xlink:label="lab_insm_ConvertibleDebtInterestExpenseTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Interest Expense, Total</link:label>
    <link:label id="lab_insm_ConvertibleDebtInterestExpenseTotal_documentation_en-US" xlink:label="lab_insm_ConvertibleDebtInterestExpenseTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Interest Expense, Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConvertibleDebtInterestExpenseTotal" xlink:href="insm-20220630.xsd#insm_ConvertibleDebtInterestExpenseTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ConvertibleDebtInterestExpenseTotal" xlink:to="lab_insm_ConvertibleDebtInterestExpenseTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_495b7183-8ba8-4f85-844d-50b0ee403ec9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_84273402-0ab2-40e9-b35d-a5f2455fa899_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_36f06835-8801-48f5-b414-e5d998cb8aff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12988ce9-e858-44dd-b2a7-0b302d3d9bd5_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and New Accounting Pronouncements (Not Yet Adopted)</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75440e99-05b7-4371-ad1d-c1705767862f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6b5c4a05-1a77-4ce2-a7ec-c6aa5806dbc6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5dbaab21-c2a3-4ee2-b166-6a138ab06028_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_4d7487b6-fc24-44a5-b24d-f1b05844bd06_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc74159e-8c9e-4815-a4b5-befd9316068a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bd19ac42-95a1-4ff6-94e8-ecc8fd35388e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eac47f71-36c0-423c-81e3-108559b66153_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ContingentConsiderationMember_18cfcca4-9906-4c2a-8161-96f0736043eb_terseLabel_en-US" xlink:label="lab_insm_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_insm_ContingentConsiderationMember_label_en-US" xlink:label="lab_insm_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_insm_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_insm_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContingentConsiderationMember" xlink:href="insm-20220630.xsd#insm_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ContingentConsiderationMember" xlink:to="lab_insm_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7ac04d7b-5f42-49de-806b-3e2e78d04eb1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_fb09fb66-d479-4f8b-a0b6-ab2d63d412e2_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_ae8a7826-3ad0-44cc-9250-3fbedae0ba83_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2228dccc-6137-4894-94e7-95fa5cc4c483_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_3c3d9be8-278a-4120-9eda-ce096c2f6f32_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_a601c04e-ba28-47e9-914f-f467d60eed65_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PARI milestones</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_73fd655e-2d8f-4955-a4ab-ef0dada19764_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_1d8b19a8-08c4-4c1a-9764-3037ce2d1b61_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_WeightedAverageProbabilityOfReachingMilestone_0a328c1d-d1e3-4efb-b8bb-6fedf40231c5_terseLabel_en-US" xlink:label="lab_insm_WeightedAverageProbabilityOfReachingMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average probability of reaching milestone, percentage</link:label>
    <link:label id="lab_insm_WeightedAverageProbabilityOfReachingMilestone_label_en-US" xlink:label="lab_insm_WeightedAverageProbabilityOfReachingMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Probability Of Reaching Milestone</link:label>
    <link:label id="lab_insm_WeightedAverageProbabilityOfReachingMilestone_documentation_en-US" xlink:label="lab_insm_WeightedAverageProbabilityOfReachingMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Probability Of Reaching Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_WeightedAverageProbabilityOfReachingMilestone" xlink:href="insm-20220630.xsd#insm_WeightedAverageProbabilityOfReachingMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_WeightedAverageProbabilityOfReachingMilestone" xlink:to="lab_insm_WeightedAverageProbabilityOfReachingMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_9d11b902-8683-435a-b41d-7ab5e9f93a4c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product revenues (excluding amortization of intangible assets)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d0a10a7a-7807-4156-96e5-d0fe7d6996cd_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average diluted common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a9e2fcf8-2c52-47e8-abec-d314721412f4_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_301ebaf4-1f86-4dbe-974c-205c75f68b14_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_5cd5cec1-364b-46f9-9bb4-d80530fff031_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2467869b-856b-4ad8-a9c5-24ba4c691d4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage_ba3a336d-3336-480b-9c08-221c5d1455a1_terseLabel_en-US" xlink:label="lab_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential payout, average sales prices, percentage</link:label>
    <link:label id="lab_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage_label_en-US" xlink:label="lab_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Sales Prices Of Publicly Disclosed Priority Review Voucher Sales Obligated to Pay Equity Holders, Percentage</link:label>
    <link:label id="lab_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage_documentation_en-US" xlink:label="lab_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Sales Prices Of Publicly Disclosed Priority Review Voucher Sales Obligated to Pay Equity Holders, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" xlink:href="insm-20220630.xsd#insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" xlink:to="lab_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities_24af76d7-8675-42cc-b31a-4cfc3f01582f_terseLabel_en-US" xlink:label="lab_insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain or loss</link:label>
    <link:label id="lab_insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities_label_en-US" xlink:label="lab_insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities, Gross Unrealized Gain (Loss), Number Of Securities</link:label>
    <link:label id="lab_insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities_documentation_en-US" xlink:label="lab_insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities, Gross Unrealized Gain (Loss), Number Of Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities" xlink:href="insm-20220630.xsd#insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities" xlink:to="lab_insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_a76388b6-73d8-4e16-b012-e89723f6bcbe_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_9856566a-afe2-4477-8d5d-492e21863582_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value; 500,000,000 authorized shares, 119,865,023 and 118,738,266 issued and outstanding shares at June&#160;30, 2022 and December&#160;31, 2021,&#160;respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_7fde7236-86af-4bae-923a-82cfe5e0eda7_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_926a77b2-6c2c-4c63-9a05-6c1743a5397f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_fb77b02e-eaa0-45e2-aed5-222652b34183_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_90b0b591-4576-4b2e-893e-2392051f9c80_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_36960ef5-5493-4ce4-889d-7f08520d9248_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_61221987-d8f2-4e73-8406-670ee43e075a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Value and Fair Value of Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_4c9e1ff7-9ee5-4bd2-bcdb-1260423c153c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5a79f521-dfdf-4887-9f39-2c8359cfcca3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ca4ac05-baa6-4a82-97a6-c9f3ee3e6c78_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d31b058-5853-4da9-8012-4a4c89b033f6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_022dabca-5574-4b58-9798-0b634599f4c7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_16824817-ce3e-4f4b-b29a-a7ea2f2a1cd3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insmed share price as of June&#160;30, 2022</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_84200896-352a-4576-9b16-5aaf1c3e4ed3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d936ad64-b8f2-42ed-9209-34bef3e4d26a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options, ESPP, and RSU vestings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f05d7fe9-2d8a-445c-86f6-f9120d3cadab_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0b0a42d1-180f-4823-b22c-bcc0baf9cbc7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_d879ce0c-c275-4d7e-b616-e498f53c9f51_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_PublicStockOfferingMember_f6bf5c85-3ffc-4e79-8da1-afaddca911a9_terseLabel_en-US" xlink:label="lab_insm_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_insm_PublicStockOfferingMember_label_en-US" xlink:label="lab_insm_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_insm_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_insm_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PublicStockOfferingMember" xlink:href="insm-20220630.xsd#insm_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_PublicStockOfferingMember" xlink:to="lab_insm_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_3841791b-825f-447a-b907-6e7cc0a3e166_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease interest expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_1cc87a95-e5b1-4d34-8c52-6540981ffca7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_f760f0f5-6787-4c99-82fb-75334df08ae4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7bc24318-d1c2-4317-afdb-24485b3f3a5f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e4769a39-5446-4e1b-b888-13b495d75cc8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_31cb08fc-837d-4460-b2e7-a861e1de9d73_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_16891b82-e8c7-4332-bed1-26512acc0020_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_786a198e-38e9-4043-afc5-6f3902ff3b7e_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_8b7438db-6d7e-46d1-9941-541bb9b17e90_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress (CIP)</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5d163422-e37c-4a10-aab3-c8d8a533dd20_verboseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_98ae6cdd-f58b-4467-854b-1c792ddfd6bd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year Ending December&#160;31:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_9c6ce8f3-9494-4648-a343-03c3446a3911_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential award payout</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_b0fcc3e4-513f-42d0-9bd9-bc2fb9ae74ed_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_0307b5c3-c037-4abe-acc4-cd599a2af3f4_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f3c6b1aa-f7d3-416a-b3c2-f68ec32ed6e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_efd4d140-bd43-4433-ba30-29526d058699_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_80dedaae-ed27-4a94-aef8-d5e42861bbef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d8750d9b-b205-4d9b-b536-18deb1887231_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18f30ece-975b-4fe5-ac3c-2be9735e7408_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_723ab5b0-eceb-4589-bdc1-c3674e357267_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2cc54ab8-9c99-422c-92c7-6aceb208cf1c_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_45db3e6f-2605-4873-9023-4f98b3bebee5_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d8fd3df4-8023-4137-97d4-e7bef5eba395_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_b443eb7e-916e-4191-afad-e634b4c7b5ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_578bd6b3-1651-48b5-a5b2-5c287a066eaf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_98087c75-ebdf-4bf7-b12f-424e8df88898_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_7c34a56a-8b2c-47da-8b9f-11cd29201a05_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_4fc9256d-9f97-46f8-9fbc-e5971fc53e87_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_bbb118d5-d9bf-4a97-98f8-504b9eafa3df_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9966f81d-3fe7-41a0-a6d9-9f40001dec0f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_be49c830-72c9-4c64-9141-8bed7334d455_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_0b7c327b-57b3-479c-8e45-f8985dad8434_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5dcef486-89ec-4abf-bf42-aa4ea6b55a18_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_261be21c-286b-497e-bf80-b2a4b84ce46a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_37a0497b-6112-43a7-a834-12e883fd630d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_508f9a47-b250-49a3-aa14-a9314773fdf5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock_10a3eaac-7396-4d3a-8026-762367f45384_terseLabel_en-US" xlink:label="lab_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets)</link:label>
    <link:label id="lab_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) [Policy Text Block]</link:label>
    <link:label id="lab_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock_documentation_en-US" xlink:label="lab_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" xlink:href="insm-20220630.xsd#insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" xlink:to="lab_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_34d74180-235e-409a-9199-8d2e2869886d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_0b76ee16-4f5c-40cb-b3e0-fbd258387d31_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_97dbf265-ed8d-448c-9696-87635b5a0682_verboseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_e636a4c3-655e-405b-96b0-659c156f8c31_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_1aa03c93-72c9-4584-9087-848ff9108e6b_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_f57384f6-fe96-4a5f-ad71-7c09c521ca3e_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4ebc01c8-1eb0-4b14-ba76-879826172ce7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_8a5cffac-260b-490c-b251-77ebb980b79e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_e4ca3059-e254-4737-b219-ff8039b743d4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_945d5570-fe92-4cb5-aeca-c791a1554132_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AtTheMarketAgreementMember_0d03754c-fa96-4e4e-ad26-1f698e91babc_terseLabel_en-US" xlink:label="lab_insm_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program</link:label>
    <link:label id="lab_insm_AtTheMarketAgreementMember_label_en-US" xlink:label="lab_insm_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Agreement [Member]</link:label>
    <link:label id="lab_insm_AtTheMarketAgreementMember_documentation_en-US" xlink:label="lab_insm_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AtTheMarketAgreementMember" xlink:href="insm-20220630.xsd#insm_AtTheMarketAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AtTheMarketAgreementMember" xlink:to="lab_insm_AtTheMarketAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_e521193b-2092-4d36-8b60-256f924f50bb_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_fb4ca0c2-3e14-4e72-ace2-377aa33ec178_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_da2c1133-328a-4d54-8e34-2a2e1ffd4e7b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_680ceba3-bf32-4246-930d-1608939e090d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Assets, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_506820fa-cfac-4eeb-85a0-0e3df92d0f9c_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Percentage of Total Gross Product Revenue Represented by the Three Largest Customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_15dd8b53-1f19-46b6-82b8-8b2c26e61053_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AccruedConstructionLiabilitiesCurrent_e3884cad-0f3a-4fe2-adf8-3e4ea8e5511f_terseLabel_en-US" xlink:label="lab_insm_AccruedConstructionLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction costs</link:label>
    <link:label id="lab_insm_AccruedConstructionLiabilitiesCurrent_label_en-US" xlink:label="lab_insm_AccruedConstructionLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Construction Liabilities, Current</link:label>
    <link:label id="lab_insm_AccruedConstructionLiabilitiesCurrent_documentation_en-US" xlink:label="lab_insm_AccruedConstructionLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Construction Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedConstructionLiabilitiesCurrent" xlink:href="insm-20220630.xsd#insm_AccruedConstructionLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedConstructionLiabilitiesCurrent" xlink:to="lab_insm_AccruedConstructionLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_336c76fd-ee21-4927-a1a0-9208a95e3272_terseLabel_en-US" xlink:label="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities, accrued compensation and other</link:label>
    <link:label id="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Current Liabilities</link:label>
    <link:label id="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the sum of accrued expenses and Other Current Liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:href="insm-20220630.xsd#insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0ec0e30c-d203-4d31-b41b-7731ab5b3b5c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_LeaseRemainingLeaseTerm_fb2af225-6752-4971-9c52-ecfcce03b383_terseLabel_en-US" xlink:label="lab_insm_LeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_insm_LeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_insm_LeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Remaining Lease Term</link:label>
    <link:label id="lab_insm_LeaseRemainingLeaseTerm_documentation_en-US" xlink:label="lab_insm_LeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LeaseRemainingLeaseTerm" xlink:href="insm-20220630.xsd#insm_LeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_LeaseRemainingLeaseTerm" xlink:to="lab_insm_LeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6cf02fcc-ba46-4400-9f61-14f08328ba37_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9bdb1a68-bf3b-4ab7-97a4-f82f9cfc9be1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8c8dc24b-7a66-4e52-b70b-47c4f3fbb707_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Company and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_19c76ba3-66c2-4cc3-b7ba-27b46a653893_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_5b174147-7e7e-4a81-9540-fbeace8fbed2_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_5670b911-585d-41e9-9dfc-86709459f0ab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3ff764eb-bcf0-4c3d-aa3f-1203b7f8f8d0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1bde7ce8-778f-4b78-b94a-ccddf2987501_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and ESPP shares issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_9f7ee554-1014-4a4b-8c21-fd1e70dc0e98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_84e01b46-b36d-4fdd-8ff8-402856cc3f23_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_93dd4746-e06b-4148-b542-5eb568b506e3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ba1a28fd-07cc-40b2-9e2b-0d82c0d4e4a8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3d5c28e9-5bab-4a33-97ab-f383f32ca848_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ae23f4ae-8b36-4e38-bef9-118f796ed2cc_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DevelopmentAndRegulatoryMilestonesMember_7546f174-c65a-4609-9c07-fa5d28dbc1ee_terseLabel_en-US" xlink:label="lab_insm_DevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and regulatory milestones</link:label>
    <link:label id="lab_insm_DevelopmentAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_insm_DevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_insm_DevelopmentAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_insm_DevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DevelopmentAndRegulatoryMilestonesMember" xlink:href="insm-20220630.xsd#insm_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DevelopmentAndRegulatoryMilestonesMember" xlink:to="lab_insm_DevelopmentAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_MotusBiosciencesIncMember_72eae168-c062-44fa-8f77-17de32e1285a_terseLabel_en-US" xlink:label="lab_insm_MotusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Motus</link:label>
    <link:label id="lab_insm_MotusBiosciencesIncMember_label_en-US" xlink:label="lab_insm_MotusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Motus Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_insm_MotusBiosciencesIncMember_documentation_en-US" xlink:label="lab_insm_MotusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Motus Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncMember" xlink:href="insm-20220630.xsd#insm_MotusBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MotusBiosciencesIncMember" xlink:to="lab_insm_MotusBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_e0a0de2d-07a5-4403-964d-946347b72d93_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_846d0c86-f827-44cc-8b5c-59aeb8072bc9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate net proceeds from stock offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_d2e7755d-7fbe-41ec-9626-c59b9ff092d9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_b271535d-b26c-4ac8-a929-6a7c9b2c8e0e_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e2e213f4-6c5e-43d9-abba-60650a710d2c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_0ef22437-6dbe-4e44-a88f-195272cbb8b3_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_e79de4f7-1684-4038-a5a0-c41d03fa1af9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount on debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_d72e1001-5c64-43b2-bb69-9de923fd9dbc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percent of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5a846a70-62ed-4805-82da-ddcc31b65765_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_bf645223-ed11-4584-8cde-e374e211a91f_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Product Line</link:label>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueProductLineMember" xlink:to="lab_us-gaap_SalesRevenueProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AcquiredResearchAndDevelopmentMember_8650ee7c-f2dc-4930-bd71-8c8e44c1349e_terseLabel_en-US" xlink:label="lab_insm_AcquiredResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired ARIKAYCE R&amp;D</link:label>
    <link:label id="lab_insm_AcquiredResearchAndDevelopmentMember_label_en-US" xlink:label="lab_insm_AcquiredResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Research And Development [Member]</link:label>
    <link:label id="lab_insm_AcquiredResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_insm_AcquiredResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AcquiredResearchAndDevelopmentMember" xlink:href="insm-20220630.xsd#insm_AcquiredResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AcquiredResearchAndDevelopmentMember" xlink:to="lab_insm_AcquiredResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_033125be-a7c4-4cba-b0d7-70b8f4cfa932_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_5aece418-eee8-489e-8c34-956246c90453_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_219d937f-007e-4070-a6b1-3b6e5c845dd6_verboseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8af04992-a471-40ff-8700-60fc1e706922_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b8ca2174-6fe1-4e56-a5fc-7cbe40ca1265_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average basic common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f9707199-61a1-4296-91e6-a228e6c90107_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares used in calculation of basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_e7a0cbec-1f26-4ecd-b667-242fb8d12a64_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c17f830b-1680-4093-b550-10ec29906b55_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_37e7b1eb-a0db-4112-af11-ab6c9bac8d41_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments_71ac0666-7ba9-40ac-a382-edc45da5a78e_negatedTerseLabel_en-US" xlink:label="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments_label_en-US" xlink:label="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments</link:label>
    <link:label id="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments_documentation_en-US" xlink:label="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" xlink:href="insm-20220630.xsd#insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" xlink:to="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_2a447861-2a34-4c98-adf8-87b223358cb1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Debt Balance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_87536cbd-64b6-4dad-8c95-e9962209fd2d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_72961b4c-c0ce-4774-a361-fbf41469125c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c580784f-efa7-4ffd-a5e4-8d02c490166c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenues, net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f0b0e6b7-e8e3-4dc2-afae-28709e9160a7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_81adbd25-cdcc-4e47-a7f5-57fc30db252b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_3fc9886d-67e1-499f-a432-d6da8490516d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_8d888d50-8df9-4f1f-972d-3aa286dd8feb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f8034043-c12a-4ae2-83c9-5318ec47f2e7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_54dbb45b-d695-48e5-be98-1ef4f0d39904_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f7bcec68-b0dc-4889-9010-a21e6db6f5e9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_a16a938c-5f7a-4d1f-b96b-93c878170678_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_1deec1d7-f1e0-437d-ad11-22a75bb15b02_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d8fd860b-7980-40d8-b1f7-ca498b0db039_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6d689bd0-f486-4619-b678-6c1d07e2e6d2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList_698eab33-c4ef-4828-aa48-e16897a8430f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Product and Service [Extensible List]</link:label>
    <link:label id="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:to="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_eebd7c76-5054-48b3-af1a-151b618c7057_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_4f42bb23-765b-47aa-a7b8-6f27df1fd1bb_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a9013bc1-bf58-465a-a9af-b5c0ddb48dc0_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities, share-based payment (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AccruedClinicalTrialExpenses_45edfc03-c26a-4728-8403-72a7bd40d75b_terseLabel_en-US" xlink:label="lab_insm_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_insm_AccruedClinicalTrialExpenses_label_en-US" xlink:label="lab_insm_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:label id="lab_insm_AccruedClinicalTrialExpenses_documentation_en-US" xlink:label="lab_insm_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedClinicalTrialExpenses" xlink:href="insm-20220630.xsd#insm_AccruedClinicalTrialExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedClinicalTrialExpenses" xlink:to="lab_insm_AccruedClinicalTrialExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_acd7a0f6-f06f-4ea9-b871-b908e55c142f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_0b92419d-54f4-42d8-9222-fdac63a57ab1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of convertible debt redemption</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5c33ad03-7cb9-4ec7-893f-15ea600e5e95_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5d72ce15-9bf9-4fbd-8dc0-aa21142c67ed_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_efbee822-efc2-4b57-ac05-6efbc698b350_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_b80b1fb6-430d-4415-9a9a-c099df27e006_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_BusinessCombinationDeferredLiability_4fe59aa8-dc56-4daa-8452-2001b6509904_terseLabel_en-US" xlink:label="lab_insm_BusinessCombinationDeferredLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred consideration</link:label>
    <link:label id="lab_insm_BusinessCombinationDeferredLiability_label_en-US" xlink:label="lab_insm_BusinessCombinationDeferredLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Deferred Liability</link:label>
    <link:label id="lab_insm_BusinessCombinationDeferredLiability_documentation_en-US" xlink:label="lab_insm_BusinessCombinationDeferredLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Deferred Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredLiability" xlink:href="insm-20220630.xsd#insm_BusinessCombinationDeferredLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_BusinessCombinationDeferredLiability" xlink:to="lab_insm_BusinessCombinationDeferredLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ComputerHardwareAndSoftwareMember_8e0bed67-4a34-4bb2-ab9c-7443a5240122_terseLabel_en-US" xlink:label="lab_insm_ComputerHardwareAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware and software</link:label>
    <link:label id="lab_insm_ComputerHardwareAndSoftwareMember_label_en-US" xlink:label="lab_insm_ComputerHardwareAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Hardware And Software [Member]</link:label>
    <link:label id="lab_insm_ComputerHardwareAndSoftwareMember_documentation_en-US" xlink:label="lab_insm_ComputerHardwareAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Hardware And Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember" xlink:href="insm-20220630.xsd#insm_ComputerHardwareAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ComputerHardwareAndSoftwareMember" xlink:to="lab_insm_ComputerHardwareAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_611d549d-89d6-448d-968b-2d3ecc87e1b6_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_76624524-8c3e-433e-961f-f31c5da2270a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_127a993b-e7ea-43e5-bfe0-cd66147854d0_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_059ff0ec-b645-49ee-a977-45466622bff5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6cef068a-fe91-4c60-816c-7c4100378a83_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_f2aaa8ce-21e6-41f5-baec-a0d9fa36766c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_df18377d-dafe-4864-99b3-38fb9298b702_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second anniversary of closing date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_0293235b-463b-493e-87b7-911241a0adb2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_397df5b0-465d-4386-a446-8c7c6bdf1975_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_3cda2776-f488-4423-9aa1-d26c61435666_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_30d88684-fc96-4e3a-ba3b-bf518fd584e6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_A2019IncentivePlanThirdAmendmentMember_c1772a80-1053-4522-98f4-b8a28e408bba_terseLabel_en-US" xlink:label="lab_insm_A2019IncentivePlanThirdAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Plan</link:label>
    <link:label id="lab_insm_A2019IncentivePlanThirdAmendmentMember_label_en-US" xlink:label="lab_insm_A2019IncentivePlanThirdAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Plan, Third Amendment [Member]</link:label>
    <link:label id="lab_insm_A2019IncentivePlanThirdAmendmentMember_documentation_en-US" xlink:label="lab_insm_A2019IncentivePlanThirdAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Plan, Third Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2019IncentivePlanThirdAmendmentMember" xlink:href="insm-20220630.xsd#insm_A2019IncentivePlanThirdAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_A2019IncentivePlanThirdAmendmentMember" xlink:to="lab_insm_A2019IncentivePlanThirdAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_924514b4-725b-4e93-a7fe-3170f12c10c4_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1b35a952-9c0a-43df-891e-5ac21802b5eb_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2a6ff120-a1d2-4e23-9662-079ed92ab7b0_verboseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AccruedSalesAllowancesAndRelatedCosts_55195fb4-a307-4bf7-93f6-f0ddbe93a1d2_terseLabel_en-US" xlink:label="lab_insm_AccruedSalesAllowancesAndRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued sales allowances and related costs</link:label>
    <link:label id="lab_insm_AccruedSalesAllowancesAndRelatedCosts_label_en-US" xlink:label="lab_insm_AccruedSalesAllowancesAndRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Allowances And Related Costs</link:label>
    <link:label id="lab_insm_AccruedSalesAllowancesAndRelatedCosts_documentation_en-US" xlink:label="lab_insm_AccruedSalesAllowancesAndRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Allowances And Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedSalesAllowancesAndRelatedCosts" xlink:href="insm-20220630.xsd#insm_AccruedSalesAllowancesAndRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedSalesAllowancesAndRelatedCosts" xlink:to="lab_insm_AccruedSalesAllowancesAndRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_726c1924-d70c-4307-9fdc-0a6286936d76_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConversionTermTwoMember_ab07199a-0cef-4144-906a-6986718da83e_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Term (ii)</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermTwoMember_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion Term Two [Member]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermTwoMember_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion Term Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermTwoMember" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermTwoMember" xlink:to="lab_insm_DebtInstrumentConversionTermTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_51326c4d-5769-40df-82d3-8cb5ba483351_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_4236a514-e8fb-4702-b531-df29774eb17a_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_8c3b9286-b6fc-45af-8a83-c73e22d1f117_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c0b45d06-3179-4a5f-8e12-b055a24fe3be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_5caecfdd-a3d8-4b4e-abee-def2e96f1ccb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue_34fb550c-1d59-4ace-b699-439d92e015d1_terseLabel_en-US" xlink:label="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value</link:label>
    <link:label id="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue_label_en-US" xlink:label="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Increase (Decrease) In Fair Value</link:label>
    <link:label id="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue_documentation_en-US" xlink:label="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Increase (Decrease) In Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue" xlink:href="insm-20220630.xsd#insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue" xlink:to="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_3925645e-24db-4f17-bd6c-89e02f9e09dd_terseLabel_en-US" xlink:label="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.75% convertible senior notes due 2025</link:label>
    <link:label id="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_label_en-US" xlink:label="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]</link:label>
    <link:label id="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_documentation_en-US" xlink:label="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:href="insm-20220630.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:to="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_FairValueLevel1Level2Level3TransfersAmount_8318dd8d-9795-4664-902f-7536e59fe15f_terseLabel_en-US" xlink:label="lab_insm_FairValueLevel1Level2Level3TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value transfers in or out of Level 1, Level 2, or Level 3</link:label>
    <link:label id="lab_insm_FairValueLevel1Level2Level3TransfersAmount_label_en-US" xlink:label="lab_insm_FairValueLevel1Level2Level3TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Level 1, Level 2, Level 3 Transfers, Amount</link:label>
    <link:label id="lab_insm_FairValueLevel1Level2Level3TransfersAmount_documentation_en-US" xlink:label="lab_insm_FairValueLevel1Level2Level3TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Level 1, Level 2, Level 3 Transfers, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FairValueLevel1Level2Level3TransfersAmount" xlink:href="insm-20220630.xsd#insm_FairValueLevel1Level2Level3TransfersAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_FairValueLevel1Level2Level3TransfersAmount" xlink:to="lab_insm_FairValueLevel1Level2Level3TransfersAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ad90bb8f-c599-4af8-a2d1-0551344e5e72_verboseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_26384750-f9ba-4657-93d1-34881b68ed9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock, maximum authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConversionTermOneMember_c2b1242a-6fe1-4a33-aa0b-d8f449a97bdc_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Term (i)</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermOneMember_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion Term One [Member]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermOneMember_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion Term One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermOneMember" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermOneMember" xlink:to="lab_insm_DebtInstrumentConversionTermOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders_ec76eb65-0b3f-4515-9664-d571af3c1d56_terseLabel_en-US" xlink:label="lab_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of publicly disclosed sales used to determine average sales price owed to equity holders</link:label>
    <link:label id="lab_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders_label_en-US" xlink:label="lab_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Publicly Disclosed Sales Used To Determine Average Sales Price Owed To Equity Holders</link:label>
    <link:label id="lab_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders_documentation_en-US" xlink:label="lab_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Publicly Disclosed Sales Used To Determine Average Sales Price Owed To Equity Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" xlink:href="insm-20220630.xsd#insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" xlink:to="lab_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_51d1976d-34a2-46d2-a18f-1add433e63da_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold trading days following fundamental change</link:label>
    <link:label id="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_label_en-US" xlink:label="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change</link:label>
    <link:label id="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:to="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_b49d2f7a-3ba2-42ee-b32d-3ab47c11710f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a9c7f502-5c7b-418d-a1a9-68d840ee5564_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e4db8f24-7b7e-4738-84cc-fa0cd8779af4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_10da6dbf-6225-426c-9ce7-ebff14d224c9_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_5023a2f2-40da-4026-a060-002e981faa1c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_LongTermDebtMaturityAfterYearFour_379cf31c-1ef9-406e-9dad-843ce92079f3_terseLabel_en-US" xlink:label="lab_insm_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 and thereafter</link:label>
    <link:label id="lab_insm_LongTermDebtMaturityAfterYearFour_label_en-US" xlink:label="lab_insm_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Four</link:label>
    <link:label id="lab_insm_LongTermDebtMaturityAfterYearFour_documentation_en-US" xlink:label="lab_insm_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LongTermDebtMaturityAfterYearFour" xlink:href="insm-20220630.xsd#insm_LongTermDebtMaturityAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_LongTermDebtMaturityAfterYearFour" xlink:to="lab_insm_LongTermDebtMaturityAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_77bb4ae9-1128-4882-a531-0a9400063fb4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_27d142ff-6bb9-4a41-af53-b24197e0de79_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_b6dbf846-ccd5-4fd9-ad7a-63ed18bb3a25_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_d4ed71a4-2c76-4ada-a4f5-76b598621068_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b8aa142f-882d-418b-921d-fc342faa48f2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f5cd3c8a-722c-40e4-ac96-da61f37f8d50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_f78074f6-ca17-4932-bbec-318042d0ca02_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_54882975-55bb-4bb8-a58a-6189189091f3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_48fca236-edab-4b62-854b-493ca00900e9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_00df6fe2-ac5e-455d-bf64-8693a98a7e8f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_f1c0844a-e3c6-459e-863e-faba7f67c201_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e4d6710b-7693-42ab-b255-9ac2ac7b30b4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_1b0b30bf-8329-4692-af09-3439f6c9b313_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_4a6de35e-e618-4dbb-a8ab-b24341f5fe80_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ed4d4f7c-eabc-43f1-b960-04444dfda752_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_aeb2ec1f-0afb-49fb-98cd-79316d4eefac_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_22b916f9-91ce-4f1f-94d7-510f34943104_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_945fce6b-2999-4bb1-9070-bb48763927d3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_2d266f78-1c5c-41b6-8795-a76667d207ff_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_43a52ebe-5cff-4967-9e6a-738fd38e3a55_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_448220bc-424d-4d75-97dc-057bd9bc6797_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_995b6f41-a161-4a2a-89a6-f71b00f37381_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fbc0995d-ee78-4930-8f44-6fb0e50d6273_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_PriorityReviewVoucherMilestoneMember_21520c4c-c92b-4062-b2ec-15b54bca2fbe_terseLabel_en-US" xlink:label="lab_insm_PriorityReviewVoucherMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Priority review voucher milestone</link:label>
    <link:label id="lab_insm_PriorityReviewVoucherMilestoneMember_label_en-US" xlink:label="lab_insm_PriorityReviewVoucherMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Priority Review Voucher Milestone [Member]</link:label>
    <link:label id="lab_insm_PriorityReviewVoucherMilestoneMember_documentation_en-US" xlink:label="lab_insm_PriorityReviewVoucherMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Priority Review Voucher Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PriorityReviewVoucherMilestoneMember" xlink:href="insm-20220630.xsd#insm_PriorityReviewVoucherMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_PriorityReviewVoucherMilestoneMember" xlink:to="lab_insm_PriorityReviewVoucherMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_29346fba-4d25-4043-830c-4461421210af_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_344aa7be-8eab-45ed-aed1-30d260590599_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_57f869ce-11e6-4c2d-9d66-a7a00c9ad3f0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6ee95bcb-a55c-4176-bc7b-664ec9e5a712_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_995b46c4-9db3-44db-a1bc-c9d8053596f9_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_055d69d2-2b2f-499f-a223-a1c925c8c125_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>insm-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f29bbe7c-3fe7-4edc-bd43-5e98e923844d,g:47f91642-8422-4809-9855-6a3312b42bf8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.insmed.com/role/CoverPage" xlink:type="simple" xlink:href="insm-20220630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_bce8bf49-dcc5-4a8e-8925-9572f38ef100" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_DocumentType_bce8bf49-dcc5-4a8e-8925-9572f38ef100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_9bffd78e-7b1c-4524-b717-38ac496d9da3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_DocumentQuarterlyReport_9bffd78e-7b1c-4524-b717-38ac496d9da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2b4661f1-ba95-4037-b7b3-ec2919bb7d3b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_DocumentPeriodEndDate_2b4661f1-ba95-4037-b7b3-ec2919bb7d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_81f06140-270f-46c5-a6be-028e8cbea0b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_DocumentTransitionReport_81f06140-270f-46c5-a6be-028e8cbea0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1e781301-a6ca-40fc-837d-8c9f2c0f504c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_EntityFileNumber_1e781301-a6ca-40fc-837d-8c9f2c0f504c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_75ead2bb-da36-42fd-93a8-1101e87cf973" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_EntityRegistrantName_75ead2bb-da36-42fd-93a8-1101e87cf973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5bf691c8-2b02-4dc6-9657-a095e04cafbc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5bf691c8-2b02-4dc6-9657-a095e04cafbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c8c956ec-e27f-4770-9795-7348e8179113" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_EntityTaxIdentificationNumber_c8c956ec-e27f-4770-9795-7348e8179113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_399f5833-139e-47a0-826b-910bceb773be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_EntityAddressAddressLine1_399f5833-139e-47a0-826b-910bceb773be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_055127d5-a78e-4c11-bc64-9081bc79052b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_EntityAddressCityOrTown_055127d5-a78e-4c11-bc64-9081bc79052b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_85b925a8-19e9-4bca-ac0d-10dfe53a9fd6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_EntityAddressStateOrProvince_85b925a8-19e9-4bca-ac0d-10dfe53a9fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f932f3f0-8e3b-45a4-aa7b-fbab731b1bd4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_EntityAddressPostalZipCode_f932f3f0-8e3b-45a4-aa7b-fbab731b1bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fa854436-ee07-45b9-a9ef-f7700fa7c49c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_CityAreaCode_fa854436-ee07-45b9-a9ef-f7700fa7c49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c758ae79-a502-40e0-a097-2e5b1931a0f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_LocalPhoneNumber_c758ae79-a502-40e0-a097-2e5b1931a0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0729b2c4-defd-486a-ae1a-4e6d6ff2bcda" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_Security12bTitle_0729b2c4-defd-486a-ae1a-4e6d6ff2bcda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7ec552f8-fb85-4812-91c2-0c2903c22f4a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_TradingSymbol_7ec552f8-fb85-4812-91c2-0c2903c22f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1a58cf2d-4d9c-4189-9444-dc3bfeda18cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_SecurityExchangeName_1a58cf2d-4d9c-4189-9444-dc3bfeda18cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d2990409-ef60-42b0-8e27-605257f921f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_EntityCurrentReportingStatus_d2990409-ef60-42b0-8e27-605257f921f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d9c10f5b-847e-4580-8153-879d8e28e9ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_EntityInteractiveDataCurrent_d9c10f5b-847e-4580-8153-879d8e28e9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_27f457f3-82ee-429a-a5b9-74c85a1e4d13" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_EntityFilerCategory_27f457f3-82ee-429a-a5b9-74c85a1e4d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_bbc7ec6a-87ec-43e3-b960-ab57241431e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_EntitySmallBusiness_bbc7ec6a-87ec-43e3-b960-ab57241431e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9f5ff681-329a-421b-a649-078375cc40b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_EntityEmergingGrowthCompany_9f5ff681-329a-421b-a649-078375cc40b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_46169383-2811-4c3a-af55-6ee58fcb906a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_EntityShellCompany_46169383-2811-4c3a-af55-6ee58fcb906a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_de1ad703-e209-4963-b4f5-735edb2886bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_de1ad703-e209-4963-b4f5-735edb2886bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2664bc88-a273-42d4-8632-def9d16910a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_EntityCentralIndexKey_2664bc88-a273-42d4-8632-def9d16910a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_bb6e190b-b81d-409f-8b8c-4e066f717926" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_AmendmentFlag_bb6e190b-b81d-409f-8b8c-4e066f717926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f1639c03-e526-44a5-bd36-b02569f81b2e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_CurrentFiscalYearEndDate_f1639c03-e526-44a5-bd36-b02569f81b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ab9cbab6-4810-4273-845d-467efd71c98d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_DocumentFiscalYearFocus_ab9cbab6-4810-4273-845d-467efd71c98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_861d9731-8f0b-4c25-b1d4-55888c210028" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d33ce69-006d-4879-8ba5-a61c4a5f9ca5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_861d9731-8f0b-4c25-b1d4-55888c210028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="insm-20220630.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f21b4c51-edd0-40d6-965b-a09e520727eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8024fba6-ac9b-49ce-be89-462920364996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f21b4c51-edd0-40d6-965b-a09e520727eb" xlink:to="loc_us-gaap_AssetsAbstract_8024fba6-ac9b-49ce-be89-462920364996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3718995a-c2c7-4ccd-9db2-f803b3885e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8024fba6-ac9b-49ce-be89-462920364996" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3718995a-c2c7-4ccd-9db2-f803b3885e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd522165-2224-4b91-afcc-4e6243e8ebf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3718995a-c2c7-4ccd-9db2-f803b3885e1b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd522165-2224-4b91-afcc-4e6243e8ebf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_c9cf0330-33e1-45c9-a021-f17524222fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3718995a-c2c7-4ccd-9db2-f803b3885e1b" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_c9cf0330-33e1-45c9-a021-f17524222fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_586fc12f-159c-458a-a2f7-7850e3d99e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3718995a-c2c7-4ccd-9db2-f803b3885e1b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_586fc12f-159c-458a-a2f7-7850e3d99e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9962d4b6-f194-4015-8417-c208ca4f84d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3718995a-c2c7-4ccd-9db2-f803b3885e1b" xlink:to="loc_us-gaap_InventoryNet_9962d4b6-f194-4015-8417-c208ca4f84d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4a6b4fde-a95e-4f5c-a024-f12d2dacf718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3718995a-c2c7-4ccd-9db2-f803b3885e1b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4a6b4fde-a95e-4f5c-a024-f12d2dacf718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e772279e-1f66-40f7-9552-8e5585d7a20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3718995a-c2c7-4ccd-9db2-f803b3885e1b" xlink:to="loc_us-gaap_AssetsCurrent_e772279e-1f66-40f7-9552-8e5585d7a20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_29715628-c195-4aaf-9611-5d82b5a99bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8024fba6-ac9b-49ce-be89-462920364996" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_29715628-c195-4aaf-9611-5d82b5a99bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0183778d-0420-4c0d-9e86-932e79aae632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8024fba6-ac9b-49ce-be89-462920364996" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0183778d-0420-4c0d-9e86-932e79aae632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_99a08ce3-582f-481c-8e51-6f56e7d66633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8024fba6-ac9b-49ce-be89-462920364996" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_99a08ce3-582f-481c-8e51-6f56e7d66633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_235a3366-9c32-470e-a325-6913b8e2d74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8024fba6-ac9b-49ce-be89-462920364996" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_235a3366-9c32-470e-a325-6913b8e2d74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e943e402-cf65-4aa9-8795-811882774f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8024fba6-ac9b-49ce-be89-462920364996" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e943e402-cf65-4aa9-8795-811882774f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d98c1279-00b9-42bf-bad4-7b040e437236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8024fba6-ac9b-49ce-be89-462920364996" xlink:to="loc_us-gaap_Goodwill_d98c1279-00b9-42bf-bad4-7b040e437236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_670b2d06-8a37-49ab-bf85-8d595b138f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8024fba6-ac9b-49ce-be89-462920364996" xlink:to="loc_us-gaap_OtherAssets_670b2d06-8a37-49ab-bf85-8d595b138f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a88baab2-486e-44eb-ad35-d9e05af9463a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8024fba6-ac9b-49ce-be89-462920364996" xlink:to="loc_us-gaap_Assets_a88baab2-486e-44eb-ad35-d9e05af9463a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80215d0f-4702-460b-8151-c4a104126ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f21b4c51-edd0-40d6-965b-a09e520727eb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80215d0f-4702-460b-8151-c4a104126ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9951296d-ea60-47ae-a035-98071d239a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80215d0f-4702-460b-8151-c4a104126ffe" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9951296d-ea60-47ae-a035-98071d239a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_250e1cc1-727e-464a-81af-1011a0865f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9951296d-ea60-47ae-a035-98071d239a0c" xlink:to="loc_us-gaap_AccountsPayableCurrent_250e1cc1-727e-464a-81af-1011a0865f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bb7704fb-d2dc-4040-9f4a-26a67f570421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9951296d-ea60-47ae-a035-98071d239a0c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bb7704fb-d2dc-4040-9f4a-26a67f570421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9f1bb3b9-7249-4ad7-b1c7-5243f851bbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9951296d-ea60-47ae-a035-98071d239a0c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9f1bb3b9-7249-4ad7-b1c7-5243f851bbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_46c6eec2-2462-4b8e-94de-1b5c4a76b456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9951296d-ea60-47ae-a035-98071d239a0c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_46c6eec2-2462-4b8e-94de-1b5c4a76b456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1ecc73f4-12ae-4585-a84b-9dd797317172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9951296d-ea60-47ae-a035-98071d239a0c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1ecc73f4-12ae-4585-a84b-9dd797317172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_28981649-57b8-46ee-a258-62d48a650c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9951296d-ea60-47ae-a035-98071d239a0c" xlink:to="loc_us-gaap_LiabilitiesCurrent_28981649-57b8-46ee-a258-62d48a650c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8c527456-42d9-4797-81b5-04db9606b496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80215d0f-4702-460b-8151-c4a104126ffe" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8c527456-42d9-4797-81b5-04db9606b496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_28690275-be11-4f77-a8b7-abeeb26c8f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80215d0f-4702-460b-8151-c4a104126ffe" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_28690275-be11-4f77-a8b7-abeeb26c8f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_26cd440d-c7ea-42aa-84cd-0a657ce26330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80215d0f-4702-460b-8151-c4a104126ffe" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_26cd440d-c7ea-42aa-84cd-0a657ce26330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3eeb4bd3-1f51-4165-89bf-16a1d65a62f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80215d0f-4702-460b-8151-c4a104126ffe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3eeb4bd3-1f51-4165-89bf-16a1d65a62f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bf2e3801-a547-4157-ac78-cc025983c636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80215d0f-4702-460b-8151-c4a104126ffe" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bf2e3801-a547-4157-ac78-cc025983c636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_451c418f-ab2b-4702-8265-413efbe303f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80215d0f-4702-460b-8151-c4a104126ffe" xlink:to="loc_us-gaap_Liabilities_451c418f-ab2b-4702-8265-413efbe303f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1b6846d8-7ffc-45c3-ab49-451ff18245a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80215d0f-4702-460b-8151-c4a104126ffe" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1b6846d8-7ffc-45c3-ab49-451ff18245a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cbfbb702-24ed-4260-9c62-af168c17f921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1b6846d8-7ffc-45c3-ab49-451ff18245a6" xlink:to="loc_us-gaap_CommonStockValue_cbfbb702-24ed-4260-9c62-af168c17f921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_99eefa16-a222-4a3b-b87e-1ae5699176fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1b6846d8-7ffc-45c3-ab49-451ff18245a6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_99eefa16-a222-4a3b-b87e-1ae5699176fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e797e71c-f9ad-4ee2-a0f0-802d9bffde62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1b6846d8-7ffc-45c3-ab49-451ff18245a6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e797e71c-f9ad-4ee2-a0f0-802d9bffde62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2e7b498e-32b3-4d45-a57b-3f2ea8f5862b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1b6846d8-7ffc-45c3-ab49-451ff18245a6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2e7b498e-32b3-4d45-a57b-3f2ea8f5862b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6eadf4df-43f4-4674-a073-91485615492c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1b6846d8-7ffc-45c3-ab49-451ff18245a6" xlink:to="loc_us-gaap_StockholdersEquity_6eadf4df-43f4-4674-a073-91485615492c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3d0feedd-e4da-4846-9c64-4058497f4013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80215d0f-4702-460b-8151-c4a104126ffe" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3d0feedd-e4da-4846-9c64-4058497f4013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="insm-20220630.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5f58b17e-2d7d-49a4-88c4-368d0ffb3980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_40d1d000-21c3-4976-864c-86730a0f2a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5f58b17e-2d7d-49a4-88c4-368d0ffb3980" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_40d1d000-21c3-4976-864c-86730a0f2a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_cbd055b8-537f-410b-8af3-17bde0005a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5f58b17e-2d7d-49a4-88c4-368d0ffb3980" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_cbd055b8-537f-410b-8af3-17bde0005a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_aa13d92f-e7b7-4cea-a387-1bb7766eebe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5f58b17e-2d7d-49a4-88c4-368d0ffb3980" xlink:to="loc_us-gaap_CommonStockSharesIssued_aa13d92f-e7b7-4cea-a387-1bb7766eebe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4ca46a11-1bf8-4b65-9994-bf128c4ebd01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5f58b17e-2d7d-49a4-88c4-368d0ffb3980" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4ca46a11-1bf8-4b65-9994-bf128c4ebd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="simple" xlink:href="insm-20220630.xsd#ConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_29ae3f71-b16f-4f92-b956-3b27329340cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_29ae3f71-b16f-4f92-b956-3b27329340cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_3c165412-c7f7-4b26-b126-16f5aaee4ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_3c165412-c7f7-4b26-b126-16f5aaee4ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c72f8b9b-db3f-44a8-8bac-dc2bc0107323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c72f8b9b-db3f-44a8-8bac-dc2bc0107323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ea112055-dac6-4e03-b120-f96c9ed77dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c72f8b9b-db3f-44a8-8bac-dc2bc0107323" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ea112055-dac6-4e03-b120-f96c9ed77dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_4c06b16a-ee5f-4669-9203-e6eed0e33a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c72f8b9b-db3f-44a8-8bac-dc2bc0107323" xlink:to="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_4c06b16a-ee5f-4669-9203-e6eed0e33a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_06051394-c7f9-4a39-b19e-1d767067d469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c72f8b9b-db3f-44a8-8bac-dc2bc0107323" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_06051394-c7f9-4a39-b19e-1d767067d469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c042d462-f5e5-48a6-89b5-7e8a42c42a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c72f8b9b-db3f-44a8-8bac-dc2bc0107323" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c042d462-f5e5-48a6-89b5-7e8a42c42a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_dea86256-15c3-429f-a9a0-722f577e3744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c72f8b9b-db3f-44a8-8bac-dc2bc0107323" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_dea86256-15c3-429f-a9a0-722f577e3744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_d7f59d83-0def-4311-aa53-8d09b76828e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c72f8b9b-db3f-44a8-8bac-dc2bc0107323" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_d7f59d83-0def-4311-aa53-8d09b76828e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9b3d6c0d-4076-461e-8c56-b5416ba7b01f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c72f8b9b-db3f-44a8-8bac-dc2bc0107323" xlink:to="loc_us-gaap_CostsAndExpenses_9b3d6c0d-4076-461e-8c56-b5416ba7b01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bb9cac78-e2f8-44dc-b4a4-57b1cabb6290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_OperatingIncomeLoss_bb9cac78-e2f8-44dc-b4a4-57b1cabb6290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_73b21b66-dcd7-4eec-aa4e-7aa4881bedc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_73b21b66-dcd7-4eec-aa4e-7aa4881bedc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_950297fd-88cd-4027-b5b5-c49e417fab82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_InterestExpense_950297fd-88cd-4027-b5b5-c49e417fab82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5595d747-a1fb-4ea3-bd8c-5856f6441900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5595d747-a1fb-4ea3-bd8c-5856f6441900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_00e74c6b-3450-4781-8802-527a8ad34676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_00e74c6b-3450-4781-8802-527a8ad34676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5f46437c-4898-4ace-8a93-faef5419f79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5f46437c-4898-4ace-8a93-faef5419f79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8ddaf283-4dc9-4a09-b9dc-8c6353f95745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8ddaf283-4dc9-4a09-b9dc-8c6353f95745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6bad9ffc-7f24-4680-877a-9f8d55295cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_NetIncomeLoss_6bad9ffc-7f24-4680-877a-9f8d55295cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cbd423f7-d127-418a-958d-d1b3086a8051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_EarningsPerShareBasic_cbd423f7-d127-418a-958d-d1b3086a8051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_89c0a08b-19ac-4bc0-97ee-57a121ac790c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_EarningsPerShareDiluted_89c0a08b-19ac-4bc0-97ee-57a121ac790c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_12597ec9-f2f6-4f15-b0e0-41b3b8276bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_12597ec9-f2f6-4f15-b0e0-41b3b8276bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_36330e0c-f596-45b7-ae1c-92f464461ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_36330e0c-f596-45b7-ae1c-92f464461ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b596b949-ea3e-4f8a-b207-9c2195ba6a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b596b949-ea3e-4f8a-b207-9c2195ba6a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f70625a4-adf6-4dfe-897f-f1520c6d5a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f70625a4-adf6-4dfe-897f-f1520c6d5a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d3775d96-3218-47be-8051-2de7e25624e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f70625a4-adf6-4dfe-897f-f1520c6d5a18" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d3775d96-3218-47be-8051-2de7e25624e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_13659fce-6ff7-4211-a2be-d3b649818cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f70625a4-adf6-4dfe-897f-f1520c6d5a18" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_13659fce-6ff7-4211-a2be-d3b649818cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b63eadbf-4e4c-4d57-963d-0248c8c2644a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_554cce22-5d2f-4cd7-a05f-e6d9cfffd624" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b63eadbf-4e4c-4d57-963d-0248c8c2644a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" xlink:type="simple" xlink:href="insm-20220630.xsd#ConsolidatedStatementsofShareholdersEquityunaudited"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_67df6c91-9c00-470f-bb14-c6c83a5e70fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3108012b-99bf-46f2-81fd-43e5a40f21c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_67df6c91-9c00-470f-bb14-c6c83a5e70fe" xlink:to="loc_us-gaap_StatementTable_3108012b-99bf-46f2-81fd-43e5a40f21c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b88fc45c-cce2-4c0a-85d1-d9851191da48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3108012b-99bf-46f2-81fd-43e5a40f21c8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b88fc45c-cce2-4c0a-85d1-d9851191da48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8ff0d021-bbdc-4e85-9eca-c799ef6a3f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b88fc45c-cce2-4c0a-85d1-d9851191da48" xlink:to="loc_us-gaap_EquityComponentDomain_8ff0d021-bbdc-4e85-9eca-c799ef6a3f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e647ff0d-edcd-40fe-b432-f3f8ba55b996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8ff0d021-bbdc-4e85-9eca-c799ef6a3f75" xlink:to="loc_us-gaap_CommonStockMember_e647ff0d-edcd-40fe-b432-f3f8ba55b996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8a15c39d-e1d1-4c11-9487-01d4774729fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8ff0d021-bbdc-4e85-9eca-c799ef6a3f75" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8a15c39d-e1d1-4c11-9487-01d4774729fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_91e89434-5468-42f5-a93f-9f27d95bb8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8ff0d021-bbdc-4e85-9eca-c799ef6a3f75" xlink:to="loc_us-gaap_RetainedEarningsMember_91e89434-5468-42f5-a93f-9f27d95bb8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_611feb83-d9d6-490e-a051-2aaeb225614d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8ff0d021-bbdc-4e85-9eca-c799ef6a3f75" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_611feb83-d9d6-490e-a051-2aaeb225614d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_35e429b4-5200-4892-afe5-8e3a18547aed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3108012b-99bf-46f2-81fd-43e5a40f21c8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_35e429b4-5200-4892-afe5-8e3a18547aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_00b96945-d864-4858-ab6c-4660540e7815" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_35e429b4-5200-4892-afe5-8e3a18547aed" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_00b96945-d864-4858-ab6c-4660540e7815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_943431a1-71fe-449c-b9d1-ea42449196a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_00b96945-d864-4858-ab6c-4660540e7815" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_943431a1-71fe-449c-b9d1-ea42449196a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_48b85f8d-324c-49bf-9cca-1b7b354084bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3108012b-99bf-46f2-81fd-43e5a40f21c8" xlink:to="loc_us-gaap_StatementLineItems_48b85f8d-324c-49bf-9cca-1b7b354084bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48b85f8d-324c-49bf-9cca-1b7b354084bd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_5917f4a9-c5c6-4748-9f2a-cde7fc2c33d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_SharesOutstanding_5917f4a9-c5c6-4748-9f2a-cde7fc2c33d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_375445df-6d2c-4a04-86e0-04f23ec8f34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_StockholdersEquity_375445df-6d2c-4a04-86e0-04f23ec8f34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_71b61463-8abf-49c5-998a-e589bdd526be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_71b61463-8abf-49c5-998a-e589bdd526be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ef34baa5-b0cc-4812-9732-7ba719ba3b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_71b61463-8abf-49c5-998a-e589bdd526be" xlink:to="loc_us-gaap_NetIncomeLoss_ef34baa5-b0cc-4812-9732-7ba719ba3b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3ab2bcbb-0b85-42ba-95a0-005e42c77530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_71b61463-8abf-49c5-998a-e589bdd526be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3ab2bcbb-0b85-42ba-95a0-005e42c77530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_489d2f61-52c2-430c-a60a-434d9b8fb02a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_489d2f61-52c2-430c-a60a-434d9b8fb02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_acd71cb9-c62a-44f1-971a-018429b666e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_acd71cb9-c62a-44f1-971a-018429b666e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_694e80a1-41c7-48ba-b017-07edfa4e76a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_694e80a1-41c7-48ba-b017-07edfa4e76a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_777f2701-dbe2-4682-b121-a15777e48be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_777f2701-dbe2-4682-b121-a15777e48be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_1951255b-4635-4ffa-8d9d-6cf9ab74f4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_1951255b-4635-4ffa-8d9d-6cf9ab74f4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_611630a1-1d37-4679-b09d-4af40756cb88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_611630a1-1d37-4679-b09d-4af40756cb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_36b3fcff-6e45-4041-b6e6-b8f5d9aae127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_36b3fcff-6e45-4041-b6e6-b8f5d9aae127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_49fd1952-d5cd-4ddd-b871-64e6d43a5ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_49fd1952-d5cd-4ddd-b871-64e6d43a5ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6a9cbf1b-eea8-42e9-81cb-02f6041e6ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6a9cbf1b-eea8-42e9-81cb-02f6041e6ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b04d873c-8761-41bc-befc-d5d5cc1cd1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_SharesOutstanding_b04d873c-8761-41bc-befc-d5d5cc1cd1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6ccc054c-2f1d-4648-89d1-e0de8fa17973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_StockholdersEquity_6ccc054c-2f1d-4648-89d1-e0de8fa17973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_1a233c94-307d-4123-970d-73a73eac7cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f64a41f-940d-4350-acb0-31547ee54aa0" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_1a233c94-307d-4123-970d-73a73eac7cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="insm-20220630.xsd#ConsolidatedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1e40116f-59a7-4cde-91c6-ad36c37faf29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ce9c5e01-0d3c-4b79-941b-4006f95ec696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1e40116f-59a7-4cde-91c6-ad36c37faf29" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ce9c5e01-0d3c-4b79-941b-4006f95ec696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_82b77830-4d81-41e5-946a-18cbd3d021ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ce9c5e01-0d3c-4b79-941b-4006f95ec696" xlink:to="loc_us-gaap_NetIncomeLoss_82b77830-4d81-41e5-946a-18cbd3d021ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f997d6a8-f42c-44a1-9f6d-37a3bd928c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ce9c5e01-0d3c-4b79-941b-4006f95ec696" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f997d6a8-f42c-44a1-9f6d-37a3bd928c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2c672c20-bdad-489b-a350-cda89ca3cfa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f997d6a8-f42c-44a1-9f6d-37a3bd928c29" xlink:to="loc_us-gaap_Depreciation_2c672c20-bdad-489b-a350-cda89ca3cfa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e70ec3c7-9411-4303-842a-945709f8a80a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f997d6a8-f42c-44a1-9f6d-37a3bd928c29" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e70ec3c7-9411-4303-842a-945709f8a80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_dc40eb7d-70b3-4ef3-bebe-18dba6892485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f997d6a8-f42c-44a1-9f6d-37a3bd928c29" xlink:to="loc_us-gaap_ShareBasedCompensation_dc40eb7d-70b3-4ef3-bebe-18dba6892485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_23835501-2408-4ce4-af2f-14e3320e626b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f997d6a8-f42c-44a1-9f6d-37a3bd928c29" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_23835501-2408-4ce4-af2f-14e3320e626b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7d986fad-4f56-4845-adec-0f8db6cd6a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f997d6a8-f42c-44a1-9f6d-37a3bd928c29" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7d986fad-4f56-4845-adec-0f8db6cd6a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ca7a4a9a-b146-4957-91de-26fae30eb14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f997d6a8-f42c-44a1-9f6d-37a3bd928c29" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ca7a4a9a-b146-4957-91de-26fae30eb14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NoncashOperatingLeaseExpense_c8f03dd9-9bba-4a3d-9398-4e7ace1cac8a" xlink:href="insm-20220630.xsd#insm_NoncashOperatingLeaseExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f997d6a8-f42c-44a1-9f6d-37a3bd928c29" xlink:to="loc_insm_NoncashOperatingLeaseExpense_c8f03dd9-9bba-4a3d-9398-4e7ace1cac8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a75ae42f-8763-4138-b3bb-5917b646bf74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f997d6a8-f42c-44a1-9f6d-37a3bd928c29" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a75ae42f-8763-4138-b3bb-5917b646bf74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27bbb382-e4ea-430a-a580-6dba4f69c3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f997d6a8-f42c-44a1-9f6d-37a3bd928c29" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27bbb382-e4ea-430a-a580-6dba4f69c3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_56d4c2c0-7939-48b7-aaac-76ecc06a68a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27bbb382-e4ea-430a-a580-6dba4f69c3ca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_56d4c2c0-7939-48b7-aaac-76ecc06a68a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ccd199e9-923c-42e7-a2b9-c350ff5ff20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27bbb382-e4ea-430a-a580-6dba4f69c3ca" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ccd199e9-923c-42e7-a2b9-c350ff5ff20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cd85d333-c5d8-49ff-8811-d412e9826882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27bbb382-e4ea-430a-a580-6dba4f69c3ca" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cd85d333-c5d8-49ff-8811-d412e9826882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e83cf862-0f89-4ca0-93e0-4918cbf08775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27bbb382-e4ea-430a-a580-6dba4f69c3ca" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e83cf862-0f89-4ca0-93e0-4918cbf08775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ebd3a40a-b985-411d-9326-cfeded3b2221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27bbb382-e4ea-430a-a580-6dba4f69c3ca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ebd3a40a-b985-411d-9326-cfeded3b2221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_6d615f8a-7296-4679-a55d-6580be957097" xlink:href="insm-20220630.xsd#insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27bbb382-e4ea-430a-a580-6dba4f69c3ca" xlink:to="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_6d615f8a-7296-4679-a55d-6580be957097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dabe7341-97c3-4643-a72e-0a529e308371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27bbb382-e4ea-430a-a580-6dba4f69c3ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dabe7341-97c3-4643-a72e-0a529e308371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff15884-1610-4f84-98ff-6299ae91e72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1e40116f-59a7-4cde-91c6-ad36c37faf29" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff15884-1610-4f84-98ff-6299ae91e72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_68880f5b-6d68-4481-8de4-9cd302a4656d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff15884-1610-4f84-98ff-6299ae91e72e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_68880f5b-6d68-4481-8de4-9cd302a4656d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c4509b52-4163-441c-85f0-6e339dacd8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff15884-1610-4f84-98ff-6299ae91e72e" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c4509b52-4163-441c-85f0-6e339dacd8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8de7d4c2-36bb-480d-aae4-10e4a83769bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff15884-1610-4f84-98ff-6299ae91e72e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8de7d4c2-36bb-480d-aae4-10e4a83769bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6b43452-6771-40cd-9f7c-a24c2087dbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1e40116f-59a7-4cde-91c6-ad36c37faf29" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6b43452-6771-40cd-9f7c-a24c2087dbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d5b80263-97f9-404a-ae5c-96576c816790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6b43452-6771-40cd-9f7c-a24c2087dbcc" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d5b80263-97f9-404a-ae5c-96576c816790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2b9bb829-d1cf-41b6-9172-a37a8b764771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6b43452-6771-40cd-9f7c-a24c2087dbcc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2b9bb829-d1cf-41b6-9172-a37a8b764771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_19112045-b554-4d58-98db-e271b7d0e406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6b43452-6771-40cd-9f7c-a24c2087dbcc" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_19112045-b554-4d58-98db-e271b7d0e406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_6ca7c677-b255-4e9d-868b-335287848981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6b43452-6771-40cd-9f7c-a24c2087dbcc" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_6ca7c677-b255-4e9d-868b-335287848981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_01691206-a483-4964-8059-9a6c259228be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6b43452-6771-40cd-9f7c-a24c2087dbcc" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_01691206-a483-4964-8059-9a6c259228be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_a2d60634-4a0d-4b49-986a-0277cb128621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6b43452-6771-40cd-9f7c-a24c2087dbcc" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_a2d60634-4a0d-4b49-986a-0277cb128621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_2349e282-4eb7-4d2f-ba32-078ee0959f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6b43452-6771-40cd-9f7c-a24c2087dbcc" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_2349e282-4eb7-4d2f-ba32-078ee0959f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c9e6c394-6de5-497b-a95d-81178dec42de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6b43452-6771-40cd-9f7c-a24c2087dbcc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c9e6c394-6de5-497b-a95d-81178dec42de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78c5c919-4959-4286-a94a-af24d5e2f35f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1e40116f-59a7-4cde-91c6-ad36c37faf29" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78c5c919-4959-4286-a94a-af24d5e2f35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2cb4ea92-85b9-4284-b0f7-eb874726d226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1e40116f-59a7-4cde-91c6-ad36c37faf29" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2cb4ea92-85b9-4284-b0f7-eb874726d226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_46d1f570-99d1-46be-8452-0a7e0905424d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1e40116f-59a7-4cde-91c6-ad36c37faf29" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_46d1f570-99d1-46be-8452-0a7e0905424d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c6a9232d-6467-4cad-9137-c26ee833ac08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1e40116f-59a7-4cde-91c6-ad36c37faf29" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c6a9232d-6467-4cad-9137-c26ee833ac08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_eb24ca14-0c5b-47af-bcc2-f97d2c51816c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1e40116f-59a7-4cde-91c6-ad36c37faf29" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_eb24ca14-0c5b-47af-bcc2-f97d2c51816c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_98ef6951-5a77-4e98-9354-a3220fc7ce9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_eb24ca14-0c5b-47af-bcc2-f97d2c51816c" xlink:to="loc_us-gaap_InterestPaidNet_98ef6951-5a77-4e98-9354-a3220fc7ce9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_6305a545-e111-4f31-94e1-084f529becf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_eb24ca14-0c5b-47af-bcc2-f97d2c51816c" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_6305a545-e111-4f31-94e1-084f529becf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical" xlink:type="simple" xlink:href="insm-20220630.xsd#ConsolidatedStatementsofCashFlowsunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9643ac54-65e6-4259-b707-88444664a6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_375ccbda-0b13-4894-a576-c3fa11b5ae86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9643ac54-65e6-4259-b707-88444664a6a9" xlink:to="loc_us-gaap_StatementTable_375ccbda-0b13-4894-a576-c3fa11b5ae86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_21340fb2-9191-4c8c-bae0-846950c2df2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_375ccbda-0b13-4894-a576-c3fa11b5ae86" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_21340fb2-9191-4c8c-bae0-846950c2df2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019ba5dc-7f80-46bc-9e55-ed66394917db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_21340fb2-9191-4c8c-bae0-846950c2df2c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019ba5dc-7f80-46bc-9e55-ed66394917db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_7f5e32fe-d3e5-4c05-a6fc-b0413bd07776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019ba5dc-7f80-46bc-9e55-ed66394917db" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_7f5e32fe-d3e5-4c05-a6fc-b0413bd07776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c1fc40af-18d1-4da6-b410-416e6c3faf62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_375ccbda-0b13-4894-a576-c3fa11b5ae86" xlink:to="loc_us-gaap_DebtInstrumentAxis_c1fc40af-18d1-4da6-b410-416e6c3faf62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9df16bb7-e7dd-4e4b-9c4c-c19b45196f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c1fc40af-18d1-4da6-b410-416e6c3faf62" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9df16bb7-e7dd-4e4b-9c4c-c19b45196f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_abdb4b37-64a4-47d5-aec7-07bf8f37f0bf" xlink:href="insm-20220630.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9df16bb7-e7dd-4e4b-9c4c-c19b45196f10" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_abdb4b37-64a4-47d5-aec7-07bf8f37f0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_8e0fd072-7e91-4686-93cd-b0e81214e28d" xlink:href="insm-20220630.xsd#insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9df16bb7-e7dd-4e4b-9c4c-c19b45196f10" xlink:to="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_8e0fd072-7e91-4686-93cd-b0e81214e28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3ffff402-ea47-4678-8502-1d4eec0b8f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_375ccbda-0b13-4894-a576-c3fa11b5ae86" xlink:to="loc_us-gaap_StatementLineItems_3ffff402-ea47-4678-8502-1d4eec0b8f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ed294423-2539-4f16-bc9a-82f5af55ff50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ffff402-ea47-4678-8502-1d4eec0b8f1d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ed294423-2539-4f16-bc9a-82f5af55ff50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/TheCompanyandBasisofPresentation" xlink:type="simple" xlink:href="insm-20220630.xsd#TheCompanyandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/TheCompanyandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6cf7cd1-3a57-47ea-ac8a-294a682cf64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2f1094cf-c99c-46cb-81ca-d2feacc31984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6cf7cd1-3a57-47ea-ac8a-294a682cf64c" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2f1094cf-c99c-46cb-81ca-d2feacc31984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#TheCompanyandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1cbd1f44-c108-4998-a319-5adb44f9fe86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_82179058-2ddd-4829-ac8f-343f9985623e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1cbd1f44-c108-4998-a319-5adb44f9fe86" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_82179058-2ddd-4829-ac8f-343f9985623e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_d5d44b63-f729-4fa3-8df7-81cbe2ba6dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1cbd1f44-c108-4998-a319-5adb44f9fe86" xlink:to="loc_us-gaap_MarketableSecurities_d5d44b63-f729-4fa3-8df7-81cbe2ba6dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2c658e1a-b12c-4226-a48d-c406ce28b07d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1cbd1f44-c108-4998-a319-5adb44f9fe86" xlink:to="loc_us-gaap_NetIncomeLoss_2c658e1a-b12c-4226-a48d-c406ce28b07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8f8753b8-9a1f-4e50-ae36-c0930ad1b569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c26cb7ba-2369-410f-a72f-c471042cf14f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f8753b8-9a1f-4e50-ae36-c0930ad1b569" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c26cb7ba-2369-410f-a72f-c471042cf14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_79540c6e-4926-49ad-9924-fd6dcd62846a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7199ce04-e55c-48cc-97da-bfcb67ed662d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_79540c6e-4926-49ad-9924-fd6dcd62846a" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7199ce04-e55c-48cc-97da-bfcb67ed662d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_466e2c7b-a050-425f-bfe2-4d4fe2e13bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_79540c6e-4926-49ad-9924-fd6dcd62846a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_466e2c7b-a050-425f-bfe2-4d4fe2e13bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_11bf7b78-56f6-4e76-8906-9cee9604fa35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_79540c6e-4926-49ad-9924-fd6dcd62846a" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_11bf7b78-56f6-4e76-8906-9cee9604fa35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6fdbea08-b352-4c3e-b39a-b12aea028c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_79540c6e-4926-49ad-9924-fd6dcd62846a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6fdbea08-b352-4c3e-b39a-b12aea028c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock_32badfcc-7b7c-49b4-bcee-0c361e8427b0" xlink:href="insm-20220630.xsd#insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_79540c6e-4926-49ad-9924-fd6dcd62846a" xlink:to="loc_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock_32badfcc-7b7c-49b4-bcee-0c361e8427b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_0a40c812-fef0-4a59-a559-6e33a80f8189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_79540c6e-4926-49ad-9924-fd6dcd62846a" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_0a40c812-fef0-4a59-a559-6e33a80f8189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_aa6e2bee-e70f-4a19-8bc8-fe4138c5446d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_79540c6e-4926-49ad-9924-fd6dcd62846a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_aa6e2bee-e70f-4a19-8bc8-fe4138c5446d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_e4a55f00-7ee7-4245-a9ab-54a855cea3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_79540c6e-4926-49ad-9924-fd6dcd62846a" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_e4a55f00-7ee7-4245-a9ab-54a855cea3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c9818140-024b-4ac0-9d5b-d0207ebf41f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_79540c6e-4926-49ad-9924-fd6dcd62846a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c9818140-024b-4ac0-9d5b-d0207ebf41f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_827567fc-b9bf-45e7-8505-af5e916b4251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c2ece0e9-9721-411a-8a73-27dca7116bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827567fc-b9bf-45e7-8505-af5e916b4251" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c2ece0e9-9721-411a-8a73-27dca7116bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_94fe3517-2ef9-4165-9be9-df64db37caaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827567fc-b9bf-45e7-8505-af5e916b4251" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_94fe3517-2ef9-4165-9be9-df64db37caaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6023bd75-9f2a-420f-bea6-32b301a5f6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827567fc-b9bf-45e7-8505-af5e916b4251" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6023bd75-9f2a-420f-bea6-32b301a5f6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_a72d91c1-db44-471f-872a-1d46bc08f842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827567fc-b9bf-45e7-8505-af5e916b4251" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_a72d91c1-db44-471f-872a-1d46bc08f842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_758df99f-eb1a-479a-878b-55921124e10e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827567fc-b9bf-45e7-8505-af5e916b4251" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_758df99f-eb1a-479a-878b-55921124e10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_a1de2f78-f6ee-40b0-afb0-102129c64587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827567fc-b9bf-45e7-8505-af5e916b4251" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_a1de2f78-f6ee-40b0-afb0-102129c64587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_c2e36a42-3ae1-41e1-a571-e54412e0507f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_827567fc-b9bf-45e7-8505-af5e916b4251" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_c2e36a42-3ae1-41e1-a571-e54412e0507f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0b43950b-3148-4e62-96df-a2d3c70d2284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_54afbac9-d725-40e3-b71c-14231eed7673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0b43950b-3148-4e62-96df-a2d3c70d2284" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_54afbac9-d725-40e3-b71c-14231eed7673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1ecc8c3-a86a-4ece-90fa-ce7179774365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_54afbac9-d725-40e3-b71c-14231eed7673" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1ecc8c3-a86a-4ece-90fa-ce7179774365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e098a362-f57b-4a55-b569-2adecf7fa780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1ecc8c3-a86a-4ece-90fa-ce7179774365" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e098a362-f57b-4a55-b569-2adecf7fa780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f9b8ef96-8f43-4de0-96cf-5b2908d85cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e098a362-f57b-4a55-b569-2adecf7fa780" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f9b8ef96-8f43-4de0-96cf-5b2908d85cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_147c01c5-66af-4ab6-b22c-0d4c5accb6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_54afbac9-d725-40e3-b71c-14231eed7673" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_147c01c5-66af-4ab6-b22c-0d4c5accb6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7d6600fa-fb49-4ccc-ae28-2c151065d0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_147c01c5-66af-4ab6-b22c-0d4c5accb6e5" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7d6600fa-fb49-4ccc-ae28-2c151065d0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6d0aabfb-d463-452b-a9a6-cda6c445faf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_7d6600fa-fb49-4ccc-ae28-2c151065d0cd" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6d0aabfb-d463-452b-a9a6-cda6c445faf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_2ff87ed2-e074-4dcc-beaf-f24d24ecceb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6d0aabfb-d463-452b-a9a6-cda6c445faf2" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_2ff87ed2-e074-4dcc-beaf-f24d24ecceb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0098c304-bfb6-4065-94a6-73f5c6d38a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6d0aabfb-d463-452b-a9a6-cda6c445faf2" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0098c304-bfb6-4065-94a6-73f5c6d38a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_48fcab87-42de-4570-9866-72ded91fa3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_54afbac9-d725-40e3-b71c-14231eed7673" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_48fcab87-42de-4570-9866-72ded91fa3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8926cd7-a259-4c45-bceb-df3b8b7889e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_48fcab87-42de-4570-9866-72ded91fa3dc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8926cd7-a259-4c45-bceb-df3b8b7889e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6c4fab64-c3af-46f6-827d-a5dee8a167a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8926cd7-a259-4c45-bceb-df3b8b7889e3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6c4fab64-c3af-46f6-827d-a5dee8a167a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8feef5c6-418b-4c76-87af-0f98403eacb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8926cd7-a259-4c45-bceb-df3b8b7889e3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8feef5c6-418b-4c76-87af-0f98403eacb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_67ab4287-0ec7-481b-8411-c322e3debbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8926cd7-a259-4c45-bceb-df3b8b7889e3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_67ab4287-0ec7-481b-8411-c322e3debbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_407952f6-718d-43a6-85f7-024dd1a294ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_54afbac9-d725-40e3-b71c-14231eed7673" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_407952f6-718d-43a6-85f7-024dd1a294ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_59030c96-c4f4-4cd2-8c83-ad2d63dae0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_407952f6-718d-43a6-85f7-024dd1a294ae" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_59030c96-c4f4-4cd2-8c83-ad2d63dae0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_bf420569-b6b4-4d35-a3df-29b0c214745d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_407952f6-718d-43a6-85f7-024dd1a294ae" xlink:to="loc_us-gaap_MarketableSecurities_bf420569-b6b4-4d35-a3df-29b0c214745d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredLiability_a5ba53b6-802d-4fb6-95fc-041bedc5e4b1" xlink:href="insm-20220630.xsd#insm_BusinessCombinationDeferredLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_407952f6-718d-43a6-85f7-024dd1a294ae" xlink:to="loc_insm_BusinessCombinationDeferredLiability_a5ba53b6-802d-4fb6-95fc-041bedc5e4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1a3c48c3-b3b3-4cd9-9478-8927739c5825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_407952f6-718d-43a6-85f7-024dd1a294ae" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1a3c48c3-b3b3-4cd9-9478-8927739c5825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_058e892b-e6fb-4797-9bec-5be5024f1ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_058e892b-e6fb-4797-9bec-5be5024f1ca6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4efa8485-a843-491b-bea0-706ba85f41bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4efa8485-a843-491b-bea0-706ba85f41bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd887f85-0194-457b-8fa1-2895eada11c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4efa8485-a843-491b-bea0-706ba85f41bc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd887f85-0194-457b-8fa1-2895eada11c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncMember_2eddfe01-b42e-4977-88f9-d91ec2f019a8" xlink:href="insm-20220630.xsd#insm_MotusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd887f85-0194-457b-8fa1-2895eada11c8" xlink:to="loc_insm_MotusBiosciencesIncMember_2eddfe01-b42e-4977-88f9-d91ec2f019a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AlgaeneXIncMember_fb5492a7-982b-4f17-8dcd-ddefde5dee64" xlink:href="insm-20220630.xsd#insm_AlgaeneXIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd887f85-0194-457b-8fa1-2895eada11c8" xlink:to="loc_insm_AlgaeneXIncMember_fb5492a7-982b-4f17-8dcd-ddefde5dee64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_23f3a4fd-e75d-414d-bb31-f41461383c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_VestingAxis_23f3a4fd-e75d-414d-bb31-f41461383c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_9594e9a5-8971-4cc6-9811-8dd29639ad74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_23f3a4fd-e75d-414d-bb31-f41461383c02" xlink:to="loc_us-gaap_VestingDomain_9594e9a5-8971-4cc6-9811-8dd29639ad74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e855ca2d-eba0-4c9a-8207-fb294f082f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_9594e9a5-8971-4cc6-9811-8dd29639ad74" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e855ca2d-eba0-4c9a-8207-fb294f082f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_41a05cb4-8ac7-4b76-9698-469eee6edba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_9594e9a5-8971-4cc6-9811-8dd29639ad74" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_41a05cb4-8ac7-4b76-9698-469eee6edba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_bb1a2bad-c2c3-428d-a574-be0ad38faece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_9594e9a5-8971-4cc6-9811-8dd29639ad74" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_bb1a2bad-c2c3-428d-a574-be0ad38faece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_73d3e4ed-868a-4497-9b43-9ef09f341d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_73d3e4ed-868a-4497-9b43-9ef09f341d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ab023e6a-1374-479f-9da6-1ed377b3685b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_73d3e4ed-868a-4497-9b43-9ef09f341d5f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ab023e6a-1374-479f-9da6-1ed377b3685b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedLiabilitiesCurrentMember_67fbd991-cf58-4cae-848c-e046e2164832" xlink:href="insm-20220630.xsd#insm_AccruedLiabilitiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ab023e6a-1374-479f-9da6-1ed377b3685b" xlink:to="loc_insm_AccruedLiabilitiesCurrentMember_67fbd991-cf58-4cae-848c-e046e2164832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_424c85d7-439f-4c82-bd15-ae064e54edfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ab023e6a-1374-479f-9da6-1ed377b3685b" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_424c85d7-439f-4c82-bd15-ae064e54edfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_25110d12-5fd6-47d5-b4e7-2e01c78782ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_25110d12-5fd6-47d5-b4e7-2e01c78782ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_46fb770d-6c62-4f65-8aa6-0a720a824acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_25110d12-5fd6-47d5-b4e7-2e01c78782ec" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_46fb770d-6c62-4f65-8aa6-0a720a824acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DevelopmentAndRegulatoryMilestonesMember_e2c51f1d-ddd7-4f45-bf84-12a1dc6994f3" xlink:href="insm-20220630.xsd#insm_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_46fb770d-6c62-4f65-8aa6-0a720a824acd" xlink:to="loc_insm_DevelopmentAndRegulatoryMilestonesMember_e2c51f1d-ddd7-4f45-bf84-12a1dc6994f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PriorityReviewVoucherMilestoneMember_506f8563-d785-4441-8d6e-b20ab75245f7" xlink:href="insm-20220630.xsd#insm_PriorityReviewVoucherMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_46fb770d-6c62-4f65-8aa6-0a720a824acd" xlink:to="loc_insm_PriorityReviewVoucherMilestoneMember_506f8563-d785-4441-8d6e-b20ab75245f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_760df49a-9aaa-4526-90ef-b7b164863959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_DebtInstrumentAxis_760df49a-9aaa-4526-90ef-b7b164863959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fc8e3870-d4bb-4120-b2c9-fd3005ccd546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_760df49a-9aaa-4526-90ef-b7b164863959" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fc8e3870-d4bb-4120-b2c9-fd3005ccd546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_560e3563-ccbc-4f6a-9514-7071338a8db0" xlink:href="insm-20220630.xsd#insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fc8e3870-d4bb-4120-b2c9-fd3005ccd546" xlink:to="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_560e3563-ccbc-4f6a-9514-7071338a8db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_e13d7583-ad37-44b8-bb09-d3d1a02d843c" xlink:href="insm-20220630.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fc8e3870-d4bb-4120-b2c9-fd3005ccd546" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_e13d7583-ad37-44b8-bb09-d3d1a02d843c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d3410619-25b3-4632-8824-b16c0d7749ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d3410619-25b3-4632-8824-b16c0d7749ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a9bfbb24-0236-4fa8-ae1d-f71351399204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d3410619-25b3-4632-8824-b16c0d7749ab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a9bfbb24-0236-4fa8-ae1d-f71351399204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_56299dad-86fa-42dc-9cd3-98b5b79a689a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a9bfbb24-0236-4fa8-ae1d-f71351399204" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_56299dad-86fa-42dc-9cd3-98b5b79a689a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41715d26-a5e3-40c4-9da6-9d75417190f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41715d26-a5e3-40c4-9da6-9d75417190f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78f45302-3999-4219-a313-58c347a881aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41715d26-a5e3-40c4-9da6-9d75417190f3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78f45302-3999-4219-a313-58c347a881aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_373a3507-cbce-4194-a787-8fd652545c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78f45302-3999-4219-a313-58c347a881aa" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_373a3507-cbce-4194-a787-8fd652545c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_2abdbaf5-6e53-42e5-9996-8e2fb27f31a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_2abdbaf5-6e53-42e5-9996-8e2fb27f31a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fe56a888-25eb-44ac-9517-1d6be2fde746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_2abdbaf5-6e53-42e5-9996-8e2fb27f31a4" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fe56a888-25eb-44ac-9517-1d6be2fde746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1112d92d-71f4-4fcf-95d8-f8edb6fe63ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fe56a888-25eb-44ac-9517-1d6be2fde746" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1112d92d-71f4-4fcf-95d8-f8edb6fe63ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_f1ee02b7-4520-4029-9a38-565401548114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fe56a888-25eb-44ac-9517-1d6be2fde746" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_f1ee02b7-4520-4029-9a38-565401548114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_1ce4ab2f-ba56-44c8-b04b-a2110fddc165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fe56a888-25eb-44ac-9517-1d6be2fde746" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_1ce4ab2f-ba56-44c8-b04b-a2110fddc165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0ace23c-8d5c-498c-ade7-a4dba6e37339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0ace23c-8d5c-498c-ade7-a4dba6e37339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_12c79312-9159-4175-a144-b236348094f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0ace23c-8d5c-498c-ade7-a4dba6e37339" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_12c79312-9159-4175-a144-b236348094f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d7de3caa-327d-470e-a0fa-e7a20d76c107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_12c79312-9159-4175-a144-b236348094f4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d7de3caa-327d-470e-a0fa-e7a20d76c107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f9cec09f-2928-4784-adb2-2726a4a7c922" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f9cec09f-2928-4784-adb2-2726a4a7c922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_143665a2-4548-46ed-8678-f5a57d6724c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f9cec09f-2928-4784-adb2-2726a4a7c922" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_143665a2-4548-46ed-8678-f5a57d6724c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f6d141d4-2081-40c8-bd1d-46ba93b9f1d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_143665a2-4548-46ed-8678-f5a57d6724c9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f6d141d4-2081-40c8-bd1d-46ba93b9f1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3505fd8a-54bb-4ea9-8f36-5179c70e6773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3505fd8a-54bb-4ea9-8f36-5179c70e6773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1676bd9c-e710-4a30-af06-11f370a2b5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3505fd8a-54bb-4ea9-8f36-5179c70e6773" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1676bd9c-e710-4a30-af06-11f370a2b5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_1e6d0cb7-f661-43fd-b754-eee1092ffdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1676bd9c-e710-4a30-af06-11f370a2b5a8" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_1e6d0cb7-f661-43fd-b754-eee1092ffdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_dc0cd9a3-41ea-496d-95c7-ac0774df439d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MarketableSecuritiesAdditional_b8063e4c-ce06-41e0-b5e1-77894dcaf512" xlink:href="insm-20220630.xsd#insm_MarketableSecuritiesAdditional"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_MarketableSecuritiesAdditional_b8063e4c-ce06-41e0-b5e1-77894dcaf512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FairValueLevel1Level2Level3TransfersAmount_d8213c8c-ab08-45dd-a02a-d7f26dde8ee6" xlink:href="insm-20220630.xsd#insm_FairValueLevel1Level2Level3TransfersAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_FairValueLevel1Level2Level3TransfersAmount_d8213c8c-ab08-45dd-a02a-d7f26dde8ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1357330f-b5a4-43f4-ba61-f4e1a97e0918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1357330f-b5a4-43f4-ba61-f4e1a97e0918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9d9642a5-0816-48bb-acea-c5387b15c38d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9d9642a5-0816-48bb-acea-c5387b15c38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_58d1facc-516e-41ea-8a07-e0c5694e9087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_58d1facc-516e-41ea-8a07-e0c5694e9087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities_9fba1665-15f5-4df9-b3da-f2d4558f1e79" xlink:href="insm-20220630.xsd#insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities_9fba1665-15f5-4df9-b3da-f2d4558f1e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_f834f911-2eb5-4fc0-834c-3c9e698774bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_f834f911-2eb5-4fc0-834c-3c9e698774bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredLiability_e80a2cec-3fb6-47e2-aee3-7fe205f1e5a8" xlink:href="insm-20220630.xsd#insm_BusinessCombinationDeferredLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_BusinessCombinationDeferredLiability_e80a2cec-3fb6-47e2-aee3-7fe205f1e5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_25dd0569-5b2d-4189-a643-fea076895f93" xlink:href="insm-20220630.xsd#insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_25dd0569-5b2d-4189-a643-fea076895f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_WeightedAverageProbabilityOfReachingMilestone_5e65dba1-41f8-4eed-b56f-9abe8e1a98be" xlink:href="insm-20220630.xsd#insm_WeightedAverageProbabilityOfReachingMilestone"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_WeightedAverageProbabilityOfReachingMilestone_5e65dba1-41f8-4eed-b56f-9abe8e1a98be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage_fa1bc19f-d707-498b-b7fd-ebc3934923f0" xlink:href="insm-20220630.xsd#insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage_fa1bc19f-d707-498b-b7fd-ebc3934923f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage_0239cb58-8474-45b8-9742-3f9d581c54d7" xlink:href="insm-20220630.xsd#insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage_0239cb58-8474-45b8-9742-3f9d581c54d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders_ca83e98c-e633-4f0b-a599-e314d0b8cc0e" xlink:href="insm-20220630.xsd#insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders_ca83e98c-e633-4f0b-a599-e314d0b8cc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_75f171dc-6e4c-446e-8726-c2a18750af68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_75f171dc-6e4c-446e-8726-c2a18750af68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_d217942d-d65f-4faf-b946-e61e5c2351e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_d217942d-d65f-4faf-b946-e61e5c2351e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_de2e625c-4b38-4280-984c-d2c8b94e8b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_de2e625c-4b38-4280-984c-d2c8b94e8b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5682b4e2-c367-4c7a-b885-1c1715fedffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5682b4e2-c367-4c7a-b885-1c1715fedffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_b711e9c5-faf2-4557-869a-8680ca9be8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_b711e9c5-faf2-4557-869a-8680ca9be8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_afaa9d90-ee26-4f8e-9282-bad778d26285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_afaa9d90-ee26-4f8e-9282-bad778d26285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0d8b734-69a5-457e-b1bc-716430173676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0d8b734-69a5-457e-b1bc-716430173676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2dc507a3-182d-49f7-9629-7da3a48de28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_497688b0-031a-42d9-b5db-f826d8db24af" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2dc507a3-182d-49f7-9629-7da3a48de28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_060d49a7-98e6-4193-8109-c20d036e5ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ab8d3c-72bb-47f9-8624-5c4695428749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_060d49a7-98e6-4193-8109-c20d036e5ec8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ab8d3c-72bb-47f9-8624-5c4695428749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17aa76a9-5259-4ac8-9d11-12a8f7f74505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ab8d3c-72bb-47f9-8624-5c4695428749" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17aa76a9-5259-4ac8-9d11-12a8f7f74505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e898ecc3-b3d4-40fa-995c-d4f0a1c8d051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_17aa76a9-5259-4ac8-9d11-12a8f7f74505" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e898ecc3-b3d4-40fa-995c-d4f0a1c8d051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_402ab36a-f27f-4297-bdbb-79e4bfbd41ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e898ecc3-b3d4-40fa-995c-d4f0a1c8d051" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_402ab36a-f27f-4297-bdbb-79e4bfbd41ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_41ad6bf9-cf15-4a18-b758-bfc136b3941e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ab8d3c-72bb-47f9-8624-5c4695428749" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_41ad6bf9-cf15-4a18-b758-bfc136b3941e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a42bff0d-7215-4d8d-b606-4e33a32726b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_41ad6bf9-cf15-4a18-b758-bfc136b3941e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a42bff0d-7215-4d8d-b606-4e33a32726b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_92cb49f5-eb8e-49b7-ae6a-e809ff6bbd82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a42bff0d-7215-4d8d-b606-4e33a32726b0" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_92cb49f5-eb8e-49b7-ae6a-e809ff6bbd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d8a5de8b-ff48-4e47-a7a3-d3a6bc051a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ab8d3c-72bb-47f9-8624-5c4695428749" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d8a5de8b-ff48-4e47-a7a3-d3a6bc051a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46d29fe8-dbf0-45f8-8e2a-43bddf00b455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d8a5de8b-ff48-4e47-a7a3-d3a6bc051a46" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46d29fe8-dbf0-45f8-8e2a-43bddf00b455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncMember_567c6120-2dda-4f99-bcb2-1bbbe8dfd159" xlink:href="insm-20220630.xsd#insm_MotusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46d29fe8-dbf0-45f8-8e2a-43bddf00b455" xlink:to="loc_insm_MotusBiosciencesIncMember_567c6120-2dda-4f99-bcb2-1bbbe8dfd159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2b2a7e82-11ff-4e0f-a4aa-b0152f880946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_30ab8d3c-72bb-47f9-8624-5c4695428749" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2b2a7e82-11ff-4e0f-a4aa-b0152f880946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredLiability_610b5833-4f89-433d-b23c-0bf618016a1e" xlink:href="insm-20220630.xsd#insm_BusinessCombinationDeferredLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2b2a7e82-11ff-4e0f-a4aa-b0152f880946" xlink:to="loc_insm_BusinessCombinationDeferredLiability_610b5833-4f89-433d-b23c-0bf618016a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_46f4f9ff-e82e-4b59-a972-a911572c25d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2b2a7e82-11ff-4e0f-a4aa-b0152f880946" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_46f4f9ff-e82e-4b59-a972-a911572c25d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_176a21fc-8d0e-42f8-b97f-ddd53e88a7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0584592f-f031-427a-9a94-cd3ff1ee9666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_176a21fc-8d0e-42f8-b97f-ddd53e88a7bc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0584592f-f031-427a-9a94-cd3ff1ee9666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d4914ac-7167-42da-8964-612b9e81fe0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0584592f-f031-427a-9a94-cd3ff1ee9666" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d4914ac-7167-42da-8964-612b9e81fe0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ccff161c-2f9b-4bcd-8527-8ae8938e0d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d4914ac-7167-42da-8964-612b9e81fe0f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ccff161c-2f9b-4bcd-8527-8ae8938e0d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_06d02494-6da0-4339-bc9a-9a9277d110de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ccff161c-2f9b-4bcd-8527-8ae8938e0d58" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_06d02494-6da0-4339-bc9a-9a9277d110de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_abd3813d-d741-491f-9b77-b9f374f0536b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0584592f-f031-427a-9a94-cd3ff1ee9666" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_abd3813d-d741-491f-9b77-b9f374f0536b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_895f1778-d11c-4c78-b988-e48e9a1b590d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_abd3813d-d741-491f-9b77-b9f374f0536b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_895f1778-d11c-4c78-b988-e48e9a1b590d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DevelopmentAndRegulatoryMilestonesMember_21dfa22e-77ae-4bcb-ab17-7a44f104d1b8" xlink:href="insm-20220630.xsd#insm_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_895f1778-d11c-4c78-b988-e48e9a1b590d" xlink:to="loc_insm_DevelopmentAndRegulatoryMilestonesMember_21dfa22e-77ae-4bcb-ab17-7a44f104d1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PriorityReviewVoucherMilestoneMember_5352d2d5-9970-4b84-8ca5-445e95e6aab3" xlink:href="insm-20220630.xsd#insm_PriorityReviewVoucherMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_895f1778-d11c-4c78-b988-e48e9a1b590d" xlink:to="loc_insm_PriorityReviewVoucherMilestoneMember_5352d2d5-9970-4b84-8ca5-445e95e6aab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_d0fa5fa4-3721-4e63-8d47-1f711480562f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0584592f-f031-427a-9a94-cd3ff1ee9666" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_d0fa5fa4-3721-4e63-8d47-1f711480562f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cc06ad9a-4f9f-43fc-9eaa-e1ff70ae17cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d0fa5fa4-3721-4e63-8d47-1f711480562f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cc06ad9a-4f9f-43fc-9eaa-e1ff70ae17cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MeasurementInputProbabilityOfSuccessMember_bd2e9a3d-9f0a-4be1-af4a-9744e8c5bec1" xlink:href="insm-20220630.xsd#insm_MeasurementInputProbabilityOfSuccessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cc06ad9a-4f9f-43fc-9eaa-e1ff70ae17cf" xlink:to="loc_insm_MeasurementInputProbabilityOfSuccessMember_bd2e9a3d-9f0a-4be1-af4a-9744e8c5bec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_46ca1e10-4bf2-4c73-bc7c-ca4e43812458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cc06ad9a-4f9f-43fc-9eaa-e1ff70ae17cf" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_46ca1e10-4bf2-4c73-bc7c-ca4e43812458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_78e270a8-3e74-4506-bb3e-12b8bfbc3e09" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0584592f-f031-427a-9a94-cd3ff1ee9666" xlink:to="loc_srt_RangeAxis_78e270a8-3e74-4506-bb3e-12b8bfbc3e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3bdfeed0-cce6-443a-b1d8-4d61ec958ce6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_78e270a8-3e74-4506-bb3e-12b8bfbc3e09" xlink:to="loc_srt_RangeMember_3bdfeed0-cce6-443a-b1d8-4d61ec958ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3c91db05-0500-4b8f-8ab7-84e6c76b21da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3bdfeed0-cce6-443a-b1d8-4d61ec958ce6" xlink:to="loc_srt_MinimumMember_3c91db05-0500-4b8f-8ab7-84e6c76b21da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_769a6d28-26a5-4ee2-b4df-e1c289db97af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3bdfeed0-cce6-443a-b1d8-4d61ec958ce6" xlink:to="loc_srt_MaximumMember_769a6d28-26a5-4ee2-b4df-e1c289db97af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6a82c037-9b0e-4b39-9bb5-944dd0bb1c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0584592f-f031-427a-9a94-cd3ff1ee9666" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6a82c037-9b0e-4b39-9bb5-944dd0bb1c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_16b854c6-d081-48d3-8615-d34da4f907fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6a82c037-9b0e-4b39-9bb5-944dd0bb1c8c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_16b854c6-d081-48d3-8615-d34da4f907fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_00196675-d7d1-45d3-bfcd-32a8811b507b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6a82c037-9b0e-4b39-9bb5-944dd0bb1c8c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_00196675-d7d1-45d3-bfcd-32a8811b507b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9d72c64a-9ba5-4df7-bd11-b7922b27661f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ffeb77bd-06d3-435e-b730-f5da8a286b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d72c64a-9ba5-4df7-bd11-b7922b27661f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ffeb77bd-06d3-435e-b730-f5da8a286b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_46e1e967-9df2-40a5-9ae9-83ddb66fc378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ffeb77bd-06d3-435e-b730-f5da8a286b4a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_46e1e967-9df2-40a5-9ae9-83ddb66fc378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e932e60-c791-4bad-86f2-5dcab7ab98ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_46e1e967-9df2-40a5-9ae9-83ddb66fc378" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e932e60-c791-4bad-86f2-5dcab7ab98ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_41cd2016-984e-4712-8ad2-77c7a8438b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e932e60-c791-4bad-86f2-5dcab7ab98ae" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_41cd2016-984e-4712-8ad2-77c7a8438b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_a825ce36-5956-48d9-8e5d-ad1c88a3d053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ffeb77bd-06d3-435e-b730-f5da8a286b4a" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_a825ce36-5956-48d9-8e5d-ad1c88a3d053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35c494ec-7ddb-444f-b5d6-2b2c92444a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_a825ce36-5956-48d9-8e5d-ad1c88a3d053" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35c494ec-7ddb-444f-b5d6-2b2c92444a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredConsiderationMember_19ea09d5-6a32-4fa9-8811-b4770e4dd404" xlink:href="insm-20220630.xsd#insm_DeferredConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35c494ec-7ddb-444f-b5d6-2b2c92444a01" xlink:to="loc_insm_DeferredConsiderationMember_19ea09d5-6a32-4fa9-8811-b4770e4dd404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContingentConsiderationMember_51d79ab3-f927-4e34-a5d7-30c03a77c9cd" xlink:href="insm-20220630.xsd#insm_ContingentConsiderationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35c494ec-7ddb-444f-b5d6-2b2c92444a01" xlink:to="loc_insm_ContingentConsiderationMember_51d79ab3-f927-4e34-a5d7-30c03a77c9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6f090bca-c809-4b28-a112-794147c40368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ffeb77bd-06d3-435e-b730-f5da8a286b4a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6f090bca-c809-4b28-a112-794147c40368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9d0a3a27-d747-4546-a95c-2e83dd620e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6f090bca-c809-4b28-a112-794147c40368" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9d0a3a27-d747-4546-a95c-2e83dd620e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e14ed3b0-14d9-43af-a799-ad50d6b08586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9d0a3a27-d747-4546-a95c-2e83dd620e71" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e14ed3b0-14d9-43af-a799-ad50d6b08586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ae6adb85-d600-4ad4-9144-bbaa699a4afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ffeb77bd-06d3-435e-b730-f5da8a286b4a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ae6adb85-d600-4ad4-9144-bbaa699a4afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8d01d81-b548-4ff6-b2a5-40a4aefa1241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ae6adb85-d600-4ad4-9144-bbaa699a4afe" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8d01d81-b548-4ff6-b2a5-40a4aefa1241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_aed2cc4a-4101-425f-abc4-53ac5e7db963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8d01d81-b548-4ff6-b2a5-40a4aefa1241" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_aed2cc4a-4101-425f-abc4-53ac5e7db963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_e72912fe-5e20-4633-a139-7bd52fd8c678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8d01d81-b548-4ff6-b2a5-40a4aefa1241" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_e72912fe-5e20-4633-a139-7bd52fd8c678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue_f0a8ec13-73ac-48c0-a474-648eee8795a6" xlink:href="insm-20220630.xsd#insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8d01d81-b548-4ff6-b2a5-40a4aefa1241" xlink:to="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue_f0a8ec13-73ac-48c0-a474-648eee8795a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments_ceaa7921-566f-49dd-ba62-3212b7b5d796" xlink:href="insm-20220630.xsd#insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8d01d81-b548-4ff6-b2a5-40a4aefa1241" xlink:to="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments_ceaa7921-566f-49dd-ba62-3212b7b5d796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7b2bc694-7742-42b3-81ba-f613f542503f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8d01d81-b548-4ff6-b2a5-40a4aefa1241" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7b2bc694-7742-42b3-81ba-f613f542503f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5faf611c-0a56-4fe7-bcab-3e89afc99c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_15565ad9-4726-413c-8cf5-d882ea90241a" xlink:href="insm-20220630.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5faf611c-0a56-4fe7-bcab-3e89afc99c22" xlink:to="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_15565ad9-4726-413c-8cf5-d882ea90241a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac4779c3-78bd-4eb0-bb9f-17fe330b1799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_15565ad9-4726-413c-8cf5-d882ea90241a" xlink:to="loc_us-gaap_AwardTypeAxis_ac4779c3-78bd-4eb0-bb9f-17fe330b1799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385ce82b-28c5-4b4b-9665-414acb0ade2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ac4779c3-78bd-4eb0-bb9f-17fe330b1799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385ce82b-28c5-4b4b-9665-414acb0ade2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_22ce432e-7eaf-4e62-8c29-c84ed149d685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385ce82b-28c5-4b4b-9665-414acb0ade2c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_22ce432e-7eaf-4e62-8c29-c84ed149d685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_15e62e2f-24bf-4903-9ffa-80c290aec860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385ce82b-28c5-4b4b-9665-414acb0ade2c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_15e62e2f-24bf-4903-9ffa-80c290aec860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_24ac305d-9b3a-4636-9e55-f1c70b9fb6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_385ce82b-28c5-4b4b-9665-414acb0ade2c" xlink:to="loc_us-gaap_PerformanceSharesMember_24ac305d-9b3a-4636-9e55-f1c70b9fb6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_ddced350-fb94-4f0e-99e9-ffb79ae44b06" xlink:href="insm-20220630.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_15565ad9-4726-413c-8cf5-d882ea90241a" xlink:to="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_ddced350-fb94-4f0e-99e9-ffb79ae44b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8bfe9e49-82b3-4980-89e8-1c7cac0412af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_ddced350-fb94-4f0e-99e9-ffb79ae44b06" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8bfe9e49-82b3-4980-89e8-1c7cac0412af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9a4215f5-bf76-4eab-90fa-d272e6bcd494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8bfe9e49-82b3-4980-89e8-1c7cac0412af" xlink:to="loc_us-gaap_NetIncomeLoss_9a4215f5-bf76-4eab-90fa-d272e6bcd494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d16da805-7a94-46d6-9e13-1dba9522a32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_ddced350-fb94-4f0e-99e9-ffb79ae44b06" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d16da805-7a94-46d6-9e13-1dba9522a32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3dbbc66d-feb7-413f-8a83-212942ad27fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d16da805-7a94-46d6-9e13-1dba9522a32d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3dbbc66d-feb7-413f-8a83-212942ad27fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_7a6ea3db-3e77-4ee7-a17a-0408b196a04a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d16da805-7a94-46d6-9e13-1dba9522a32d" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_7a6ea3db-3e77-4ee7-a17a-0408b196a04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_50c39c91-02c1-476f-b9d3-962136127996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_7a6ea3db-3e77-4ee7-a17a-0408b196a04a" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_50c39c91-02c1-476f-b9d3-962136127996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_390b5a76-66d5-4dbf-b1f3-9d5951b1be8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_7a6ea3db-3e77-4ee7-a17a-0408b196a04a" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_390b5a76-66d5-4dbf-b1f3-9d5951b1be8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1981cddf-602b-4f5d-b92e-ab19dceebf35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d16da805-7a94-46d6-9e13-1dba9522a32d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1981cddf-602b-4f5d-b92e-ab19dceebf35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_56adaed7-f2be-446c-8b1c-5eb7bd9a9a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_ddced350-fb94-4f0e-99e9-ffb79ae44b06" xlink:to="loc_us-gaap_EarningsPerShareAbstract_56adaed7-f2be-446c-8b1c-5eb7bd9a9a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d7232be7-1de3-4c4f-98bc-de2f0e849f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_56adaed7-f2be-446c-8b1c-5eb7bd9a9a0e" xlink:to="loc_us-gaap_EarningsPerShareBasic_d7232be7-1de3-4c4f-98bc-de2f0e849f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3f0f0ec7-f1e3-484b-9e32-5f40ec1a5dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_56adaed7-f2be-446c-8b1c-5eb7bd9a9a0e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3f0f0ec7-f1e3-484b-9e32-5f40ec1a5dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_176230e7-b019-4a77-95c9-d6b38976885b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_17bf130b-bd58-4194-84f9-0e9e90227c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_176230e7-b019-4a77-95c9-d6b38976885b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_17bf130b-bd58-4194-84f9-0e9e90227c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e97d7897-86b6-40b8-8858-22955591a189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_17bf130b-bd58-4194-84f9-0e9e90227c1d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e97d7897-86b6-40b8-8858-22955591a189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f025f473-6140-4470-80c3-907a704a1144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e97d7897-86b6-40b8-8858-22955591a189" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f025f473-6140-4470-80c3-907a704a1144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_85eba2b5-65e0-414f-a0b2-41f4023f34e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f025f473-6140-4470-80c3-907a704a1144" xlink:to="loc_us-gaap_EmployeeStockOptionMember_85eba2b5-65e0-414f-a0b2-41f4023f34e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_69b12a03-bf47-4153-81f7-95f943a4deb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f025f473-6140-4470-80c3-907a704a1144" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_69b12a03-bf47-4153-81f7-95f943a4deb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ba92badc-6421-4169-ab33-69d445e59b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f025f473-6140-4470-80c3-907a704a1144" xlink:to="loc_us-gaap_PerformanceSharesMember_ba92badc-6421-4169-ab33-69d445e59b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_bdde15d9-372c-47a1-80ec-37a98de59e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f025f473-6140-4470-80c3-907a704a1144" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_bdde15d9-372c-47a1-80ec-37a98de59e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c106b9e-e612-41aa-8624-b0d9a446d598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_17bf130b-bd58-4194-84f9-0e9e90227c1d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c106b9e-e612-41aa-8624-b0d9a446d598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2c70df20-6aa7-4efc-9a18-96a63a54687a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c106b9e-e612-41aa-8624-b0d9a446d598" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2c70df20-6aa7-4efc-9a18-96a63a54687a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a2d63194-62aa-4629-8ed8-3993ff721d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_10eb8301-6e0d-4a14-8963-45cc394922bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a2d63194-62aa-4629-8ed8-3993ff721d2f" xlink:to="loc_us-gaap_ConcentrationRiskTable_10eb8301-6e0d-4a14-8963-45cc394922bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_942aedaa-211f-4613-b55b-2b82b30f0722" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_10eb8301-6e0d-4a14-8963-45cc394922bf" xlink:to="loc_srt_MajorCustomersAxis_942aedaa-211f-4613-b55b-2b82b30f0722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5d110c00-4b6f-428a-992e-54dfdcad444a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_942aedaa-211f-4613-b55b-2b82b30f0722" xlink:to="loc_srt_NameOfMajorCustomerDomain_5d110c00-4b6f-428a-992e-54dfdcad444a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerAMember_295ed0ea-f9b2-49d7-a9c8-b512e4ac9d27" xlink:href="insm-20220630.xsd#insm_CustomerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5d110c00-4b6f-428a-992e-54dfdcad444a" xlink:to="loc_insm_CustomerAMember_295ed0ea-f9b2-49d7-a9c8-b512e4ac9d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerBMember_46271127-d55b-4219-9299-1ddf77b2e2ff" xlink:href="insm-20220630.xsd#insm_CustomerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5d110c00-4b6f-428a-992e-54dfdcad444a" xlink:to="loc_insm_CustomerBMember_46271127-d55b-4219-9299-1ddf77b2e2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerCMember_bbc5a29c-e1e2-41d9-ad69-0f32a33af357" xlink:href="insm-20220630.xsd#insm_CustomerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5d110c00-4b6f-428a-992e-54dfdcad444a" xlink:to="loc_insm_CustomerCMember_bbc5a29c-e1e2-41d9-ad69-0f32a33af357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_49241b2d-e7a0-4711-bc97-107b84625bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_10eb8301-6e0d-4a14-8963-45cc394922bf" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_49241b2d-e7a0-4711-bc97-107b84625bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a09cd1a3-2850-4f6c-b444-c28e7389c37d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_49241b2d-e7a0-4711-bc97-107b84625bf3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a09cd1a3-2850-4f6c-b444-c28e7389c37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_5e75701c-dae1-46ff-b870-d53cbb8f0208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a09cd1a3-2850-4f6c-b444-c28e7389c37d" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_5e75701c-dae1-46ff-b870-d53cbb8f0208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d6da03a2-f028-4cd5-a7aa-6eb3d5b9906d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_10eb8301-6e0d-4a14-8963-45cc394922bf" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d6da03a2-f028-4cd5-a7aa-6eb3d5b9906d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cb0d1c19-5593-4d64-bed9-88d08a244280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d6da03a2-f028-4cd5-a7aa-6eb3d5b9906d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cb0d1c19-5593-4d64-bed9-88d08a244280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e403796d-fff7-4ef3-ac34-ac008916189f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_cb0d1c19-5593-4d64-bed9-88d08a244280" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e403796d-fff7-4ef3-ac34-ac008916189f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_594c53ba-5aa1-4b05-90f2-0efca8ac1958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_10eb8301-6e0d-4a14-8963-45cc394922bf" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_594c53ba-5aa1-4b05-90f2-0efca8ac1958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fc6af9ab-21ce-49f0-ac2d-764d6c1f9000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_594c53ba-5aa1-4b05-90f2-0efca8ac1958" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fc6af9ab-21ce-49f0-ac2d-764d6c1f9000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_17323bc9-84f0-4432-9209-444c8d49f48d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_75ecc766-85c6-4610-a7a1-959c164f1a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_17323bc9-84f0-4432-9209-444c8d49f48d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_75ecc766-85c6-4610-a7a1-959c164f1a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bb3015c4-d21c-4239-9d0f-52c7123cbd89" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75ecc766-85c6-4610-a7a1-959c164f1a44" xlink:to="loc_srt_StatementGeographicalAxis_bb3015c4-d21c-4239-9d0f-52c7123cbd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_737b87d4-060e-4a4f-96e2-ef77bfb57dbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_bb3015c4-d21c-4239-9d0f-52c7123cbd89" xlink:to="loc_srt_SegmentGeographicalDomain_737b87d4-060e-4a4f-96e2-ef77bfb57dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_535093d9-5951-4ce3-8be1-e89dfc1be325" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_737b87d4-060e-4a4f-96e2-ef77bfb57dbb" xlink:to="loc_country_US_535093d9-5951-4ce3-8be1-e89dfc1be325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_729caf62-d96d-4b6c-876f-b9a43be311e5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_737b87d4-060e-4a4f-96e2-ef77bfb57dbb" xlink:to="loc_country_JP_729caf62-d96d-4b6c-876f-b9a43be311e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EuropeAndTheRestOfTheWorldMember_4c7f03ff-29e8-43ab-a411-10ded586b901" xlink:href="insm-20220630.xsd#insm_EuropeAndTheRestOfTheWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_737b87d4-060e-4a4f-96e2-ef77bfb57dbb" xlink:to="loc_insm_EuropeAndTheRestOfTheWorldMember_4c7f03ff-29e8-43ab-a411-10ded586b901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5a71ec6c-d888-4328-a888-dbcc299608cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75ecc766-85c6-4610-a7a1-959c164f1a44" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5a71ec6c-d888-4328-a888-dbcc299608cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_027e2205-ca94-4b61-9701-abcb2a8b280a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5a71ec6c-d888-4328-a888-dbcc299608cd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_027e2205-ca94-4b61-9701-abcb2a8b280a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/Inventory" xlink:type="simple" xlink:href="insm-20220630.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_49157e13-b429-4e43-81e1-cafd53724535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_292e08b5-d873-4486-8f1c-6a3ba268d54c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_49157e13-b429-4e43-81e1-cafd53724535" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_292e08b5-d873-4486-8f1c-6a3ba268d54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryTables" xlink:type="simple" xlink:href="insm-20220630.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a075ade3-b8f0-456e-bbbb-00e437eb97ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_7253372b-1baa-40e4-acec-32fa2502c65b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a075ade3-b8f0-456e-bbbb-00e437eb97ee" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_7253372b-1baa-40e4-acec-32fa2502c65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#InventoryScheduleofInventoryCurrentDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_03dfbe92-6364-47e7-8a84-9103ced033fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_ce27b8d8-0f17-44ee-829e-2573cc436c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03dfbe92-6364-47e7-8a84-9103ced033fb" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_ce27b8d8-0f17-44ee-829e-2573cc436c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6ac23653-007e-46f7-86ce-05405de2f301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03dfbe92-6364-47e7-8a84-9103ced033fb" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6ac23653-007e-46f7-86ce-05405de2f301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_13a34dec-0b62-4b74-b012-2b0c18899670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03dfbe92-6364-47e7-8a84-9103ced033fb" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_13a34dec-0b62-4b74-b012-2b0c18899670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_29ed7c68-e5b3-459e-94a4-a22a69406eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_03dfbe92-6364-47e7-8a84-9103ced033fb" xlink:to="loc_us-gaap_InventoryNet_29ed7c68-e5b3-459e-94a4-a22a69406eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNetandGoodwill" xlink:type="simple" xlink:href="insm-20220630.xsd#IntangiblesNetandGoodwill"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangiblesNetandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d3d5dcca-ea2c-4150-8836-968049850c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_082c0088-8578-4151-a9df-fe360db1e2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d3d5dcca-ea2c-4150-8836-968049850c7e" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_082c0088-8578-4151-a9df-fe360db1e2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNetandGoodwillTables" xlink:type="simple" xlink:href="insm-20220630.xsd#IntangiblesNetandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangiblesNetandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c2f7763f-ff99-4f8f-812d-1f03a73b669e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5ff55b7f-c0b6-41eb-b463-5fa9e89015c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c2f7763f-ff99-4f8f-812d-1f03a73b669e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5ff55b7f-c0b6-41eb-b463-5fa9e89015c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#IntangiblesNetandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_71973712-7a97-4c3f-b70d-ea45ad1de895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0b17f383-21e1-441c-8b18-72f8ae366ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_71973712-7a97-4c3f-b70d-ea45ad1de895" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0b17f383-21e1-441c-8b18-72f8ae366ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_f58b75bf-6ec2-4c33-a3d2-d26fb229607f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_71973712-7a97-4c3f-b70d-ea45ad1de895" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_f58b75bf-6ec2-4c33-a3d2-d26fb229607f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7e8b3a75-ee39-4826-8437-d3af6ca58ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_71973712-7a97-4c3f-b70d-ea45ad1de895" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7e8b3a75-ee39-4826-8437-d3af6ca58ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_55a14fe5-d32d-47d2-b820-6718ab85f9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_71973712-7a97-4c3f-b70d-ea45ad1de895" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_55a14fe5-d32d-47d2-b820-6718ab85f9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a67a2ef7-b292-44ef-96c7-b2d2c9795656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_71973712-7a97-4c3f-b70d-ea45ad1de895" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a67a2ef7-b292-44ef-96c7-b2d2c9795656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_84bfbf85-fe80-4cf8-8cfd-72c4b386cfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_71973712-7a97-4c3f-b70d-ea45ad1de895" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_84bfbf85-fe80-4cf8-8cfd-72c4b386cfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a6e82328-8119-43e5-bedb-d980de91dcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_71973712-7a97-4c3f-b70d-ea45ad1de895" xlink:to="loc_us-gaap_Goodwill_a6e82328-8119-43e5-bedb-d980de91dcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d4b1329a-6e27-4e08-8ef8-f17f28c0fe35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_71973712-7a97-4c3f-b70d-ea45ad1de895" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d4b1329a-6e27-4e08-8ef8-f17f28c0fe35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3d7e2db-40ed-4200-9348-f20b4b832b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d4b1329a-6e27-4e08-8ef8-f17f28c0fe35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3d7e2db-40ed-4200-9348-f20b4b832b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fd3d7b1-1653-436a-90b6-5f63762eb401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3d7e2db-40ed-4200-9348-f20b4b832b3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fd3d7b1-1653-436a-90b6-5f63762eb401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AcquiredResearchAndDevelopmentMember_69ebf176-99f9-4b40-9f2e-9e0d77e7d505" xlink:href="insm-20220630.xsd#insm_AcquiredResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fd3d7b1-1653-436a-90b6-5f63762eb401" xlink:to="loc_insm_AcquiredResearchAndDevelopmentMember_69ebf176-99f9-4b40-9f2e-9e0d77e7d505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8089bf5b-1908-4ff5-9847-f82eafaaeb08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fd3d7b1-1653-436a-90b6-5f63762eb401" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8089bf5b-1908-4ff5-9847-f82eafaaeb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_3625347f-cc8f-4cc3-b6f2-f8b376b314a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fd3d7b1-1653-436a-90b6-5f63762eb401" xlink:to="loc_us-gaap_LicensingAgreementsMember_3625347f-cc8f-4cc3-b6f2-f8b376b314a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9d806a8d-71c0-4275-986c-e9c6085f5bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d4b1329a-6e27-4e08-8ef8-f17f28c0fe35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9d806a8d-71c0-4275-986c-e9c6085f5bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6a855817-5ba0-42d7-a28b-7dc4ca7346e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9d806a8d-71c0-4275-986c-e9c6085f5bc5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6a855817-5ba0-42d7-a28b-7dc4ca7346e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3409103d-69bb-4345-b995-62c63685997c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6a855817-5ba0-42d7-a28b-7dc4ca7346e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3409103d-69bb-4345-b995-62c63685997c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_eca530e9-f752-446d-b41a-f355e8d4f698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6a855817-5ba0-42d7-a28b-7dc4ca7346e0" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_eca530e9-f752-446d-b41a-f355e8d4f698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c6b810ae-955b-4065-9b6b-9bcefc69b0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6a855817-5ba0-42d7-a28b-7dc4ca7346e0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c6b810ae-955b-4065-9b6b-9bcefc69b0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b133af81-5289-48a1-a978-d4c02f81c0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6a855817-5ba0-42d7-a28b-7dc4ca7346e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b133af81-5289-48a1-a978-d4c02f81c0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0db2ac59-70d3-4102-8321-244e5e300204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9d806a8d-71c0-4275-986c-e9c6085f5bc5" xlink:to="loc_us-gaap_Goodwill_0db2ac59-70d3-4102-8321-244e5e300204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNet" xlink:type="simple" xlink:href="insm-20220630.xsd#FixedAssetsNet"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FixedAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c4643cfe-295c-410e-9cf7-464f8eb534c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1d055400-a428-4adc-aaaa-814849f74893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c4643cfe-295c-410e-9cf7-464f8eb534c8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1d055400-a428-4adc-aaaa-814849f74893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNetTables" xlink:type="simple" xlink:href="insm-20220630.xsd#FixedAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FixedAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c3756bc0-fce8-40f1-a61a-fd39c353aa95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_05168d61-b1e7-4174-9a89-e944d45a87f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c3756bc0-fce8-40f1-a61a-fd39c353aa95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_05168d61-b1e7-4174-9a89-e944d45a87f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#FixedAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_391cb1c8-036b-405c-989d-a39a34d95c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34cef78f-0f45-470d-8677-11c97fd1ace4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_391cb1c8-036b-405c-989d-a39a34d95c56" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34cef78f-0f45-470d-8677-11c97fd1ace4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_beb64343-a6d6-4c60-a96d-1da7fb173a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34cef78f-0f45-470d-8677-11c97fd1ace4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_beb64343-a6d6-4c60-a96d-1da7fb173a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_beb64343-a6d6-4c60-a96d-1da7fb173a81" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_b746b407-8ca0-4dce-9266-f19c59ce3b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:to="loc_us-gaap_EquipmentMember_b746b407-8ca0-4dce-9266-f19c59ce3b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_bc02a35a-6186-4b3b-9a42-256104052c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_bc02a35a-6186-4b3b-9a42-256104052c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember_d30ecbfa-d183-4426-9b22-c5390eb5f97e" xlink:href="insm-20220630.xsd#insm_ComputerHardwareAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:to="loc_insm_ComputerHardwareAndSoftwareMember_d30ecbfa-d183-4426-9b22-c5390eb5f97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_cc411871-3245-4156-be1c-917020623aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:to="loc_us-gaap_OfficeEquipmentMember_cc411871-3245-4156-be1c-917020623aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ManufacturingEquipmentMember_ab889d68-510c-4cc3-b11c-79297be371c0" xlink:href="insm-20220630.xsd#insm_ManufacturingEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:to="loc_insm_ManufacturingEquipmentMember_ab889d68-510c-4cc3-b11c-79297be371c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1d2dd8bc-a426-457e-a8e5-6faad48ebca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1d2dd8bc-a426-457e-a8e5-6faad48ebca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_4f657990-f40d-4579-a5ce-7f663341bd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b94628ee-53f8-4970-b566-8d0c14933105" xlink:to="loc_us-gaap_ConstructionInProgressMember_4f657990-f40d-4579-a5ce-7f663341bd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_16a88eb1-aa12-41b1-ab71-469af39a28a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34cef78f-0f45-470d-8677-11c97fd1ace4" xlink:to="loc_srt_RangeAxis_16a88eb1-aa12-41b1-ab71-469af39a28a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8007cfb4-4f54-40b7-b7e4-86d0c8c3af6a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_16a88eb1-aa12-41b1-ab71-469af39a28a3" xlink:to="loc_srt_RangeMember_8007cfb4-4f54-40b7-b7e4-86d0c8c3af6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_617994f4-2afa-4743-b985-0b5486e8521e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8007cfb4-4f54-40b7-b7e4-86d0c8c3af6a" xlink:to="loc_srt_MinimumMember_617994f4-2afa-4743-b985-0b5486e8521e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5d9a1be3-56fb-4d0e-94d7-052880af8130" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8007cfb4-4f54-40b7-b7e4-86d0c8c3af6a" xlink:to="loc_srt_MaximumMember_5d9a1be3-56fb-4d0e-94d7-052880af8130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243b3064-d34a-402d-add7-217ee8d3380d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34cef78f-0f45-470d-8677-11c97fd1ace4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243b3064-d34a-402d-add7-217ee8d3380d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_94dd6f85-ef6e-4f4b-84aa-abb1d96c3806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243b3064-d34a-402d-add7-217ee8d3380d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_94dd6f85-ef6e-4f4b-84aa-abb1d96c3806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7e597766-d05c-4a3c-a4a3-e0978a9ec172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243b3064-d34a-402d-add7-217ee8d3380d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7e597766-d05c-4a3c-a4a3-e0978a9ec172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f5b43579-7350-487f-9355-4d88cd95e6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243b3064-d34a-402d-add7-217ee8d3380d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f5b43579-7350-487f-9355-4d88cd95e6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8111203b-2457-4162-aed1-66b293c2d188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243b3064-d34a-402d-add7-217ee8d3380d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8111203b-2457-4162-aed1-66b293c2d188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="insm-20220630.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_efefa9db-a60f-4122-8e99-9fd613c46770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e5b74295-4b3b-4ce4-b703-00698c167949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_efefa9db-a60f-4122-8e99-9fd613c46770" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e5b74295-4b3b-4ce4-b703-00698c167949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="insm-20220630.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_dce395c5-ea90-4574-8615-ac5a1c7b8a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c80b8306-66bc-4626-b8e9-09f84e3c40d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dce395c5-ea90-4574-8615-ac5a1c7b8a92" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c80b8306-66bc-4626-b8e9-09f84e3c40d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_904fff14-74fd-455c-b184-3bfcd013e214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedClinicalTrialExpenses_02524bff-8b46-44e8-a3e0-2a6ba54e05d6" xlink:href="insm-20220630.xsd#insm_AccruedClinicalTrialExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_904fff14-74fd-455c-b184-3bfcd013e214" xlink:to="loc_insm_AccruedClinicalTrialExpenses_02524bff-8b46-44e8-a3e0-2a6ba54e05d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_4b7bc046-9daf-4501-8718-063125e3ed6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_904fff14-74fd-455c-b184-3bfcd013e214" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_4b7bc046-9daf-4501-8718-063125e3ed6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedTechnicalOperationExpenses_bee1c8a6-e1e7-4d8d-8157-01d352612dfa" xlink:href="insm-20220630.xsd#insm_AccruedTechnicalOperationExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_904fff14-74fd-455c-b184-3bfcd013e214" xlink:to="loc_insm_AccruedTechnicalOperationExpenses_bee1c8a6-e1e7-4d8d-8157-01d352612dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedRoyaltiesAndMilestonePaymentsCurrent_25ddc2df-a169-48db-ab34-378b6c3e751a" xlink:href="insm-20220630.xsd#insm_AccruedRoyaltiesAndMilestonePaymentsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_904fff14-74fd-455c-b184-3bfcd013e214" xlink:to="loc_insm_AccruedRoyaltiesAndMilestonePaymentsCurrent_25ddc2df-a169-48db-ab34-378b6c3e751a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_626c7f63-52dc-4bcb-80d5-9f4a752d5c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_904fff14-74fd-455c-b184-3bfcd013e214" xlink:to="loc_us-gaap_InterestPayableCurrent_626c7f63-52dc-4bcb-80d5-9f4a752d5c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedSalesAllowancesAndRelatedCosts_1a7cefac-031e-45aa-8228-14625effe61b" xlink:href="insm-20220630.xsd#insm_AccruedSalesAllowancesAndRelatedCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_904fff14-74fd-455c-b184-3bfcd013e214" xlink:to="loc_insm_AccruedSalesAllowancesAndRelatedCosts_1a7cefac-031e-45aa-8228-14625effe61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredPaymentsCurrent_7737708c-2192-4529-a015-f4c27e43b154" xlink:href="insm-20220630.xsd#insm_BusinessCombinationDeferredPaymentsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_904fff14-74fd-455c-b184-3bfcd013e214" xlink:to="loc_insm_BusinessCombinationDeferredPaymentsCurrent_7737708c-2192-4529-a015-f4c27e43b154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedConstructionLiabilitiesCurrent_e380c8af-716e-4dd2-b91a-6cc072531d05" xlink:href="insm-20220630.xsd#insm_AccruedConstructionLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_904fff14-74fd-455c-b184-3bfcd013e214" xlink:to="loc_insm_AccruedConstructionLiabilitiesCurrent_e380c8af-716e-4dd2-b91a-6cc072531d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_965944de-64d3-418a-86d0-b011896e19ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_904fff14-74fd-455c-b184-3bfcd013e214" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_965944de-64d3-418a-86d0-b011896e19ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8fd86f33-0d3f-4470-bc5b-eadf1ec798a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_904fff14-74fd-455c-b184-3bfcd013e214" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8fd86f33-0d3f-4470-bc5b-eadf1ec798a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/Leases" xlink:type="simple" xlink:href="insm-20220630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1db25d62-b8be-470a-8d10-76f0061ba64f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_76eed327-d182-40b9-a0cc-85b884d64b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1db25d62-b8be-470a-8d10-76f0061ba64f" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_76eed327-d182-40b9-a0cc-85b884d64b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_e8d40f93-b817-47f4-98d7-ce154a4340dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1db25d62-b8be-470a-8d10-76f0061ba64f" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_e8d40f93-b817-47f4-98d7-ce154a4340dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesTables" xlink:type="simple" xlink:href="insm-20220630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b735cf00-09b6-4db3-9982-c516bf957890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_82cf9d38-6a8d-434b-8383-74281918186b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b735cf00-09b6-4db3-9982-c516bf957890" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_82cf9d38-6a8d-434b-8383-74281918186b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f555822e-43a5-4a58-928d-6e9e37543f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_508a38d1-da47-4033-ac13-3876f4083645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f555822e-43a5-4a58-928d-6e9e37543f6b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_508a38d1-da47-4033-ac13-3876f4083645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f353e1fb-ab87-4c5f-8b00-20e5e240414d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_508a38d1-da47-4033-ac13-3876f4083645" xlink:to="loc_srt_RangeAxis_f353e1fb-ab87-4c5f-8b00-20e5e240414d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a38211cb-0f28-4db8-b8f1-95432fde9ab1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f353e1fb-ab87-4c5f-8b00-20e5e240414d" xlink:to="loc_srt_RangeMember_a38211cb-0f28-4db8-b8f1-95432fde9ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_febb1ef5-bebb-423a-88bf-3f11d1efebe5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a38211cb-0f28-4db8-b8f1-95432fde9ab1" xlink:to="loc_srt_MinimumMember_febb1ef5-bebb-423a-88bf-3f11d1efebe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8b00c53c-bf3b-4bc7-997f-4f18679a6602" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a38211cb-0f28-4db8-b8f1-95432fde9ab1" xlink:to="loc_srt_MaximumMember_8b00c53c-bf3b-4bc7-997f-4f18679a6602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1ece60d-1a19-4d2c-90c8-1d0eb18b4a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_508a38d1-da47-4033-ac13-3876f4083645" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1ece60d-1a19-4d2c-90c8-1d0eb18b4a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LeaseRemainingLeaseTerm_a1935f61-15ed-4e31-a291-e79cacd4521c" xlink:href="insm-20220630.xsd#insm_LeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1ece60d-1a19-4d2c-90c8-1d0eb18b4a8b" xlink:to="loc_insm_LeaseRemainingLeaseTerm_a1935f61-15ed-4e31-a291-e79cacd4521c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_cf118c0b-be9d-4f33-84ef-18ba02c13011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1ece60d-1a19-4d2c-90c8-1d0eb18b4a8b" xlink:to="loc_us-gaap_VariableLeaseCost_cf118c0b-be9d-4f33-84ef-18ba02c13011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount_cdc28448-ec6d-4a4b-83e7-0b924a0e5925" xlink:href="insm-20220630.xsd#insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1ece60d-1a19-4d2c-90c8-1d0eb18b4a8b" xlink:to="loc_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount_cdc28448-ec6d-4a4b-83e7-0b924a0e5925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesLeasecostsDetailsDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#LeasesLeasecostsDetailsDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/LeasesLeasecostsDetailsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a8a9c4da-e2c8-4de2-9f87-b809db1e8b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_3d9fea40-b364-465c-b2c8-d250fc4d43d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a8a9c4da-e2c8-4de2-9f87-b809db1e8b24" xlink:to="loc_us-gaap_LeaseCostAbstract_3d9fea40-b364-465c-b2c8-d250fc4d43d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_b1a1d35b-0adc-4a86-8d7f-4cc937cc2fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_3d9fea40-b364-465c-b2c8-d250fc4d43d0" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_b1a1d35b-0adc-4a86-8d7f-4cc937cc2fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d5cf01ac-42ea-4b77-b8d7-4c8e3ead0c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_3d9fea40-b364-465c-b2c8-d250fc4d43d0" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d5cf01ac-42ea-4b77-b8d7-4c8e3ead0c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/Debt" xlink:type="simple" xlink:href="insm-20220630.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f0ebaa05-00e8-4018-95bf-1c02466f448c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_2fc71788-1f79-474f-967c-4a17fc55d6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f0ebaa05-00e8-4018-95bf-1c02466f448c" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_2fc71788-1f79-474f-967c-4a17fc55d6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtTables" xlink:type="simple" xlink:href="insm-20220630.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_42c3a15d-4717-442e-b428-747919beddd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_ae0c83d2-14c2-49c0-9a61-4bd862e2f010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_42c3a15d-4717-442e-b428-747919beddd6" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_ae0c83d2-14c2-49c0-9a61-4bd862e2f010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_61983e96-76ad-4397-b17d-a82ddfb6cf53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_42c3a15d-4717-442e-b428-747919beddd6" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_61983e96-76ad-4397-b17d-a82ddfb6cf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_cb6ef70a-69b1-4ac9-8260-dabfeb2a5d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_42c3a15d-4717-442e-b428-747919beddd6" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_cb6ef70a-69b1-4ac9-8260-dabfeb2a5d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_396de50d-db3b-4997-9e5a-f18c036350a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_07accd24-e37b-4f63-a83e-3d3f14f597cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_396de50d-db3b-4997-9e5a-f18c036350a4" xlink:to="loc_us-gaap_DebtInstrumentTable_07accd24-e37b-4f63-a83e-3d3f14f597cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bfc6a203-ac89-43d1-88cd-cbdb4a931ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_07accd24-e37b-4f63-a83e-3d3f14f597cd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bfc6a203-ac89-43d1-88cd-cbdb4a931ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c230224f-d008-4bcf-ac73-941c31f635d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfc6a203-ac89-43d1-88cd-cbdb4a931ec5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c230224f-d008-4bcf-ac73-941c31f635d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_dfb8ae97-ad53-454c-bfea-3c7984879769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c230224f-d008-4bcf-ac73-941c31f635d4" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_dfb8ae97-ad53-454c-bfea-3c7984879769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0452000e-eaad-4c96-b829-a0b79d37dae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_07accd24-e37b-4f63-a83e-3d3f14f597cd" xlink:to="loc_us-gaap_DebtInstrumentAxis_0452000e-eaad-4c96-b829-a0b79d37dae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2b5fc68f-06fb-425c-8abf-e613502fdae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0452000e-eaad-4c96-b829-a0b79d37dae0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2b5fc68f-06fb-425c-8abf-e613502fdae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_ccf72e0a-c41c-4c10-b87b-66e4b7eaf6c6" xlink:href="insm-20220630.xsd#insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2b5fc68f-06fb-425c-8abf-e613502fdae2" xlink:to="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_ccf72e0a-c41c-4c10-b87b-66e4b7eaf6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_0ac2a693-4bec-4861-8300-13f1d65d6174" xlink:href="insm-20220630.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2b5fc68f-06fb-425c-8abf-e613502fdae2" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_0ac2a693-4bec-4861-8300-13f1d65d6174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermAxis_622c5801-7732-4b3e-a134-74f3c10b0b94" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_07accd24-e37b-4f63-a83e-3d3f14f597cd" xlink:to="loc_insm_DebtInstrumentConversionTermAxis_622c5801-7732-4b3e-a134-74f3c10b0b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_2a283175-9a9f-483e-9af4-a1d3e8ba1c0a" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_622c5801-7732-4b3e-a134-74f3c10b0b94" xlink:to="loc_insm_DebtInstrumentConversionTermDomain_2a283175-9a9f-483e-9af4-a1d3e8ba1c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermOneMember_f7cbd67d-5995-47e8-8d15-d6668d42ce8a" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_2a283175-9a9f-483e-9af4-a1d3e8ba1c0a" xlink:to="loc_insm_DebtInstrumentConversionTermOneMember_f7cbd67d-5995-47e8-8d15-d6668d42ce8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermTwoMember_6792b35e-7647-4295-83c0-a8f67792543a" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_2a283175-9a9f-483e-9af4-a1d3e8ba1c0a" xlink:to="loc_insm_DebtInstrumentConversionTermTwoMember_6792b35e-7647-4295-83c0-a8f67792543a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermThreeMember_db9e7b73-5c33-40bd-b747-74721ac250f6" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_2a283175-9a9f-483e-9af4-a1d3e8ba1c0a" xlink:to="loc_insm_DebtInstrumentConversionTermThreeMember_db9e7b73-5c33-40bd-b747-74721ac250f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermFourMember_3de3d1de-b8e4-4daa-afc9-604cb96ab9d2" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConversionTermFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_2a283175-9a9f-483e-9af4-a1d3e8ba1c0a" xlink:to="loc_insm_DebtInstrumentConversionTermFourMember_3de3d1de-b8e4-4daa-afc9-604cb96ab9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_07accd24-e37b-4f63-a83e-3d3f14f597cd" xlink:to="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ae626a75-71d8-4e32-8737-6eec44b4b9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ae626a75-71d8-4e32-8737-6eec44b4b9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_4200d377-0fcc-4129-b884-c5ab45b0dd1d" xlink:href="insm-20220630.xsd#insm_DebtInstrumentOptionToPurchaseAdditionalDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_4200d377-0fcc-4129-b884-c5ab45b0dd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_0c9c262e-b66a-41d4-b401-7de4a9125cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_0c9c262e-b66a-41d4-b401-7de4a9125cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_ebdfd548-0d45-4349-bc0f-696da2be2a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_ebdfd548-0d45-4349-bc0f-696da2be2a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_26284758-c21f-4077-b145-58e0a8cda842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_26284758-c21f-4077-b145-58e0a8cda842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d2da896d-6249-4076-93af-1d4b3599bf25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d2da896d-6249-4076-93af-1d4b3599bf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_300304bb-5a64-49a1-b3c0-a9aec8e25bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_300304bb-5a64-49a1-b3c0-a9aec8e25bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7fa708d4-0155-44e0-830b-1d82061f6eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7fa708d4-0155-44e0-830b-1d82061f6eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5815ebb4-1c0b-44fd-9ddc-29f792af8c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5815ebb4-1c0b-44fd-9ddc-29f792af8c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_574f74cb-14d3-413e-bb9c-e0eabb5707f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_574f74cb-14d3-413e-bb9c-e0eabb5707f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_1b3362e3-28ae-4eac-81bb-50bbaa2dec0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_1b3362e3-28ae-4eac-81bb-50bbaa2dec0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_9b2a5c58-9c39-441b-b8a7-ffbd0473c06e" xlink:href="insm-20220630.xsd#insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_9b2a5c58-9c39-441b-b8a7-ffbd0473c06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining_fbd764c6-79fd-4b1b-aff6-f4bb67b4b199" xlink:href="insm-20220630.xsd#insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_20c4c993-9c45-4249-8e78-2d81f0d5d579" xlink:to="loc_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining_fbd764c6-79fd-4b1b-aff6-f4bb67b4b199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtComponentsofDebtDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#DebtComponentsofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtComponentsofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a9528ed9-cb2a-408d-b348-7b86cd7dd6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_ef4373f1-f4ea-4762-98c2-820bf99efc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a9528ed9-cb2a-408d-b348-7b86cd7dd6f2" xlink:to="loc_us-gaap_SecuredDebt_ef4373f1-f4ea-4762-98c2-820bf99efc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_a350a06f-0bc7-4988-bee8-6d00e6683953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a9528ed9-cb2a-408d-b348-7b86cd7dd6f2" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_a350a06f-0bc7-4988-bee8-6d00e6683953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8a80e7fa-a24b-465a-b804-878d7143cd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a9528ed9-cb2a-408d-b348-7b86cd7dd6f2" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8a80e7fa-a24b-465a-b804-878d7143cd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f4160a16-9f26-4acc-94ba-8ab19e04117f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a9528ed9-cb2a-408d-b348-7b86cd7dd6f2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f4160a16-9f26-4acc-94ba-8ab19e04117f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#DebtFuturePrincipalRepaymentsofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_79982a1b-bdee-4033-a432-f899da6c6969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_bd54accc-6ee5-4899-b6c1-15e07b745183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_79982a1b-bdee-4033-a432-f899da6c6969" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_bd54accc-6ee5-4899-b6c1-15e07b745183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_41350390-e425-4c42-a490-7ffc00d4ed8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_bd54accc-6ee5-4899-b6c1-15e07b745183" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_41350390-e425-4c42-a490-7ffc00d4ed8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_94260542-bc2d-4046-94f4-f65c10e07225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_bd54accc-6ee5-4899-b6c1-15e07b745183" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_94260542-bc2d-4046-94f4-f65c10e07225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1e48390a-86fd-445d-b8da-728b9b9d08a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_bd54accc-6ee5-4899-b6c1-15e07b745183" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1e48390a-86fd-445d-b8da-728b9b9d08a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8cdcf9f2-5fda-48d5-b777-febafbe86498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_bd54accc-6ee5-4899-b6c1-15e07b745183" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8cdcf9f2-5fda-48d5-b777-febafbe86498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_eb7dfc9b-f448-44a6-8afa-0717005ff5da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_bd54accc-6ee5-4899-b6c1-15e07b745183" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_eb7dfc9b-f448-44a6-8afa-0717005ff5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LongTermDebtMaturityAfterYearFour_9fbea7e3-2ba2-494c-b917-be024a2ec9f4" xlink:href="insm-20220630.xsd#insm_LongTermDebtMaturityAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_bd54accc-6ee5-4899-b6c1-15e07b745183" xlink:to="loc_insm_LongTermDebtMaturityAfterYearFour_9fbea7e3-2ba2-494c-b917-be024a2ec9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_fdbaf51e-cf18-46c2-a6b6-d55a5a8ffa80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_bd54accc-6ee5-4899-b6c1-15e07b745183" xlink:to="loc_us-gaap_LongTermDebt_fdbaf51e-cf18-46c2-a6b6-d55a5a8ffa80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#DebtInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_753dff38-0ce3-4815-bfcf-60188d020a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_67e8398a-ec25-493c-9223-333dcd66e805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_753dff38-0ce3-4815-bfcf-60188d020a8b" xlink:to="loc_us-gaap_InterestExpenseDebt_67e8398a-ec25-493c-9223-333dcd66e805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_a5f2ebce-4039-49e2-87cf-20c33f69e876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_753dff38-0ce3-4815-bfcf-60188d020a8b" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_a5f2ebce-4039-49e2-87cf-20c33f69e876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_e052ee53-0046-4232-85e3-b802f1cfd4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_753dff38-0ce3-4815-bfcf-60188d020a8b" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_e052ee53-0046-4232-85e3-b802f1cfd4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConvertibleDebtInterestExpenseTotal_98835210-f597-433d-8a67-f5808545dbf5" xlink:href="insm-20220630.xsd#insm_ConvertibleDebtInterestExpenseTotal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_753dff38-0ce3-4815-bfcf-60188d020a8b" xlink:to="loc_insm_ConvertibleDebtInterestExpenseTotal_98835210-f597-433d-8a67-f5808545dbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_eabf1c78-4514-466d-b841-2dec1d0bc4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_753dff38-0ce3-4815-bfcf-60188d020a8b" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_eabf1c78-4514-466d-b841-2dec1d0bc4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_06926034-77be-41d7-843b-b83d39be7dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_753dff38-0ce3-4815-bfcf-60188d020a8b" xlink:to="loc_us-gaap_InterestExpense_06926034-77be-41d7-843b-b83d39be7dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="insm-20220630.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_251a887d-f1df-4e0d-8b19-6b54f7fcae6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5b8d7bb4-3795-466e-aef2-aeeac9496d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_251a887d-f1df-4e0d-8b19-6b54f7fcae6d" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5b8d7bb4-3795-466e-aef2-aeeac9496d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c4796730-ae0c-4e12-81a2-f087f9348a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_798d49b7-00f2-41be-bc89-94ec482d6957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c4796730-ae0c-4e12-81a2-f087f9348a3d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_798d49b7-00f2-41be-bc89-94ec482d6957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3ac1a4ee-a908-4e89-83f7-ba2d26ed7ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_798d49b7-00f2-41be-bc89-94ec482d6957" xlink:to="loc_us-gaap_AwardTypeAxis_3ac1a4ee-a908-4e89-83f7-ba2d26ed7ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_afa9071a-6f49-498e-96f5-12bc6604d20a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3ac1a4ee-a908-4e89-83f7-ba2d26ed7ed0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_afa9071a-6f49-498e-96f5-12bc6604d20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_24247904-6e71-49e1-8464-16237ab0ac29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_afa9071a-6f49-498e-96f5-12bc6604d20a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_24247904-6e71-49e1-8464-16237ab0ac29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_aa13a182-d397-4d37-b650-a2aebdb5c72a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_afa9071a-6f49-498e-96f5-12bc6604d20a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_aa13a182-d397-4d37-b650-a2aebdb5c72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_8111e6c7-871d-47ff-9758-045d2060ccde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_afa9071a-6f49-498e-96f5-12bc6604d20a" xlink:to="loc_us-gaap_PerformanceSharesMember_8111e6c7-871d-47ff-9758-045d2060ccde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_532f2e14-7299-4bbe-bc23-abba08d7cd18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_798d49b7-00f2-41be-bc89-94ec482d6957" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_532f2e14-7299-4bbe-bc23-abba08d7cd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_41e3d6e5-86d5-42b0-b8c5-3bf7fd19b57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_532f2e14-7299-4bbe-bc23-abba08d7cd18" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_41e3d6e5-86d5-42b0-b8c5-3bf7fd19b57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_03ceec7a-98a7-4c8c-b602-3bd7d035bb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_41e3d6e5-86d5-42b0-b8c5-3bf7fd19b57f" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_03ceec7a-98a7-4c8c-b602-3bd7d035bb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ddbe99fc-02ba-4cb2-ba1d-9f6d8a2b06ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_798d49b7-00f2-41be-bc89-94ec482d6957" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ddbe99fc-02ba-4cb2-ba1d-9f6d8a2b06ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_21536ad2-e43d-4fd8-bf3a-40c035f5022b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ddbe99fc-02ba-4cb2-ba1d-9f6d8a2b06ab" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_21536ad2-e43d-4fd8-bf3a-40c035f5022b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PublicStockOfferingMember_f669421d-2f59-4d90-a04c-f77357505aa8" xlink:href="insm-20220630.xsd#insm_PublicStockOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_21536ad2-e43d-4fd8-bf3a-40c035f5022b" xlink:to="loc_insm_PublicStockOfferingMember_f669421d-2f59-4d90-a04c-f77357505aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_ecd3e61f-e4c8-4cfa-a824-2899f41c9884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_21536ad2-e43d-4fd8-bf3a-40c035f5022b" xlink:to="loc_us-gaap_OverAllotmentOptionMember_ecd3e61f-e4c8-4cfa-a824-2899f41c9884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AtTheMarketAgreementMember_236fabba-6054-439e-bf38-f755b1acc3f2" xlink:href="insm-20220630.xsd#insm_AtTheMarketAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_21536ad2-e43d-4fd8-bf3a-40c035f5022b" xlink:to="loc_insm_AtTheMarketAgreementMember_236fabba-6054-439e-bf38-f755b1acc3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c7f15337-b67c-44ab-9727-3113bc8e9629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_798d49b7-00f2-41be-bc89-94ec482d6957" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c7f15337-b67c-44ab-9727-3113bc8e9629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0d03e04f-fde7-4b01-8318-cc144e9b94f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c7f15337-b67c-44ab-9727-3113bc8e9629" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0d03e04f-fde7-4b01-8318-cc144e9b94f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncMember_b377dc7b-f3d5-402c-90fb-ed77fc54213e" xlink:href="insm-20220630.xsd#insm_MotusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0d03e04f-fde7-4b01-8318-cc144e9b94f5" xlink:to="loc_insm_MotusBiosciencesIncMember_b377dc7b-f3d5-402c-90fb-ed77fc54213e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_798d49b7-00f2-41be-bc89-94ec482d6957" xlink:to="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4a540f1d-9425-4a4a-8865-fffbbcb864ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4a540f1d-9425-4a4a-8865-fffbbcb864ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_13b3953c-0486-4a89-b376-2941c39696e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_13b3953c-0486-4a89-b376-2941c39696e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_788814c8-a9c3-47c6-a64e-3598f4f261be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_CommonStockSharesIssued_788814c8-a9c3-47c6-a64e-3598f4f261be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e52fb68e-aeee-4a1e-936d-170274080665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e52fb68e-aeee-4a1e-936d-170274080665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dd411ad0-45df-4b04-b25a-d34d2cdb6e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dd411ad0-45df-4b04-b25a-d34d2cdb6e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0d8deae2-b5a5-4e75-8c81-052c4a4c29ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0d8deae2-b5a5-4e75-8c81-052c4a4c29ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_30330c4f-554e-46eb-9525-f3f84880740d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_30330c4f-554e-46eb-9525-f3f84880740d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0d55bc1b-25d3-47b5-99bb-80aaaa2a2407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0d55bc1b-25d3-47b5-99bb-80aaaa2a2407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e57b62d0-17fc-4317-b491-cc565f98a176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e57b62d0-17fc-4317-b491-cc565f98a176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_09ec1f04-7447-402d-8d26-109c271fb3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_09ec1f04-7447-402d-8d26-109c271fb3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommonStockAuthorizedAggregateGrossSalesProceeds_5248742f-55b3-4c7c-8039-ba33b2fe67be" xlink:href="insm-20220630.xsd#insm_CommonStockAuthorizedAggregateGrossSalesProceeds"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_insm_CommonStockAuthorizedAggregateGrossSalesProceeds_5248742f-55b3-4c7c-8039-ba33b2fe67be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f519f2a1-6b53-4329-b129-1cc3a3b320aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f519f2a1-6b53-4329-b129-1cc3a3b320aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_492e0d76-3478-4a08-8f76-6952e7c076ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_492e0d76-3478-4a08-8f76-6952e7c076ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7b1db8f6-9eca-46b3-949d-e523b0e620ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7b1db8f6-9eca-46b3-949d-e523b0e620ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f8cd3216-5531-44f4-bda2-3dd5adcec146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e5013ed2-0eaf-42df-960d-7774f1ff64eb" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f8cd3216-5531-44f4-bda2-3dd5adcec146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="insm-20220630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62773e5e-b601-481f-ab27-f975aef75f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3c814159-fc7e-4349-8ce1-e61c953532bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62773e5e-b601-481f-ab27-f975aef75f09" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3c814159-fc7e-4349-8ce1-e61c953532bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="insm-20220630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9d1c1470-a883-4cd6-bda2-3c6f97d722a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2d19caa9-715c-45dc-936e-93971f85046d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9d1c1470-a883-4cd6-bda2-3c6f97d722a5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2d19caa9-715c-45dc-936e-93971f85046d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e8d97883-90ab-44f9-ab8f-fb45dd20fbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72daae71-e379-4945-a919-48d9f8bb6b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e8d97883-90ab-44f9-ab8f-fb45dd20fbe4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72daae71-e379-4945-a919-48d9f8bb6b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9d3aed09-0fcd-4d84-bc65-d792d5e6de1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72daae71-e379-4945-a919-48d9f8bb6b9c" xlink:to="loc_us-gaap_PlanNameAxis_9d3aed09-0fcd-4d84-bc65-d792d5e6de1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c2ab39f3-eaad-40cb-8e26-a287e5b19e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9d3aed09-0fcd-4d84-bc65-d792d5e6de1b" xlink:to="loc_us-gaap_PlanNameDomain_c2ab39f3-eaad-40cb-8e26-a287e5b19e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2019IncentivePlanThirdAmendmentMember_29d03182-1bb5-4890-a5b1-44dc034163f9" xlink:href="insm-20220630.xsd#insm_A2019IncentivePlanThirdAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c2ab39f3-eaad-40cb-8e26-a287e5b19e3b" xlink:to="loc_insm_A2019IncentivePlanThirdAmendmentMember_29d03182-1bb5-4890-a5b1-44dc034163f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2019IncentivePlanSecondAmendmentMember_f32af6b1-516d-4b25-95c1-dc15c532b15e" xlink:href="insm-20220630.xsd#insm_A2019IncentivePlanSecondAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c2ab39f3-eaad-40cb-8e26-a287e5b19e3b" xlink:to="loc_insm_A2019IncentivePlanSecondAmendmentMember_f32af6b1-516d-4b25-95c1-dc15c532b15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EmployeeStockPurchasePlan2018Member_a47f323d-b872-4dca-8ed7-2deca6b1b3fe" xlink:href="insm-20220630.xsd#insm_EmployeeStockPurchasePlan2018Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c2ab39f3-eaad-40cb-8e26-a287e5b19e3b" xlink:to="loc_insm_EmployeeStockPurchasePlan2018Member_a47f323d-b872-4dca-8ed7-2deca6b1b3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b6d532ef-0ea5-4635-a2f9-c028c0a2fcab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72daae71-e379-4945-a919-48d9f8bb6b9c" xlink:to="loc_us-gaap_AwardTypeAxis_b6d532ef-0ea5-4635-a2f9-c028c0a2fcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f7804bd-4237-4a42-a4b8-150f85c12223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b6d532ef-0ea5-4635-a2f9-c028c0a2fcab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f7804bd-4237-4a42-a4b8-150f85c12223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3678f620-9d40-41e3-907e-897aca46f421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f7804bd-4237-4a42-a4b8-150f85c12223" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3678f620-9d40-41e3-907e-897aca46f421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_43d8902d-9608-4e36-86a1-17de914e18ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f7804bd-4237-4a42-a4b8-150f85c12223" xlink:to="loc_us-gaap_PerformanceSharesMember_43d8902d-9608-4e36-86a1-17de914e18ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8be88ace-d6c1-4121-9cef-bc4c5f6b9b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f7804bd-4237-4a42-a4b8-150f85c12223" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8be88ace-d6c1-4121-9cef-bc4c5f6b9b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_082f9287-761c-4f7b-895f-3f6bdd377edf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72daae71-e379-4945-a919-48d9f8bb6b9c" xlink:to="loc_srt_RangeAxis_082f9287-761c-4f7b-895f-3f6bdd377edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f3354906-81ba-461f-b242-4085967a4a74" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_082f9287-761c-4f7b-895f-3f6bdd377edf" xlink:to="loc_srt_RangeMember_f3354906-81ba-461f-b242-4085967a4a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e59c0c69-86ba-4f02-b348-73c5b3f298da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f3354906-81ba-461f-b242-4085967a4a74" xlink:to="loc_srt_MinimumMember_e59c0c69-86ba-4f02-b348-73c5b3f298da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_137206dc-0acb-4ff1-b394-b8da47044a4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f3354906-81ba-461f-b242-4085967a4a74" xlink:to="loc_srt_MaximumMember_137206dc-0acb-4ff1-b394-b8da47044a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72daae71-e379-4945-a919-48d9f8bb6b9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ad32ff4e-67fe-453a-b34a-a34b0860e272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ad32ff4e-67fe-453a-b34a-a34b0860e272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b1efbbba-9624-4109-91df-c0eb0b51ba27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b1efbbba-9624-4109-91df-c0eb0b51ba27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22d5f517-0b93-4151-8cd9-7a784ec3f362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22d5f517-0b93-4151-8cd9-7a784ec3f362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_3ed09ccf-8b08-4a6f-a7fe-7dafb33a291a" xlink:href="insm-20220630.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_3ed09ccf-8b08-4a6f-a7fe-7dafb33a291a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_df7be340-1124-4aff-8f09-a5ab621bca4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_df7be340-1124-4aff-8f09-a5ab621bca4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4d4aa120-9efa-42bd-9bf8-a5947e736dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4d4aa120-9efa-42bd-9bf8-a5947e736dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9964ad1a-dadd-4fdc-ac09-b6220aa53c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9964ad1a-dadd-4fdc-ac09-b6220aa53c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_319a6c93-71bc-40ea-80fd-6c32b523bec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_319a6c93-71bc-40ea-80fd-6c32b523bec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d7e16f52-defc-4c46-8856-1d12da726b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d7e16f52-defc-4c46-8856-1d12da726b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_871384a3-ba0b-4c3d-967b-d2caa3b97d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_871384a3-ba0b-4c3d-967b-d2caa3b97d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a4d79250-fc83-4b48-9bf1-34a5cdd97a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a4d79250-fc83-4b48-9bf1-34a5cdd97a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e0b751c2-2472-4993-a788-bb4dd37514f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e0b751c2-2472-4993-a788-bb4dd37514f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1377e57f-8c78-4b6c-ad45-9ca12ec46184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1377e57f-8c78-4b6c-ad45-9ca12ec46184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ea94d067-18e1-47ab-bdcf-ff87a02a831e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ea94d067-18e1-47ab-bdcf-ff87a02a831e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2d256575-d5b8-4f68-b6d9-1f1daf34ba8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc74947-243c-4e96-a4a6-46db0c4e40ff" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2d256575-d5b8-4f68-b6d9-1f1daf34ba8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1e56a5b-7ef6-4125-a8dc-b1fe351bfc70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8319b83e-601e-4da9-a088-928f15366316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1e56a5b-7ef6-4125-a8dc-b1fe351bfc70" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8319b83e-601e-4da9-a088-928f15366316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c06efc81-fe13-44d7-9b2f-0bd08a1d1810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8319b83e-601e-4da9-a088-928f15366316" xlink:to="loc_us-gaap_AwardTypeAxis_c06efc81-fe13-44d7-9b2f-0bd08a1d1810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e8d5e60-49cd-44a9-a942-134ffa92b271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c06efc81-fe13-44d7-9b2f-0bd08a1d1810" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e8d5e60-49cd-44a9-a942-134ffa92b271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember_99ef1cee-991c-473f-b61f-6f93786850c6" xlink:href="insm-20220630.xsd#insm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e8d5e60-49cd-44a9-a942-134ffa92b271" xlink:to="loc_insm_StockOptionsAndRestrictedStockUnitsMember_99ef1cee-991c-473f-b61f-6f93786850c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_24ba6b64-08b8-4948-a43f-c3e5b752bd41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8319b83e-601e-4da9-a088-928f15366316" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_24ba6b64-08b8-4948-a43f-c3e5b752bd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_db0ff62a-dc6c-4f8e-8137-00b3bfa649ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24ba6b64-08b8-4948-a43f-c3e5b752bd41" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_db0ff62a-dc6c-4f8e-8137-00b3bfa649ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_61b8b72d-87cc-4136-8041-98b412dae4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db0ff62a-dc6c-4f8e-8137-00b3bfa649ad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_61b8b72d-87cc-4136-8041-98b412dae4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1e08546e-99ce-4681-8f58-da937362a2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db0ff62a-dc6c-4f8e-8137-00b3bfa649ad" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1e08546e-99ce-4681-8f58-da937362a2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_974aed95-2d21-404c-b4fa-3b28da38048e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8319b83e-601e-4da9-a088-928f15366316" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_974aed95-2d21-404c-b4fa-3b28da38048e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3bf72b8d-eba4-49ab-8547-46ce3960d726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_974aed95-2d21-404c-b4fa-3b28da38048e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3bf72b8d-eba4-49ab-8547-46ce3960d726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxes" xlink:type="simple" xlink:href="insm-20220630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3c6cec9b-265d-49af-a1dd-73f35e8f8fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_cffa30bf-527c-4acf-97df-a05085a13958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3c6cec9b-265d-49af-a1dd-73f35e8f8fa1" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_cffa30bf-527c-4acf-97df-a05085a13958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_16c74075-2204-4ff9-a848-2af8580156c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8861acda-d226-46f8-99ab-1a59091b06e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16c74075-2204-4ff9-a848-2af8580156c5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8861acda-d226-46f8-99ab-1a59091b06e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ffefa737-abd0-467a-9481-f94d74d08820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16c74075-2204-4ff9-a848-2af8580156c5" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ffefa737-abd0-467a-9481-f94d74d08820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a5d54c1b-318d-4b75-b8f6-61b873500361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16c74075-2204-4ff9-a848-2af8580156c5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a5d54c1b-318d-4b75-b8f6-61b873500361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="insm-20220630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f3d04e15-6718-411a-b790-a5ac5639624c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d711bfef-67e9-4122-a6d4-6c458c22e5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f3d04e15-6718-411a-b790-a5ac5639624c" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d711bfef-67e9-4122-a6d4-6c458c22e5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_73287776-a060-405f-a6c7-1475c59c13cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_bb33b6be-2511-4686-b4d7-7ffeca8352ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_73287776-a060-405f-a6c7-1475c59c13cc" xlink:to="loc_us-gaap_OperatingLeaseExpense_bb33b6be-2511-4686-b4d7-7ffeca8352ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/BusinessAcquisition" xlink:type="simple" xlink:href="insm-20220630.xsd#BusinessAcquisition"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/BusinessAcquisition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5d79423d-410b-486e-bada-e622ad64c246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_d93c1a2a-8d4f-4319-be0e-f49cfe4043d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5d79423d-410b-486e-bada-e622ad64c246" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_d93c1a2a-8d4f-4319-be0e-f49cfe4043d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails" xlink:type="simple" xlink:href="insm-20220630.xsd#BusinessAcquisitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_81bc2ac7-c589-415d-84c7-cc6bf52d16b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4135a7f6-fc82-4b06-a90b-358efd4b6065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_81bc2ac7-c589-415d-84c7-cc6bf52d16b1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4135a7f6-fc82-4b06-a90b-358efd4b6065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ff3c8b4c-9be1-427d-92a9-655afc958081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4135a7f6-fc82-4b06-a90b-358efd4b6065" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ff3c8b4c-9be1-427d-92a9-655afc958081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f3e537b-a0f1-49cf-8617-ecb0613279a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ff3c8b4c-9be1-427d-92a9-655afc958081" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f3e537b-a0f1-49cf-8617-ecb0613279a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember_4a3e7c97-21ad-4d2e-99b4-de7b13100cd3" xlink:href="insm-20220630.xsd#insm_MotusBiosciencesIncAndAlgaeneXIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1f3e537b-a0f1-49cf-8617-ecb0613279a6" xlink:to="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember_4a3e7c97-21ad-4d2e-99b4-de7b13100cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncMember_c38ab139-3364-4ca2-a029-b2f474be3ff0" xlink:href="insm-20220630.xsd#insm_MotusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember_4a3e7c97-21ad-4d2e-99b4-de7b13100cd3" xlink:to="loc_insm_MotusBiosciencesIncMember_c38ab139-3364-4ca2-a029-b2f474be3ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AlgaeneXIncMember_62f4c204-3ad4-4d8b-aa0e-0e7d132cd2d2" xlink:href="insm-20220630.xsd#insm_AlgaeneXIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember_4a3e7c97-21ad-4d2e-99b4-de7b13100cd3" xlink:to="loc_insm_AlgaeneXIncMember_62f4c204-3ad4-4d8b-aa0e-0e7d132cd2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_43067f28-b127-4616-85d6-0ce759f58415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4135a7f6-fc82-4b06-a90b-358efd4b6065" xlink:to="loc_us-gaap_VestingAxis_43067f28-b127-4616-85d6-0ce759f58415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_0c23a903-a8bb-4fdc-b4af-e4aa97db978f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_43067f28-b127-4616-85d6-0ce759f58415" xlink:to="loc_us-gaap_VestingDomain_0c23a903-a8bb-4fdc-b4af-e4aa97db978f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f4f66f8a-bbd9-4feb-8cd4-e532a02cfe84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_0c23a903-a8bb-4fdc-b4af-e4aa97db978f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f4f66f8a-bbd9-4feb-8cd4-e532a02cfe84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c6c911cc-061d-4563-8906-d47daef47df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_0c23a903-a8bb-4fdc-b4af-e4aa97db978f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c6c911cc-061d-4563-8906-d47daef47df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_db6897e8-7d6e-4aee-af6b-082b38eef599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_0c23a903-a8bb-4fdc-b4af-e4aa97db978f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_db6897e8-7d6e-4aee-af6b-082b38eef599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4135a7f6-fc82-4b06-a90b-358efd4b6065" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_b8b2436f-c015-4afd-a051-de279879051b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_b8b2436f-c015-4afd-a051-de279879051b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_67ac0578-32b9-41d7-b2de-7f703411ad0e" xlink:href="insm-20220630.xsd#insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:to="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_67ac0578-32b9-41d7-b2de-7f703411ad0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a268d7b1-b6bf-404d-a575-ff0f13a1b78e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a268d7b1-b6bf-404d-a575-ff0f13a1b78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f06ad81a-8b18-41d2-85c7-5532a12b3ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f06ad81a-8b18-41d2-85c7-5532a12b3ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_a0d7ee05-7aaf-4667-8f85-c512f5677d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_a0d7ee05-7aaf-4667-8f85-c512f5677d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessAcquisitionConsecutiveTradingDayPeriod_497b18d3-a961-43ed-9d6c-156d0e873574" xlink:href="insm-20220630.xsd#insm_BusinessAcquisitionConsecutiveTradingDayPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:to="loc_insm_BusinessAcquisitionConsecutiveTradingDayPeriod_497b18d3-a961-43ed-9d6c-156d0e873574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2389e514-aa56-4438-a4bf-18df92b6be3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_000b399b-478d-4b1c-af4e-ee28b4baad4b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2389e514-aa56-4438-a4bf-18df92b6be3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197229171136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INSMED INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">54-1972729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">700 US Highway 202/206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bridgewater<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">977-9900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INSM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,975,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001104506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197228222416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 416,078<span></span>
</td>
<td class="nump">$ 716,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">138,790<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">29,481<span></span>
</td>
<td class="nump">24,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">67,017<span></span>
</td>
<td class="nump">67,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">23,360<span></span>
</td>
<td class="nump">28,898<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">674,726<span></span>
</td>
<td class="nump">837,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">9,764<span></span>
</td>
<td class="nump">50,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">53,946<span></span>
</td>
<td class="nump">52,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">17,178<span></span>
</td>
<td class="nump">9,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">24,047<span></span>
</td>
<td class="nump">33,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">71,283<span></span>
</td>
<td class="nump">73,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">136,110<span></span>
</td>
<td class="nump">136,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">66,300<span></span>
</td>
<td class="nump">50,990<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,053,354<span></span>
</td>
<td class="nump">1,243,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">31,144<span></span>
</td>
<td class="nump">35,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">58,770<span></span>
</td>
<td class="nump">60,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">18,653<span></span>
</td>
<td class="nump">28,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">5,037<span></span>
</td>
<td class="nump">9,527<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">113,816<span></span>
</td>
<td class="nump">135,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, long-term</a></td>
<td class="nump">783,977<span></span>
</td>
<td class="nump">566,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">55,600<span></span>
</td>
<td class="nump">75,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, long-term</a></td>
<td class="nump">23,135<span></span>
</td>
<td class="nump">14,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, long-term</a></td>
<td class="nump">18,201<span></span>
</td>
<td class="nump">21,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">14,384<span></span>
</td>
<td class="nump">20,074<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,009,113<span></span>
</td>
<td class="nump">833,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 500,000,000 authorized shares, 119,865,023 and 118,738,266 issued and outstanding shares at June&#160;30, 2022 and December&#160;31, 2021,&#160;respectively</a></td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,449,281<span></span>
</td>
<td class="nump">2,673,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,405,310)<span></span>
</td>
<td class="num">(2,265,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(929)<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">44,241<span></span>
</td>
<td class="nump">410,468<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 1,053,354<span></span>
</td>
<td class="nump">$ 1,243,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197229138832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="nump">119,865,023<span></span>
</td>
<td class="nump">118,738,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares (in shares)</a></td>
<td class="nump">119,865,023<span></span>
</td>
<td class="nump">118,738,266<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197227681392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues, net</a></td>
<td class="nump">$ 65,221<span></span>
</td>
<td class="nump">$ 45,366<span></span>
</td>
<td class="nump">$ 118,328<span></span>
</td>
<td class="nump">$ 85,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible List]</a></td>
<td class="text">Product [Member]<span></span>
</td>
<td class="text">Product [Member]<span></span>
</td>
<td class="text">Product [Member]<span></span>
</td>
<td class="text">Product [Member]<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product revenues (excluding amortization of intangible assets)</a></td>
<td class="nump">$ 16,395<span></span>
</td>
<td class="nump">$ 10,837<span></span>
</td>
<td class="nump">$ 28,586<span></span>
</td>
<td class="nump">$ 20,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList', window );">Cost, Product and Service [Extensible List]</a></td>
<td class="text">Product [Member]<span></span>
</td>
<td class="text">Product [Member]<span></span>
</td>
<td class="text">Product [Member]<span></span>
</td>
<td class="text">Product [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 88,527<span></span>
</td>
<td class="nump">$ 64,655<span></span>
</td>
<td class="nump">$ 172,883<span></span>
</td>
<td class="nump">$ 126,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">59,974<span></span>
</td>
<td class="nump">57,177<span></span>
</td>
<td class="nump">116,722<span></span>
</td>
<td class="nump">108,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">2,526<span></span>
</td>
<td class="nump">2,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of deferred and contingent consideration liabilities</a></td>
<td class="num">(12,622)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(24,240)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">153,537<span></span>
</td>
<td class="nump">133,932<span></span>
</td>
<td class="nump">296,477<span></span>
</td>
<td class="nump">257,979<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(88,316)<span></span>
</td>
<td class="num">(88,566)<span></span>
</td>
<td class="num">(178,149)<span></span>
</td>
<td class="num">(172,399)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Investment income</a></td>
<td class="nump">835<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">972<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,357)<span></span>
</td>
<td class="num">(10,319)<span></span>
</td>
<td class="num">(6,648)<span></span>
</td>
<td class="num">(17,878)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,689)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,689)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(4,306)<span></span>
</td>
<td class="num">(159)<span></span>
</td>
<td class="num">(5,555)<span></span>
</td>
<td class="num">(202)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(95,144)<span></span>
</td>
<td class="num">(116,699)<span></span>
</td>
<td class="num">(189,380)<span></span>
</td>
<td class="num">(208,101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">501<span></span>
</td>
<td class="nump">622<span></span>
</td>
<td class="nump">886<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (95,645)<span></span>
</td>
<td class="num">$ (117,321)<span></span>
</td>
<td class="num">$ (190,266)<span></span>
</td>
<td class="num">$ (208,962)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.80)<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.60)<span></span>
</td>
<td class="num">$ (1.97)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.80)<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.60)<span></span>
</td>
<td class="num">$ (1.97)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average basic common shares outstanding (in shares)</a></td>
<td class="nump">119,602<span></span>
</td>
<td class="nump">109,580<span></span>
</td>
<td class="nump">119,267<span></span>
</td>
<td class="nump">106,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average diluted common shares outstanding (in shares)</a></td>
<td class="nump">119,602<span></span>
</td>
<td class="nump">109,580<span></span>
</td>
<td class="nump">119,267<span></span>
</td>
<td class="nump">106,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (95,645)<span></span>
</td>
<td class="num">$ (117,321)<span></span>
</td>
<td class="num">$ (190,266)<span></span>
</td>
<td class="num">$ (208,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation (loss) income</a></td>
<td class="num">(208)<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="num">(702)<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(491)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,195)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (96,344)<span></span>
</td>
<td class="num">$ (116,987)<span></span>
</td>
<td class="num">$ (192,163)<span></span>
</td>
<td class="num">$ (208,731)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920602&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of cost from product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920602&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfCostGoodOrServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197224685424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 275,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,028<span></span>
</td>
<td class="nump">$ 2,105,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,830,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(208,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(208,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and ESPP shares issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options and ESPP shares issuance</a></td>
<td class="nump">13,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">13,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Equity component of convertible debt redemption</a></td>
<td class="nump">269,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">269,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of convertible debt issuance</a></td>
<td class="nump">196,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments', window );">Equity component of convertible debt redemption</a></td>
<td class="num">(37,846)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,846)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">22,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">531,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,152<span></span>
</td>
<td class="nump">2,569,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,039,551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">275,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,028<span></span>
</td>
<td class="nump">2,105,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,830,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 410,468<span></span>
</td>
<td class="num">$ (214,410)<span></span>
</td>
<td class="nump">$ 1,187<span></span>
</td>
<td class="nump">2,673,556<span></span>
</td>
<td class="num">$ (264,609)<span></span>
</td>
<td class="num">(2,265,243)<span></span>
</td>
<td class="nump">$ 50,199<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 201,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,033<span></span>
</td>
<td class="nump">2,122,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,922,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(117,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and ESPP shares issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options and ESPP shares issuance</a></td>
<td class="nump">6,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">6,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Equity component of convertible debt redemption</a></td>
<td class="nump">269,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">269,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of convertible debt issuance</a></td>
<td class="nump">196,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments', window );">Equity component of convertible debt redemption</a></td>
<td class="num">(37,846)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,846)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">11,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">531,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,152<span></span>
</td>
<td class="nump">2,569,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,039,551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">410,468<span></span>
</td>
<td class="num">$ (214,410)<span></span>
</td>
<td class="nump">$ 1,187<span></span>
</td>
<td class="nump">2,673,556<span></span>
</td>
<td class="num">$ (264,609)<span></span>
</td>
<td class="num">(2,265,243)<span></span>
</td>
<td class="nump">$ 50,199<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(190,266)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(190,266)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,897)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and ESPP shares issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options and ESPP shares issuance</a></td>
<td class="nump">13,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">13,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">27,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 44,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,199<span></span>
</td>
<td class="nump">2,449,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,405,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(929)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 119,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,193<span></span>
</td>
<td class="nump">2,428,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,309,665)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(95,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(699)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and ESPP shares issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options and ESPP shares issuance</a></td>
<td class="nump">6,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">6,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">14,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 44,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,199<span></span>
</td>
<td class="nump">$ 2,449,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,405,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (929)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=123466103&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197227929168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (190,266)<span></span>
</td>
<td class="num">$ (208,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,244<span></span>
</td>
<td class="nump">4,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">2,526<span></span>
</td>
<td class="nump">2,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">27,082<span></span>
</td>
<td class="nump">22,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and accretion of debt discount</a></td>
<td class="nump">1,643<span></span>
</td>
<td class="nump">13,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease amortization expense</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_NoncashOperatingLeaseExpense', window );">Noncash operating lease expense</a></td>
<td class="nump">9,765<span></span>
</td>
<td class="nump">9,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of deferred and contingent consideration liabilities</a></td>
<td class="num">(24,240)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(6,784)<span></span>
</td>
<td class="num">(1,855)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">724<span></span>
</td>
<td class="num">(11,557)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,101<span></span>
</td>
<td class="num">(7,484)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(15,531)<span></span>
</td>
<td class="num">(22,623)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,558)<span></span>
</td>
<td class="num">(11,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities', window );">Accrued liabilities, accrued compensation and other</a></td>
<td class="num">(16,533)<span></span>
</td>
<td class="num">(10,629)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(207,462)<span></span>
</td>
<td class="num">(203,725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(4,605)<span></span>
</td>
<td class="num">(4,666)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(99,706)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(104,311)<span></span>
</td>
<td class="num">(4,666)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options, ESPP, and RSU vestings</a></td>
<td class="nump">13,264<span></span>
</td>
<td class="nump">13,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">269,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payment on extinguishment of 1.75% convertible senior notes due 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,578)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payment of principal on 1.75% convertible senior notes due 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(225,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of 0.75% convertible senior notes due 2028</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">575,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments of finance lease principal</a></td>
<td class="num">(494)<span></span>
</td>
<td class="num">(522)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">12,770<span></span>
</td>
<td class="nump">604,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash and cash equivalents</a></td>
<td class="num">(1,701)<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(300,704)<span></span>
</td>
<td class="nump">395,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">716,782<span></span>
</td>
<td class="nump">532,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">416,078<span></span>
</td>
<td class="nump">928,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">5,004<span></span>
</td>
<td class="nump">5,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 1,194<span></span>
</td>
<td class="nump">$ 997<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the sum of accrued expenses and Other Current Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Operating Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197231693424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (unaudited) (Parenthetical) - Convertible Notes<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">1.75% convertible senior notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">0.75% convertible senior notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197229762368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company and Basis of Presentation</a></td>
<td class="text">The Company and Basis of Presentation<div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States (US) as ARIKAYCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mycobacterium avium</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nontuberculous mycobacterial (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NTM) lung infections caused by MAC in adults with limited treatment options who do not have </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cystic fibrosis (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F). In March 2021, Japan's Ministry of Health, Labour and Welfare (MHLW) approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis, CF and other neutrophil-mediated diseases</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the Commonwealth of Virginia on November&#160;29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules&#160;and regulations for reporting on Form&#160;10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the US for complete consolidated financial statements are not included herein. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000110450622000008/insm-20211231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Report on Form&#160;10-K for the year ended December&#160;31, 20</a>21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;The Company had $416.1 million in cash and cash equivalents and marketable securities totaling $148.6 million as of June&#160;30, 2022 and reported a net loss of $190.3 million for the six months ended June&#160;30, 2022. Historically, the Company has funded its operations through public offerings of equity securities and debt financings. The Company expects to continue to incur consolidated operating losses, including losses in its US and certain international entities, while funding research and development (R&amp;D) activities for ARIKAYCE, brensocatib, TPIP and its other pipeline programs, and continuing and commencing pre-commercial, commercialization and regulatory activities for ARIKAYCE, and funding other general and administrative activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects its future cash requirements to be substantial, and the Company may need to raise additional capital to fund operations, including the Phase 3 ASPEN study, the continued commercialization of ARIKAYCE, the ARISE and ENCORE clinical trials related to ARIKAYCE, launch readiness activities for the potential launch of brensocatib, if approved, other clinical trials for brensocatib, TPIP, and its future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company&#8217;s commercial, regulatory and development activities. Any equity or debt financing will also be contingent upon equity and debt market conditions and interest rates at the time. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts. The Company believes it currently has sufficient funds to meet its financial needs for at least the next 12 months.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many uncertainties regarding the novel coronavirus (COVID-19) pandemic, and the Company is closely monitoring the impact of the pandemic on all aspects of its business, including how the pandemic will impact its patients, employees, suppliers, vendors, business partners and distribution channels. While the pandemic did not materially affect the Company's financial results and business operations for the six months ended June 30, 2022, the Company is unable to predict the impact that COVID-19 will have on its financial position and operating results in future periods due to </span></div>numerous uncertainties. The Company will continue to assess the evolving impact of the COVID-19 pandemic and will make adjustments to its operations as necessary.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197227286416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The following are the required interim disclosure updates to the Company's significant accounting policies described in Note 2 of the notes to the consolidated financial statements in the Company's </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000110450622000008/insm-20211231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:36.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June&#160;30, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:36.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> six months ended June&#160;30, 2022, the Company purchased $99.7&#160;million of additional m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arketable securities consisting of US Treasury Notes. There were no other transfers in or out of Level 1, Level 2 or Level 3 during the six months ended June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company held $138.8 million and $9.8 million of current and non-current available-for-sale securities, respectively, net of an unrealized loss of $1.3&#160;million recorded in accumulated other comprehensive income. Marketable securities maturing in one year or less are classified as current assets and marketable securities maturing in more </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">than one year are classified as non-current assets. As of December&#160;31, 2021, the Company held no securities that were in an unrealized gain or loss position.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2) whether the security was rated below investment grade; (3) how long the security has been in an unrealized loss position; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover. The Company has determined that there were no other-than-temporary impairments during the quarter ended June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred consideration arose from the acquisitions of Motus Biosciences, Inc. (Motus) and AlgaeneX, Inc. (AlgaeneX) (the Business Acquisition) in August 2021 (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i252108b308054887a46901fe227627f1_70" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company&#8217;s common stock on each of the first, second and third anniversaries of the closing date, subject to certain reductions. A valuation of the deferred consideration is performed quarterly with gains and losses included within change in fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss. As the deferred consideration is settled in shares, there is no discount rate applied in the fair value calculation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred consideration has been classified as a Level 2 recurring liability as its valuation utilizes an input, the Insmed share price on the valuation date, which is a directly observable input at the measurement date and for the duration of the liabilities' anticipated lives. Deferred consideration expected to be settled within twelve months or less is classified as a current liability and are included in accrued liabilities. As of June&#160;30, 2022, the fair value of deferred consideration included in accrued liabilities was $3.5 million. Deferred consideration expected to be settled in more than twelve months is classified as a non-current liability and is included in other long-term liabilities. As of June&#160;30, 2022, the fair value of deferred consideration included in other long-term liabilities was $7.3 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following observable input was used in the valuation of the deferred consideration as of June&#160;30, 2022:</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"/><td style="width:21.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.531%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June&#160;30, 2022 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Input</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.8</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed share price as of June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$19.72</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities arose from the Business Acquisition in August 2021 (Note 13). The contingent consideration liabilities consist of developmental and regulatory milestones, a priority review voucher milestone and net sales milestones. Upon the achievement of certain development and regulatory milestone events, the Company is obligated to issue to Motus equityholders up to 5,348,572 shares in the aggregate and AlgaeneX equityholders up to 368,867 shares in the aggregate. The fair value of the development and regulatory milestones are estimated utilizing a probability-adjusted approach. At June&#160;30, 2022, the weighted average probability of success was 42%. The development and regulatory milestones will be settled in shares of the Company's common stock. As such, there is no discount rate applied in the fair value calculation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company were to receive a priority review voucher, the Company is obligated to pay to the Motus equityholders a portion of the value of the priority review voucher, subject to certain reductions. The potential payout will be either 50% of the after tax net proceeds received by the Company from a sale of the priority review voucher or 50% of the average of the sales prices for the last three publicly disclosed priority review voucher sales, less certain adjustments. The fair value of the priority review voucher milestone is estimated utilizing a probability-adjusted discounted cash flow approach. This obligation will be settled in cash. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities for net sales milestones were valued using an option pricing model with Monte Carlo simulation. As of June&#160;30, 2022, the fair value of these net sales milestones were deemed immaterial to the overall fair value of the contingent consideration. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities have been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the inputs to the valuation approach, the estimated fair value could be significantly different than the fair value the Company determined. Contingent consideration liabilities expected to be settled in more than twelve months are classified as a non-current liability. A valuation of the contingent consideration liabilities is performed quarterly with gains and losses included within change in fair value of contingent consideration liabilities in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the contingent consideration liabilities as of June&#160;30, 2022 (in millions):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June&#160;30, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50.6</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probabilities of success</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14% - 95%</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority review voucher milestone</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.0</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5%</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7%</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the six months ended June 30, 2022 (in thousands):</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:22.401%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,172)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,068)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the liability component of the Company's 0.75% convertible senior notes due 2028 (the 2028 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of June&#160;30, 2022 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$496.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the 2028 Convertible Notes. The $561.6 million carrying value of the 2028 Convertible Notes as of June&#160;30, 2022 excludes the $13.4 million of the unamortized portion of the debt issuance costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the liability component of the Company's 1.75% convertible senior notes due 2025 (the 2025 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of June&#160;30, 2022 was $208.3 million, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the 2025 Convertible Notes. The $222.4 million carrying value of the 2025 Convertible Notes as of June&#160;30, 2022 excludes the $2.6 million of the unamortized portion of the debt issuance costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock, restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three and six months ended June&#160;30, 2022 and 2021: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.366%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,645)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of basic net loss per share:</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,602&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,580&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,267&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.80)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.07)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.60)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.97)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of June&#160;30, 2022 and 2021, respectively, as their effect would have been anti-dilutive (in thousands):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:66.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.553%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.555%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock and RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for collectible trade receivables. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the six months ended June&#160;30, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"><tr><td style="width:1.0%"/><td style="width:33.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.936%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating results. A change in the relationship with the suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract to determine which are performance obligations and to assess whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consist of net sales of ARIKAYCE. The Company's customers in the US include specialty pharmacies and specialty distributors. In December 2020, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Europe. In July 2021, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Japan. Globally, product revenues are recognized once the Company performs and satisfies all five steps of the revenue recognition criteria mentioned above.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the Company's product revenues, net, by geographic location for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:33.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total product revenues, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,328&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,580&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer credits: The Company's customers are offered various forms of consideration, including prompt payment discounts. The payment terms for sales to specialty pharmacies for prompt payment discounts are based on contractual rates agreed with the respective specialty pharmacies. The Company anticipates that its customers will earn these discounts and, therefore, deducts the full amount of these discounts from total gross product revenues at the time such revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates: The Company contracts with government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accrued liabilities on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recognizes revenue related to various early access programs (EAPs) in Europe, predominantly in France. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Cost of Product Revenues (excluding amortization of intangible assets) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Inventory is stated at the lower of cost and net realizable value. The Company began capitalizing inventory costs following US Food and Drug Administration (FDA) approval of ARIKAYCE in September 2018. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestone payments. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to FDA approval of ARIKAYCE, the Company expensed all inventory-related costs in the period incurred. Inventory used for clinical development purposes is expensed to R&amp;D expense when consumed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business combinations and asset acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for the Company&#8217;s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets&#8217; carrying amounts on the acquiring entity&#8217;s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Indefinite-lived intangible assets consist of In Process Research &amp; Development (IPR&amp;D). IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&amp;D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#8217;s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company&#8217;s outlook and market performance of the Company&#8217;s industry and recent and forecasted financial performance. The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finite-lived Intangible Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Finite-lived intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the acquired ARIKAYCE R&amp;D intangible asset, at the date of subsequent adjustments of fair value. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Assessment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing to the carrying value of the assets to the fair value of the assets. The Company determined that no indicators of impairment of finite-lived intangible assets or long-lived assets existed at June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#8217;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassesses its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company will perform its next annual impairment testing for goodwill on October 1, 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7 - Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for details about the Company's lease portfolio, including required disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also promote consistent application of and simplify US generally accepted accounting principles (GAAP) for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance was effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. The Company adopted this guidance January 1, 2021. The adoption of the guidance did not have a material impact on the Company's consolidated financial statements and accompanying notes.</span></div>In August 2020, the FASB issued <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNTQ_a1983cb3-6ebb-4561-babb-c381ced619fe">ASU 2020-06</span>, Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, to reduce the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. For convertible instruments, the number of accounting models for convertible debt instruments is reduced, which results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Only convertible instruments that meet the definition of a derivative or are issued with substantial premiums will continue to be subject to the separation models. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and a share of convertible preferred stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation and recognition as derivatives. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021. The Company transitioned using the modified retrospective method. The impact of adopting ASU 2020-06 on January 1, 2022 resulted in an opening balance sheet adjustment increasing debt by $221.9&#160;million, increasing issuance costs classified to debt by $6.1&#160;million, decreasing the deferred tax liability by $1.4&#160;million, and causing an increase to retained earnings of $50.2 million, with an offsetting reduction to additional paid-in-capital of $264.6 million, net of tax.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197229700592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, the Company's inventory balance consists of the following (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"/><td style="width:49.266%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.261%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,541&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,017&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,009&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company began capitalizing inventory costs following FDA approval of ARIKAYCE in September 2018. The Company has not recorded any significant inventory write-downs since that time. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197232780432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles, Net and Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangibles, Net and Goodwill</a></td>
<td class="text">Intangibles, Net and Goodwill<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangibles, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finite-lived Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&amp;D and the milestones paid to PARI Pharma GmbH (PARI) for the license to use PARI's Lamira&#174; Nebulizer System (Lamira) for the delivery of ARIKAYCE to patients as a result of the FDA and EC approvals of ARIKAYCE in September 2018 and October 2020, respectively. The Company began amortizing its acquired ARIKAYCE R&amp;D and PARI milestones intangible assets in </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 2018, over ARIKAYCE's initial regulatory exclusivity period of 12 years. Amortization of these assets during each of the next five years is estimated to be approximately $5.1 million per year.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-lived Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company's indefinite-lived intangible assets consisted of acquired in process research and development (IPR&amp;D) from the Business Acquisition (Note 13). Indefinite-lived intangible assets are not amortized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the Company's intangible assets for the six months ended June 30, 2022 and June&#160;30, 2021 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"/><td style="width:36.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.303%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Intangible Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,425)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,809&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,526)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,283&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Intangible Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,425)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,261&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,526)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div>The Company's goodwill balance of $136.1 million as of June&#160;30, 2022, resulted from the Business Acquisition (Note 13).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197232780432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets, Net</a></td>
<td class="text">Fixed Assets, Net<div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:31.926%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.333%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.635%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,862&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-10</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress (CIP)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,251&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,016&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,305)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,061)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,955&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197232751024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">Accrued Liabilities<div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, the Company's accrued liabilities balance consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"/><td style="width:57.515%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.207%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,019&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued technical operation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,182&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,655&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales allowances and related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,770&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197228993760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $1.5 million and $0.2 million for the three months ended June&#160;30, 2022 and 2021, respectively, and $1.6 million and $0.3 million for the six months ended June 30, 2022 and 2021, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the supplemental noncash disclosures of the Company's leases included in its consolidated financial statements (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.256%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $36.3 million incurred by the </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company under these additional agreements have been classified within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span>other assets in the Company's consolidated balance sheet. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $1.5 million and $0.2 million for the three months ended June&#160;30, 2022 and 2021, respectively, and $1.6 million and $0.3 million for the six months ended June 30, 2022 and 2021, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the supplemental noncash disclosures of the Company's leases included in its consolidated financial statements (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.256%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $36.3 million incurred by the </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company under these additional agreements have been classified within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span>other assets in the Company's consolidated balance sheet. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197229564384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company completed an underwritten public offering of the 2028 Convertible Notes, in which the Company sold $575.0 million aggregate principal amount of the 2028 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $75.0 million in aggregate principal amount of 2028 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $15.7&#160;million, were approximately $559.3 million. The 2028 Convertible Notes bear interest payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2021. The 2028 Convertible Notes mature on June 1, 2028, unless earlier converted, redeemed, or repurchased. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company completed an underwritten public offering of the 2025 Convertible Notes, in which the Company sold $450.0 million aggregate principal amount of the 2025 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $50.0 million in aggregate principal amount of 2025 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $14.2 million, were approximately $435.8 million. The 2025 Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The 2025 Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the net proceeds from the 2028 Convertible Notes was used to repurchase $225.0 million of the Company's outstanding 2025 Convertible Notes. The Company recorded a loss on early extinguishment of debt of $17.7 million, primarily related to the premium paid on extinguishment of a portion the 2025 Convertible Notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after October&#160;15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their 2025 Convertible Notes at any time. The initial conversion rate for the 2025 Convertible Notes is 25.5384 shares of common stock per $1,000 principal amount of 2025 Convertible Notes (equivalent to an initial conversion price of approximately $39.16 per share of common stock). On or after March 1, 2028, until the close of business on the second scheduled trading day immediately preceding June 1, 2028, holders may convert their 2028 Convertible Notes at any time. The initial conversion rate for the 2028 Convertible Notes is 30.7692 shares of common stock per $1,000 principal amount of 2028 Convertible Notes (equivalent to an initial conversion price of approximately $32.50 per share of common stock). Upon conversion of either the 2025 Convertible Notes or the 2028 Convertible Notes, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The conversion rates will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2025 Convertible Notes prior to October 15, 2024 or their 2028 Convertible Notes prior to March 1, 2028, only under the following circumstances, subject to the conditions set forth in the applicable indenture: (i) during the five business day period immediately after any five consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of the applicable series of convertible notes, as determined following a request by a holder of such convertible notes, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than 45 days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company's assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding 10% of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the applicable series of convertible notes may be surrendered by a holder for conversion at any time from or after the date that is 30 scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2018 or June 30, 2021 for the 2025 Convertible Notes and the 2028 Convertible Notes, respectively (and only during such calendar quarter), the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, or (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its convertible notes to which the notice of redemption relates for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a)&#160;the second business day immediately preceding the related redemption date or (b)&#160;if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid. To date, there have not been any holder-initiated redemption requests of either series of convertible notes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each series of convertible notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in both series of convertible notes are not required to be separately accounted for as a derivative. The 2025 Convertible Notes and 2028 Convertible Notes have remaining terms of approximately 2.54 years and 5.92 years, respectively. The following table presents the carrying value of the Company's debt balance (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:58.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.230%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of outstanding convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs, unamortized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,023)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,873)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783,977&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,588&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, future principal repayments of the notes for each of the years through maturity were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.543%"><tr><td style="width:1.0%"/><td style="width:64.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to debt and finance leases for the three and six months ended June&#160;30, 2022 and 2021 is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.237%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,021&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible debt interest expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,883&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,217&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,319&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Company's transition using the modified retrospective method upon adopting ASU 2020-06, Debt &#8212; Accounting for Convertible Instruments, on January 1, 2022, the Company ceased accreting debt discount.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197229584016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders&#8217; Equity<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; As of June&#160;30, 2022, the Company had 500,000,000 shares of common stock authorized with a par value of $0.01 per share and 119,865,023 shares of common stock issued and outstanding. In addition, as of June&#160;30, 2022, the Company had reserved 17,805,766 shares of common stock for issuance upon the exercise of outstanding stock options, 1,619,225 shares of common stock for issuance upon the vesting of RSUs and 670,168 shares for issuance upon the vesting of PSUs. The Company has also reserved 23,438,430</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock in the aggregate for issuance upon conversion of the 2025 Convertible Notes and 2028 Convertible Notes, subject to adjustment in accordance with the applicable indentures. In </span><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">connection with the Business Acquisition, the Company reser</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ved 9,406,112 s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hares of the Company&#8217;s common stock, subject to certain closing-related reductions. The shares of the Company&#8217;s common stock reserved in connection with the Motus acquisition were partly issued as acquisition consideration at closing, and will also be issued upon the first, second and third anniversaries of the closing date of the acquisition and upon the achievement of certain development and regulatory milestone events, subject to certain reductions. The shares of the Company&#8217;s common stock reserved in connection with the AlgaeneX acquisition will be issued upon the achievement of a development milestone event, subject to certain reductions. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Of the 9,406,112 shares reserved, subject to certain closing-related reductions, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company issued 2,889,367 shares of the Company's common stock in connection with the Business Acquisition (Note 13) i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n the third quarter</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of 2021, after certain closing-related deductions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of 2021, the Company completed an underwritten public offering of 11,500,000 shares of the Company's common stock, including 1,500,000 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares from the Company, a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t a public offering price of $25.00 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expenses of $17.5 million, were $270.1 million. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, the Company entered into a sales agreement with SVB Leerink LLC (now known as SVB Securities LLC) (SVB Securities), to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $250.0&#160;million, from time to time, through an &#8220;at the market&#8221; equity offering program (the ATM program), under which SVB Securities acts as sales agent. As of June&#160;30, 2022, the Company had not sold or issued any shares under the ATM program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of 2020, the Company completed an underwritten public offering of 11,155,000 shares of the Company's common stock, including 1,455,000 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares from the Company, a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t a public offering price of $23.25 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expenses of $13.5 million, were $245.9 million. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; As of June&#160;30, 2022, the Company had 200,000,000 shares of preferred stock authorized with a par value of $0.01 per share and no shares of preferred stock were issued and outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197229538720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's current equity compensation plan, the Insmed Incorporated 2019 Incentive Plan (as amended, the 2019 Incentive Plan), was approved by shareholders at the Company's Annual Meeting of Shareholders in May&#160;2019.&#160;The 2019 Incentive Plan is administered by the Compensation Committee of the Board of Directors of the Company.&#160;Under the terms of the 2019 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards to eligible employees and non-employee directors.&#160;On May&#160;16, 2019, upon the approval of the 2019 Incentive Plan by shareholders, 3,500,000 shares were authorized for issuance thereunder, plus any shares subject to then-outstanding awards under the Company's 2017 Incentive Plan, the 2015 Incentive Plan and the 2013 Incentive Plan that subsequently were canceled, terminated unearned, expired, were forfeited, lapsed for any reason or were settled in cash without the delivery of shares. On May 12, 2020, at the Company's 2020 Annual Meeting of Shareholders, the Company's shareholders approved an amendment of the 2019 Incentive Plan providing for the issuance of an additional 4,500,000 shares under the plan. On May 12, 2021, at the Company's 2021 Annual Meeting of Shareholders, the Company's shareholders approved the second amendment to the 2019 Incentive Plan providing for the issuance of an additional 2,750,000 shares under the plan. On May 11, 2022, at the Company's 2022 Annual Meeting of Shareholders, the Company's shareholders approved the third amendment to the 2019 Incentive Plan, providing for the issuance of an additional 3,000,000 shares under the plan. As of June&#160;30, 2022, 2,145,104 shares remain available for future issuance under the 2019 Incentive Plan. The 2019 Incentive Plan will terminate on May&#160;16, 2029 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options to new hires, which awards are made pursuant to the Nasdaq's inducement grant exception to the shareholder approval requirement for grants of equity compensation. During the six months ended June&#160;30, 2022, the Company granted inducement stock options covering 471,790 shares of the Company's common stock to new employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2018, the 2018 Employee Stock Purchase Plan (2018 ESPP) was approved by shareholders at the Company's 2018 Annual Meeting of Shareholders. The Company has reserved the following for issuance under the 2018 ESPP: (i) 1,000,000 shares of common stock,&#160;plus&#160;(ii)&#160;commencing on January&#160;1, 2019 and ending on December&#160;31, 2023, an additional number of shares to be added on the first day of each calendar year equal to the lesser of (A) 1,200,000 shares of common stock, (B) 2% of the number of outstanding shares of common stock on such date and (C)&#160;an amount determined by the administrator.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; As of June&#160;30, 2022, there was $122.5&#160;million of unrecognized compensation expense related to unvested stock options.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted performance-conditioned options to certain of its employees. Vesting of these options is subject to the Company achieving certain performance criteria established at the date of grant and the grantees </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fulfilling a service condition (continued employment). As of June&#160;30, 2022, the Company had performance-conditioned options totaling 114,780 shares outstanding which had not yet met the recognition criteria. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; As of June&#160;30, 2022, there was $32.5&#160;million of unrecognized compensation expense related to unvested RSU awards.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Stock Units</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#8212; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company issued 271,612 PSUs. For these PSUs, there are two performance conditions, a service condition, and a market condition. The performance conditions are the issuance of a press release announcing certain top-line results from a clinical trial and the acceptance of a new drug application (NDA) by the FDA for brensocatib. The service condition is continuous employment with the Company through the later of the third anniversary of the grant date of the PSU award and the date an NDA for brensocatib is accepted by the FDA. The potential payout of the awards ranges from 0% to 250% of the target, dependent on a market condition that is based on the Company's total shareholder return compared to a defined peer group. Due to the multiple vesting conditions, uncertain timing and variable payout of these PSUs, a Monte Carlo simulation was performed to determine the fair value of the awards. Compensation cost will be recognized on the date the performance conditions become probable, with an initial recording of the cumulative expense that would have been recognized if the PSU expense had been recognized on a straight-line basis since the date of grant. The remaining unamortized fair value of the awards will then be expensed prospectively on a straight-line basis over the remaining service period. Since the market condition is reflected in the grant-date fair value and is not a condition for the award to vest, it does not impact the requisite service period. The volatility, risk-free interest rate and weighted-average grant date fair value of the PSUs granted are 65.4%, 1.03% and $39.12, respectively. Any forfeitures that occur after compensation cost recognition commences will result in the cumulative reversal of expense in the period in which the forfeiture occurs. As of June&#160;30, 2022, there was $10.5 million of unrecognized compensation expense related to unvested PSU awards, which assumes a payout of 100% of the target.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the three and six months ended June&#160;30, 2022 and 2021, respectively (in millions):&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"><tr><td style="width:1.0%"/><td style="width:34.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to PSUs during the three and six months ended June&#160;30, 2022, as the performance conditions associated with the PSU awards were not probable as of June&#160;30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197229739904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a provision for income taxes of $0.5 million and $0.6 million for the three months ended June 30, 2022 and 2021, respectively, and $0.9 million and $0.9 million for the six months ended June 30, 2022 and 2021, respectively. The provisions are primarily a result of certain of the Company's international subsidiaries, which had taxable income during the periods. Additionally, the Company is impacted by certain state taxes which effectively impose income tax on modified gross revenues. In jurisdictions where the Company has net losses, there was a full valuation allowance recorded against the Company's deferred tax assets and therefore no tax benefit was recorded. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to US federal and state income taxes and the statute of limitations for tax audit is open for the Company's federal tax returns for the years ended 2018 and later, and is generally open for certain states for the years 2017 and later. The Company has incurred net operating losses since inception, except for the year ended December&#160;31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin. As of June&#160;30, 2022 and December&#160;31, 2021, the Company had recorded reserves for unrecognized income tax benefits against certain deferred tax assets in the US.&#160;However, given the Company&#8217;s valuation allowance position, these reserves do not have an impact on the balance sheet as of June&#160;30, 2022 and December&#160;31, 2021 or the consolidated statements of comprehensive loss for the three and six months ended June&#160;30, 2022 and 2021.&#160;The Company has not recorded any accrued interest or penalties related to uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197229564384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and ContingenciesRent expense charged to operations was $1.9 million and $1.1 million for the three months ended June 30, 2022 and 2021, respectively, and $3.9 million and $2.3 million for the six months ended June 30, 2022 and 2021, respectively.<div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197229496960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Acquisition</a></td>
<td class="text">Business Acquisition<div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2021, the Company acquired all of the equity interests of Motus and AlgaeneX, each a privately held, preclinical stage company. In connection with the closing of the Company&#8217;s acquisition of Motus, the Company issued an aggregate of 2,889,367 shares of the Company&#8217;s common stock, following certain closing-related reductions, to Motus&#8217;s former stockholders and option holders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, Motus equityholders), subject to certain adjustments. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company&#8217;s common stock on each of the first, second and third anniversaries of the closing date and up to 5,348,572 shares in the aggregate upon the achievement of certain development and regulatory milestone events, and to pay to the Motus equityholders an aggregate of $35&#160;million upon the achievement of certain net sales-based milestones and a portion of the value of a priority review voucher (to the extent issued to the Company), in each case, subject to certain reductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing of the Company&#8217;s acquisition of AlgaeneX, the Company paid $1.5&#160;million in cash to AlgaeneX&#8217;s former stockholders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, the AlgaeneX equityholders). The Company is obligated to issue to AlgaeneX&#8217;s equityholders an aggregate of 368,867 shares of the Company&#8217;s common stock upon the achievement of a development milestone event and pay to AlgaeneX equityholders a mid-single digits licensing fee on certain future payments received by the Company in licensing transactions for AlgaeneX&#8217;s manufacturing technology, in each case, subject to certain reductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the Company&#8217;s common stock issued to the Motus equityholders and the AlgaeneX equityholders were issued, and the shares issuable in the future will be issued, pursuant to Section 4(a)(2) of the Securities Act of 1933, and the numbers of such issued and issuable shares was calculated based on a per share value of $27.11, which is the weighted average price per share of the Company's common stock preceding the closing of the Business Acquisition for the 45 consecutive trading day period beginning on May 24, 2021. The Company will not receive any proceeds from the issuance of common stock to the Motus equityholders or the AlgaeneX equityholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Business Acquisition under ASC 805 and ASU 2017-01. The Company concluded that substantially all of the fair value of the gross assets acquired is not concentrated in a single identifiable asset or a group of similar identifiable assets. The transaction does not pass the screen test and thus management performed a full assessment to determine if the acquired entities met the definition of a business. For the full assessment, management considered whether it has acquired (a) inputs, (b) substantive processes, and (c) outputs. Under ASC 805, to be considered a business, a set of activities and assets is required to have only the first two of the three elements, which together are or will be used in the future to create outputs. Management determined that the acquired entities met the definition of a business since the Company acquired inputs and substantive processes capable of producing outputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, the transaction has been accounted for under the acquisition method of accounting. Under the acquisition method, the total purchase price of the acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on the fair values as of the date of the acquisition. The fair value of the consideration totaled approximately $165.5&#160;million. The results of Motus's and AlgaeneX's operations have been included in the Company's consolidated statements of comprehensive loss beginning on the acquisition date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D was capitalized as of the acquisition date and accounted for as indefinite-lived intangible assets until completion or disposition of the assets or abandonment of the associated research and development efforts. Upon successful completion of the development efforts, the useful lives of the IPR&amp;D assets will be determined based on the anticipated period of regulatory exclusivity and will be amortized within operating expenses. Until that time, the IPR&amp;D assets will be subject to impairment testing and will not be amortized. The goodwill recorded related to the acquisition is the excess of the fair value of the consideration transferred by the acquirer over the fair value of the net identifiable assets acquired and liabilities assumed at the date of acquisition. The goodwill recorded is not deductible for tax purposes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197229191392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:36.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June&#160;30, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:36.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> six months ended June&#160;30, 2022, the Company purchased $99.7&#160;million of additional m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arketable securities consisting of US Treasury Notes. There were no other transfers in or out of Level 1, Level 2 or Level 3 during the six months ended June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company held $138.8 million and $9.8 million of current and non-current available-for-sale securities, respectively, net of an unrealized loss of $1.3&#160;million recorded in accumulated other comprehensive income. Marketable securities maturing in one year or less are classified as current assets and marketable securities maturing in more </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">than one year are classified as non-current assets. As of December&#160;31, 2021, the Company held no securities that were in an unrealized gain or loss position.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2) whether the security was rated below investment grade; (3) how long the security has been in an unrealized loss position; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover. The Company has determined that there were no other-than-temporary impairments during the quarter ended June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred consideration arose from the acquisitions of Motus Biosciences, Inc. (Motus) and AlgaeneX, Inc. (AlgaeneX) (the Business Acquisition) in August 2021 (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i252108b308054887a46901fe227627f1_70" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company&#8217;s common stock on each of the first, second and third anniversaries of the closing date, subject to certain reductions. A valuation of the deferred consideration is performed quarterly with gains and losses included within change in fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss. As the deferred consideration is settled in shares, there is no discount rate applied in the fair value calculation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred consideration has been classified as a Level 2 recurring liability as its valuation utilizes an input, the Insmed share price on the valuation date, which is a directly observable input at the measurement date and for the duration of the liabilities' anticipated lives. Deferred consideration expected to be settled within twelve months or less is classified as a current liability and are included in accrued liabilities. As of June&#160;30, 2022, the fair value of deferred consideration included in accrued liabilities was $3.5 million. Deferred consideration expected to be settled in more than twelve months is classified as a non-current liability and is included in other long-term liabilities. As of June&#160;30, 2022, the fair value of deferred consideration included in other long-term liabilities was $7.3 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following observable input was used in the valuation of the deferred consideration as of June&#160;30, 2022:</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"/><td style="width:21.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.531%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June&#160;30, 2022 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Input</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.8</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed share price as of June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$19.72</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities arose from the Business Acquisition in August 2021 (Note 13). The contingent consideration liabilities consist of developmental and regulatory milestones, a priority review voucher milestone and net sales milestones. Upon the achievement of certain development and regulatory milestone events, the Company is obligated to issue to Motus equityholders up to 5,348,572 shares in the aggregate and AlgaeneX equityholders up to 368,867 shares in the aggregate. The fair value of the development and regulatory milestones are estimated utilizing a probability-adjusted approach. At June&#160;30, 2022, the weighted average probability of success was 42%. The development and regulatory milestones will be settled in shares of the Company's common stock. As such, there is no discount rate applied in the fair value calculation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company were to receive a priority review voucher, the Company is obligated to pay to the Motus equityholders a portion of the value of the priority review voucher, subject to certain reductions. The potential payout will be either 50% of the after tax net proceeds received by the Company from a sale of the priority review voucher or 50% of the average of the sales prices for the last three publicly disclosed priority review voucher sales, less certain adjustments. The fair value of the priority review voucher milestone is estimated utilizing a probability-adjusted discounted cash flow approach. This obligation will be settled in cash. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities for net sales milestones were valued using an option pricing model with Monte Carlo simulation. As of June&#160;30, 2022, the fair value of these net sales milestones were deemed immaterial to the overall fair value of the contingent consideration. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities have been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the inputs to the valuation approach, the estimated fair value could be significantly different than the fair value the Company determined. Contingent consideration liabilities expected to be settled in more than twelve months are classified as a non-current liability. A valuation of the contingent consideration liabilities is performed quarterly with gains and losses included within change in fair value of contingent consideration liabilities in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the contingent consideration liabilities as of June&#160;30, 2022 (in millions):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June&#160;30, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50.6</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probabilities of success</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14% - 95%</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority review voucher milestone</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.0</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5%</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7%</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock, restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for collectible trade receivables. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the six months ended June&#160;30, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"><tr><td style="width:1.0%"/><td style="width:33.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.936%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future </span></div>operating results. A change in the relationship with the suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract to determine which are performance obligations and to assess whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consist of net sales of ARIKAYCE. The Company's customers in the US include specialty pharmacies and specialty distributors. In December 2020, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Europe. In July 2021, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Japan. Globally, product revenues are recognized once the Company performs and satisfies all five steps of the revenue recognition criteria mentioned above.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the Company's product revenues, net, by geographic location for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:33.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total product revenues, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,328&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,580&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer credits: The Company's customers are offered various forms of consideration, including prompt payment discounts. The payment terms for sales to specialty pharmacies for prompt payment discounts are based on contractual rates agreed with the respective specialty pharmacies. The Company anticipates that its customers will earn these discounts and, therefore, deducts the full amount of these discounts from total gross product revenues at the time such revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates: The Company contracts with government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accrued liabilities on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recognizes revenue related to various early access programs (EAPs) in Europe, predominantly in France. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock', window );">Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets)</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Cost of Product Revenues (excluding amortization of intangible assets) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Inventory is stated at the lower of cost and net realizable value. The Company began capitalizing inventory costs following US Food and Drug Administration (FDA) approval of ARIKAYCE in September 2018. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestone payments. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to FDA approval of ARIKAYCE, the Company expensed all inventory-related costs in the period incurred. Inventory used for clinical development purposes is expensed to R&amp;D expense when consumed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations and Asset Acquisitions</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business combinations and asset acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for the Company&#8217;s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets&#8217; carrying amounts on the acquiring entity&#8217;s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Indefinite-Lived Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Indefinite-lived intangible assets consist of In Process Research &amp; Development (IPR&amp;D). IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&amp;D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#8217;s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company&#8217;s outlook and market performance of the Company&#8217;s industry and recent and forecasted financial performance. The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finite-lived Intangible Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Finite-lived intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the acquired ARIKAYCE R&amp;D intangible asset, at the date of subsequent adjustments of fair value. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Assessment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing to the carrying value of the assets to the fair value of the assets. The Company determined that no indicators of impairment of finite-lived intangible assets or long-lived assets existed at June&#160;30, 2022.</span></div>Goodwill - Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#8217;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassesses its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company will perform its next annual impairment testing for goodwill on October 1, 2022.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in </span><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7 - Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for details about the Company's lease portfolio, including required disclosures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and New Accounting Pronouncements (Not Yet Adopted)</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also promote consistent application of and simplify US generally accepted accounting principles (GAAP) for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance was effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. The Company adopted this guidance January 1, 2021. The adoption of the guidance did not have a material impact on the Company's consolidated financial statements and accompanying notes.</span>In August 2020, the FASB issued <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNTQ_a1983cb3-6ebb-4561-babb-c381ced619fe">ASU 2020-06</span>, Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, to reduce the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. For convertible instruments, the number of accounting models for convertible debt instruments is reduced, which results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Only convertible instruments that meet the definition of a derivative or are issued with substantial premiums will continue to be subject to the separation models. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and a share of convertible preferred stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation and recognition as derivatives. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021. The Company transitioned using the modified retrospective method. The impact of adopting ASU 2020-06 on January 1, 2022 resulted in an opening balance sheet adjustment increasing debt by $221.9&#160;million, increasing issuance costs classified to debt by $6.1&#160;million, decreasing the deferred tax liability by $1.4&#160;million, and causing an increase to retained earnings of $50.2 million, with an offsetting reduction to additional paid-in-capital of $264.6 million, net of tax.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197227148880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Carrying Value and Fair Value of Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:36.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June&#160;30, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:36.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Observable Inputs in Valuation of Deferred Consideration</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following observable input was used in the valuation of the deferred consideration as of June&#160;30, 2022:</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"/><td style="width:21.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.531%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June&#160;30, 2022 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Input</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.8</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed share price as of June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$19.72</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payables</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the contingent consideration liabilities as of June&#160;30, 2022 (in millions):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June&#160;30, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50.6</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probabilities of success</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14% - 95%</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority review voucher milestone</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.0</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5%</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7%</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the six months ended June 30, 2022 (in thousands):</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:22.401%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,172)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,068)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three and six months ended June&#160;30, 2022 and 2021: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.366%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,645)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of basic net loss per share:</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,602&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,580&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,267&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.80)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.07)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.60)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.97)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of June&#160;30, 2022 and 2021, respectively, as their effect would have been anti-dilutive (in thousands):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:66.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.553%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.555%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock and RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Percentage of Total Gross Product Revenue Represented by the Three Largest Customers</a></td>
<td class="text">The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the six months ended June&#160;30, 2022 and 2021.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"><tr><td style="width:1.0%"/><td style="width:33.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.936%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the Company's product revenues, net, by geographic location for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:33.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total product revenues, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,328&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,580&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197229486096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, the Company's inventory balance consists of the following (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"/><td style="width:49.266%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.261%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,541&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,017&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,009&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197229486096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles, Net and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Rollforward of Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the Company's intangible assets for the six months ended June 30, 2022 and June&#160;30, 2021 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"/><td style="width:36.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.303%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Intangible Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,425)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,809&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,526)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,283&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Intangible Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,425)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,261&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,526)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197230509824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Fixed Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:31.926%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.333%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.635%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,862&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-10</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress (CIP)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,251&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,016&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,305)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,061)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,955&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197231584672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, the Company's accrued liabilities balance consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"/><td style="width:57.515%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.207%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,019&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued technical operation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,182&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,655&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales allowances and related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,770&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197229739904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Supplemental Noncash Disclosures included in Consolidated Financial Statements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the supplemental noncash disclosures of the Company's leases included in its consolidated financial statements (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.256%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197231601088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Components of Debt Balance</a></td>
<td class="text">The following table presents the carrying value of the Company's debt balance (in thousands):<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:58.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.230%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of outstanding convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs, unamortized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,023)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,873)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783,977&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,588&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Principal Repayments of Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, future principal repayments of the notes for each of the years through maturity were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.543%"><tr><td style="width:1.0%"/><td style="width:64.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Summary of Interest Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to debt and finance leases for the three and six months ended June&#160;30, 2022 and 2021 is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.237%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,021&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible debt interest expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,883&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,217&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,319&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197227147424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Allocation of Employee Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the three and six months ended June&#160;30, 2022 and 2021, respectively (in millions):&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"><tr><td style="width:1.0%"/><td style="width:34.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197227963344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 416,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 416,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 716,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">148,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (95,645)<span></span>
</td>
<td class="num">$ (117,321)<span></span>
</td>
<td class="num">$ (190,266)<span></span>
</td>
<td class="num">$ (208,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197227214064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 148.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">416.1<span></span>
</td>
<td class="nump">$ 716.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">148.6<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="nump">10.8<span></span>
</td>
<td class="nump">14.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">55.6<span></span>
</td>
<td class="nump">75.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Fair Value | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">416.1<span></span>
</td>
<td class="nump">716.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">148.6<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Fair Value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="nump">10.8<span></span>
</td>
<td class="nump">14.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Fair Value | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">$ 55.6<span></span>
</td>
<td class="nump">$ 75.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_BusinessCombinationDeferredLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Deferred Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_BusinessCombinationDeferredLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197221426928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 04, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>sale </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_MarketableSecuritiesAdditional', window );">Marketable securities, additional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (99,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_FairValueLevel1Level2Level3TransfersAmount', window );">Fair value transfers in or out of Level 1, Level 2, or Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Current available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities', window );">Unrealized gain or loss | security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 783,977,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 566,588,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,023,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,539,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,405,310,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,265,243,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,449,281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,673,556,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (264,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value | Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value | Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member', window );">0.75% convertible senior notes due 2028 | Level 2 | Fair Value | Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member', window );">0.75% convertible senior notes due 2028 | Level 2 | Carrying Value | Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 561,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member', window );">0.75% convertible senior notes due 2028 | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Proceeds from issuance of 0.75% convertible senior notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member', window );">1.75% convertible senior notes due 2025 | Level 2 | Fair Value | Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member', window );">1.75% convertible senior notes due 2025 | Level 2 | Carrying Value | Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member', window );">1.75% convertible senior notes due 2025 | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Proceeds from issuance of 0.75% convertible senior notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=insm_DevelopmentAndRegulatoryMilestonesMember', window );">Development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_WeightedAverageProbabilityOfReachingMilestone', window );">Weighted-average probability of reaching milestone, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=insm_AccruedLiabilitiesCurrentMember', window );">Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares) | shares</a></td>
<td class="nump">2,889,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,889,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares', window );">Shares issued upon milestone achievements (in shares) | shares</a></td>
<td class="nump">5,348,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus | Priority review voucher milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage', window );">Potential payout percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage', window );">Potential payout, average sales prices, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders', window );">Number of publicly disclosed sales used to determine average sales price owed to equity holders | sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus | Second anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares) | shares</a></td>
<td class="nump">184,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus | Third anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares) | shares</a></td>
<td class="nump">184,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus | First anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares) | shares</a></td>
<td class="nump">184,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_AlgaeneXIncMember', window );">AlgaeneX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares', window );">Shares issued upon milestone achievements (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-For-Sale Securities, Gross Unrealized Gain (Loss), Number Of Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average Sales Prices Of Publicly Disclosed Priority Review Voucher Sales Obligated to Pay Equity Holders, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_BusinessCombinationDeferredLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Deferred Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_BusinessCombinationDeferredLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_FairValueLevel1Level2Level3TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Level 1, Level 2, Level 3 Transfers, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_FairValueLevel1Level2Level3TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_MarketableSecuritiesAdditional">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Additional</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_MarketableSecuritiesAdditional</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Publicly Disclosed Sales Used To Determine Average Sales Price Owed To Equity Holders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds Of Sale of Priority Review Voucher Obligated to Pay to Equity Holders, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_WeightedAverageProbabilityOfReachingMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Probability Of Reaching Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_WeightedAverageProbabilityOfReachingMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=insm_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=insm_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=insm_AccruedLiabilitiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=insm_AccruedLiabilitiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=insm_PriorityReviewVoucherMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=insm_PriorityReviewVoucherMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=insm_AlgaeneXIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=insm_AlgaeneXIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197227869120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Significant Observable Inputs of Deferred Business Acquisition Liabilities (Details) - Motus - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Share price used to calculate issuable shares (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Insmed share price as of June&#160;30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Share price used to calculate issuable shares (in dollars per share)</a></td>
<td class="nump">$ 19.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="nump">$ 10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_BusinessCombinationDeferredLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Deferred Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_BusinessCombinationDeferredLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197227839968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Significant Unobservable Inputs Of Contingent Consideration Liability (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=insm_DevelopmentAndRegulatoryMilestonesMember', window );">Development and regulatory milestones | Probabilities of success | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=insm_DevelopmentAndRegulatoryMilestonesMember', window );">Development and regulatory milestones | Probabilities of success | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=insm_PriorityReviewVoucherMilestoneMember', window );">Priority review voucher milestone | Probabilities of success</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">13.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=insm_PriorityReviewVoucherMilestoneMember', window );">Priority review voucher milestone | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">10.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">$ 50.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Priority review voucher milestone</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=insm_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=insm_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=insm_MeasurementInputProbabilityOfSuccessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=insm_MeasurementInputProbabilityOfSuccessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=insm_PriorityReviewVoucherMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=insm_PriorityReviewVoucherMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197228354480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Changes in the Fair Value of Deferred and Contingent Consideration Liabilities (Details) - Level 3 - Recurring basis<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Deferred Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 14,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue', window );">Change in Fair Value</a></td>
<td class="num">(4,172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments', window );">Adjustments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">10,759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">75,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue', window );">Change in Fair Value</a></td>
<td class="num">(20,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments', window );">Adjustments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 55,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Increase (Decrease) In Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=insm_DeferredConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=insm_DeferredConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=insm_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=insm_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197228244672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (95,645)<span></span>
</td>
<td class="num">$ (117,321)<span></span>
</td>
<td class="num">$ (190,266)<span></span>
</td>
<td class="num">$ (208,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares used in calculation of basic net loss per share (in shares)</a></td>
<td class="nump">119,602<span></span>
</td>
<td class="nump">109,580<span></span>
</td>
<td class="nump">119,267<span></span>
</td>
<td class="nump">106,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Dilutive securities, convertible debt (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">119,602<span></span>
</td>
<td class="nump">109,580<span></span>
</td>
<td class="nump">119,267<span></span>
</td>
<td class="nump">106,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.80)<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.60)<span></span>
</td>
<td class="num">$ (1.97)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.80)<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.60)<span></span>
</td>
<td class="num">$ (1.97)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive securities, share-based payment (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive securities, share-based payment (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive securities, share-based payment (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197228366736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">17,806<span></span>
</td>
<td class="nump">14,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">1,619<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">670<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">23,438<span></span>
</td>
<td class="nump">23,438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197229009072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentration Risk (Details) - Sales Revenue, Product Line - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=insm_CustomerAMember', window );">Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=insm_CustomerBMember', window );">Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=insm_CustomerCMember', window );">Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=insm_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=insm_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=insm_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=insm_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=insm_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=insm_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197224372096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Revenues by Geographic Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues, net</a></td>
<td class="nump">$ 65,221<span></span>
</td>
<td class="nump">$ 45,366<span></span>
</td>
<td class="nump">$ 118,328<span></span>
</td>
<td class="nump">$ 85,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues, net</a></td>
<td class="nump">47,190<span></span>
</td>
<td class="nump">41,754<span></span>
</td>
<td class="nump">87,972<span></span>
</td>
<td class="nump">79,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">JAPAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues, net</a></td>
<td class="nump">15,849<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,525<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=insm_EuropeAndTheRestOfTheWorldMember', window );">Europe And The Rest Of The World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues, net</a></td>
<td class="nump">$ 2,182<span></span>
</td>
<td class="nump">$ 3,612<span></span>
</td>
<td class="nump">$ 3,831<span></span>
</td>
<td class="nump">$ 6,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=insm_EuropeAndTheRestOfTheWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=insm_EuropeAndTheRestOfTheWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197224453520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory, Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 29,320<span></span>
</td>
<td class="nump">$ 29,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">15,908<span></span>
</td>
<td class="nump">18,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">21,789<span></span>
</td>
<td class="nump">18,940<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="nump">$ 67,017<span></span>
</td>
<td class="nump">$ 67,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197225558304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles, Net and Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Amortization of intangible assets, 2022</a></td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Amortization of intangible assets, 2023</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Amortization of intangible assets, 2024</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Amortization of intangible assets, 2025</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Amortization of intangible assets, 2026</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">136,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,809<span></span>
</td>
<td class="nump">$ 49,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(1,263)<span></span>
</td>
<td class="num">$ (1,263)<span></span>
</td>
<td class="num">(2,526)<span></span>
</td>
<td class="num">(2,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">71,283<span></span>
</td>
<td class="nump">46,735<span></span>
</td>
<td class="nump">71,283<span></span>
</td>
<td class="nump">46,735<span></span>
</td>
<td class="nump">73,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">136,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=insm_AcquiredResearchAndDevelopmentMember', window );">Acquired ARIKAYCE R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,439<span></span>
</td>
<td class="nump">47,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,425)<span></span>
</td>
<td class="num">(2,425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">40,014<span></span>
</td>
<td class="nump">44,864<span></span>
</td>
<td class="nump">40,014<span></span>
</td>
<td class="nump">44,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">PARI milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,770<span></span>
</td>
<td class="nump">$ 1,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">$ 1,669<span></span>
</td>
<td class="nump">$ 1,871<span></span>
</td>
<td class="nump">$ 1,669<span></span>
</td>
<td class="nump">$ 1,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=insm_AcquiredResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=insm_AcquiredResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197221339712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 93,251<span></span>
</td>
<td class="nump">$ 90,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(39,305)<span></span>
</td>
<td class="num">(37,061)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">$ 53,946<span></span>
</td>
<td class="nump">52,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 14,144<span></span>
</td>
<td class="nump">11,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 6,306<span></span>
</td>
<td class="nump">5,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember', window );">Computer hardware and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 7,053<span></span>
</td>
<td class="nump">7,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember', window );">Computer hardware and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember', window );">Computer hardware and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ManufacturingEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 1,203<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 37,009<span></span>
</td>
<td class="nump">36,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress (CIP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 27,447<span></span>
</td>
<td class="nump">$ 27,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197224450048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedClinicalTrialExpenses', window );">Accrued clinical trial expenses</a></td>
<td class="nump">$ 17,019<span></span>
</td>
<td class="nump">$ 19,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">11,336<span></span>
</td>
<td class="nump">10,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedTechnicalOperationExpenses', window );">Accrued technical operation expenses</a></td>
<td class="nump">4,816<span></span>
</td>
<td class="nump">6,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedRoyaltiesAndMilestonePaymentsCurrent', window );">Accrued royalty payable</a></td>
<td class="nump">7,182<span></span>
</td>
<td class="nump">6,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="nump">2,175<span></span>
</td>
<td class="nump">2,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedSalesAllowancesAndRelatedCosts', window );">Accrued sales allowances and related costs</a></td>
<td class="nump">11,470<span></span>
</td>
<td class="nump">8,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_BusinessCombinationDeferredPaymentsCurrent', window );">Deferred consideration</a></td>
<td class="nump">3,459<span></span>
</td>
<td class="nump">4,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedConstructionLiabilitiesCurrent', window );">Accrued construction costs</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">1,208<span></span>
</td>
<td class="nump">1,851<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 58,770<span></span>
</td>
<td class="nump">$ 60,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedClinicalTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedClinicalTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedConstructionLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Construction Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedConstructionLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedRoyaltiesAndMilestonePaymentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Royalties and Milestone Payments, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedRoyaltiesAndMilestonePaymentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedSalesAllowancesAndRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Allowances And Related Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedSalesAllowancesAndRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedTechnicalOperationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedTechnicalOperationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_BusinessCombinationDeferredPaymentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Deferred Payments, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_BusinessCombinationDeferredPaymentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197228335088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease, cost</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount', window );">Lease cost, future right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_LeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_LeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_LeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_LeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197221416800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease, costs (Details) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,287<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 507<span></span>
</td>
<td class="nump">$ 8,641<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197226266832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Underwriting discounts and commissions and other offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 17,689<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 17,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member', window );">0.75% convertible senior notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate</a></td>
<td class="nump">0.0307692<span></span>
</td>
<td class="nump">30.7692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member', window );">1.75% convertible senior notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate</a></td>
<td class="nump">0.0255384<span></span>
</td>
<td class="nump">25.5384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 0.75% convertible senior notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount | $</a></td>
<td class="nump">$ 575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentOptionToPurchaseAdditionalDebt', window );">Option to purchase additional debt | $</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Underwriting discounts and commissions and other offering expenses | $</a></td>
<td class="nump">15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds | $</a></td>
<td class="nump">$ 559,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 32.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining', window );">Remaining discount amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 0.75% convertible senior notes due 2028 | Conversion Term (i)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percent of stock price trigger</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 0.75% convertible senior notes due 2028 | Conversion Term (ii)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percent of stock price trigger</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 0.75% convertible senior notes due 2028 | Conversion Term (iii)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange', window );">Threshold trading days following fundamental change</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 0.75% convertible senior notes due 2028 | Conversion Term (iv)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percent of stock price trigger</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 1.75% convertible senior notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentOptionToPurchaseAdditionalDebt', window );">Option to purchase additional debt | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Underwriting discounts and commissions and other offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchased amount | $</a></td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt | $</a></td>
<td class="nump">$ 17,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining', window );">Remaining discount amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 1.75% convertible senior notes due 2025 | Conversion Term (i)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percent of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 1.75% convertible senior notes due 2025 | Conversion Term (ii)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percent of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 1.75% convertible senior notes due 2025 | Conversion Term (iii)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange', window );">Threshold trading days following fundamental change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 1.75% convertible senior notes due 2025 | Conversion Term (iv)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percent of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Debt Instrument, Discount Amortization Period, Remaining</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentOptionToPurchaseAdditionalDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Option To Purchase Additional Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentOptionToPurchaseAdditionalDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197230692656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Components of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Face value of outstanding convertible notes</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, unamortized</a></td>
<td class="num">(16,023)<span></span>
</td>
<td class="num">(11,539)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(221,873)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, long-term</a></td>
<td class="nump">$ 783,977<span></span>
</td>
<td class="nump">$ 566,588<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197227113632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Future Principal Repayments of Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Year Ending December&#160;31:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_LongTermDebtMaturityAfterYearFour', window );">2027 and thereafter</a></td>
<td class="nump">575,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_LongTermDebtMaturityAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_LongTermDebtMaturityAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197227838208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Contractual interest expense</a></td>
<td class="nump">$ 2,062<span></span>
</td>
<td class="nump">$ 2,052<span></span>
</td>
<td class="nump">$ 4,125<span></span>
</td>
<td class="nump">$ 4,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">821<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="nump">1,643<span></span>
</td>
<td class="nump">807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,482<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,389<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ConvertibleDebtInterestExpenseTotal', window );">Total convertible debt interest expense</a></td>
<td class="nump">2,883<span></span>
</td>
<td class="nump">9,991<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
<td class="nump">17,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance lease interest expense</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">880<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 3,357<span></span>
</td>
<td class="nump">$ 10,319<span></span>
</td>
<td class="nump">$ 6,648<span></span>
</td>
<td class="nump">$ 17,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ConvertibleDebtInterestExpenseTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Debt, Interest Expense, Total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ConvertibleDebtInterestExpenseTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197224972896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 04, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,865,023<span></span>
</td>
<td class="nump">118,738,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,865,023<span></span>
</td>
<td class="nump">118,738,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,406,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares)</a></td>
<td class="nump">2,889,367<span></span>
</td>
<td class="nump">2,889,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=insm_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,455,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=insm_AtTheMarketAgreementMember', window );">ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CommonStockAuthorizedAggregateGrossSalesProceeds', window );">Common stock authorized, aggregate gross sales proceeds (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,438,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,805,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,619,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CommonStockAuthorizedAggregateGrossSalesProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Authorized, Aggregate Gross Sales Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CommonStockAuthorizedAggregateGrossSalesProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=insm_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=insm_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=insm_AtTheMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=insm_AtTheMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197224811648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 12, 2021</div></th>
<th class="th"><div>May 12, 2020</div></th>
<th class="th"><div>May 15, 2018</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 16, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross', window );">Inducement stock options granted to new employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,500,000<span></span>
</td>
<td class="nump">$ 122,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,780<span></span>
</td>
<td class="nump">114,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">PSUs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Potential award payout</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Potential award payout</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Potential award payout</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to unvested RSU awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500,000<span></span>
</td>
<td class="nump">$ 32,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=insm_A2019IncentivePlanThirdAmendmentMember', window );">2019 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock, maximum authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,145,104<span></span>
</td>
<td class="nump">2,145,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=insm_A2019IncentivePlanSecondAmendmentMember', window );">2019 Incentive Plan, Second Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=insm_EmployeeStockPurchasePlan2018Member', window );">2018 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock, maximum authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of inducement share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=insm_A2019IncentivePlanThirdAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=insm_A2019IncentivePlanThirdAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=insm_A2019IncentivePlanSecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=insm_A2019IncentivePlanSecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=insm_EmployeeStockPurchasePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=insm_EmployeeStockPurchasePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197224154720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details) - Stock options and RSUs - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 14.3<span></span>
</td>
<td class="nump">$ 11.8<span></span>
</td>
<td class="nump">$ 27.1<span></span>
</td>
<td class="nump">$ 22.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="nump">$ 14.8<span></span>
</td>
<td class="nump">$ 14.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197230771536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 501,000<span></span>
</td>
<td class="nump">$ 622,000<span></span>
</td>
<td class="nump">$ 886,000<span></span>
</td>
<td class="nump">$ 861,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197228306672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense charged to operations</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140197226166352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisition - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 04, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 24, 2021 </div>
<div>days</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_BusinessAcquisitionConsecutiveTradingDayPeriod', window );">Consecutive trading day period | days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncAndAlgaeneXIncMember', window );">Motus and AlgaeneX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of total consideration | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares)</a></td>
<td class="nump">2,889,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,889,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares', window );">Shares issued upon milestone achievements (in shares)</a></td>
<td class="nump">5,348,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Cash to be paid upon achievement of milestones | $</a></td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Share price used to calculate issuable shares (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus | First anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares)</a></td>
<td class="nump">184,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus | Second anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares)</a></td>
<td class="nump">184,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus | Third anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares)</a></td>
<td class="nump">184,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_AlgaeneXIncMember', window );">AlgaeneX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares', window );">Shares issued upon milestone achievements (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid in acquisition | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Share price used to calculate issuable shares (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_BusinessAcquisitionConsecutiveTradingDayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Consecutive Trading Day Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_BusinessAcquisitionConsecutiveTradingDayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncAndAlgaeneXIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncAndAlgaeneXIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=insm_AlgaeneXIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=insm_AlgaeneXIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>insm-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:insm="http://www.insmed.com/20220630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="insm-20220630.xsd" xlink:type="simple"/>
    <context id="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie4a1faee4d59482ea066bbdc84f02467_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i92ecd30d90114111bd1344c30c28673d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2dbe805af0654b00851eb3609fe8fc0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i164351f40c6a48a5bce7be7cbbb95393_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iefa9467fe6ae4ae7be463ef02bd03331_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i35baa1a10636413abb12d0a528eb7da0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i74180eb633f24734a1c4c9c66a934ef6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i14d1bd5fb1694a178730b0cd705a3cd4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id2de1a6fdaa74c7cade5245529b85f53_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i828764c93d1d45929aa04ca248ea4fad_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if48dc576429648f1a4016567fa86b396_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7ac8060b82014b21b0613cda3d7a60c6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i55f0b2b681c841419600222a85ea3546_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3276d1a28daa4225b9fcdb3cc08af201_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifd691c6a90574493ba24a86f882bb91a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i24591cad2f4544ef997c8b46679d9352_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i34b29fd1e2a04660a3bb612c3f24dde5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i06b533b795524ae29ed13dc8973a1aba_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia867ec38918e444f8e2d1d14ce332ec5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4f812dff96b74536ae44f954590aa428_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie86bfdf9f6d24ddfa8e132dc25af8978_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4c0613ed6dde4e01bc2b4e47830856f9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4d40fdfd16fc451fb491730b4a9173d4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9db84f87eeb341579e4fe91899a2f3f5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4c724ef416fd4b8d83a5292521f39be3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7ccd6a0b87204d16adb14a3d22bcda4e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0182cad036cc492c902e8768cc1bdc6a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5f7e3e3f5c7949eb926f4685e8a1dd75_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic0b176cdccb74943960953e16068e6a8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iadd45892aa3342cbbeff3a291a11105b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3ea404b9803f4458944b7dbf3eefe5d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3f49f20915e465aa2c3491edb04f079_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b6083ac1b4641ee80d7fbb9322f6ff4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3240a301c3b4a8092fcd0ff21adb6f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic11e1e3142e048009002fc987716b4e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6afe0edb9cc44adca52bd18a9cba27db_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5d76fce0871a49f997118895b8cc5d9e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i048e3b2eae994f98967e9743c0322e99_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0471829afd7d49ec8d77526fcd9e579e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0b3892dcb478479cbc9399beec69b27e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4522e02284f8410db6010810d897bb79_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5eb0968295fa457c8b850a6bb24fd24e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if525baf875694aeebfb3e8f1ee7895c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib522b19ddff7498ba35a485c8ecf846e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf38b8e15b4544b69ae00a7699d5915d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86ea5250e3bb45aa81e5c43a0000647d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide697d4ed12846f7b2b2e749378e6fb5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05cbb40265d44701a893071c4123f466_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2d0519eefc5a4372aa09bac3494eed11_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i94bf3b66b78947dcb8fe7cb4478bc7f1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5e5d191ee0284b228ad30f1ed1e95735_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if2feebc246964bc390c0f21deae432ad_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7a28ddcd6f5348cc9084640011f760dd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iec080385c64348cb8d266b6830480fb9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2d7e6f6374b34f27b308f84f2889e800_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic90ba27634af46b9a9e3cde8cc10fe96_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i47041a589d9840429204e4bf3b7e196d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i93327d100c39469e95dec29690f01bda_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ee4597ee72a49a1b044f1c8dbb4f863_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i71d3efb8da424928ad39dfb3ae7f93e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie148fe14821246d98cdbbf096f0dc154_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib690063402dd47c4ae80bed8cc5946a2_D20210804-20210804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-04</startDate>
            <endDate>2021-08-04</endDate>
        </period>
    </context>
    <context id="ibbf98dd2c06941fba02468ff74fe15f4_D20210804-20210804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-04</startDate>
            <endDate>2021-08-04</endDate>
        </period>
    </context>
    <context id="i63cf6ce83c0a452894be75c49ed8e241_D20210804-20210804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-04</startDate>
            <endDate>2021-08-04</endDate>
        </period>
    </context>
    <context id="ie99f3a85a4be4eee9b9643513ffb1f49_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">insm:AccruedLiabilitiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic0173aaf93ae46c0804c04edc71dcf3d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if515e39443fc4bab983e5485d58c4067_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i060750a8e6764e58986207b6fa039245_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4fc0d05a849b4f9f8363d09eb7a2297f_D20210804-20210804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-04</startDate>
            <endDate>2021-08-04</endDate>
        </period>
    </context>
    <context id="i7d34c58061f249e18f61f07687b0331b_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:AlgaeneXIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i8a656fb7732145c9a71bf1d21a49bd5d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4df89726368c42908ecdb1dc00da2381_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:PriorityReviewVoucherMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i281fbad9a3524e6396eb4972fe1bde0a_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:PriorityReviewVoucherMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="ia8937d9bce474ef99c2f8fd821f06dfd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i26bcf703891e40a19cb16e952a3c238c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">insm:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7956fe4d32d6415888053fe7ac3dece8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">insm:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibfb81df3017f4c52b5f695219f80bcb0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:PriorityReviewVoucherMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i01b8767d1be2471ea778276a43af86f0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:PriorityReviewVoucherMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">insm:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i694933442abe4684b8238d717a4bc7b2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:PriorityReviewVoucherMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9029a1175b8d4c0bb7ad648dd57b8b45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DeferredConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id65b00fb345d4a73968a60a9f00ec86b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DeferredConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8cfafbc2904c4fd78825be70c0ebb580_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DeferredConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i32f0450653644e2c821879326a4be32c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e6f98ddcb9a41259b5ad644d8e7762b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibf3af52789dd4962b7190f4bb7f153e7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i008ce45b9b5447059371d7e92096d9ff_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8a35e946668040f5b6acb3c5b856b0e7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7436f64e366c4208874055741be8f683_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id3ba44aaad2b44359ffdef500ffbb2d8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icb495f010db54c2ebbb407f2ea54e2ba_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idae99b8ad22540cba6959e639a4bc3d9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i18c239d8a4b84368b0ec193e679d9382_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i45292554e7184f898ba749676eba1941_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibd20c886bcbb4ec881a57bf89c5feefa_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i75d345a205d14a869a001fc3d932ca19_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i32487a941bfc4076b54815cf8c60211b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5de10744d8f445ae87da00f994d29fcd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i826dc379d52b4e8d8be78b58060e1979_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i11458fa48bb841a7b70bf22cafac3a40_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i04f0a1a4c2144c658e9faeab5bacbf34_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0771a886122a4116af16d7e597aac7e8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2f46d4b8f14b4f9a9806c15e65465675_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib57ecc23938042cfa725b197115046c8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i88a276ac0d54475b9c03c7440a1608fe_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1cfd6327542a4ec28651deb81d520e2c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i62c8f1c4a72145a8a38686730f07d96d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibaa2f8ddc972496d9af74169e0443d41_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7d56f2cd3eaf416e8ea5e63692228a23_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2ae9ec03bdda4b058bca71221c9a7996_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8297b16fe1be40cb95165a0bea1fa1fe_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i34fcb92cc2b441f1a0c7f4c6e848c031_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8f40504b772844eb858783a727551877_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i661418bb0674414b9010ff5b70067d3d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i30c3f2d8839a4faa9a1c05047301e4f7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if5334091cc884a859ad2228b90a2795f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7b44c6e566f24a9882c1b3f8f3b4c0ee_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iea9322ea7e7a46f9bb59dc10b38f0897_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1448668a7228445d80ba936243ca7fe7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie5726053c5da4536a1e11ec19e99b532_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3bed069934724804b94a28374dea16e9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6931c30dc02f44cf8d0a90632e1f5ce4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i80224a3dd22c4d58966aae71eacb8cc4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2cd49603d9354e39a28f04178c247b10_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0e5abaf4f46249c2b605b4b4d53db50a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:EuropeAndTheRestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iad77b69398bc4c9dbef47393b9c7c0e7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:EuropeAndTheRestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie1df549ad601429bbc4b64c37aee2eb3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:EuropeAndTheRestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i77947eb926944d7f9ef2b3f148ffcb51_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:EuropeAndTheRestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iefdd31e6154343f0a080337167a74a77_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ieaf84c60d3d749089c4d2329ec941ffe_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="if1380329539b4132829f56ecd925fdf8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7cd9cfdd737546e99d0b622013e7ca48_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifc4ec61359d24f0caa4c62d971da1288_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i278371e151d544e6a212c9d2aa2a655b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0dd5b90d56364a53a5da8bdf154bec64_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ife46a9fb88034d28981626beb4a29946_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5640268efe1f4be6b786aed558989d41_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b3c794885af4e1f921fd241ba143529_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0f13532abba943b0b557fd68637dbf22_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i413f715068c444d2a9f6c5865f2e54fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i58319fe25f124f3b8246c1b27bb7cb08_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iefdd99d19aab444dbfcd286f3daa9339_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1686617c86b644caae372fe8d75fcec3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if38a8d02ea544cb4b9317034c9910cb3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id72977157672403489742e38fb8ca59b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i344bca01b9d34f3aa441d482b0f2f475_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7c4bd98ffad14ac78e43425f54977d3d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iedecef4e6b1d4166a9b79f3e0c853064_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51ea7721be4640ed9298ced46bffdeae_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icb7b544503ac43e48d6444664e6c74da_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i805564f130794c159907d4cd7218c011_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaef54a8191e044bf93f11f4bc2a4e911_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic131085d4cfa45ffaa948fcbbe39e100_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i74052c73b62e4b3ca8e440d6a7b6b48a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia326b8c20ab24d99baac8636d47b1d21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1378d80bd52a41168942eacca8002c0e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i34f0289767e04e32a7cfdbeba5d34a52_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1eae84db78bc47d8b25e7ed4a65b6f34_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4791157952514b1fb66954d88f405f1a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i483f5f82cf52494c8e648b074f86b53e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if7daf1615bf64212badeff54cd466033_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ce4bf905b02467b8dfd8172fa04331a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icfd0d2a201514ed9a710f3e15a4be0ec_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibf90ef381262457fb02ac15abe61db23_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5ff8e585d8da4a4eadbb4f76e2229297_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7bcb57d4e9ec41c3913ce6375172ce80_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id1e1185e028b41649a95d8db0860d1ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab7551ae213f49089690e61c379022e7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i345e38b73d984ac7acfa140fc7af5a1a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3905fa6bad2f4f878b2411f148bf023a_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i3b10eb0c1f2944019b12df6a3c668f5b_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i78d8e00c8ae5498c94772ed4b961f0bb_I20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="ibc290352fb8049bea385a8284c77e6de_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i3b3c8791efbd4b76898c1f2be69fa04b_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i2aafae0ef97940e9afdb689e748f167a_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="iccd7845446c64a369164bb9ead8f5b59_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i0f13738b91a24ea68cfbd83444c1fda2_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i360c8f6cf0d349aa971816bd2ab768a8_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i677c8198ab1b4318bd9f81ef52a60fbd_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i0d34cc38f62945cc8de38c2b34b77333_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i120ab819124c4ec7955b853c7979a0e0_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="ie08ca784c1914a3d9e58680c070a1adb_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="ief82ea409318476187e7caeb47194f48_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="ibbcdfbf9e8254e929522a467310b9522_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="ie0d8b12165884f4ab863204524ec1168_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i82d7c106dda746228e53977a22a4368f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i94cb8d7603c84b26a3152ca2f217dbcf_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibb904a2de5514e68a11f4cbaec8fa4d2_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i3e690606ed2949018b852163daddc302_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i63fc774e8854431ba4eafe553558adf0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4043f106b7ff4d2aa5e7c93a3a3ae9cd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1861d72030824ced8ef920fa4c278220_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2e74b1e1d79d4206a35bd3d6cae5a699_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie5cf4cca2bb1485f813f9ef62c61797a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0b9b0a45175146259bc231dc8f5ee5c6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i171123b4124b445eba208fcf196842fc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7f2cf2d9e0294d689a5e13786a2e00a2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7a78bc5894c84095aa559149f1fe6c13_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib7b0a51fe15b40af849fca272f472e3a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i317c38eb43ca4b2da0d5950221ff472a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id2c3209fc64e4317a4091a1502a77db1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i91561c5c770b4119b0528f79d05ba9b9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i47631aa0607443aa837dd0c862dfd781_I20190516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-16</instant>
        </period>
    </context>
    <context id="ib4fa2223aeb44fe2b0cdb87788b4adaf_D20200512-20200512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-12</startDate>
            <endDate>2020-05-12</endDate>
        </period>
    </context>
    <context id="ie5861a2f40e5462983cc26a47179e376_D20210512-20210512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanSecondAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-12</startDate>
            <endDate>2021-05-12</endDate>
        </period>
    </context>
    <context id="i0288ec411bda42658bcabbda47913862_D20210512-20210512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-12</startDate>
            <endDate>2021-05-12</endDate>
        </period>
    </context>
    <context id="i89ae304eebb24882b6d4e002897820e6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i62d1dc130d494fe6805b85220bf3941a_I20180515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-15</instant>
        </period>
    </context>
    <context id="ic196e790147b4d15a6d6b4c68f8a6472_D20180515-20180515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-15</startDate>
            <endDate>2018-05-15</endDate>
        </period>
    </context>
    <context id="ib97d0fd95e2844cd80ddb0c2a4049481_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i22331278b70c4d298ba0751f16fcf4b1_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="iab99f87cba69456faa7114cb972e768f_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i6ceb0c5b59ec456684a1a621d375db23_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i117be86acfcb4eebbf356e9bca57ec66_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie3990da618f7430d9bbd1e66442f7851_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id4386f9644da41bea1baa490a37085c2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0a8cd663f8b34900a9dc46cfc889dbb2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2d1f7158600c4c6fb173fb60e3b43c76_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7dcac17f493744c29df2003d99cf399b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie4249e6eea7944feab2165125682bd3e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id29b955148664a0eb00d37f9dc631961_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic006f1ab997e4bf98ba5840a6a977cfb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i700526f8aa8c42d3b0a44747d7347c9a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iad0d6bd3de9743b49ef5056bd1b0629d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2574040e81cf45fdb63c1f0620c5cc9a_I20210804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="icfe80c21994c4bb9b647c882148aa2b8_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i1ff8bc31f64b484687adf08bd1e1364c_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:AlgaeneXIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i07acd876919448939ae3e9671ddb5ce7_D20210524-20210524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2021-05-24</startDate>
            <endDate>2021-05-24</endDate>
        </period>
    </context>
    <context id="ieb37f5b95f6243009bf267154d33f563_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncAndAlgaeneXIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="security">
        <measure>insm:security</measure>
    </unit>
    <unit id="sale">
        <measure>insm:sale</measure>
    </unit>
    <unit id="day">
        <measure>insm:day</measure>
    </unit>
    <unit id="days">
        <measure>insm:days</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80L2ZyYWc6OTMyZDk4NTgxNGI3NGM0NzkwMjhiOGIyYmJkZGVkYjEvdGFibGU6Yjg4NjFmYjlhYThkNDkwZGIwYzdjMGYxMDVlZTU1MmMvdGFibGVyYW5nZTpiODg2MWZiOWFhOGQ0OTBkYjBjN2MwZjEwNWVlNTUyY18zLTEtMS0xLTI4OTQ3_624a896e-7c5e-44a3-93ef-83200b643dcb">0001104506</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80L2ZyYWc6OTMyZDk4NTgxNGI3NGM0NzkwMjhiOGIyYmJkZGVkYjEvdGFibGU6Yjg4NjFmYjlhYThkNDkwZGIwYzdjMGYxMDVlZTU1MmMvdGFibGVyYW5nZTpiODg2MWZiOWFhOGQ0OTBkYjBjN2MwZjEwNWVlNTUyY180LTEtMS0xLTI4OTQ3_02dd1398-e7ec-4ea6-bd6c-434064aba73e">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80L2ZyYWc6OTMyZDk4NTgxNGI3NGM0NzkwMjhiOGIyYmJkZGVkYjEvdGFibGU6Yjg4NjFmYjlhYThkNDkwZGIwYzdjMGYxMDVlZTU1MmMvdGFibGVyYW5nZTpiODg2MWZiOWFhOGQ0OTBkYjBjN2MwZjEwNWVlNTUyY181LTEtMS0xLTI4OTQ3_ad2898e8-ab48-45ff-ba57-dd0de2a8fdf6">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80L2ZyYWc6OTMyZDk4NTgxNGI3NGM0NzkwMjhiOGIyYmJkZGVkYjEvdGFibGU6Yjg4NjFmYjlhYThkNDkwZGIwYzdjMGYxMDVlZTU1MmMvdGFibGVyYW5nZTpiODg2MWZiOWFhOGQ0OTBkYjBjN2MwZjEwNWVlNTUyY182LTEtMS0xLTI4OTQ3_2a7b9371-2b25-4913-87ef-6cc868298064">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80L2ZyYWc6OTMyZDk4NTgxNGI3NGM0NzkwMjhiOGIyYmJkZGVkYjEvdGFibGU6Yjg4NjFmYjlhYThkNDkwZGIwYzdjMGYxMDVlZTU1MmMvdGFibGVyYW5nZTpiODg2MWZiOWFhOGQ0OTBkYjBjN2MwZjEwNWVlNTUyY183LTEtMS0xLTI4OTQ3_40478f43-2c76-4b64-be7a-d6dadae3a9bb">Q2</dei:DocumentFiscalPeriodFocus>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy0wLTEtMS0yODk0Nw_5170a57a-1eda-4542-9bcc-d9f790c05e2e">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy0wLTEtMS0yODk0Nw_5fbc7803-cbbe-4bcb-b5af-540dd0804389">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy0wLTEtMS0yODk0Nw_62156160-2395-4d30-a04e-38d15c472e4f">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy0wLTEtMS0yODk0Nw_71b55fa8-736f-46bf-86da-41456bd986cc">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi0wLTEtMS0yODk0Nw_2e37e237-166c-4368-81f8-ac870cd6c5b4">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi0wLTEtMS0yODk0Nw_4aef5557-06f5-48ae-8810-c00dfa86ec5a">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi0wLTEtMS0yODk0Nw_e533229d-73dc-4061-a116-6e06fda709bc">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi0wLTEtMS0yODk0Nw_ff82a8a8-fd7a-4c2e-a1b3-ebc868884937">http://fasb.org/us-gaap/2022#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="ib522b19ddff7498ba35a485c8ecf846e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTUtMC0xLTEtMzAzOTY_6eb28c14-79b4-4b78-b3a4-04fcfc83126c">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNTQ_a1983cb3-6ebb-4561-babb-c381ced619fe">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="iccd7845446c64a369164bb9ead8f5b59_D20180101-20180131"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81NS9mcmFnOjcxZWQ5MTg4MTEzYzQzMjg4OGYwNDUzNWM2OWJhZTA4L3RhYmxlOjc0M2ZjY2ZkOTRjMTQwY2JiMjgxNmM4NmU0MGZmN2NlL3RhYmxlcmFuZ2U6NzQzZmNjZmQ5NGMxNDBjYmIyODE2Yzg2ZTQwZmY3Y2VfMi0xLTEtMS0yODk0Nw_5437fee6-3734-4401-a19d-a50bdd31c946"
      unitRef="number">25.5384</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ibb904a2de5514e68a11f4cbaec8fa4d2_D20210501-20210531"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81NS9mcmFnOjcxZWQ5MTg4MTEzYzQzMjg4OGYwNDUzNWM2OWJhZTA4L3RhYmxlOjc0M2ZjY2ZkOTRjMTQwY2JiMjgxNmM4NmU0MGZmN2NlL3RhYmxlcmFuZ2U6NzQzZmNjZmQ5NGMxNDBjYmIyODE2Yzg2ZTQwZmY3Y2VfNC0xLTEtMS0yODk0Nw_0e3aec01-05d3-463e-b0ba-a0b6d0b1c2d8"
      unitRef="number">0.0255384</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i0f13738b91a24ea68cfbd83444c1fda2_D20180101-20180131"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81NS9mcmFnOjcxZWQ5MTg4MTEzYzQzMjg4OGYwNDUzNWM2OWJhZTA4L3RhYmxlOjc0M2ZjY2ZkOTRjMTQwY2JiMjgxNmM4NmU0MGZmN2NlL3RhYmxlcmFuZ2U6NzQzZmNjZmQ5NGMxNDBjYmIyODE2Yzg2ZTQwZmY3Y2VfNi0xLTEtMS0yODk0Nw_4e06a061-5c92-4463-9503-c2cb40c28297"
      unitRef="number">30.7692</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i3e690606ed2949018b852163daddc302_D20210501-20210531"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81NS9mcmFnOjcxZWQ5MTg4MTEzYzQzMjg4OGYwNDUzNWM2OWJhZTA4L3RhYmxlOjc0M2ZjY2ZkOTRjMTQwY2JiMjgxNmM4NmU0MGZmN2NlL3RhYmxlcmFuZ2U6NzQzZmNjZmQ5NGMxNDBjYmIyODE2Yzg2ZTQwZmY3Y2VfOC0xLTEtMS0yODk0Nw_563db70a-b4a0-4433-959c-1ed29e259257"
      unitRef="number">0.0307692</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTky_32c12730-3d5b-46bc-ae1d-d78e7b184e23">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTg2_0bc43272-d0fd-462c-b99f-c9230f88b74a">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMjQ_2b21062c-d825-4a2e-ab5a-91cbd88b479d">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTg3_77747433-7264-46c3-8d01-ff847232387a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTg4_b718c4bf-045c-44b0-b34c-07273a5f4df3">000-30739</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTkz_18e16006-9641-496d-9271-d2bd24f2d366">INSMED INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YzBjMDhmZjllNDE4NGM3N2IzYjRlNzFhMDYwMDJjNzMvdGFibGVyYW5nZTpjMGMwOGZmOWU0MTg0Yzc3YjNiNGU3MWEwNjAwMmM3M18wLTAtMS0xLTI4OTQ3_835a6bb6-519c-45b8-9af5-4642329ee754">VA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YzBjMDhmZjllNDE4NGM3N2IzYjRlNzFhMDYwMDJjNzMvdGFibGVyYW5nZTpjMGMwOGZmOWU0MTg0Yzc3YjNiNGU3MWEwNjAwMmM3M18wLTItMS0xLTI4OTQ3_b1ea255e-4ec2-47d5-91e8-fc38a091806c">54-1972729</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YzBjMDhmZjllNDE4NGM3N2IzYjRlNzFhMDYwMDJjNzMvdGFibGVyYW5nZTpjMGMwOGZmOWU0MTg0Yzc3YjNiNGU3MWEwNjAwMmM3M18zLTAtMS0xLTI4OTQ3L3RleHRyZWdpb246MGI3YWI4ODdlMDJlNDlmOTgwN2E5Zjg4MTNkYjg3OGFfNA_e48d7fae-5603-4002-bd50-a30e9a52e275">700 US Highway 202/206</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YzBjMDhmZjllNDE4NGM3N2IzYjRlNzFhMDYwMDJjNzMvdGFibGVyYW5nZTpjMGMwOGZmOWU0MTg0Yzc3YjNiNGU3MWEwNjAwMmM3M180LTAtMS0xLTI4OTQ3L3RleHRyZWdpb246ZTkwZGMwNmUxYmI4NDI1ODk1NDk1MGMxN2Q0ZmYzMjRfNA_6524f075-9753-4669-9e02-de30a127bbfc">Bridgewater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YzBjMDhmZjllNDE4NGM3N2IzYjRlNzFhMDYwMDJjNzMvdGFibGVyYW5nZTpjMGMwOGZmOWU0MTg0Yzc3YjNiNGU3MWEwNjAwMmM3M180LTAtMS0xLTI4OTQ3L3RleHRyZWdpb246ZTkwZGMwNmUxYmI4NDI1ODk1NDk1MGMxN2Q0ZmYzMjRfOA_0a5d4cb4-2fd1-4b6f-be0c-d00ed5e52d43">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YzBjMDhmZjllNDE4NGM3N2IzYjRlNzFhMDYwMDJjNzMvdGFibGVyYW5nZTpjMGMwOGZmOWU0MTg0Yzc3YjNiNGU3MWEwNjAwMmM3M180LTItMS0xLTI4OTQ3_784514e2-666f-4c6b-9dff-6ea8e4d91a25">08807</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTk0_38788310-2aeb-4e48-ba37-c9959f32da38">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTk1_27ff7f41-3811-4ae1-bc32-c9d037c7f8a9">977-9900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6NWQ0ZjAwNjc4ZGQzNDQ3YWFhODc4MGEwMjA3ZDdkNTMvdGFibGVyYW5nZTo1ZDRmMDA2NzhkZDM0NDdhYWE4NzgwYTAyMDdkN2Q1M18xLTAtMS0xLTI4OTQ3_a52c4db2-5f28-46b7-8ed5-981c55b9c850">Common stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6NWQ0ZjAwNjc4ZGQzNDQ3YWFhODc4MGEwMjA3ZDdkNTMvdGFibGVyYW5nZTo1ZDRmMDA2NzhkZDM0NDdhYWE4NzgwYTAyMDdkN2Q1M18xLTEtMS0xLTI4OTQ3_2e94bc3b-7127-486b-8e2f-7d7d4afe04d3">INSM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6NWQ0ZjAwNjc4ZGQzNDQ3YWFhODc4MGEwMjA3ZDdkNTMvdGFibGVyYW5nZTo1ZDRmMDA2NzhkZDM0NDdhYWE4NzgwYTAyMDdkN2Q1M18xLTItMS0xLTI4OTQ3_2e17aae3-68d6-4a85-bfb1-f09762a11367">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTkw_5ebe2f1d-1138-4374-90e2-a167b3593773">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTg5_8453d5c2-5602-4657-bfbf-3990a4c9edef">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YmYwMjUxMDYyNTM2NGJmYjhhMTM2NWEzMmI1YjY2ZDgvdGFibGVyYW5nZTpiZjAyNTEwNjI1MzY0YmZiOGExMzY1YTMyYjViNjZkOF8wLTAtMS0xLTI4OTQ3L3RleHRyZWdpb246M2EyZjFhYjAwOTc0NDZlOGEzN2E1Zjc0Y2RlMmU2YzBfNQ_c65d3dc0-839c-48e2-9505-239bb58482a0">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YmYwMjUxMDYyNTM2NGJmYjhhMTM2NWEzMmI1YjY2ZDgvdGFibGVyYW5nZTpiZjAyNTEwNjI1MzY0YmZiOGExMzY1YTMyYjViNjZkOF8yLTItMS0xLTI4OTQ3L3RleHRyZWdpb246YzE0NGM3MjhkNzE4NDEzZWI5NGM2NmJkZDBiNzhmYzBfMzE_7ed4af81-67ef-480d-84bc-3780a23034fb">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGFibGU6YmYwMjUxMDYyNTM2NGJmYjhhMTM2NWEzMmI1YjY2ZDgvdGFibGVyYW5nZTpiZjAyNTEwNjI1MzY0YmZiOGExMzY1YTMyYjViNjZkOF8zLTAtMS0xLTI4OTQ3L3RleHRyZWdpb246ZWIwMjhhNjFhOTQyNDIzOTkwNTAyNThjOTM1ZmI0MmVfMjk_49c50227-76e1-4af5-a53c-ca41a30c2be9">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTkx_fb037ed5-fa85-4925-9b22-c3bc8d58f19a">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ie4a1faee4d59482ea066bbdc84f02467_I20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xL2ZyYWc6ZGM0OTc1OTkzODAwNDIxZWJmOWY0OWQ0YTdmMWI3MTAvdGV4dHJlZ2lvbjpkYzQ5NzU5OTM4MDA0MjFlYmY5ZjQ5ZDRhN2YxYjcxMF8yMTMw_17709b47-5be5-41d2-ae04-69ec3a236d03"
      unitRef="shares">119975265</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNS0xLTEtMS0yODk0Nw_2607d978-9e38-4605-8b3f-9b1b677d7da5"
      unitRef="usd">416078000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNS0zLTEtMS0yODk0Nw_6d4391c8-125a-4190-b427-286a841c2c2d"
      unitRef="usd">716782000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNi0xLTEtMS0yODk0Nw_74e8d0ec-f015-4645-bdf3-78823ca1cdbe"
      unitRef="usd">138790000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNi0zLTEtMS0yODk0Nw_997c90ed-099c-417f-90fe-814d168c53c4"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNy0xLTEtMS0yODk0Nw_86fdc309-78e7-40a7-b69a-4527bf627ea2"
      unitRef="usd">29481000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNy0zLTEtMS0yODk0Nw_b3277476-eb3c-42ee-8985-c9498e582fff"
      unitRef="usd">24351000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfOC0xLTEtMS0yODk0Nw_dce60381-2d1b-4bdd-956a-99ffa89fd6de"
      unitRef="usd">67017000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfOC0zLTEtMS0yODk0Nw_f37d7ad6-e1d4-4b90-bcb4-ce73a68c42c5"
      unitRef="usd">67009000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfOS0xLTEtMS0yODk0Nw_ef777c84-0abf-4fce-8829-d8a4f0aa4c37"
      unitRef="usd">23360000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfOS0zLTEtMS0yODk0Nw_be4e34be-591b-4c22-830e-782701264264"
      unitRef="usd">28898000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTAtMS0xLTEtMjg5NDc_519448f9-2a4c-475a-ad36-87aaf766bd93"
      unitRef="usd">674726000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTAtMy0xLTEtMjg5NDc_1b35fe0c-7bb8-452d-91b3-4e8967d9e933"
      unitRef="usd">837040000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTEtMS0xLTEtMjg5NDc_02a9d2c7-3c6b-4df1-bf4c-0230bc4990f7"
      unitRef="usd">9764000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTEtMy0xLTEtMjg5NDc_d1d6b7ff-435e-4762-a6ac-028765ecc39a"
      unitRef="usd">50043000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTItMS0xLTEtMjg5NDc_729a892b-1bd2-42f8-9797-176737015252"
      unitRef="usd">53946000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTItMy0xLTEtMjg5NDc_67a64dc6-e86d-4a1a-a03b-d0ad4d3e8158"
      unitRef="usd">52955000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTMtMS0xLTEtMjg5NDc_f6f20b56-e94d-41cb-b858-a9db92945a18"
      unitRef="usd">17178000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTMtMy0xLTEtMjg5NDc_a683d5bb-8134-49d2-bc84-29779affaf1a"
      unitRef="usd">9256000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTQtMS0xLTEtMjg5NDc_283dab01-082e-49b4-8d4c-d372b72c2372"
      unitRef="usd">24047000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTQtMy0xLTEtMjg5NDc_d9e368e9-fe22-4365-8618-f8c225232dca"
      unitRef="usd">33305000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTUtMS0xLTEtMjg5NDc_3b4641ac-3c2e-4204-98ae-259d1d659136"
      unitRef="usd">71283000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTUtMy0xLTEtMjg5NDc_8a4215f1-9116-404b-956a-2a1768c15a28"
      unitRef="usd">73809000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTYtMS0xLTEtMjg5NDc_1c42c9e6-a7b3-4c77-a2f6-c4cd0d99298d"
      unitRef="usd">136110000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTYtMy0xLTEtMjg5NDc_b04c629f-9acc-4e2c-9b0d-c653fe1fae7c"
      unitRef="usd">136110000</us-gaap:Goodwill>
    <us-gaap:OtherAssets
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTctMS0xLTEtMjg5NDc_ecef1028-d787-4e71-a12f-c5134e93a934"
      unitRef="usd">66300000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTctMy0xLTEtMjg5NDc_7de19b3a-7058-45f4-8bed-375ea45ae437"
      unitRef="usd">50990000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTgtMS0xLTEtMjg5NDc_f341414f-1931-494f-a5c4-cf7afc7f5e84"
      unitRef="usd">1053354000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMTgtMy0xLTEtMjg5NDc_493ab6c4-3069-478a-9e6b-c3377b580cd6"
      unitRef="usd">1243508000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjItMS0xLTEtMjg5NDc_001c8b3f-dcbb-4074-8e31-4beceecc0739"
      unitRef="usd">31144000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjItMy0xLTEtMjg5NDc_11f64916-af7d-40d2-a7a5-8d1364bf0d06"
      unitRef="usd">35784000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjMtMS0xLTEtMjg5NDc_7898c60b-cad2-4df7-9432-e297db5f6c41"
      unitRef="usd">58770000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjMtMy0xLTEtMjg5NDc_fe15fd8b-f900-44ab-b8e6-dde47423404f"
      unitRef="usd">60665000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjQtMS0xLTEtMjg5NDc_186e1a1e-f429-4086-b488-4f724e8fb2bb"
      unitRef="usd">18653000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjQtMy0xLTEtMjg5NDc_a59fd840-150a-4e8f-979c-71114a10d6bc"
      unitRef="usd">28581000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjUtMS0xLTEtMjg5NDc_a5359e0b-cd5a-499d-97cd-1edf7183d52a"
      unitRef="usd">212000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjUtMy0xLTEtMjg5NDc_72c3f204-ee05-43c6-888e-040b0c0a4c24"
      unitRef="usd">609000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjYtMS0xLTEtMjg5NDc_cf8dcc88-6fdd-428d-93db-082c50eedd6a"
      unitRef="usd">5037000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjYtMy0xLTEtMjg5NDc_22f644ea-c089-41c4-b6c3-1ed253b7c099"
      unitRef="usd">9527000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjgtMS0xLTEtMjg5NDc_283ae226-a5f8-45c4-b77a-6fc89483381f"
      unitRef="usd">113816000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMjgtMy0xLTEtMjg5NDc_8b818aed-4d7e-4441-9a1c-996f734105ad"
      unitRef="usd">135166000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzAtMS0xLTEtMjg5NDc_d5c4856f-7d1b-40df-a8d7-2957e6fd9ff2"
      unitRef="usd">783977000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzAtMy0xLTEtMjg5NDc_fd34ccff-85c1-41d7-a716-dc8eb5e59aba"
      unitRef="usd">566588000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzEtMS0xLTEtMjg5NDc_782248ed-910c-4440-a091-3a910a59f282"
      unitRef="usd">55600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzEtMy0xLTEtMjg5NDc_b5526629-6953-460a-aa56-3d538770f963"
      unitRef="usd">75668000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzItMS0xLTEtMjg5NDc_12bfb070-e241-490a-a609-c398db53b8c2"
      unitRef="usd">23135000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzItMy0xLTEtMjg5NDc_1f8edf7e-372d-40b1-a53d-c9c907d95b52"
      unitRef="usd">14103000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzMtMS0xLTEtMjg5NDc_89f9f658-ae64-4a0b-b3d6-dc6135deaf99"
      unitRef="usd">18201000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzMtMy0xLTEtMjg5NDc_423342fd-cd66-48a5-ba6a-42c3cc588145"
      unitRef="usd">21441000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzQtMS0xLTEtMjg5NDc_a4fd8955-589d-450b-9cd3-cb7fdc0a91fd"
      unitRef="usd">14384000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzQtMy0xLTEtMjg5NDc_e4016cb8-2fae-4207-9cb6-c4bcc8d6b28f"
      unitRef="usd">20074000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzUtMS0xLTEtMjg5NDc_92a49199-4681-4591-a533-e3d9b68f2eaf"
      unitRef="usd">1009113000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzUtMy0xLTEtMjg5NDc_1887eda9-dace-4035-a5af-27eb3135dd7c"
      unitRef="usd">833040000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjozNjJkNGRiMmYxNzI0YTUzODNmODkyZDdkNzkwNzFkZl8xOQ_02a54711-a8d6-4461-bdb5-ac1cb6140bfc"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjozNjJkNGRiMmYxNzI0YTUzODNmODkyZDdkNzkwNzFkZl8xOQ_09943df4-af85-4a52-966c-c0153d483c7f"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjozNjJkNGRiMmYxNzI0YTUzODNmODkyZDdkNzkwNzFkZl8zMw_5e0eb7d8-b73f-4435-8353-8f607af64de7"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjozNjJkNGRiMmYxNzI0YTUzODNmODkyZDdkNzkwNzFkZl8zMw_bfc7e49e-881b-47a6-89ca-ef9745c871c5"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjozNjJkNGRiMmYxNzI0YTUzODNmODkyZDdkNzkwNzFkZl81NQ_c7a5ba9f-5658-4a68-ac35-45d33f60cd72"
      unitRef="shares">119865023</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjozNjJkNGRiMmYxNzI0YTUzODNmODkyZDdkNzkwNzFkZl81NQ_f38db630-3ce8-4e52-a794-163cdf534116"
      unitRef="shares">119865023</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjozNjJkNGRiMmYxNzI0YTUzODNmODkyZDdkNzkwNzFkZl82Mg_531c17c8-e51a-46e6-804f-1ee4be74ac96"
      unitRef="shares">118738266</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjozNjJkNGRiMmYxNzI0YTUzODNmODkyZDdkNzkwNzFkZl82Mg_8b4165be-5b62-4ccd-ad2f-53f5aa6246c3"
      unitRef="shares">118738266</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMS0xLTEtMjg5NDc_e6f89a71-beab-4b05-ab18-4acf14d1ef25"
      unitRef="usd">1199000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzgtMy0xLTEtMjg5NDc_8edf0abc-564f-44d6-92b1-692d3b2ebc23"
      unitRef="usd">1187000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzktMS0xLTEtMjg5NDc_4bdd8660-b253-4e0f-8df7-49303c9cb445"
      unitRef="usd">2449281000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfMzktMy0xLTEtMjg5NDc_9d9d0de2-e432-4a6f-bb3b-656c82df8cf7"
      unitRef="usd">2673556000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNDAtMS0xLTEtMjg5NDc_5086bc59-4daa-4c85-b505-5a6906728963"
      unitRef="usd">-2405310000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNDAtMy0xLTEtMjg5NDc_7ec45b1b-68e8-47c1-9397-cf1ea0b237bd"
      unitRef="usd">-2265243000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNDEtMS0xLTEtMjg5NDc_5c7b1e5c-65be-418a-a309-d9df1b4e3773"
      unitRef="usd">-929000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNDEtMy0xLTEtMjg5NDc_5b620085-b866-4aad-98ac-f4b380f2e13a"
      unitRef="usd">968000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNDItMS0xLTEtMjg5NDc_784d9799-107b-4937-96b0-e1ad00741142"
      unitRef="usd">44241000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNDItMy0xLTEtMjg5NDc_99adaaca-667d-4d5d-a939-9947d0c627a3"
      unitRef="usd">410468000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNDMtMS0xLTEtMjg5NDc_c81aa444-817b-40f2-9dbe-5390b16fe86c"
      unitRef="usd">1053354000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xNi9mcmFnOmRjZGMzMzhkNjViMTRiOGRhMGQ5ODY0NWY0ZTBjYzc3L3RhYmxlOmYzMGJjZGEzYWQ5YTRmNjQ5NDhhMjExMzFkNGViYzhmL3RhYmxlcmFuZ2U6ZjMwYmNkYTNhZDlhNGY2NDk0OGEyMTEzMWQ0ZWJjOGZfNDMtMy0xLTEtMjg5NDc_09af7ee3-443b-44b8-8685-494e5f7dbd61"
      unitRef="usd">1243508000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy0xLTEtMS0yODk0Nw_5eb8c872-b53d-405a-b1b0-46167ccad53a"
      unitRef="usd">65221000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy0zLTEtMS0yODk0Nw_828985a2-6d8f-45e4-901d-6adc80edd6bc"
      unitRef="usd">45366000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy01LTEtMS0yODk0Nw_8784e0c1-acf3-4219-b31b-272ac357a091"
      unitRef="usd">118328000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMy03LTEtMS0yODk0Nw_10615e32-b248-4bb4-91a9-fc775e1f69e8"
      unitRef="usd">85580000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi0xLTEtMS0yODk0Nw_1e4f82f8-f3ea-4d1b-886d-58e23448088c"
      unitRef="usd">16395000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi0zLTEtMS0yODk0Nw_610fbdb7-b7df-48f0-a8f1-76a00ccf2ed9"
      unitRef="usd">10837000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi01LTEtMS0yODk0Nw_47aa1eb1-99f4-4c3a-a434-806aea5bab4f"
      unitRef="usd">28586000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNi03LTEtMS0yODk0Nw_1f5dcd2e-0f4c-4c67-8935-9f9168bc1d66"
      unitRef="usd">20681000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNy0xLTEtMS0yODk0Nw_9e1837e3-139e-483a-bd0f-d9d9ba66662d"
      unitRef="usd">88527000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNy0zLTEtMS0yODk0Nw_4fa44974-2e4a-4728-a970-2768aa7e12af"
      unitRef="usd">64655000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNy01LTEtMS0yODk0Nw_59ecc59a-be4b-49b7-a8da-c80aaa74dff8"
      unitRef="usd">172883000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfNy03LTEtMS0yODk0Nw_6d5a6623-d72e-4889-a34d-3692c157e54a"
      unitRef="usd">126045000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfOC0xLTEtMS0yODk0Nw_63512397-313e-4844-8b98-0785848429c0"
      unitRef="usd">59974000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfOC0zLTEtMS0yODk0Nw_98566766-0aa5-4d3a-9ed0-a1e8c2b6f430"
      unitRef="usd">57177000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfOC01LTEtMS0yODk0Nw_f3260863-2e28-466a-867f-b5f46944da93"
      unitRef="usd">116722000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfOC03LTEtMS0yODk0Nw_e2d5da28-7ccd-447d-86fb-dc31bdbc7548"
      unitRef="usd">108727000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfOS0xLTEtMS0yODk0Nw_9f018b8c-940a-4584-85b8-8c820d6ba38c"
      unitRef="usd">1263000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfOS0zLTEtMS0yODk0Nw_83b671d5-2f73-4f3b-8fbb-3541fea1cc44"
      unitRef="usd">1263000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfOS01LTEtMS0yODk0Nw_8cb76d76-4401-48ef-8bc4-f9405a05dd49"
      unitRef="usd">2526000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfOS03LTEtMS0yODk0Nw_311b0432-3fe8-409c-b41b-2638174983c9"
      unitRef="usd">2526000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTAtMS0xLTEtMjg5NDc_42bf965d-c924-4470-91f7-cf5bd0afd563"
      unitRef="usd">-12622000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTAtMy0xLTEtMjg5NDc_1e2d7435-8981-4f14-a3fb-53204a3838be"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTAtNS0xLTEtMjg5NDc_6a45110a-cc7f-4b55-b27a-7a43adc11a3d"
      unitRef="usd">-24240000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTAtNy0xLTEtMjg5NDc_a2eeb2d3-583c-4001-b143-7eefd487b4cf"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:CostsAndExpenses
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTEtMS0xLTEtMjg5NDc_d4f9a2cc-9cf8-4626-ab6c-65d7b1dea1b0"
      unitRef="usd">153537000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTEtMy0xLTEtMjg5NDc_1675706f-4e9f-4c54-97da-f66252a86d08"
      unitRef="usd">133932000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTEtNS0xLTEtMjg5NDc_1b57b459-6258-4ebc-9b16-41ec7f7047c5"
      unitRef="usd">296477000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTEtNy0xLTEtMjg5NDc_17361646-39dc-4f39-82dc-6732056042c0"
      unitRef="usd">257979000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTMtMS0xLTEtMjg5NDc_1c42ff09-c43a-4154-9f7d-d80914921d50"
      unitRef="usd">-88316000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTMtMy0xLTEtMjg5NDc_0a9aed5f-bcd5-4a05-9003-47c00b1cbcf4"
      unitRef="usd">-88566000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTMtNS0xLTEtMjg5NDc_690bdf7f-e7ce-4a58-b1b6-5cbccfeed57a"
      unitRef="usd">-178149000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTMtNy0xLTEtMjg5NDc_eb66289d-19df-4973-918e-630b76b63ca6"
      unitRef="usd">-172399000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTUtMS0xLTEtMjg5NDc_67917a64-5344-4172-9733-9810da2f6149"
      unitRef="usd">835000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTUtMy0xLTEtMjg5NDc_0cf1a375-7834-456d-b0f7-22611cbc9542"
      unitRef="usd">34000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTUtNS0xLTEtMjg5NDc_65094417-6831-4848-a10d-106ca581b331"
      unitRef="usd">972000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTUtNy0xLTEtMjg5NDc_1152de5d-2203-457c-bbf7-bf7b303608ab"
      unitRef="usd">67000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InterestExpense
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTYtMS0xLTEtMjg5NDc_ce858a20-8454-4b90-9b80-019057f3f7ab"
      unitRef="usd">3357000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTYtMy0xLTEtMjg5NDc_1cfb2d66-430f-41cd-81a9-bfaa5c5f1697"
      unitRef="usd">10319000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTYtNS0xLTEtMjg5NDc_3f69f05d-bd17-4136-b718-26e578d94011"
      unitRef="usd">6648000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTYtNy0xLTEtMjg5NDc_8975a307-450d-4db9-8b12-57a3c83abdb0"
      unitRef="usd">17878000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTctMS0xLTEtMjg5NDc_4bd26852-4abc-41b4-b4f3-ebd4126e4d2e"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTctMy0xLTEtMjg5NDc_14bcc9cf-79f8-42fa-9211-702670445c90"
      unitRef="usd">-17689000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTctNS0xLTEtMjg5NDc_14d1cbd1-7796-4b27-9d5e-9111b803c196"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTctNy0xLTEtMjg5NDc_f17b4f7e-2f5b-4599-9865-55ddd6eddc4c"
      unitRef="usd">-17689000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTgtMS0xLTEtMjg5NDc_3486a701-a5a0-4745-a1d3-64666639b880"
      unitRef="usd">-4306000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTgtMy0xLTEtMjg5NDc_294c42b7-35b7-45fc-8940-583ef3ae227a"
      unitRef="usd">-159000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTgtNS0xLTEtMjg5NDc_e8b2d1ec-c80c-411a-b957-11895273a09a"
      unitRef="usd">-5555000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTgtNy0xLTEtMjg5NDc_8e0a65ed-08cc-4730-af07-6818697ce23e"
      unitRef="usd">-202000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTktMS0xLTEtMjg5NDc_dac6ff35-aceb-4c7d-83ab-9e1851fe6ec2"
      unitRef="usd">-95144000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTktMy0xLTEtMjg5NDc_761ec55c-d30d-4d1b-b02d-4c3227114ce3"
      unitRef="usd">-116699000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTktNS0xLTEtMjg5NDc_c1e16dd0-9496-46df-a2c7-26f83fe4466b"
      unitRef="usd">-189380000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMTktNy0xLTEtMjg5NDc_bfbdc243-9593-47b9-a89d-12ea610047ef"
      unitRef="usd">-208101000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjEtMS0xLTEtMjg5NDc_bf882885-3aa7-4b6a-b64d-a8f500dff3ff"
      unitRef="usd">501000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjEtMy0xLTEtMjg5NDc_cb7b2320-4f1b-455a-b584-f7a69855a51a"
      unitRef="usd">622000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjEtNS0xLTEtMjg5NDc_722171e4-9e17-4774-8744-dff8b0f6715d"
      unitRef="usd">886000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjEtNy0xLTEtMjg5NDc_6ec08203-889c-462c-9d6c-f9e06cbf51cd"
      unitRef="usd">861000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjMtMS0xLTEtMjg5NDc_e4f1733a-ea25-4ba5-a990-9614741ba606"
      unitRef="usd">-95645000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjMtMy0xLTEtMjg5NDc_9d0c7e03-3f33-4e32-8ca6-d82a22f2cd38"
      unitRef="usd">-117321000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjMtNS0xLTEtMjg5NDc_0fa2d9c5-6144-4afa-ad85-7d421ed131e7"
      unitRef="usd">-190266000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjMtNy0xLTEtMjg5NDc_0eec960d-5b3f-42a1-876e-ede6f0e000b5"
      unitRef="usd">-208962000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjUtMS0xLTEtMjg5NDc_158cf2be-137e-443c-9177-c66c4b20a62c"
      unitRef="usdPerShare">-0.80</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjUtMS0xLTEtMjg5NDc_d9d6b2cd-ece6-4507-b60d-602d23b2bd36"
      unitRef="usdPerShare">-0.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjUtMy0xLTEtMjg5NDc_eb23f72c-ed77-429c-86b3-f4d621d3c29c"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjUtMy0xLTEtMjg5NDc_fce503b7-520d-41ce-8082-568827a7d801"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjUtNS0xLTEtMjg5NDc_ae60624a-6caf-45a8-ab2f-271392cb2a1d"
      unitRef="usdPerShare">-1.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjUtNS0xLTEtMjg5NDc_dcfe8ea5-6517-46de-bb88-6c78ffd31d7c"
      unitRef="usdPerShare">-1.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjUtNy0xLTEtMjg5NDc_0b72783b-0c9f-48e0-8519-71114bd82987"
      unitRef="usdPerShare">-1.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjUtNy0xLTEtMjg5NDc_cd37c5b0-2b10-49bf-b88a-d3322a2bb84d"
      unitRef="usdPerShare">-1.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjctMS0xLTEtMjg5NDc_30e62dbe-a9b8-4112-af03-fff7f7109a9e"
      unitRef="shares">119602000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjctMS0xLTEtMjg5NDc_4ce10b2f-b028-41b6-bfb0-ea319a2db242"
      unitRef="shares">119602000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjctMy0xLTEtMjg5NDc_36612006-4d48-47eb-9074-e011af665b78"
      unitRef="shares">109580000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjctMy0xLTEtMjg5NDc_6a11d76b-a1dc-452e-9300-423620700251"
      unitRef="shares">109580000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjctNS0xLTEtMjg5NDc_c515cb85-9b6a-4f13-b33c-aa17bfe62b1b"
      unitRef="shares">119267000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjctNS0xLTEtMjg5NDc_e267c423-ce4c-4049-8afa-566243b08276"
      unitRef="shares">119267000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjctNy0xLTEtMjg5NDc_0f7c6f19-55d2-4394-9823-8cc932be5782"
      unitRef="shares">106328000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjctNy0xLTEtMjg5NDc_a131d3fe-d527-4cae-90be-dec09f4ce3a5"
      unitRef="shares">106328000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjktMS0xLTEtMjg5NDc_98b05ce8-0065-492a-b35b-113be52524e1"
      unitRef="usd">-95645000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjktMy0xLTEtMjg5NDc_710b699f-0c80-4bf4-8fe9-2912e01ac502"
      unitRef="usd">-117321000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjktNS0xLTEtMjg5NDc_4a6756cf-3b00-4bed-a248-3201583f3b55"
      unitRef="usd">-190266000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMjktNy0xLTEtMjg5NDc_c2eef02d-3948-4a92-91c3-48a73854b96a"
      unitRef="usd">-208962000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzEtMS0xLTEtMjg5NDc_9003deb3-88b9-4b89-8c2f-076d536c9f8d"
      unitRef="usd">-208000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzEtMy0xLTEtMjg5NDc_495488c1-96dc-46a7-b9d4-14ba9bfd6ac6"
      unitRef="usd">334000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzEtNS0xLTEtMjg5NDc_53fbcb38-9bbc-4f73-b935-28e5bdabab0f"
      unitRef="usd">-702000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzEtNy0xLTEtMjg5NDc_affc55ca-c084-497d-9fab-57b3faefc3e4"
      unitRef="usd">231000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzItMS0xLTEtMjk1ODM_607fa55e-564e-4b63-ac08-9cc22a0c97d8"
      unitRef="usd">-491000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzItMy0xLTEtMjk1ODM_dac74579-6c82-4431-bf0c-f02a509f33d4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzItNS0xLTEtMjg5NDc_824388b6-0f37-4db9-8ed5-b61246d18caa"
      unitRef="usd">-1195000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzItNy0xLTEtMjg5NDc_965a4071-7e38-4846-b77c-d020c0a00201"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzMtMS0xLTEtMjg5NDc_6b43c904-33d0-4718-9944-68abe064de65"
      unitRef="usd">-96344000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzMtMy0xLTEtMjg5NDc_d9e42c9f-98c2-4800-ae09-1fdbeb3c2892"
      unitRef="usd">-116987000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzMtNS0xLTEtMjg5NDc_a1849e6e-b288-4870-9b98-7251d840a22d"
      unitRef="usd">-192163000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8xOS9mcmFnOjMwMmZmZTc4YjMxYzQ5MDliNTgzMjJlOTJmYWZhOGI3L3RhYmxlOmQ5OTQzOThkYTQzNjRiODM5NzIzOTcxYjUzMTc1NzJmL3RhYmxlcmFuZ2U6ZDk5NDM5OGRhNDM2NGI4Mzk3MjM5NzFiNTMxNzU3MmZfMzMtNy0xLTEtMjg5NDc_7c75ae95-7896-41e6-956d-b8741a35c6a2"
      unitRef="usd">-208731000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i164351f40c6a48a5bce7be7cbbb95393_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMi0xLTEtMS0yODk0Nw_9a912101-e02f-46fe-b02c-99df63c65c54"
      unitRef="shares">103279000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i164351f40c6a48a5bce7be7cbbb95393_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMi0zLTEtMS0yODk0Nw_65891b08-c7ad-4ac8-ab39-6a6d780bd558"
      unitRef="usd">1033000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iefa9467fe6ae4ae7be463ef02bd03331_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMi01LTEtMS0yODk0Nw_6c0de8ba-3dcb-4d3a-9294-fd840c86a6cf"
      unitRef="usd">2122743000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i35baa1a10636413abb12d0a528eb7da0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMi03LTEtMS0yODk0Nw_eb8ab600-a6dc-45b2-af18-f2e80536731f"
      unitRef="usd">-1922230000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i74180eb633f24734a1c4c9c66a934ef6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMi05LTEtMS0yODk0Nw_cdf14b1a-0aa0-4c24-970b-b3149c5ba02d"
      unitRef="usd">90000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i14d1bd5fb1694a178730b0cd705a3cd4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMi0xMS0xLTEtMjg5NDc_cf5c8757-ca55-4ed4-a600-5781f2311f0b"
      unitRef="usd">201636000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="id2de1a6fdaa74c7cade5245529b85f53_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNC03LTEtMS0yODk0Nw_4858d488-3cff-4ac2-907f-cbbd529ade10"
      unitRef="usd">-117321000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNC0xMS0xLTEtMjg5NDc_befa90b5-74a7-4533-a90f-3eaf6c389e28"
      unitRef="usd">-117321000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i828764c93d1d45929aa04ca248ea4fad_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNS05LTEtMS0yODk0Nw_18843314-8ed3-4534-9fbd-96bcf562cadc"
      unitRef="usd">334000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNS0xMS0xLTEtMjg5NDc_da8e5bf2-8b8c-4304-93c4-12bface5df34"
      unitRef="usd">334000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if48dc576429648f1a4016567fa86b396_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNi0xLTEtMS0yODk0Nw_0a332534-ef31-4a92-b1af-6e57aef8a79e"
      unitRef="shares">344000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if48dc576429648f1a4016567fa86b396_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNi0zLTEtMS0yODk0Nw_25606f8e-fcb5-4aa9-918b-f523cd70ffd3"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7ac8060b82014b21b0613cda3d7a60c6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNi01LTEtMS0yODk0Nw_54c3a0aa-96b7-4e38-b064-80f6e1485bda"
      unitRef="usd">6562000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNi0xMS0xLTEtMjg5NDc_7d75de0d-10f9-494c-8c46-ba228df11f86"
      unitRef="usd">6565000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if48dc576429648f1a4016567fa86b396_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNy0xLTEtMS0yOTUyNw_d187f8c0-b27f-475a-a439-7458760474f4"
      unitRef="shares">11500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if48dc576429648f1a4016567fa86b396_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNy0zLTEtMS0yOTUyNw_186bd324-78a4-4abb-93fa-2f4df6ee8591"
      unitRef="usd">115000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7ac8060b82014b21b0613cda3d7a60c6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNy01LTEtMS0yOTUyNw_252ec528-4991-486c-bde5-c13c12faafed"
      unitRef="usd">269771000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfNy0xMS0xLTEtMjk1Mjc_5c619c67-a9b9-456f-9fbd-8fc91631b063"
      unitRef="usd">269886000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i7ac8060b82014b21b0613cda3d7a60c6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOC01LTEtMS0yOTUyNw_87514ee6-ed12-4f31-bb51-f016ba2c432b"
      unitRef="usd">196063000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOC0xMS0xLTEtMjk1Mjc_4891c124-e0e7-4fcb-8d81-4e8f42412097"
      unitRef="usd">196063000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="i7ac8060b82014b21b0613cda3d7a60c6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOS01LTEtMS0yOTUyNw_8eef3d72-67c6-4405-820a-0c83b92dfe91"
      unitRef="usd">37846000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOS0xMS0xLTEtMjk1Mjc_53277b78-bd8f-453e-a376-b3914a203929"
      unitRef="usd">37846000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="if48dc576429648f1a4016567fa86b396_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOC0xLTEtMS0yODk0Nw_0e4352cd-c6cf-41d2-a1be-99c2cded6806"
      unitRef="shares">116000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="if48dc576429648f1a4016567fa86b396_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOC0zLTEtMS0yODk0Nw_5ec82b09-10da-4598-8fae-70dee788f98a"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOC0xMS0xLTEtMjg5NDc_1a5196a1-6ae8-44a4-bcc3-17967cfbd471"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7ac8060b82014b21b0613cda3d7a60c6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOS01LTEtMS0yODk0Nw_dca457c3-885e-4ee5-8e41-fd836d094a5b"
      unitRef="usd">11735000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfOS0xMS0xLTEtMjg5NDc_93f6465f-2f41-48f8-ab68-c71c634bf398"
      unitRef="usd">11735000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="i55f0b2b681c841419600222a85ea3546_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTAtMS0xLTEtMjg5NDc_a1fb58aa-4061-4a41-a2f2-76e4a5289439"
      unitRef="shares">115239000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i55f0b2b681c841419600222a85ea3546_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTAtMy0xLTEtMjg5NDc_eb4273a2-aff4-4424-88fe-05f884a589a4"
      unitRef="usd">1152000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3276d1a28daa4225b9fcdb3cc08af201_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTAtNS0xLTEtMjg5NDc_58c227e4-65e4-45fc-ae6e-6cdf74c86fdc"
      unitRef="usd">2569028000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifd691c6a90574493ba24a86f882bb91a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTAtNy0xLTEtMjg5NDc_3fabade6-ac22-4673-8c27-caa986f211e9"
      unitRef="usd">-2039551000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i24591cad2f4544ef997c8b46679d9352_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTAtOS0xLTEtMjg5NDc_1629403e-ae65-4bca-b325-37d792795828"
      unitRef="usd">424000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i34b29fd1e2a04660a3bb612c3f24dde5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTAtMTEtMS0xLTI4OTQ3_70d599e6-f25d-4c59-8a7b-0d102acd3fe8"
      unitRef="usd">531053000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i06b533b795524ae29ed13dc8973a1aba_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTItMS0xLTEtMjg5NDc_dee403fc-bd49-4f9b-881d-9d5053e22b5b"
      unitRef="shares">119346000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i06b533b795524ae29ed13dc8973a1aba_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTItMy0xLTEtMjg5NDc_35d9db2f-052d-4323-b200-7ea485e1a77e"
      unitRef="usd">1193000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia867ec38918e444f8e2d1d14ce332ec5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTItNS0xLTEtMjg5NDc_3acdcece-2ebe-409a-97ca-0b99482679ba"
      unitRef="usd">2428582000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4f812dff96b74536ae44f954590aa428_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTItNy0xLTEtMjg5NDc_5fe0ebb8-09ec-477a-b870-65fe3b56783d"
      unitRef="usd">-2309665000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie86bfdf9f6d24ddfa8e132dc25af8978_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTItOS0xLTEtMjg5NDc_4ce34e48-965b-474a-a63f-8b13e19eef9f"
      unitRef="usd">-230000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c0613ed6dde4e01bc2b4e47830856f9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTItMTEtMS0xLTI4OTQ3_36ee53b3-a7c5-47dd-bf75-6dd9d8c25e9f"
      unitRef="usd">119880000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i4d40fdfd16fc451fb491730b4a9173d4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTUtNy0xLTEtMjg5NDc_7d68817a-9da4-4858-a1bf-2210565777bb"
      unitRef="usd">-95645000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTUtMTEtMS0xLTI4OTQ3_954ce802-ef2f-4776-bb0a-e0cb915f7d0c"
      unitRef="usd">-95645000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9db84f87eeb341579e4fe91899a2f3f5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTYtOS0xLTEtMjg5NDc_73e81f4e-662c-4195-8e84-6c7f0cd67231"
      unitRef="usd">-699000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTYtMTEtMS0xLTI4OTQ3_e0631ee6-e1a0-414f-bba0-a2ca0177c82e"
      unitRef="usd">-699000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i4c724ef416fd4b8d83a5292521f39be3_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTctMS0xLTEtMjg5NDc_2f18c458-5f89-44bd-a76a-297cd6104d98"
      unitRef="shares">345000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4c724ef416fd4b8d83a5292521f39be3_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTctMy0xLTEtMjg5NDc_bab606f0-6853-45be-9e9a-0f0ca829e654"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7ccd6a0b87204d16adb14a3d22bcda4e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTctNS0xLTEtMjg5NDc_83df2f15-58be-429d-89e9-f58618151c4a"
      unitRef="usd">6440000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMTctMTEtMS0xLTI4OTQ3_10dd6cb3-2d59-41d6-ab69-4fa979d3cfc1"
      unitRef="usd">6444000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i4c724ef416fd4b8d83a5292521f39be3_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjAtMS0xLTEtMjg5NDc_8b9198b2-926c-498f-add0-50aa7db7bbc4"
      unitRef="shares">174000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i4c724ef416fd4b8d83a5292521f39be3_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjAtMy0xLTEtMjg5NDc_4fd6cc88-fd74-45fd-b562-35d070a4777c"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjAtMTEtMS0xLTI4OTQ3_2bbd6a35-d37f-40a9-b7f5-707206c5f264"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7ccd6a0b87204d16adb14a3d22bcda4e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjItNS0xLTEtMjg5NDc_4952457c-2984-49dd-a4c1-d3f5f8785c12"
      unitRef="usd">14259000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjItMTEtMS0xLTI4OTQ3_e8dc9a8e-d35d-40ae-8a68-f3d5f7f97a0d"
      unitRef="usd">14259000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="i0182cad036cc492c902e8768cc1bdc6a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjMtMS0xLTEtMjg5NDc_83789d39-1b78-4a9c-98e7-a5491e984986"
      unitRef="shares">119865000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0182cad036cc492c902e8768cc1bdc6a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjMtMy0xLTEtMjg5NDc_13503e48-bb45-4d40-bf27-d75ad3cf2b45"
      unitRef="usd">1199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5f7e3e3f5c7949eb926f4685e8a1dd75_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjMtNS0xLTEtMjg5NDc_2a684dbb-1f3c-4e1a-9329-3f68227ddb28"
      unitRef="usd">2449281000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0b176cdccb74943960953e16068e6a8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjMtNy0xLTEtMjg5NDc_35b68540-f65c-40d9-ade8-dcb615d27ffb"
      unitRef="usd">-2405310000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iadd45892aa3342cbbeff3a291a11105b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjMtOS0xLTEtMjg5NDc_65f1587e-531d-4fd2-a224-04faba197761"
      unitRef="usd">-929000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjVlNDQ3Y2U4ZGI0MjQ5ZDc4MTY5ZGM5MDA0NDI0ZDBlL3RhYmxlcmFuZ2U6NWU0NDdjZThkYjQyNDlkNzgxNjlkYzkwMDQ0MjRkMGVfMjMtMTEtMS0xLTI4OTQ3_a0ab27f0-9a44-48f1-81ee-808ceefc77d6"
      unitRef="usd">44241000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i3ea404b9803f4458944b7dbf3eefe5d8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMi0xLTEtMS0yOTM0Ng_864de8f7-ec30-4277-ac3c-760dac715873"
      unitRef="shares">102763000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3ea404b9803f4458944b7dbf3eefe5d8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMi0zLTEtMS0yOTM0Ng_80545474-fde5-4e55-af0d-b2e89a212bff"
      unitRef="usd">1028000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie3f49f20915e465aa2c3491edb04f079_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMi01LTEtMS0yOTM0Ng_bbdaf47f-1997-4bcd-911f-d470c865b0a4"
      unitRef="usd">2105252000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9b6083ac1b4641ee80d7fbb9322f6ff4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMi03LTEtMS0yOTM0Ng_ec421382-5f6e-41d1-8793-f4bd94e83fcb"
      unitRef="usd">-1830589000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if3240a301c3b4a8092fcd0ff21adb6f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMi05LTEtMS0yOTM0Ng_8daa9875-f4dc-4eec-91c9-a174bcd99e82"
      unitRef="usd">193000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic11e1e3142e048009002fc987716b4e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMi0xMS0xLTEtMjkzNDY_2e5738c5-ff15-44b5-a87d-777514183978"
      unitRef="usd">275884000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i6afe0edb9cc44adca52bd18a9cba27db_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNC03LTEtMS0yOTM0Ng_af6ad58c-c957-4451-97c2-7497affe8e91"
      unitRef="usd">-208962000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNC0xMS0xLTEtMjkzNDY_52b9600b-d3c9-43fe-9bc8-aa83307ffff5"
      unitRef="usd">-208962000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5d76fce0871a49f997118895b8cc5d9e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNS05LTEtMS0yOTM0Ng_749af3a2-9929-4f60-a04e-981d4d87b2e8"
      unitRef="usd">231000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNS0xMS0xLTEtMjkzNDY_eccde558-eb00-4d6a-96ca-8d8d5285bf91"
      unitRef="usd">231000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i048e3b2eae994f98967e9743c0322e99_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNi0xLTEtMS0yOTM0Ng_5b901eb8-33c2-4cb1-876b-909e59e49dc3"
      unitRef="shares">760000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i048e3b2eae994f98967e9743c0322e99_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNi0zLTEtMS0yOTM0Ng_dbc46183-dc27-463d-82d6-8a40580026ba"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0471829afd7d49ec8d77526fcd9e579e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNi01LTEtMS0yOTM0Ng_d78ca729-f808-4c20-b0a2-f4fa8801840d"
      unitRef="usd">13518000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNi0xMS0xLTEtMjkzNDY_11c66d28-51e7-4267-8d0b-03b4a48f2aa2"
      unitRef="usd">13525000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i048e3b2eae994f98967e9743c0322e99_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNy0xLTEtMS0yOTM0Ng_6bd9f5e8-4394-46ef-bd44-fbbc2e38ca8f"
      unitRef="shares">11500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i048e3b2eae994f98967e9743c0322e99_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNy0zLTEtMS0yOTM0Ng_fb30a6e8-4f4a-4821-aad7-72371d77414d"
      unitRef="usd">115000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0471829afd7d49ec8d77526fcd9e579e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNy01LTEtMS0yOTM0Ng_f09439c5-b8d4-4b16-85f3-e7141112438e"
      unitRef="usd">269771000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfNy0xMS0xLTEtMjkzNDY_92af8646-ae82-42c4-a0e3-c0ba3b0af837"
      unitRef="usd">269886000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i0471829afd7d49ec8d77526fcd9e579e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfOC01LTEtMS0yOTM0Ng_383950cd-fac5-4ab3-b7b7-716781793944"
      unitRef="usd">196063000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfOC0xMS0xLTEtMjkzNTk_31737e44-9471-42aa-a19f-71f7bf3f509b"
      unitRef="usd">196063000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="i0471829afd7d49ec8d77526fcd9e579e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfOS01LTEtMS0yOTM0Ng_df26ec66-8c3d-4584-879a-c942bed09c77"
      unitRef="usd">37846000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfOS0xMS0xLTEtMjkzNTk_f95350a8-f7cd-4e3e-8d38-a91d7e9bbeda"
      unitRef="usd">37846000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i048e3b2eae994f98967e9743c0322e99_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTAtMS0xLTEtMjkzNDY_77a3765d-639e-4c4b-b2a5-9c4a3734039d"
      unitRef="shares">216000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i048e3b2eae994f98967e9743c0322e99_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTAtMy0xLTEtMjkzNDY_e9693845-92ba-4d65-9ea1-d025327790d1"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTAtMTEtMS0xLTI5MzQ2_4daa6491-7c59-42d4-94f5-186ebe87682d"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0471829afd7d49ec8d77526fcd9e579e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTEtNS0xLTEtMjkzNDY_ebe18872-c8ae-4a93-973e-0c6321ab92cc"
      unitRef="usd">22270000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTEtMTEtMS0xLTI5MzQ2_bb61144c-6bae-4240-8899-589a979f19d9"
      unitRef="usd">22270000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="i55f0b2b681c841419600222a85ea3546_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItMS0xLTEtMjkzNDY_a18c0af1-82bb-4b6f-98c9-ba933d03b3af"
      unitRef="shares">115239000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i55f0b2b681c841419600222a85ea3546_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItMy0xLTEtMjkzNDY_f2f5da05-9b81-4c4a-96dc-6632e967b038"
      unitRef="usd">1152000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3276d1a28daa4225b9fcdb3cc08af201_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItNS0xLTEtMjkzNDY_7d0d86d0-cde0-4614-8304-df43181694bf"
      unitRef="usd">2569028000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifd691c6a90574493ba24a86f882bb91a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItNy0xLTEtMjkzNDY_bed5f2ea-27e3-4759-a25f-d9f1252c869c"
      unitRef="usd">-2039551000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i24591cad2f4544ef997c8b46679d9352_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItOS0xLTEtMjkzNDY_5a31d85e-9d64-4a67-9988-e11460313265"
      unitRef="usd">424000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i34b29fd1e2a04660a3bb612c3f24dde5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItMTEtMS0xLTI5MzQ2_a69f3e6f-b028-4d73-a48b-8fbf87662ce5"
      unitRef="usd">531053000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i0b3892dcb478479cbc9399beec69b27e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItMS0xLTEtMjkzMjY_178d468e-0158-4887-9058-e03a572f4bed"
      unitRef="shares">118738000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0b3892dcb478479cbc9399beec69b27e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItMy0xLTEtMjkzMjY_fe4a3d6d-3ce0-4a83-b91d-c9c023b9993f"
      unitRef="usd">1187000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4522e02284f8410db6010810d897bb79_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItNS0xLTEtMjkzMjY_46568dbd-590d-4be2-a99d-6272dfcf07bf"
      unitRef="usd">2673556000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5eb0968295fa457c8b850a6bb24fd24e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItNy0xLTEtMjkzMjY_8589bee0-a977-4d02-af03-2efa1b313605"
      unitRef="usd">-2265243000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if525baf875694aeebfb3e8f1ee7895c3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItOS0xLTEtMjkzMjY_ff15d462-2736-45be-9232-7c99e3690806"
      unitRef="usd">968000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTItMTEtMS0xLTI5MzI2_d17d53a0-ce26-45e2-b2f3-229dcc79e999"
      unitRef="usd">410468000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icf38b8e15b4544b69ae00a7699d5915d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTUtNS0xLTEtMjkzNzM_e952f6a0-5051-4909-9453-7be7eb3ddf75"
      unitRef="usd">-264609000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i86ea5250e3bb45aa81e5c43a0000647d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTUtNy0xLTEtMjkzNzM_271665c4-2633-4660-9d11-0ecff2c956be"
      unitRef="usd">50199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ide697d4ed12846f7b2b2e749378e6fb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTUtMTEtMS0xLTI5Mzcz_e3afd109-1b91-4105-aad5-687e3548a160"
      unitRef="usd">-214410000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i05cbb40265d44701a893071c4123f466_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTQtNy0xLTEtMjkzMjY_b047fb14-7edd-438e-9321-32a45cf7698f"
      unitRef="usd">-190266000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTQtMTEtMS0xLTI5MzI2_557a1755-2b5a-4787-93e3-5b2409bec84b"
      unitRef="usd">-190266000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2d0519eefc5a4372aa09bac3494eed11_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTUtOS0xLTEtMjkzMjY_cf2b596d-04b5-4ca4-9277-19050f779d7f"
      unitRef="usd">-1897000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTUtMTEtMS0xLTI5MzI2_f16a1691-b51c-49e7-a723-9db586142de1"
      unitRef="usd">-1897000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i94bf3b66b78947dcb8fe7cb4478bc7f1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTYtMS0xLTEtMjkzMjY_9b5a2ce5-a9f2-4b25-9cca-ff2f9bbaa58a"
      unitRef="shares">795000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i94bf3b66b78947dcb8fe7cb4478bc7f1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTYtMy0xLTEtMjkzMjY_c62656d2-cc7b-4a0f-96c6-989258511bab"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5e5d191ee0284b228ad30f1ed1e95735_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTYtNS0xLTEtMjkzMjY_17c548a4-f84e-49b6-8256-cca002a3d9eb"
      unitRef="usd">13252000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMTYtMTEtMS0xLTI5MzI2_2ce005a3-36eb-44d1-91e9-fcda1afb99a4"
      unitRef="usd">13260000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i94bf3b66b78947dcb8fe7cb4478bc7f1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItMS0xLTEtMjkzNzM_539bd9da-77a1-4af8-a55e-993284524c02"
      unitRef="shares">332000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i94bf3b66b78947dcb8fe7cb4478bc7f1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItMy0xLTEtMjkzNzM_160752a8-6bda-49ce-9adc-c2f257612ae3"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItMTEtMS0xLTI5Mzcz_7f14f1ef-78fd-4a99-8647-c4cc52712d44"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5e5d191ee0284b228ad30f1ed1e95735_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjEtNS0xLTEtMjkzMjY_c98b270f-9908-4fcf-a966-e397b50f8bb1"
      unitRef="usd">27082000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjEtMTEtMS0xLTI5MzI2_6c02d157-98d7-4a4c-87d6-5ad68f5d1d5b"
      unitRef="usd">27082000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="i0182cad036cc492c902e8768cc1bdc6a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItMS0xLTEtMjkzMjY_76c6a0ed-f4ac-451f-816f-8b65828b6bd7"
      unitRef="shares">119865000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0182cad036cc492c902e8768cc1bdc6a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItMy0xLTEtMjkzMjY_27cdef87-a736-4a20-959b-face3a25c284"
      unitRef="usd">1199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5f7e3e3f5c7949eb926f4685e8a1dd75_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItNS0xLTEtMjkzMjY_cabfe89e-b29f-4c21-8b00-5e657a016c58"
      unitRef="usd">2449281000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0b176cdccb74943960953e16068e6a8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItNy0xLTEtMjkzMjY_1f8aaf8b-1ea3-4b48-b3e0-eace53bbcde6"
      unitRef="usd">-2405310000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iadd45892aa3342cbbeff3a291a11105b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItOS0xLTEtMjkzMjY_fec3d436-3ceb-49b8-861c-2a5ecceeb1d2"
      unitRef="usd">-929000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yMi9mcmFnOjQ2ZTBmYmQ2ODM2NTRkOGViMTQ3MDAxYzEyMjYxNDVkL3RhYmxlOjEwNDA0NmRkZjE3NjQ2Yjk4ODdiYTljMWUzM2IxMjhmL3RhYmxlcmFuZ2U6MTA0MDQ2ZGRmMTc2NDZiOTg4N2JhOWMxZTMzYjEyOGZfMjItMTEtMS0xLTI5MzI2_33f52dc6-a692-46e3-ba12-5214257153db"
      unitRef="usd">44241000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMy0xLTEtMS0yODk0Nw_5f8c1a91-4c9e-47f8-a6ad-11762bfb5742"
      unitRef="usd">-190266000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMy0zLTEtMS0yODk0Nw_f55ede71-e9fc-42a2-a867-9ea330acfec8"
      unitRef="usd">-208962000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNS0xLTEtMS0yODk0Nw_e5bacac5-7b73-4792-8fe8-48a924229f16"
      unitRef="usd">2244000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNS0zLTEtMS0yODk0Nw_dd3f2112-9c63-4a04-9b93-651d06090ed0"
      unitRef="usd">4773000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNi0xLTEtMS0yODk0Nw_518f196b-0b16-4c3f-8467-51dd3c4b4a42"
      unitRef="usd">2526000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNi0zLTEtMS0yODk0Nw_6660a68c-54f6-42f0-bdc5-c5aed510c90e"
      unitRef="usd">2526000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNy0xLTEtMS0yODk0Nw_290de874-9c44-4c6e-8bff-842eb6a2ac5e"
      unitRef="usd">27082000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNy0zLTEtMS0yODk0Nw_558bc39f-baed-4abd-8903-6b85568d5cd3"
      unitRef="usd">22270000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfOC0xLTEtMS0yODk0Nw_372ddcdc-48fe-4d9d-bacc-061600cce048"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfOC0zLTEtMS0yODk0Nw_7d273011-691e-4865-9176-dbf964795ed1"
      unitRef="usd">-17689000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfOS0xLTEtMS0yODk0Nw_837ad996-7ca0-44c6-8014-c3450ed246f5"
      unitRef="usd">1643000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfOS0zLTEtMS0yODk0Nw_32f7f1a2-4ead-4919-8704-0842f4de2a6a"
      unitRef="usd">13196000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTEtMS0xLTEtMjg5NDc_e9e5a70a-3eb4-42a6-8ac9-0f94d10709f6"
      unitRef="usd">1365000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTEtMy0xLTEtMjg5NDc_b832828c-efc7-4968-ab3c-01228a360375"
      unitRef="usd">539000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <insm:NoncashOperatingLeaseExpense
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTItMS0xLTEtMjg5NDc_62d096fc-a07a-4b07-824e-44f28a90103c"
      unitRef="usd">9765000</insm:NoncashOperatingLeaseExpense>
    <insm:NoncashOperatingLeaseExpense
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTItMy0xLTEtMjg5NDc_269da958-dd27-4852-bc7b-e6951f106a3d"
      unitRef="usd">9550000</insm:NoncashOperatingLeaseExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTMtMS0xLTEtMjg5NDc_f58876e1-f34e-4a43-8ca1-db2a9dcce0c0"
      unitRef="usd">-24240000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTMtMy0xLTEtMjg5NDc_03f886d3-59a4-4791-894d-f82ead7685aa"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTUtMS0xLTEtMjg5NDc_cc0ba23f-eca5-4e5c-a931-533458a97eb4"
      unitRef="usd">6784000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTUtMy0xLTEtMjg5NDc_c4e83e27-9473-43b5-a8e8-ef17971545d4"
      unitRef="usd">1855000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTYtMS0xLTEtMjg5NDc_cba4701f-39a8-40e5-a80f-86d11bd3cf6b"
      unitRef="usd">-724000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTYtMy0xLTEtMjg5NDc_f6a8d0b9-5121-45d8-adbe-61e985340dba"
      unitRef="usd">11557000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTctMS0xLTEtMjg5NDc_737b4f4a-0989-4eef-a69b-7de057a1f66e"
      unitRef="usd">-4101000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTctMy0xLTEtMjg5NDc_621eaff3-1711-41d7-90fe-8385b051cd3c"
      unitRef="usd">7484000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTgtMS0xLTEtMjg5NDc_63e7dabf-71aa-44d2-8205-0208c0ed4b58"
      unitRef="usd">15531000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTgtMy0xLTEtMjg5NDc_684b0da4-72cd-48fd-825b-871f4911647d"
      unitRef="usd">22623000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTktMS0xLTEtMjg5NDc_72fbdadd-559a-47dd-9480-b9ea80638b6b"
      unitRef="usd">-3558000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMTktMy0xLTEtMjg5NDc_224f3232-7070-4043-be94-b440145a04f2"
      unitRef="usd">-11158000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjAtMS0xLTEtMjg5NDc_23794767-cf66-4030-a692-1faf15d910ac"
      unitRef="usd">-16533000</insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities>
    <insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjAtMy0xLTEtMjg5NDc_fc7bcb37-bb77-457c-a7b9-6ae11196d42d"
      unitRef="usd">-10629000</insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjItMS0xLTEtMjg5NDc_b97c5dc5-4d49-4178-97e5-1c979c568dc7"
      unitRef="usd">-207462000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjItMy0xLTEtMjg5NDc_a5e67332-0ad9-419d-8327-f81bfe231966"
      unitRef="usd">-203725000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjQtMS0xLTEtMjg5NDc_b81b0149-2b67-4f82-b141-d5c2d55a5da6"
      unitRef="usd">4605000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjQtMy0xLTEtMjg5NDc_68f672ee-44ec-474c-9623-c1041ec0d4ab"
      unitRef="usd">4666000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjUtMS0xLTEtMjg5NDc_889b6eaa-a7e4-4f78-bdc7-1d742edb020e"
      unitRef="usd">99706000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjUtMy0xLTEtMjg5NDc_5442fc8a-a712-4a8c-815a-6d9299f2b56b"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjgtMS0xLTEtMjg5NDc_417cab3d-933a-47fa-8c64-1d57d2b9a945"
      unitRef="usd">-104311000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMjgtMy0xLTEtMjg5NDc_c0c047af-60ea-4c3f-ac60-5372bcf28518"
      unitRef="usd">-4666000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzAtMS0xLTEtMjg5NDc_dae1c190-7dee-465e-8cfb-a2f034ae07e8"
      unitRef="usd">13264000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzAtMy0xLTEtMjg5NDc_ee6709e5-63ad-4e68-a324-0f90670930db"
      unitRef="usd">13527000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzEtMS0xLTEtMjg5NDc_b1c0e174-a6ad-4911-9e0e-d701b3ed9151"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzEtMy0xLTEtMjg5NDc_109f8dd8-b8f4-40fc-8190-23e1af40b2c0"
      unitRef="usd">269886000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if2feebc246964bc390c0f21deae432ad_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzItMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjo0Yzk2YmYxODU5Mzk0YTUzYTk5NWEyYWYwNTFmOGMyZl8zMw_cbc3592e-f818-4689-b259-d304c1c13ab7"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzItMS0xLTEtMjg5NDc_0f6adf04-fd26-4adf-aac9-e4282679d35b"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzItMy0xLTEtMjg5NDc_377f4bc3-7d09-4014-86a2-2f13648bb35c"
      unitRef="usd">12578000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if2feebc246964bc390c0f21deae432ad_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzMtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjplZWI3MGFkNzNiMjc0NjdjYjJhNzcwODJlZGI4Y2E0Nl8yOA_cbc3592e-f818-4689-b259-d304c1c13ab7"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzMtMS0xLTEtMjg5NDc_7826b71c-ba38-45ed-8101-e47561ee951c"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzMtMy0xLTEtMjg5NDc_e4195cc6-2868-4b98-a08c-3a37cfb47101"
      unitRef="usd">225000000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7a28ddcd6f5348cc9084640011f760dd_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzQtMC0xLTEtMjg5NDcvdGV4dHJlZ2lvbjo5MjYwYmQ5ZjY4NTM0Zjc2OWY1OTBiYjMwODNiNTU1M18zMA_88f1aeb4-37f3-482e-9737-51136e21db02"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzQtMS0xLTEtMjg5NDc_91bda5e7-a41f-41a0-b6a9-a2ea68c045e3"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzQtMy0xLTEtMjg5NDc_7d0f1f14-1c23-4ce8-9741-3d5682e5a473"
      unitRef="usd">575000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzUtMS0xLTEtMjg5NDc_13008aa5-c721-4f5e-92b9-c844147e5823"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzUtMy0xLTEtMjg5NDc_8e6cd781-1802-4e5a-b98a-c4a511ef3d7a"
      unitRef="usd">16013000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzYtMS0xLTEtMjg5NDc_6681db9d-c65e-4c2e-8d2a-78e9c2091cfb"
      unitRef="usd">494000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzYtMy0xLTEtMjg5NDc_c0860905-dda2-4168-a53e-f2e997541858"
      unitRef="usd">522000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzgtMS0xLTEtMjg5NDc_afca1201-3a7b-4deb-953c-c848cc2e5b45"
      unitRef="usd">12770000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzgtMy0xLTEtMjg5NDc_86e13db8-0c3c-49ec-9136-c4e76d1df876"
      unitRef="usd">604300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzktMS0xLTEtMjg5NDc_3b2605dc-2e01-4bd6-ab60-0e18a482bba4"
      unitRef="usd">-1701000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfMzktMy0xLTEtMjg5NDc_cfe89de9-6dc9-46f1-809e-5dbec30eb068"
      unitRef="usd">-338000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDAtMS0xLTEtMjg5NDc_eb07ff4c-c5a5-427b-9677-2ad002de1da5"
      unitRef="usd">-300704000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDAtMy0xLTEtMjg5NDc_7d23cf5f-22dc-4b84-b4f9-e3939827edc8"
      unitRef="usd">395571000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDEtMS0xLTEtMjg5NDc_cfec8400-fb71-48bd-90d6-272349146b8b"
      unitRef="usd">716782000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic11e1e3142e048009002fc987716b4e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDEtMy0xLTEtMjg5NDc_fef69cf3-18fd-46ab-94ab-de1309937990"
      unitRef="usd">532756000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDItMS0xLTEtMjg5NDc_ac23a72b-6c32-4cd2-8056-fa2a3b61fa17"
      unitRef="usd">416078000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i34b29fd1e2a04660a3bb612c3f24dde5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDItMy0xLTEtMjg5NDc_7866b43f-25f7-4f2c-bc1d-9c31ebcbf834"
      unitRef="usd">928327000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDQtMS0xLTEtMjg5NDc_057bac2e-54ac-41d5-b7a5-90791b53fb3e"
      unitRef="usd">5004000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDQtMy0xLTEtMjg5NDc_fb69e983-2e6d-44c7-9c8d-f35d1ed522ae"
      unitRef="usd">5911000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDUtMS0xLTEtMjg5NDc_aaa21f03-168a-4a14-9b12-d9ecc896e703"
      unitRef="usd">1194000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8yNS9mcmFnOjYwYzJlYzdjM2RjYzQ4ZWQ4OWY1N2Q0ZGQwNjRiNDlkL3RhYmxlOjdlNjlmZThiMDZjODQxZTFhYzNhODM1NjM3YjZmYjkwL3RhYmxlcmFuZ2U6N2U2OWZlOGIwNmM4NDFlMWFjM2E4MzU2MzdiNmZiOTBfNDUtMy0xLTEtMjg5NDc_5f8aad99-1c70-4a1b-b246-41135c775d43"
      unitRef="usd">997000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zMS9mcmFnOmNmMDA2YTA2ZTFlMTQ4Zjk5NmM5OWE0MmEyNGMzNTliL3RleHRyZWdpb246Y2YwMDZhMDZlMWUxNDhmOTk2Yzk5YTQyYTI0YzM1OWJfNjEyNg_ae9bf907-6d20-4bcd-81d8-6c344a0c3aa3">The Company and Basis of Presentation&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States (US) as ARIKAYCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mycobacterium avium&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nontuberculous mycobacterial (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NTM) lung infections caused by MAC in adults with limited treatment options who do not have &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cystic fibrosis (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;C&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;F). In March 2021, Japan's Ministry of Health, Labour and Welfare (MHLW) approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis, CF and other neutrophil-mediated diseases&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, including chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was incorporated in the Commonwealth of Virginia on November&#160;29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules&#160;and regulations for reporting on Form&#160;10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the US for complete consolidated financial statements are not included herein. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000110450622000008/insm-20211231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Annual Report on Form&#160;10-K for the year ended December&#160;31, 20&lt;/a&gt;21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;The Company had $416.1 million in cash and cash equivalents and marketable securities totaling $148.6 million as of June&#160;30, 2022 and reported a net loss of $190.3 million for the six months ended June&#160;30, 2022. Historically, the Company has funded its operations through public offerings of equity securities and debt financings. The Company expects to continue to incur consolidated operating losses, including losses in its US and certain international entities, while funding research and development (R&amp;amp;D) activities for ARIKAYCE, brensocatib, TPIP and its other pipeline programs, and continuing and commencing pre-commercial, commercialization and regulatory activities for ARIKAYCE, and funding other general and administrative activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects its future cash requirements to be substantial, and the Company may need to raise additional capital to fund operations, including the Phase 3 ASPEN study, the continued commercialization of ARIKAYCE, the ARISE and ENCORE clinical trials related to ARIKAYCE, launch readiness activities for the potential launch of brensocatib, if approved, other clinical trials for brensocatib, TPIP, and its future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company&#x2019;s commercial, regulatory and development activities. Any equity or debt financing will also be contingent upon equity and debt market conditions and interest rates at the time. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts. The Company believes it currently has sufficient funds to meet its financial needs for at least the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are many uncertainties regarding the novel coronavirus (COVID-19) pandemic, and the Company is closely monitoring the impact of the pandemic on all aspects of its business, including how the pandemic will impact its patients, employees, suppliers, vendors, business partners and distribution channels. While the pandemic did not materially affect the Company's financial results and business operations for the six months ended June 30, 2022, the Company is unable to predict the impact that COVID-19 will have on its financial position and operating results in future periods due to &lt;/span&gt;&lt;/div&gt;numerous uncertainties. The Company will continue to assess the evolving impact of the COVID-19 pandemic and will make adjustments to its operations as necessary.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zMS9mcmFnOmNmMDA2YTA2ZTFlMTQ4Zjk5NmM5OWE0MmEyNGMzNTliL3RleHRyZWdpb246Y2YwMDZhMDZlMWUxNDhmOTk2Yzk5YTQyYTI0YzM1OWJfMzQ3MA_6a65c2c4-1362-4475-bbfd-8238c495ad2d"
      unitRef="usd">416100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zMS9mcmFnOmNmMDA2YTA2ZTFlMTQ4Zjk5NmM5OWE0MmEyNGMzNTliL3RleHRyZWdpb246Y2YwMDZhMDZlMWUxNDhmOTk2Yzk5YTQyYTI0YzM1OWJfMTY0OTI2NzQ0Nzk1Nw_2758945b-3f35-46a3-8506-7299d7af9b36"
      unitRef="usd">148600000</us-gaap:MarketableSecurities>
    <us-gaap:NetIncomeLoss
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zMS9mcmFnOmNmMDA2YTA2ZTFlMTQ4Zjk5NmM5OWE0MmEyNGMzNTliL3RleHRyZWdpb246Y2YwMDZhMDZlMWUxNDhmOTk2Yzk5YTQyYTI0YzM1OWJfMzU3Ng_cec23ba5-bb9f-456e-83dc-e873560c4cd2"
      unitRef="usd">-190300000</us-gaap:NetIncomeLoss>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNDI_ab0a91d3-6594-420b-984a-04fca2015d8e">Summary of Significant Accounting Policies&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The following are the required interim disclosure updates to the Company's significant accounting policies described in Note 2 of the notes to the consolidated financial statements in the Company's &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;&lt;a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000110450622000008/insm-20211231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2014; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2014; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2014; Inputs reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; six months ended June&#160;30, 2022, the Company purchased $99.7&#160;million of additional m&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;arketable securities consisting of US Treasury Notes. There were no other transfers in or out of Level 1, Level 2 or Level 3 during the six months ended June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the Company held $138.8 million and $9.8 million of current and non-current available-for-sale securities, respectively, net of an unrealized loss of $1.3&#160;million recorded in accumulated other comprehensive income. Marketable securities maturing in one year or less are classified as current assets and marketable securities maturing in more &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;than one year are classified as non-current assets. As of December&#160;31, 2021, the Company held no securities that were in an unrealized gain or loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2) whether the security was rated below investment grade; (3) how long the security has been in an unrealized loss position; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover. The Company has determined that there were no other-than-temporary impairments during the quarter ended June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The deferred consideration arose from the acquisitions of Motus Biosciences, Inc. (Motus) and AlgaeneX, Inc. (AlgaeneX) (the Business Acquisition) in August 2021 (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i252108b308054887a46901fe227627f1_70" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 13&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company&#x2019;s common stock on each of the first, second and third anniversaries of the closing date, subject to certain reductions. A valuation of the deferred consideration is performed quarterly with gains and losses included within change in fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss. As the deferred consideration is settled in shares, there is no discount rate applied in the fair value calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The deferred consideration has been classified as a Level 2 recurring liability as its valuation utilizes an input, the Insmed share price on the valuation date, which is a directly observable input at the measurement date and for the duration of the liabilities' anticipated lives. Deferred consideration expected to be settled within twelve months or less is classified as a current liability and are included in accrued liabilities. As of June&#160;30, 2022, the fair value of deferred consideration included in accrued liabilities was $3.5 million. Deferred consideration expected to be settled in more than twelve months is classified as a non-current liability and is included in other long-term liabilities. As of June&#160;30, 2022, the fair value of deferred consideration included in other long-term liabilities was $7.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following observable input was used in the valuation of the deferred consideration as of June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value as of June&#160;30, 2022 (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Observable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$10.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insmed share price as of June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$19.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liabilities arose from the Business Acquisition in August 2021 (Note 13). The contingent consideration liabilities consist of developmental and regulatory milestones, a priority review voucher milestone and net sales milestones. Upon the achievement of certain development and regulatory milestone events, the Company is obligated to issue to Motus equityholders up to 5,348,572 shares in the aggregate and AlgaeneX equityholders up to 368,867 shares in the aggregate. The fair value of the development and regulatory milestones are estimated utilizing a probability-adjusted approach. At June&#160;30, 2022, the weighted average probability of success was 42%. The development and regulatory milestones will be settled in shares of the Company's common stock. As such, there is no discount rate applied in the fair value calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company were to receive a priority review voucher, the Company is obligated to pay to the Motus equityholders a portion of the value of the priority review voucher, subject to certain reductions. The potential payout will be either 50% of the after tax net proceeds received by the Company from a sale of the priority review voucher or 50% of the average of the sales prices for the last three publicly disclosed priority review voucher sales, less certain adjustments. The fair value of the priority review voucher milestone is estimated utilizing a probability-adjusted discounted cash flow approach. This obligation will be settled in cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liabilities for net sales milestones were valued using an option pricing model with Monte Carlo simulation. As of June&#160;30, 2022, the fair value of these net sales milestones were deemed immaterial to the overall fair value of the contingent consideration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liabilities have been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the inputs to the valuation approach, the estimated fair value could be significantly different than the fair value the Company determined. Contingent consideration liabilities expected to be settled in more than twelve months are classified as a non-current liability. A valuation of the contingent consideration liabilities is performed quarterly with gains and losses included within change in fair value of contingent consideration liabilities in the consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration liabilities as of June&#160;30, 2022 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent Consideration Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value as of June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$50.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability-adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14% - 95%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Priority review voucher milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability-adjusted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the six months ended June 30, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the liability component of the Company's 0.75% convertible senior notes due 2028 (the 2028 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of June&#160;30, 2022 was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$496.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the 2028 Convertible Notes. The $561.6 million carrying value of the 2028 Convertible Notes as of June&#160;30, 2022 excludes the $13.4 million of the unamortized portion of the debt issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the liability component of the Company's 1.75% convertible senior notes due 2025 (the 2025 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of June&#160;30, 2022 was $208.3 million, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the 2025 Convertible Notes. The $222.4 million carrying value of the 2025 Convertible Notes as of June&#160;30, 2022 excludes the $2.6 million of the unamortized portion of the debt issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock, restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three and six months ended June&#160;30, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(190,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(208,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares used in calculation of basic net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of June&#160;30, 2022 and 2021, respectively, as their effect would have been anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for collectible trade receivables. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the six months ended June&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;operating results. A change in the relationship with the suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- In accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract to determine which are performance obligations and to assess whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenues, net consist of net sales of ARIKAYCE. The Company's customers in the US include specialty pharmacies and specialty distributors. In December 2020, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Europe. In July 2021, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Japan. Globally, product revenues are recognized once the Company performs and satisfies all five steps of the revenue recognition criteria mentioned above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the Company's product revenues, net, by geographic location for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.854%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe and rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total product revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer credits: The Company's customers are offered various forms of consideration, including prompt payment discounts. The payment terms for sales to specialty pharmacies for prompt payment discounts are based on contractual rates agreed with the respective specialty pharmacies. The Company anticipates that its customers will earn these discounts and, therefore, deducts the full amount of these discounts from total gross product revenues at the time such revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates: The Company contracts with government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accrued liabilities on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also recognizes revenue related to various early access programs (EAPs) in Europe, predominantly in France. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory and Cost of Product Revenues (excluding amortization of intangible assets) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- Inventory is stated at the lower of cost and net realizable value. The Company began capitalizing inventory costs following US Food and Drug Administration (FDA) approval of ARIKAYCE in September 2018. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestone payments. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to FDA approval of ARIKAYCE, the Company expensed all inventory-related costs in the period incurred. Inventory used for clinical development purposes is expensed to R&amp;amp;D expense when consumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business combinations and asset acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration for the Company&#x2019;s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets&#x2019; carrying amounts on the acquiring entity&#x2019;s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indefinite-lived intangible assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- Indefinite-lived intangible assets consist of In Process Research &amp;amp; Development (IPR&amp;amp;D). IPR&amp;amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;amp;D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&amp;amp;D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#x2019;s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company&#x2019;s outlook and market performance of the Company&#x2019;s industry and recent and forecasted financial performance. The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finite-lived Intangible Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- Finite-lived intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the acquired ARIKAYCE R&amp;amp;D intangible asset, at the date of subsequent adjustments of fair value. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment Assessment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing to the carrying value of the assets to the fair value of the assets. The Company determined that no indicators of impairment of finite-lived intangible assets or long-lived assets existed at June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#x2019;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassesses its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company will perform its next annual impairment testing for goodwill on October 1, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7 - Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for details about the Company's lease portfolio, including required disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also promote consistent application of and simplify US generally accepted accounting principles (GAAP) for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance was effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. The Company adopted this guidance January 1, 2021. The adoption of the guidance did not have a material impact on the Company's consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;In August 2020, the FASB issued &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNTQ_a1983cb3-6ebb-4561-babb-c381ced619fe"&gt;ASU 2020-06&lt;/span&gt;, Debt &#x2014; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, to reduce the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. For convertible instruments, the number of accounting models for convertible debt instruments is reduced, which results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Only convertible instruments that meet the definition of a derivative or are issued with substantial premiums will continue to be subject to the separation models. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and a share of convertible preferred stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation and recognition as derivatives. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021. The Company transitioned using the modified retrospective method. The impact of adopting ASU 2020-06 on January 1, 2022 resulted in an opening balance sheet adjustment increasing debt by $221.9&#160;million, increasing issuance costs classified to debt by $6.1&#160;million, decreasing the deferred tax liability by $1.4&#160;million, and causing an increase to retained earnings of $50.2 million, with an offsetting reduction to additional paid-in-capital of $264.6 million, net of tax.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNzA_0a2d5689-4b97-4a3d-b0e2-3282c1b1c90f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:&lt;/span&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2014; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2014; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2014; Inputs reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; six months ended June&#160;30, 2022, the Company purchased $99.7&#160;million of additional m&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;arketable securities consisting of US Treasury Notes. There were no other transfers in or out of Level 1, Level 2 or Level 3 during the six months ended June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the Company held $138.8 million and $9.8 million of current and non-current available-for-sale securities, respectively, net of an unrealized loss of $1.3&#160;million recorded in accumulated other comprehensive income. Marketable securities maturing in one year or less are classified as current assets and marketable securities maturing in more &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;than one year are classified as non-current assets. As of December&#160;31, 2021, the Company held no securities that were in an unrealized gain or loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2) whether the security was rated below investment grade; (3) how long the security has been in an unrealized loss position; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover. The Company has determined that there were no other-than-temporary impairments during the quarter ended June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The deferred consideration arose from the acquisitions of Motus Biosciences, Inc. (Motus) and AlgaeneX, Inc. (AlgaeneX) (the Business Acquisition) in August 2021 (&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i252108b308054887a46901fe227627f1_70" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 13&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company&#x2019;s common stock on each of the first, second and third anniversaries of the closing date, subject to certain reductions. A valuation of the deferred consideration is performed quarterly with gains and losses included within change in fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss. As the deferred consideration is settled in shares, there is no discount rate applied in the fair value calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The deferred consideration has been classified as a Level 2 recurring liability as its valuation utilizes an input, the Insmed share price on the valuation date, which is a directly observable input at the measurement date and for the duration of the liabilities' anticipated lives. Deferred consideration expected to be settled within twelve months or less is classified as a current liability and are included in accrued liabilities. As of June&#160;30, 2022, the fair value of deferred consideration included in accrued liabilities was $3.5 million. Deferred consideration expected to be settled in more than twelve months is classified as a non-current liability and is included in other long-term liabilities. As of June&#160;30, 2022, the fair value of deferred consideration included in other long-term liabilities was $7.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following observable input was used in the valuation of the deferred consideration as of June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value as of June&#160;30, 2022 (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Observable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$10.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insmed share price as of June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$19.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liabilities arose from the Business Acquisition in August 2021 (Note 13). The contingent consideration liabilities consist of developmental and regulatory milestones, a priority review voucher milestone and net sales milestones. Upon the achievement of certain development and regulatory milestone events, the Company is obligated to issue to Motus equityholders up to 5,348,572 shares in the aggregate and AlgaeneX equityholders up to 368,867 shares in the aggregate. The fair value of the development and regulatory milestones are estimated utilizing a probability-adjusted approach. At June&#160;30, 2022, the weighted average probability of success was 42%. The development and regulatory milestones will be settled in shares of the Company's common stock. As such, there is no discount rate applied in the fair value calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company were to receive a priority review voucher, the Company is obligated to pay to the Motus equityholders a portion of the value of the priority review voucher, subject to certain reductions. The potential payout will be either 50% of the after tax net proceeds received by the Company from a sale of the priority review voucher or 50% of the average of the sales prices for the last three publicly disclosed priority review voucher sales, less certain adjustments. The fair value of the priority review voucher milestone is estimated utilizing a probability-adjusted discounted cash flow approach. This obligation will be settled in cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liabilities for net sales milestones were valued using an option pricing model with Monte Carlo simulation. As of June&#160;30, 2022, the fair value of these net sales milestones were deemed immaterial to the overall fair value of the contingent consideration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liabilities have been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the inputs to the valuation approach, the estimated fair value could be significantly different than the fair value the Company determined. Contingent consideration liabilities expected to be settled in more than twelve months are classified as a non-current liability. A valuation of the contingent consideration liabilities is performed quarterly with gains and losses included within change in fair value of contingent consideration liabilities in the consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration liabilities as of June&#160;30, 2022 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent Consideration Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value as of June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$50.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability-adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14% - 95%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Priority review voucher milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability-adjusted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNzE_78fcb8d3-0449-4160-942d-ed8cbbc3b77e">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iec080385c64348cb8d266b6830480fb9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfMy0xLTEtMS0yODk0Nw_63fa237f-9d50-4ff8-b38f-a9d90a3daf02"
      unitRef="usd">416100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2d7e6f6374b34f27b308f84f2889e800_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfMy0zLTEtMS0yODk0Nw_d97f6510-ae21-4482-a925-37fd4491d3fc"
      unitRef="usd">416100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic90ba27634af46b9a9e3cde8cc10fe96_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfMy01LTEtMS0yODk0Nw_fef88d88-9082-40d4-9d26-e4091b48e40a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i47041a589d9840429204e4bf3b7e196d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfMy03LTEtMS0yODk0Nw_bd530e80-c0c3-4762-8980-762ea01805bd"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MarketableSecurities
      contextRef="iec080385c64348cb8d266b6830480fb9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNC0xLTEtMS0yODk0Nw_a47e131a-3018-4fb3-98e4-bf5256c9cf83"
      unitRef="usd">148600000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i2d7e6f6374b34f27b308f84f2889e800_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNC0zLTEtMS0yODk0Nw_28213017-b701-411c-ab6c-14dd7d33ab7a"
      unitRef="usd">148600000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="ic90ba27634af46b9a9e3cde8cc10fe96_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNC01LTEtMS0yODk0Nw_e68a3002-75d7-4c43-8dca-aa8b2cd5283e"
      unitRef="usd">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i47041a589d9840429204e4bf3b7e196d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNC03LTEtMS0yODk0Nw_d21c7acc-9227-4b24-903f-24ff39aeb07b"
      unitRef="usd">0</us-gaap:MarketableSecurities>
    <insm:BusinessCombinationDeferredLiability
      contextRef="iec080385c64348cb8d266b6830480fb9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNS0xLTEtMS0yODk0Nw_d36c61b2-bf1a-4f49-a44b-ab71690e7d67"
      unitRef="usd">10800000</insm:BusinessCombinationDeferredLiability>
    <insm:BusinessCombinationDeferredLiability
      contextRef="i2d7e6f6374b34f27b308f84f2889e800_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNS0zLTEtMS0yODk0Nw_2fab413c-163f-4417-a887-57a3dfbb1a68"
      unitRef="usd">0</insm:BusinessCombinationDeferredLiability>
    <insm:BusinessCombinationDeferredLiability
      contextRef="ic90ba27634af46b9a9e3cde8cc10fe96_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNS01LTEtMS0yODk0Nw_f4086e6a-38bd-4eab-bd2a-2b049e7006d9"
      unitRef="usd">10800000</insm:BusinessCombinationDeferredLiability>
    <insm:BusinessCombinationDeferredLiability
      contextRef="i47041a589d9840429204e4bf3b7e196d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNS03LTEtMS0yODk0Nw_762fee13-1da0-43c0-b4ca-2939dbf75dde"
      unitRef="usd">0</insm:BusinessCombinationDeferredLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iec080385c64348cb8d266b6830480fb9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNi0xLTEtMS0yODk0Nw_208f54b1-5291-491a-83a2-211b856ca227"
      unitRef="usd">55600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2d7e6f6374b34f27b308f84f2889e800_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNi0zLTEtMS0yODk0Nw_48dff41d-9521-4e9f-93bc-c7ff76258baa"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic90ba27634af46b9a9e3cde8cc10fe96_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNi01LTEtMS0yODk0Nw_b55ebd9e-b6d1-4312-90cc-71cfd165d439"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i47041a589d9840429204e4bf3b7e196d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmY4MDJhMTc4MmFiMDRkZGI4ZThkMWYyN2YwYmY3ZWQyL3RhYmxlcmFuZ2U6ZjgwMmExNzgyYWIwNGRkYjhlOGQxZjI3ZjBiZjdlZDJfNi03LTEtMS0yODk0Nw_750d68de-aa03-44b2-b99b-afe27851f983"
      unitRef="usd">55600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i93327d100c39469e95dec29690f01bda_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfMy0xLTEtMS0yODk0Nw_790ea9bd-4c62-4c56-81c1-fc2767a1b303"
      unitRef="usd">716800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1ee4597ee72a49a1b044f1c8dbb4f863_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfMy0zLTEtMS0yODk0Nw_1241be3d-18b1-4166-9ce5-aa620273338e"
      unitRef="usd">716800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i71d3efb8da424928ad39dfb3ae7f93e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfMy01LTEtMS0yODk0Nw_465a3222-7165-46c1-a14a-88778f1701cb"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie148fe14821246d98cdbbf096f0dc154_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfMy03LTEtMS0yODk0Nw_7f71b398-4af7-445d-98df-02fa32f0b358"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MarketableSecurities
      contextRef="i93327d100c39469e95dec29690f01bda_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNC0xLTEtMS0yODk0Nw_555f3aa1-3e6a-42a7-b8e3-975d6fc9b3cc"
      unitRef="usd">50000000.0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i1ee4597ee72a49a1b044f1c8dbb4f863_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNC0zLTEtMS0yODk0Nw_bf333812-e381-4134-b893-34d76958230d"
      unitRef="usd">50000000.0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i71d3efb8da424928ad39dfb3ae7f93e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNC01LTEtMS0yODk0Nw_7a0d8e28-c7af-4fed-9837-83880802e055"
      unitRef="usd">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="ie148fe14821246d98cdbbf096f0dc154_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNC03LTEtMS0yODk0Nw_20ad9d4c-d8ba-4c94-8c90-b4c8237fbbfa"
      unitRef="usd">0</us-gaap:MarketableSecurities>
    <insm:BusinessCombinationDeferredLiability
      contextRef="i93327d100c39469e95dec29690f01bda_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNS0xLTEtMS0yODk0Nw_d63f798f-ffde-4aca-a317-1d6239ff273f"
      unitRef="usd">14900000</insm:BusinessCombinationDeferredLiability>
    <insm:BusinessCombinationDeferredLiability
      contextRef="i1ee4597ee72a49a1b044f1c8dbb4f863_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNS0zLTEtMS0yODk0Nw_7d230bf7-2c9d-4991-bd56-cb09d619c4e1"
      unitRef="usd">0</insm:BusinessCombinationDeferredLiability>
    <insm:BusinessCombinationDeferredLiability
      contextRef="i71d3efb8da424928ad39dfb3ae7f93e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNS01LTEtMS0yODk0Nw_8c3a24a7-8946-4343-9128-4caef8f69233"
      unitRef="usd">14900000</insm:BusinessCombinationDeferredLiability>
    <insm:BusinessCombinationDeferredLiability
      contextRef="ie148fe14821246d98cdbbf096f0dc154_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNS03LTEtMS0yODk0Nw_ad331a7b-4994-4152-875d-7d94567c5f7b"
      unitRef="usd">0</insm:BusinessCombinationDeferredLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i93327d100c39469e95dec29690f01bda_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNi0xLTEtMS0yODk0Nw_59e19f02-482d-4ee4-a516-35da9dae302e"
      unitRef="usd">75700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1ee4597ee72a49a1b044f1c8dbb4f863_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNi0zLTEtMS0yODk0Nw_f6059230-efc3-4aa8-827d-bcf986ddd8ed"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i71d3efb8da424928ad39dfb3ae7f93e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNi01LTEtMS0yODk0Nw_1d315fba-b83c-4eaa-998b-d68e42779fb8"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie148fe14821246d98cdbbf096f0dc154_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjRiMzBmZmZjNTE2ZjQ0ODM5MWVhNmNhMTMwMGJkYjg0L3RhYmxlcmFuZ2U6NGIzMGZmZmM1MTZmNDQ4MzkxZWE2Y2ExMzAwYmRiODRfNi03LTEtMS0yODk0Nw_5a8c917c-a289-48c1-ac2a-eed0b5267a70"
      unitRef="usd">75700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <insm:MarketableSecuritiesAdditional
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMjQ0MQ_05e626db-bbea-425e-9004-85d5db8835ca"
      unitRef="usd">99700000</insm:MarketableSecuritiesAdditional>
    <insm:FairValueLevel1Level2Level3TransfersAmount
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNzI_15b251da-2199-4777-b98f-773bb41f0229"
      unitRef="usd">0</insm:FairValueLevel1Level2Level3TransfersAmount>
    <insm:FairValueLevel1Level2Level3TransfersAmount
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNzI_819765af-b8d3-4bdc-ad1e-1f7a652a5a2b"
      unitRef="usd">0</insm:FairValueLevel1Level2Level3TransfersAmount>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMjY2Mw_2af81f3b-aecb-4f27-9bcd-f072238c2c07"
      unitRef="usd">138800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMjY3MA_ec3ec963-2ab6-4f24-a767-e1b11ca2cec8"
      unitRef="usd">9800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMjc3NA_3810478c-88c1-45e2-bfe5-f30450ac03bd"
      unitRef="usd">1300000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <insm:AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMjg1Ng_ac1e8a0e-57be-4281-a1c9-ad082ab53ce1"
      unitRef="security">0</insm:AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="ib690063402dd47c4ae80bed8cc5946a2_D20210804-20210804"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzc5Mw_10df3dcf-c035-4ae8-84b3-227068a45494"
      unitRef="shares">184433</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="ibbf98dd2c06941fba02468ff74fe15f4_D20210804-20210804"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzc5Mw_b56647dd-78a2-4b73-9a8b-ed734d3ebc6f"
      unitRef="shares">184433</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i63cf6ce83c0a452894be75c49ed8e241_D20210804-20210804"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzc5Mw_e86db486-0dca-40c3-b55c-d1df63ba9786"
      unitRef="shares">184433</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <insm:BusinessCombinationDeferredLiability
      contextRef="ie99f3a85a4be4eee9b9643513ffb1f49_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfNDgwOQ_7268a789-ae70-41d1-a829-0a46ac7e5609"
      unitRef="usd">3500000</insm:BusinessCombinationDeferredLiability>
    <insm:BusinessCombinationDeferredLiability
      contextRef="ic0173aaf93ae46c0804c04edc71dcf3d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfNTA3MA_09f9a086-9b76-4ed0-b115-6a56eebfa8a5"
      unitRef="usd">7300000</insm:BusinessCombinationDeferredLiability>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNTU_93837828-4d58-444d-b94c-628be2bf7b4c">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following observable input was used in the valuation of the deferred consideration as of June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value as of June&#160;30, 2022 (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Observable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$10.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insmed share price as of June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$19.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <insm:BusinessCombinationDeferredLiability
      contextRef="if515e39443fc4bab983e5485d58c4067_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjQwOWFjOTlhMmY0MzQ2YzU4NWQ0NjQyYTA2MGZmNGU0L3RhYmxlcmFuZ2U6NDA5YWM5OWEyZjQzNDZjNTg1ZDQ2NDJhMDYwZmY0ZTRfMS0xLTEtMS0yODk0Nw_d966bb40-5fdb-4f7e-8093-2a7c2b597ae9"
      unitRef="usd">10800000</insm:BusinessCombinationDeferredLiability>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i060750a8e6764e58986207b6fa039245_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjQwOWFjOTlhMmY0MzQ2YzU4NWQ0NjQyYTA2MGZmNGU0L3RhYmxlcmFuZ2U6NDA5YWM5OWEyZjQzNDZjNTg1ZDQ2NDJhMDYwZmY0ZTRfMS0zLTEtMS0yODk0Nw_4cba88f6-e6dc-49a6-97c5-7407a0770661"
      unitRef="usdPerShare">19.72</us-gaap:BusinessAcquisitionSharePrice>
    <insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares
      contextRef="i4fc0d05a849b4f9f8363d09eb7a2297f_D20210804-20210804"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfNTYwMA_8a7cf677-5d05-45d7-9feb-d2e953685384"
      unitRef="shares">5348572</insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares>
    <insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares
      contextRef="i7d34c58061f249e18f61f07687b0331b_D20210801-20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfNTY2MA_df84c9d3-ef12-41e0-bba6-949165c43452"
      unitRef="shares">368867</insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares>
    <insm:WeightedAverageProbabilityOfReachingMilestone
      contextRef="i8a656fb7732145c9a71bf1d21a49bd5d_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfNTg2MA_103174e8-1924-4df4-b956-0dc6cc722b9e"
      unitRef="number">0.42</insm:WeightedAverageProbabilityOfReachingMilestone>
    <insm:ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage
      contextRef="i4df89726368c42908ecdb1dc00da2381_I20210831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfNjI3Ng_50618d2c-4b54-4890-a7b5-88660fc5863b"
      unitRef="number">0.50</insm:ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage>
    <insm:AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage
      contextRef="i4df89726368c42908ecdb1dc00da2381_I20210831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfNjM3OQ_87e5d242-abb1-44a8-8605-4acde37dad2e"
      unitRef="number">0.50</insm:AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage>
    <insm:NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders
      contextRef="i281fbad9a3524e6396eb4972fe1bde0a_D20210801-20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfNjQzMA_1fb46f28-c532-44ab-bcd2-efac9688f967"
      unitRef="sale">3</insm:NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNjY_d3251ba4-6d48-446a-b415-4acc11ec1a5c">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration liabilities as of June&#160;30, 2022 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent Consideration Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value as of June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$50.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability-adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14% - 95%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Priority review voucher milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability-adjusted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the six months ended June 30, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia8937d9bce474ef99c2f8fd821f06dfd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjg4ZGI1NzRlMjQyMjQwZWY5ODE5MzM5ZjNiY2Y0N2Q2L3RhYmxlcmFuZ2U6ODhkYjU3NGUyNDIyNDBlZjk4MTkzMzlmM2JjZjQ3ZDZfMS0xLTEtMS0yODk0Nw_7bfde89b-4279-4429-96a0-bd1f80ce51c5"
      unitRef="usd">50600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i26bcf703891e40a19cb16e952a3c238c_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjg4ZGI1NzRlMjQyMjQwZWY5ODE5MzM5ZjNiY2Y0N2Q2L3RhYmxlcmFuZ2U6ODhkYjU3NGUyNDIyNDBlZjk4MTkzMzlmM2JjZjQ3ZDZfMS00LTEtMS0yODk0Ny90ZXh0cmVnaW9uOjVkYjFlODQ5ZTZjODQzNWE4NjM3ZmQwNWZmYzIxYjQ2XzQ_1b71e4e5-af08-46b6-b4b9-284c296add0b"
      unitRef="number">0.14</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i7956fe4d32d6415888053fe7ac3dece8_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjg4ZGI1NzRlMjQyMjQwZWY5ODE5MzM5ZjNiY2Y0N2Q2L3RhYmxlcmFuZ2U6ODhkYjU3NGUyNDIyNDBlZjk4MTkzMzlmM2JjZjQ3ZDZfMS00LTEtMS0yODk0Ny90ZXh0cmVnaW9uOjVkYjFlODQ5ZTZjODQzNWE4NjM3ZmQwNWZmYzIxYjQ2Xzk_99cd3802-67bf-4db4-af91-80c3d61c8ec2"
      unitRef="number">0.95</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibfb81df3017f4c52b5f695219f80bcb0_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjg4ZGI1NzRlMjQyMjQwZWY5ODE5MzM5ZjNiY2Y0N2Q2L3RhYmxlcmFuZ2U6ODhkYjU3NGUyNDIyNDBlZjk4MTkzMzlmM2JjZjQ3ZDZfMi0xLTEtMS0yODk0Nw_6a0a5858-6331-49a4-bb17-03d41958ea44"
      unitRef="usd">5000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i01b8767d1be2471ea778276a43af86f0_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjg4ZGI1NzRlMjQyMjQwZWY5ODE5MzM5ZjNiY2Y0N2Q2L3RhYmxlcmFuZ2U6ODhkYjU3NGUyNDIyNDBlZjk4MTkzMzlmM2JjZjQ3ZDZfMi00LTEtMS0yODk0Nw_de7de334-aa5d-47a5-857e-6cd6a60b3075"
      unitRef="number">13.5</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i694933442abe4684b8238d717a4bc7b2_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjg4ZGI1NzRlMjQyMjQwZWY5ODE5MzM5ZjNiY2Y0N2Q2L3RhYmxlcmFuZ2U6ODhkYjU3NGUyNDIyNDBlZjk4MTkzMzlmM2JjZjQ3ZDZfMy00LTEtMS0yODk0Nw_d3862473-5366-4c3e-9ac3-e6824e397923"
      unitRef="number">10.7</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i9029a1175b8d4c0bb7ad648dd57b8b45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMi0yLTEtMS0yODk0Nw_6197816b-ed64-47c9-8370-7fa2c4812f8e"
      unitRef="usd">14931000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="id65b00fb345d4a73968a60a9f00ec86b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMi00LTEtMS0yODk0Nw_0db3dfba-0ca3-40c5-9bcf-bcecd28f3f01"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue
      contextRef="id65b00fb345d4a73968a60a9f00ec86b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMi02LTEtMS0yODk0Nw_d15b8497-8e7d-49f8-a310-cca639aabc4d"
      unitRef="usd">-4172000</insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue>
    <insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments
      contextRef="id65b00fb345d4a73968a60a9f00ec86b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMi04LTEtMS0yODk0Nw_1a2e3e71-6470-4d1b-9c51-b14fb6408b9a"
      unitRef="usd">0</insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i8cfafbc2904c4fd78825be70c0ebb580_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMi0xMC0xLTEtMjg5NDc_ce43192e-fc37-4267-8bd5-8f0b79d08759"
      unitRef="usd">10759000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i32f0450653644e2c821879326a4be32c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMy0yLTEtMS0yODk0Nw_e0677547-1bc2-4c89-844e-49224296dc07"
      unitRef="usd">75668000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i1e6f98ddcb9a41259b5ad644d8e7762b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMy00LTEtMS0yODk0Nw_0eab99a5-7773-45c7-9ee1-ef3b0cef99bd"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue
      contextRef="i1e6f98ddcb9a41259b5ad644d8e7762b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMy02LTEtMS0yODk0Nw_f98a954e-b406-4ed6-8b24-12d900bbe8ac"
      unitRef="usd">-20068000</insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue>
    <insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments
      contextRef="i1e6f98ddcb9a41259b5ad644d8e7762b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMy04LTEtMS0yODk0Nw_e73a4faa-ab67-464d-a7f3-38a5f95302c5"
      unitRef="usd">0</insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ibf3af52789dd4962b7190f4bb7f153e7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjBkNGY0MzVjM2YwYzRjNmM4MTZhYzFmNTg3NGFjMmZkL3RhYmxlcmFuZ2U6MGQ0ZjQzNWMzZjBjNGM2YzgxNmFjMWY1ODc0YWMyZmRfMy0xMC0xLTEtMjg5NDc_458d19ea-0a87-43e2-bba0-09a40ede81b0"
      unitRef="usd">55600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7a28ddcd6f5348cc9084640011f760dd_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfODE0Mg_48875725-1e99-4b14-b61a-f0ea0cfee3d5"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i008ce45b9b5447059371d7e92096d9ff_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfODI5NA_17fd57b1-dece-4624-a0db-94805916315f"
      unitRef="usd">496000000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i8a35e946668040f5b6acb3c5b856b0e7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfODQzOQ_65068504-2858-4803-8a58-6f52338a4ed3"
      unitRef="usd">561600000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i7a28ddcd6f5348cc9084640011f760dd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfODUwOQ_adb7c62f-8264-4a74-aeac-4f0c0e303304"
      unitRef="usd">13400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if2feebc246964bc390c0f21deae432ad_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfODYzNg_26be90e9-0cc0-4187-8198-426bf80da17c"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i7436f64e366c4208874055741be8f683_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfODc4OA_366664b9-59f2-4f96-8ec4-4ff56fda275e"
      unitRef="usd">208300000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="id3ba44aaad2b44359ffdef500ffbb2d8_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfODkzMw_b50e46ec-d9a7-4f14-8dee-7ceddc9053ce"
      unitRef="usd">222400000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="if2feebc246964bc390c0f21deae432ad_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfOTAwMw_d81dbf33-b137-4f52-977a-a3bec817619f"
      unitRef="usd">2600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNTY_66631dfe-88ed-4efd-9cd0-13fd535652a7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock, restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNjc_c43785b5-1694-47e8-ab5e-cc28a5b15b41">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three and six months ended June&#160;30, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(190,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(208,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares used in calculation of basic net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfNC0xLTEtMS0yODk0Nw_0fa841cb-4408-49b8-b26f-c56b016befc9"
      unitRef="usd">-95645000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfNC0zLTEtMS0yODk0Nw_a9c9bb01-ad9f-44e3-afac-4810e4b9af4b"
      unitRef="usd">-117321000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfNC01LTEtMS0yODk0Nw_7a9f7763-516e-444f-9d03-4ed1720f4327"
      unitRef="usd">-190266000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfNC03LTEtMS0yODk0Nw_d86864ca-22f1-4b39-9c12-88250a12b4b5"
      unitRef="usd">-208962000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfNi0xLTEtMS0yODk0Nw_aa00f784-a20f-4901-af67-a06b38d76ef4"
      unitRef="shares">119602000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfNi0zLTEtMS0yODk0Nw_8d68d3da-adc5-4cc6-90cf-7a0f36ada5d0"
      unitRef="shares">109580000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfNi01LTEtMS0yODk0Nw_bea6d411-3b04-40c2-928e-f32f4019dd5a"
      unitRef="shares">119267000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfNi03LTEtMS0yODk0Nw_bcd5d814-2da4-4e5a-b9fd-08c2c7215fe0"
      unitRef="shares">106328000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="icb495f010db54c2ebbb407f2ea54e2ba_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfOC0xLTEtMS0yODk0Nw_ebc91f2b-9267-48cc-bc49-8b8be4445ef5"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="idae99b8ad22540cba6959e639a4bc3d9_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfOC0zLTEtMS0yODk0Nw_ff00a43a-5b51-4dfb-a1e5-4af26479f6f8"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i18c239d8a4b84368b0ec193e679d9382_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfOC01LTEtMS0yODk0Nw_be981fb4-2e06-4c9a-8596-fff1a041857f"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i45292554e7184f898ba749676eba1941_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfOC03LTEtMS0yODk0Nw_3632d162-55c6-4db7-ba3a-8a1111283a0c"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ibd20c886bcbb4ec881a57bf89c5feefa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfOS0xLTEtMS0yODk0Nw_b2fa229a-fed5-4b06-aefb-146186116f9a"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i75d345a205d14a869a001fc3d932ca19_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfOS0zLTEtMS0yODk0Nw_89d81f0d-63da-4e6d-8880-2908a6c9c879"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i32487a941bfc4076b54815cf8c60211b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfOS01LTEtMS0yODk0Nw_2ecb3795-5acd-445f-8a61-a7e9931d6a09"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i5de10744d8f445ae87da00f994d29fcd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfOS03LTEtMS0yODk0Nw_3ed74e1d-947d-46e4-9de2-93ceb074d0b0"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i826dc379d52b4e8d8be78b58060e1979_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTAtMS0xLTEtMzA5OTg_5a0f11e7-ee5e-423e-ba4b-06d50b5dbcd5"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i11458fa48bb841a7b70bf22cafac3a40_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTAtMy0xLTEtMzA5OTg_7dabdf2c-9e87-4685-bc8b-f3be05c0ef8f"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i04f0a1a4c2144c658e9faeab5bacbf34_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTAtNS0xLTEtMjg5NDc_8b1a178e-db44-45ec-85a0-c34cda468d6a"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i0771a886122a4116af16d7e597aac7e8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTAtNy0xLTEtMjg5NDc_952e90a2-9df7-41bb-a5a3-94ae09586a6f"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTEtMS0xLTEtMjg5NDc_bb906f52-85d0-4dc0-bc1c-5f510aee6922"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTEtMy0xLTEtMjg5NDc_9df15973-f5dd-4de3-93f6-8710bf4327c0"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTEtNS0xLTEtMjg5NDc_a6027673-2804-4457-981a-3e2ffa4cbd31"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTEtNy0xLTEtMjg5NDc_0d7c31db-5600-415f-807c-98b8cdeceb94"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTItMS0xLTEtMjg5NDc_d679a62b-f751-4b35-b564-7bb2c96484f0"
      unitRef="shares">119602000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTItMy0xLTEtMjg5NDc_d3bdd63c-99df-41f0-9eb4-73c939730def"
      unitRef="shares">109580000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTItNS0xLTEtMjg5NDc_fb03a1ab-3ccd-42a6-9229-dc5fb9548511"
      unitRef="shares">119267000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTItNy0xLTEtMjg5NDc_33d36e96-f763-4dcf-bf36-ba0231697873"
      unitRef="shares">106328000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTQtMS0xLTEtMjg5NDc_79fdc737-dc90-450b-b615-6e2f199fac6d"
      unitRef="usdPerShare">-0.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTQtMS0xLTEtMjg5NDc_dc9a6b0f-614f-47cd-bcbd-cb8751789c88"
      unitRef="usdPerShare">-0.80</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTQtMy0xLTEtMjg5NDc_60865546-5bcd-4ef1-96b0-88752e49c756"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTQtMy0xLTEtMjg5NDc_9ebb67cd-2d2d-4fa8-bf84-2d04cec0b8ae"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTQtNS0xLTEtMjg5NDc_ad58294b-38af-435f-8d19-121f9a8d00b8"
      unitRef="usdPerShare">-1.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTQtNS0xLTEtMjg5NDc_f88b12c6-0400-4fac-b559-d4c7cc142d17"
      unitRef="usdPerShare">-1.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTQtNy0xLTEtMjg5NDc_d2e5ebd2-0577-47f5-87e7-4d42c07114b3"
      unitRef="usdPerShare">-1.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzYzRkNDQyYTE1MjRmOTM4YzQxNDNkYzc2YTRkMTQ2L3RhYmxlcmFuZ2U6NTNjNGQ0NDJhMTUyNGY5MzhjNDE0M2RjNzZhNGQxNDZfMTQtNy0xLTEtMjg5NDc_e3f99b0e-9b87-4e22-b3d5-c5b842b3074a"
      unitRef="usdPerShare">-1.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNzg_3e105956-5f00-41c8-b854-a54476ea5912">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of June&#160;30, 2022 and 2021, respectively, as their effect would have been anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2f46d4b8f14b4f9a9806c15e65465675_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmRjMzBkNzZkYWMxMjQzNmE5NjBhYzE0NzRhZjVhYzk3L3RhYmxlcmFuZ2U6ZGMzMGQ3NmRhYzEyNDM2YTk2MGFjMTQ3NGFmNWFjOTdfMi0xLTEtMS0yODk0Nw_b96cf7b3-8de1-4c80-a48b-b79f14e51597"
      unitRef="shares">17806000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib57ecc23938042cfa725b197115046c8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmRjMzBkNzZkYWMxMjQzNmE5NjBhYzE0NzRhZjVhYzk3L3RhYmxlcmFuZ2U6ZGMzMGQ3NmRhYzEyNDM2YTk2MGFjMTQ3NGFmNWFjOTdfMi0zLTEtMS0yODk0Nw_066c3997-44b4-4790-80bd-e97ebeab9b6f"
      unitRef="shares">14449000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i88a276ac0d54475b9c03c7440a1608fe_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmRjMzBkNzZkYWMxMjQzNmE5NjBhYzE0NzRhZjVhYzk3L3RhYmxlcmFuZ2U6ZGMzMGQ3NmRhYzEyNDM2YTk2MGFjMTQ3NGFmNWFjOTdfMy0xLTEtMS0yODk0Nw_ca8ccb39-2870-4c1e-91ba-9eaf83dd3a3d"
      unitRef="shares">1619000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1cfd6327542a4ec28651deb81d520e2c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmRjMzBkNzZkYWMxMjQzNmE5NjBhYzE0NzRhZjVhYzk3L3RhYmxlcmFuZ2U6ZGMzMGQ3NmRhYzEyNDM2YTk2MGFjMTQ3NGFmNWFjOTdfMy0zLTEtMS0yODk0Nw_69063923-da28-4695-8f31-c310b3213a7b"
      unitRef="shares">1125000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i62c8f1c4a72145a8a38686730f07d96d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmRjMzBkNzZkYWMxMjQzNmE5NjBhYzE0NzRhZjVhYzk3L3RhYmxlcmFuZ2U6ZGMzMGQ3NmRhYzEyNDM2YTk2MGFjMTQ3NGFmNWFjOTdfNC0xLTEtMS0yODk0Nw_1b3463d4-d9ef-4e5f-bff7-456f9b5b752d"
      unitRef="shares">670000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibaa2f8ddc972496d9af74169e0443d41_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmRjMzBkNzZkYWMxMjQzNmE5NjBhYzE0NzRhZjVhYzk3L3RhYmxlcmFuZ2U6ZGMzMGQ3NmRhYzEyNDM2YTk2MGFjMTQ3NGFmNWFjOTdfNC0zLTEtMS0yODk0Nw_ebc6bf4c-8865-43ea-a8c0-1c896f77976e"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7d56f2cd3eaf416e8ea5e63692228a23_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmRjMzBkNzZkYWMxMjQzNmE5NjBhYzE0NzRhZjVhYzk3L3RhYmxlcmFuZ2U6ZGMzMGQ3NmRhYzEyNDM2YTk2MGFjMTQ3NGFmNWFjOTdfNS0xLTEtMS0yODk0Nw_172e2764-bc44-4f03-9100-54909dcee879"
      unitRef="shares">23438000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2ae9ec03bdda4b058bca71221c9a7996_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOmRjMzBkNzZkYWMxMjQzNmE5NjBhYzE0NzRhZjVhYzk3L3RhYmxlcmFuZ2U6ZGMzMGQ3NmRhYzEyNDM2YTk2MGFjMTQ3NGFmNWFjOTdfNS0zLTEtMS0yODk0Nw_2d794adf-c920-49c4-adbd-576f13223dcf"
      unitRef="shares">23438000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNDY_0e049d87-25ad-4697-84a7-82a029949f27">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for collectible trade receivables. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the six months ended June&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future &lt;/span&gt;&lt;/div&gt;operating results. A change in the relationship with the suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNzk_60270b67-9aac-447f-9625-24876b4c0864">The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the six months ended June&#160;30, 2022 and 2021.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8297b16fe1be40cb95165a0bea1fa1fe_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzZDA5NjBiMGI1NjRiM2Q4M2M2NTAzNmNiMjcwNjQ0L3RhYmxlcmFuZ2U6NTNkMDk2MGIwYjU2NGIzZDgzYzY1MDM2Y2IyNzA2NDRfMi0xLTEtMS0yODk0Nw_dda8ae57-e37f-4b2e-b87e-70d9908c1c6e"
      unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i34fcb92cc2b441f1a0c7f4c6e848c031_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzZDA5NjBiMGI1NjRiM2Q4M2M2NTAzNmNiMjcwNjQ0L3RhYmxlcmFuZ2U6NTNkMDk2MGIwYjU2NGIzZDgzYzY1MDM2Y2IyNzA2NDRfMi0zLTEtMS0yODk0Nw_43b6c1cb-d060-4156-b39d-22c4a4f02c3b"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8f40504b772844eb858783a727551877_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzZDA5NjBiMGI1NjRiM2Q4M2M2NTAzNmNiMjcwNjQ0L3RhYmxlcmFuZ2U6NTNkMDk2MGIwYjU2NGIzZDgzYzY1MDM2Y2IyNzA2NDRfMy0xLTEtMS0yODk0Nw_f927fb54-4d2c-4d21-a011-9ff65f0b55b7"
      unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i661418bb0674414b9010ff5b70067d3d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzZDA5NjBiMGI1NjRiM2Q4M2M2NTAzNmNiMjcwNjQ0L3RhYmxlcmFuZ2U6NTNkMDk2MGIwYjU2NGIzZDgzYzY1MDM2Y2IyNzA2NDRfMy0zLTEtMS0yODk0Nw_785826e4-5c4f-48ac-966f-532950769d7f"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i30c3f2d8839a4faa9a1c05047301e4f7_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzZDA5NjBiMGI1NjRiM2Q4M2M2NTAzNmNiMjcwNjQ0L3RhYmxlcmFuZ2U6NTNkMDk2MGIwYjU2NGIzZDgzYzY1MDM2Y2IyNzA2NDRfNC0xLTEtMS0yODk0Nw_b61c82b8-2b62-4810-88c9-d00afa3e8efc"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if5334091cc884a859ad2228b90a2795f_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUzZDA5NjBiMGI1NjRiM2Q4M2M2NTAzNmNiMjcwNjQ0L3RhYmxlcmFuZ2U6NTNkMDk2MGIwYjU2NGIzZDgzYzY1MDM2Y2IyNzA2NDRfNC0zLTEtMS0yODk0Nw_98987177-fc88-4038-9006-39c023d7e58e"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNzY_25811d64-bd55-4c56-8fb6-2aaf9835b330">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- In accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract to determine which are performance obligations and to assess whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenues, net consist of net sales of ARIKAYCE. The Company's customers in the US include specialty pharmacies and specialty distributors. In December 2020, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Europe. In July 2021, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Japan. Globally, product revenues are recognized once the Company performs and satisfies all five steps of the revenue recognition criteria mentioned above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the Company's product revenues, net, by geographic location for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.854%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe and rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total product revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer credits: The Company's customers are offered various forms of consideration, including prompt payment discounts. The payment terms for sales to specialty pharmacies for prompt payment discounts are based on contractual rates agreed with the respective specialty pharmacies. The Company anticipates that its customers will earn these discounts and, therefore, deducts the full amount of these discounts from total gross product revenues at the time such revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates: The Company contracts with government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accrued liabilities on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also recognizes revenue related to various early access programs (EAPs) in Europe, predominantly in France. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNjI_1272141b-c7a5-4f4e-9df2-680a842db996">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the Company's product revenues, net, by geographic location for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.854%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe and rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total product revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b44c6e566f24a9882c1b3f8f3b4c0ee_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfMi0xLTEtMS0yODk0Nw_484212d3-e35e-4d23-9f8f-a043fc090050"
      unitRef="usd">47190000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea9322ea7e7a46f9bb59dc10b38f0897_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfMi0zLTEtMS0yODk0Nw_7db51831-ed5c-47bf-a77e-a9df69df4b91"
      unitRef="usd">41754000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1448668a7228445d80ba936243ca7fe7_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfMi01LTEtMS0yODk0Nw_e5d1f8cb-cf64-4979-9fc0-935a64cd4c37"
      unitRef="usd">87972000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5726053c5da4536a1e11ec19e99b532_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfMi03LTEtMS0yODk0Nw_974547ce-f18d-4008-aba8-f98834dd4e35"
      unitRef="usd">79008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3bed069934724804b94a28374dea16e9_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfMy0xLTEtMS0yODk0Nw_a081daa3-8c92-440e-b1e5-44a210edd2b7"
      unitRef="usd">15849000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6931c30dc02f44cf8d0a90632e1f5ce4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfMy0zLTEtMS0yODk0Nw_bdd6195c-9acb-4b9e-be17-ad18ba6f7104"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80224a3dd22c4d58966aae71eacb8cc4_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfMy01LTEtMS0yODk0Nw_78f25cac-5833-40bb-ad9c-4c309b74c765"
      unitRef="usd">26525000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cd49603d9354e39a28f04178c247b10_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfMy03LTEtMS0yOTczNg_f91b10eb-baa5-430c-810d-7d9854fc6548"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e5abaf4f46249c2b605b4b4d53db50a_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfNC0xLTEtMS0yODk0Nw_b8de8a18-c191-40ce-ad1a-fdc0452ff468"
      unitRef="usd">2182000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad77b69398bc4c9dbef47393b9c7c0e7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfNC0zLTEtMS0yODk0Nw_b487aa16-9086-41bb-9b2e-435018f3d2ba"
      unitRef="usd">3612000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1df549ad601429bbc4b64c37aee2eb3_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfNC01LTEtMS0yODk0Nw_41433c15-b66c-4377-93e3-f295d95ec2d7"
      unitRef="usd">3831000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77947eb926944d7f9ef2b3f148ffcb51_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfNC03LTEtMS0yODk0Nw_ca506835-b4af-49c4-8d03-f20065c38522"
      unitRef="usd">6572000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfNS0xLTEtMS0yODk0Nw_2b164e93-715e-4027-b4f0-e338704cf100"
      unitRef="usd">65221000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfNS0zLTEtMS0yODk0Nw_f6e56e75-3252-4692-880a-06ae7e5cdf71"
      unitRef="usd">45366000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfNS01LTEtMS0yODk0Nw_530c3a39-4972-4b26-bbed-143ebe990715"
      unitRef="usd">118328000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RhYmxlOjUxYTMzYThjYTRmOTQ0NTBiMjAzYzU2MmQyYWI0NzEwL3RhYmxlcmFuZ2U6NTFhMzNhOGNhNGY5NDQ1MGIyMDNjNTYyZDJhYjQ3MTBfNS03LTEtMS0yODk0Nw_d8f2ed00-1782-4c86-b74a-95dcc6fa44b8"
      unitRef="usd">85580000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <insm:InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNTg_41b22ea3-77e4-4819-affb-3b54e4b34874">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory and Cost of Product Revenues (excluding amortization of intangible assets) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- Inventory is stated at the lower of cost and net realizable value. The Company began capitalizing inventory costs following US Food and Drug Administration (FDA) approval of ARIKAYCE in September 2018. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestone payments. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to FDA approval of ARIKAYCE, the Company expensed all inventory-related costs in the period incurred. Inventory used for clinical development purposes is expensed to R&amp;amp;D expense when consumed.&lt;/span&gt;&lt;/div&gt;</insm:InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyODE_73d6c496-6f56-4e0b-bf8a-50756c7d72ab">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business combinations and asset acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration for the Company&#x2019;s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets&#x2019; carrying amounts on the acquiring entity&#x2019;s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNjM_567f0cef-a4ac-4796-8970-f086a2256162">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indefinite-lived intangible assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- Indefinite-lived intangible assets consist of In Process Research &amp;amp; Development (IPR&amp;amp;D). IPR&amp;amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;amp;D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&amp;amp;D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#x2019;s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company&#x2019;s outlook and market performance of the Company&#x2019;s industry and recent and forecasted financial performance. The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finite-lived Intangible Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- Finite-lived intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the acquired ARIKAYCE R&amp;amp;D intangible asset, at the date of subsequent adjustments of fair value. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment Assessment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing to the carrying value of the assets to the fair value of the assets. The Company determined that no indicators of impairment of finite-lived intangible assets or long-lived assets existed at June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;Goodwill - Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#x2019;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassesses its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company will perform its next annual impairment testing for goodwill on October 1, 2022.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNjE_0a3db3d9-835a-4c7c-83ca-3e12a808ff65">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in &lt;/span&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7 - Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for details about the Company's lease portfolio, including required disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNjk_c546d673-657e-487b-bbc1-9baddc67b3ca">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also promote consistent application of and simplify US generally accepted accounting principles (GAAP) for other areas of Topic 740 by clarifying and amending the existing guidance. For public business entities, the guidance was effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. The Company adopted this guidance January 1, 2021. The adoption of the guidance did not have a material impact on the Company's consolidated financial statements and accompanying notes.&lt;/span&gt;In August 2020, the FASB issued &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyNTQ_a1983cb3-6ebb-4561-babb-c381ced619fe"&gt;ASU 2020-06&lt;/span&gt;, Debt &#x2014; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, to reduce the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. For convertible instruments, the number of accounting models for convertible debt instruments is reduced, which results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Only convertible instruments that meet the definition of a derivative or are issued with substantial premiums will continue to be subject to the separation models. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and a share of convertible preferred stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation and recognition as derivatives. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021. The Company transitioned using the modified retrospective method. The impact of adopting ASU 2020-06 on January 1, 2022 resulted in an opening balance sheet adjustment increasing debt by $221.9&#160;million, increasing issuance costs classified to debt by $6.1&#160;million, decreasing the deferred tax liability by $1.4&#160;million, and causing an increase to retained earnings of $50.2 million, with an offsetting reduction to additional paid-in-capital of $264.6 million, net of tax.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iefdd31e6154343f0a080337167a74a77_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMwMTI_b234aa0e-136c-414f-9ac8-8cf000c3013a"
      unitRef="usd">221900000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="iefdd31e6154343f0a080337167a74a77_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMwNjQ_777c12ac-3c62-4dbe-8b5a-9aa9170df321"
      unitRef="usd">6100000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="iefdd31e6154343f0a080337167a74a77_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMxMDk_0b8ad9eb-77d2-472f-bb9d-159771786fe1"
      unitRef="usd">-1400000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ieaf84c60d3d749089c4d2329ec941ffe_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMxNjE_05e1c47a-c014-4259-86b0-abb8137bbe5d"
      unitRef="usd">50200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iefdd31e6154343f0a080337167a74a77_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNC9mcmFnOjJhNjMwZTdlZGM0MjRjMTlhZDA5YWI0MjU3ZmI0ZDI3L3RleHRyZWdpb246MmE2MzBlN2VkYzQyNGMxOWFkMDlhYjQyNTdmYjRkMjdfMzMyMjc_12737303-729e-4521-9773-a3883821989b"
      unitRef="usd">-264600000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RleHRyZWdpb246YzA3NmQyZjlhY2VhNGIwMTlkM2YyMjFjZGM1NGUwNjBfNTY1_ffce17e9-a112-4587-8052-54351fa7b2ab">Inventory&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022 and December&#160;31, 2021, the Company's inventory balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company began capitalizing inventory costs following FDA approval of ARIKAYCE in September 2018. The Company has not recorded any significant inventory write-downs since that time. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RleHRyZWdpb246YzA3NmQyZjlhY2VhNGIwMTlkM2YyMjFjZGM1NGUwNjBfNTY2_9d9707a5-6bd6-41f4-96da-0b833edd4741">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022 and December&#160;31, 2021, the Company's inventory balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RhYmxlOjFlYzU5YTFmNzQ5ZjQ5ZGVhNDZkYzM0ZjcxZjJmYmY0L3RhYmxlcmFuZ2U6MWVjNTlhMWY3NDlmNDlkZWE0NmRjMzRmNzFmMmZiZjRfMi0xLTEtMS0yODk0Nw_f72f27d2-36d1-42d7-9573-2d055ca2c77e"
      unitRef="usd">29320000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RhYmxlOjFlYzU5YTFmNzQ5ZjQ5ZGVhNDZkYzM0ZjcxZjJmYmY0L3RhYmxlcmFuZ2U6MWVjNTlhMWY3NDlmNDlkZWE0NmRjMzRmNzFmMmZiZjRfMi0zLTEtMS0yODk0Nw_9824613b-cc78-4e0a-8226-92c30f5585c5"
      unitRef="usd">29541000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RhYmxlOjFlYzU5YTFmNzQ5ZjQ5ZGVhNDZkYzM0ZjcxZjJmYmY0L3RhYmxlcmFuZ2U6MWVjNTlhMWY3NDlmNDlkZWE0NmRjMzRmNzFmMmZiZjRfMy0xLTEtMS0yODk0Nw_b8d4c80e-c714-4a73-9b44-37ffab41dc8c"
      unitRef="usd">15908000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RhYmxlOjFlYzU5YTFmNzQ5ZjQ5ZGVhNDZkYzM0ZjcxZjJmYmY0L3RhYmxlcmFuZ2U6MWVjNTlhMWY3NDlmNDlkZWE0NmRjMzRmNzFmMmZiZjRfMy0zLTEtMS0yODk0Nw_fce72d94-e60d-42a3-98d6-c456034b540d"
      unitRef="usd">18528000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RhYmxlOjFlYzU5YTFmNzQ5ZjQ5ZGVhNDZkYzM0ZjcxZjJmYmY0L3RhYmxlcmFuZ2U6MWVjNTlhMWY3NDlmNDlkZWE0NmRjMzRmNzFmMmZiZjRfNC0xLTEtMS0yODk0Nw_0cd5d02e-572b-481e-ad1d-4b8dc1025aff"
      unitRef="usd">21789000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RhYmxlOjFlYzU5YTFmNzQ5ZjQ5ZGVhNDZkYzM0ZjcxZjJmYmY0L3RhYmxlcmFuZ2U6MWVjNTlhMWY3NDlmNDlkZWE0NmRjMzRmNzFmMmZiZjRfNC0zLTEtMS0yODk0Nw_8beb5633-27da-4245-917d-dd3651abac81"
      unitRef="usd">18940000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RhYmxlOjFlYzU5YTFmNzQ5ZjQ5ZGVhNDZkYzM0ZjcxZjJmYmY0L3RhYmxlcmFuZ2U6MWVjNTlhMWY3NDlmNDlkZWE0NmRjMzRmNzFmMmZiZjRfNS0xLTEtMS0yODk0Nw_2edf4095-e82f-448d-845e-2424fa85d88e"
      unitRef="usd">67017000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV8zNy9mcmFnOmMwNzZkMmY5YWNlYTRiMDE5ZDNmMjIxY2RjNTRlMDYwL3RhYmxlOjFlYzU5YTFmNzQ5ZjQ5ZGVhNDZkYzM0ZjcxZjJmYmY0L3RhYmxlcmFuZ2U6MWVjNTlhMWY3NDlmNDlkZWE0NmRjMzRmNzFmMmZiZjRfNS0zLTEtMS0yODk0Nw_afa6c68b-3f1c-41a0-9ed2-febb63e0eed2"
      unitRef="usd">67009000</us-gaap:InventoryNet>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfMTIyMw_88912313-1ef1-46a7-9ce3-b3252396d178">Intangibles, Net and Goodwill&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangibles, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Finite-lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&amp;amp;D and the milestones paid to PARI Pharma GmbH (PARI) for the license to use PARI's Lamira&#xae; Nebulizer System (Lamira) for the delivery of ARIKAYCE to patients as a result of the FDA and EC approvals of ARIKAYCE in September 2018 and October 2020, respectively. The Company began amortizing its acquired ARIKAYCE R&amp;amp;D and PARI milestones intangible assets in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;October 2018, over ARIKAYCE's initial regulatory exclusivity period of 12 years. Amortization of these assets during each of the next five years is estimated to be approximately $5.1 million per year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indefinite-lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the Company's indefinite-lived intangible assets consisted of acquired in process research and development (IPR&amp;amp;D) from the Business Acquisition (Note 13). Indefinite-lived intangible assets are not amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A rollforward of the Company's intangible assets for the six months ended June 30, 2022 and June&#160;30, 2021 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Intangible Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired ARIKAYCE R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PARI milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Intangible Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired ARIKAYCE R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PARI milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;The Company's goodwill balance of $136.1 million as of June&#160;30, 2022, resulted from the Business Acquisition (Note 13).</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfNjM5_7e25c660-2a4f-4035-ae33-80c809dd753f">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfNzQw_21027bfe-ecf2-433a-969e-5f8d5ce676ef"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfNzQw_2521f9ad-60b9-463a-af9d-5ed56270386d"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfNzQw_26f07fe2-18b9-4885-9619-16979d7bf41e"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfNzQw_4d9e95f2-45ab-484f-a9e1-2af45fdc734f"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfNzQw_c64930ac-1273-4e3e-a375-7bdc90a59de6"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfMTIyMA_a5072df4-aec4-4c2a-a189-c2ec8a57afa4">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A rollforward of the Company's intangible assets for the six months ended June 30, 2022 and June&#160;30, 2021 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Intangible Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired ARIKAYCE R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PARI milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Intangible Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired ARIKAYCE R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PARI milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if1380329539b4132829f56ecd925fdf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMi0xLTEtMS0yODk0Nw_90f802ce-90cf-4740-a5fe-55009a297218"
      unitRef="usd">42439000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i7cd9cfdd737546e99d0b622013e7ca48_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMi0zLTEtMS0yODk0Nw_7884990d-44e5-4548-97d2-a8ce66d58355"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7cd9cfdd737546e99d0b622013e7ca48_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMi01LTEtMS0yODk0Nw_c66ba15a-03c6-4266-91cd-e7c304c8cc12"
      unitRef="usd">2425000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifc4ec61359d24f0caa4c62d971da1288_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMi03LTEtMS0yODk0Nw_a8607716-00fa-46d1-9074-bfe03ab6c533"
      unitRef="usd">40014000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i278371e151d544e6a212c9d2aa2a655b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMy0xLTEtMS0yODk0Nw_de415bdd-5694-4e44-8ca7-931c65ff9408"
      unitRef="usd">29600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i0dd5b90d56364a53a5da8bdf154bec64_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMy0zLTEtMS0yODk0Nw_71c6d90f-30b7-4609-a086-eb1d1c7387a7"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0dd5b90d56364a53a5da8bdf154bec64_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMy01LTEtMS0yODk0Nw_7cf78a5a-70cd-47a8-9720-50260bfe5281"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ife46a9fb88034d28981626beb4a29946_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMy03LTEtMS0yODk0Nw_6add4a08-fe38-4f31-9f65-47b23982e1bf"
      unitRef="usd">29600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5640268efe1f4be6b786aed558989d41_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfNC0xLTEtMS0yODk0Nw_6c18e19d-fa9a-4b92-bb77-66937a0ac8c2"
      unitRef="usd">1770000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i2b3c794885af4e1f921fd241ba143529_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfNC0zLTEtMS0yODk0Nw_fd1a4691-6647-47b4-ac01-8051d626a0e8"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2b3c794885af4e1f921fd241ba143529_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfNC01LTEtMS0yODk0Nw_2dfba3d7-622b-494d-b42f-2a9b87210abe"
      unitRef="usd">101000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0f13532abba943b0b557fd68637dbf22_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfNC03LTEtMS0yODk0Nw_7fc677ea-78da-4f90-b0ce-2697f10845e7"
      unitRef="usd">1669000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfNS0xLTEtMS0yODk0Nw_4df069e6-5f34-475b-bfb0-fe51dee5121f"
      unitRef="usd">73809000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfNS0zLTEtMS0yODk0Nw_f6e3d262-1f5d-46b0-878d-37088401e1ed"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfNS01LTEtMS0yODk0Nw_63a0c0be-3372-4112-b3e3-e7909db4b630"
      unitRef="usd">2526000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfNS03LTEtMS0yODk0Nw_1421e04d-25f1-4cb8-b595-ca1760c4bbff"
      unitRef="usd">71283000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i413f715068c444d2a9f6c5865f2e54fa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfOC0xLTEtMS0yODk0Nw_601608ec-c6a7-4d1e-958a-c1e46e87d491"
      unitRef="usd">47289000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i58319fe25f124f3b8246c1b27bb7cb08_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfOC0zLTEtMS0yODk0Nw_31efb23d-aa94-4680-a4e6-b5e84d5cc756"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i58319fe25f124f3b8246c1b27bb7cb08_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfOC01LTEtMS0yODk0Nw_ff0254d0-112b-4e77-9485-498a8ab086e7"
      unitRef="usd">2425000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iefdd99d19aab444dbfcd286f3daa9339_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfOC03LTEtMS0yODk0Nw_687ffae4-48e1-4393-ab62-83b8890d162d"
      unitRef="usd">44864000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1686617c86b644caae372fe8d75fcec3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMTAtMS0xLTEtMjg5NDc_4e32330e-3031-4118-8651-a7be5ce80acb"
      unitRef="usd">1972000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="if38a8d02ea544cb4b9317034c9910cb3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMTAtMy0xLTEtMjg5NDc_1500e983-9fdd-49f4-ba2f-5f67ef0266cb"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if38a8d02ea544cb4b9317034c9910cb3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMTAtNS0xLTEtMjg5NDc_354081a1-0265-497a-8913-51aea1c79f3a"
      unitRef="usd">101000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id72977157672403489742e38fb8ca59b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMTAtNy0xLTEtMjg5NDc_b0792863-1619-4f93-8d4f-90fdd7a5a755"
      unitRef="usd">1871000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic11e1e3142e048009002fc987716b4e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMTEtMS0xLTEtMjg5NDc_f09e0353-ac18-4688-a4de-77f76524d4d3"
      unitRef="usd">49261000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMTEtMy0xLTEtMjg5NDc_d9640a95-3b9a-4265-8e29-2b7f22a35f65"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMTEtNS0xLTEtMjg5NDc_872e0358-789c-4927-9a6c-9b8b8b3297c0"
      unitRef="usd">2526000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i34b29fd1e2a04660a3bb612c3f24dde5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RhYmxlOmMzZTIwZjQzMzdhMDRhZWZhMGFkYmFjYjI0MTY1NWI0L3RhYmxlcmFuZ2U6YzNlMjBmNDMzN2EwNGFlZmEwYWRiYWNiMjQxNjU1YjRfMTEtNy0xLTEtMjg5NDc_ce0b197e-1e67-4497-9c9b-532547696b51"
      unitRef="usd">46735000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80MC9mcmFnOmE1Y2E4YjkwYWI2MDQ2MmJiOWVlMzY2NjUwNzM2NzY5L3RleHRyZWdpb246YTVjYThiOTBhYjYwNDYyYmI5ZWUzNjY2NTA3MzY3NjlfMTE1NA_51e87c31-8405-4a0f-85be-c322f2eed211"
      unitRef="usd">136100000</us-gaap:Goodwill>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RleHRyZWdpb246MDIyZDViNzAxOWJlNDQxOTk2ZmZjOWUxYjU4ZjA4Y2ZfMTU3_097f0cf7-5e61-4a94-8c10-8ebd2d48108e">Fixed Assets, Net&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Useful Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress (CIP)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,061)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RleHRyZWdpb246MDIyZDViNzAxOWJlNDQxOTk2ZmZjOWUxYjU4ZjA4Y2ZfMTU4_5c57161c-5a14-4468-b74d-5c8b9288f7ce">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Useful Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress (CIP)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,061)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i344bca01b9d34f3aa441d482b0f2f475_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMy0yLTEtMS0yODk0Nw_458ec0a6-e180-4ff3-bced-dee9f61867c0">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7c4bd98ffad14ac78e43425f54977d3d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMy00LTEtMS0yODk0Nw_58522dc5-cb5b-463d-976c-e9d2b33c7005"
      unitRef="usd">14144000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iedecef4e6b1d4166a9b79f3e0c853064_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMy02LTEtMS0yODk0Nw_69d8eed7-2513-429b-97aa-f05ee8a1a599"
      unitRef="usd">11862000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i51ea7721be4640ed9298ced46bffdeae_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNC0yLTEtMS0yODk0Nw_0d71d33d-1790-479c-aee8-8ff0b5d04658">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icb7b544503ac43e48d6444664e6c74da_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNC00LTEtMS0yODk0Nw_7c82ce01-d3e6-4e5a-9d11-d16698b5e909"
      unitRef="usd">6306000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i805564f130794c159907d4cd7218c011_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNC02LTEtMS0yODk0Nw_19626c8f-5bc0-4ca2-86a7-cd08bc744e53"
      unitRef="usd">5799000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iaef54a8191e044bf93f11f4bc2a4e911_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNS0yLTEtMS0yODk0Ny90ZXh0cmVnaW9uOmZlYjA2NzUyNmE1NzQ5MmNiNDM4MGRhNDdiODMwYTk2XzQ_784cb2c3-d4c3-4349-af96-5d157ded768a">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic131085d4cfa45ffaa948fcbbe39e100_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNS0yLTEtMS0yODk0Ny90ZXh0cmVnaW9uOmZlYjA2NzUyNmE1NzQ5MmNiNDM4MGRhNDdiODMwYTk2Xzc_371f242a-ea87-484c-b932-f10f8d2730c4">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i74052c73b62e4b3ca8e440d6a7b6b48a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNS00LTEtMS0yODk0Nw_eba44f83-3974-490a-946c-65e19e62482d"
      unitRef="usd">7053000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia326b8c20ab24d99baac8636d47b1d21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNS02LTEtMS0yODk0Nw_363a7618-21c6-43c4-9e54-46fec06c6c9d"
      unitRef="usd">7264000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1378d80bd52a41168942eacca8002c0e_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNi0yLTEtMS0yODk0Nw_b60bd648-ba84-4324-90d4-5be5ec378be9">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i34f0289767e04e32a7cfdbeba5d34a52_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNi00LTEtMS0yODk0Nw_c91cd72f-3cfd-4b35-8c04-7a087c8457ff"
      unitRef="usd">89000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1eae84db78bc47d8b25e7ed4a65b6f34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNi02LTEtMS0yODk0Nw_2679e3dc-4e4e-480f-83d3-b4db35f802bf"
      unitRef="usd">89000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4791157952514b1fb66954d88f405f1a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNy0yLTEtMS0yODk0Nw_5d7ac262-b075-4a33-b14a-f6d68d5cc224">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i483f5f82cf52494c8e648b074f86b53e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNy00LTEtMS0yODk0Nw_8ef81da7-a780-4da3-8108-3fc11563c8a5"
      unitRef="usd">1203000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if7daf1615bf64212badeff54cd466033_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfNy02LTEtMS0yODk0Nw_e2106dfd-6ecb-486b-91f3-4499aa7a0b8a"
      unitRef="usd">1145000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0ce4bf905b02467b8dfd8172fa04331a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfOC0yLTEtMS0yODk0Ny90ZXh0cmVnaW9uOmQ0ODRkYmI3YTNiYzQwYTZiNThlMTMwZTNmZTNjNTQ4XzE2NDkyNjc0NDE2NzI_df41f858-cf72-4cd7-9511-35a65b9d2ca1">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="icfd0d2a201514ed9a710f3e15a4be0ec_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfOC0yLTEtMS0yODk0Ny90ZXh0cmVnaW9uOmQ0ODRkYmI3YTNiYzQwYTZiNThlMTMwZTNmZTNjNTQ4XzE2NDkyNjc0NDE2NzY_393027cc-ccc6-49f9-9c6e-1cb60ee29506">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibf90ef381262457fb02ac15abe61db23_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfOC00LTEtMS0yODk0Nw_230f3303-5bfe-47d0-950a-46ad3f256daf"
      unitRef="usd">37009000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5ff8e585d8da4a4eadbb4f76e2229297_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfOC02LTEtMS0yODk0Nw_450e3efd-5881-4ad1-bb6a-5833ad0cbfc0"
      unitRef="usd">36073000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7bcb57d4e9ec41c3913ce6375172ce80_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfOS00LTEtMS0yODk0Nw_6767c663-b0ed-4402-a659-04bd16c61997"
      unitRef="usd">27447000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id1e1185e028b41649a95d8db0860d1ed_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfOS02LTEtMS0yODk0Nw_81a45d3e-6fa2-41f6-9126-c31df74dd490"
      unitRef="usd">27784000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMTAtNC0xLTEtMjg5NDc_3e32329c-695d-4a13-9e56-b45e8eec2ba3"
      unitRef="usd">93251000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMTAtNi0xLTEtMjg5NDc_aecf528a-3f1d-42e4-a10d-023d5e39cba3"
      unitRef="usd">90016000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMTEtNC0xLTEtMjg5NDc_1249cd34-7e50-4e66-af5e-3f7bca02e5f4"
      unitRef="usd">39305000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMTEtNi0xLTEtMjg5NDc_5985298a-1c1e-4cc2-9c56-6bda7f5b035e"
      unitRef="usd">37061000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMTItNC0xLTEtMjg5NDc_cd67cc9a-e896-42cc-b01e-57108ac45f9b"
      unitRef="usd">53946000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80My9mcmFnOjAyMmQ1YjcwMTliZTQ0MTk5NmZmYzllMWI1OGYwOGNmL3RhYmxlOjg3YmZhNjk3MGJiODQ0YTBhMmM2NTNkN2QxNWMxM2RkL3RhYmxlcmFuZ2U6ODdiZmE2OTcwYmI4NDRhMGEyYzY1M2Q3ZDE1YzEzZGRfMTItNi0xLTEtMjg5NDc_b2e92b16-fc50-4d17-ba70-c94040fc2c78"
      unitRef="usd">52955000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RleHRyZWdpb246MzEzMzE4MTQ5NTE4NDNlNjgxNGYyODNiMDYyODU4MmZfMTcw_ee7ea84a-e066-4547-bd81-cd1097a03354">Accrued Liabilities&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022 and December&#160;31, 2021, the Company's accrued liabilities balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued technical operation expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalty payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales allowances and related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RleHRyZWdpb246MzEzMzE4MTQ5NTE4NDNlNjgxNGYyODNiMDYyODU4MmZfMTcy_218c405c-e15c-4a6d-ade4-b14c92365a79">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022 and December&#160;31, 2021, the Company's accrued liabilities balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued technical operation expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalty payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales allowances and related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <insm:AccruedClinicalTrialExpenses
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfMS0xLTEtMS0yODk0Nw_cea52145-c282-4963-bc3d-d0bf4c35425a"
      unitRef="usd">17019000</insm:AccruedClinicalTrialExpenses>
    <insm:AccruedClinicalTrialExpenses
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfMS0zLTEtMS0yODk0Nw_0df72799-a996-42b2-befe-150ca800d2e6"
      unitRef="usd">19410000</insm:AccruedClinicalTrialExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfMi0xLTEtMS0yODk0Nw_76cba81f-f178-449f-91ba-f834b47b73b3"
      unitRef="usd">11336000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfMi0zLTEtMS0yODk0Nw_4cab2f77-51c0-482b-97be-026638649a56"
      unitRef="usd">10678000</us-gaap:AccruedProfessionalFeesCurrent>
    <insm:AccruedTechnicalOperationExpenses
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfMy0xLTEtMS0yODk0Nw_1925ea72-bb80-4b67-be7f-680167087792"
      unitRef="usd">4816000</insm:AccruedTechnicalOperationExpenses>
    <insm:AccruedTechnicalOperationExpenses
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfMy0zLTEtMS0yODk0Nw_938a893c-88c9-4438-9770-5a04ef648447"
      unitRef="usd">6187000</insm:AccruedTechnicalOperationExpenses>
    <insm:AccruedRoyaltiesAndMilestonePaymentsCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfNC0xLTEtMS0yODk0Nw_4ec06238-bcf4-4de8-bf35-b92161951d58"
      unitRef="usd">7182000</insm:AccruedRoyaltiesAndMilestonePaymentsCurrent>
    <insm:AccruedRoyaltiesAndMilestonePaymentsCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfNC0zLTEtMS0yODk0Nw_4fa62d47-6f9f-4904-b250-7562bfaaa3bb"
      unitRef="usd">6655000</insm:AccruedRoyaltiesAndMilestonePaymentsCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfNS0xLTEtMS0yODk0Nw_436fac95-3c41-4302-b591-c915cf60902f"
      unitRef="usd">2175000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfNS0zLTEtMS0yODk0Nw_f92a929f-71a3-4e7f-8b52-059e82e09ecd"
      unitRef="usd">2175000</us-gaap:InterestPayableCurrent>
    <insm:AccruedSalesAllowancesAndRelatedCosts
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfNi0xLTEtMS0yODk0Nw_bf95da8b-c03a-4a39-bb2f-54988665b4eb"
      unitRef="usd">11470000</insm:AccruedSalesAllowancesAndRelatedCosts>
    <insm:AccruedSalesAllowancesAndRelatedCosts
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfNi0zLTEtMS0yODk0Nw_71501136-e310-449d-a05e-7730555acbf0"
      unitRef="usd">8275000</insm:AccruedSalesAllowancesAndRelatedCosts>
    <insm:BusinessCombinationDeferredPaymentsCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfNy0xLTEtMS0yODk0Nw_a7205b21-ae47-4b7e-bd84-3701530b1f0d"
      unitRef="usd">3459000</insm:BusinessCombinationDeferredPaymentsCurrent>
    <insm:BusinessCombinationDeferredPaymentsCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfNy0zLTEtMS0yODk0Nw_dd39e2ff-e5d3-4ca3-929b-10321215c70b"
      unitRef="usd">4883000</insm:BusinessCombinationDeferredPaymentsCurrent>
    <insm:AccruedConstructionLiabilitiesCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfOC0xLTEtMS0yODk0Nw_855dcbbe-5242-4d9b-8eb8-22beac9a690b"
      unitRef="usd">105000</insm:AccruedConstructionLiabilitiesCurrent>
    <insm:AccruedConstructionLiabilitiesCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfOC0zLTEtMS0yODk0Nw_d87d8dbf-bc08-40a5-90c4-365c2916eedc"
      unitRef="usd">551000</insm:AccruedConstructionLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfOS0xLTEtMS0yODk0Nw_48d13737-5642-4362-bf1a-60a8d75eed67"
      unitRef="usd">1208000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfOS0zLTEtMS0yODk0Nw_460f9346-e21b-45fb-a6e8-1cb3c8821b6e"
      unitRef="usd">1851000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfMTAtMS0xLTEtMjg5NDc_57b7e41f-7630-42c5-97c9-84463f940f90"
      unitRef="usd">58770000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80Ni9mcmFnOjMxMzMxODE0OTUxODQzZTY4MTRmMjgzYjA2Mjg1ODJmL3RhYmxlOmM5NmE1YTMyMjQ5MjQ1MWJiZWI3YzdkODQ4YzA5ODZhL3RhYmxlcmFuZ2U6Yzk2YTVhMzIyNDkyNDUxYmJlYjdjN2Q4NDhjMDk4NmFfMTAtMy0xLTEtMjg5NDc_d3888018-aa3c-4cc9-9144-fcb1d7018479"
      unitRef="usd">60665000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfMzUxOQ_284f597f-bc62-47ad-a955-6db0b16b352a">Leases&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $1.5 million and $0.2 million for the three months ended June&#160;30, 2022 and 2021, respectively, and $1.6 million and $0.3 million for the six months ended June 30, 2022 and 2021, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the supplemental noncash disclosures of the Company's leases included in its consolidated financial statements (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $36.3 million incurred by the &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company under these additional agreements have been classified within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;other assets in the Company's consolidated balance sheet. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfMzUxOQ_b8e74e8d-bb58-4e82-a355-33328a11e8c9">Leases&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $1.5 million and $0.2 million for the three months ended June&#160;30, 2022 and 2021, respectively, and $1.6 million and $0.3 million for the six months ended June 30, 2022 and 2021, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the supplemental noncash disclosures of the Company's leases included in its consolidated financial statements (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $36.3 million incurred by the &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company under these additional agreements have been classified within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;other assets in the Company's consolidated balance sheet. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.</us-gaap:LesseeFinanceLeasesTextBlock>
    <insm:LeaseRemainingLeaseTerm
      contextRef="iab7551ae213f49089690e61c379022e7_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfNDg1_7a49d804-e392-496b-bafe-57e68b63930f">P1Y</insm:LeaseRemainingLeaseTerm>
    <insm:LeaseRemainingLeaseTerm
      contextRef="i345e38b73d984ac7acfa140fc7af5a1a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfNDkx_cf17fd5f-18d1-46d5-bdc8-0272bde2e54b">P10Y10M</insm:LeaseRemainingLeaseTerm>
    <us-gaap:VariableLeaseCost
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfMTk4Ng_531dcf37-c775-487d-99f0-dbfa44ef9ecb"
      unitRef="usd">1500000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfMTk5Mw_49511a40-3d16-4c33-a97d-12490614a5ac"
      unitRef="usd">200000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfMjc0ODc3OTA3MzAyMA_04eaf325-e29f-4f9c-815f-8468521c9777"
      unitRef="usd">1600000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfMjc0ODc3OTA3MzAyNw_638e51c2-dd74-47a9-b7db-50b28137007b"
      unitRef="usd">300000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfMzUxOA_609ae0f3-3220-4ed5-b81d-5ce7b8ec448e">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the supplemental noncash disclosures of the Company's leases included in its consolidated financial statements (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RhYmxlOjUzMjE1ZTEzNzU2YTRkYTdiYzg3ZjZmZmE3YTUzYjkyL3RhYmxlcmFuZ2U6NTMyMTVlMTM3NTZhNGRhN2JjODdmNmZmYTdhNTNiOTJfMi0xLTEtMS0yODk0Nw_a86f5e56-f55d-4406-a8e9-6daac88ff3a4"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RhYmxlOjUzMjE1ZTEzNzU2YTRkYTdiYzg3ZjZmZmE3YTUzYjkyL3RhYmxlcmFuZ2U6NTMyMTVlMTM3NTZhNGRhN2JjODdmNmZmYTdhNTNiOTJfMi0zLTEtMS0yODk0Nw_aa0a40c3-44cf-4c7d-b22c-a8b2f7d699c6"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RhYmxlOjUzMjE1ZTEzNzU2YTRkYTdiYzg3ZjZmZmE3YTUzYjkyL3RhYmxlcmFuZ2U6NTMyMTVlMTM3NTZhNGRhN2JjODdmNmZmYTdhNTNiOTJfMi01LTEtMS0yODk0Nw_daca5dc4-6730-4dd4-b713-705e1038e0ab"
      unitRef="usd">9287000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RhYmxlOjUzMjE1ZTEzNzU2YTRkYTdiYzg3ZjZmZmE3YTUzYjkyL3RhYmxlcmFuZ2U6NTMyMTVlMTM3NTZhNGRhN2JjODdmNmZmYTdhNTNiOTJfMi03LTEtMS0yODk0Nw_6afd11c7-2583-40fb-86e0-cee9823862c5"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RhYmxlOjUzMjE1ZTEzNzU2YTRkYTdiYzg3ZjZmZmE3YTUzYjkyL3RhYmxlcmFuZ2U6NTMyMTVlMTM3NTZhNGRhN2JjODdmNmZmYTdhNTNiOTJfMy0xLTEtMS0yODk0Nw_fda9daaf-81c5-4541-a9e1-a05e56f5afb4"
      unitRef="usd">166000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RhYmxlOjUzMjE1ZTEzNzU2YTRkYTdiYzg3ZjZmZmE3YTUzYjkyL3RhYmxlcmFuZ2U6NTMyMTVlMTM3NTZhNGRhN2JjODdmNmZmYTdhNTNiOTJfMy0zLTEtMS0yODk0Nw_7145a166-f459-4fbc-8760-1a24a90e2d53"
      unitRef="usd">2100000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RhYmxlOjUzMjE1ZTEzNzU2YTRkYTdiYzg3ZjZmZmE3YTUzYjkyL3RhYmxlcmFuZ2U6NTMyMTVlMTM3NTZhNGRhN2JjODdmNmZmYTdhNTNiOTJfMy01LTEtMS0yODk0Nw_9b876b0c-291d-4970-85c8-4f5c87be3b59"
      unitRef="usd">507000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RhYmxlOjUzMjE1ZTEzNzU2YTRkYTdiYzg3ZjZmZmE3YTUzYjkyL3RhYmxlcmFuZ2U6NTMyMTVlMTM3NTZhNGRhN2JjODdmNmZmYTdhNTNiOTJfMy03LTEtMS0yODk0Nw_d2dbd245-a2e9-4916-aa2e-3ae88e5d10e9"
      unitRef="usd">8641000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <insm:LesseeOperatingLeaseLeaseNotYetCommencedAmount
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV80OS9mcmFnOjNjOGI2YzQ4Yjc0NDRmOTJiOGY5YTM1ZmRmOTg2ZTA5L3RleHRyZWdpb246M2M4YjZjNDhiNzQ0NGY5MmI4ZjlhMzVmZGY5ODZlMDlfMzE4OQ_328b9bd9-30a6-44d2-a718-2257ea088d16"
      unitRef="usd">36300000</insm:LesseeOperatingLeaseLeaseNotYetCommencedAmount>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNzg0OA_62f02a4e-a978-4a17-8978-af56d449c909">Debt&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company completed an underwritten public offering of the 2028 Convertible Notes, in which the Company sold $575.0 million aggregate principal amount of the 2028 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $75.0 million in aggregate principal amount of 2028 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $15.7&#160;million, were approximately $559.3 million. The 2028 Convertible Notes bear interest payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2021. The 2028 Convertible Notes mature on June 1, 2028, unless earlier converted, redeemed, or repurchased. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, the Company completed an underwritten public offering of the 2025 Convertible Notes, in which the Company sold $450.0 million aggregate principal amount of the 2025 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $50.0 million in aggregate principal amount of 2025 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $14.2 million, were approximately $435.8 million. The 2025 Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The 2025 Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of the net proceeds from the 2028 Convertible Notes was used to repurchase $225.0 million of the Company's outstanding 2025 Convertible Notes. The Company recorded a loss on early extinguishment of debt of $17.7 million, primarily related to the premium paid on extinguishment of a portion the 2025 Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after October&#160;15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their 2025 Convertible Notes at any time. The initial conversion rate for the 2025 Convertible Notes is 25.5384 shares of common stock per $1,000 principal amount of 2025 Convertible Notes (equivalent to an initial conversion price of approximately $39.16 per share of common stock). On or after March 1, 2028, until the close of business on the second scheduled trading day immediately preceding June 1, 2028, holders may convert their 2028 Convertible Notes at any time. The initial conversion rate for the 2028 Convertible Notes is 30.7692 shares of common stock per $1,000 principal amount of 2028 Convertible Notes (equivalent to an initial conversion price of approximately $32.50 per share of common stock). Upon conversion of either the 2025 Convertible Notes or the 2028 Convertible Notes, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The conversion rates will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their 2025 Convertible Notes prior to October 15, 2024 or their 2028 Convertible Notes prior to March 1, 2028, only under the following circumstances, subject to the conditions set forth in the applicable indenture: (i) during the five business day period immediately after any five consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of the applicable series of convertible notes, as determined following a request by a holder of such convertible notes, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than 45 days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company's assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding 10% of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the applicable series of convertible notes may be surrendered by a holder for conversion at any time from or after the date that is 30 scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2018 or June 30, 2021 for the 2025 Convertible Notes and the 2028 Convertible Notes, respectively (and only during such calendar quarter), the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, or (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its convertible notes to which the notice of redemption relates for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a)&#160;the second business day immediately preceding the related redemption date or (b)&#160;if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid. To date, there have not been any holder-initiated redemption requests of either series of convertible notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each series of convertible notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in both series of convertible notes are not required to be separately accounted for as a derivative. The 2025 Convertible Notes and 2028 Convertible Notes have remaining terms of approximately 2.54 years and 5.92 years, respectively. The following table presents the carrying value of the Company's debt balance (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.230%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Face value of outstanding convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt issuance costs, unamortized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount on debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt, long-term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, future principal repayments of the notes for each of the years through maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.543%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense related to debt and finance leases for the three and six months ended June&#160;30, 2022 and 2021 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total convertible debt interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the Company's transition using the modified retrospective method upon adopting ASU 2020-06, Debt &#x2014; Accounting for Convertible Instruments, on January 1, 2022, the Company ceased accreting debt discount.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3905fa6bad2f4f878b2411f148bf023a_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMTcy_1cefba15-63ff-4fe4-804b-4b9ffeb39903"
      unitRef="usd">575000000</us-gaap:DebtInstrumentFaceAmount>
    <insm:DebtInstrumentOptionToPurchaseAdditionalDebt
      contextRef="i3905fa6bad2f4f878b2411f148bf023a_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMzE4_b15933bd-24d3-4c96-a3e1-8abf6e9a1f80"
      unitRef="usd">75000000</insm:DebtInstrumentOptionToPurchaseAdditionalDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i3905fa6bad2f4f878b2411f148bf023a_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNTEw_bc44149d-ff86-4e84-9536-d7f0d63e7c21"
      unitRef="usd">15700000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i3b10eb0c1f2944019b12df6a3c668f5b_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNTMz_ff75ef31-e9c0-4a36-afeb-c574be03effc"
      unitRef="usd">559300000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i78d8e00c8ae5498c94772ed4b961f0bb_I20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfOTEy_920d5d10-fa24-4797-ab12-1535e63cbcbc"
      unitRef="usd">450000000</us-gaap:DebtInstrumentFaceAmount>
    <insm:DebtInstrumentOptionToPurchaseAdditionalDebt
      contextRef="i78d8e00c8ae5498c94772ed4b961f0bb_I20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMTA1OA_c0a748d4-d3f9-4427-9914-f7fa94300350"
      unitRef="usd">50000000</insm:DebtInstrumentOptionToPurchaseAdditionalDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i78d8e00c8ae5498c94772ed4b961f0bb_I20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMTI1MA_d071af20-4ea1-4f04-92db-2b430b8948a8"
      unitRef="usd">14200000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ibc290352fb8049bea385a8284c77e6de_D20180101-20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMTI3Mw_90844759-2c3c-4b7f-8192-680d6454e267"
      unitRef="usd">435800000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="i3b3c8791efbd4b76898c1f2be69fa04b_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMTYxMQ_45dd9dc5-00b8-4183-bf10-26222f1cc44e"
      unitRef="usd">225000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2aafae0ef97940e9afdb689e748f167a_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMTczMA_0bc44c9e-58b4-48ef-b31e-86809dfaf15e"
      unitRef="usd">-17700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="iccd7845446c64a369164bb9ead8f5b59_D20180101-20180131"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMjA4OQ_5437fee6-3734-4401-a19d-a50bdd31c946"
      unitRef="number">25.5384</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i78d8e00c8ae5498c94772ed4b961f0bb_I20180131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMjIyOQ_e0de3a19-7ee1-4137-8e2c-c3004aa47212"
      unitRef="usdPerShare">39.16</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i0f13738b91a24ea68cfbd83444c1fda2_D20180101-20180131"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMjUxMQ_4e06a061-5c92-4463-9503-c2cb40c28297"
      unitRef="number">30.7692</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i3905fa6bad2f4f878b2411f148bf023a_I20210531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMjY1MQ_a005b621-15d9-409c-b893-c9bc9e9ef81d"
      unitRef="usdPerShare">32.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i360c8f6cf0d349aa971816bd2ab768a8_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMzMwMA_0b2165cb-623d-427b-af50-8a5abe8a41d6"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i677c8198ab1b4318bd9f81ef52a60fbd_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMzMwMA_30de4bb1-bb15-41dd-b858-00c97c1099d3"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i677c8198ab1b4318bd9f81ef52a60fbd_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMzM0NQ_1a041a52-5bfb-4d0a-a0cf-97307dcf640e"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i360c8f6cf0d349aa971816bd2ab768a8_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMzM0NQ_ed2146b8-390d-48d2-bf3e-2b2e94c5177a"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i677c8198ab1b4318bd9f81ef52a60fbd_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMzY0MA_09fa8de6-1982-4e99-aec5-fed6e06f3b3a"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i360c8f6cf0d349aa971816bd2ab768a8_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfMzY0MA_88b61ef3-a480-48dd-a187-793df27253ce"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i0d34cc38f62945cc8de38c2b34b77333_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNDA5OQ_4eb4c166-734a-4eab-bb95-4910b944c621"
      unitRef="day">45</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i120ab819124c4ec7955b853c7979a0e0_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNDA5OQ_764c19e2-8f96-4956-aad6-b7f2a02c4846"
      unitRef="day">45</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i120ab819124c4ec7955b853c7979a0e0_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNDMyMA_737c6d6f-53d3-44da-94c5-6f9b9a68c41c"
      unitRef="day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i0d34cc38f62945cc8de38c2b34b77333_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNDMyMA_8fa3305a-fb34-454a-bb89-89ced26d27cf"
      unitRef="day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i120ab819124c4ec7955b853c7979a0e0_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNDY2MA_5762dbd9-e16b-4883-884f-a825f6cba314"
      unitRef="number">0.10</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i0d34cc38f62945cc8de38c2b34b77333_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNDY2MA_91eaf0d6-f62a-47d3-bbf1-8ea4079a0dab"
      unitRef="number">0.10</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange
      contextRef="ie08ca784c1914a3d9e58680c070a1adb_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNTU1OA_2c716545-402f-428c-8f02-4bedb94386f8"
      unitRef="day">30</insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange>
    <insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange
      contextRef="ief82ea409318476187e7caeb47194f48_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNTU1OA_30c32a69-853d-433f-8f7e-793901920ef3"
      unitRef="day">30</insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ibbcdfbf9e8254e929522a467310b9522_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNTkzNg_0a74d119-0020-4699-8cd5-33818e3ac440"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ie0d8b12165884f4ab863204524ec1168_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNTkzNg_4eedb926-02e1-4bed-8809-f56a2b42d6da"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ibbcdfbf9e8254e929522a467310b9522_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNjAwMg_98b56e3d-23cb-4303-997d-a50a1ea8b8f1"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ie0d8b12165884f4ab863204524ec1168_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNjAwMg_a2185195-79c1-43d2-a7ff-cf0bdfb7b042"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ibbcdfbf9e8254e929522a467310b9522_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNjEzNQ_1fc410d3-865b-4bdb-84b9-1d540f9d6cd5"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ie0d8b12165884f4ab863204524ec1168_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNjEzNQ_f2b24bf6-45c0-4f1a-b756-23d0184c023d"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <insm:ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining
      contextRef="i82d7c106dda746228e53977a22a4368f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNzI0Mw_12c5a51b-9280-4fb2-898e-dfc56fd12ab4">P2Y6M14D</insm:ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining>
    <insm:ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining
      contextRef="i94cb8d7603c84b26a3152ca2f217dbcf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNzI1MA_5fa48c08-9c7b-44cc-9e74-c28a845c6714">P5Y11M1D</insm:ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNzg1MQ_68e140e9-3e3c-45f3-bfb9-3426bb1d84fe">The following table presents the carrying value of the Company's debt balance (in thousands):&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.230%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Face value of outstanding convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt issuance costs, unamortized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount on debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt, long-term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:SecuredDebt
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjEyY2VhMzFhMWMxMTQ3MGJhN2FmNWJiYjE4YzFmNWRjL3RhYmxlcmFuZ2U6MTJjZWEzMWExYzExNDcwYmE3YWY1YmJiMThjMWY1ZGNfMS0xLTEtMS0yODk0Nw_6178aac6-2eb5-436f-97f1-1f008eb1dbe2"
      unitRef="usd">800000000</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjEyY2VhMzFhMWMxMTQ3MGJhN2FmNWJiYjE4YzFmNWRjL3RhYmxlcmFuZ2U6MTJjZWEzMWExYzExNDcwYmE3YWY1YmJiMThjMWY1ZGNfMS0zLTEtMS0yODk0Nw_3499e579-b47f-4a30-9f3a-b66932fb8444"
      unitRef="usd">800000000</us-gaap:SecuredDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjEyY2VhMzFhMWMxMTQ3MGJhN2FmNWJiYjE4YzFmNWRjL3RhYmxlcmFuZ2U6MTJjZWEzMWExYzExNDcwYmE3YWY1YmJiMThjMWY1ZGNfMi0xLTEtMS0yODk0Nw_9b750a8e-0201-4b7b-92e3-b4aeae65cec1"
      unitRef="usd">16023000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjEyY2VhMzFhMWMxMTQ3MGJhN2FmNWJiYjE4YzFmNWRjL3RhYmxlcmFuZ2U6MTJjZWEzMWExYzExNDcwYmE3YWY1YmJiMThjMWY1ZGNfMi0zLTEtMS0yODk0Nw_50b5bfd3-1b1e-459f-9a9e-dacf0759bd7a"
      unitRef="usd">11539000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjEyY2VhMzFhMWMxMTQ3MGJhN2FmNWJiYjE4YzFmNWRjL3RhYmxlcmFuZ2U6MTJjZWEzMWExYzExNDcwYmE3YWY1YmJiMThjMWY1ZGNfMy0xLTEtMS0yODk0Nw_9bcaf11f-6b9a-422d-8474-4db0a158bf0e"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjEyY2VhMzFhMWMxMTQ3MGJhN2FmNWJiYjE4YzFmNWRjL3RhYmxlcmFuZ2U6MTJjZWEzMWExYzExNDcwYmE3YWY1YmJiMThjMWY1ZGNfMy0zLTEtMS0yODk0Nw_e3d4e8b6-739f-4af0-9560-e1f1e30493ab"
      unitRef="usd">221873000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjEyY2VhMzFhMWMxMTQ3MGJhN2FmNWJiYjE4YzFmNWRjL3RhYmxlcmFuZ2U6MTJjZWEzMWExYzExNDcwYmE3YWY1YmJiMThjMWY1ZGNfNC0xLTEtMS0yODk0Nw_76640a30-ad3f-4fb5-a5fe-ecc21333ce56"
      unitRef="usd">783977000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjEyY2VhMzFhMWMxMTQ3MGJhN2FmNWJiYjE4YzFmNWRjL3RhYmxlcmFuZ2U6MTJjZWEzMWExYzExNDcwYmE3YWY1YmJiMThjMWY1ZGNfNC0zLTEtMS0yODk0Nw_b2e0eedc-cecf-4bd8-bb6f-7e2ec3327afe"
      unitRef="usd">566588000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNzg0NQ_7e9556a8-7510-4403-aa32-ed8fa559e758">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, future principal repayments of the notes for each of the years through maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.543%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOmFkZWU2N2QxNDAwMTQ2YmY4NTVmZGQ1ZjI3ZTEzNzIyL3RhYmxlcmFuZ2U6YWRlZTY3ZDE0MDAxNDZiZjg1NWZkZDVmMjdlMTM3MjJfMS0xLTEtMS0yODk0Nw_46171134-26c4-4fb9-be71-62372253a80b"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOmFkZWU2N2QxNDAwMTQ2YmY4NTVmZGQ1ZjI3ZTEzNzIyL3RhYmxlcmFuZ2U6YWRlZTY3ZDE0MDAxNDZiZjg1NWZkZDVmMjdlMTM3MjJfMi0xLTEtMS0yODk0Nw_30872827-b1ff-435e-8dca-42e5cb2823f6"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOmFkZWU2N2QxNDAwMTQ2YmY4NTVmZGQ1ZjI3ZTEzNzIyL3RhYmxlcmFuZ2U6YWRlZTY3ZDE0MDAxNDZiZjg1NWZkZDVmMjdlMTM3MjJfMy0xLTEtMS0yODk0Nw_3978a6ac-fb8b-44f4-a150-739bf058f53f"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOmFkZWU2N2QxNDAwMTQ2YmY4NTVmZGQ1ZjI3ZTEzNzIyL3RhYmxlcmFuZ2U6YWRlZTY3ZDE0MDAxNDZiZjg1NWZkZDVmMjdlMTM3MjJfNC0xLTEtMS0yODk0Nw_e71ed570-8084-4381-a126-608ea6ecd783"
      unitRef="usd">225000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOmFkZWU2N2QxNDAwMTQ2YmY4NTVmZGQ1ZjI3ZTEzNzIyL3RhYmxlcmFuZ2U6YWRlZTY3ZDE0MDAxNDZiZjg1NWZkZDVmMjdlMTM3MjJfNS0xLTEtMS0yODk0Nw_0c2e34df-634d-4317-aac3-4d09fa0abfb6"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <insm:LongTermDebtMaturityAfterYearFour
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOmFkZWU2N2QxNDAwMTQ2YmY4NTVmZGQ1ZjI3ZTEzNzIyL3RhYmxlcmFuZ2U6YWRlZTY3ZDE0MDAxNDZiZjg1NWZkZDVmMjdlMTM3MjJfNi0xLTEtMS0yODk0Nw_e6916dc7-701f-4beb-bdc5-714bb7f0c8b6"
      unitRef="usd">575000000</insm:LongTermDebtMaturityAfterYearFour>
    <us-gaap:LongTermDebt
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOmFkZWU2N2QxNDAwMTQ2YmY4NTVmZGQ1ZjI3ZTEzNzIyL3RhYmxlcmFuZ2U6YWRlZTY3ZDE0MDAxNDZiZjg1NWZkZDVmMjdlMTM3MjJfNy0xLTEtMS0yODk0Nw_e4ba93d5-ccb6-4ade-bdf5-d32cfa305d01"
      unitRef="usd">800000000</us-gaap:LongTermDebt>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RleHRyZWdpb246MGIwYTZiMmUyN2UzNDQ5MjlkMzg5MjEyNjk3MWE2NmFfNzg1NQ_d7af5d90-ebe7-452c-9ff4-2f2c2081f300">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense related to debt and finance leases for the three and six months ended June&#160;30, 2022 and 2021 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total convertible debt interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebt
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfMi0xLTEtMS0yODk0Nw_6b02a679-e14a-4b93-97a8-58e8d2e48a43"
      unitRef="usd">2062000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfMi0zLTEtMS0yODk0Nw_98f79f6a-8f11-4bb4-89b9-683bb0788174"
      unitRef="usd">2052000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfMi01LTEtMS0yODk0Nw_6ef752f8-8929-4d71-a972-726e9ce2031c"
      unitRef="usd">4125000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfMi03LTEtMS0yODk0Nw_b3a6993f-4104-4f8d-976c-a2411075ce82"
      unitRef="usd">4021000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfMy0xLTEtMS0yODk0Nw_e15af06a-fb4a-42c5-8e0a-5d2cfeff4dff"
      unitRef="usd">821000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfMy0zLTEtMS0yODk0Nw_09f99ae1-39fb-41db-8901-3c724293073b"
      unitRef="usd">457000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfMy01LTEtMS0yODk0Nw_209dc564-8ff7-40c5-ad97-e0de0d8d6755"
      unitRef="usd">1643000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfMy03LTEtMS0yODk0Nw_ebb56437-f05c-4c76-9eef-19b5a328f6ff"
      unitRef="usd">807000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNS0xLTEtMS0yODk0Nw_3285c2b7-5fbd-43bc-91f6-983d136c0647"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNS0zLTEtMS0yODk0Nw_4170eb2c-abbf-47c1-991e-85000cded2bf"
      unitRef="usd">7482000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNS01LTEtMS0yODk0Nw_f34928bb-ba5c-4b6b-8403-ab1968987c76"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNS03LTEtMS0yODk0Nw_98de35f2-7719-445e-a178-e275e62409e6"
      unitRef="usd">12389000</us-gaap:AmortizationOfDebtDiscountPremium>
    <insm:ConvertibleDebtInterestExpenseTotal
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNi0xLTEtMS0yODk0Nw_fe45ee21-054c-4d39-be86-34cb23f9c9c7"
      unitRef="usd">2883000</insm:ConvertibleDebtInterestExpenseTotal>
    <insm:ConvertibleDebtInterestExpenseTotal
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNi0zLTEtMS0yODk0Nw_9db9e5c7-c8b1-4676-b5b1-f7e4ad24ffe6"
      unitRef="usd">9991000</insm:ConvertibleDebtInterestExpenseTotal>
    <insm:ConvertibleDebtInterestExpenseTotal
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNi01LTEtMS0yODk0Nw_d49e9752-0768-4ae9-842c-9cd1e09c9dc7"
      unitRef="usd">5768000</insm:ConvertibleDebtInterestExpenseTotal>
    <insm:ConvertibleDebtInterestExpenseTotal
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNi03LTEtMS0yODk0Nw_7d2973e5-7751-4dc9-89a3-a5b4b0e86206"
      unitRef="usd">17217000</insm:ConvertibleDebtInterestExpenseTotal>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNy0xLTEtMS0yODk0Nw_8375b0cd-e5ca-4cde-ad52-a72b32824aa1"
      unitRef="usd">474000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNy0zLTEtMS0yODk0Nw_e521dd40-c8fb-4706-aee9-8b0a511cc347"
      unitRef="usd">328000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNy01LTEtMS0yODk0Nw_06944604-cfde-4f15-94e2-7df97d4b86b6"
      unitRef="usd">880000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfNy03LTEtMS0yODk0Nw_4da6c5fa-740e-478d-96de-6d325455a510"
      unitRef="usd">661000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfOC0xLTEtMS0yODk0Nw_243fc86d-2979-4214-b0d5-927dcab1ee34"
      unitRef="usd">3357000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfOC0zLTEtMS0yODk0Nw_38b3f48e-a82a-435a-9781-efae54f553bc"
      unitRef="usd">10319000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfOC01LTEtMS0yODk0Nw_3838b551-35f6-4541-a6a7-9ed522c26066"
      unitRef="usd">6648000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81Mi9mcmFnOjBiMGE2YjJlMjdlMzQ0OTI5ZDM4OTIxMjY5NzFhNjZhL3RhYmxlOjczNzZjZDQwODgyYzRiZDZhY2FjYWI3ODU3ODIwZWM2L3RhYmxlcmFuZ2U6NzM3NmNkNDA4ODJjNGJkNmFjYWNhYjc4NTc4MjBlYzZfOC03LTEtMS0yODk0Nw_4bf59a08-b314-4b32-889f-90369e858c55"
      unitRef="usd">17878000</us-gaap:InterestExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMzI4Mw_d1741e3f-3148-4dd9-a910-15d8f1a81bd3">Shareholders&#x2019; Equity&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; As of June&#160;30, 2022, the Company had 500,000,000 shares of common stock authorized with a par value of $0.01 per share and 119,865,023 shares of common stock issued and outstanding. In addition, as of June&#160;30, 2022, the Company had reserved 17,805,766 shares of common stock for issuance upon the exercise of outstanding stock options, 1,619,225 shares of common stock for issuance upon the vesting of RSUs and 670,168 shares for issuance upon the vesting of PSUs. The Company has also reserved 23,438,430&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares of common stock in the aggregate for issuance upon conversion of the 2025 Convertible Notes and 2028 Convertible Notes, subject to adjustment in accordance with the applicable indentures. In &lt;/span&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;connection with the Business Acquisition, the Company reser&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ved 9,406,112 s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hares of the Company&#x2019;s common stock, subject to certain closing-related reductions. The shares of the Company&#x2019;s common stock reserved in connection with the Motus acquisition were partly issued as acquisition consideration at closing, and will also be issued upon the first, second and third anniversaries of the closing date of the acquisition and upon the achievement of certain development and regulatory milestone events, subject to certain reductions. The shares of the Company&#x2019;s common stock reserved in connection with the AlgaeneX acquisition will be issued upon the achievement of a development milestone event, subject to certain reductions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Of the 9,406,112 shares reserved, subject to certain closing-related reductions, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company issued 2,889,367 shares of the Company's common stock in connection with the Business Acquisition (Note 13) i&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n the third quarter&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of 2021, after certain closing-related deductions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of 2021, the Company completed an underwritten public offering of 11,500,000 shares of the Company's common stock, including 1,500,000 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares from the Company, a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;t a public offering price of $25.00 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expenses of $17.5 million, were $270.1 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2021, the Company entered into a sales agreement with SVB Leerink LLC (now known as SVB Securities LLC) (SVB Securities), to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $250.0&#160;million, from time to time, through an &#x201c;at the market&#x201d; equity offering program (the ATM program), under which SVB Securities acts as sales agent. As of June&#160;30, 2022, the Company had not sold or issued any shares under the ATM program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of 2020, the Company completed an underwritten public offering of 11,155,000 shares of the Company's common stock, including 1,455,000 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares from the Company, a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;t a public offering price of $23.25 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expenses of $13.5 million, were $245.9 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; As of June&#160;30, 2022, the Company had 200,000,000 shares of preferred stock authorized with a par value of $0.01 per share and no shares of preferred stock were issued and outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMTA3_84f2e7e7-aa6b-46ae-a196-ea7c1e85032d"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMTY0_7ccf62f0-d5cc-4662-aae7-d955ba3bd105"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMTgx_43714ff7-a5ad-4bb3-925b-54a7942e5146"
      unitRef="shares">119865023</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMTgx_e462868d-96ba-4b4a-b5dc-672dcc606de4"
      unitRef="shares">119865023</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i63fc774e8854431ba4eafe553558adf0_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMjc5_ab8262b5-3e71-44c8-b3a8-6539cbc86f07"
      unitRef="shares">17805766</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i4043f106b7ff4d2aa5e7c93a3a3ae9cd_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMzY2_0b9c3d1a-4441-49be-a135-2744a2d6ec6d"
      unitRef="shares">1619225</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1861d72030824ced8ef920fa4c278220_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfNDM0_0738cd0e-9265-406b-a31e-4d3a517aba65"
      unitRef="shares">670168</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2e74b1e1d79d4206a35bd3d6cae5a699_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfNTEz_5d827237-37bc-4322-81ed-8d0005604bb6"
      unitRef="shares">23438430</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie5cf4cca2bb1485f813f9ef62c61797a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfNzc4_147758ee-4efc-497e-9814-d0f70ba78941"
      unitRef="shares">9406112</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie5cf4cca2bb1485f813f9ef62c61797a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMTQzOA_75e2cb0e-869b-4515-8666-ffdcd4aab3d6"
      unitRef="shares">9406112</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i0b9b0a45175146259bc231dc8f5ee5c6_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMTUyNA_f4862f4b-0f40-4def-9ce5-af9f426bdd36"
      unitRef="shares">2889367</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i171123b4124b445eba208fcf196842fc_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMTg0OQ_6d44f35e-5764-41e4-825e-8464fb1f5338"
      unitRef="shares">11500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i7f2cf2d9e0294d689a5e13786a2e00a2_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMTkwMA_8325ef04-a12e-40ae-ac88-1e6e5d8daf3d"
      unitRef="shares">1500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i34b29fd1e2a04660a3bb612c3f24dde5_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMjA1Ng_ac999290-06cb-4e17-ac5a-370c1a747e58"
      unitRef="usdPerShare">25.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMjE5NA_b4d90a47-30a2-4312-b363-8c7c22e9b8cd"
      unitRef="usd">17500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i171123b4124b445eba208fcf196842fc_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMjIwMw_277d3418-3e0c-48ae-9997-5ba20975e499"
      unitRef="usd">270100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <insm:CommonStockAuthorizedAggregateGrossSalesProceeds
      contextRef="i7a78bc5894c84095aa559149f1fe6c13_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMjQ0Mg_2c9ed86c-fd2e-4f54-a2a7-f7a8537467ee"
      unitRef="usd">250000000</insm:CommonStockAuthorizedAggregateGrossSalesProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib7b0a51fe15b40af849fca272f472e3a_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMjc0Nw_c963567d-96db-46e8-bcc8-0745566fa3cc"
      unitRef="shares">11155000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i317c38eb43ca4b2da0d5950221ff472a_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMjc5OA_f4490102-4bee-41eb-929d-a79d90fb9953"
      unitRef="shares">1455000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="id2c3209fc64e4317a4091a1502a77db1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMjk1NA_1cac932f-576e-464a-aac7-1b1140c5e57d"
      unitRef="usdPerShare">23.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i91561c5c770b4119b0528f79d05ba9b9_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMzA5Mg_a4522973-becd-4779-acab-8042e9a89140"
      unitRef="usd">13500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ib7b0a51fe15b40af849fca272f472e3a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMzEwMQ_d3e75353-c396-4fe2-bd76-6538092b9161"
      unitRef="usd">245900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMzE1MA_5b7c0c30-7f07-4928-a6c5-218d9a0930a7"
      unitRef="shares">200000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMzIxMA_4bae7a23-1ff5-4f7a-9c8d-fc15fbcb1500"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMzIyNw_83578d7d-2894-4706-a281-b9b3a396246c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV81OC9mcmFnOjcxNjU3ZGRkYWZjNjQxZjI4Y2MxNzU5YmJiNDM5ZTI1L3RleHRyZWdpb246NzE2NTdkZGRhZmM2NDFmMjhjYzE3NTliYmI0MzllMjVfMzIyNw_e175c1b6-21f6-49ed-bcc4-8ed63699d55a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNjE1Mw_41d0e573-aede-4848-9085-e08de98cc2ba">Stock-Based Compensation&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's current equity compensation plan, the Insmed Incorporated 2019 Incentive Plan (as amended, the 2019 Incentive Plan), was approved by shareholders at the Company's Annual Meeting of Shareholders in May&#160;2019.&#160;The 2019 Incentive Plan is administered by the Compensation Committee of the Board of Directors of the Company.&#160;Under the terms of the 2019 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards to eligible employees and non-employee directors.&#160;On May&#160;16, 2019, upon the approval of the 2019 Incentive Plan by shareholders, 3,500,000 shares were authorized for issuance thereunder, plus any shares subject to then-outstanding awards under the Company's 2017 Incentive Plan, the 2015 Incentive Plan and the 2013 Incentive Plan that subsequently were canceled, terminated unearned, expired, were forfeited, lapsed for any reason or were settled in cash without the delivery of shares. On May 12, 2020, at the Company's 2020 Annual Meeting of Shareholders, the Company's shareholders approved an amendment of the 2019 Incentive Plan providing for the issuance of an additional 4,500,000 shares under the plan. On May 12, 2021, at the Company's 2021 Annual Meeting of Shareholders, the Company's shareholders approved the second amendment to the 2019 Incentive Plan providing for the issuance of an additional 2,750,000 shares under the plan. On May 11, 2022, at the Company's 2022 Annual Meeting of Shareholders, the Company's shareholders approved the third amendment to the 2019 Incentive Plan, providing for the issuance of an additional 3,000,000 shares under the plan. As of June&#160;30, 2022, 2,145,104 shares remain available for future issuance under the 2019 Incentive Plan. The 2019 Incentive Plan will terminate on May&#160;16, 2029 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options to new hires, which awards are made pursuant to the Nasdaq's inducement grant exception to the shareholder approval requirement for grants of equity compensation. During the six months ended June&#160;30, 2022, the Company granted inducement stock options covering 471,790 shares of the Company's common stock to new employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 15, 2018, the 2018 Employee Stock Purchase Plan (2018 ESPP) was approved by shareholders at the Company's 2018 Annual Meeting of Shareholders. The Company has reserved the following for issuance under the 2018 ESPP: (i) 1,000,000 shares of common stock,&#160;plus&#160;(ii)&#160;commencing on January&#160;1, 2019 and ending on December&#160;31, 2023, an additional number of shares to be added on the first day of each calendar year equal to the lesser of (A) 1,200,000 shares of common stock, (B) 2% of the number of outstanding shares of common stock on such date and (C)&#160;an amount determined by the administrator.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; As of June&#160;30, 2022, there was $122.5&#160;million of unrecognized compensation expense related to unvested stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has granted performance-conditioned options to certain of its employees. Vesting of these options is subject to the Company achieving certain performance criteria established at the date of grant and the grantees &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fulfilling a service condition (continued employment). As of June&#160;30, 2022, the Company had performance-conditioned options totaling 114,780 shares outstanding which had not yet met the recognition criteria. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; As of June&#160;30, 2022, there was $32.5&#160;million of unrecognized compensation expense related to unvested RSU awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance Stock Units&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &#x2014; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company issued 271,612 PSUs. For these PSUs, there are two performance conditions, a service condition, and a market condition. The performance conditions are the issuance of a press release announcing certain top-line results from a clinical trial and the acceptance of a new drug application (NDA) by the FDA for brensocatib. The service condition is continuous employment with the Company through the later of the third anniversary of the grant date of the PSU award and the date an NDA for brensocatib is accepted by the FDA. The potential payout of the awards ranges from 0% to 250% of the target, dependent on a market condition that is based on the Company's total shareholder return compared to a defined peer group. Due to the multiple vesting conditions, uncertain timing and variable payout of these PSUs, a Monte Carlo simulation was performed to determine the fair value of the awards. Compensation cost will be recognized on the date the performance conditions become probable, with an initial recording of the cumulative expense that would have been recognized if the PSU expense had been recognized on a straight-line basis since the date of grant. The remaining unamortized fair value of the awards will then be expensed prospectively on a straight-line basis over the remaining service period. Since the market condition is reflected in the grant-date fair value and is not a condition for the award to vest, it does not impact the requisite service period. The volatility, risk-free interest rate and weighted-average grant date fair value of the PSUs granted are 65.4%, 1.03% and $39.12, respectively. Any forfeitures that occur after compensation cost recognition commences will result in the cumulative reversal of expense in the period in which the forfeiture occurs. As of June&#160;30, 2022, there was $10.5 million of unrecognized compensation expense related to unvested PSU awards, which assumes a payout of 100% of the target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the three and six months ended June&#160;30, 2022 and 2021, respectively (in millions):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to PSUs during the three and six months ended June&#160;30, 2022, as the performance conditions associated with the PSU awards were not probable as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i47631aa0607443aa837dd0c862dfd781_I20190516"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfODA3_7cc609ea-b22b-4196-a182-1b136d64db9e"
      unitRef="shares">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ib4fa2223aeb44fe2b0cdb87788b4adaf_D20200512-20200512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMTM0MA_ae7017bd-aee7-417f-b1ed-d2b52355f973"
      unitRef="shares">4500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ie5861a2f40e5462983cc26a47179e376_D20210512-20210512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMTU2NQ_a943ddb8-40e3-415c-9b3f-8dfd314c9959"
      unitRef="shares">2750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i0288ec411bda42658bcabbda47913862_D20210512-20210512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMTg1Ng_52a5ab27-dfbf-4e7c-a74d-5f2a6708746d"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i89ae304eebb24882b6d4e002897820e6_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMTg3Nw_0976bec7-6b79-400b-bbb3-6ecaa362e908"
      unitRef="shares">2145104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMjQwMg_4283c9a8-115a-4531-9082-a86e037cf9bd"
      unitRef="shares">471790</insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i62d1dc130d494fe6805b85220bf3941a_I20180515"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMjY4Nw_cc2d5e0f-b6e9-4bee-899b-8654dc472d51"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ic196e790147b4d15a6d6b4c68f8a6472_D20180515-20180515"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMjg5Ng_e92ef0d7-bbdd-4233-b507-b2689828b2d8"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="ic196e790147b4d15a6d6b4c68f8a6472_D20180515-20180515"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMjkyNw_bb9b5ba1-ce44-41f5-affc-f5aff7b52045"
      unitRef="number">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i63fc774e8854431ba4eafe553558adf0_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMzA4Mg_c05419f1-80c3-45f7-bd3e-c7bec600704c"
      unitRef="usd">122500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1861d72030824ced8ef920fa4c278220_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMzUyMw_13a10f62-caac-42c0-bf09-8e85a8512b5d"
      unitRef="shares">114780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i4043f106b7ff4d2aa5e7c93a3a3ae9cd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMzYzOQ_f3f86cb1-7742-4777-bd57-65bb5613c3b8"
      unitRef="usd">32500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib97d0fd95e2844cd80ddb0c2a4049481_D20220101-20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfMzc3Mw_5a163704-581b-41a0-ab5b-748ba68d9f90"
      unitRef="shares">271612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i22331278b70c4d298ba0751f16fcf4b1_D20220101-20220131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNDMzMA_e8292a8f-c787-4597-82d5-84e04ec1028c"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="iab99f87cba69456faa7114cb972e768f_D20220101-20220131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNDMzNg_5346fb42-fd13-4377-9a70-255d36af6e23"
      unitRef="number">2.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib97d0fd95e2844cd80ddb0c2a4049481_D20220101-20220131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNTMyOQ_b57f7e72-0d23-4b19-9f43-5c100c342460"
      unitRef="number">0.654</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib97d0fd95e2844cd80ddb0c2a4049481_D20220101-20220131"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNTMzMw_c5807554-f6fc-4353-bcd4-204922e03bd4"
      unitRef="number">0.0103</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="ib97d0fd95e2844cd80ddb0c2a4049481_D20220101-20220131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNTM0MA_b8e578d4-2c96-41f7-9c5d-f28efe61a96f"
      unitRef="usdPerShare">39.12</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i1861d72030824ced8ef920fa4c278220_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNTU0Nw_1bce32c1-2727-4078-9a06-1cbfe118cdc4"
      unitRef="usd">10500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ib97d0fd95e2844cd80ddb0c2a4049481_D20220101-20220131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNTY0NQ_965372a8-6dc3-4803-9794-88374fd83029"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNjE1MA_42d701f5-2702-40b2-9216-229449b51fc1">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the three and six months ended June&#160;30, 2022 and 2021, respectively (in millions):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6ceb0c5b59ec456684a1a621d375db23_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfMi0xLTEtMS0yODk0Nw_18a5209c-8301-46d0-84d5-a3a4ba7ec91c"
      unitRef="usd">6700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i117be86acfcb4eebbf356e9bca57ec66_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfMi0zLTEtMS0yODk0Nw_d6397dfd-e0f4-40cc-a409-7a32d1f86ddc"
      unitRef="usd">4400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie3990da618f7430d9bbd1e66442f7851_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfMi01LTEtMS0yODk0Nw_5c652690-268b-4866-b1b9-17b70e6fd09c"
      unitRef="usd">12300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id4386f9644da41bea1baa490a37085c2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfMi03LTEtMS0yODk0Nw_659b5110-b77d-49eb-838b-d01a16d9d1ab"
      unitRef="usd">8100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0a8cd663f8b34900a9dc46cfc889dbb2_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfMy0xLTEtMS0yODk0Nw_e1c1dea8-373a-4f06-b249-47aaa0ddb106"
      unitRef="usd">7600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2d1f7158600c4c6fb173fb60e3b43c76_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfMy0zLTEtMS0yODk0Nw_1f2f43bd-bd46-43d4-918b-067984e0cd37"
      unitRef="usd">7400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7dcac17f493744c29df2003d99cf399b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfMy01LTEtMS0yODk0Nw_bcbf70ac-834e-4270-9634-b86658454223"
      unitRef="usd">14800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie4249e6eea7944feab2165125682bd3e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfMy03LTEtMS0yODk0Nw_3b915996-bc73-46b6-b25e-2cf370905e16"
      unitRef="usd">14200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id29b955148664a0eb00d37f9dc631961_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfNC0xLTEtMS0yODk0Nw_f9a6ad09-135e-4381-abb8-6a66703fc9c7"
      unitRef="usd">14300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic006f1ab997e4bf98ba5840a6a977cfb_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfNC0zLTEtMS0yODk0Nw_f662731b-eabd-4ec5-ac20-6e0730ce98c6"
      unitRef="usd">11800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i700526f8aa8c42d3b0a44747d7347c9a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfNC01LTEtMS0yODk0Nw_0dbf98a6-d4d5-4341-8111-ab88c8108c09"
      unitRef="usd">27100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iad0d6bd3de9743b49ef5056bd1b0629d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RhYmxlOmZiM2FkYTQzN2EyYjQxNjU4ZThkM2I5NGEwMzk2OWE4L3RhYmxlcmFuZ2U6ZmIzYWRhNDM3YTJiNDE2NThlOGQzYjk0YTAzOTY5YThfNC03LTEtMS0yODk0Nw_083eff16-b0cd-4769-8164-6cf5c39f4495"
      unitRef="usd">22300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i04f0a1a4c2144c658e9faeab5bacbf34_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNjE0OQ_7810a8e2-d978-45ec-a67c-f2bb97b8ad01"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i826dc379d52b4e8d8be78b58060e1979_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82MS9mcmFnOmZjNmIzN2IxNGZkYTQzZGM4YzQ0MTNmZWU5NWRjYjJhL3RleHRyZWdpb246ZmM2YjM3YjE0ZmRhNDNkYzhjNDQxM2ZlZTk1ZGNiMmFfNjE0OQ_f6bcca76-2d08-4d83-8e13-52458e6d4968"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82NC9mcmFnOjZiZmUxNWNiNzc3YTQ3OGI5YTgxZWRhZWY1ZWQ1ZjQ3L3RleHRyZWdpb246NmJmZTE1Y2I3NzdhNDc4YjlhODFlZGFlZjVlZDVmNDdfMTY3Ng_4453dca1-bfe9-4803-9659-2e9a687beb1f">Income Taxes&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded a provision for income taxes of $0.5 million and $0.6 million for the three months ended June 30, 2022 and 2021, respectively, and $0.9 million and $0.9 million for the six months ended June 30, 2022 and 2021, respectively. The provisions are primarily a result of certain of the Company's international subsidiaries, which had taxable income during the periods. Additionally, the Company is impacted by certain state taxes which effectively impose income tax on modified gross revenues. In jurisdictions where the Company has net losses, there was a full valuation allowance recorded against the Company's deferred tax assets and therefore no tax benefit was recorded. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to US federal and state income taxes and the statute of limitations for tax audit is open for the Company's federal tax returns for the years ended 2018 and later, and is generally open for certain states for the years 2017 and later. The Company has incurred net operating losses since inception, except for the year ended December&#160;31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin. As of June&#160;30, 2022 and December&#160;31, 2021, the Company had recorded reserves for unrecognized income tax benefits against certain deferred tax assets in the US.&#160;However, given the Company&#x2019;s valuation allowance position, these reserves do not have an impact on the balance sheet as of June&#160;30, 2022 and December&#160;31, 2021 or the consolidated statements of comprehensive loss for the three and six months ended June&#160;30, 2022 and 2021.&#160;The Company has not recorded any accrued interest or penalties related to uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82NC9mcmFnOjZiZmUxNWNiNzc3YTQ3OGI5YTgxZWRhZWY1ZWQ1ZjQ3L3RleHRyZWdpb246NmJmZTE1Y2I3NzdhNDc4YjlhODFlZGFlZjVlZDVmNDdfMTA3_fcf722b9-6e8a-4742-9c3c-2cee617ef3a3"
      unitRef="usd">500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82NC9mcmFnOjZiZmUxNWNiNzc3YTQ3OGI5YTgxZWRhZWY1ZWQ1ZjQ3L3RleHRyZWdpb246NmJmZTE1Y2I3NzdhNDc4YjlhODFlZGFlZjVlZDVmNDdfMTE0_46998994-91ed-4a8e-b669-d3963b6cd2cd"
      unitRef="usd">600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82NC9mcmFnOjZiZmUxNWNiNzc3YTQ3OGI5YTgxZWRhZWY1ZWQ1ZjQ3L3RleHRyZWdpb246NmJmZTE1Y2I3NzdhNDc4YjlhODFlZGFlZjVlZDVmNDdfMjc0ODc3OTA3MTE2OQ_fb040c4f-f8a1-407d-bf12-395aa48bda8a"
      unitRef="usd">900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82NC9mcmFnOjZiZmUxNWNiNzc3YTQ3OGI5YTgxZWRhZWY1ZWQ1ZjQ3L3RleHRyZWdpb246NmJmZTE1Y2I3NzdhNDc4YjlhODFlZGFlZjVlZDVmNDdfMjc0ODc3OTA3MTE3Mg_9e665722-ead9-432e-904f-5f779aa6cde9"
      unitRef="usd">900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82NC9mcmFnOjZiZmUxNWNiNzc3YTQ3OGI5YTgxZWRhZWY1ZWQ1ZjQ3L3RleHRyZWdpb246NmJmZTE1Y2I3NzdhNDc4YjlhODFlZGFlZjVlZDVmNDdfNTY3_51b47281-663e-4ae8-abf2-600d98b852d8"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i2dbe805af0654b00851eb3609fe8fc0b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82NC9mcmFnOjZiZmUxNWNiNzc3YTQ3OGI5YTgxZWRhZWY1ZWQ1ZjQ3L3RleHRyZWdpb246NmJmZTE1Y2I3NzdhNDc4YjlhODFlZGFlZjVlZDVmNDdfMTQ3Mw_abe8a078-9fe9-4784-8821-5bf77cc781a3"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i92ecd30d90114111bd1344c30c28673d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82NC9mcmFnOjZiZmUxNWNiNzc3YTQ3OGI5YTgxZWRhZWY1ZWQ1ZjQ3L3RleHRyZWdpb246NmJmZTE1Y2I3NzdhNDc4YjlhODFlZGFlZjVlZDVmNDdfMTQ3Mw_c474ee7a-da82-46a9-88be-e6198ddc0b8a"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82Ny9mcmFnOjgyZGFjNTA3MGUwYzQ1NmE4MjIzM2RhZTk1ZjNjOTRmL3RleHRyZWdpb246ODJkYWM1MDcwZTBjNDU2YTgyMjMzZGFlOTVmM2M5NGZfNTY0_e477aadb-be00-4424-91f0-d0b22a7dca6d">Commitments and ContingenciesRent expense charged to operations was $1.9 million and $1.1 million for the three months ended June 30, 2022 and 2021, respectively, and $3.9 million and $2.3 million for the six months ended June 30, 2022 and 2021, respectively.&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82Ny9mcmFnOjgyZGFjNTA3MGUwYzQ1NmE4MjIzM2RhZTk1ZjNjOTRmL3RleHRyZWdpb246ODJkYWM1MDcwZTBjNDU2YTgyMjMzZGFlOTVmM2M5NGZfMTA4_f8ef1c55-bcfc-4df7-8233-a402d8c91627"
      unitRef="usd">1900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i2283f5ea4b134c62a25a2e101d2d538a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82Ny9mcmFnOjgyZGFjNTA3MGUwYzQ1NmE4MjIzM2RhZTk1ZjNjOTRmL3RleHRyZWdpb246ODJkYWM1MDcwZTBjNDU2YTgyMjMzZGFlOTVmM2M5NGZfMTE1_6a3a3730-7bed-4251-8eb2-b9e225c3fdeb"
      unitRef="usd">1100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82Ny9mcmFnOjgyZGFjNTA3MGUwYzQ1NmE4MjIzM2RhZTk1ZjNjOTRmL3RleHRyZWdpb246ODJkYWM1MDcwZTBjNDU2YTgyMjMzZGFlOTVmM2M5NGZfMjc0ODc3OTA3MDA1NQ_e985e45c-3585-4836-ba1e-e6b761b3be01"
      unitRef="usd">3900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i18bbc7573344437cbd3697a505c1f787_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV82Ny9mcmFnOjgyZGFjNTA3MGUwYzQ1NmE4MjIzM2RhZTk1ZjNjOTRmL3RleHRyZWdpb246ODJkYWM1MDcwZTBjNDU2YTgyMjMzZGFlOTVmM2M5NGZfMjc0ODc3OTA3MDA1OA_dbe271e8-72e9-4ce4-8cf1-2fc29051069c"
      unitRef="usd">2300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i68a9c88fddc548479e98550527d1fccb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfNDg3NQ_fdf98686-dc8f-4c45-a91d-67ec9c3b7bc4">Business Acquisition&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 4, 2021, the Company acquired all of the equity interests of Motus and AlgaeneX, each a privately held, preclinical stage company. In connection with the closing of the Company&#x2019;s acquisition of Motus, the Company issued an aggregate of 2,889,367 shares of the Company&#x2019;s common stock, following certain closing-related reductions, to Motus&#x2019;s former stockholders and option holders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, Motus equityholders), subject to certain adjustments. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company&#x2019;s common stock on each of the first, second and third anniversaries of the closing date and up to 5,348,572 shares in the aggregate upon the achievement of certain development and regulatory milestone events, and to pay to the Motus equityholders an aggregate of $35&#160;million upon the achievement of certain net sales-based milestones and a portion of the value of a priority review voucher (to the extent issued to the Company), in each case, subject to certain reductions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing of the Company&#x2019;s acquisition of AlgaeneX, the Company paid $1.5&#160;million in cash to AlgaeneX&#x2019;s former stockholders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, the AlgaeneX equityholders). The Company is obligated to issue to AlgaeneX&#x2019;s equityholders an aggregate of 368,867 shares of the Company&#x2019;s common stock upon the achievement of a development milestone event and pay to AlgaeneX equityholders a mid-single digits licensing fee on certain future payments received by the Company in licensing transactions for AlgaeneX&#x2019;s manufacturing technology, in each case, subject to certain reductions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The shares of the Company&#x2019;s common stock issued to the Motus equityholders and the AlgaeneX equityholders were issued, and the shares issuable in the future will be issued, pursuant to Section 4(a)(2) of the Securities Act of 1933, and the numbers of such issued and issuable shares was calculated based on a per share value of $27.11, which is the weighted average price per share of the Company's common stock preceding the closing of the Business Acquisition for the 45 consecutive trading day period beginning on May 24, 2021. The Company will not receive any proceeds from the issuance of common stock to the Motus equityholders or the AlgaeneX equityholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Business Acquisition under ASC 805 and ASU 2017-01. The Company concluded that substantially all of the fair value of the gross assets acquired is not concentrated in a single identifiable asset or a group of similar identifiable assets. The transaction does not pass the screen test and thus management performed a full assessment to determine if the acquired entities met the definition of a business. For the full assessment, management considered whether it has acquired (a) inputs, (b) substantive processes, and (c) outputs. Under ASC 805, to be considered a business, a set of activities and assets is required to have only the first two of the three elements, which together are or will be used in the future to create outputs. Management determined that the acquired entities met the definition of a business since the Company acquired inputs and substantive processes capable of producing outputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Therefore, the transaction has been accounted for under the acquisition method of accounting. Under the acquisition method, the total purchase price of the acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on the fair values as of the date of the acquisition. The fair value of the consideration totaled approximately $165.5&#160;million. The results of Motus's and AlgaeneX's operations have been included in the Company's consolidated statements of comprehensive loss beginning on the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of IPR&amp;amp;D was capitalized as of the acquisition date and accounted for as indefinite-lived intangible assets until completion or disposition of the assets or abandonment of the associated research and development efforts. Upon successful completion of the development efforts, the useful lives of the IPR&amp;amp;D assets will be determined based on the anticipated period of regulatory exclusivity and will be amortized within operating expenses. Until that time, the IPR&amp;amp;D assets will be subject to impairment testing and will not be amortized. The goodwill recorded related to the acquisition is the excess of the fair value of the consideration transferred by the acquirer over the fair value of the net identifiable assets acquired and liabilities assumed at the date of acquisition. The goodwill recorded is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i4fc0d05a849b4f9f8363d09eb7a2297f_D20210804-20210804"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfMjc3_4d1da8b6-d7ed-460b-acca-b79ba674986f"
      unitRef="shares">2889367</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="ib690063402dd47c4ae80bed8cc5946a2_D20210804-20210804"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfNjUx_10df3dcf-c035-4ae8-84b3-227068a45494"
      unitRef="shares">184433</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="ibbf98dd2c06941fba02468ff74fe15f4_D20210804-20210804"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfNjUx_b56647dd-78a2-4b73-9a8b-ed734d3ebc6f"
      unitRef="shares">184433</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i63cf6ce83c0a452894be75c49ed8e241_D20210804-20210804"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfNjUx_e86db486-0dca-40c3-b55c-d1df63ba9786"
      unitRef="shares">184433</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares
      contextRef="i4fc0d05a849b4f9f8363d09eb7a2297f_D20210804-20210804"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfNzc0_8a7cf677-5d05-45d7-9feb-d2e953685384"
      unitRef="shares">5348572</insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2574040e81cf45fdb63c1f0620c5cc9a_I20210804"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfOTMy_3d10960b-d139-43e9-b0e1-91dce0e9501d"
      unitRef="usd">35000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i7d34c58061f249e18f61f07687b0331b_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfMTIwOA_8d227353-3e32-41cf-bbb6-280c97f980b6"
      unitRef="usd">1500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares
      contextRef="i7d34c58061f249e18f61f07687b0331b_D20210801-20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfMTQ3MA_df84c9d3-ef12-41e0-bba6-949165c43452"
      unitRef="shares">368867</insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="icfe80c21994c4bb9b647c882148aa2b8_I20210831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfMjEyMw_19f2c816-0c42-47c3-95d9-3b7265eeead8"
      unitRef="usdPerShare">27.11</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i1ff8bc31f64b484687adf08bd1e1364c_I20210831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfMjEyMw_a4618e7c-3c63-41fd-ab0d-6f1f1dcd86a6"
      unitRef="usdPerShare">27.11</us-gaap:BusinessAcquisitionSharePrice>
    <insm:BusinessAcquisitionConsecutiveTradingDayPeriod
      contextRef="i07acd876919448939ae3e9671ddb5ce7_D20210524-20210524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfMjI2MQ_018223ef-7ce0-4301-935b-cd619729aa93"
      unitRef="days">45</insm:BusinessAcquisitionConsecutiveTradingDayPeriod>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ieb37f5b95f6243009bf267154d33f563_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1MjEwOGIzMDgwNTQ4ODdhNDY5MDFmZTIyNzYyN2YxL3NlYzoyNTIxMDhiMzA4MDU0ODg3YTQ2OTAxZmUyMjc2MjdmMV83MC9mcmFnOmEyODY4ZmU3Y2UyNjRkZmZiY2UzZDM2YWE5MmRlNzJiL3RleHRyZWdpb246YTI4NjhmZTdjZTI2NGRmZmJjZTNkMzZhYTkyZGU3MmJfMzg2NA_1511c777-d1ed-40c4-958c-aaf6374f17af"
      unitRef="usd">165500000</us-gaap:BusinessCombinationConsiderationTransferred1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MWKQ""7SO\NX/=7;@*]GY2D*]+RZH7 &]:J P']COEF]HJ9UWKF+?5=)U90+
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M42W?&.C?;X503P_F7=+NW>'B?U!+ P04    " #:.P15*LN(%:,"  !J!P
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M+&B_U')GG\W?R+J66WNYX:S@RAC _]<2*I7#%W.#[O6.Y7]02P,$%     @
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M$UWNAH:6U[I61-0X*3=M 6[*/#C&Y7!PQL+@$X0$(;<:9"<-8*+-D 9JMRJ
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M;4AOY; .%3]8J#M5("5_:?,5/H:#J: E[.I>-VNZ2Y?;%AIL\5$@M P,+\%
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MGEQ?P]A%<+#]-,\USA[D>Y,,+@41R1!JA_M!]_W(NF]'<)TU 4CU/?Y35HG
M%T<&F#.8K*HE%"@L-'$\!)<L&^7[SFV:W)#:>V#":P66_LGL] J8SDX6.?3)
M=? #-('*AK Q7"NK\MA]OP/5BX0X!E1S;-*((A-8;[,E,*L*6+!2T=S A+4E
MD*8@VPE^$0WRR6QZZGI$/JES:QNR=M,R6F::93#X6JTQ&G*'ZAR^@WT:E@\
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M8QCAV;;U%M 6QE8'A)6\];/K"^!^FZ:9A,%E1AM64TM=B;6)-B$?2$)H6L!
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M9"C.9RT=4:K7-HMYF":5LV1Q2?#$1JD1-8W;@\['^M# Y0S$<)$X,N_R(2Q
MM@>.S?F@]D\?D[>8Q<*F7]?M*KG)\4A&8^NQ#M^^OCGB.-5=6G2C]Q_5MK&9
MB-G5M#.3JF#1XA-CCC486OZ$E2B';]^]_>&(5ZE35$5LB*JR\&="^1F@((-X
M:%F%:@']*),I,0YT#%NID.W2&B3M'J/[)LG!"9<EAFD7.Q)%6Y%%JMHFT8W;
M(KG!0U-][79<_4";DHV-N>IPXMAE@VFWY9++SYA/>M[*E_%)+*0^N39UC/@[
M.Q@LA&/X)D90OC /=:JN8NJ$?()\$$8JABM.. ]GT"QN ="D*ZKX=I4$RYJP
M. ,0R8/*5!"I JS-[>.TTYKKE:A^H-J1%7:!6\Y$$(F.6?_[/71BXHP059O^
M]I T,5)\P2O+A5[N+&64E,]B*T29XVTR<"I3Q^ P<C_OP\-"(TQE3WF+'PX9
M9&Y0Y#J(@2=$Y/ ,>&S7A5>IPS6E/_?,,JS;QHLGDQ% "0](L/MII$R/.X0A
M?OASNME^_=K^)KX(<!"6X4_]Z1Z@;Q=RGIJQ)%!-?*96?!BWXDV!1+[XX*W@
M[#O>>&&A5A!6-0-)>]Z!U O FK7;X)!9/+ZTP?O%P 0XLM\9/N)VTFKDC^Z$
M0[):\9G"ON1 +\/]VFA]BL(=J=7;<,7XV\XXL^>VFZ"85?S^!+D239AHA-3)
M-(X7VFFWM+]3:-6_S;B3)F38FJH7)SV":3- J;)/DH'V1)V"'+<UK4ETTAXC
M/YEC:CA$WUN[,/OO*>*/$A:-;)UY<B$(2]OSL:F"E8Y!:QM\*H[YDE/!L#2N
M///,P#OB@V/K*"TUS"R=J',6Y/2Z=,5PA1SK'? 5ZY4@;25EXZB&,[OZ-Q]_
M0M-[>7PRFWBANPV%[O#':@N._]7).6Z.!A;0RYTU::_54DL6G";ZRI6QV72F
MG#3@!D=Z6JIZB/L&!:4)4.( @R/G=UA[TMGF37I$E";0C_;:<\U9P8 &%H'*
MI,M@;)(^]WE7TZ,J'Q9FNH.*MA!6&G'OC0<+HV5R7?GLGIALMR7!*(?H%-7@
M!GN=1P_%MX><[D.)*)\53-6[,KXH-9?# 6,A'JA _'B+C#3":N-D(I^=*&S(
MV%$HT7??72"[Y8&V$!DSKB7CQ!*%41 -C-P=%"0ABNXLGCO'HY/8#^;DCZRW
MTX],%%?O<UF/S8D)GO#QQ6"97=Q!CB.5<T)3\=1;5-=4JXU:D(NV>9!AG1J%
M'%HI=!O<0^[&$#GGO:.[AQ;BD;--HGHY]K)*9[]S+I;C F]"S.(#WSYT/L!8
M7Y,D>*N"/6$@Y^.P[ 0GW5HALN31P;.,_80$O;,S^L/Y=QT).6A7!DSK%UL5
MD=CC\Y/]=?I O[%&WU?M12J(P+)]JTBW6RYKL'M-@C4@_[!7E!/.T^'<$/3'
MZT-O>)@FWU<Q,T3QIH>U(5"3CG+J<PCI8]HMQ$3AMTFDIC,$CB";:,<JW"X:
MQ6_T=EGS<I!07@-5U2?3?9F%/;,;U\36C+KQV5R@.[S?K8Z<O^46Z9"I;=;I
MV!/[:&,BQ%%2C6GC/9E(UAY+%@B85B3B>"- :!X90MEI\A=K5[3=W^.6=HRI
M+;H0,Y.-$O,!HS)@209+=0=P=[1CI\OYYH&SC)Q&UP.SZE5,DFO6A'H\VS'O
M@X:Z4SXOT3]BEPQJ+94,^'W'-5.!-(PJ1<33[J#;"&7"+?J.YCOQ >',9G0D
M3^_[K%UIBKSCI/3\XVA^).<PAH6=CQTL)&2<A-T.%-[8^$V KO(!!\OY4J7,
M5QT75-O2"[50R._1FX(B8T!B[]FYP6W""E\WD)#_'9T\=/CNO7CE0 SWV0_9
M9>((MX<J-#"M(X">WBOC"ZRU2Y'\HCBARYK">W<T+"[>XRU;T'2!U5W"YPR/
M6J.^YM[OM0FBM#;2T#TFCU2TGYKTWY>_$;C- ,S/(XX[^@RC.\H8)_D=)B&.
MWW, Y0UKBC=< )1\QSY:[VU7#QVE$JQ,?]C#Y)<:'IXM3<2?I*7#D^'L:6MQ
MB<Z&SDBT)]7;:C]7!BCGG!B8,<;>J)(,FFFX+ZD/M;L.[5%]$A!L35/O<"NJ
MVU,:3)W7F KF[:E3 4X,LJ!V^PF75@NYW"&!09%D?(ZFS3Y9.M9\:D/#QEP_
M+F+H5!>$QPKE CP+F%I5VH*,D,TIORGI*UMA$O3M#U)QY@(\2MEB  NV; MZ
M5Q;V$H2(R=D)YH@:I#M0<K[\A/C@ZM!Y=$S%&+CAO=MT"+]_\P%(;?B-XPA4
M?%.C]%'PG/+H]%*F=H-+CR_@PVCY7ZM[-,&3Q+_G2=O7',D22A2,8V\<6K=&
M3<X?[(3#4KP+V^+;@K$UBH.O+HX_3=Z*:L%+Y/<:KH#T[S3DQ9+!N8Z 3!%L
M"0?&8[4VP-5.$L8H]">L4"2ER!$H)$WY.%LYB!:^"] D8C"Q!=HM'N$]NV'R
MD:9[)!(;(6&JJE3'N-L!AID6.S25-&@^AT@-@5<")MU.F-F&!BEAO<[OU'G9
M;P=1%9[:2F]4=-T2!P7S&$#BT:Y!A0O&&B)M!*E-N]5U\F:.4-'1?D'1C##4
M\%T;;OJ:(-1>PL;YU0IQ22)OM."2!R>#P&=M0[<4&H2"9&+B%2?@A'MHM_:9
M6XLK^/Q=*<U8--9 3:Q!2O \F6JCLV@?]E!8 M_G"WY!XM\.$^^Z&G[7@U/C
MXAS;4PR#JFU_9$'07B]K)]MP(A$C-N67@>REDJW&$7?L!UA+3"_.Z#5O_L%
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MB,5NJL8;X/JRJAK[!3NXK^I/-+R7_P=02P,$%     @ VCL$52#.!CYB P
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M>>XCSP?P?N5<W#XP@^XG'C?_ E!+ P04    " #:.P15PA:R ;P,  ":)@
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M$\0.(KDPTK*G9!IR>F/!GGJ@7H(DCH=??Q':ZW+K?ZM21 6$!4WU/0B73@9
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M8WOYU(TR6R^I@>08'\#Y_AKEK:DK;ZXON<[/+<)B:,0\V/$0U)JZ'</:U&Z
M:]XP;/C?KZRIE^$9A=FV-;+A@&5)FPHGP[ZB2ZPNZ>C)30N&SKBF5HKW#U7F
MO37;WE=,6-9$Q'@B8W!3)>]I8].LT% 9/B)J'#M^3H"<'(V[JNZE72H?H2)7
MQ"IH&U+NB'W8L>G!?GVS+7/.;C >JT M2TX.:4,B2#IPY*)?*474Q]0541S5
MEK4"$- 5N.E=4PJ'2 5R6M#H@@L3_$9'"\QF-TSO<D#RJ1X4!;LT8%!8(&"$
MLKI!<M"MZTBAK4IM(3NOU:8SX\W3E=0X'\COO"L\?_;NX8#ZQW-FCAGH*J ^
M<[(A"D"CDQVJ7TP64V.SOB>(M X6@'BWA88#LS9UGJ$<XOE<J7*HB^[AUDZA
MLKD]C*-.[9?.@4-*(M34>71SF+#9,@+TPJ:"%*Q+M';KPS'$(]YK]@DKK#SO
M#,C(?E<I/M_.[Q]7A!AK4^';1=L<AG^UR< :.ET?X%=3&5K0:7HX">B2\H#-
M&JA,L,)HZBMR(*#=J(6<!6((HQ%M:C*CPG -J*=M%P*;=^@^#W0DM]T9"F(.
MNA\)J]WG@X4%4=8EG>,!4;8E36L^E5?9 0)KY7*CC#QT,D&^8R)4CX^/XMGS
M2"3Q>/J<Y3V;OHQIVX]5.H>C::.B-8<I-=-,0I1)TQK;E@45M_0!YC>:;."\
MJ@EO*.2MBP> M8IK(A]YM4AL1@7?T%WHZX&FMQH%7=SC[**C?^,?T:6[PMSO
M"='3"CKJ&U299+Q=0T-H^]V%Y[H4/A=! Q?0LUQ:M:3X,<D\".7T$=TH^7NT
M HK.Y#J3@:+BAYI32[W1:5?TL0F.SDWHN:UE#\]'Z0149/W6$OU,!<0]O<GD
M(>',: @A['W*UN]N_Q7\0.*&WU-Z,;=88/<;7H!/GOHKT#;L8B@$6#@#@')3
M<4M^)H[C$_R?Q3/\3R;Q%#^G<2)N%;/62"Q5B9P)U&&PN2 'G<3'^)N)9!:?
MTK^)^,CMZQG=D* DP8MGX%<0B!^2_K&#66G^C[&[^9N10NMS3[4>0-JDFE?I
MV$T/_'!N2B6M[4TD;COWXEW?A@X''_,*A;R@3Y9$K+#M"]_UNJ?=5]'+\#&P
M'QX^J;Y#6FGHFJL%IH[CDZ,1JB5_I@PW((_\:7!NO#<%7ZZ4!/F@ 7B_,&!&
MS0TMT'TKOO@O4$L#!!0    ( -H[!%4-J;V4Y00  - +   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;)56VW+;-A#]%0S325\\NCJ.DTB:L9-VXLQD
M)A,G[4.G#Q"Y$I&   N NO3K>Q8@*<EV'/=% D'LV3U[=I>8;:W[[DNB(':5
M-GZ>E2'4KX=#GY=423^P-1F\65E7R8!'MQ[ZVI$LHE&EAY/1Z&)8266RQ2SN
M?7*+F6V"5H8^.>&;JI)N?TW:;N?9..LV/JMU&7ACN)C5<DVW%+[6GQR>ACU*
MH2HR7EDC'*WFV=7X]?4YGX\'_E"T]4=KP4R6UG[GAYMBGHTX(-*4!T:0^-O0
M6]*:@1#&/RUFUKMDP^-UA_Y[Y XN2^GIK=5_JB*4\^PR$P6M9*/#9[M]3RV?
M%XR76^WCK]BFL]-I)O+&!UNUQHB@4B;]RUV;AR.#R]$/#":MP23&G1S%*-_)
M(!<S9[?"\6F@\2)2C=8(3AD6Y38XO%6P"XL;D]N*Q!>Y(S\;!B#R_C!OK:^3
M]>0'UA?BHS6A].(W4U!Q:C]$)'TXDRZ<Z\FC@!\:,Q#3T9F8C":31_"F/;UI
MQ)O^E)YXIWRNK6\<B;^NECXX%,3?#U%.B.</(W*3O/:US&F>H0L\N0UEB^?/
MQA>C-X_$>]['>_X8^D_E>+JU^%*2>&NK6IH]NB>W#@H)*6IG-RJV%#I:J&01
MHH5=B5]&@Q<H,ZUCQYB"-R[Z#;8(@ VE(Q)5DIY8>@'AJ!<N6F(Q/H-G7U/L
M/+T_ZQ!?W77QZIX+KW;_W\$@DNX9>B$=/RJ,&Z7W((_#Z%8FFI,+&%F\#(=$
M_>J1D4#.2!X94F-6+;TJ%.S)GXEMJ?)2E++@A,FEIBY_1>.464>DFIRRA1^(
MJZ)0"869'SD1"EZPR@-H+?=]*#[(T$F1/-%JU5%C"^OI2#"!;%6V4"L%F+6S
MWH/>ADQ#<'YCQ#?$Y L5AQ\#DJ.3*$KIA<'41T]X)A?BB2UVI5@U6HN-U(U,
MHU-C=DN3TU$AK1&R#W>2AW%(SE',CY# #3Y*%;$A+0ECX[LE&5JI$-UUF(.3
MDD62D/QOX"^"%5]OQ8H*<I"$\5*J3HJW=1-?-7@)8;6J5)")?ZPK#JJ!*@S.
MG[6^V@X,.B]\UE%H7&>+4WN2KBO'R6A\&7UJ1.)290-U#5Z.%3_@G\A[%PPP
M+P\PIQE@@4"QB0EEI0#I0 >%EC1#D[ F_%,SRS-!.UZ>^&CC?4<Y54MR8CKF
M%AJ]&HC;!B7&2"*7SNUAM)6N0*G81J,PZ3C_;=JX8?<Q-Q$:SZE00\FUV4;%
M3=<$I=6_5)Q!\+!5:., EEV/1&,(9)U:*PS\JSA[[G?XG:"YW4\KN#@49#N+
M4X(;P_MKPR$<MTQ;=KXOWTZ<APH7V^SMZ^U O+=;M!9D7J,9S7$0SY]=3L8O
MW_@'NP4=JY(PL/!TB+&PG!<0V!"(MM. &YJ1EU)'ZW0IDT_-C6A%SU'N5JM"
M\GB)18<[5(@HR .^625?J39)KCLC/?;6TR;O_5IE1H?Y@$V9YZZ) J"V"=F&
M+W2%U '3%$=U#!'5U9A.!TY_ES5_ZJ*PE'Q($U2N:IX O%]QYRBT;%Y*LZ9>
M-UG9QL19?U(-)QZ$A:KQM*%=$.-)RWSPT*=\>'3+JLBMXUT2S<-NTH6KW^VO
MJU?IEG8XGNZZ'Z5#X7NA:073T>#EBTRX='],#\'6\<ZVM $WP+@L<>4FQP?P
M?F5MZ![807^)7_P'4$L#!!0    ( -H[!%6E".H9.P,  %L'   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;*55WV_;-A#^5PY:T;T8EBTG69?:!I)T
MQ3JL0)!BZ\.P!UHZ640I4N-15O+?[R/E:%Z;!NCV8(L\WGWWDQ_7@_.?I&$.
M=-\:*YNL":&[S',I&VZ5S%W'%B>U\ZT*V/I]+IUG526CUN3%8G&1MTK;;+M.
MLEN_7;L^&&WYUI/T;:O\PS4;-VRR9?8HN-/[)D1!OEUW:L\?./S6W7KL\@FE
MTBU;T<Z2YWJ372TOK\^B?E+X7?,@)VN*F>R<^Q0W[ZI-MH@!L>$R1 2%SX%O
MV)@(A##^.F)FD\MH>+I^1'^;<D<N.R5\X\Q'785FD[W*J.):]2;<N>%G/N9S
M'O%*9R3]TS#JGA<9E;T$UQZ-$4&K[?A5]\<ZG!B\6GS%H#@:%"GNT5&*\HT*
M:KOV;B ?M8$6%RG59(W@M(U-^1 \3C7LPO;&M:T.J'(04K:B&V>#MGNVI699
MYP$NHF)>'N&N1[CB*W 7]!X C=!/MN+JW_8Y0IOB*Q[CNRZ>!?REMW-:+694
M+(KB&;S5E.\JX:W^2[[T1DMIG/2>Z8^KG02/H?GSJ2J,3LZ>=A(OTJ5TJN1-
MAILB[ ^<;5]^M[Q8O'XFA;,IA;/GT+^]9?\#[@YBXGM0@#"5C?)[KB@X BEX
M%:^5T*"$7BSG/V(ZC4D7#2 0+"<!J(-"P_AY9FK' >$X((3V\M3>9(G%<H;K
M+AVG"VL>9B/BZG,7Q7SUA0O1]]_N8$Z_\EX9NO6N9*Z0O-!;[UH*H)^8;?S.
M$CZ*U2G[0!JUHD[Y\!#/#\IKUPL9-4BO@\RH-$JW8ST=[#R9Y*$[\1 :%0B&
M**RV"=QYG( 9J72]A]C5M.L%[1*9T\=&&Q[5^E"Z%M.*<^RA"'(*[.$.<]O;
MDGT &\\@MN#5V%FJ'/2M&WM9AM%Y! -Y:9BCN4XP $@&E7'FP)]!#R@T-0IR
M%67L-=)1U8%CH%S7$=39TQI]+\"TP-(5]"NJD1MF*E;!B8ZSD[J  %(F)Q.%
M7I9*&JKQ8LC\J1N3GQ!>RQC*2.O17V_#R'V3='HYKD;"_$=]?';>8Z8UG!JN
M8;J8_W">D1^I?-P$UR7ZW+D ,D[+!J\?^ZB \]JY\+B)#J;W=/LW4$L#!!0
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MW,.^KJ_<XTIL0''/7L!HNQI+^\MY'?IO [_'?G/RBY\*1=KDO]Q\DX=%GNB
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MF 8U%]*;C%K;5$]&:FTK(7&JP:SKFNMO]UBIS=B+O)UA)I8KZPS!9-3P)7Y
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M_I+(N]FX=^]NF/=<+P55I,(%0</K;."![J9VM[&J:2?E7%F:N^UR11<=:N=
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M.>?89Z;.C'=<W,D,0*&?.65RXF1*%2/7E4D&.9:7O "FWZRYR+'24[%Q92$
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MF #]?LVYNI\8@:;OC_\ 4$L#!!0    ( -H[!%4/G*[W=@0  )H8   9
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M[_4:!G%WIR?E&^>+SM-L6K\W[<,T6]9'C#?5K?];%>7ZD/*'\[TS,C041K4
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MT]7ZG4SC:DKU_3,M^RYT;054"U!-H%J(:A+5(E2+44U1FME2370]Z)]BIC5
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MV1Y->.Z=)#SWT/ <U0)4$Z@6HII$M0C58E13E&9V41.>>_;PO,/$"DW$42U
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M VZVU^R?O';4,J4:+B7_SC*S& 7]@&0PHY:;.[GZ#)6>4\>72J[]+UE5:Z.
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M]=J^!P2)H5A4&+_$J'\RAZ7O.2H_#FTGGTM-/-?WNU+AN91M!ZX3=,6B<['
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MV."*JCM>?X;63VCX4DZE_:*ZB9WHX+22BA<M6"LH"&O^^*E=AQ[ '[\#"%I
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MCM5LI%D(&0%C=D^P(&N6Q("F&\Z>2%&0[6Y:Y1Y;:LVP]]Y>#?KZRN[[JR'
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M&Q7=L:MK*-[:D\N**WT.LH^5/JJ", 'Z^X9S]=0PAZ'A\%O\!%!+ P04
M" #:.P15$ :33X$#  !S$@  &0   'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6RUF%U/VS 4AO^*E:&)2=!\M85V;23:9!H33 @$NYAVX;:GK442=[;3PK^?
M[8300)K1S=S0Q/'[')_W.";V8$/9/5\""/20Q"D?6DLA5GW;YM,E))BWZ I2
M^61.68*%O&4+FZ\8X)D6);'M.4[73C!)K6"@VZY8,*"9B$D*5PSQ+$DP>QQ!
M3#=#R[6>&J[)8BE4@QT,5G@!-R!N5U=,WMDE94822#FA*6(P'UIG;C]RM4#W
MN".PX5O72*4RH?1>W9S/AI:C1@0Q3(5"8/FSAC'$L2+)<?PNH%894PFWKY_H
M7W3R,ID)YC"F\0\R$\NA=6JA&<QQ%HMKNOD*14(=Q9O2F.N_:)/W[?@6FF9<
MT*00RQ$D),U_\4-AQ)9 <NH%7B'P7@K:.P1^(?!?"GH[!.U"T'YKA$XAT*G;
M>>[:N! +' P8W2"F>DN:NM#N:[7TBZ1JHMP()I\2J1/!!4B7.3I&WS%C6!4-
M'88@,(GY)]EZ>Q.BPX-/Z "1%%V2.);%Y0-;R,A*;T^+**,\BK<CBH\N:2J6
M'$7I#&8U^K!9WVW0VS+C,FWO*>V1UPC\EJ4MY#M'R',\KV8\X[?+W;IT_B]Z
M],_1*V;XY1SP-<_?.0<X!SA">BX<H1#XE)&5?H]_7LB^Z%Q PG_5E3T'M^O!
M:I'K\Q6>PM"2JQ@'M@8K^/C![3J?ZSPW"0M-PB)#L$IUVF5UVDWTX XS@B<Q
MH#@OSY1R45>*G-+3%/7O81VXK<[ 7F\[_+J/T_*J?<(Z3K?:)ZKC^&6?2IJ=
M,LU.8YIZ\NGDCM \$QD#Q-0B?TSGQYE\@N4<K<V[$;OO%#0)"SNO7/*[6S;E
M5AJ*6/&\6WK>;?3\DJ0DR9(Z5QN%^[IJ$A::A$6&8!7W3TKW3]YKV3TQ61V3
ML- D+#($JU3GM*S.:>.[<0WJ,YNDBWS=10)8[8O22-FW%"9A87-^+GH$S.I<
M-S2(BNN]TO5>\XJ$'W:M2(W"?8TV"0M-PB)#L(K[KO.\&W#>:TTJR(8*9)06
M&J5%IFC5&FWMV%PC*U,S9N^"F*2%?TG1=?3JQ)&\2/3.K[8.AH:4U\'>VD0G
MP!;Z](+++](L%?E>JFPM3TC.]+G B_:1VQ^[->VA.E'1F_9G?'X<<XG9@J1<
MUG,N0SFM$_E1R/(3COQ&T)7>PD^H$#31ETO ,V"J@WP^IU0\W:@ Y3E3\ =0
M2P,$%     @ VCL$5<B;<];8 @  "0D  !D   !X;"]W;W)K<VAE971S+W-H
M965T-#4N>&ULM5;;;M- $/V5E:E0*S7U+4E+2"PUEPH0%55+X0'QL+$GME5[
MU^RND_+WS*X=DXL;*B@O]E[FG)DY>YD=KKAXD F (H]YQN3(2I0J!K8MPP1R
M*L]X 0QG%ESD5&%7Q+8L!-#(@/+,]ARG;^<T958P-&,W(ACR4F4I@QM!9)GG
M5/P<0\97(\NUU@.W:9PH/6 'PX+&< ?JOK@1V+,;EBC-@<F4,R)@,;(NW<&L
MI^V-P9<45G*C370F<\X?=.=]-+(<'1!D$"K-0/&WA EDF2;",'[4G%;C4@,W
MVVOV*Y,[YC*G$B8\^YI&*AE9%Q:)8$'+3-WRU3NH\S$!ACR3YDM6E>VY;Y&P
ME(KG-1@CR%-6_>ECK<,& 'G: 5X-\'8!W2< ?@WPG^NA6P.ZS_70JP$F=;O*
MW0@WI8H&0\%71&AK9-,-H[Y!HUXIT_OD3@F<31&G@H^ *DO2(:9Q2D(NE23'
M4U TS>3)1JM#[N^FY/CHA!R1E)'/"2\E99$<V@KCT&QV6/L<5SZ])WSZY)HS
ME4@R8Q%$+?CI87S_ -[&_!L1O+4(8^\@X8>2G1'?.26>XWDM\4R>#W?;TODW
M[[._]KXEAM_L"-_P^8=VQ"F9X$8@WR[G4@D\S-_;5KGBZ;;SZ MN( L:PLC"
M&TR"6((5O'[E]IVW;1*_)-GT)<EF+T2VM1C=9C&ZA]B#JY11%@(1^K[K\$6G
ME$"HE("'E,_Q9#*(]&F$QS"A+ :"E8-D>@5Q.DMCJF_CUB-:^>T;O[J8+ -G
M:"\W5^2/%M-]BS?>Q?FVT>P0S98FO4:3WD%-/A4@,"\6_P=5>GO!NOW^CB[[
M-I[K[$JS;]1S=I79M[GH=]T=<>R-NST'$9NB*O&>+IFJ#G4SVM3M2U.N=L;'
M[F#BMHQ/L<Y79?DW??5(N*8B3IE$Y1;HRCD[QX!%57BKCN*%J2QSKK!.F6:"
M;Q40V@#G%YRK=4<[:%X_P2]02P,$%     @ VCL$51]5Y+Y_#   6:,  !D
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MW6';>0<JU#% T4PA:L? M::#?R;MILZ\U5?.SS)?J0MGU\VV-_8Z]-8LU&:
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M#* T"J6Q)QK$K3<V"??[FOC'+#\.K9A T4PE:K_ ?S&_X/2=3>QUZ"U:J(L
MI5$HC4%I'$H3*)KYX#7M(@18%R& N@A06@2E42B-06D<2A,HFBE![2($=A?A
M]'N0[*#>XG/::=W&L! :D$)I#$KC4)I T4Q%:>,@L!L'S[L%R0[MK:X.TZ"I
M+JAA *4Q*(U#:0)%,]6E#8/@U/4-_>] LJ-[:\QKW\_4WB<E@@:E4!J#TCB4
M)E T4V?:8@CL%@-Z2M$]I[!7HK<BD;0(2J-0&H/2.)0F4#13N =/<\:N:PBP
MSW;&/MP9^W1G[..=H;8'E"90-%."VO8(4.L:[*#>XFNODFCNDQ)!(U(HC4%I
M'$H3*)HI*>US!"^QKL$.[2VOCJ<_-/U_:$0*I3$HC4-I D4SY:6MC.#EUC78
MT;U%UK%*HK5/2@2-2:$T!J5Q*$V@:*;,M$\1_+$^Q;%9!=2I@-(B*(U":0Q*
MXU":0-$,Y8;:J0BQ3D4(=2J@M A*HU :@](XE"90-%."VJD(G^-4]-[9Q!ZE
MMS+;-D9SY6P$C4BA- :E<2A-H&BFWK2/$=I]#'1GW;VSB;T2O>4(W0(*2J-0
M&H/2.)0F4#13N-HB"3UL7PVU1:"T"$JC4!J#TCB4)E T4X+:/0GM[LGI&4 [
MJ+?X_%9WW-PG)8)&I% :@](XE"90-%-2VM<(3WVD19\,H!W:6U[!":,]J&<!
MI3$HC4-I D4SY:4]B_!4SZ)_!M".[BVRL)T!;.V3$D%C4BB-06D<2A,HVDYF
MPV(A91G%97Q]N9+Y7-[*Y;(@VYOAJR '1TDN[ZKGU%Z\<0?#UO$;Y^+6Z3@>
M.1>TZSAS+OCV^%"'O;Y<QW/Y+L[G25J0I;Q35:BV8AP0)=W%_DV9K96Z!N1K
M5I;9:OMR(>.9S*L3U-_O,C67J=]4 1ZR_-OV8U[_'U!+ P04    " #:.P15
M@$=\G*\"   *!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6RM55U/
MVS 4_2M6AB:0@'PU:6%M)&B%MDF3$(SM8=J#F]RV%HZ=V4[+]NMW[82HM*'L
M87UH_''/N>?XXWJ\D>I1KP ,>2JYT!-O94QUZ?LZ7T%)];FL0.#,0JJ2&NRJ
MI:\K!;1PH)+[41"D?DF9\+*Q&[M5V5C6AC,!MXKHNBRI^GT-7&XF7N@]#]RQ
MY<K8 3\;5W0)]V >JEN%/;]C*5@)0C,IB(+%Q+L*+Z>IC7<!WQAL]%:;6"=S
M*1]MYU,Q\0(K"#CDQC)0_*QA"IQ;(I3QJ^7TNI06N-U^9K]QWM'+G&J82OZ=
M%68U\48>*6!!:V[NY.8CM'X2RY=+KMT_V32Q*6;,:VUDV8*Q7S+1?.E3NPY;
M@'#P"B!J =&_ N(6$#NCC3)G:T8-S<9*;HBRT<AF&VYM'!K=,&%W\=XHG&6(
M,]D,YH:<D:DL*RE &$WD@KC!XQD8RK@^P>F'^QDY/CHA1X0)\G4E:TU%H<>^
M0066Q\_;;-=-MNB5;)]K<4[BX)1$013UP*>'X3/($1XZ>/@2[J/OSGS4F8\<
M7WS(_(SIG$M=*R _KN;:*#Q9/_NL-5R#?BY[VRYU17.8>'B=-*@U>-G[=V$:
M?.@S^I_(7MB..]OQ(?;L!HG)FO(:[&;CU=8&MY.))<FE6(,R;,Z!"&F@=XL;
M\M21VR*QSD:!_8W]];;#-\->:!]TV@<'M;LM8UK75*")7&JC3TDM:"E1]A\H
M^@0WC,F6DC-<R2C>$=P7%B;Q1;_@I!.<'!:,QTO6PA"L606*[Q.8[&7>7<S]
MB+,H"D?#N%]<VHE+WUS-4\*E6)X94&6?MG1O&X>C^&(XW!&X'Y:D:3(:[>CS
MMRJ5?26^4+5D0A,."P0&YT.TJ)K*VW2,K%SQFDN#I= U5_A8@;(!.+^0>$S;
MCJV'W?.7_0502P,$%     @ VCL$57S)HV5O @  LP8  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#@N>&ULC95M;YLP%(7_BL6JJ96V0IQ 7D:0UF95-VE2
ME+:;]M&!2[!J;&:;I/WWLPU!F4*:?@DVW'.><PE<XIV0SZH T.BE9%S-O4+K
M:N;[*BV@).I:5,#-E5S(DFBSE1M?51)(YD0E\W$01'Y)*/>2V)U;RB06M6:4
MPU(B59<ED:\WP,1N[@V\_8D5W13:GO"3N"(;> #]5"VEV?F=2T9+X(H*CB3D
M<^_K8'8SM?6NX!>%G3I8(]O)6HAGN_F>S;W !@(&J;8.Q!RV< N,62,3XV_K
MZ75(*SQ<[]WO7.^FES51<"O8;YKI8NY-/)1!3FJF5V)W#VT_H?5+!5/N%^V:
MVL@4I[72HFS%)D%)>7,D+^U].!!@?$* 6P%VN1N02[D@FB2Q%#LD;;5QLPO7
MJE.;<)3;/^5!2W.5&IU.%K#6Z#.ZJW4M 2TEY2FM"$,KJ,BKN?E:(9$C5W6Y
M $TH4U?H E&.'@M1*\(S%?O:!+%V?MI";QHH/@']4?-K- P^(1Q@C)X>%NCR
MXNI_&]_TT36#NV:P\QV>\/T#1*)O/*-\8R*G4*Y!?OPPB((OP\&L+V9C-^JW
ML^_#3%4DA;EG'G@%<@M>TOB]$7;8A1V^Y9[8WOLR-:K(J>PKM4V"V-_V@$8=
M:'0.-.P#-:KP/"CL0.$YT*@/%+X7%'6@Z!PH[ -%1R",PR X01MWM/$Y6M1'
M&[^WK4D'FIP#C9%YHY NP S87(/LXTZ.N.'X=)?3#CY]$_XH-&%]N.G1\S@)
M@F.<?S"#[#C_2>2&<H48Y$887(]-8-F,R&:C1>7&TEIH,^3<LC!?%9"VP%S/
MA=#[C9UTW7<J^0=02P,$%     @ VCL$5=$5=[N( P  @PP  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#DN>&ULK5=M;]LV$/XKA%8,+;!%[V^9+2"Q7#0%
M"@1-NWT8]H&6SK90B?1(RL[VZTM2BN9(C&9L^6*+Y'//\>'=4:?%B;)O? \@
MT&-3$[ZT]D(<KFV;%WMH,+^B!R!R94M9@X4<LIW-#PQPJ8V:VO8<)[(;7!$K
M6^BY>Y8M:"OJBL ]0[QM&LS^NH6:GI:6:SU-?*YV>Z$F[&QQP#MX /'U<,_D
MR!Y8RJH!PBM*$(/MTKIQK]>IPFO KQ6<^-DS4DHVE'Y3@[MR:3EJ0U!#(10#
MEG]'6$%=*R*YC3][3FMPJ0S/GY_8WVOM4LL&<UC1^K>J%/NEE5BHA"UN:_&9
MGCY KR=4? 6MN?Y%IPX;IA8J6BYHTQO+'305Z?[Q8W\.9P:2QVS@]0;>V"!X
MP<#O#?Q+/02]07"IA[ WT-+M3KL^N!P+G"T8/2&FT))-/>C3U];RO"JB\N1!
M,+E:23N1Y; 1Z&=T1P0PX *M'V4&<D!O<Q"XJOD[N?CU(4=OW[Q#;U!%T)<]
M;3DF)5_80OI7+';1^[KM?'DO^/+1)TK$GJ,U*:$TV.?S]M&,O2UU#^*])_&W
MWBSAQY9<(=_Y"7F.YQGVL[K<W#7)^7_>U__9^[/#\(=,\#6?/Y<)><6+FO*6
M ?K]9L,%DX7\ARG2'5=@YE*7VS4_X *6EKR].+ C6-F//[B1\XOIF%^3+']-
MLO4KD3T+2# $))ACSU8RV=7YM[B6A=?7)W3U:0I)QQ9I-O5Z.&:>$\G$.IX?
MM0D4CD#Y%!2X7O@<M#: ="(>#9+#07(X*_FFH4Q4?V/]#J%;>>/+G*PX;S$I
M !64"^.UTY&&9UM)SG;2"9]B@C >Z9YBW"CP1[H-SIS8+#L:9$?SLHN"P3/-
MI:Q#VA)A4AM--N",M$X1<9",@_RO-.LIPO7\)#5KC0>M\:S6+U3(?"XH.8(,
M]::&/L@7)'@\V8^7)*/PK*:@-$U'R9!/06$<)2/Y4Y ;>^X+H4X&^<FL_/<5
MT;E<@^QN+E*=3!,W#D:BIQC?&\G)IY@D&4=\BHFB%THZ'02GLX+O+I"83JX2
MWQ\7YVH*<AW?34<JIZ@H"L:1-5#%29R,A-IG754#;*?;68YT77:OU6%VZ)AO
M=*,XFK]UKU>N83Z7'7;7$/]#W[7GGS#;583++-E*5\Y5+$/"NI:W&PAZT#W=
MA@K9(>K'O?Q* *8 <GU+J7@:* ?#=T?V'5!+ P04    " #:.P15X)<H2*X(
M  "<7P  &0   'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6R]G%USXC@6AO^*
MBIV:[:[J 7_PV9ND*AU9]DQMME.=S<[%UEXX(,#5QJ(ED4S/KQ_;&(S *'CJ
MG>V+#AB?Y]CAC8]U7EE7KT)^54O.-?EME6;JNK/4>OVQUU/3)5_%JBO6/,L_
MF0NYBG7^5BYZ:BUY/"N#5FG/<YQA;Q4G6>?FJMSV(&^NQ$:G2<8?)%&;U2J6
MWS_Q5+Q>=]S.;L.79+'4Q8;>S=4Z7O!'KI_6#S)_U]M39LF*9RH1&9%\?MVY
M=3]&_J0(*/?X3\)?U<%K4IS*LQ!?BS<_SZX[3G%$/.5372#B_,<+O^-I6I#R
MX_A603O[G$7@X>L=G94GGY_,<ZSXG4A_369Z>=T9=\B,S^--JK^(UXA7)S0H
M>%.1JO)_\EKMZW3(=*.T6%7!^1&LDFS[,_ZM^D4<!+C],P%>%> =!PS.!/A5
M@']IAGX5T+\T8% %#"X-&%8!PTL#1E7 Z-* <14P+K_=[==1?I<TUO'-E12O
M1!9[Y[3B12F(,CK_"I.LT.ZCEOFG21ZG;QZ7L>1+D<ZX5'\GP;=-HK^3G\B_
M8BGC0E7D'>4Z3E+U/M_Z]$C)NQ_>DQ](CZ@B4)$D(T]9HM6'?&/^^CY)TUR2
MZJJG\X,K4O2FU8'<;0_$.W,@/KD7F5XJ$F0S/C/C>_E)[<_,VYW9)\\*O-TL
MNL3I?R">X[E-QV,/?^3K+O&=L^'4'O[+)K.&!_;P^UCFX>[9<'9Y=J<A/+P\
MW&L(C^SAE$_/';SQ3?I[C?HESS_#NTMCI8B8DT<MIE_)?_^9?TY^UGRE_M=P
M<)^VL'XSK*@%']4ZGO+K3GZQ5UR^\,[-CW]SA\X_FD2"A%$D+$#"&!(6(F$1
M"&8(K[\77M]&O[D3JU5>7U4ANP\DWNBED,GO?+:[^+W+KWC;E^^;A&B%MQ4B
M$D:1L  )8TA8N(4-2EAQ$_=R,W"J?U>]ET.57;*G(:'!7D*#%A):QY*\Q.F&
ME]*9B32-I2)K+K<R:E21E=]614@81<(")(PA8>$6-CK0AM-UW",!O;&3H9WA
M7CO#%MI)E-I<?.FQ@MN*!@FC2%B A#$D+!R>7%!<=S(>#AS//U).TY[CD3_V
MAL-F^8SV\AFUD$\^;E4ZSF9)MKA00U9Z6PTA810)"Y PAH2%HXLUU+2G54/C
MO8;&5@U]GL^Y+"2SELF4UY6J1?VR)F@K(R2,;F'#@]^:-S!_L0$R'QN?U C/
M[QZG#)$I(Q#,T,YDKYV)53L/\?<5SW0Y<BLO0F4)B[-<1U.A=%./X).5V%8L
M2!C=PB:'?V*C[K%<D!E90T;_.&.(S!B!8(9:7*?N1#EVO4B>7VQD<8]S,N!Z
MHU39R6UU Z51*"V TAB4%E:TPS+DG1EOH1*;4CMH>KKMI/9G!F;V'*U%AZ11
M*"V TAB4%E:T-X9GJ)RFWKQ:;UX[O>VZY]LQW5M7-RN\M="0- JE!5 :@]+"
MBG9X=3NYJH$2FBJKV^2NM1EZ5F6'0[^WI 9MGD-I%$H+H#0&I845S2JUOZ(O
M[M:-<=?>&;\7>M-X V^/:RT@:-<;2@N@- :EA5!:A**96JL[Z.X :?^YT(8Y
ME$:AM !*8U!:"*5%*)JIP+H/[U[>B-\5U2K/C,R%K!L;;Y57:%\>2J-06@"E
M,2@M=$];[I.^,W1=[[C(@M*:LJO[]ZZ]@?]H#!*28J+7MTVBDG+2UUM*.VT)
M>^/QQ!^.S'.\NW1':C_8UOJ MMVAM!!*BU T4T1U ]^U=_ ?-L]I,JUJYZZ=
MWZ@8:*,>2J-06@"E,2@MA-(B%,W47FT N!/HG1NT^P^E42@M@-(8E!9":1&*
M9DX!K3T%S^XI5"54B;0LH&)G9[Y1/>W4MDJ$TJAWVF5WW4%#DSV YF6->=W!
MX"1O",T;H6BF@FJKP+-;!;>+A>2+6'.2<4W64DPYGRDREV)5#0B$I:C:X:V%
M!/4(*MJAP>B-G*Y[K")H\[\I:7_0G1Q+")DT0M%,"=7=?\_>_?_\PN5/MVDJ
M=.&'D\_KX@:^42W01C^41J&T $IC4%H(I44HFJF]VA/PH'/G/6C_'TJC4%H
MI3$H+832(A3-5&!M%7AVJ^#/WH)!C00HC58TXU:H^0X,ZA$TI>TWWH!!V_\H
MFJF?NOWOV6?0W_[[GCQ(L9#QJE$GT'8_E$:AM !*8U!:"*5%*)JIN+K=[PVA
M-1/:U(?2*)060&D,2@NAM A%,Q58=_Z]RZ?N'TR#_$#B_6AT(44N4A6G>6W=
MCTK?;=9$B^9Z"IW.#Z51*"VH:.:\[J,2R: I0R@M0M%,\=6.@6=W#.Y$E@]8
M=?*<<C+CSYHH/MW(1">\<<:'G=9:6%#? $H+H#0&I8506H2BF0JL?0,/ZAMX
M4-\ 2J-06@"E,2@MA-(B%,U<<*#V#7R[;P";\6'/TU:;4!J%T@(HC4%IH=_P
M9(+?]\=]_WA>)2JOJ;O:;?#M;H.A.U$VBAN+KAW36E907P%*"Z T!J6%4%J$
MHIG2JUT*WT,671_J54!I%$H+H#0&I8506H2BF0H\6.;'_OP"KNABEP#"K@&$
M700(NPH0=AF@TZ<8W-'8&8P.'DJO=/=7.!1^[5#X=H?B*1_O*IUK+(=KF4SU
M[@D:$F<S\N7QJ;D$0PT**(U":0&4QJ"T$$J+4#13B+75X4.?=/"AU@>41J&T
M $IC4%H(I44HFJG VOKP_T]/.MCSM-8FU!2!T@(HC4%IH=^PN-#0G7C'BXY$
MJ+2F[&J_P[?['0_G:BS4M(#2*)060&D,2@NAM A%,Z56NQO^&%ICH>X&E$:A
MM !*8U!:"*5%*)JIP-K=\.WK(N%J+-3W@-(HE!9 :0Q*"RO:88T=CAQW.#XN
ML5!'HW>PY/>*RT6Y_+LB4[')]':-[/W6_1+SM^7"ZD?;[]R/;+M0?(W9KEM_
M'\M%DBF2\GF.=+JC_!3E=BGX[1LMUN7"XL]":[$J7RYY/..RV"'_?"Z$WKTI
M$NP7Y+_Y U!+ P04    " #:.P154E4A,KL(   78   &0   'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6RUG6MOVS@6AO\*X1TL.D ;Z^);NHF!)J3$+M"9
MH$9F/C,6[0C5Q2O)2;/8'[^DK%BBH] VYIU^:&V'YR%EO>&1WD.Q5\]Y\:-\
ME+(B/],D*Z\'CU6U^3P<ELM'F8KR(M_(3/UDE1>IJ-3;8CTL-X4441V4)D//
M<2;#5,398'Y5?W97S*_R;97$F;PK2+E-4U&\W,@D?[X>N(/7#[['Z\=*?S"<
M7VW$6BYD=;^Y*]2[X9X2Q:G,RCC/2"%7UX,O[F?N7^J NL4?L7PN.Z^)/I2'
M//^AWWR-K@>.'I%,Y++2"*'^>9*W,DDT28WC/PUTL.]3!W9?O]*#^N#5P3R(
M4M[FR9]Q5#U>#V8#$LF5V";5]_R9R^: QIJWS).R_IL\[]I.5./EMJSRM E6
M(TCC;/>O^-E\$9T UW\GP&L"O%,#_"; /S5@U 2,#@/&[P2,FX#QJ0&3)F!R
M:L"T"9B>>@RS)F!6G]W=Z:C/)165F%\5^3,I=&M%TR]J0=31ZA3&F=;NHBK4
M3V,55\T75;[\\>E&G?V(W.:I^I4H12VJ3^0W411"*XM\H+(2<5+^JCZ]7U#R
MX9=?KX:5ZETSALNF)[;KR7NG)Y=\R[/JL20LBV34$Q_8X_UC\:$]?F*)'ZIO
M;?_5>:]?W8UG!7X3+\3U/A+/\=R>X=R>'.WT1-,3HL<ZVIWUG0I[]+]%=D%\
MM^[<ZSL31\*W.MQY-SS\:^'\A$.?U(=^:3F+_OX7P*]Q_IF_ #T#N]F11OTD
MG64^EQNQE-<#E49*63S)P?R?_W GSK_ZY(&$422,(6$!$A8B81P$,U0WVJMN
M9*//OV;1=BG5-4!%2BU DF^TZ$JR+D16*2E6.<E4XI?I)LE?I"S)AS@CY:-0
M0^F;>V^LW9TK322,(F$,"0N0L' '&]<P?<'X-!]-W>FEFMN?NJ(#]6F(;KP7
MW=@J.C6]I2JS&X+KTY*5<JZ6D#"*A#$D+$#"0B2,@V"&XB9[Q4U@R76"5!T2
M1I$PAH0%2%B(A'$0S%#==*^ZJ76>N\\*N<S76?Q?);ME]Z9&_M2OI;KI3D23
M9;?9DRSUZZ/3HK73<P6*A%$DC"%AP0XVZ61%U_/&COYC)L;PY)8<-$!#6K.]
MM&96:=W)HO:+LJ6T2<4*.5<J2!A%PA@2%B!A(1+&03!#<)=[P5W",N@E4G5(
M&$7"&!(6(&$A$L9!,$-UKM/:@HYUHON]N1_-MU59B2R*L_6Q6U [\5S]06D4
M2F-06M#0NK>.KCN:S@XSY(GM.&ITIG(ZAK)K3Y&+^Y+$9;GM-6EO[-%GJP1)
MHU ::VC=\^5-W8GKF><K@/8:0FD<13.UY+5:\NQ:RBN95;%(B'@6140VXD5-
M2+VRLH+.EA621J$TUM!<MSL/'$H*V6,(I7$4S914:_>[5E]W_D>N;OWB)*Y>
M2*'N 7NU!/7YH30*I;&&-NM(R;F8C$>'<H*:^% :1]%,.;4^OFLW\K_'Y8]/
MJT)*$F>55#U4[\L*ZM%#:11*8PW-E)7C.OZAKJ ./)3&43135ZU5[]J]^C_K
M11?JID\\R4*LY:XP1"*E+;(2<4&>1+*5]25YE">)*$JRD<7N\KS_ZASJZD-I
M%$IC#6W:49]_>?'VL@MJV4-I'$4SQ=>Z]J[5GCUNH/8*#&K@0VD42F-06M#0
M#.?3Z;5(3V[)42,T]=/Z[Z[=@/^2)/FR-MCK^>C30VU?G2PDJ-$.I5$HC4%I
M04/KWF^^4=#1)APU)E,ZK;_NGFVPD_^1;W$6I]NT5RU0KQU*HU :@]("*"V$
MTCB*9FJPM=Q=G.?N0DUW*(U":0Q*"Z"T$$KC*)JYJK2UWCV[]7ZZZ64'G2L^
M*(U"::RA&:;70>8*H#V&4!I'T4Q)M9Z\=\23[\^JXN=[6=7..UM94)<>2F-0
M6@"EA5 :1]%,#;9>ON?!LJH'=?.A- JE,2@M@-)"*(VC:*;\6M_?L_O^9V15
MJ/T/I5$HC34T(ZMZ%^/#O IU_Z$TCJ*9HFK=?\_N_M^_+A[4QG\1+]MUA"*+
MR/?%?>_J,#OT;(%!"P%0&H/2 B@MA-(XBF8*L2T7>&-<<H56 J T"J4Q*"V
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MA*!%"2B-0FD,2@O\G@<1W-'8=0[6^8:G-N2H\9D2:DL)OOVQ@)[[@8]DH>Y
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MBA>]93&1;&5ZH1F3JK,RPZ5JQX%K _5]SIC<3K1 U>"'?P%02P,$%     @
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MX>HE^\0KK@K!VGZT 6"" "8' V1'$QY I@ADND?(J8?P/[!,S]F%KE<!9(9
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M"](M!'8+XBT$>BOJK01Z*^JM!'KKZ&&;0&]%O95 ;T6]E4!O1;V50&]%O95
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MLKX;L_SK%^CM-:UUV1SR6?>5PN034$L! A0#%     @ VCL$50=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " #:.P15HY<CG>\    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " #:.P15F5R<(Q &  "<)P  $P
M        @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -H[
M!%5Y@39%V@4  -4>   8              " @0X(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " #:.P15W[[]*ZH&  !''   &
M        @($>#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ VCL$52K+B!6C @  :@<  !@              ("!_A0  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( -H[!%4=Z%++N0<  &@D   8
M              " @=<7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " #:.P151C#0>D<.  "RJ   &               @('&'P  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ VCL$52T ,&+.!P
MZB$  !@              ("!0RX  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( -H[!%7](3SC/0(  (P%   8              " @4<V
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #:.P15^P+4
M$]4+  "$'   &               @(&Z.   >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ VCL$596TC6<W)P  -88  !@
M ("!Q40  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( -H[
M!%4@S@8^8@,  $D'   9              " @3)L  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ VCL$5=M6'3^'!   )@L  !D
M         ("!RV\  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " #:.P15+9'?+5(#  #A!@  &0              @(&)=   >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -H[!%7#]R77& ,  .8&
M   9              " @1)X  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ VCL$5>I!^H]P!P  [B$  !D              ("!87L
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #:.P15PA:R
M ;P,  ":)@  &0              @($(@P  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( -H[!%7?!Q92"08    2   9
M  " @?N/  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
MVCL$5<OS??;("@  -QX  !D              ("!.Y8  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " #:.P15#:F]E.4$  #0"P  &0
M            @($ZH0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( -H[!%6E".H9.P,  %L'   9              " @5:F  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ VCL$59,K#7.?"
MXQ<  !D              ("!R*D  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " #:.P15<TXBWE0F  !)@0  &0              @(&>
ML@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( -H[!%6U
MPE3/,P@  *@9   9              " @2G9  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ VCL$54;&89&? @  M 4  !D
M     ("!D^$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -H[!%7=Z"Y)2 0  &4*   9              "
M@;KQ  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ VCL$
M5=T-NTL: P  Q 8  !D              ("!.?8  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    " #:.P15F1S0-4$#   ##   &0
M        @(&*^0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( -H[!%4/G*[W=@0  )H8   9              " @0+]  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ VCL$56Z]^39A$0  O  !
M !D              ("!KP$! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    " #:.P15^6&YYCH#  #N"P  &0              @(%'$P$
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( -H[!%4\<31#
MEP,  !@0   9              " @;@6 0!X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ VCL$5?+/WCZ) P   @P  !D
M ("!AAH! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #:
M.P15\9+^M"<%  "Q'@  &0              @(%&'@$ >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( -H[!%4\"DSWDP,  #L1   9
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M970T,2YX;6Q02P$"% ,4    " #:.P15$>:_SML%  #Y*   &0
M    @($%.0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M -H[!%4#NB-Y9@,   @+   9              " @1<_ 0!X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ VCL$51 &DT^! P  <Q(  !D
M             ("!M$(! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    " #:.P15R)MSUM@"   )"0  &0              @(%L1@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( -H[!%4?5>2^?PP
M %FC   9              " @7M) 0!X;"]W;W)K<VAE971S+W-H965T-#8N
M>&UL4$L! A0#%     @ VCL$58!'?)RO @  "@<  !D              ("!
M,58! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " #:.P15
M?,FC96\"  "S!@  &0              @($760$ >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;%!+ 0(4 Q0    ( -H[!%71%7>[B ,  (,,   9
M      " @;U; 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%
M  @ VCL$5>"7*$BN"   G%\  !D              ("!?%\! 'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " #:.P154E4A,KL(   78
M&0              @(%A: $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+
M 0(4 Q0    ( -H[!%7-#/9!@@,  &D0   9              " @5-Q 0!X
M;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ VCL$57 0KAL,
M P  [ L  !D              ("!#'4! 'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6Q02P$"% ,4    " #:.P15[*.J^*4"  #S!P  &0
M@(%/> $ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( -H[
M!%61J.6#P 4  #,L   9              " @2M[ 0!X;"]W;W)K<VAE971S
M+W-H965T-34N>&UL4$L! A0#%     @ VCL$55#'\$I/ P  EA4   T
M         ( !(H$! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #:.P15EXJ[
M',     3 @  "P              @ &<A $ 7W)E;',O+G)E;'-02P$"% ,4
M    " #:.P15]FJTHF\$  !G)   #P              @ &%A0$ >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ VCL$5;P!UL'@ 0  ["   !H
M     ( !(8H! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ VCL$5134<>30 0  K2   !,              ( !.8P! %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     #\ /P P$0  .HX!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>232</ContextCount>
  <ElementCount>282</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Shareholders' Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - The Company and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/TheCompanyandBasisofPresentation</Role>
      <ShortName>The Company and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2115103 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2118104 - Disclosure - Intangibles, Net and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangiblesNetandGoodwill</Role>
      <ShortName>Intangibles, Net and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - Fixed Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FixedAssetsNet</Role>
      <ShortName>Fixed Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2124106 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127107 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2131108 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137109 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2143111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2145112 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2147113 - Disclosure - Business Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/BusinessAcquisition</Role>
      <ShortName>Business Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.insmed.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2316302 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/Inventory</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - Intangibles, Net and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangiblesNetandGoodwillTables</Role>
      <ShortName>Intangibles, Net and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/IntangiblesNetandGoodwill</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Fixed Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FixedAssetsNetTables</Role>
      <ShortName>Fixed Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/FixedAssetsNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/AccruedLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2332307 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/Debt</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/StockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - The Company and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails</Role>
      <ShortName>The Company and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/TheCompanyandBasisofPresentation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Significant Observable Inputs of Deferred Business Acquisition Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Significant Observable Inputs of Deferred Business Acquisition Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Significant Unobservable Inputs Of Contingent Consideration Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Significant Unobservable Inputs Of Contingent Consideration Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies - Changes in the Fair Value of Deferred and Contingent Consideration Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Changes in the Fair Value of Deferred and Contingent Consideration Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2412408 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2413409 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2414410 - Disclosure - Summary of Significant Accounting Policies - Summary of Revenues by Geographic Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Revenues by Geographic Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2417411 - Disclosure - Inventory - Schedule of Inventory, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails</Role>
      <ShortName>Inventory - Schedule of Inventory, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Intangibles, Net and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangiblesNetandGoodwillDetails</Role>
      <ShortName>Intangibles, Net and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/IntangiblesNetandGoodwillTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Fixed Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FixedAssetsNetDetails</Role>
      <ShortName>Fixed Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/FixedAssetsNetTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Leases - Lease, costs (Details) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/LeasesLeasecostsDetailsDetails</Role>
      <ShortName>Leases - Lease, costs (Details) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Debt - Components of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtComponentsofDebtDetails</Role>
      <ShortName>Debt - Components of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Debt - Future Principal Repayments of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails</Role>
      <ShortName>Debt - Future Principal Repayments of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Debt - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtInterestExpenseDetails</Role>
      <ShortName>Debt - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Shareholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ShareholdersEquityNarrativeDetails</Role>
      <ShortName>Shareholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/IncomeTaxes</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="insm-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2448426 - Disclosure - Business Acquisition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails</Role>
      <ShortName>Business Acquisition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="insm-20220630.htm">insm-20220630.htm</File>
    <File>insm-20220630.xsd</File>
    <File>insm-20220630_cal.xml</File>
    <File>insm-20220630_def.xml</File>
    <File>insm-20220630_lab.xml</File>
    <File>insm-20220630_pre.xml</File>
    <File>insm-20220630ex101.htm</File>
    <File>insm-20220630ex311.htm</File>
    <File>insm-20220630ex312.htm</File>
    <File>insm-20220630ex321.htm</File>
    <File>insm-20220630ex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="758">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>74
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "insm-20220630.htm": {
   "axisCustom": 1,
   "axisStandard": 25,
   "contextCount": 232,
   "dts": {
    "calculationLink": {
     "local": [
      "insm-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "insm-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "insm-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "insm-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "insm-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "insm-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 471,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 14,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 19
   },
   "keyCustom": 30,
   "keyStandard": 252,
   "memberCustom": 28,
   "memberStandard": 39,
   "nsprefix": "insm",
   "nsuri": "http://www.insmed.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.insmed.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115103 - Disclosure - Inventory",
     "role": "http://www.insmed.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118104 - Disclosure - Intangibles, Net and Goodwill",
     "role": "http://www.insmed.com/role/IntangiblesNetandGoodwill",
     "shortName": "Intangibles, Net and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - Fixed Assets, Net",
     "role": "http://www.insmed.com/role/FixedAssetsNet",
     "shortName": "Fixed Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124106 - Disclosure - Accrued Liabilities",
     "role": "http://www.insmed.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127107 - Disclosure - Leases",
     "role": "http://www.insmed.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131108 - Disclosure - Debt",
     "role": "http://www.insmed.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137109 - Disclosure - Shareholders' Equity",
     "role": "http://www.insmed.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Stock-Based Compensation",
     "role": "http://www.insmed.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143111 - Disclosure - Income Taxes",
     "role": "http://www.insmed.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145112 - Disclosure - Commitments and Contingencies",
     "role": "http://www.insmed.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.insmed.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147113 - Disclosure - Business Acquisition",
     "role": "http://www.insmed.com/role/BusinessAcquisition",
     "shortName": "Business Acquisition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOfFinancialInstrumentsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOfFinancialInstrumentsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316302 - Disclosure - Inventory (Tables)",
     "role": "http://www.insmed.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - Intangibles, Net and Goodwill (Tables)",
     "role": "http://www.insmed.com/role/IntangiblesNetandGoodwillTables",
     "shortName": "Intangibles, Net and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Fixed Assets, Net (Tables)",
     "role": "http://www.insmed.com/role/FixedAssetsNetTables",
     "shortName": "Fixed Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://www.insmed.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Leases (Tables)",
     "role": "http://www.insmed.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332307 - Disclosure - Debt (Tables)",
     "role": "http://www.insmed.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.insmed.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - The Company and Basis of Presentation (Details)",
     "role": "http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails",
     "shortName": "The Company and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
     "shortName": "Summary of Significant Accounting Policies - Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "iec080385c64348cb8d266b6830480fb9_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "insm:MarketableSecuritiesAdditional",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "insm:MarketableSecuritiesAdditional",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "icfe80c21994c4bb9b647c882148aa2b8_I20210831",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Significant Observable Inputs of Deferred Business Acquisition Liabilities (Details)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Significant Observable Inputs of Deferred Business Acquisition Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i060750a8e6764e58986207b6fa039245_I20220630",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i26bcf703891e40a19cb16e952a3c238c_I20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Significant Unobservable Inputs Of Contingent Consideration Liability (Details)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails",
     "shortName": "Summary of Significant Accounting Policies - Significant Unobservable Inputs Of Contingent Consideration Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i26bcf703891e40a19cb16e952a3c238c_I20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i9029a1175b8d4c0bb7ad648dd57b8b45_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Changes in the Fair Value of Deferred and Contingent Consideration Liabilities (Details)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Changes in the Fair Value of Deferred and Contingent Consideration Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i9029a1175b8d4c0bb7ad648dd57b8b45_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i2f46d4b8f14b4f9a9806c15e65465675_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412408 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i2f46d4b8f14b4f9a9806c15e65465675_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i8297b16fe1be40cb95165a0bea1fa1fe_D20220101-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413409 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails",
     "shortName": "Summary of Significant Accounting Policies - Concentration Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i8297b16fe1be40cb95165a0bea1fa1fe_D20220101-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414410 - Disclosure - Summary of Significant Accounting Policies - Summary of Revenues by Geographic Location (Details)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Revenues by Geographic Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i7b44c6e566f24a9882c1b3f8f3b4c0ee_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)",
     "role": "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
     "shortName": "Consolidated Statements of Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417411 - Disclosure - Inventory - Schedule of Inventory, Current (Details)",
     "role": "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails",
     "shortName": "Inventory - Schedule of Inventory, Current (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Intangibles, Net and Goodwill (Details)",
     "role": "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails",
     "shortName": "Intangibles, Net and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Fixed Assets, Net (Details)",
     "role": "http://www.insmed.com/role/FixedAssetsNetDetails",
     "shortName": "Fixed Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "insm:AccruedClinicalTrialExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Accrued Liabilities (Details)",
     "role": "http://www.insmed.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "insm:AccruedClinicalTrialExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.insmed.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Leases - Lease, costs (Details) (Details)",
     "role": "http://www.insmed.com/role/LeasesLeasecostsDetailsDetails",
     "shortName": "Leases - Lease, costs (Details) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.insmed.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i3905fa6bad2f4f878b2411f148bf023a_I20210531",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Debt - Components of Debt (Details)",
     "role": "http://www.insmed.com/role/DebtComponentsofDebtDetails",
     "shortName": "Debt - Components of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Debt - Future Principal Repayments of Debt (Details)",
     "role": "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails",
     "shortName": "Debt - Future Principal Repayments of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Debt - Interest Expense (Details)",
     "role": "http://www.insmed.com/role/DebtInterestExpenseDetails",
     "shortName": "Debt - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i3ea404b9803f4458944b7dbf3eefe5d8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Shareholders' Equity (unaudited)",
     "role": "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited",
     "shortName": "Consolidated Statements of Shareholders' Equity (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i6afe0edb9cc44adca52bd18a9cba27db_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i92ecd30d90114111bd1344c30c28673d_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Shareholders' Equity - Narrative (Details)",
     "role": "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
     "shortName": "Shareholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i34b29fd1e2a04660a3bb612c3f24dde5_I20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "id29b955148664a0eb00d37f9dc631961_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)",
     "role": "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "id29b955148664a0eb00d37f9dc631961_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Income Taxes (Details)",
     "role": "http://www.insmed.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i9182dcbb65704f8da6bd08bf13f20c3f_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i07acd876919448939ae3e9671ddb5ce7_D20210524-20210524",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "insm:BusinessAcquisitionConsecutiveTradingDayPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "days",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448426 - Disclosure - Business Acquisition - Narrative (Details)",
     "role": "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails",
     "shortName": "Business Acquisition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i07acd876919448939ae3e9671ddb5ce7_D20210524-20210524",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "insm:BusinessAcquisitionConsecutiveTradingDayPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "days",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Cash Flows (unaudited)",
     "role": "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
     "shortName": "Consolidated Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "if2feebc246964bc390c0f21deae432ad_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows (unaudited) (Parenthetical)",
     "role": "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - The Company and Basis of Presentation",
     "role": "http://www.insmed.com/role/TheCompanyandBasisofPresentation",
     "shortName": "The Company and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20220630.htm",
      "contextRef": "i68a9c88fddc548479e98550527d1fccb_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 70,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "JAPAN"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "verboseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "verboseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "verboseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "verboseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "verboseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "verboseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "verboseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "verboseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "verboseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "verboseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "insm_A2019IncentivePlanSecondAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Incentive Plan, Second Amendment",
        "label": "2019 Incentive Plan, Second Amendment [Member]",
        "terseLabel": "2019 Incentive Plan, Second Amendment"
       }
      }
     },
     "localname": "A2019IncentivePlanSecondAmendmentMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_A2019IncentivePlanThirdAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Incentive Plan, Third Amendment",
        "label": "2019 Incentive Plan, Third Amendment [Member]",
        "terseLabel": "2019 Incentive Plan"
       }
      }
     },
     "localname": "A2019IncentivePlanThirdAmendmentMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_AccruedClinicalTrialExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.",
        "label": "Accrued Clinical Trial Expenses",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenses",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AccruedConstructionLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Construction Liabilities, Current",
        "label": "Accrued Construction Liabilities, Current",
        "terseLabel": "Accrued construction costs"
       }
      }
     },
     "localname": "AccruedConstructionLiabilitiesCurrent",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AccruedLiabilitiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities, Current",
        "label": "Accrued Liabilities, Current [Member]",
        "terseLabel": "Accrued Liabilities, Current"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_AccruedRoyaltiesAndMilestonePaymentsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Royalties and Milestone Payments, Current",
        "label": "Accrued Royalties and Milestone Payments, Current",
        "terseLabel": "Accrued royalty payable"
       }
      }
     },
     "localname": "AccruedRoyaltiesAndMilestonePaymentsCurrent",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AccruedSalesAllowancesAndRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Sales Allowances And Related Costs",
        "label": "Accrued Sales Allowances And Related Costs",
        "terseLabel": "Accrued sales allowances and related costs"
       }
      }
     },
     "localname": "AccruedSalesAllowancesAndRelatedCosts",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AccruedTechnicalOperationExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.",
        "label": "Accrued Technical Operation Expenses",
        "terseLabel": "Accrued technical operation expenses"
       }
      }
     },
     "localname": "AccruedTechnicalOperationExpenses",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AcquiredResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Research And Development",
        "label": "Acquired Research And Development [Member]",
        "terseLabel": "Acquired ARIKAYCE R&amp;D"
       }
      }
     },
     "localname": "AcquiredResearchAndDevelopmentMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_AlgaeneXIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AlgaeneX, Inc.",
        "label": "AlgaeneX, Inc. [Member]",
        "terseLabel": "AlgaeneX"
       }
      }
     },
     "localname": "AlgaeneXIncMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_AtTheMarketAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Agreement",
        "label": "At The Market Agreement [Member]",
        "terseLabel": "ATM Program"
       }
      }
     },
     "localname": "AtTheMarketAgreementMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-For-Sale Securities, Gross Unrealized Gain (Loss), Number Of Securities",
        "label": "Available-For-Sale Securities, Gross Unrealized Gain (Loss), Number Of Securities",
        "terseLabel": "Unrealized gain or loss"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesGrossUnrealizedGainLossNumberOfSecurities",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average Sales Prices Of Publicly Disclosed Priority Review Voucher Sales Obligated to Pay Equity Holders, Percentage",
        "label": "Average Sales Prices Of Publicly Disclosed Priority Review Voucher Sales Obligated to Pay Equity Holders, Percentage",
        "terseLabel": "Potential payout, average sales prices, percentage"
       }
      }
     },
     "localname": "AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "insm_BusinessAcquisitionConsecutiveTradingDayPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Consecutive Trading Day Period",
        "label": "Business Acquisition, Consecutive Trading Day Period",
        "terseLabel": "Consecutive trading day period"
       }
      }
     },
     "localname": "BusinessAcquisitionConsecutiveTradingDayPeriod",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares",
        "label": "Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares",
        "terseLabel": "Shares issued upon milestone achievements (in shares)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "insm_BusinessCombinationDeferredLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Deferred Liability",
        "label": "Business Combination, Deferred Liability",
        "terseLabel": "Deferred consideration"
       }
      }
     },
     "localname": "BusinessCombinationDeferredLiability",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_BusinessCombinationDeferredPaymentsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Deferred Payments, Current",
        "label": "Business Combination, Deferred Payments, Current",
        "terseLabel": "Deferred consideration"
       }
      }
     },
     "localname": "BusinessCombinationDeferredPaymentsCurrent",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_CommonStockAuthorizedAggregateGrossSalesProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Authorized, Aggregate Gross Sales Proceeds",
        "label": "Common Stock Authorized, Aggregate Gross Sales Proceeds",
        "terseLabel": "Common stock authorized, aggregate gross sales proceeds (up to)"
       }
      }
     },
     "localname": "CommonStockAuthorizedAggregateGrossSalesProceeds",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_ComputerHardwareAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Hardware And Software",
        "label": "Computer Hardware And Software [Member]",
        "terseLabel": "Computer hardware and software"
       }
      }
     },
     "localname": "ComputerHardwareAndSoftwareMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Debt Instrument, Discount Amortization Period, Remaining",
        "label": "Convertible Debt Instrument, Discount Amortization Period, Remaining",
        "terseLabel": "Remaining discount amortization period"
       }
      }
     },
     "localname": "ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_ConvertibleDebtInterestExpenseTotal": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Debt, Interest Expense, Total",
        "label": "Convertible Debt, Interest Expense, Total",
        "totalLabel": "Total convertible debt interest expense"
       }
      }
     },
     "localname": "ConvertibleDebtInterestExpenseTotal",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer A [Member]",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B [Member]",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer C [Member]",
        "label": "Customer C [Member]",
        "terseLabel": "Customer C"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_DebtInstrumentConversionTermAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Conversion Term [Axis]",
        "label": "Debt Instrument Conversion Term [Axis]",
        "terseLabel": "Debt Instrument Conversion Term [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentConversionTermAxis",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_DebtInstrumentConversionTermDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Debt Instrument Conversion Term [Axis]",
        "label": "Debt Instrument Conversion Term [Domain]",
        "terseLabel": "Debt Instrument Conversion Term [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentConversionTermDomain",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_DebtInstrumentConversionTermFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion Term Four [Member]",
        "label": "Debt Instrument, Conversion Term Four [Member]",
        "terseLabel": "Conversion Term (iv)"
       }
      }
     },
     "localname": "DebtInstrumentConversionTermFourMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_DebtInstrumentConversionTermOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion Term One [Member]",
        "label": "Debt Instrument, Conversion Term One [Member]",
        "terseLabel": "Conversion Term (i)"
       }
      }
     },
     "localname": "DebtInstrumentConversionTermOneMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_DebtInstrumentConversionTermThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion Term Three [Member]",
        "label": "Debt Instrument, Conversion Term Three [Member]",
        "terseLabel": "Conversion Term (iii)"
       }
      }
     },
     "localname": "DebtInstrumentConversionTermThreeMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_DebtInstrumentConversionTermTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion Term Two [Member]",
        "label": "Debt Instrument, Conversion Term Two [Member]",
        "terseLabel": "Conversion Term (ii)"
       }
      }
     },
     "localname": "DebtInstrumentConversionTermTwoMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change",
        "label": "Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change",
        "terseLabel": "Threshold trading days following fundamental change"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "insm_DebtInstrumentOptionToPurchaseAdditionalDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Option To Purchase Additional Debt",
        "label": "Debt Instrument, Option To Purchase Additional Debt",
        "terseLabel": "Option to purchase additional debt"
       }
      }
     },
     "localname": "DebtInstrumentOptionToPurchaseAdditionalDebt",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_DeferredConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Consideration",
        "label": "Deferred Consideration [Member]",
        "terseLabel": "Deferred Consideration"
       }
      }
     },
     "localname": "DeferredConsiderationMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_DevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Regulatory Milestones",
        "label": "Development And Regulatory Milestones [Member]",
        "terseLabel": "Development and regulatory milestones"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_EmployeeStockPurchasePlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan 2018 [Member]",
        "label": "Employee Stock Purchase Plan 2018 [Member]",
        "terseLabel": "2018 ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2018Member",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_EuropeAndTheRestOfTheWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Europe And The Rest Of The World",
        "label": "Europe And The Rest Of The World [Member]",
        "terseLabel": "Europe And The Rest Of The World"
       }
      }
     },
     "localname": "EuropeAndTheRestOfTheWorldMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_FairValueLevel1Level2Level3TransfersAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Level 1, Level 2, Level 3 Transfers, Amount",
        "label": "Fair Value Level 1, Level 2, Level 3 Transfers, Amount",
        "terseLabel": "Fair value transfers in or out of Level 1, Level 2, or Level 3"
       }
      }
     },
     "localname": "FairValueLevel1Level2Level3TransfersAmount",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Increase (Decrease) In Fair Value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Increase (Decrease) In Fair Value",
        "terseLabel": "Change in Fair Value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIncreaseDecreaseInFairValue",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments",
        "negatedTerseLabel": "Adjustments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the sum of accrued expenses and Other Current Liabilities.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Current Liabilities",
        "terseLabel": "Accrued liabilities, accrued compensation and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets)",
        "label": "Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) [Policy Text Block]",
        "terseLabel": "Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets)"
       }
      }
     },
     "localname": "InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "insm_LeaseRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Remaining Lease Term",
        "label": "Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "LeaseRemainingLeaseTerm",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount",
        "terseLabel": "Lease cost, future right-of-use asset"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAmount",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_LongTermDebtMaturityAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Maturity, after Year Four",
        "label": "Long-Term Debt, Maturity, after Year Four",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturityAfterYearFour",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_ManufacturingEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Equipment",
        "label": "Manufacturing Equipment [Member]",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "ManufacturingEquipmentMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_MarketableSecuritiesAdditional": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Additional",
        "label": "Marketable Securities, Additional",
        "negatedTerseLabel": "Marketable securities, additional"
       }
      }
     },
     "localname": "MarketableSecuritiesAdditional",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_MeasurementInputProbabilityOfSuccessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Probability Of Success",
        "label": "Measurement Input, Probability Of Success [Member]",
        "terseLabel": "Probabilities of success"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfSuccessMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_MotusBiosciencesIncAndAlgaeneXIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Motus Biosciences, Inc. And AlgaeneX, Inc.",
        "label": "Motus Biosciences, Inc. And AlgaeneX, Inc. [Member]",
        "terseLabel": "Motus and AlgaeneX"
       }
      }
     },
     "localname": "MotusBiosciencesIncAndAlgaeneXIncMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_MotusBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Motus Biosciences, Inc.",
        "label": "Motus Biosciences, Inc. [Member]",
        "terseLabel": "Motus"
       }
      }
     },
     "localname": "MotusBiosciencesIncMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_NoncashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Operating Lease Expense",
        "label": "Noncash Operating Lease Expense",
        "terseLabel": "Noncash operating lease expense"
       }
      }
     },
     "localname": "NoncashOperatingLeaseExpense",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Publicly Disclosed Sales Used To Determine Average Sales Price Owed To Equity Holders",
        "label": "Number Of Publicly Disclosed Sales Used To Determine Average Sales Price Owed To Equity Holders",
        "terseLabel": "Number of publicly disclosed sales used to determine average sales price owed to equity holders"
       }
      }
     },
     "localname": "NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]",
        "label": "One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]",
        "terseLabel": "1.75% convertible senior notes due 2025"
       }
      }
     },
     "localname": "OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_PriorityReviewVoucherMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Priority Review Voucher Milestone",
        "label": "Priority Review Voucher Milestone [Member]",
        "terseLabel": "Priority review voucher milestone"
       }
      }
     },
     "localname": "PriorityReviewVoucherMilestoneMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds Of Sale of Priority Review Voucher Obligated to Pay to Equity Holders, Percentage",
        "label": "Proceeds Of Sale of Priority Review Voucher Obligated to Pay to Equity Holders, Percentage",
        "terseLabel": "Potential payout percentage"
       }
      }
     },
     "localname": "ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "insm_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Public Stock Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_ScheduleofEarningsPerShareBasicandDilutedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule of Earnings Per Share, Basic and Diluted [Table]",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Line Items]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Line Items]"
       }
      }
     },
     "localname": "ScheduleofEarningsPerShareBasicandDilutedLineItems",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_ScheduleofEarningsPerShareBasicandDilutedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Earnings Per Share, Basic and Diluted [Table]",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table]"
       }
      }
     },
     "localname": "ScheduleofEarningsPerShareBasicandDilutedTable",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of inducement share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Inducement Options Grants In Period Gross",
        "terseLabel": "Inducement stock options granted to new employees (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "insm_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. It also includes stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock options and RSUs"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_WeightedAverageProbabilityOfReachingMilestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Probability Of Reaching Milestone",
        "label": "Weighted Average Probability Of Reaching Milestone",
        "terseLabel": "Weighted-average probability of reaching milestone, percentage"
       }
      }
     },
     "localname": "WeightedAverageProbabilityOfReachingMilestone",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero Point Seven Five Percent Convertible Senior Note Due 2028",
        "label": "Zero Point Seven Five Percent Convertible Senior Note Due 2028 [Member]",
        "terseLabel": "0.75% convertible senior notes due 2028"
       }
      }
     },
     "localname": "ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member",
     "nsuri": "http://www.insmed.com/20220630",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r111",
      "r118",
      "r124",
      "r186",
      "r374",
      "r375",
      "r376",
      "r390",
      "r391",
      "r437",
      "r440",
      "r442",
      "r443",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r111",
      "r118",
      "r124",
      "r186",
      "r374",
      "r375",
      "r376",
      "r390",
      "r391",
      "r437",
      "r440",
      "r442",
      "r443",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r111",
      "r118",
      "r124",
      "r186",
      "r374",
      "r375",
      "r376",
      "r390",
      "r391",
      "r437",
      "r440",
      "r442",
      "r443",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r173",
      "r313",
      "r316",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r240",
      "r280",
      "r332",
      "r334",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r566",
      "r569",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/LeasesNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r240",
      "r280",
      "r332",
      "r334",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r566",
      "r569",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/LeasesNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r173",
      "r313",
      "r316",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r213",
      "r218",
      "r219",
      "r220",
      "r221",
      "r240",
      "r280",
      "r322",
      "r332",
      "r334",
      "r362",
      "r363",
      "r364",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r566",
      "r569",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/LeasesNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r213",
      "r218",
      "r219",
      "r220",
      "r221",
      "r240",
      "r280",
      "r322",
      "r332",
      "r334",
      "r362",
      "r363",
      "r364",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r566",
      "r569",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/LeasesNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r170",
      "r171",
      "r313",
      "r315",
      "r567",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r313",
      "r315",
      "r567",
      "r584",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r112",
      "r113",
      "r114",
      "r115",
      "r177",
      "r178",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r374",
      "r375",
      "r376",
      "r390",
      "r391",
      "r408",
      "r409",
      "r410",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r482",
      "r483",
      "r490",
      "r491",
      "r492",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r41",
      "r516"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r174",
      "r175"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/AccruedLiabilitiesDetails",
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r15",
      "r209"
     ],
     "calculation": {
      "http://www.insmed.com/role/FixedAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r29",
      "r53",
      "r54",
      "r55",
      "r557",
      "r577",
      "r581"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r52",
      "r55",
      "r62",
      "r63",
      "r64",
      "r108",
      "r109",
      "r110",
      "r427",
      "r513",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r27",
      "r516"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r374",
      "r375",
      "r376",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r112",
      "r113",
      "r114",
      "r115",
      "r124",
      "r177",
      "r178",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r374",
      "r375",
      "r376",
      "r388",
      "r389",
      "r390",
      "r391",
      "r408",
      "r409",
      "r410",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r482",
      "r483",
      "r490",
      "r491",
      "r492",
      "r493",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r530",
      "r531",
      "r532",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of convertible debt issuance"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments",
        "negatedTerseLabel": "Equity component of convertible debt redemption"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r336",
      "r377",
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r76",
      "r91",
      "r260",
      "r485"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": 3.0,
       "parentTag": "insm_ConvertibleDebtInterestExpenseTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Accretion of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r71",
      "r91",
      "r260",
      "r487"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "insm_ConvertibleDebtInterestExpenseTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r91",
      "r260",
      "r270",
      "r271",
      "r487"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and accretion of debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r91",
      "r196",
      "r203"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "negatedTerseLabel": "Amortization",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r18",
      "r102",
      "r158",
      "r161",
      "r167",
      "r182",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r424",
      "r428",
      "r466",
      "r514",
      "r516",
      "r537",
      "r555"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r40",
      "r102",
      "r182",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r424",
      "r428",
      "r466",
      "r514",
      "r516"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "negatedTerseLabel": "Unrealized loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r180",
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Current available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r13",
      "r180",
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Noncurrent available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r331",
      "r333",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r331",
      "r333",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Shares issued in acquisition (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Share price used to calculate issuable shares (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r412",
      "r413",
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Fair value of total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r90",
      "r420"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of deferred and contingent consideration liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r411",
      "r414",
      "r419"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Cash to be paid upon achievement of milestones",
        "verboseLabel": "Contingent consideration liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r411",
      "r415"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r406",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations and Asset Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r12",
      "r93"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r87",
      "r93",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r87",
      "r475"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r222",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r108",
      "r109",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r26",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r26",
      "r516"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value; 500,000,000 authorized shares, 119,865,023 and 118,738,266 issued and outstanding shares at June\u00a030, 2022 and December\u00a031, 2021,\u00a0respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r61",
      "r68",
      "r545",
      "r562"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r151",
      "r152",
      "r173",
      "r463",
      "r464",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r151",
      "r152",
      "r173",
      "r463",
      "r464",
      "r582",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r151",
      "r152",
      "r173",
      "r463",
      "r464",
      "r582",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r147",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r151",
      "r152",
      "r173",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r148",
      "r151",
      "r152",
      "r153",
      "r463",
      "r465",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r151",
      "r152",
      "r173",
      "r463",
      "r464",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress (CIP)"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible debt securities"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r19",
      "r538",
      "r553",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes",
        "verboseLabel": "Convertible debt securities"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r73",
      "r528"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product revenues (excluding amortization of intangible assets)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r149",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r254",
      "r261",
      "r262",
      "r264",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r101",
      "r106",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r268",
      "r269",
      "r270",
      "r271",
      "r488",
      "r538",
      "r540",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r239",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Initial conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r47",
      "r239",
      "r295",
      "r298",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Initial conversion rate"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percent of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r237",
      "r268",
      "r269",
      "r486",
      "r488",
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r46",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Proceeds from issuance of 0.75% convertible senior notes due 2028",
        "verboseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r48",
      "r101",
      "r106",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r268",
      "r269",
      "r270",
      "r271",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Repurchased amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r48",
      "r101",
      "r106",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r263",
      "r268",
      "r269",
      "r270",
      "r271",
      "r295",
      "r299",
      "r300",
      "r301",
      "r485",
      "r486",
      "r488",
      "r489",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r250",
      "r485",
      "r489"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtComponentsofDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Discount on debt"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r250",
      "r487"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtComponentsofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Debt issuance costs, unamortized",
        "terseLabel": "Underwriting discounts and commissions and other offering expenses",
        "verboseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsofDebtDetails",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r103",
      "r387",
      "r394",
      "r395",
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r22",
      "r23",
      "r385",
      "r539",
      "r552"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTerseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r91",
      "r207"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r339",
      "r340",
      "r368",
      "r369",
      "r371",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r69",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r125",
      "r128",
      "r136",
      "r137",
      "r138",
      "r142",
      "r143",
      "r443",
      "r444",
      "r546",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share (in dollars per share)",
        "verboseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r69",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r128",
      "r136",
      "r137",
      "r138",
      "r142",
      "r143",
      "r443",
      "r444",
      "r546",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share (in dollars per share)",
        "verboseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r139",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to unvested RSU awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r62",
      "r63",
      "r64",
      "r108",
      "r109",
      "r110",
      "r113",
      "r121",
      "r123",
      "r144",
      "r186",
      "r294",
      "r302",
      "r374",
      "r375",
      "r376",
      "r390",
      "r391",
      "r442",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r513",
      "r572",
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of Observable Inputs in Valuation of Deferred Consideration"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r447",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r446",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r446",
      "r447",
      "r449",
      "r450",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r252",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r252",
      "r323",
      "r324",
      "r329",
      "r330",
      "r447",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r323",
      "r324",
      "r329",
      "r330",
      "r447",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r447",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r451",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r451",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payables"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r453",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesChangesintheFairValueofDeferredandContingentConsiderationLiabilitiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r457",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r496",
      "r501",
      "r506"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Finance lease interest expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities, long-term"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r498",
      "r503"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payments of finance lease principal"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r494"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r496",
      "r501",
      "r506"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Finance lease amortization expense"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible assets estimated useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Amortization of intangible assets, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Amortization of intangible assets, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Amortization of intangible assets, 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Amortization of intangible assets, 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Amortization of intangible assets, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r197",
      "r199",
      "r202",
      "r205",
      "r529",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r202",
      "r533"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intangibles, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r197",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r202",
      "r529"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangibles, net",
        "verboseLabel": "Intangibles, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Finite-Lived Intangible Assets [Roll Forward]",
        "terseLabel": "Finite-lived Intangible Assets [Roll Forward]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r91",
      "r272",
      "r273"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r16",
      "r192",
      "r193",
      "r194",
      "r195",
      "r516",
      "r535"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Indefinite-Lived Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r158",
      "r160",
      "r163",
      "r166",
      "r168",
      "r534",
      "r543",
      "r548",
      "r564"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r211",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r382",
      "r384",
      "r386",
      "r392",
      "r397",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r105",
      "r122",
      "r123",
      "r157",
      "r381",
      "r393",
      "r398",
      "r565"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "verboseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r132",
      "r133",
      "r138"
     ],
     "calculation": {
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Dilutive securities, convertible debt (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r138",
      "r338"
     ],
     "calculation": {
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Dilutive securities, share-based payment (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangibles, Net and Goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r65",
      "r156",
      "r484",
      "r487",
      "r547"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r76",
      "r258",
      "r267",
      "r270",
      "r271"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "insm_ConvertibleDebtInterestExpenseTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Summary of Interest Expense"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r86",
      "r88",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r33",
      "r190"
     ],
     "calculation": {
      "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r39",
      "r516"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Inventory, Net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r35",
      "r190"
     ],
     "calculation": {
      "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r34",
      "r190"
     ],
     "calculation": {
      "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "terseLabel": "Investment income"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease, Cost [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeasecostsDetailsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Supplemental Noncash Disclosures included in Consolidated Financial Statements"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43",
      "r102",
      "r162",
      "r182",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r425",
      "r428",
      "r429",
      "r466",
      "r514",
      "r515"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r32",
      "r102",
      "r182",
      "r466",
      "r516",
      "r541",
      "r559"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r45",
      "r102",
      "r182",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r425",
      "r428",
      "r429",
      "r466",
      "r514",
      "r515",
      "r516"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "PARI milestones"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r21",
      "r251",
      "r265",
      "r268",
      "r269",
      "r540",
      "r556"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Year Ending December\u00a031:"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r106",
      "r223",
      "r256"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r106",
      "r223",
      "r256"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r106",
      "r223",
      "r256"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r106",
      "r223",
      "r256"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/DebtComponentsofDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Debt, long-term",
        "totalLabel": "Debt, long-term"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/DebtComponentsofDebtDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r48",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities, non-current"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Insmed share price as of June\u00a030, 2022"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantObservableInputsofDeferredBusinessAcquisitionLiabilitiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSignificantUnobservableInputsOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r87",
      "r89",
      "r92"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r56",
      "r59",
      "r64",
      "r67",
      "r92",
      "r102",
      "r112",
      "r116",
      "r117",
      "r118",
      "r119",
      "r122",
      "r123",
      "r134",
      "r158",
      "r160",
      "r163",
      "r166",
      "r168",
      "r182",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r444",
      "r466",
      "r544",
      "r561"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails",
      "http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119",
      "r125",
      "r126",
      "r135",
      "r138",
      "r158",
      "r160",
      "r163",
      "r166",
      "r168"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and New Accounting Pronouncements (Not Yet Adopted)"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r158",
      "r160",
      "r163",
      "r166",
      "r168"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense charged to operations"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, long-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r494"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "The Company and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/TheCompanyandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r17",
      "r536",
      "r554"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r422",
      "r423",
      "r426"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r422",
      "r423",
      "r426"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Foreign currency translation (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r57",
      "r60",
      "r422",
      "r423",
      "r426"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "negatedTerseLabel": "Payment on extinguishment of 1.75% convertible senior notes due 2025"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payments of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r78",
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid in acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs",
        "verboseLabel": "Performance options"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r25",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of 0.75% convertible senior notes due 2028",
        "verboseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r80",
      "r373"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options, ESPP, and RSU vestings"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r212",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Fixed Assets, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r14",
      "r208"
     ],
     "calculation": {
      "http://www.insmed.com/role/FixedAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Fixed assets, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r210",
      "r516",
      "r549",
      "r560"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.insmed.com/role/FixedAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Fixed assets, net",
        "totalLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful Life (years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedTerseLabel": "Payment of principal on 1.75% convertible senior notes due 2025"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r380",
      "r527",
      "r601"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock and RSUs",
        "verboseLabel": "Restricted stock and RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r28",
      "r302",
      "r516",
      "r558",
      "r576",
      "r581"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r108",
      "r109",
      "r110",
      "r113",
      "r121",
      "r123",
      "r186",
      "r374",
      "r375",
      "r376",
      "r390",
      "r391",
      "r442",
      "r572",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r154",
      "r155",
      "r159",
      "r164",
      "r165",
      "r169",
      "r170",
      "r173",
      "r312",
      "r313",
      "r528"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Product revenues, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofRevenuesbyGeographicLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible List]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r504",
      "r506"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Finance right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeasecostsDetailsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r504",
      "r506"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeasecostsDetailsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate net proceeds from stock offering"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold in offering (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service Benchmark [Member]",
        "terseLabel": "Sales Revenue, Product Line"
       }
      }
     },
     "localname": "SalesRevenueProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Components of Debt Balance"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Allocation of Employee Stock-Based Compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Carrying Value and Fair Value of Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r197",
      "r201",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r197",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Rollforward of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r36",
      "r37",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Principal Repayments of Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r335",
      "r337",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r99",
      "r145",
      "r146",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r287",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r148",
      "r151",
      "r152",
      "r153",
      "r463",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Percentage of Total Gross Product Revenue Represented by the Three Largest Customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebt": {
     "auth_ref": [
      "r21",
      "r540",
      "r556"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtComponentsofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.",
        "label": "Secured Debt",
        "terseLabel": "Face value of outstanding convertible notes"
       }
      }
     },
     "localname": "SecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "PSUs issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares of common stock, maximum authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "First anniversary of closing date"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Third anniversary of closing date"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Second anniversary of closing date"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Potential award payout"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r96",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r51",
      "r62",
      "r63",
      "r64",
      "r108",
      "r109",
      "r110",
      "r113",
      "r121",
      "r123",
      "r144",
      "r186",
      "r294",
      "r302",
      "r374",
      "r375",
      "r376",
      "r390",
      "r391",
      "r442",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r513",
      "r572",
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical",
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r144",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunauditedParenthetical",
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r25",
      "r26",
      "r294",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Net proceeds from issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r25",
      "r26",
      "r294",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock for vesting of RSUs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r25",
      "r26",
      "r294",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options and ESPP shares issuance (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r25",
      "r26",
      "r294",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Equity component of convertible debt redemption"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r294",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock for vesting of RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r25",
      "r26",
      "r302",
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options and ESPP shares issuance"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r26",
      "r30",
      "r31",
      "r102",
      "r176",
      "r182",
      "r466",
      "r516"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r279",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r302",
      "r303",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r112",
      "r113",
      "r114",
      "r115",
      "r124",
      "r177",
      "r178",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r374",
      "r375",
      "r376",
      "r388",
      "r389",
      "r390",
      "r391",
      "r408",
      "r409",
      "r410",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r482",
      "r483",
      "r490",
      "r491",
      "r492",
      "r493",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r530",
      "r531",
      "r532",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfCostGoodOrServiceExtensibleList": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of cost from product sold and service rendered.",
        "label": "Cost, Product and Service [Extensible Enumeration]",
        "terseLabel": "Cost, Product and Service [Extensible List]"
       }
      }
     },
     "localname": "TypeOfCostGoodOrServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, interest and penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r502",
      "r506"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease, cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r127",
      "r138"
     ],
     "calculation": {
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average diluted common shares outstanding (in shares)",
        "totalLabel": "Weighted average common shares outstanding used\u00a0in calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r125",
      "r138"
     ],
     "calculation": {
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares used in calculation of basic net loss per share (in shares)",
        "verboseLabel": "Weighted average basic common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466103&loc=SL6014347-161799"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r602": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r603": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r604": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r605": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r606": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r607": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001104506-22-000019-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104506-22-000019-xbrl.zip
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MXZ)^]%>GV?JKV_ZT#Z#MT+=T][#=/>LTN^\Y '/1!"& ZU\TCG8!X#IO7.S
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M[@;@8[D#/E-"^:&7 _';^[",?E)R3QDW!'&/F5%"&WC1,7E(2ASH9?7]Y'S
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M KK3(WPR@T.0E6&_]ZRV\?S-\QH!(Z>_.^R)BB6Y$[>9G#D!L=7<K?_W/[!
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M,,*)#&:*0TKZ5+>W\_Z/[V3PKJIIW L3:<W)O)6>UD%/RRU+M$DF2:'!1HF
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M]3[9_7-I]%>K6/1\F%U9KUAGKMYI)*4)YIYOS--F0ZH)U!U'+??,5AJ#4<8
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M]&K)4\!12ZORGEEA":!" 98&#A)E_H\;IW4V(W#(R2H%WC4 T6-@K[%?PU\
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MTE:9F)GJDLD0=S<>N7K$NE4_-H7C?]N3LUAAW 6,VX573$@BDXZ0O!,9QM:
MH=I!$HR79)J4 L\PKB#>61 KZS61Q&E&*#I&'9$T;[WE05E)_&9 7#W>G2&\
M75LDT'-+K"V. 058IO?E+4;0),E(40L7[-Z^' K)=ACE]1J5]=;J.:FL=[?F
M2=N3HH(2(9( E"0#:-"#]F5HJ<U;'Q*E2<L%[2V/+KX[VKL/B:0EH>S==)(7
M+<P&:3HY_>(S*=X5O^BT./MNI\7[Y??M@0\E/V'S4DU.Z(ZT/E[PJ1S_^C&K
M:H%JE;0GX)A*@$I8L,@-*!1:28(*4VD#1(>"K%P<5*,Z/4'W';M5+B"[@O<F
MX/W4 B_-FQ,X0U#:(J!U#@Q/%EC"D"VMJ(6A!;PKJQL5N;U%[D9]*54FKP/6
MM 5K)ECT@NEL0A@*J*4'%Z( GS>6LF1MBF%OGTDS5&HY7W!WH%VO4:GNSAPH
ME>K68GY\]9F\S>OA_Q!>4N.E FN< 10R+5+*=/*&2E[$&5]PG=8KU^;6#)2;
M9: L9D25S.C).([G"U_)N+G%,A@I1#?_Z^23OKB?^W*-^^X&[UQA?13>G,WF
MS9RSX\G7@1]EUL>S\?F4C\51?OSY)!^EQU_/\9-\C"O)=T7R1X^7]%FM!,48
M)<1 &6!)WG%.4$B$2F>91\Y<F8DMA^22F=@U(+BKU[CO3-BY/EN9L&=,N*3N
MHC8TV_ (D425J= [T$%G(S_JA PI(T;UD0KO0Y#P6NKN-(9XVN1AUZK ^^RV
MN$D1=R\UWI=G;A;_>Y9?NG"U2OZ=D?_+934XLW'><@92>0F(1$ ^$1:(U]P9
M%E(LT1JNAAJ7/1W7KP*O#MVMN<:]9\9>:L"5&=?-C,M>8,Z4<DJ#"SJ5PN((
MEBL)CAN*EA%NF.D7-=X'_^^S*W+D"A0&[^-LGA^DO/;BY:]7MVJ[7T9^#_+F
M7N2-F8[\/(;F;8_^M-/0U%'_8S)-<30_F];$FQO;\>U*Q(A<,)\/LO29K[*X
M DM=!&-\_FT,,NO[)?&FJVZR??1FWB]@WW'*7 5U]Z!NUR6*Z#5SQ  EP68E
MQ&C0R490),2HM$Y&VPSJ'89TO48_KW'?J7:CB3^5:M<:!UF42E$KJ)&6@K11
M Z)%<-YSH,I(Y9,+J&B_N/8^1$": P^N5 TV89#/98.#^*'\?+L<GVUSRE7'
MWI;F^#3FKVN7O+Z(_ST;S4;S^#).WX]\7##]B^@GK\;-51K2K^Z]M00^%HIU
M\!:%RNRNM8B ,0K0$6D9-<IE( :M<$V-F>*[7*E2KU%)\LZ#'Y4D>T*22RJQ
MX4FB%*E4[Y6JGU3FT<LRGIYZR=$E;G0/67*W B'J4E#_9$^:.(B=#_YY-HX#
M3H:# LE5@AZK30_<'MZ[-"(B1"*.Y=--O4:*V10DA#%FLWY@N<#/@T+_VHYO
M+GYT-I_-[;BL6*6HS@;I'3^:MRG*TN2$MA8PZ_.0C78*EB4&2D8LPZX-<M/4
M&P\9-]LR2*\C9]UZ\5ZGA?;CN6^@WG7&<75:Z'I)[N.W)!<=,L5MF0"?$! 9
M9KLU12 B:9UI3AM;.J(,J>BJ>5VEN$IQ_7GN&U <9TH&:ID.UB)CPIGD@^/>
M$VT3([127#\H[K"EQPGM&5,108K\!XKDP4890?J0%'HM4YGCP89"FB%ANM)<
MI;F=H[F;I"FG( WUTAHB%*+ASC*T&25:,^<,M5?SW!7#]RKAK9GP6CH=3];9
M$"783'R 4G'(%%@&PEN3]Y%1&DTA/,+-4(@.9O!5KJM<UY_GODE0 D6F.AM8
M0H$8DS'*:X=2*A,,%VP5E:Z2V(U([*B=,R.905)*(Z(4@,Y;<)P)X"HHPY01
MNHP1S?9JU=<JA]UG#N/HF$F!1F9)9BYBN7.2,L\3PQ"BJ&9I/PCN8)$FDDGN
M&1[E>_I#D2",R6I:8B( >F% 6^6 !$J8]8&GF!E.<#HDHJON"&MGN?, Z><;
M^7RHL>&P.\C+N/# /#]2F)R5Y@;M)[[K[)%ZE_4N=^0N[UF&Q(&=^M>#S-$E
M18+5NM"KLR"(=()SES5WP=!&9F*@/'AM%+?4NH5;B1'.:<V"N#,UY=E2%D2(
M,9MAJ31E1@.8C .M:0 31%9+(F-ND<YJAOR2:O6MKQ9;&;5;;U'MI-'4&1E5
MHVF];-1V;8M@@F,)B&#99N*,@V.$@(H6M8C4*A6;= 73IWYRE8LJ%UW-159+
M%3W7ANJ(B$E'%FB@Z"/G931"Y:)^<%$[KX!;'WST$5AT$9 8"T9Y"\09@YI)
M99PM839D>BCT#L[^K'RT/7QTDP2 3$&4A93*/%L47-I,2\D(%(:4S"=]-2'5
M!("[8::6EB12)-$Y#<1$#ZB4!:<5 9E?X$Y(I7D9J3/DQ SE)>,Y;YP 4$FI
MDM*:22EJZ5)()LE0XEK)ZD@Y"YX)F[+9U@TI5=ZY$>^T8_9%9<6(&HP4+O,.
M6K"2)]".\DA-/ITF9=[AR[,U*^/T")8[S#@WT8)\:>,0@PPA8B34>>;RX<ZR
MDV@ADZEF63](:"FNSF6,@CL.5GF162@$<$D)R!MI@LX"(Q86*AYKK5>>\EM[
M[MRHYTXIPY_&UW$\&[V/@Y/);/:PMMFIU[B7U^@H4MYPC>HY[@_CO$%[G9NW
M9=?8R<2%&SG# I)L=P8JDT=!DT-#%2<.;?D[8-.WAGWN6\-N4!:3,?%L[">G
M\5\9&%4G[$XG_'7)(::"U)HJ"R:4T?%:Z-+!.@%CE @IE%+.[>T;,92X6]ZP
MWEWCWO.)H9H%[UP^=023#E:Z0+1+E"=&/$^53WK()TLVIA'HHR8,8F*I>-@E
M.$<L1.*=H2*I0'R_"*4CZW(KM,VC^>LX;7JZ?K4U1PTT!C\4+71I WIA#]1K
M]/\:.]G%\4;B*SB=Q9:*T7&D0IF(99*;-L:RQ).XO?AJ0/N-?^BK-&LZDA_;
M#\\GTW*#C^;SZ<B=S:T[B<>3YW8:Q_,JTVXDTWY;"MXH'C5-&$%*Y@&I*7UK
M-8+T*A$?I&*<[NU+L]SJ;">F]55DKTTQK<C>++*7M-68-XLV(^FI)1G:F+*V
MFG^RS%M"E?*:Q1Y!>[=*B*X8O_PA3OUHUDR;6XR9FS1SEF<#.PZ#IR^?/Q\L
MJF@&H_.Y=+6VZ.K:(O2*84Q(90KH=-#<"F:88#1QXR*_!G?=8.9<\^=/[:[2
ME:9N1%-^J=*():H]"@TB:0.(+H!5T@(S*JL?E& H+:'Y)0;UUF?2WE,L7Y9T
ML1D@-QW>*XZ[P7'+V>ZLDT0F E(+#BC*I,AH+)!L1EC-3)0"]_:[ZMM24=P_
M%"N?"=L2IU6&:J#2!D?1\L"8\\%BW B*J_^[.XBW2U\T#RF+:P%"E](79@+H
MC'%(0DNJJ: >;38HAHA]2K#J8SQLEZYQWVFO P]*I;T^T=Z2(X62$*1W'%@0
MIDS"EF5J36F+8(TR@?ODZ8+W^J3>_(4_)8QF[T[LQW*S\?O44-^YG>^\#YG%
MS\[=9,6AYB>GIY/QN5\M$^+@?9S-\X.4UUZ\_/7J+,2=# +TV956QP]W+;;>
M+ \RTLY0HQT#PZ0'-#I!/L0$!+%6!:><\V7&AUI99M7P7D^0?<>.M8KJ=:"Z
MY6;#E%51KS6DH)JQ%@&<D RX"$01BTJI,M9BAS%=K]'/:]QWKMVH'Z!R[3JX
MMFWX,^>"M%Q X"H!$FO J21 $97WSXO$)/:+;.]#$D5SXJ&9[]QD^W[V@@WB
MA_+SU2D3??&8]N4:]]USVWG J@XGWQZZ7^[LAD8P%,H#,SJKUB8$L.AI)O\D
MDE9:>,JRP8Q#)KH:_%OC6_V_QGUGR<[UVLJ2V\22RVG%.GAC=<R\6 :8$!M!
M6ZDA\2"22D99$GI(D[L5#?G+"07_/!O' 2<K#"@X?_[S81"+Y[IL'L1JHZ>V
MAQDO'V^0R=';0+CT'@WSAK"HE=3>4Q>\_-Q1_*]M_3K>8'TD=K <&^%*F\ -
M4*<TH#4>C(X*K$!#8U;_C);GS:(N:91Y._.^.R#=L2?VCAEC>_OF=;\^V\FD
MEPQFZ(I&:]>]]?)H*QI%N2"\M/YT#@64ICG@$E,0E+ E+XKE7R\&,ZRL"E86
MK2Q:6?2[+)K-K\@C3\(K@R8ZPV1"J474EH8,R<JB_6#1MN.19?,9@W- $_>
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M22)F/8T;S.983. "(J0LK%CD69/3I1$&'0JRLF.EQG5Z@NX[=JQ<0'8%[TW
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MG 8M(I@@$=!*!<9H#9%2E(13SJ38VT>&55^K'':?.8RC8R8%&IDEF;F(Y27
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M06O0-/W&UU T6J<@Y:F8[=;[#RE6B1$N"^,[TT<]U+6/GF]5CYNX"%QDRJI
MA$VYL[;4)F!L9*FU%QKH8.TB6#$ F=H7=;'[.6A!8PDKI<""(*ZQ1IH+AJ0-
M$KB.]U$F%T')UX'VK$9%\EJ)E\MR51D,6-4X, M:;(PB03@.[ G^5W+Y'1VN
M5?=>5?=\6G6I)&4),X5HR1A*6;](>T(0#BY&ZK0H;5C;%'B=Z%M7IEAA]5V5
M9SQ)&+D)%_"AU-+SX E5O(S24DN#Y)I)%<IH1<T%5@Q0ILUF=_$Y,!,] 0I
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M',.;V%"<PD#= %KG&LU0M(?4+_TU?7;)^3I(=4,:[:*SP%#Z;1FU0QZI(?"
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M@/>PR-EN)Q&8!QW]ERLY1*]_R;JY:[KN.&DF6:_6!N &NXUVH]<')09-^U<
MO3]>+_XVMC/HYE7D8X!5 :C%B]U__?WQVBH[#2T@D=.X-2V-6<@:/DM9;Q!C
MPZ5[F^> ,+W3#K0!^-!I-YV7>_F._%Q@3"#$C4EXV[CKQ>1'JO>]CKXX.V[
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M-=U#+IS^C0T0SR12IX-FJ],V@*#'Y\"_^Q6!!WT&2:_NRJ*5$^_AA?U$$*9
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MEK0_N]#&#^,F_PV_U2*W6.0<V]OZS!3!7"J'5/(P<1$HLC$(%!GF AN'F?4
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M\'YR.B=$[]BA$8F,/X$U)07^3N'/ -,;Q5;_RJ!=M=REJX$XFZ,P^:C4NMX
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MZ*L<DG.V:I+NEK293:]^NI!4M/?V]?_;.WK^,L_O*SE!^>DY<046.J>NE#T
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M4EJU7N4[AK[+7N6@$XT!8T24!O3U&M!7<8N,"-[+9#EW^M$S+7:$_NZJ,5L
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MU?!>A035<N)2W H@ROH?Z@OJ3POPS?2LP;P"!E+LY:>**(>+!%")NBH5M##
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MCU^]V*NJ#GZJ$I^FS:FZ_<Z[7!&IJ2JE%U]R;&<]RNN^5Q<+G75FK\SM(2.
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M7=/AJ#BWF"M'>;D7[HPJK6ZW,PY>%*OW1^'5^30>[V)V4QCV<@G$U[877GS
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M*.ZMUII6@&;4BY*>*$?6W96ZC3Q$HW  !D\<NL-\RC8>^:OU+*]^@M8;UI^
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MBAQK)P;UK2*3>I2Q!7QGW/GSQ+$6!UZ.8'ND9U6IH;#L(_ 0"LWT@]J8K):
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M*1&UF!'V1?M&T -AZ:9S="!O)=O=WEQR<6H$?!3.<BO=QN13O';'>*/O/N5
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M8U%(SG0T; 783;C(A-Z/:TSI!:+J]2,8!\0TVTA;K^=89_SI8K+LNB>!*"!
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M'$N6#H"2.T-?ZPB3XE#+W%._B]2Z/0+;&L&Y3^<:MBX"&\#.<BZR_!4.&55
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M0,1[^!T],%1&SY$J>)N,6_,$E17] >?H"RM)%V]_54U,R-)D17L?+:[X$A2
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MFNQ?\.F<D9BG.JZG\3@['UR+5N%[GL\=!KU<!@;.AV0D6C/F_D%TY 3)C2I
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MTRPJ:AQ[R;0_RI=]X#LHR$6NNU5=7>3'?]P8FW=NJDK=CVR;LEC_4ZYM2HW
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M'R^7S\0!8.\T]J>\!"]?3D?%,K+.#2]2T<Q2M6.0A(N%A5X?'O%C7]3]R6+
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M322V]!"$OU,&CF"!%%AM-,U<R&@U+ H ;EI+3ZX >.V1]QN+GX>R2-@P<U8
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ML*G2$]'+(P$-ATTV"#$=OD@M,D Z@FCTXB!\U&9CZMZ=GW^V-G@R;).)R].
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M.@ V%J;.8"BJ(%%F&46K[Y^NC"O:6NV*?M<+!H_POU$\&?_Z_P%02P,$%
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M2Z8$*7(R:9,GJASF1]-[!OPNJ)'F7#WXT=<@PZ97)XA\-88C^ *E(B=\*6O
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M$:[5$ 1(RE3("H,IRKIB["!DO #EAND7_%!,VD_Q_>.F4\*1\]4'29"2$1S
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M]2/.3I@],3Y(ZX0":UJ?O+*Y9B(F\"H%$ZKC>*SW?O>U@&YXN.MOX6;Z66C
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MO9,:;>!TP(%O!C.4+ 2G)"@,,J-0VG>_8>QR)'O?M==*U=IJ>UI/C+9>5.-
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M+^:_\_O[[C/-/M%OB_GZPVK"/IHUD@(4']EOI]QN3:@$3JODO,XFQ-X)\EZ
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M"FK*C7FW/Y4L:4'C^_&';DJ/^]N/;%<&+>;<[,W9O!I!U:X<:<]M4<%#TLF
MLLJ!+R) RFA+$DG*;%M/C)L@]L^"0=76M93Y;1+PG4EP:Z@C:;52.A<P6= 4
M"$R!,\B J2(D)E>D*LV7QYLH'CD-=I/Z;1Z(77GPO#O]3#MPM>R^T-#)0L#?
M</ZF? A_/HNS^32D^<CR:+@R$ER@95'YI,%[%P"U\S%G+4Q<8ZGM1(P>L!XW
M4UKKY39UY*[4(3Q+8*^[V6R$1-08@H;($O'8D3/KK11@8[#<QR CCXU)<@W
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M'<2]/S*P6M1!YP2V.'(534S@46O ;(ST9-K9W+J>QCY)<,]![KXXL(V4!SG
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M#Y<$][W=$-^*2 ^[(;Z-0@]^>[</V*<;XBTUOM,UWH>HZ^ <0^<=IB0ARJQ
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M*[^$Z81>6%^Q>'@UZ0A+?C$^.9MC?GV119)S(NIJ,MFB5^3N,03OT4.A<?F
M2D76+_UO^W?ONE"2%%]-2/-89?GL"PFOVJ0?NG.9SKOTST_="4VQV?F;G\79
M?!K2?.1B08^*/-N:#J:\8^ \.N#)II"8XJ+?S=DM5L\'@]W?DKH/"MU<7O>C
MPP%.OJX!'_F@!-=%0RRV-NT.$3PK ;*P DU,F=SO(0FU_WUW3XJ[BRY;27T
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M&''O>,JY@&$BDE6K,TT4@;5G@2>#%V.1>C]6VB:(W^7N.J0:!SC;O.E$7<A
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M%Q+WNO6QQV8T#=; ZT^FM;I^(WQ$/BK)A.)#!,$3@O*%04@B@S4JF\2+9VR
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MY[&9Q0@NAS');T_"Y,I]KCYC&N@F]1#C.<PM[!UH<G-Y.A8=?RO\#84&97D
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MMY(32R!<6L%,BL P!@)2. 'Q"@(!4)8IBA4&?8;=1M[#07] \G:VV<:5UUT
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MH'][Y#.:AHX)^$-8MR'[J@)F",!.U_=;P1WG"K\)E0/<8W\>CN(PO,BLI0V
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M#N BG3>YWKHQ$4ONTQ]R&+S#!^E[$#GL:=G>+/00*=@*]>-_9ZL TT3/>8Q
M&0E%.-I(<%5#)RF;,%.0F8HXN,/<P3MOA]F-A:/L,!^)^Y5WIV"<M]F!32:#
MPIRA]I@ YD20+N>BO3^\R]P#/'.GV9&)C9'ECK77W]&X,%C.Z?+O;VI5\GQ"
M,?2;Z<WE7>'0_'I Y?4(5ZD#SN]]I0X]K@2[P13N"K#W6X#U9>J[\BK-'FID
MMUU":X?85R(DQMG-HDSLPS5.4VW1^L^O":\SC<Z8Z3*/86,>? MXCL'OU#S&
MF&UC?+!AW2[_<_U'[1S]C[_]'U!+ P04    " #:.P15IDIS!_/:  "%\0@
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M)0*RP&,B31,>"JMK<".I<^-=K31HM :_"J)7RT99RSH-1GB;<:5S%$>FQ"T
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M6&4%[ X_MS5KZU1^4#;0,_#L;BAFE_]C@<;@6XI1,GZ>#?XB-Q6G<WR.?&I
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M>3#CA''0'9DP-+!-'$:O-J!/X(>O+<H_;I5^OSX/LS6EV"/FB&\L!$]*1O:
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M\ 1,B,!,4L4N(75[<K\E?6[4\N4^*_F49_?;,^'J]'X@OG,YOV_4?Y$3_ /
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M12G6_?-TJ*-RHY4,M>,NG][7XJ'ZJ(S4SG6Q5)+N>K]F$2$9>TF"88(]#Z)
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M9O$]5GTS Z2J&,#ALY;_S$CCU_,/NWRRIO_"):Y=I'Z(Y59\4E9^_*F>0L5
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M*OJT( ^SDK(49@D"/&$I4#^5@$A.00HARFDF,Y(;:9D?W7EJE+ S+M+6F?'
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M*<5:OQB?:_DJ1<9-57M=W\Y7BP595_N_VI:ZGT/;<)O' X:A]V9(K]#GIM4
M4W8VFS$>MU$N0.%K[^/<,.-N6%QP]FB7X=+GG?NT=.I9]>VJV^WF<;6>_[?@
M,XP+%3LD'&12J#A"+3H *3A6P02,XSCA@L56=#$PUM08HW]"?Q.1G9VM&H:[
M,,80WF:$X0G%P)QQJ _8&!KM+?7:FN42'/Y:LYP=:>S6+)=</M&:Y>(ECJN0
M;35?BJI2(]#YL@YAFE*!!['<Z*8.<]Y6"^Q::.^/Y6940,Q0%H,R91A 5D"
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M[]J$:B-XW42NJFNW^_^NZVQ^7VW^*C;?!%LI&M;:XIRD+$FR#&0I(BI0RR%
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M (>_@[BS(XU]$'?)Y1,'<1<O\=X!M*^YU1YD_U60]?T_5C.<<0Y+Q2TB+BB
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M?^$Q/$@8'&$XQVH2]BCX5HO>Z1J6^[K5A_BY>;?0A[$I@;!$10)2DNDL0XP
MX1(!5-(TS;(<,6H4_YL,-K6U@%Y>K9:BWUG\'5GH0T'+4I(A@,VV&7S!%GJ=
MT)JYP^O/VM1(VQK5QOHL'C' Q%?MR-!0XY:.&#A]5#EB<HUS)LVS6&]>[M37
M0/>8T(U!ZP3H+_.E^+P13]4,E7E6,,I! 6D!("<<((9S(# NU'L%2YYRRU2:
M"T-.C4<ZBV^BVN9=#]RV]D';'=6&&]8_6(!OQBY^(0W,,1[0=$FH,03(7T;-
MI0''3JDQ!.!$3HWIE6X4]*M8BC59J%O?\J?Y<JX5I#;S'Z+=$-TUH\%%0B$#
M+&8"P+*$@&0JK)%4P@06.$ES*Z$5HU&G1D3?Q6)1G_ _--;7SPXYL-^.@<RP
M-R,A[X@&YJ%?>Q@>6MP=H01(_+<"R1,7F8TY*AU9P?":D>PN=B.EMDY7)Q*^
M7RUK33N]UGNOEFRK)['^^),MMCHOX[:JA/H_?D]^SEB.XA)!"80D)8!2<D!R
M 0'B<<H@CI.BL*(H!QNF1EA=/?JZ<:5RR#=VF0DSP@J,;V#Z:JUO4I([^YOM
MKLX#?1;<^A!U3FBM37]T=@6$GLC-Q8)1J>X*B%X3WS6W<A8'[E*GWY/G^88L
MFLPT732[_B'XI]7ZTW:S78LNVWHF8QJ+@I9 ()&IU2+3Y\U$@!25,18X*6)B
ME4MK;<'4*/!]K]RB2Z)=M\9'<K7>UV8XI\K:SY(900;%/C ]]@LS;J+6_"Y;
M]EL?_\:%756'5Y5A-_C\:0Y;CC^V K$;/"?TB!UO9)]C\W[U0ZP-];J//C^I
MQT/9Y55;^ZRW3CD@AW<:+?GCI /]K(_3'_"A/5MOZ\Y00CCE:0X89TPK[9>
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M0I!D"D.6491)'&2,685H.LB<FWM@E 9;K8%1VR5WN1W.W40P$GHC,\,9X&Y
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M#J9H@S8;8^1C2;3[X.<1<GKPFIO IY7(.T#/:UH'H1:9W,N,D#I(2;NQ3U*
MLHS\-BDT&,]E="BR5:W#\T<)ZL%C;H*@=F+O $.T'*9K?#G]C/D%J6/^84I[
M\YFPJCU%KR0J)B 5L]F0?:U&H:"2<^>$M:KXTMX(/4)1#VYT*SO42O =P.@O
MBT7^?3J;3;)WB5,D (Q%7PO="L20%=C(%$,EK9"MCY8OGCU.V[L!H+&7,#L
MP;4C@XFQ+(K,#+@@*;3T(4(LCO";M=>12U?D8YW@]]I]KAX_3EN[(?::/47:
M 1K.J0[.Q1!B'31A$)3"""%+#=DCTZ%X963K6'H'##1/MAKLQGLG079PQ/)R
M&N)TM@GP*4C;U!]\7,Q(Z*L:L*V_7A<-U[GV@+:U>XIAL5:]<D@J<*:X,*6T
M]E.WI6W<8Y?!\VT&45$'EN<:7[=//+W77'B3 4.MP[>!O'-&B\@[9GD6D@+
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M*8ZT-&((M<XMU<857("W4H"-P7(?@XR\=4'8'B7Z0T&IN7H?K<K?1=8= .7
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M3%QY/F\S+NJ>]!N34F):)1"%DTR,<N VJ<HLHRN!6V^WRB4?/@%JN*;&(V=
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M].VIZ[+&HAE.%D=16A?!\AW>_AJ6?\=--^9W2('8F=E/2C,?M2!?N%XA*9[
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M>(2<<>]]1]TY]U=+/Z;L>@79F^64A/:I-KT]8W,BI/(HG"#+'"FDSZ) #%(
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M10PF-V\RUE_;Q?$!=[!N.L#7C5%@$Y&,=LCKB,\ZV4N(3:N##$DQDU"XR.P
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MI(1?OM:OOY*8%\MK*YIG%,4Z* 81%(N,A$U?.!-<^&24=JV/;O<@L]M[JA:
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MO<7@7\)T7IE\=5J/;5Z7JS=.?(F!&Z.!ZZ*!@EX2LLP!BLA*:U<X6K^5?]R
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MORYO,9!NYQ\NFPA/-!I=9]$14\6!0LPD:E/ TZ>Z>@3D(FZ%])T>^V.FQC8
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MMGDCON\T7XAII[07!0J3G"1E _C@%:0L2YTK[XWY3GSNOO.%=D'D4?.%=@%
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MNZ[FD$H!7C!//ZGD,N%5N=;!U'")&#],E^'SYT6= +E.<-K(^^JTL!I3LL:
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M[^:SS_6F^P'^#/=.HC=@3:B9=YZ<(6XS!"=R+M&DH@^:CW,2N ZC<5R_=5#
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MX\XC' )5;?5P/+#\%;!F^+D./_PT4.RV97YO[S0^5L7QB21%,!4CZ%!; ?C
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MGD-*VNCB7>#-V\H]1L]!&/(O!T/-9-\!CK;V0YU//R5=K#7S$1-.R45]?\?
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M/G&97K01?/\[5I'//K_#L+Q^"9O$*&4T$4%HSNL;F(%8,_8L.;,I.*D%MGX
M?Y"0EV32CD'*KDD[7PM]6J[7E\OI#)?+5^G?E]/ENC'\*1;JH<\TL$1/4M?(
MXERO0WB*T]D5?&?YU7*)JZVE;X"DL_6JCDE7O#92<08AAAP C1 A&Y6$:OUX
M=1R%Y]J<!U9[\.#V,O$@ KBL"BC)/41D"$7Y5% Q);,?7@[=.5H#HFG7+ V@
MJ!=CIUIX5H=\=A@[]BR>U)%(=#PF$>A$3-I51UQG<*K^-IE8M,C<Q-:W0\]K
MUVZ30A[0R/+U]ZW?7>5^*"YUL,74/C\"5&3D/'C:I5([+%E%PTSKF_YC:7Q1
MMNX8A.VOQQM >1W<ZS[ U3HQN!297%0)?*PM"H3-X$7P8+0.)7GM6/,>97M(
MZ:44;PC][SE8SU%&IYBJ/R[PNI*&%XE:VDA!4>&UG*: ,]P")I(7E\+Z,)0O
MNY>H/DS:6:H_ $ZGZV'L8K=?YJO+Y>OI?$F!]BQA?;JH1O_B<\ 9_F_ZW291
M5P6)-GD+@@=R;[.H*;M1048;N>2,I2R?\M".6; _W)RAX_G  N\01!LNDG2!
MR/4@I5&@4A D,$$ABRC*JHBR%'8J;,8$RG"J? (K)\AU;'3<%X@A*E-];94A
M$_79T38*%,,RM)GV3LHBBX-0<9K9:)[U\#QH.$^.'7@PM>O==/9Y?0(KR8PM
MPD'DHF8;<P-.9P,LH=6^:*=XZVAL:_E>ZE:?P?L]5>C]X&5SXK(D)'$M(;@8
MK^:@1!4*H K!VQR]=:V?2>X0,*Y'<K(:'X;#"3+M !![2BK6]3V+,*-M]7YV
M75E65#&FN  Q9D^L8:QS/160UR;HJ$P%AVF]>AAY78#I%! <5A1UMD9>!-@^
M_3&_=L=,\IRG!.3[TYFNC03GR4IG97- <LER>:;Y)P^1-^YI]YQ@.TTC+P-L
MA)OKG92C<=ZB YL-@@J($(J)P)R(TB$6[5L_UAU%X+C)GL\*N!.UT@'D'O ]
MW]U4'K):XDUA"2B[3D[EB7A1"(C"114#Q1MQ^*O$&WIZJ3\>Y[;Z-+7T";'K
MP5!7N=#+GY?+2\SO%_5_J^CN3FN_^M-)=%$H:0HDQG6=LIMKE1FGB%E8[ZRG
MGY\!C"=0WMTEYHE(>AJB0ZMU[#NL!]Y&;U+45O33<IK7266[DKABM6;_/RB)
MB;$A,6T=2!'K(VJV$$5&L,4R63-U,WLR\6%( L=U'9LCN!M==F2<GQ;#NVF(
MZWE)DR",RS9RB":6VI" MFSM;EX**UP&'FWSYB4GD#FNMS"XV1U*81U@\KKI
M\Z?YYKGMFF=<_K28+Y>3PDS(C@=P<5W*D 4XG2SH>H? R<_&V/H2\"F:#D+;
M8-,\!D-;4U5T *T'!+6VV^L9BY/ LD5D&FR@V% 98\$5IR%I+HHVUF;7NK?A
MHP0=!*K!9FL\I^=XHA)Z<0BW.*DF&--E303]M AU@OL/X?MFOJWR9(1=EA0'
M&@Y*8@:?30*N#7D%M=[3JJ/\O,/6/0A&YL7 :&C)=V2F[A[RMT=[O7=:7E'&
M)T(ZCYHK"$$;4$K6/J-TSA._Q8M:S2);UTL=0]]!Z+,O!GV#JVCX=/W-']1?
MZI"-__G?_A]02P,$%     @ VCL$5:QJ0O5 7P  SVD" !8   !I;G-M+3(P
M,C(P-C,P97@Q,#$N:'1M[7UID]O6U>;W^1489R;IKH+:O6BU,ZZ26NU$'D=2
M27(T[Z>W+H%+\EH@0&/I%O/KYVQW T!VRUI(B9VJ)&H2Q')Q[EF?\YR__\^G
M+\[?_-?+BV3>+HKDY6]/?GUVGGQWY_OOWYZ=?__]TS=/DW^^^=>OR=VCXY/D
M3:W*QK2F*E7Q_?<7S[]+OINW[?*'[[^_NKHZNCH[JNK9]V]>?8^GNOM]456-
M/LK;_+N?_HZ?P/]JE?_T/_[^/^_<29Y66;?099MDM5:MSI.N,>4L>9OKYEUR
MYXX<=5XM5[69S=OD]/CT-'E;U>_,I>+O6],6^B=[GK]_SW___7NZR-\G5;[Z
MZ>^YN4Q,_G^^,VIZ>I+=O??PP?U[C^YFD_S1Z?VIOC?-IO?O95-]K/[[!&[R
M>SB<?].TJT+_G^\6IKPSUWC]'QZ<+ML?KTS>SG\X.3[^W]_1<3_]?5J5+5RL
MAA_S/_D<PS.I>@8GFU1M6RU^N _GDD_::DE_MOI]>T<59E;^D,'CZ)H_,64.
M?_UP!H=\QU>S9\RJHJI_^,LQ_>='_.;.5"U,L?KA;V_,0C?)<WV5O*H6JOQ;
MVL!KN]/HVDSYP,;\1_]P@D]$?U[)(\)Y"E-J^\@GI_B<%_]Z^>N+__K7Q?,W
MR>-_O+JXP'_%#_LG'_/WKFG-=/7EG_/NZ'.^F9LFN5@LBVI%<OEX5FM-_SKX
MZU\>GIX>_^@^H;]/?CQ,X!=Z.M59:RYU4I7)O]0J.3U+65@/VKE.Y*<7[JBG
M(.SV]VDR626JS).);J^T+I-G9;. K?"LS*IZ6=6X+])$)?\VN(9&)?9CV(#N
MKO@W_I1XOE^.DJ>U6K5PV%O3Z.1@KFMM2C4%N4J3\+[>ZZS#^Y+?TZ]AQ0N^
MVV*57)EV+O<5_?*EJENC&WO=HR1Y.X<GJ/54US7NY+:BP]T5^-=P PM[BKF[
M:E7;SQK_83NOJVXVK[H6_@DK[5\(_&%@BX#(Y'B9B4YF^$>=E+IK:U4<?1+Y
MY&VXI5WW]MF;YQ>O7U^\^>=?_W+OX8\?^4#;WUUO_WGQZN+QZ]2*.*AY4\/I
MX?5E\&-3=AK_K6G_Q8)#,AE_LN;7( A\ K@ ["RY%&P"*WE-PAL!3Y#59J+S
M3R,J.Z;*GK]XFR9O<,5_?O'J(H7-@LO4&-@BK#NJ*2W)LJX6H!X:6N%%UW:J
M@ ,O=:G*MDD:W2;3JH;MSXO&J@4^22KX<9W,JBJGCRY5T:E)H>.+\'ZO=:;-
MLJ7CFFXZ-9G19;;".[B:FVR>J%K+I4'9J.Q=65T5.I]9;2-JAFX!E27J@$0U
M<!M%45TU'[DYEBK/05?=*?247]AU+_7.R<.MO=43)ZN?Z>ITQA],"X^?7:NB
MXK5[A*OR5$_!2N&[;S[SG6Y<IR.V1%T#>]^4/=O!4L720U:*M$(S!_%+Y@I4
M2_SU0JL2_I_E+/E$@D:NY X+FOK<@K;AZCVQ.KI/RR#.P2[)_W<_/<ZRN@,9
M>S&!MZBV+O;6;4*1_:1Z\>3XX0WD]?3NT=G9UD36[(S(\KY%=:)$/B;@P';E
M4ID\>:+ &7^M"E6OK'M+"@>\5VN3WZ"##/_VD0B\RT=?^%T^.+J_/>_%[-S+
M+%?V!8+STY7@#"TF78WV1;]?ZA(]*%-F75VSQ8$77]6Y*C,=1D_)L@*]LD)O
M+"LZO$:B%E6'GE8.[FM' <QKC+O 0;MWH [)YZFFJ8VDX U1\&.OE'<<9^V(
MT)P='SUZM$6AV46I&5$!$UV"FP0O'9SO2X,1++]Y'\:?//BQL7&,ML<GRP+N
M+@4?>O([R C*!+K4(]+F8QW2*!5H'/HM203^Z$M+Q3;-PN6."45"R4P*7'&%
M%J6!B(AC,HAN+DW=@BH02Q#E9D@HEA4G7S$ 4AC%P8]!=$ IY1 .9RV&9E,7
M]M8)BAD(#,1D1M5&XCP\M1-"ECT457N&1JY&Q\H5W&>%41-3F'8%=]]T-0D=
MJ[5DH4S9PG_#T#L=DT^\+,MGRPKN(T+PK\JMGNQZ_&;3G/#2X46[-.4VG5KV
M9DE X?6QX$GB0,1\CGN!I+Q5<(0J1)))_DOYM_ZCX]^"X.FF/=J72"[;&?6W
MTY%<X);OCLRCGFXX5'"NPI2$VGF)=[V7B.*.NP2\PUHK=$WEMS/0TBWGR7W^
M= G>:P>?XZ<C)]L7C9SOSO;8W;U!KD*&BO7%50F^P-PL=R'-T4O92:(./"/.
MZZ-D-QV8"2HXP9YYU14Z.3G+[YQ1VKLK9EQU)@<(SP#[  (J2C9?O,_FJISI
MY#':D6ER\NCL;DI.UX**3ONR/_3N[(^=-A^5JO-=V!/><- MH>@^M6Z]CPSV
MQON9[HSXGIP<'9_LL/R6W>ZDKLF-F> M)4NUHKIB'TJPQG^9[)O_,ML9 =]=
M_^5<=8W>&>'>7)<)H68VU_-#K0N%0C\ G]E?B3 ?^Y^H25,573O\R35X-?[?
M>6W/O%0S?6<"\<2[.P0=^D$55VK5?+<MC-QM6>IC<]((T;@T60@""0!:&$,F
MRT(K_*Z$NR1T#4&K-)4A5#+5145AYF557%*%O*HA-&B[>FG:+M><9:[JVWK5
M]M[RE2F*:5<D"]/ ^\L[3H;-ZJIIDE+/8!TU9F,G?9Q5K9NN:.%DE+?5AE ^
MF6HT_;V >*G&,%##2:N%R2#X@M *I,(GG-%T!^G#+8C";16JO^.M-$R5*;IZ
MY+4CB$[5]2IAI"7*@6JJDCPO+ (4Z@I_SZE41#E8S<%!!H'"-IR[UB <_+D]
M#.L C,RIVU5R<'9\F.1@5Q(R,@XRAA Q",A!_X N:DU&A9$&0O!D"@&\OX-M
MR=EM7<N+V;1679XF>C'1__E/X9%6TY:K4\V\*C7<);Y"Y55)J=I1L5$S9<JF
M7:=9Q%(Y/6=/=VFJPA73XC/2=:54!3]>UE6F<[QV5##K7256B/CE5Z8-3Q]L
M341W34)'Q 4]VVP^*BL]P/D'Z+C^V477G1U_C(K;EX!VOC-"L\,!+:>F0:;.
MX=BZ*KZ2X/8VNOO<*NX-J N5_=$908E0<]$J>:GKAL.]L5H.6<8V@: /[.W=
MX_^-?XOK?_#XD%00XOL=*J5%;#5XBEAN)Q!; X9/DT^858L%7*AIJ^Q=8%?#
M/J@7P0_/J\42[^^<?_8:?^8ZJ\!\'CSAR\-I)X0KN:S0%H,5O]+UVMN1@QI?
MS?%W0A""@HM#<!RU#>F:.@\,-XGH0KO@V"%BKGV"?_,U?07)/<8!P\EK/:OP
MB-$7$/1F)1.-AW$3%=\GP1ODVK+A"SSFF6 9[*78O["5XC29PRI=<K>7HCX.
M3)HNJT8WSK[E#J_?1\4'4F3!\6"?J+\#5K"#E:MJ\8[(,TI$*<&9Y1X9,']P
M>9@P#LY+)2\K+#F9. M[PYL_N!H>[;!$<LC[T4,",:?'52Y&B1OODNH*'FCM
M-DC&%Y@NO%I[X5&H7G) *U10D;&M07D=)LT2UJ^JV3D<PTM9I]%AME9>>*W_
MF!S\9^V=A.V!88I<P1V IE$LV@R?@5VU+'![$"@K*S!-VN"63VGCH<=S<'Y(
M_@C<C>R* PAP#^$Y04QN$SW;5_A/&0&,KWX)YZP81'Y%:;O&NJ<KK5"%X?X-
MD,?^)TOXW]J56*+M<D@(*E HG2I 4.95J &",F,YMM5"I?FLS#H(#6'-)&(7
M]9@A5(64$]X0YQVDJ<]>QMDF#!M_KVK#060O^E^G]Q@28Y\!)!?$GI[?(R9)
MO/_H-&^5D0>Y(@RMM0P4>V+$5_(^PYMW5B/05@+9).LXKXH<U$R:7*$V7^+-
M\K97;(9"$SQ\3&^'R-CAQJU-8Z'?O:45;3WQS7AP)84_I68#@D0$"P*65.,E
M,7!W-K5WRI3@R_J]R$Y*CTP&1"Q**DHK/O7VJASV)U^^E[>_<1^>P2V=#E9B
M'\HP6]+1O%G)K0$95$W3+9;6H6,T<U)EX*8U[%B)#X,;$)'*U %+TDVD%&B<
MW=ZF4@AL4+*7\+NEP/!CMQ&-_J*ZQ-.$'J1KFAV]1H-Y*0@ [8V"@GA/GFO-
MFAQ[1":4MT(=HV&'3]E?L:X]G1H47KG]K.AM]CTPT.!/@@ NW(M%@:OJF2K-
M?Z1'>J'K&5HKB"G W%7@\9'%0'4K+C7+ $A(KJR(-0;N7M7.W].1?^=K<[%7
M"=?O-P0@N42C"NWE,S>-ZS+ &RY(5@-X-79I%X4U%;#!=!N$6"E+=AR'XGGD
MN-I'AZKD*PJN>^ $C]QN<D I-1<//4'.&-TT&(A-Q"![(@RL8>'AG+/MR@*.
M3(,@APS6V"E2BGRO>W3>>^P6D1FEK=</+5*K*HA-([4_OBX.)O_[1J%F8A:P
M:)AA+E;>EUO[;!*D9/PX$ ZE/B +$/-XJXN*'@J4RGU."WQ(^&\[33XV>/^3
M(7O*/H^FEP\>%<B7=HL?ADDNQ<_AZ/IU.W#.<THF (ME!>S#5D0F)F<1;H/8
MQ# >-=BI%(T&4K]!XGINI>PG2=2$;]"VE58E[6IZB>$>.DP.Z#[\@^.5<;=2
M+!$^!'AX829"J#-D86VSB/OEN?^EY\<I>T_#H/8%44_ T9Q@X#.:&M>#H_'T
M0Z7ZDV^K<0'"R+BLK-D]<#XQ'3FZ%%:;W3A)$-6CZ(%'SWLXV,C-37;RW0_?
MR1^S:<08?((,'ETCO =8>[UL>[VQ%//1H4Z4X"O3X/I&<>ZXVK=)CPW!&$=*
MO1)X'V?[I]>+[$CO$OT 3W&1O@7/Q1ZBN1;E]X'S?SWM1>467$7P'PGQ.("F
M6[1R-VY=;VOMVW8J.8& V0S1IT&*(50?4[))H'<TF,W"@!+Q'B2X>10\BR (
M,/Q3<B%MB_JH:M$Z.V42Y=]35-[Z$O<2JH(P)VJ*(LHZ)8,R&]D_;A=A7Q+<
M4[#.39BM"G+UF?M])K^G"]N"6=SN?_?XT6.[(<^K7.]+O?>6:>9F)=\73UX]
MWIDRKTBIC4F1 6=1FDG7@,7(9[I-7B$F)B/8"PJW:Z)Z>"]LHA*( YHQ-,KP
M__LB]9^]$?Q;0#F %MPMB:=Z8 EF]Q4J\HX5M0CV_9MU!^Y;YOOLF\Y\[[J:
MN6W^OZ&F62PUN&]8[WN,>3J(]G9'\QR80RD"-LC,64,TC^2G,\S;@1XJJB6'
M=_!]6X,1EJRRJM]IF]SA!"\YE[5:8CR-(5Z-6>:B@T/@IUB&)7:8O_[E[H,?
M.3ZH:JY9(N0 J_Z4D[4U#%HE=FYE]<B)%OHAAX&4(V,43IS?=0#9IM]U8#&W
MXA>_;O$@CQW7R6\0Y<+Y^(N4,^4=^-HF/NRJJ@NFHHF(0];=1B(]$TTRD0#X
M*$E^'I0\;20]>#RB9>H]&'YVA?'#^H.2O'(73#D>F2#1+?:O4^[$8UJTJ@OC
M$RBY:ETF &+#PA(*#6$^-A_SAL[)1V&)>U\<KUN^AYNHPW)J\$WA_GU6@JK@
M\M7NJ$3,B$/L#LY7H[,:T^#,A.9NE91E436<MNYAN^L$*89'.@0H64_E5@2#
M,!0[R*?CP5UIX+LD+)#A!M.>-#[D^^MW  0EA.AN,5C2< =4/#,SW)CX;ZOQ
M^4RB[!DV,J3'#L_'R?PQ7)F_%8J]2)LWARXSFB:2KR8HHE,MEH80KX,H(E^!
M(5#A!.0*_LVK>A"4HGO5CZY473N')_P/<A?R&QK#TR.%_02K*^ON78C-O'9>
M)[*"=T(%C @6>%-X^U2T(=% FX Y&2Q"P+]SL(+6NL(_T+)UN!#+NIK5:H$?
MF3KKX-IITF1SC1?)J*)8+[H"?ZN*&2:+YWAL)*$I&J%WI,!Y$;C(L5#-._XF
MLN:,#T!JR=K(WWA0RETK38,/U.IL3M*(=[X@1!$>VF!%&2Z0T[5@XW531!S4
ME/S"5W1G7EVE^%X5W#B(6DFURDA\F.1;@PG&T\&IJ8-0^ >]9T$?,*]WBS7H
M&55-0)8RS#;2;S/0_]4"EI#^EMD"8* M",(3YW*],&2%LS>9RWP/?W,L8L$M
MBVV'>X#M0J_#:X"4ZRLRD&!MIT]0W$-1Z<N)7RFLT]N5]I_"(OTNS7&I$TR[
M9/CPR"']H<^/ EB5!/Y )P7".!K+T/'U0#C:56I5DI/:=6_?5_A)<D!QSU9#
MG\RMR+YX!+<,-S=R"IZ:1H@?=\<-&*?(A"W)-TKQ@/1L4>\Z;!A2#>1!-XV8
MBVE7^J96<O#%N'.5'T]BJ_UA6VQ&)=)<U(\%L'H0;F/>)PMXH'GCBO 2S9R<
MWJ$OY& : 2/ 5P+%K!(L?&=D7ZWW3]=<SE<-?DXG9*L BE^9&O_8E_WZV2E]
M/H)#LT_R<\&DDX^O5)WO&+V.5/:78K&PS0'L-EH[^F;X"=H9\GL81;%<@G\@
MZ7UFM 7+#SY?B]5M/K<U-TR]>6="G(2*UL)Q$GH'M>^G[XL\[QB#3[*3UN?B
M?89#K-ZH][NUBS3?5ZO>HR:F>!,DVM5T'SUZ%-9TT0C--.T)LBS<FL ]1N3^
M+76I"H'T\=EBJ#'ZA12DU?%O,0IS/^6N!S(W0A,_B!?[ &8'WO?/LR_;[[;?
M^/K=]P\<\_2*/)3=V7XHT83CKVVJ)L@4.XBO-"%B\MKGI'.(Z\I.\@-KO$BT
M5IS:+IL ]\1Y\ \[E20]T"'-.T86<N\D-@,:\E6I853.?]T%;G8ZNQ)-!U[F
M)>;R<:-?S853P.L"@GA*NHAX#!"4:6_F\K /.QV26L@7?!(+N(FX$28Z$>/?
MRDOB+HPZ*2J;J>Y:;%7"N[YWG(#P8(W"$B#XHZ:W/46VLGIW'RNKV\H1^/0N
M5M-P0V5Z;8MQ:I&I4X:87>K"1XXKO]MD/TM4JD2+C>N0<6V!A;G+?EV.,[@0
M,O*_R1V(\6DC]"<>,1CSGDCA:] X'DQ3"ZQ#T"A.E2LMCCT!<"UF;OP!VZ @
MA?P#?L5Q%<-K2/.6E/>",#L8Z18 8!G\:[/YI5MCK/'9]G;P@\S4\"MQ?=!4
M=N7,/RWRI+(33 ,64FXZ=1!^<JR&?"Z,T WN0[#,<@?V61Y%##%K'R*Z>T[*
MR^4QV='TV&@&5XEY:#"/'G#1T(WQC>^+![A#'6,G1_<?[*X7"'OAJ^1]M^'8
MR=E!?NBP!)NYWO=%^'^_%?X;"3_W^WS-TG]VH X/'MU4_LFJV/FIKRWK(^\@
M_.KD+OY+"E5[0R?_;H=SSV'ZX&5=W7FE6I40K_MN#;2A6Y)XL'(=][Z/.7*'
MNQ9"<'3&'MRCKC5$0Q"Y!9Y$)/&8&]J6M$.Q,AJ< #NE0-YTFQR<CIZ!B2S@
M,.1(H7]Q^7=J^]; 8XWZ"X>>JW=5L<;?%5*>OL)$&FW3B09G<"V1O;W2U#18
MVJ'[<$"U,:B6.,!ILL".,F3P<1D^[P%/:W;_??X#OR\[2_)!'B ]>"\SJ)JQ
M >INT"022?D;18@*CR6"0RDU<G;_WEJL'+]Y.L>?6"?':A( XF"=: 0Y^+V4
M3G4Q%368@@B4&!,Q($Y.JCA.*Q6Q@06$CSSF[I.T0GU5.JVX]0!NY &\\O6P
MEU2WW1UG8*+7J"9?C5X#4+,]^A@7D^:17X2]UW%8'<;I[7[-VECLS$ZYM\L;
MY35BL,CZ/J;AQKNS3] )(98?NB^L2^/<@FK-Y@'K@=\'DP&IQ0<1ZI3N&R<H
MV&=P=;DS&V1W:VEOV!W=F8%+<R&YL'%DKFT@&4V9G!SNBQ!7MT)\O1 /ALWO
M@BC[&%.\&(E:?"@U$DV,!#LA;ZIU>48K'WQBN9@](PC^&CI,"_XUV#H*!L@4
MSIO2HW/<[?:[OV=#S9:W6_!&6S#T,79K W)#6C^+$:N,1)=Y\ZE$^FR<@F1G
M1/ITUS.'NZ'*C]Q,=U!XR(Z+RK81/F!6G%A.IGL=Z8&*/]EX#BSBZT%Z:U1.
M19NS&1 E[DK'FG*%H*R9&VU?Y/ELU^7Y:6=14$X@MBO83S?)6!]7,'1/J,N*
M9%8<]O.YT5.BMM,ULTUR"I./]$4B*@8Q4"QI5TOI*U!-4R%\VV(6N&2$/(M1
M)]08S>'8,DY4]FY60U2=WY$5G=)_?OQB64RMJ*MR5E03*B>X9<$VJ:##:EFH
M%=-_O],K3!&KF1_P@V<1SKBZ*C@WSRIBN[+S9D0X*.<][>AEEMA.24/]D/K/
MMKG@48)5:I@+O&E= C!L=$&18GY#E M0-\+V:!:W<#L+M[OW3</MUIB;;;$C
MK8+*3+!%I5+&)(A<Z3%$5($=MB!,1\GH3LDUT<:BQ.-^\=V9R#B5)@K!6JZU
M5$_1G#<V]NN!\XA,@74IT[?U0\*:1J6R.G5[3\XU(:@^G\2UJ$F=G3X,VLOH
MV.!>EG6UJ&3D@H7]1P/=1Y\<@7BZG*F99](@F*!; >S1R;)N*4WSFTW4=?2W
M-)%$>$&HRH=E1] [4S#A;>.Y04;NWW9TQ\S45%&DHZ?X W\&;GZU[\MD!J5C
M_:OR:CP5@'6,AQSC?Q'6D\OQ&P#QK*E30B[T>Y?/2$1AF7N :7J3[I'A16WD
M)W2<)/2>"%[8A$P>@:B9-H9;*@OGA%/X,8B#'[J"<P31QL$[[%[ ;[HEB>Q5
MY6#9OCR/^%=:;P/KGJB<H.4XK9W:NFB!.!<NZ$=L5\'W%%!6IGX7IS3.QUTX
M@Z7/B,5E#B+0\D[@,Q.URV*!R$H2C=4A[.O"8+LWM437^"EL[RG2IC1+4+.X
MFBS\"^Z@QL9G(@^'39%W#"FGSG<6!6Z$D_$ZK'4\J !I II6NKZ;*BDJPMSP
M1@](8/*J/R9I7+R8PWU6XBHJLMI.S%S7:?Q]KJEKW*/B_Q1N.&B!'TDX];&_
M>Q+,W-WU8.8\Z$/9JB>Z)PG(STY*^C$"(2P!05UR]X(30I1CK!J63RUOM116
M:R&M^E_WCH]3N,FCX^/K/! ?JH:GM9 A4Y(NA^NSPN^'/#W#7*+R+/#7..^-
M^%SR#N-?<$)^MXV1'CN$IT"*99Z=93E(6O5>-^)]A??D OA:7QI]A9Z'IQ2G
MYT=6]BDU\H.E0]^J=A1L&(P1*X"T< 3 )N_L]MB[)]J=P_59,4%X/:1998P;
MAGRN5</^U)F7EB9-47M=&S[:ONB ST[1^K%&@4K(>JM%9!#\/Y'66JH:7$.S
MQ/T_])=%.X PHY-Y&3=A$J%.:OF80KI"5=>(8>:='T/^&EV"0PHKAXU8+K#D
M^0[@U,%AIIE+BFU1Y=P)--@S%F,9VF)*OY%+&D\#0$V$T0SFD*X-3RE+IRQ.
ME7"I2;7$+DQD7%A)H$E:CR9&5(Z/RB-89*@#NF\C6S8:Q!<"$.R4#E;B L7E
M.P"U",X_1!G45YMZA>:0NXRS;$TS]>,$0I\T [V&;6;2 1JN] <L9<#B.#5U
M@Q8$W%/'K#+E 3\A>)9"3ZK#-IOMR5'R4DF&?WJ-V EKA5N$!3)[C6%-2S>=
M@3YF <(;8G.Q1A2=O>2,QHWN!2[E&@VQ$]%A:>T@1*E(>";)P*Z-!PNV/I*'
M<,&0_2[85TM9.JST@6#O2:1P;]>-PL5[%!2=O-)F,>GJQN>V7Y  \G2J=KM6
M8T\\B*\ABHCEA*IE)$!;=BM^6UH#TTT6IK$I,,G[^8%2=N1JI,\XX11H.YYV
MU17B7<\Z@ZFC4M/<*<F&H#,\M/DJKY;C\Q[K_L)I63C^MVL0I@12J8O47L@&
M2/+SD6X0_MZE@MV)V3YC@4<9SIBN)7C97- 6PW5;VY':SOUONK:S6U0*6452
M3Q[7$&KG"Q/75#8P<]GQ[WPZ$QOO[?PJ/,CM'/R H4CQMC7HHX-STP9%\Z8#
M)V<5G#BKEH(DX(T)SINB3719874GM>WSP8A7C0X8^L ]V@?=1)QG>],WN?.Q
M]'E$] ,1I?A)R4MA_OTJL2/!X,Q>S,W=$$0RB;S#2"6)<].;)2VAG4P+F\SP
MEW",D@X[B&=Y/)V;.N!JF<)U0D@*,\4+-1UW@@@/+H5')0,6:*HE5[F81K@A
MTK*A#:ZF4QUS6<,W&%Z/6EE/L-THG("+M(3P9NEYP'V =WH'IZ79+%YNIUL.
ML@Q-V@^8A/4Z =]AQ@45?A*_MO1;6[,+P6$T!5,"^&;SO'K;JSE2RT&9&'F9
M_LP<ZF%.3W&+2B^WXLY <VJX(B8 9,\!1TF&T>)0 (5V1\K(1-._:_@YDDV#
M^,WT>*>IL;F/LDHN63,RD:1D/.(;\I$N:'7PQ1IJNI%(U];B=4R@O"^!QF<?
M\_() HVW54T5V9]5)J7(G5:ID;,^[>K2-/T6 J%PE-9AV <Y["1#3.B,/BV6
M$HA@39XTW=0]O!O@3;JE"M,V&+#PER#BX$EWA-(+DD5K?2/?]PG/AOJAB*C3
MQEFL#@(M%T0=K,L/O35Y4AO8RE=('94FSW_9E[WUV0>&?*SKPE.-7S"1[Q8;
M)[[[*7D<D8L9G*'#?C9BMC&\X[D7)/(QEJ4'W%8N(YI3O^:5C-@=YR1.#B2U
M_>KU;V[N-+L:0G!,1K.KLSGFQ%5 @V#''+NYQQ9^3KX#77L&=SE# WFIBHX+
MEJ?IB90L:?^Y+_ IX!X:C"O^U[W3>_X0^I0LWB6!P."\X!ET]1W*6.-GY+&X
M$B0;W"M8F]6=J7@X&"$3C<6A^T$E\^TMZR4FR%.<.%%A<A@6&2N#/,VAJTE;
ME8B8:0A?97]%5,R4QR5DBS/5Z#[6]FN;0V; J9AKR=$,3KX:/;57,S?,/$>3
M5.1)[9-SVGFP^L)G32_@)+WW('@%_J7+VR:GH5A9*V!_.C)W"8-21 P_*<"I
MN?,ZFU>82@+?.>L$9<5%D<YFK7#P! W(H%$8\J%?#-';#D3&AU%F"V_-W4+4
MH#Q5II;9&_+,_@?!O6Z^$XRZ?5SK97_L'M_T%^63B*[C)>67T'.Q9;L&\NT+
M/QOEB]L_KG0AG2 5*B=53/W53TZ/\/H?<GGTRE<APR#YE9:=SY=%;K@!OKZ]
M-=KR(M<?U<6BJND-]/;3-6@,@D/B;T%5VK,XR"*/F/&$]?T#]L49^>RS2CZ!
MH_]OE6T?IS::,^RE1%KU#JV'^,><[B?*E+YHOJRKJ:8:!&CC7RS2USYG\K*"
MQ5J13J>>"OS+$X/VD+:W:7>?=G]PFW;_<K5(FZ/CJ#6_Q+Q.@,JFM!O*+P.?
MZW2X0Y@TMK&3+$O^,3@6BOH2R!QB3P"Y':K0J,X)D;$W..+[NZR><56"IO%;
M , M   7YA^<U-Z^M1ZI4[/9]BEJ%]7P^-N&'%YB0\0?KD^<4_$BM;,;0@8S
M7U.(9G"-G^9I4.JP<QK&3]:?&W:.E.*^HVCPLUY2,?AE0'P.'@;!(@C9&[.E
M;R*E=*/)^/%"S!AB'CQNC,#*@QIE6%>EG KZW!)@!E^%#S%>D*II/B$;FK &
ME$,@E+4\#Y-G;@H,D*M,]'&O*TH<G29,&56%;3^Z9KCSOBB?G:^YOHGW )9@
M\86AN-)^V6XN,RH ()X>-1%=P5$O4[4JY:W0X_SO0RS9G7**; TNQS]Z M?'
MNIB^]'I0]7?]N);2(^<3)2D#&.319E1,N.;&K^\2P\B=5("@I%P%0:8J9-P.
MJOE9>"L+G71O-(7<*Y54*7P:#I-Q-9< 'XW$'CA%^,!,\1]X[4,+&U;A#7DV
M3'R1L,9\/5Y=$ZSWR.P*49KTKA6V2W!;)N& !7TEC1@H*Z"[:$(N3N@I5N@-
M%X(OYV7.4Q[&,^2E.AC0F 1YG*YLHI*,*2]I/BW=E6#CY#UZ/,N$'IQT*B,!
M0!$3^XY@5-9-^'#D4P>30V[N#:AVW5C*$(#'@&WX?;BNB!@WI>N:P4G71=<8
M[O?DA>?66"V%=&JG>59ZD?%9LS$H6Q-R:'FKY40_W9@&J$J&^N#9'V=9C5FR
M%WXF;^IZB\*XA^MU3"+9")7QD,!XKO)U-\UMV3D6\)Y7**<SAN1A^D#58&'5
M<NYOEC8(W9F,T\8N(C?P*BN4P1S=3&'O4Y_7E5Y)X ?U-$CXHJ03B-)T.0$N
M5'*EJ,$VOE0LL.A#X,/OBUG]&FKMNS&K]RBVH<YL<@HW';,L07]!H:YN9C1O
M9G[#CK@-M( (".P0;\0<ZNBJ!F[_GU=,>3>\J=&XX@90+AOG?#)]9?(;*2L;
M0.'82U53K:G#H4YT N9VAU?:FRJ)L*I"XQ(,6G2PRDLG3BII:MI H>N?3"S[
M:?+7OYP\?/3C^/"G OLL<^6*)3QO^6:T^AS:X2'Q&(4/O 4"6-FZ[(=2^S.F
M2D9[>1C=1+HWO/<P9U./IH._S)@\@[!T3FK$<#1=X0A( JG>$\V]\TB.IYBF
MV+;&_O3J3;(O:Z(5C!ZVH.ANBS!2A'EX6X3Y8OOKUKKNBW4EG;<OAO5K0"6$
MLO VS,KCWGA%J6GEAF0F.S+P^BAL3KPV$.H5&X9\N#<Z2V_::APYC<1:&!--
M/S0[$]UJ<B!4*G-5WL"3P!?FG==#_'/0_CAX"!S:8>@JF6+ G5>&N?#0J.2<
MQ^ 9)",HV[HJ\.2+JM9\;TB(AEK&CDX=^<&- CC&=84#RC^1HC@Y?G@#37%Z
M]^CL[';:Z@^L,=]L(9*F!J O^\X?'-V_O[UWOFLO_?&W[65]>?DZ.SYZ]&B+
M\K5K O9FB_[M5M[^-BW*Y0Z^_/X0M#1DJ6-<_R?@JJ-IIB0+)Z>B'Z3(2?Q'
MI2O+>A1]K6>=M);)27)WVIS]0F0K(DD*!M$7V-5#*!MUZ";(QR([%,<Z.9AP
MK*?=)!SK;5&O#)>RMF$.MR:MNR:L+UW;X;!%%WU^$!2-!+MA'T%&0W1G6OIN
MSU\\>?4X];[]-?0FSI;!J>FG<#XFQO97F&M5V'YS;D!WU^P#'UR$CIN*N=OB
M6)UL^R!$\"W#PVMQ+[7K!DL3@DW@L3(Y<*R=F9Q!P5"9FCU]?*#:3!#;@$^^
MX:E,_ZFND E8E79>K<R!T.%=X2GMOF\@BJJ)K0WO-74+G7>UG=4)MTRMJ';-
M[95AFU\J4UBV/'<+A]RG#G>[1\;D<M<\"8A-8/_5%$"[MJBI"\GO<+_7!<A<
MNTH>,S5<,&*9HA./\9/F(G%!O/!LUN1[PU,RW>%,ULG)T?')"&[.JXRW0\SH
M]F&]Z])/J+'U,'D5W#L^G,>!B741UT,<HW[=WQ)3!#"7?LV>$CT]&$QP'VOM
M1(2(FAY>G^BY!EKT)_(+MS4KJ5D]NJU9?;E9C!\$9QOLM0^%K*[=;CX3GD;T
MN@0C%[D-N':)/CO6#L1G)+94IF+96"2X26XU==PT!OP\D)/6EGG"0\<P^GMB
M*&<[;"B9T&N8RK>.\Y8K.C?8!.O*)@?2TT V9A5#B*O M* ,NV+FV)RBP*C8
M@5]IQ,5G]][)R6&O6'.#<DO(/GEZ-\Y+A#/3O=.YKI)2WK2<0F3+0DF,C'S,
M(Q6MP^A@Z_L'^G# \^7O2Y=SS.'066\+-=L-A%Z4HNP3XG7@7@RR2 &A.0?[
M!/PONL7R3M,M8A*)V_37;36H+UEC8!2%"F-*C"H6FN]UQNPP_1H%[8@:/?"#
M#<T>L\-4"%0P?!E^)U1+\7H-!T"'F[*_FO:$=ZFSQ&:J/AS&L^B*UBP+XPF0
M_4)-:VXR(JU-0\;P>\\!1.LZEL93S=A(^,"B!?>)[)></(4C<2+9V?WAF,C;
MLML.V(A^.>9KW+Y[E(7=N9+>;97DZZZ2/)1$=XI3QQS8[-LKGMP6-GWA!#98
M7!;Q)':@^&D2<(@\Q, Z&%]TQQ9;QCDG4W%0."*U)QVC3 YZVGJL98?[DBV:
M[WJVJ&=AMY,92E!B.7.1NEQ&+X<Q@HZ-$CS("PZ"=C^2['45",DF;0+ QU="
MY?Q!4/@/@/&&[<[,-.A)$$>29?P))Y55TFCLF\:T+O^#$KDNV<7SQQR_LO?J
ME;51;DH7L\?34&C+]A[T6Z_OM8XI1H(!-05-]I7@I%[<UG!L#>?D^+:(\^6(
MJ-I681A#(^$0U8K4.7,S,6WR.!H.Z%)2 8NR]7_D.]A+6;6@[*B+5F@+U+6^
MK+(0XGBS "BU?$?PB[OW^!=FZCU$V*^%NMH76_G90^J/@R#<)P?39G!.'Q[_
M(SG7=0L*$>0C[S)'$?O2&C"G;K\%QKG;Q/V? MO''">/0\N,&H$"0*0V+JL6
M%0%Q 1-]C@G+R:;U7D+ >$W*B;QWY88;Y#B' 4/*F)<-Z>)J%]Z)NS-P5-"W
MU^0^V4%KM@@>GIDIQMR?S##4&V?EQJ7TGML.BB),UH%R255^ *M]4Q\NEQ76
MUW%[X65BFIN?=4Z."O@N%?HQZKW/[X*NYJK=-(GVK#SR>97KH-#FN>XM29 C
M5[>8E+&5L,'O#9:VMT+1HASPL!>K-WIOL=GT4_1!>=HII^)J.]6';9TLKS_>
M*B=GYX)QW3BTP-457\F?G#44WG9G*\/O; K<G0E#2LZ#R, :3G['*\NR>UD9
M&NBZ<@-I)QHWS+JW?H.WBK?*CP"*B4 :.H-[P$V&:X)73,S">HW^/1$?_1OU
M/@T2.=%;#V.$23RU9$VMUBXI([-L3JBVUD+&,/CA2]>=&$EJ36D6H)0$<8(A
MMO#X&S?\I! >0G^AP?1>9<?V]M'W_#OR/T08_4K?/7[T.-X_ M_"-L&K*L'A
M"^ ?9>3ZXSDND0NW=6N)LAJ-7+&WAYU(#A36@O#3W*N2PQ.:1@7K9\\R6%WB
M)8-%PP27PBD L!('>$KF=0+_*_F/KJM#C#.M0KY>_4Y'=@&^ #R5!#Z):4)M
M/$6^>EU[K6Q%F@-*T_!XJC(9[$;1=B6FZN$4E$W<!=7G/!E^ GQ_^ A#;6)Y
M^HJF"M_,V%O@UK(;* B^YD*])WEO;GZO MK -6#N-?\F>(-]G')Y-J5 /]C#
MX15,X]WW@=KV]41S*%+=WZ-,5RCB:45>?(&JSJUX<:+!?3,CH!:2]<D6'#%C
M-'Y^++7BAJN2<N 9Z^,*Z'K"/'RN^-)C?LM(OC!<\(/\\.#N8;3LMR"![::3
M(_Z\)JIA6*LRBE\TASW; [M-D;:JZMCVH2'"JC96L T#+?EJE(A:=BT?UE"Q
M*<:&!5'\N3_+SW"6P)\,<M8BW_A0RA1DGXE4$W\5C+8!15JA1:SZU((Q*2<V
M-![[\:T4Q(OHCJ$L<?X8;GPF<J[=] 51''T.8C?,">P^>PB]$ASUXO+@J"#W
M=IMM<]FVDV\ZV[9.HVTKW=:!\:VQ\H1FGYP\W%F,W607FS9_2>GT$2>FUFU7
MEX.YXX&);=B/$QSS&!MK3PD,Z5B)S&/=IH;3O^5M33.<XHW=NC%(O4&)2[62
M0-"'R3>-#"/W5H;!DGMV;='#30'B$LI4RYSW<"+[V(JX\>F&%&\I^MI% #UU
MCVXR%I@M*'>#DI]4=1GX5%_6<-^"@GJ6>UB3ZL#CHJ1EZZHS4J:UWNPZUS>1
M\%4F$]._P2B1M;G1-L2M0\*;2NP$MJ0A%YR,6.# VQ8$@FE;M\'"1\20<\14
MM?TC[43$%Q!++>.L$DW]I> LYSH;W'DOQ'%3A-=>/^NU)D47_0T?;]G/91F9
M,H8$/.EHQ!UY'6/.E5N[=42%O<5.^]/P% 19M2\;YE3&U&6VLF_K&9IH7)%7
M>.8.@6,\)=76_'J>CRN2]E\SQ'I&7Q);/(K?'"04/:Z)U#NE4RTCN(F+"1H;
M-2?!>Z,SN$5._5CD\!B;J RSDQ^:]@SXPFOP25N:64\G]LY?'R"TEA%WTYN@
M?$-5%#R74$.,'.9$(P?.6=+150H%C9:)XL9:Y\$J1<<,G]#"GCYLI=IJQ@EB
MDEW+8&YU0X#XF(IMKSE:EX@2SQ_@8!\\?'!Z,#T\./TLT=ZN%[Q^_QH*7N<5
MDNMO?W!2\O.@E-J?7#VVIV<T(@7!:@UJ74HX,!N_>RQ2^G#>8B43+8+!"3(N
MS';9DM"C5V:YXOD$4X&'\"YV'B.F2G3=D)WAX2[2I&,8<[50+:?L"QXC 5N0
MY^A):CJ@0TDM @4].]#CW(Y$?Z 6IP@R8,QS3["R064J  ^\#BT'M@?F;CG:
M&M3-M,.10[!'%A7<'>=U91I$./#,Z8QTU$TW)>''9B[<[1&Z@.E!WU0234V(
M9J$@P4BG/RBCKL7I%H(]@0]P@'@ X9&9.'65:8T/UD1+R:O;>$3]G#'N<']5
M<<DUK&6%=IBQ*MCF^:ZLK@J=S^@A+TW=<NYLI&/;S2$?3BO!HT/QLF.A"0\#
M_\3<-I\#CY1AY T/*R(3@&\,<Z,,Z:P#^R"3T^T <[ @9FG(_X]+'G[L!4,(
M7+!"T" Q(^BWN\)B8/C6(W/GE*3PFP-QJE76X:+H(.@8"2KXEVB0*"4;[<6_
M_N7N@Q\I'>37;#29]/LA[T\N=5"2T7FM]C[\AN0LB[TG)C[MS\D*BPENQ[BT
ME-@K)D*SR&,WY-N].!6X;&ON>U\LVKL=MF@"=Z3T@A]W_I)FQVQ[7,30ML4P
MH5$PHK,MX*NZW1 ,':,GQ7_*HR[E47%_BIUI>+AK>ILN=.G"TV\Z7;A;X#SO
MDMA"80$63J8UH>2B*N[01T+]NF2LQ%S5^96J9=!3-6WQ#V0ET85>SJL2"\93
ME9&MQ.@YFQOZC !]9$;1%^M*F_+(-:EQ",Q!@1NL&]8Y_%5-IVABW^D5%J!A
MZU%64U'@:H^9*' 5T)]#Q8L#OZ2409A[.^4OJY8(%C[P#YO7(!C-H75Y8M-%
M 1)!\>G/@WEUA65A1.##_1U&+@Y%:L[;](T?6-7+X,U6"W2 R-TMC(66X)?H
M>"T%P3A^X,%R0]\/NY@$?5/X?(ZH$T2-RKF<,E2VV$?6'V0JU^]A+4$^P4/!
M-T7%$/%I^#7LC:4L=MA2!K$?N*!F6*1%(,@MIO$;P31^C*#LSAS=Y!F3AU!2
MFH(ZC@NHA+NV?NMTFP=#P#'"H;&F%22SR$37^K$!GD<$RJOA[HD3ZW)?;S (
MZ>I5\HI:<#VC"9NM66<X8,=8K2MF2H"8IFDZTM,V1^S2T>$5?3JZC4+% ):V
M ?5%]M8G]UI&TWNJ?;(6C45 ]\=D#N?Y;8:@43N*O,1/QL!WB_WX)+O]:81,
M!?EXG&4$Y2*1<3U(-$%.2@A;IQTB*8VD/F["'=^C*29V F2US8GWZC.41Q^E
M&JH8YM3].3ZP&#<C VSQ2>!\IN@C0TMNQ[<XF*;W)B198:&Z@ENA3FNM2F'6
M#!_^"V^[;[YR^]'[[K5YG_RK0CZIIQ !\+#HUSQG&%E0I?V[V;85[M>+3"B4
M[G9MM[J5QX/K!?) 89GHX,DAIBT#ZWDH4-;QO<JVI EGN^86(1_!SP)<\EH[
M?2!CC+$'<[%LK8Y;9]7QR9LYHE]PZ\MU51&U0!RZ.W1 \UAIC&J)&VURXIYA
MZXZ7-YZ(9MK#<,9*KX?7TU.> J,#\@],6X,X"H. YP#YDW?J. @$$Y?&X+GU
MG;2'^*.A<O><!2,2X8=N-VM$ ;GF,,)EI+!GC1@]^E!4?^PME;F%)\D[-\U:
MDW.=[R5PIY%'R5$1<(Z?T]=VN7@6!V8$J3;D:[]4*^_:".1+KA@BI7'T;+=8
M)L@((SZAS&(0I++</UW6L=J5%I8,3Z5:.*Y;VM=1@2-M2N5PQXY0YHNC@KYI
M0I>/-BT8=[0+H2V]0*3*,S^@@?78:]MF+GB9;:?+8P46=,'T0Y%H7P[BLY2!
M.;:)'BMTDLK#<%&X7,;#0"P)V@!PU/MSNRYB477]^K(GI(U' $F"WM!$+P!W
M'PS*\.#]#[@:1;*43 U.VK^%YDNCZ[]=HI:/WXKJ/7D!KVP5UO=K/"OO_%]8
MP^2)I"IV,P&W=_6BLV^Z7G3R\'BW\^AJ9R"W=MXF.FMUO'TCE%VOEBNP%UA<
M@L(ZP,*HEF?XG[3AZ?=84&*P'3K5XXZR8.NOZQD,FVC&E="P8]@B8R'T8O8_
MQ[G3'^#6RAF)XG* *8Q),H8TF+(F@MYAG.,GLUF[+N"3W1%P.^%+'",1W7%I
M\:EAWX%(X+ [[TS8?'A-RW-J^4=IZLM&*6*QI!9;8F<)1:?Q&PPW0K0]4RZY
M;KPO!]D3;JE--[(WDIGMCF3:4<<82EN7=U0N1U]V&LC.)&I1+\P?6'2QA7G0
MN$S6SK P@7OR6?8IIOW\HZ(^VI%^7B7_Z"#,*;GC@,(_7\[>;OCZ/"8;(/6!
M6;991=0#EGBYTLP8L%#O-"F?$.>UMA>40N" 2<1I-*=C1ST+XK+S:4W:)YCA
M:J:K]-H452H!2M /1PTRZ!@8U_=A4:Q^7@,^ DKTH@0!)UA;1;TU]<(1JD:H
M-UP$3\&W&O,D:FLITK#+A_YVS0J$RX:/6Z-'F;!O<B5,$)(O$A/U>$8>FX48
MUD-3>P$%?^4VJ;>H<H\@HOIJ-75'\L(QKS<\S#O=[Y"T]5C*\FKQ-"]-A7X9
MGV%Z?:+Q$VFPL_N[;;<>[+#R$I J\ZZBG)U7(%>@Q78TW/^V0%F?/9C\&,D0
M'^=Y5=ZA D1KMM^3\[@EB".SS0>3 EYYYN"75"<8;\X!ZX:#!&I00L6*/3/W
MUX%E(J-$IC ;J0+4^DSS4.&Z+;%69&N)%K*)I21J0<&B4G5%QPBYA,(?3BJD
M(EYHG(<0(#O1]-"AA *MZKA,!Y<I9XK']* Z/;=OX!()9N'_J%$/+9BZ9(7+
M#Q(^E#= <A*:XL5]-:"\ZV9NEGBK$)%SK2RE.A$<Z9Z6#U%-4X%9XD/0[&"7
M3!4W'GFKP3!Q<E]E>-*<.)9V<M737G645[WA(M78HC/9^!"LZORI,"[$,L'
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M'R$L&DM]R/XF1;DP#5Y(-L@5CE7GG3*^F/A;]*<V]MP>$49W[2F0GPK)J<$
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MD2=BZT<E2R+P::"S[,)'8(/2;7?YP.]0JL_PJQC_^YSS?P!02P,$%     @
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MS#H5.Q]CK%9U(/3.J@L?86F7?K?+![[?J'[CUR3ANY;SOP!02P,$%     @
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MMD2!24IA<A5$)%TR3&I)PO-<8\8_/9,B HB89(CM&D<)OH31@&D#+G@<<Y+
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M$0;#P%CJGM=XU(MQ%\N,A)_F4N0\JI6P8OOI?7]V[T<YYA *SFEH"A(LF5Z
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M(3.LN[G>;_*%.\KRM[@QM7>W)W\!4$L! A0#%     @ VCL$59"[EWZ(, (
M";(7 !$              ( !     &EN<VTM,C R,C V,S N:'1M4$L! A0#
M%     @ VCL$581PZF)>$   (Z<  !$              ( !MS " &EN<VTM
M,C R,C V,S N>'-D4$L! A0#%     @ VCL$53H[H?J='   =! ! !4
M         ( !1$$" &EN<VTM,C R,C V,S!?8V%L+GAM;%!+ 0(4 Q0    (
M -H[!%54-=9[,%D   ?G P 5              "  11> @!I;G-M+3(P,C(P
M-C,P7V1E9BYX;6Q02P$"% ,4    " #:.P15IDIS!_/:  "%\0@ %0
M        @ %WMP( :6YS;2TR,#(R,#8S,%]L86(N>&UL4$L! A0#%     @
MVCL$57H_6<P5C   <4X& !4              ( !G9(# &EN<VTM,C R,C V
M,S!?<')E+GAM;%!+ 0(4 Q0    ( -H[!%6L:D+U0%\  ,]I @ 6
M      "  >4>! !I;G-M+3(P,C(P-C,P97@Q,#$N:'1M4$L! A0#%     @
MVCL$53]B*T//!P  ^B,  !8              ( !67X$ &EN<VTM,C R,C V
M,S!E>#,Q,2YH=&U02P$"% ,4    " #:.P15Z(&MR[4'   R(P  %@
M        @ %<A@0 :6YS;2TR,#(R,#8S,&5X,S$R+FAT;5!+ 0(4 Q0    (
M -H[!%62 8PVDP4  *48   6              "  46.! !I;G-M+3(P,C(P
M-C,P97@S,C$N:'1M4$L! A0#%     @ VCL$584M?)-D!0  %A8  !8
M         ( !#)0$ &EN<VTM,C R,C V,S!E>#,R,BYH=&U02P4&      L
,"P#> @  I)D$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
